

**INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION**

**2019 FINAL PROGRAM**



**39TH ANNUAL MEETING AND SCIENTIFIC SESSIONS**

**ORLANDO, FLORIDA, USA**

**APRIL 3-6, 2019**

**ISHLT 2019 ACADEMIES**

**APRIL 2, 2019**

# **TABLE OF CONTENTS**

## **ABOUT ISHLT**

## **2018-2019 BOARD OF DIRECTORS and ISHLT STAFF**

## **2019 ANNUAL MEETING SCIENTIFIC PROGRAM COMMITTEE**

## **2019 ABSTRACT REVIEWERS**

## **COMMITTEE ROSTERS:**

**Education Committee**

**Finance Committee**

**Governance Committee**

**Grants and Awards Committee**

**International Engagement Committee**

**ISHLT Mechanically Assisted Circulatory Support (IMACS) Registry Steering Committee**

**International DCD Registry Steering Committee**

**International Pediatric Heart Failure Registry Steering Committee**

**International Thoracic Organ Transplant Registry Steering Committee**

**Registries and Databases Committee**

**Standards and Guidelines Committee**

## **JOURNAL FOR HEART AND LUNG TRANSPLANTATION (JHLT) EDITORIAL BOARD**

## **PULSE NEWSLETTER EDITORIAL STAFF**

## **SCIENTIFIC COUNCIL OPERATING BOARDS:**

**Basic Science and Translational Research**

**Chronic Thromboembolic Pulmonary Hypertension**

**Heart Failure and Transplantation**

**Infectious Diseases**

**Junior Faculty and Trainees**

**Mechanical Circulatory Support**

**Nursing, Health Sciences and Allied Health**

**Pathology**

**Pediatric Thoracic Transplantation and Heart Failure**

**Pharmacy and Pharmacology**

**Pulmonary Hypertension**

**Pulmonary Transplantation**

## **PAST PRESIDENTS**

## **PAST PROGRAM CHAIRS**

## **PAST REGISTRY MEDICAL DIRECTORS, JOURNAL AND NEWSLETTER EDITORS**

### **ISHLT AWARD RECIPIENTS:**

#### **OUTSTANDING ACHIEVEMENT AWARDS:**

**ISHLT Lifetime Achievement Award**

**ISHLT Lifetime Service Award**

**ISHLT Pioneer Award**

**ISHLT Emeritus Membership**

#### **GRANTS AND SCHOLARSHIPS:**

##### **GRANT AWARDS:**

**ISHLT Norman E. Shumway Career Development Award**

**ISHLT Joel D. Cooper Career Development Award**

**ISHLT/Enduring Hearts Transplant Longevity Research Award**

**ISHLT Nursing Research Grant Award**

**ISHLT Research Fellowship Award**

**ISHLT Transplant Registry Early Career Award**

**ISHLT/Bayer Pulmonary Hypertension Research Grant Award**

**ISHLT/HeartWare Award for Translational Research in MCS**

**ISHLT/O.H. Frazier Award in MCS Translational Research Sponsored by Medtronic**

**ISHLT Branislav Radovancevic Memorial Fellowship Grant (Supported by Thoratec)**

**ISHLT International Traveling Scholarship Award**

**ISHLT Leach-Abramson-Imhoff Links Travel Awards**

##### **ABSTRACT AWARDS:**

**Philip K. Caves Award**

**Nursing, Health Sciences & Allied Health Excellence in Research Award**

**Early Career Scientist Award**

**Junior Faculty Clinical Case Dilemmas in Thoracic Transplantation Best Presentation Award**

**Branislav Radovancevic Memorial Best MCSD Paper Award (Supported by Thoratec)**

## **ACCREDITATION INFORMATION/CONTINUING MEDICAL EDUCATION INFORMATION**

### **UNRESTRICTED EDUCATIONAL GRANTS**

### **COMMERCIAL SUPPORT**

### **ANNUAL MEETING HIGHLIGHTS**

### **LOEWS MEETING COMPLEX FLOOR PLANS**

### **ACRONYMS**

### **SCIENTIFIC COUNCIL MEETINGS & RECEPTIONS**

## **SCHEDULE AT A GLANCE:**

[Monday, April 1, 2019](#)

[Tuesday, April 2, 2019](#)

[Wednesday, April 3, 2019](#)

[Thursday, April 4, 2019](#)

[Friday, April 5, 2019](#)

[Saturday, April 6, 2019](#)

## **ANNUAL MEETING SCIENTIFIC SESSIONS:**

### **WEDNESDAY, APRIL 3, 2019**

#### [OPENING PLENARY SESSION](#)

[SESSION 01 \(ORAL\): The Next Frontier for Thoracic Transplantation: Diagnostics and Therapies](#)

[SESSION 02 \(SYMPOSIUM\): Future Shock: Great Debates in Cardiogenic Shock](#)

[SESSION 03 \(ORAL\): Chronic Lung Allograft Dysfunction: Anything New?](#)

[SESSION 04 \(ORAL\): So Wrong It's Right: The Right Ventricle and MCS](#)

[SESSION 05 \(SYMPOSIUM\): Limiting the Invasiveness of the VAD Therapy](#)

[SESSION 06 \(ORAL\): Pediatric Donor Utilization, MCS, Readmissions and More](#)

[SESSION 07 \(SYMPOSIUM\): Making Co-Morbidities Great Again](#)

[SESSION 08 \(ORAL\): ISHLT Spotlight: Heart Transplantation in Latin America](#)

[SESSION 09 \(SYMPOSIUM\): Re-Focusing the Blurry Vision: Biomarkers of Thoracic Allograft Rejection](#)

[SESSION 10 \(ORAL\): Heart Donor Management and Allocation: Setting It Up For Success](#)

[SESSION 11 \(ORAL\): Chronic Lung Allograft Dysfunction: Overcoming the Hurdle?](#)

[SESSION 12 \(ORAL\): When Short-Term Becomes Long-Term: Transition from Temp to Perm MCS](#)

[SESSION 13 \(SYMPOSIUM\): They Tell Me I Am Irregular: Why Do They Care? Arrhythmias in LVAD Recipients](#)

[SESSION 14 \(SYMPOSIUM\): Part of \(Their\) World: Discharging Patients Home with a New Device](#)

[SESSION 15 \(ORAL\): Pharmacotherapy in Transplantation: Reading the Tea Leaves to Improve Outcomes](#)

[SESSION 16 \(ORAL\): Junior Faculty and Trainees Clinical Case Dilemmas: The Best of the Best](#)

[SESSION 17 \(ORAL\): Tolerance Is All We Need in Thoracic Transplantation](#)

[SESSION 18 \(ORAL\): Ex-Vivo Heart Perfusion and Preservation: Some Like It Hot - or Not!](#)

[SESSION 19 \(SYMPOSIUM\): Chronic Lung Allograft Dysfunction \(CLAD\): The End of the Beginning?](#)

[SESSION 20 \(ORAL\): The Beat Goes On: Arrhythmias and Pacing During MCS](#)

[SESSION 21 \(SYMPOSIUM\): Short Term Mechanical Support: Taking the Next Leap Forward](#)

[SESSION 22 \(SYMPOSIUM\): What Do We Do? Burning Platforms in Pediatric Thoracic Transplant](#)

[MINI ORAL 01: Deciphering the Role of Antibodies and Inflammation in Thoracic Rejection](#)

[MINI ORAL 02: Cardiac Donor Selection: More Than Meets the Eye](#)

[MINI ORAL 03: Chronic Lung Allograft Dysfunction](#)

[MINI ORAL 04: MCS: A Focus on Stroke](#)

[MINI ORAL 05: Do It Quick and Do It NOW: ECMO Update](#)

**MINI ORAL 06: Pediatrics**

**POSTER SESSION 1:**

**Basic Science and Translational Research**

**Economics, Ethics, Public Policy**

**Heart Transplantation (Adult)**

**Nursing, Health Sciences, Allied Health**

**Pathology**

**Pharmacy and Pharmacology**

**Junior Faculty Clinical Case Reports:**

**Infectious Diseases**

**Mechanical Circulatory Support**

**Pediatrics**

**Pulmonary Hypertension**

**THURSDAY, APRIL 4, 2019**

**SUNRISE SYMPOSIUM 01: In the Thick of It: Hypertrophic and Amyloid Cardiomyopathies**

**SUNRISE SYMPOSIUM 02: Immunobiology of the Older Lung Transplant Recipient**

**SUNRISE SYMPOSIUM 03: From Isolated to Mainstream: Evolving ECMO Strategies Reshaping Outcomes**

**SUNRISE SYMPOSIUM 04: Nobody is CLAD to See AMR in Lung Transplantation**

**SUNRISE SYMPOSIUM 05: I Want to Ride My Bicycle: CPET for PAH and CTEPH**

**SUNRISE SYMPOSIUM 06: Making Deals with the Devil: Substances of Abuse from Pre- to Post-Transplant**

**SESSION 23 (ORAL): Hepatitis C+ Cardiac Donors: Do They Get an A+?**

**SESSION 24 (ORAL): Molecular Diagnostics in Heart Transplantation: It's All in the Genes**

**SESSION 25 (SYMPOSIUM): The Magic Kingdom of the Bronchoscopy**

**SESSION 26 (ORAL): Mechanical Lung Support for Isolated Organs and Patients**

**SESSION 27 (SYMPOSIUM): Medical Management of LVAD Patients**

**SESSION 28 (ORAL): Tissue is Not the Only Issue: Advances in Thoracic Transplant Pathology**

**SESSION 29 (ORAL): Pediatric Lung Transplantation: Are We Moving Forward?**

**SESSION 30 (ORAL): Get up and Go! Predicting Survival in Heart Failure**

**SESSION 31 (ORAL): Slaying the Dragon: Hepatitis C and Thoracic Transplantation**

**SESSION 32 (SYMPOSIUM): Ex-Vivo Lung Perfusion (EVLP) in 2019**

**SESSION 33 (ORAL): Brain Attack: Strokes and MCS**

**SESSION 34 (ORAL): Never Mind the Leaks: Addressing Valvular Disease with LVADs**

**SESSION 35 (SYMPOSIUM): Bring Out Your Dead: The Postmortem Evaluation in the Thoracic Tx Setting**

**SESSION 36 (SYMPOSIUM): Learning from the Children**

**SESSION 37 (SYMPOSIUM): JHLT at ISHLT: The Year in a Capsule**

**SESSION 38 (ORAL): Early Career Scientist Award Candidate Presentations**

**SESSION 39 (ORAL): Walking a Tightrope: The Double-Edged Sword of Drugs after Heart Transplant**

**SESSION 40 (SYMPOSIUM): Heart Failure in Adult Congenital Heart Disease**

[SESSION 41 \(ORAL\): Perfecting the Graft: LVAD Pump Management, Outcomes and Medications](#)

[SESSION 42 \(ORAL\): Too Much or Too Little? Obesity and Frailty in MCS](#)

[SESSION 43 \(SYMPOSIUM\): Changes in the World of Pulmonary Hypertension: Nice or Not Nice](#)

[SESSION 44 \(ORAL\): Philip K. Caves Award Candidate Presentations](#)

[SESSION 45 \(ORAL\): Acute Cardiac Rejection: New Approaches to an Old Problem](#)

[SESSION 46 \(SYMPOSIUM\): FUN and Games with FUNgal Infections in Lung Transplantation](#)

[SESSION 47 \(ORAL\): Back to the Basics: Physiological Alterations During Continuous Flow VAD Support](#)

[SESSION 48 \(SYMPOSIUM\): Advances in Short- and Long-Term MCS - What's Next](#)

[SESSION 49 \(ORAL\): Personal Connection: Psychological Issues & Care for Donor Families, Patients & Providers](#)

[SESSION 50 \(ORAL\): PH in Translation: From Novel Biomarkers to Cutting Edge Clinical Results](#)

[MINI ORAL 07 A&B: Basic Science and Heart Transplantation](#)

[MINI ORAL 08: Lung Donor Management and Organ Allocation](#)

[MINI ORAL 09: MCS: GI Bleeding](#)

[MINI ORAL 10 A&B: Nursing, Health Sciences, Allied Health, Pharmacy and Pharmacology](#)

[MINI ORAL 11 A&B: Heart Failure \(Adult\) and Pediatrics](#)

[MINI ORAL 12 A&B: Pulmonary Hypertension and Heart Transplantation](#)

**POSTER SESSION 2:**

[Infectious Diseases](#)

[Lung Transplantation \(Adult\)](#)

[Mechanical Circulatory Support \(Adult\)](#)

**Junior Faculty Clinical Case Reports:**

[Heart Failure/Transplantation](#)

[Lung Failure/Transplantation](#)

**FRIDAY, APRIL 5, 2019**

[SUNRISE SYMPOSIUM 07: Highways to Hell: Chronic Lung Allograft Dysfunction](#)

[SUNRISE SYMPOSIUM 08: Print, Replace or Innovate: Alternative Strategies to Cardiac Tx](#)

[SUNRISE SYMPOSIUM 09: MCS Infections: New Twists in an Old Saga](#)

[SUNRISE SYMPOSIUM 10: Cardiac Reverse Remodeling in MCS: State of the Art](#)

[SUNRISE SYMPOSIUM 11: The Mission IS Possible If You Choose to Accept it...Performing Research](#)

[SUNRISE SYMPOSIUM 12: A Bloody Mess: Management of Hematologic Complications in Tx and MCS](#)

[PLENARY SESSION](#)

[SESSION 51 \(ORAL\): Cardiac Allograft Vasculopathy: A Never-ending Story](#)

[SESSION 52: JOINT ISHLT/SCMR SYMPOSIUM: Cardiac MRI and the World of Heart Failure](#)

[SESSION 53 \(ORAL\): Chasing the Golden Snitch: Optimizing Outcomes of MCS Infections](#)

[SESSION 54 \(ORAL\): Swipe Right or Swipe Left? Matching Donors and Recipients in LTX](#)

[SESSION 55 \(ORAL\): Score Now - Or Forever Hold Your Peace: Prediction and Risk in MCS](#)

[SESSION 56: JOINT ISHLT/IPTA SYMPOSIUM](#)

[SESSION 57 \(SYMPOSIUM\): Take These Broken Lungs and Learn to Fly: Great Debates ... PAH](#)

[SESSION 58 \(SYMPOSIUM\): Resilience in the Face of Calamity: The Art of Preventing PTE Disasters](#)

[SESSION 59 \(ORAL\): Heart Transplant Short-Term Outcomes: Getting it Right From the Start](#)

[SESSION 60: JOINT ISHLT/ABTO SYMPOSIUM](#)

[SESSION 61 \(SYMPOSIUM\): Making Them Count: Enhancing Lung Donor Utilization](#)

[SESSION 62 \(ORAL\): Under New Management: Novel Strategies for MCS](#)

[SESSION 63: JOINT ISHLT/ICCAC SYMPOSIUM](#)

[SESSION 64 \(ORAL\): Highlights of Challenging Topics in Pediatric Heart Transplant and MCS](#)

[SESSION 65 \(SYMPOSIUM\): All Talk, No Action? New Strategies ... Donor Heart Utilization](#)

[SESSION 66 \(ORAL\): Between the Devil and the Deep Blue Sea: Fungus or CMV?](#)

[SESSION 67 \(ORAL\): Diagnostics and Immunosuppression in Lung Transplantation](#)

[SESSION 68 \(ORAL\): LV Recovery after MCS: From Promise to Reality?](#)

[SESSION 69 \(ORAL\): Tricks of the Trade: Management Considerations with Continuous Flow LVADs](#)

[SESSION 70 \(SYMPOSIUM\): Matters of Life and Death: Palliative and End of Life Care in Tx Medicine](#)

[SESSION 71 \(SYMPOSIUM\): Breaking Bad: The RV and Exercise Hemodynamics Rediscovered](#)

[MINI ORAL 13: Cardiac Donors and Recipients: Valuable Insights](#)

[MINI ORAL 14: Unique Considerations for Special Heart Transplant Populations](#)

[MINI ORAL 15 A&B: Infectious Diseases and Basic Science](#)

[MINI ORAL 16: Lung Transplant Outcomes](#)

[MINI ORAL 17: MCS: Right Heart Failure](#)

[MINI ORAL 18: LVAD Physiology: Effects on End Organs](#)

**POSTER SESSION 3:**

[Heart Failure/Transplantation \(Adult\)](#)

[Lung Failure/Transplantation \(Adult\)](#)

[Mechanical Circulatory Support \(Adult\)](#)

[Pediatrics](#)

[Pulmonary Hypertension and CTEPH](#)

**SATURDAY, APRIL 6, 2019**

[SUNRISE SYMPOSIUM 13: How Can We Compare Interventional Therapies in CTEPH?](#)

[SUNRISE SYMPOSIUM 14: One Size Does Not Fit All: Personalized Medicine in Heart Transplantation](#)

[SUNRISE SYMPOSIUM 15: Lung Transplant Candidate Selection: Challenging Cases](#)

[SUNRISE SYMPOSIUM 16: Fragility: Not Necessarily Failure](#)

[SUNRISE SYMPOSIUM 17: A Brand-New Day: The New Normal in Pediatric Thoracic Transplantation](#)

[SUNRISE SYMPOSIUM 18: So Your Patient is on ECMO ... Now What?](#)

[PLENARY SESSION](#)

[SESSION 72 \(SYMPOSIUM\): Seeing the Light: Antibodies in Thoracic Transplantation](#)

[SESSION 73 \(ORAL\): Life on the Cutting Edge: CTEPH and Surgical Management of PH](#)

[SESSION 74 \(ORAL\): Frontiers of Cost-Efficacy and Policy in Transplant and MCS](#)

[SESSION 75 \(SYMPOSIUM\): Cardiac Allograft Vasculopathy: Have Hope, Ye Who Enter](#)

[SESSION 76 \(SYMPOSIUM\): Location, Location, and Allocation: Worldwide ... LTX](#)

[SESSION 77 \(ORAL\): Thicker than Water? Bleeding and LVADs](#)

[SESSION 78 \(ORAL\): The Beginning of the End in Lung Transplantation: PGD, AMR and CLAD](#)

[SESSION 79 \(ORAL\): Go with the Flow: Hemodynamic Guiding Therapies in Heart Failure](#)

[SESSION 80 \(ORAL\): Heart Transplant Long-Term Outcomes: In It for the Long Haul](#)

[SESSION 81 \(ORAL\): Primary Graft Dysfunction and Acute Lung Rejection](#)

[SESSION 82 \(ORAL\): Donor Lung Management: Can We Do Better?](#)

[SESSION 83 \(ORAL\): What's Holding Me Back? Exercise in LVAD Patients](#)

#### **POSTER MAPS:**

[Poster Session 1, Wednesday](#) (Banda Sea 1&2, Gardenia 1&2, Hibiscus 1&2, Timor Sea 1&2)

[Poster Session 2, Thursday](#) (Banda Sea 1&2, Gardenia 2, Hibiscus 1&2, Timor Sea 1&2)

[Poster Session 3, Friday](#) (Banda Sea 1&2, Gardenia 2, Hibiscus 1&2, Timor Sea 1&2)

#### **ISHLT ACADEMIES:**

[CORE COMPETENCIES IN NURSING, HEALTH SCIENCES AND ALLIED HEALTH: Care of Patients Requiring Mechanical Circulatory Support and Transplantation](#)

[CORE COMPETENCIES IN PEDIATRIC HEART FAILURE](#)

[MASTER CLASS IN HEART FAILURE AND TRANSPLANTATION](#)

[MASTER CLASS IN MECHANICAL CIRCULATORY SUPPORT](#)

#### [AFFILIATE EVENTS](#)

[CORPORATE EVENTS AND INDUSTRY THEATER LISTINGS](#)

[EXHIBIT HALL FLOOR PLAN](#)

[2019 EXHIBITORS AND BOOTH NUMBERS](#)

[2019 EXHIBITOR PRODUCT DESCRIPTIONS](#)

[FUTURE ANNUAL MEETINGS](#)



## ABOUT ISHLT

The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit, multidisciplinary, professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support, and innovative therapies via research, education, and advocacy.

ISHLT was created in 1981 at a small gathering of about 15 cardiologists and cardiac surgeons. Today we have over 3800 members from over 45 countries, representing over 15 different professional disciplines involved in the management and treatment of end-stage heart and lung disease. This multinational, multidisciplinary mix is one of the biggest strengths of the Society. It brings greater breadth and depth to our educational offerings and provides an exceptional environment for networking and exchanging information on an informal basis.

Our members include anesthesiologists, basic scientists, cardiologists, cardiothoracic surgeons, ethicists, immunologists, nurses, pathologists, perfusionists, pharmacists, pulmonologists, tissue engineers, transplant coordinators, and infectious disease specialists. Despite their differing specializations, all ISHLT members share a common dedication to the advancement of the science and treatment of end-stage heart and lung disease.

The purposes of the Society are:

1. Promoting the association of persons interested in the fields of heart and lung transplantation, end-stage heart and lung disease and related sciences;
2. Encouraging and stimulating basic and clinical research in heart and lung transplantation and end-stage heart and lung disease, and promoting new therapeutic strategies;
3. Holding scientific meetings featuring presentations and discussions relevant to heart and lung transplantation and the treatment of end-stage heart and lung disease;
4. Sponsoring a scientific journal for the publication of manuscripts related to these disciplines;
5. Maintaining an international registry for heart and lung transplantation;
6. Awarding research grants and establishing endowments for the study of heart and lung transplantation and end-stage heart and lung disease, when funds are available and without jeopardizing the financial well-being of the organization; and
7. Sponsoring and conducting educational activities and providing educational resources, which promote expert development and improve standards of care in advance heart and lung disease, heart and lung transplantation, and relevant medical and device therapies.

## **2018-2019 BOARD OF DIRECTORS**

Jeffrey J. Teuteberg, MD, President  
Stuart Sweet, MD, PhD, President-Elect  
Andrew J. Fisher, FRCP, PhD, Past President  
Raymond Benza, MD, Treasurer  
Jason D. Christie, MD, Secretary  
Kevin Chan, MD, Director  
Jennifer Cowger, MD, MS, Director  
Teresa De Marco, MD, FACC, Director  
Goran Dellgren, MD, PhD, Director  
Howard J. Eisen, MD, Director  
Stephan M. Ensminger, MD, DPhil, Director  
Martin Goddard, FRCS, MRCPa, Director  
Kathleen Grady, PhD, RN, FAAN, Director  
Manreet Kanwar, MD, Director  
Michael Shullo, PharmD, Director  
Dirk Van Raemdonck, MD, PhD, Director

## **ISHLT STAFF**

Amanda W. Rowe, Executive Director  
Christy Norcross, Interim Senior Director of Meetings  
Lisa Edwards, Director of Meetings  
Lee Ann Mills, Director of Finance and Operations  
Nancy Mays, Director of Communications  
Jenny Clark, Director of Continuing Medical Education  
Susie Newton, Programs and Services Manager  
Megan Barrett, Programs and Services Assistant  
Justin Hickman, Finance and Operations Assistant  
Phyllis Glenn, Administrative Assistant

14673 Midway Road, Suite 200  
Addison, TX 75001  
Phone: 972-490-9495  
Fax: 972-490-9499  
[www.ishlt.org](http://www.ishlt.org)

## 2019 ANNUAL SCIENTIFIC PROGRAM COMMITTEE

### ◆Symposium Planning Committee

### ☆Abstract Selection Committee

### ●Liaison

\*\*All Program Committee Members also served as Abstract Reviewers

Lara Danziger-Isakov, MD, MPH, ISHLT 2019 Scientific Program Chair, Cincinnati Children's Hospital, Cincinnati, OH, USA◆☆

Jeff Teuteberg, MD, ISHLT President, Stanford University, Stanford, CA, USA◆☆

Christian Benden, MD FCCP, ISHLT 2018 Scientific Program Chair, University Hospital Zurich, Zurich, Switzerland◆☆

Stephan Ensminger, MD, DPhil, ISHLT 2020 Scientific Program Chair, University of Lübeck, Lübeck, Germany◆☆

Clemens Aigner, MD, University of Essen, Essen, Germany☆

Annalisa Angelini, MD, University of Padua, Padova, Italy◆☆●

Pavan Atluri, MD, University of Pennsylvania, Philadelphia, PA, USA☆

Estela Azeka, PhD, Heart Institute (InCor) University of São Paulo Medical School, Sao Paulo, Brazil☆

Lavanya Bellumkonda, MD, Yale University, New Haven, CT, USA☆

Ryan Butts, MD, UT Southwestern Medical Center, Dallas, TX, USA☆●

Stephen Clark, MD, Freeman Hospital, Newcastle Upon Tyne, UK◆☆

Monica Colvin, MD, University of Michigan, Ann Arbor, MI, USA☆

Melissa Cousino, PhD, C.S. Mott Children's Hospital, Ann Arbor, MI, USA◆☆

Rachel Crackett, MSc, Freeman Hospital, Newcastle Upon Tyne, UK◆☆●

Marcelo Cypel, MD, Toronto General Hospital, Toronto, ON, Canada◆☆

Todd Dardas, MD, University of Washington, Seattle, WA, USA☆●

Kyle Dawson, PharmD, BCPS, University of Kentucky, Lexington, KY, USA◆☆●

Teresa De Marco, MD, UCSF Medical Center, San Francisco, CA, USA◆☆

Eugene DePasquale, MD, UCLA Medical Center, Los Angeles, CA, USA☆

Mary Amanda Dew, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA☆

Elie Fadel, MD, Hospital Marie Lannelongue, Le Plessis Robinson, France◆☆●

Patricia Ging, PharmD, Mater Misericordiae, Dublin, Ireland◆☆

Jose Gonzalez-Costello, MD, Belvitge Hospital, Barcelona, Spain☆

Ed Horn, PharmD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA☆

Ulrich Jorde, MD, Montefiore Medical Center, Bronx, NY, USA◆☆●

Mary Keebler, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA☆

Feras Khaliel, MD, PhD, King Faisal Specialist Hospital, Riyadh, Saudi Arabia☆

Kiran Khush, MD, MAS, Stanford University, Stanford, CA, USA◆☆●

Hanneke Kwakkel van Erp, MD, PhD, UMC Utrecht, Utrecht, Netherlands☆

Erika Lease, MD, University of Washington, Seattle, WA, USA☆

Angela Lorts, MD, Cincinnati Children's Hospital, Cincinnati, OH, USA◆☆●

Monique Malouf, FRACP, St. Vincent's Hospital, Sydney, Australia◆☆●

Jiri Maly, MD, PhD, Institute for Clinical and Experimental Medicine, Prague, Czech Republic☆

Mandeep Mehra, MD, MBBS, FACC, FACP, Brigham and Women's Hosp, Harvard Med School, Boston, MA, USA◆☆

Anna L. Meyer, PD, Leipzig Heart Center, Leipzig, Germany◆☆

Orla Morrissey, MD, Alfred Hospital, Melbourne, Australia◆☆●

Ivan Netuka, MD, PhD, Institute for Clinical and Experimental Medicine, Prague, Czech Republic◆☆

Isabelle Opitz, MD, University Hospital Zurich, Zurich, Switzerland☆

Simon Pecha, MD, University Hospital Hamburg, Hamburg, Germany◆☆

Joanna Pepke-Zaba, MD, Papworth Hospital, Papworth Everard, UK◆☆

Stephanie Pouch, MD, Emory University, Atlanta, GA, USA☆

Anja Roden, MD, Mayo Clinic, Rochester, MN, USA◆☆

Jorge Silva Enciso, MD, UCSD Medical Center, San Diego, CA, USA ☆ ●  
Fernanda Silveira, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA ◆ ☆  
Marc Simon, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA ◆ ☆ ●  
Jon Singer, MD, MS, UCSF Medical Center, San Francisco, CA, USA ◆ ☆  
Jacqueline Smits, PhD, Eurotransplant International, Leiden, Netherlands ☆  
Laurie Snyder, MD, Duke University Medical Center, Durham, NC, USA ◆ ☆  
Melinda Solomon, MD, FRCPC, Hospital for Sick Children, Toronto, ON, Canada ◆ ☆  
Thenappan Thenappan, MD, University of Minnesota, Minneapolis, MN, USA ◆ ☆  
Stijn Verleden, MD, PhD, KU Leuven, Leuven, Belgium ◆ ☆ ●  
Tomasz Zielinski, MD, Institute of Cardiology, Warsaw, Poland ☆

## 2019 ABSTRACT REVIEWERS

David Abelson, FRACP, MD, St Vincent's Hospital, Sydney, Australia  
Linda Addonizio, MD, Columbia University College of Physicians and Surgeons, New York, NY, USA  
Mustafa Ahmed, MD, University of Florida, Gainesville, FL, USA  
Philipp Aigner, MSc, Medical University of Vienna, Vienna, Austria  
Natasha Aleksova, MD, University of Toronto, Toronto, ON, Canada  
Peta Alexander, MBBS, Boston Children's Hospital, Boston, MA, USA  
Tamas Alexy, MD, PhD, University of Minnesota, Minneapolis, MN, USA  
Rami Alharethi, MD, Intermountain Medical Center, Murray, UT, USA  
Arezu Aliabadi-Zuckermann, MD, PhD, Medical University of Vienna, Vienna, Austria  
Larry Allen, MD, University of Colorado, Denver, CO, USA  
Christopher Almond, MD, MPH, Stanford University, Stanford, CA, USA  
Natasha Altman, MD, University of Colorado, Denver, CO, USA  
Elvis Amao, PhD, Hospital Clínico, Valladolid, Spain  
Cristiano Amarelli, MD, Monaldi Hospital, Naples, Italy  
Amrut Ambardekar, MD, University of Colorado, Denver, CO, USA  
Antonio Amodeo, MD, Bambino Gesù Pediatric Hospital, Rome, Italy  
Samantha Anthony, PhD, The Hospital for Sick Children, Toronto, ON, Canada  
Christina Aquilante, PharmD, University of Colorado, Denver, CO, USA  
Selim Arcasoy, MD, MPH, Columbia University, New York, NY, USA  
Saima Aslam, MD, MS, UCSD Medical Center, San Diego, CA, USA  
William Auger, MD, Temple University Hospital, Philadelphia, PA, USA  
Sanjeet Singh Avtaar Singh, MRCS, MSc, Golden Jubilee National Hospital, Glasgow, UK  
Arnold Baas, MD, UCLA Medical Center, Los Angeles, CA, USA  
Roberto Badagliacca, MD, PhD, University of Rome Sapienza, Rome, Italy  
John Baddley, MD, University of Alabama at Birmingham, Birmingham, AL, USA  
Maral Bakir, RN, PHN, UCLA Medical Center, Los Angeles, CA, USA  
Carlo Banfi, MD, PhD, FCCP, University Hospital, Geneva, Switzerland  
Aliessa Barnes, MD, Children's Mercy Hospital, Kansas City, MO, USA  
Markus Barten, MD, PhD, University Heart Center Hamburg, Hamburg, Germany  
Ray Benza, MD, Allegheny General Hospital, Pittsburgh, PA, USA  
Alejandro Bertolotti, MD, Favalaro Foundation, Buenos Aires, Argentina  
Sai Kiran Bhagra, MRCP, Royal Papworth Hospital, Papworth Everard, UK  
Jay Bhamra, MD, University of Iowa Health Care, Iowa City, IA, USA  
Joshua Blatter, MD, MPH, Washington University of St. Louis, St. Louis, MO, USA  
Emily Blodget, MD, University of Southern California, Los Angeles, CA, USA  
Peggy Blood, MSN, University of Alabama at Birmingham, Birmingham, AL, USA  
Nancy Blumenthal, DNP, Hospital of the University of Pennsylvania, Philadelphia, PA, USA  
Emanuele Bobbio, MD, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden  
Entela Bollano, MD, PhD, Sahlgrenska University Hospital, Gothenburg, Sweden  
Edith Boyes, MSN, FNP-BC, Amita Health, Chicago, IL, USA  
Andrew Boyle, MD, Thomas Jefferson University, Philadelphia, PA, USA  
Michela Brambatti, MD, MS, UCSD Medical Center, San Diego, CA, USA  
Caron Burch, RN, MSN, FNP, CCTC, UCSF Benioff Children's Hospital, San Francisco, CA, USA  
Fay Burrows, BPharm (Hons), St Vincent's Hospital, Sydney, Australia  
Yasmeen Butt, MD, UT Southwestern Medical Center, Dallas, TX, USA  
Daniel Calabrese, MD, UCSF Medical Center, San Francisco, CA, USA  
Fiorella Calabrese, MD, University of Padova, Padova, Italy  
Kadir Caliskan, MD PhD, Erasmus Medical Center, Rotterdam, The Netherlands  
Paul Callan, MD (UK), Manchester Foundation Trust, Manchester, UK  
Sylvia Campos, MD, Heart Institute (InCor) University of São Paulo Medical School, Sao Paulo, Brazil  
Edward Cantu, MD, University of Pennsylvania, Philadelphia, PA, USA  
Marilia Cascalho, MD, PhD, University of Michigan, Ann Arbor, MI, USA  
Maria Angeles Castel, MD, PhD, Hospital Clinic Barcelona, Barcelona, Spain  
Javier Castrodeza, MD, Hospital Clinico Universitario Valladolid, Valladolid, Spain  
Pedro Catarino, MD, Royal Papworth Hospital, Papworth Everard, UK  
Kevin Chan, MD, University of Michigan, Ann Arbor, USA  
Wandy Chan, PhD, The Prince Charles Hospital, Brisbane, Australia  
Sandra Chaparro, MD, University of Miami, Miami, FL, USA  
Leway Chen, MD, University of Rochester Medical Center, Rochester, NY, USA  
Robert J Chen, MD, MPH, Taipei Medical University Hospital, Taipei, Taiwan

Richard K Cheng, MD, University of Washington, Seattle, WA, USA  
Laveena Chhatwani, MD, MSc, Stanford University, Stanford, CA, USA  
Sharon Chih, PhD, University of Ottawa Heart Institute, Ottawa, ON, Canada  
Marcello Chinali, MD, PhD, Bambino Gesù Bambino Gesù, Rome, Italy  
Jason Christie, MD, University of Pennsylvania, Philadelphia, USA  
Colin Church, PhD, Golden Jubilee National Hospital, Glasgow, UK  
Agnieszka Ciarka, MD PhD, Catholic University of Leuven, Leuven, Belgium  
Brian Clarke, MD, Foothills Medical Centre, University of Calgary, Calgary, AB, Canada  
Adam Cochrane, PharmD, MPH, Inova Fairfax Hospital, Falls Church, VA, USA  
Erin Coglianesi, MD, Massachusetts General Hospital, Boston, MA, USA  
Rebecca Cogswell, MD, University of Minnesota, Minneapolis, MN, USA  
Robert Cole, MD, Emory University, Atlanta, GA, USA  
Stephane Collaud, MD, Lyon University Hospital, Lyon, France  
Paolo Colombo, MD, Columbia University Medical Center, New York, NY, USA  
Pamela Combs, PhD, University of Chicago, Chicago, IL, USA  
Carol Conrad, MD, Stanford Children's Health, Stanford, CA, USA  
Hannah Copeland, MD, University of Mississippi Medical Center, Jackson, MS, USA  
Andrew Courtwright, MD, PhD, Hospital of the University of Pennsylvania, Philadelphia, PA, USA  
Jennifer Cowger, MD, Henry Ford Hospital, Detroit, MI, USA  
Marisa Crespo-Leiro, PhD, Hospital Universitario A Coruña, La Coruna, Spain  
David Crossland, MRCPCH, Freeman Hospital, Newcastle Upon Tyne, UK  
Chentel Cunningham, NP, Stollery Children's Hospital, Edmonton, AB, Canada  
Jonathan Dalzell, MD, Golden Jubilee National Hospital, Glasgow, UK  
Jonathan DCunha, MD PhD, University of Pittsburgh, Pittsburgh, PA, USA  
Marc De Perrot, MD, Toronto General Hospital, Toronto, ON, Canada  
Göran Dellgren, MD, PhD, Sahlgrenska Univ Hospital, Gothenburg University, Gothenburg, Sweden  
Josh Diamond, MD, University of Pennsylvania, Philadelphia, PA, USA  
Daniel Dilling, MD, Loyola University Stritch School of Medicine, Maywood, IL, USA  
Ioannis Dimarakis, PhD, Manchester Foundation Trust, Manchester, UK  
Karen Doucette, MD, University of Alberta, Edmonton, AB, Canada  
Anique Ducharme, MD, MSc, Montreal Heart Institute, Montreal, QC, Canada  
Ignacio Echenique, MD, Cleveland Clinic Florida, Weston, FL, USA  
Peter Eckman, MD, Minneapolis Heart Institute, Minneapolis, MN, USA  
Howard Eisen, MD, Pennsylvania State College of Medicine, Hershey, PA, USA  
Sitaramesh Emani, MD, The Ohio State University Wexner Medical Center, Columbus, OH, USA  
Amir Emtiazjoo, MD, University of Florida, Gainesville, FL, USA  
John Entwistle III, MD PhD, Thomas Jefferson University, Philadelphia, PA, USA  
Eric Epailly, MD, Les Hopitaux University, Strasbourg, France  
Flavio Epstein, PhD, Kaiser Permanente Northern California, San Francisco, CA, USA  
Michiel Erasmus, MD, PhD, Academic Medical Center Groningen, Groningen, The Netherlands  
Jerry Estep, MD, Cleveland Clinic, Cleveland, OH, USA  
Melanie Everitt, MD, Children's Hospital Colorado, Aurora, CO, USA  
MaryJane Farr, MD, Columbia University, New York, NY, USA  
Marta Farrero, MD, PhD, Hospital Clinic Barcelona, Barcelona, Spain  
Brian Feingold, MD, MS, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA  
Andrew Fisher, MD, Freeman Hospital, Newcastle Upon Tyne, UK  
Stephen Forest, MD, Montefiore Medical Center, Bronx, NY, USA  
Meg Fregoso, MSN, Inova Fairfax Hospital, Falls Church, VA, USA  
Joshua Friedland-Little, M.D., Seattle Children's Hospital, Seattle, WA, USA  
Maria Frigerio, MD, Prof, Niguarda Hospital, Milan, Italy  
Louise Fuller, PhD, The Alfred Hospital, Melbourne, Australia  
Billie Fyfe-Kirschner, MD, Rutgers Robert Wood Johnson Medical School and Newark Beth Israel Medical Center, Newark, NJ, USA  
Andrew Gelman, MD, Washington University, St. Louis, MO, USA  
Andrea Giacomini, MD, San Raffaele University Hospital, Milan, Italy  
Nisha Gilotra, MD, Johns Hopkins, Baltimore, MD, USA  
Mahazarin Ginwalla, MD, University Hospitals Cleveland Medical Center, Cleveland, OH, USA  
Reda Girgis, MB, BCh, Spectrum Health/Michigan State University, Grand Rapids, MI, USA  
Jason Gluck, DO, Hartford Hospital, Hartford, CT, USA  
Martin Goddard, FRCS, FRCPath, Royal Papworth Hospital, Papworth Everard, UK  
Justin Godown, MD, Vanderbilt University Medical Center, Nashville, TN, USA  
Samuel Goldfarb, MD, Children's Hospital of Philadelphia, Philadelphia, PA, USA  
Livia Goldraich, MD, MSc, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

Daniel Goldstein, MD, Montefiore Medical Center, Bronx, NY, USA  
Mardi Gombert-Maitland, MD, Inova Fairfax Hospital, Falls Church, VA, USA  
Kate Gould, MD, Freeman Hospital, Newcastle Upon Tyne, UK  
Kathleen Grady, PhD, Northwestern University, Chicago, IL, USA  
Jennifer Gray, PharmD, Vanderbilt University Medical Center, Nashville, TN, USA  
John Greenland, MD, UCSF Medical Center, San Francisco, CA, USA  
Steven Greenway, MD, University of Calgary, Calgary, AB, Canada  
Mark Greer, MD, Hannover Medical School, Hannover, Germany  
Douglas Greig, MD, Toronto General Hospital, Toronto, ON, Canada  
Bartley Griffith, MD, University of Maryland, Baltimore, MD, USA  
Paolo Grossi, MD, PhD, University of Insubria, Varese, Italy  
Ramsey Hachem, MD, Washington University in St. Louis, St. Louis, MO, USA  
Denis Hadjiladis, MD, University of Pennsylvania, Philadelphia, PA, USA  
Shelley Hall, MD, Baylor University Medical Center, Dallas, TX, USA  
Wayne Hancock, MD/PhD, Children's Hospital of Philadelphia, Philadelphia, PA, USA  
Matthew Hartwig, MD, Duke University Medical Center, Durham, NC, USA  
Christian Heim, MD PhD, University Clinic Erlangen, Erlangen, Germany  
Jaime Hernandez-Montfort, MD MPH, University of Texas Medical Branch, Galveston, TX, USA  
Donna Hickling, The Prince Charles Hospital, Brisbane, Australia  
William Hiesinger, MD, Stanford University, Stanford, CA, USA  
Are Martin Holm, MD, PhD, Oslo University Hospital, Oslo, Norway  
Robert Hooker, MD, University of South Florida, Tampa, FL, USA  
Peter Hopkins, MD, Prince Charles Hospital, Brisbane, Australia  
David Hormuth, MD, St Vincent Heart Center, Indianapolis, IN, USA  
Eileen Hsieh, MD, Cleveland Clinic, Cleveland, OH, USA  
Chih-Hsin Hsu, MD, PhD, National Cheng Kung University Hospital, Tainan, Taiwan  
David Hwang, MD, PhD, Sunnybrook Health Sciences Centre, Toronto, ON, Canada  
Claire Irving, MD (UK), MRCPC, Children's Hospital Westmead, Sydney, Australia  
Michael Ison, MD, Northwestern University, Chicago, IL, USA  
Marina Ivanovic, MD, University of Iowa, Iowa City, IA, USA  
Steve Ivulich, Pharm, Alfred Hospital, Melbourne, Australia  
Jama Jahanyar, MD, PhD, Mayo Clinic, Rochester, MN, USA  
George Javorsky, MBBS FRACP, The Prince Charles Hospital, Brisbane, Australia  
Aamir Jeewa, MB BCh, The Hospital for Sick Children, Toronto, ON, Canada  
Ranjit John, MD, University of Minnesota, Minneapolis, MN, USA  
Jonathan Johnson, MD, Mayo Clinic, Rochester, MN, USA  
Mary Johnson, MD, University of Wisconsin, Madison, WI, USA  
Sung-Ho Jung, MD, PhD, Asan Medical Center, Seoul, Republic of Korea  
Colleen Juricek-LaBuhn, RN, MSN, University of Chicago Medical Center, Chicago, IL, USA  
Manreet Kanwar, MD, Allegheny General Hospital, Pittsburgh, PA, USA  
Kristjan Karason, PhD, Sahlgrenska University Hospital, Gothenburg, Sweden  
Tomoko Kato, MD, PhD, Juntendo University School of Medicine, Showa University Koto Toyosu Hospital, Tokyo, Japan  
Shalika Katugaha, MD, Inova Fairfax Hospital, Inova Heart and Vascular Institute, Falls Church, VA, USA  
Beth Kaufman, MD, Stanford Children's Health, Stanford, CA, USA  
Pradeep Kaul, FRCS C Th, M Phil, Royal Papworth Hospital, Papworth Everard, UK  
Jamie Kennedy, MD, University of Virginia, Charlottesville, VA, USA  
Anne Keogh, MBBS PhD, St Vincent's Hospital, Sydney, Australia  
Hesam Keshmiri, DO, University of British Columbia, Vancouver, BC, Canada  
Sanjeev Kumar Khulbey, MCh, Apollo Hospital, Hyderabad, India  
Tam Khuu, PharmD, BCPS, UCLA Medical Center, Los Angeles, CA, USA  
Ahmet Kilic, MD, The Johns Hopkins Hospital, Baltimore, MD, USA  
Daniel Kim, MD, University of Alberta, Edmonton, AB, Canada  
Richard Kirk, MA, FRCP FRCPCH, Children's Medical Center, Dallas, TX, USA  
Liviu Klein, MD, MS, UCSF Medical Center, San Francisco, CA, USA  
Walter Klepetko, MD, Medical University of Vienna, Vienna, Austria  
Ivan Knezevic, MD, PhD, University Medical Centre, Ljubljana, Slovenia  
Christoph Knosalla, MD, PHD, German Heart Center, Berlin, Germany  
Christine Koval, MD, Cleveland Clinic, Cleveland, OH, USA  
Evan Kransdorf, MD, PhD, Cedars-Sinai Heart Institute, Los Angeles, CA, USA  
Daniel Kreisel, MD, Washington University, St. Louis, MO, USA  
Jamila Kremer, MD, University Hospital Heidelberg, Heidelberg, Germany  
Bartosz Kubisa, Prof., Pomeranian Medical University of Szczecin, Szczecin, Poland

Christiane Kugler, PhD, University of Freiburg, Freiburg, Germany  
Ashwin Lal, MD, Primary Children's Hospital, University of Utah, Salt Lake City, UT, USA  
Harveen Lamba, MD, Baylor College of Medicine / Texas Heart Institute, Houston, TX, USA  
Brent Lampert, DO, Ohio State University Medical Center, Columbus, OH, USA  
Brandon Larsen, MD, PhD, Mayo Clinic Arizona, Phoenix, AZ, USA  
Lorriana Leard, MD, UCSF Medical Center, San Francisco, CA, USA  
Hye Won Lee, PhD, Pusan National University Hospital, Seoul, Republic of Korea  
James Lee, MD, University of Pennsylvania, Philadelphia, PA, USA  
Anthony Lemaire, MD, Rutgers Robert Wood Johnson Medical School, Princeton, NJ, USA  
Karl Lemstrom, MD, PhD, University of Helsinki, Helsinki, Finland  
Deborah Levine, MD, University of Texas Health Science Center, San Antonio, TX, USA  
Bronwyn Levvey, RN, Grad Dip Clin Ep, The Alfred Hospital, Melbourne, Australia  
Clive Lewis, MA MD PhD, Royal Papworth Hospital, Papworth Everard, UK  
Sern Lim, MD, University Hospital Birmingham NHS Trust, Birmingham, UK  
Kimberly Lin, MD, Children's Hospital of Philadelphia, Philadelphia, PA, USA  
Antonio Loforte, MD, PhD, S. Orsola Hospital, Bologna University, Bologna, Italy  
Brian Lowes, MD, PhD, University of Nebraska, Omaha, NE, USA  
Me-Linh Luong, MD, St. Luc Hospital, Montreal, QC, Canada  
Haifa Lyster, MSc, Royal Brompton & Harefield NHS Foundation Trust, Middlesex, UK  
Peter Macdonald, MD, PhD, St Vincent's Hospital, Sydney, Australia  
Michael Madani, MD, UCSD Medical Center, San Diego, CA, USA  
Pradeep Mammen, MD, UT Southwestern Medical Center, Dallas, TX, USA  
Erin Mancl, PharmD, Loyola University Medical Center, Maywood, IL, USA  
Daniel Marelli, MD, MSC, Bayhealth/University of Pennsylvania, Philadelphia, PA, USA  
Tereza Martinu, MD, University of Toronto, Toronto, ON, Canada  
Marco Masetti, MD, University of Bologna, Bologna, Italy  
Sofia Carolina Masri, MD, University of Washington, Seattle, WA, USA  
Paul Mather, MD, University of Pennsylvania, Philadelphia, PA, USA  
Jeremy Mazurek, MD, University of Pennsylvania, Philadelphia, PA, USA  
David McGiffin, MB,BS, Alfred Hospital, Melbourne, Australia  
Colleen McIlvennan, DNP, University of Colorado, Denver, CO, USA  
Hirsch Mehta, MD, San Diego Cardiac Center, San Diego, CA, USA  
Bruno Meiser, MD, PhD, University of Munich Transplant Center, Munich, Germany  
Ahmed Menaouar, PhD, CRCHUM Université de Montréal, Montreal, QC, Canada  
Christopher Michaud, PharmD, Spectrum Health, Grand Rapids, MI, USA  
Sebastian Michel, MD, Ludwig Maximilian University, Munich, Germany  
Oliver Miera, MD, German Heart Center, Berlin, Germany  
Robert Miller, MD, Cedars-Sinai Heart Institute, Los Angeles, CA, USA  
Yasbanoo Moayedi, MD, University of Toronto, Toronto, ON, Canada  
Nader Moazami, MD, NYU Langone Health, New York, NY, USA  
asim Mohammed, MD, Medical College of Wisconsin, Milwaukee, WI, USA  
Joshua Mooney, MD, Stanford University, Stanford, CA, USA  
David Morales, MD, Cincinnati Childrens Hospital, Cincinnati, OH, USA  
Paola Morejon, MD, Fundación Favaloro, Buenos Aires, Argentina  
Letizia Corinna Morlacchi, PhD, Fondazione IRCCS Ca' Granda, Milan, Italy  
Alanna Morris, MD, MSc, Emory University, Atlanta, GA, USA  
Margaret Murray, DNP, University of Wisconsin Hospital and Clinics, Madison, WI, USA  
Kavitha Muthiah, PhD, St Vincents Hospital, Sydney, Australia  
Emil Najjar, MD, Karolinska University Hospital, Stockholm, Sweden  
Samer Najjar, MD, MedStar Washington Hospital Center, Washington, DC, USA  
Sanem Nalbantgil, MD, Ege University Medical School, Izmir, Turkey  
Deipanjan Nandi, MD, Nationwide Children's Hospital, Columbus, OH, USA  
Desley Neil, FRCPath, Queen Elizabeth Hospital, Birmingham, UK  
Minoru Ono, MD, PhD, The University of Tokyo, Tokyo, Japan  
Robert Padera, MD, PhD, Brigham & Women's Hospital, Boston, MA, USA  
Francis Pagani, MD, PhD, University of Michigan, Ann Arbor, MI, USA  
Maryse Palardy, MD, University of Michigan, Ann Arbor, MI, USA  
Francesco Parisi, MD, Ospedale Pediatrico Bambino Gesù, Rome, Italy  
Amit Parulekar, MD, Baylor College of Medicine, Houston, TX, USA  
Jignesh Patel, MD PhD, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, USA  
Caroline Patterson, MD, Royal Papworth Hospital, Papworth Everard, UK  
Daniel Pauly, MD, PhD, University of Missouri, Kansas City, MO, USA



Elizabeth Pavlisko, MD, Duke University, Durham, NC, USA  
Yael Peled, MD, Sheba Medical Center, Tel Hashomer, Israel  
David Peng, MD, University of Michigan, Ann Arbor, MI, USA  
Margarita Peradejordi, MD, Universidad Abierta Interamericana / Hospital El Cruce, Buenos Aires, Argentina  
Paul Perry, MD, University of California Davis, Sacramento, CA, USA  
Michael Pham, MD, MPH, California Pacific Medical Center, San Francisco, CA, USA  
Sean Pinney, MD, Mount Sinai Hospital, New York, NY, USA  
Barbara Pisani, DO, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA  
Christophe Pison, MD, PhD, Université de Grenoble, Grenoble, France  
Michelle Ploutz, MD MPH, Phoenix Children's Hospital, Phoenix, AZ, USA  
Gregor Poglajen, MD, PhD, University Medical Center, Ljubljana, Slovenia  
Luciano Potena, MD, PhD, University of Bologna, Bologna, Italy  
Ioana Preston, MD, Tufts University, Boston, MA, USA  
Ann Punnoose, MD, Children's Hospital of Wisconsin, Milwaukee, WI, USA  
Adam Putschoegl, DO, Children's Hospital Colorado, Aurora, CO, USA  
Rajalingam Raja, PhD, UCSF Medical Center, San Francisco, CA, USA  
Sanjeev Raman, MD, University of Utah Lung Transplant Program, Salt Lake City, UT, USA  
Bhavadarini Ramu, MBBS, Medical University of South Carolina, Charleston, SC, USA  
Doris Rassel, FRCPath, Royal Papworth Hospital, Papworth Everard, UK  
Ravikumar Ratnagiri, MD, Gleneagles Global Hospital, Chennai, India  
Zdenka Reinhardt, MD, Freeman Hospital, Newcastle Upon Tyne, UK  
Nosheen Reza, MD, Hospital of the University of Pennsylvania, Philadelphia, PA, USA  
Cecile Robinson, MD, University Hospital Zurich, Zurich, Switzerland  
Nicola Robinson Smith, MSc, Freeman Hospital, Newcastle Upon Tyne, UK  
Desiree Robson, RN, St Vincent's Hospital, Sydney, Australia  
Eulalia Roig, PhD, Hospital Sant Pau, Barcelona, Spain  
David Rosenthal, MD, Stanford Children's Health, Stanford, CA, USA  
Joseph Rossano, MD, Children's Hospital of Philadelphia, Philadelphia, PA, USA  
Victor Rossel, MD, National Thorax Institute, Santiago, Chile  
Ana Roussoulieries, MD, PhD, Erasme Academic Hospital, Free University of Brussels, Brussels, Belgium  
Stuart Russell, MD, Duke University, Durham, NC, USA  
Diyar Saeed, MD, PhD, Düsseldorf University Hospital, Dusseldorf, Germany  
Yoshikatsu Saiki, MD, PhD, Tohoku University Graduate School of Medicine, Sendai, Japan  
Christopher Salerno, MD, St Vincent Heart Center of Indiana, Indianapolis, IN, USA  
Pablo Sanchez, MD, University of Pittsburgh, Pittsburgh, PA, USA  
Elena Sandoval, MEBCTS, Hospital Clinic, Barcelona, Spain  
Laurent Savale, MD, Hospital Bicetre, Bicetre, France  
Gabriel Sayer, MD, University of Chicago, Chicago, IL, USA  
Joanna Schaanman, MD, PhD, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA  
Marc Schecter, MD, Cincinnati Children's Hospital, Cincinnati, OH, USA  
Sarah Schettle, PA-C, Mayo Clinic, Rochester, MN, USA  
David Schibilsky, MD, University Heart Center Freiburg / Bad Krozingen, Freiburg, Germany  
Thomas Schlöglhofer, BSc, Medical University of Vienna, Vienna, Austria  
Bastian Schmack, MD, University Hospital Heidelberg, Heidelberg, Germany  
Christof Schmid, MD, University Medical Center, Regensburg, Germany  
Jan Schmitto, MD, PhD, Hannover Medical School, Hannover, Germany  
Martin Schweiger, MD, Children's Hospital, Zurich, Switzerland  
Andrew Shaffer, MD, University of Minnesota, Minneapolis, MN, USA  
Keyur Shah, MD, Virginia Commonwealth University, Richmond, VA, USA  
Palak Shah, MD, MS, Inova Heart and Vascular Institute, Falls Church, VA, USA  
Pali Shah, MD, Johns Hopkins, Baltimore, MD, USA  
Ciara Shaver, MD, PhD, Vanderbilt University Medical Center, Nashville, TN, USA  
Akira Shimamoto, MD, PhD, Mie University Graduate School of Medicine, Tsu, Japan  
Supriya Shore, MBBS, University of Michigan, Ann Arbor, MI, USA  
Michael Shullo, PharmD, West Virginia University Medicine, Morgantown, WV, USA  
Sara Shumway, MD, University of Minnesota, Minneapolis, MN, USA  
Scott Silvestry, MD, Florida Hospital, Orlando, FL, USA  
Steve Singh, MD, MSc, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA  
Nikolaos Skartsis, MD PhD, UCSF Medical Center, San Francisco, CA, USA  
Alexis Slama, MD, Universitätsklinikum Essen, Essen, Germany  
Natalia Smirnova, PhD, University of Colorado, Denver, CO, USA  
Greg Snell, MD, Alfred Hospital, Melbourne, Australia

Stefan Söderberg, PhD, Umeå University, Umea, Sweden  
George Sokos, DO, West Virginia University, Morgantown, WV, USA  
Amparo Sole, MD, Hospital Universitario la Fe, Valencia, Spain  
Wiebke Sommer, MD, Hannover Medical School, Hannover, Germany  
Tae Song, MD, University of Chicago, Chicago, IL, USA  
Josef Stehlik, MD, University of Utah, Salt Lake City, UT, USA  
Stuart Sweet, MD, PhD, St. Louis Children's Hospital, St. Louis, MO, USA  
Laneshia Tague, MD, Washington University in Saint Louis, St. Louis, MO, USA  
Benjamin Tarrant, B.Physio, Alfred Health, Melbourne, Australia  
Mitesh Thakrar, MD, University of Calgary, Calgary, BC, Canada  
Jamie Todd, MD, Duke University, Durham, NC, USA  
Mustafa Toma, MD, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada  
Van-Khue Ton, MD PhD, University of Maryland, Baltimore, MD, USA  
Adriana Torres, MD, Fundacion Cardioinfantil, Bogota, Colombia  
Yoshiya Toyoda, MD, PhD, Temple University Hospital, Philadelphia, PA, USA  
Jaimin Trivedi, MBBS, University of Louisville, Louisville, KY, USA  
Izabella Uchmanowicz, RN, PhD, Wroclaw Medical University, Wroclaw, Poland  
Marian Urban, MD, PhD, University of Nebraska Medical Center, Omaha, NE, USA  
Nir Uriel, MD, University of Chicago, Chicago, IL, USA  
Simon Urschel, MD, University of Alberta, Edmonton, AB, Canada  
Jean-Luc Vachier, MD, Erasme University Hospital, Brussels, Belgium  
Daniel Valdivia, MD, PhD, Ruhrlandklinik, Essen, Germany  
Cassandra Vale, BPharm, GradCert, The Prince Charles Hospital, Brisbane, Australia  
Vincent Valentine, MD, University of Alabama at Birmingham, Birmingham, AL, USA  
Nicole Valenzuela, PhD, D(ABHI), UCLA Immunogenetics, Los Angeles, CA, USA  
Caroline Van de Wauwer, MD, PhD, University of Groningen, Groningen, Netherlands  
Dirk Van Raemdonck, MD, PHD, University Hospitals Leuven, Leuven, Belgium  
Bart Vanaudenaerde, PhD, KU Leuven, Leuven, Belgium  
Nikolay Vasilyev, MD, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA  
Tara Veasey, PharmD, University Florida Health Shands, Gainesville, FL, USA  
Angela Velleca, RN, BSN, CCTC, Cedars-Sinai Heart Institute, Los Angeles, CA, USA  
Erik Verschuuren, MD, PhD, University Medical Centre Groningen, Groningen, Netherlands  
Amanda Vest, MBBS, Tufts Medical Center, Boston, MA, USA  
Jan von der Thüsen, MD PhD, Erasmus Medical Center, Rotterdam, Netherlands  
Robin Vos, PhD, MD, University Hospitals Leuven, Leuven, Belgium  
Georgina Waldman, PharmD, Massachusetts General Hospital, Boston, MA, USA  
Andre Wasler, MD, Medical University of Graz, Graz, Austria  
Tatsuaki Watanabe, MD, PhD, University Health Network, Toronto, ON, Canada  
Robert Weintraub, MBBS, Royal Children's Hospital, Melbourne, Australia  
Glen Westall, FRACP, PhD, Alfred Hospital, Melbourne, Australia  
Allyson Wexler, PharmD, University of North Carolina Medical Center, Chapel Hill, NC, USA  
Helen Whitford, MBBS, The Alfred Hospital, Melbourne, Australia  
Bryan Whitson, MD, PhD, The Ohio State University, Columbus, OH, USA  
Georg Wieselthaler, MD, UCSF Medical Center, San Francisco, CA, USA  
Mark Wigger, MD, Vanderbilt Medical Center, Nashville, TN, USA  
Markus Wilhelm, MD, University Hospital Zurich, Zurich, Switzerland  
Cameron Wolfe, MBBS, MPH, Duke University Medical Center, Durham, NC, USA  
Tahir Yagdi, MD, Ege University Faculty of Medicine, Izmir, Turkey  
Yoshito Yamada, MD, PhD, Chiba University Hospital, Kyoto, Japan  
Amin Yehya, MD, MS, Piedmont Heart Institute, Atlanta, GA, USA  
Stephanie Yerkovich, PhD, The University of Queensland, Brisbane, Australia  
Jong-Chan Youn, MD, PhD, Hallym University, Chuncheon, Gangwon, Republic of Korea  
Farhan Zafar, MD, Cincinnati Children's Hospital, Cincinnati, OH, USA  
Martin Zamora, MD, University of Colorado, Denver, CO, USA  
Rashad Zayat, MD, RWTH University Hospital Aachen, Aachen, Germany  
Warren Zuckerman, MD, Columbia University Medical Center, New York, NY, USA  
Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria

## **ISHLT COMMITTEE ROSTERS** (Parentheses indicate year rotating off committee)

### **EDUCATION COMMITTEE**

To Be Determined

### **FINANCE COMMITTEE**

Raymond Benza, MD, Chair (2019)  
Stuart Sweet, MD, PhD, President-Elect (2020)  
Howard Eisen, MD, At Large Member (2021)  
Shaf Keshavjee, MD, FRCSC, At Large Member (2020)  
Scott Silvestry, MD, At Large Member (2019)  
Jeffrey Teuteberg, MD, President (2019)  
Amanda Rowe, ISHLT Executive Director  
Lee Ann Mills, ISHLT Director of Finance

### **GOVERNANCE COMMITTEE**

Andrew Fisher, FRCP, PhD, Chair (2019)  
Jeffrey Teuteberg, MD, ISHLT President (2020)  
Stuart Sweet, MD, PhD, ISHLT President-Elect (2021)  
Christian Benden, MD, FCCP, At Large Member (2021)  
Lara Danziger-Isakov, MD, MPH, At Large Member (2020)  
Michael Petty, PhD, RN, CNS, At Large Member (2021)  
David Taylor, MD, At Large Member (2019)  
Amanda Rowe, ISHLT Executive Director

### **GRANTS AND AWARDS COMMITTEE**

Kathleen Grady, PhD, RN, FAAN, Chair (2020)  
Daniel Kreisel, MD, PhD, Past Chair (2019)  
Stephan Enslinger, MD, DPhil, Board of Directors Liaison (2019)  
Louise Fuller, PT, Committee Member  
Josef Stehlik, MD, MPH, Committee Member  
Megan Barrett, ISHLT Staff Liaison

### **INTERNATIONAL ENGAGEMENT COMMITTEE**

Are Martin Holm, MD, PhD, Chair (2020)  
Jeffrey Teuteberg, MD, ISHLT President (2020)  
Stuart Sweet, MD, PhD, Board of Directors Liaison (2021)  
Bart Meyns, MD, PhD, Committee Member (2019)  
Ryan Tedford, MD, Committee Member (2020)  
Mauricio Villavicencio, MD, Committee Member (2019)  
Amanda Rowe, ISHLT Executive Director

### **ISHLT MECHANICALLY ASSISTED CIRCULATORY SUPPORT (IMACS) REGISTRY STEERING COMMITTEE**

Daniel J. Goldstein, MD, Chair  
Jennifer Cowger, MD, MS, Vice Chair for Data Studies  
Andrew Fisher, FRCP, PhD, Board of Directors Liaison (2019)  
Bart Meyns, MD, PhD, Committee Member  
Takeshi Nakatani, MD, PhD, JMACS Representative  
Steve Shaw, UK Representative  
Rongbing Xie, DrPH, MPH, Biostatistician  
Amanda Rowe, ISHLT Executive Director

### **INTERNATIONAL DCD REGISTRY STEERING COMMITTEE**

Dirk Van Raemdonck, MD, PhD, Chair  
Wida Cherikh, PhD, Biostatistician  
Andrew Fisher, FRCP, PhD, Board of Directors Liaison (2019)  
Marcelo Cypel, MD, Committee Member  
Frank D'Ovidio, MD, PhD, Committee Member  
Kumud Dhital, MD, PhD, Committee Member  
Michiel Erasmus, MD, PhD, Committee Member  
Allan Glanville, MBBS, MD, FRACP, Committee Member  
Marshall Hertz, MD, Committee Member  
Peter Hopkins, FRACP, Committee Member  
Shaf Keshavjee, MD, FRCSC, Committee Member  
Stephen Large, FRCS, Committee Member  
Bronwyn Levvey, RN, Grad Dip Clin Epi, Committee Member  
Peter MacDonald, MD, PhD, Committee Member

Kenneth McCurry, MD, FACS, Committee Member  
Michael Musk, MBBS, Committee Member  
Gregory Snell, MBBS, FRACP, MD, Committee Member  
Steven Tsui, MD, FRCS, Committee Member  
Roger Yusen, MD, MPH, Committee Member

## **INTERNATIONAL PEDIATRIC HEART FAILURE REGISTRY STEERING COMMITTEE**

Anne Dipchand, MD, Chair (2019)  
Andrew Fisher, FRCP, PhD, Board of Directors Liaison (2019)  
Scott Auerbach, MD, Committee Member (2019)  
Estela Azeka, MD, Committee Member (2019)  
Aliessa Barnes, MD, Committee Member (2019)  
Wida Cherikh, PhD, Biostatistician (2019)  
Jennifer Conway, MD, Committee Member (2019)  
Beth Kaufman, MD, Committee Member (2019)  
Richard Kirk, FRCP, FRCPC, Committee Member (2019)  
David Peng, MD, Committee Member (2019)  
Philip Thrush, MD, Committee Member (2019)  
Warren Zuckerman, MD, Committee Member (2019)

## **INTERNATIONAL THORACIC ORGAN TRANSPLANT REGISTRY STEERING COMMITTEE**

Josef Stehlik, MD, MPH, Registry Medical Director, Committee Chair  
Andrew Fisher, FRCP, PhD, Board of Directors Liaison (2019)  
Daniel Chambers, MBBS, MRCP, FRACP, MD, Associate Medical Director-Adult Lung/Heart-Lung (2021)  
Wida Cherikh, PhD, Biostatistician  
Don Hayes, MD, Associate Medical Director-Pediatric Lung  
Kiran Khush, MD, Associate Medical Director-Adult Heart (2021)  
Bronwyn Levvey, RN, Grad Dip Clin Ep, Associate Medical Director-Outcomes (September 2019)  
Bruno Meiser, MD, OEO Relations (September 2019)  
Joseph Rossano, MD, Associate Medical Director-Pediatric Heart (2019)  
Andreas Zuckermann, MD

## **REGISTRIES AND DATABASES COMMITTEE**

Josef Stehlik, MD, MPH, Chair (2022)  
Daniel J. Goldstein, MD, IMACS Registry Steering Committee Chair  
Anne Dipchand, MD, International Pediatric Heart Failure Registry Steering Committee Chair (2019)  
Dirk Van Raemdonck, MD, PhD, International DCD Registry Steering Committee Chair  
Andrew Fisher, FRCP, PhD, Board of Directors Liaison (2019)  
Wida Cherikh, PhD, Biostatistician  
Rongbing Xie, DrPH, MPH, Biostatistician  
Roger Yusen, MD, MPH, At Large Member

## **STANDARDS AND GUIDELINES COMMITTEE**

Peter Hopkins, FRACP, Chair (2021)  
David Taylor, MD, Past Chair (2019)  
Manreet Kanwar, MD, Board of Directors Liaison (2019)  
Agnieszka Ciarka, MD, Junior Faculty and Trainees Council Workforce Leader (2020)  
Kevin Daly, MD, Pediatric Thoracic Transplantation and Heart Failure Council Workforce Leader (2019)  
Elie Fadel, MD, Chronic Thromboembolic Pulmonary Hypertension Council Workforce Leader (2021)  
Steven Kindel, MD, Pediatric Thoracic Transplantation and Heart Failure Council Workforce Leader (2019)  
Hrishikesh Kulkarni, MD, Basic Science and Translational Research Council Workforce Leader (2021)  
Colleen J. LaBuhn, RN, MSN, Nursing, Health Sciences and Allied Health Council Workforce Leader (2020)  
Erika Lease, MD, Pulmonary Transplantation Council Workforce Leader (2020)  
Sern Lim, MD, Heart Failure and Transplantation Council Workforce Leader (2021)  
Robert Page, PharmD, MS, Pharmacy and Pharmacology Council Workforce Leader (2019)  
Stephanie Pouch, MD, Infectious Diseases Council Workforce Leader (2021)  
Anja Roden, MD, Pathology Council Workforce Leader (2019)  
Oksana Shlobin, MD, Pulmonary Hypertension Council Workforce Leader (2020)  
Megan Barrett, ISHLT Staff Liaison

# JOURNAL FOR HEART AND LUNG TRANSPLANTATION (JHLT) EDITORIAL BOARD

## Editor-in-Chief

Mandeep R. Mehra, MD, MBBS, FACC, FACP

## Executive Editor

Patricia A. Uber, PharmD

## Consulting Editors

Maria Rosa Costanzo, MD (Editor Emeritus 1995-1999)

James K. Kirklin, MD (Editor Emeritus 2000-2009)

## Journal Office Coordinator

Anne Lau

## Editorial Board Consultants

Annalisa Angelini, MD (Italy)

William R. Auger, MD (USA)

David A. Baran, MD (USA)

Christian Benden, MD, FCCP (Switzerland)

Christian A. Bermudez, MD (USA)

Charles E. Canter, MD (USA)

Pablo Castro, MD (Chile)

Jean Connors (USA)

Paul A. Corris, MB, FRCP (UK)

Kevin P. Daly, MD (USA)

John Dark, MB, FRCS (UK)

Kyle L. Dawson, PharmD, MBA, BCPS (USA)

S.W. Denfield, MD (USA)

Mary Amanda Dew, PhD (USA)

Fabienne Dobbels, MSc, PhD (Belgium)

Thomas M. Egan, MD, MSC (USA)

Howard Eisen, MD (USA)

Roger W. Evans, PhD (USA)

Andrew J. Fisher, FRCP, PhD (UK)

Robert Frantz, MD (USA)

Allan R. Glanville, MBBS, MD, FRACP (Australia)

Daniel J. Goldstein, MD (USA)

Paolo Grossi, MD, PhD (Italy)

Margaret Hannan, MD (Ireland)

Marius M. Hoepfer (Germany)

Peter M. Hopkins, FRACP (Australia)

Valluvan Jeevanandam, MD (USA)

Maryl R. Johnson, MD (USA)

Shaf Keshavjee, MD, FRCSC (Canada)

Kiran Kaur Khush, MD (USA)

Richard Kirk, FRCP, FRCPC (UK)

Jon Kobashigawa, MD (USA)

Neal K. Lakdawala, MD (USA)

Lorriana Leard, MD (USA)

JoAnn Lindenfeld, MD (USA)

Peter MacDonald, MD, PhD (Australia)

Stanley I. Martin, MD (USA)

Tereza Martinu, MD (Canada)

Bruno Meiser, MD (Germany)

Thalachallour Mohanakumar, PhD (USA)

David Morales, MD (USA)

Ivan Netuka, MD, PhD (Czech Republic)

Francis Pagani, MD, PhD (USA)

Sean P. Pinney, MD (USA)

Jeffery L. Platt, MD (USA)

Evgenij V. Potapov, MD, PhD (Germany)

Luciano Potena, MD, PhD (Italy)

Joseph G. Rogers, MD (USA)

Heather J. Ross, MD, MHSc, FRCPC (Canada)

Lewis Rubin, MD (USA)

Stephan Schueler, MD, PhD, FRCS (UK)

Martin Schweiger, MD (Switzerland)

Keyur B. Shah, MD (USA)

Jacqueline M. Smits, MD, PhD (The Netherlands)

Josef Stehlik, MD, MPH (USA)

Jeffrey J. Teuteberg, MD (USA)

Jean Luc Vachiery, MD (Belgium)

Hector O. Ventura, MD (USA)

Geert Verleden, MD, PhD (Belgium)

Robin Vos, MD, PhD (Belgium)

Aaron Waxman, MD, PhD (USA)

Lori J. West, MD, DPhil (Canada)

Roger D. Yusen, MD, MPH (USA)

Michael Zakliczynski, MD (Poland)

## **PULSE NEWSLETTER EDITORIAL STAFF**

### **Editor**

David Weill, MD

### **Board Members**

Paul Corris, MB, FRCP

Mary Amanda Dew, PhD

Matt Hartwig, MD

Kiran Khush, MD

Deborah Levine, MD

David McGiffin, MB, BS, FRACS

Kapil Patel, MD

Amparo Sole, MD, PhD

Jussi Tikkanen, MD

### **Associate Editors**

Natasha Altman, MD

Shahnawaz Amdani, MD

Are Martin Holm, MD, PhD

Angela Logan, PharmD

Marco Masetti, MD

Joshua Mooney, MD

Mike Mulligan, MD

David Nelson, MD

Stephanie Pouch, MD

Reinaldo Rampolla, MD

Nirmal Sharma, MD

### **ISHLT Staff**

Megan Barrett

Nancy Mays

## **ISHLT SCIENTIFIC COUNCIL OPERATING BOARDS**

### **Basic Science and Translational Research (BSTR)**

Edward Cantu, MD, Chair (2021)  
Joshua Diamond, MD, Vice Chair (2023)  
Stijn Verleden, PhD, Vice Chair Elect (2025)  
Sonja Schrepfer, MD, PhD, Past Chair (2019)  
Dirk Van Raemdonck, MD, PhD, Board of Directors Liaison (2019)  
Doris Taylor, PhD, FAHA, FACC, Senior Advisor (2019)  
Jeffrey Platt, MD, Senior Advisor (2019)  
Hrishikesh Kulkarni, MD, Standards and Guidelines Workforce Leader (2021)  
Pradeep Mamen, MD, FACC, FAHA, HFTX Council Liaison (2020)  
Aric Gregson, MD, ID Council Liaison (2020)  
Simon Pecha, MD, JFTC Liaison (2019)  
J. Michael DiMaio, MD, MCS Council Liaison (2020)  
Monica Horn, RN, NHSAH Council Liaison (2020)  
Annalisa Angelini, MD, PATH Council Liaison (2020)  
Aaron Waxman, MD, PhD, PH Council Liaison (2020)  
Pablo Sanchez, MD, PULMTX Council Liaison (2020)

### **Chronic Thromboembolic Pulmonary Hypertension (CTEPH)**

William Auger, MD, Chair (2021)  
Marc De Perrot, MD, Vice Chair (2023)  
Isabelle Opitz, MD, FEBTS, Vice Chair Elect (2025)  
Raymond Benza, MD, Board of Directors Liaison (2019)  
Irene Lang, MD, Council Advisor (2019)  
Michael Madani, MD, Education Workforce Leader (2021)  
Elie Fadel, MD, Standards and Guidelines Workforce Leader (2021)  
Anastasia Bykova, NP, NHSAH Council Liaison (2021)

### **Heart Failure and Transplantation (HFTX)**

Jignesh Patel, MD, PhD, Chair (2022)  
Marta Farrero Torres, MD, PhD, Vice Chair (2024)  
Michael Pham, MD, MPH, Past Chair (2020)  
Howard Eisen, MD, Board of Directors Liaison (2019)  
Daniel Kim, MD, Education Workforce Leader (2020)  
Sern Lim, MD, Standards and Guidelines Workforce Leader (2021)  
Pradeep Mammen, MD, FACC, FAHA, BSTR Council Liaison (2020)  
Natasha Altman, MD, JFTC Liaison (2020)  
Jamila Kremer, MD, JFTC Liaison (2021)  
Edith Boyes, MSN, FNP-BC, CHFNP, NHSAH Council Liaison (2020)

### **Infectious Diseases (ID)**

Me-Linh Luong, MD, Chair (2022)  
Saima Aslam, MD, MS, Vice Chair (2024)  
Paolo Grossi, MD, PhD, Past Chair (2020)  
Goran Dellgren, MD, PhD, Board of Directors Liaison (2019)  
Joanna Schaanman, MD, PhD, Education Workforce Leader (2020)  
Stephanie Pouch, MD, Standards and Guidelines Workforce Leader (2021)  
Aric Gregson, MD, BSTR Council Liaison (2020)  
Jonathan Hand, MD, JFTC Liaison (2021)

### **Junior Faculty and Trainees (JFTC)**

Evan Kransdorf, MD, PhD, Chair (2022)  
Martin Schweiger, MD, Vice Chair (2024)  
Keyur Shah, MD, Past Chair (2020)  
Andrew Fisher, FRCP, PhD, Board of Directors Liaison (2019)  
Marco Masetti, MD, PhD, Education Workforce Leader (2021)  
Agnieszka Ciarka, MD, Standards and Guidelines Workforce Leader (2020)  
Simon Pecha, MD, BSTR Council Liaison (2019)  
Natasha Altman, MD, HFTX Council Liaison (2020)  
Jamila Kremer, MD, HFTX Council Liaison (2021)

Jonathan Hand, MD, ID Council Liaison (2021)  
Jaime Hernandez Montfort, MD, MPH, MCS Council Liaison (2020)  
Jaime-Juergen Eulert-Grehn, MD, MCS Council Liaison (2021)  
Colleen McIlvennan, DNP, ANP, NHSAA Council Liaison (2019)  
Ann Punnoose, MD, PEDTXHF Council Liaison (2020)  
Kyle Hope, MD, PEDTXHF Council Liaison (2021)  
Marco Caccamo, DO, PH Council Liaison (2019)  
Joshua Mooney, MD, PULMTX Council Liaison (2020)

### **Mechanical Circulatory Support (MCS)**

Nir Uriel, MD, Chair (2021)  
Simon Maltais, MD, PhD, Vice Chair (2023)  
Diyar Saeed, MD, PhD, Vice Chair Elect (2025)  
Stephan Schueler, MD, PhD, FRCS, Past Chair (2019)  
Jennifer Cowger, MD, MS, Board of Directors Liaison (2019)  
Diyar Saeed, MD, PhD, Education Workforce Leader (2019)  
Dawn Christensen, MS, CRNP, VAD Coordinator Liaison (2019)  
J. Michael DiMaio, MD, BSTR Council Liaison (2020)  
Jaime-Juergen Eulert-Grehn, MD, JFTC Liaison (2021)  
Jennifer Beckman, ARNP, NHSAA Council Liaison (2019)  
Angela Lorts, MD, PEDTXHF Council Liaison (2019)

### **Nursing, Health Sciences and Allied Health (NHSAA)**

Pamela Combs, PhD, RN, Chair (2022)  
Caron Burch, RN, MSA, FNP, CCTC, Vice Chair (2024)  
Kevin Carney, MSN, CRNP, CCTC, Past Chair (2020)  
Kathleen Grady, PhD, RN, FAAN, Board of Directors Liaison (2019)  
Angela Velleca, RN, BSN, CCTC, Education Workforce Leader (2021)  
Louise Fuller, PT, Grants and Awards Committee Workforce Leader  
Colleen LaBuhn, RN, MSN, Standards and Guidelines Workforce Leader (2020)  
Jesus Casida, PhD, Research Workforce Leader (2022)  
Monica Horn, RN, BSTR Council Liaison (2020)  
Anastasia Bykova, NP, CTEPH Council Liaison (2021)  
Edith Boyes, MSN, FNP-BC, CHFNP, HFTX Council Liaison (2020)  
Colleen McIlvennan, DNP, ANP, JFTC Liaison (2019)  
Jennifer Beckmann, ARNP, MCS Council Liaison (2019)  
Jodie Lantz, CNS, PEDTXHF Council Liaison (2020)  
Rachel Crackett, MSc, PH Council Liaison (2019)  
Nicole Davis, BSN, MPH, PULMTX Council Liaison (2020)

### **Pathology (PATH)**

Robert Padera, MD, PhD, Chair (2021)  
Fiorella Calabrese, MD, Vice Chair (2023)  
Anja Roden, MD, Vice Chair Elect (2025)  
Martin Goddard, FRCS, MRCPa, Board of Directors Liaison (2019)  
Anja Roden, MD, Standards and Guidelines Workforce Leader (2019)

### **Pediatric Thoracic Transplantation and Heart Failure (PEDTXHF)**

Brian Feingold, MD, MS, Chair (2021)  
Carol Conrad, MD, Vice Chair (2023)  
Simon Urschel, MD, Vice Chair Elect (2025)  
Tajinder Singh, MD, MSc, Past Chair (2019)  
Kevin Chan, MD, Board of Directors Liaison (2019)  
Beth Kaufman, MD, Education Workforce Leader (2020)  
Steven Kindel, MD, Standards and Guidelines Workforce Leader (2019)  
Kevin Daly, MD, Standards and Guidelines Workforce Leader (2019)  
Ashwin Lal, MD, Pediatric Heart Failure Workforce Leader (2021)  
Marc Schecter, MD, Pediatric Lung Failure Workforce Leader (2020)  
Ann Punnoose, MD, JFTC Liaison (2020)  
Kyle Hope, MD, JFTC Liaison (2021)  
Angela Lorts, MD, MCS Council Liaison (2020)  
Jodie Lantz, CNS, NHSAA Council Liaison (2020)



### **Pharmacy and Pharmacology (PHARM)**

Adam Cochrane, PharmD, MPH, Chair (2021)  
Haifa Lyster, MSc, Vice Chair (2023)  
Edward Horn, PharmD, Vice Chair Elect (2025)  
Walter Uber, PharmD, Past Chair (2019)  
Michael Shullo, PharmD, Board of Directors Liaison (2019)  
Jennifer Eshelman, PharmD, Education Workforce Leader (2020)  
Robert Page, PharmD, MS, Standards and Guidelines Workforce Leader (2019)

### **Pulmonary Hypertension (PH)**

Jean-Luc Vachiery, MD, Chair (2022)  
Ioana Preston, MD, Vice Chair (2024)  
Dana McGlothlin, MD, Past Chair (2020)  
Teresa De Marco, MD, FACC, Board of Directors Liaison (2019)  
Colin Church, MD, Education Workforce Leader (2021)  
Oksana Shlobin, MD, Standards and Guidelines Workforce Leader (2020)  
Aaron Waxman, MD, PhD, BSTR Council Liaison (2020)  
Marco Caccamo, DO, JFTC Liaison (2019)

### **Pulmonary Transplantation (PULMTX)**

Ramsey Hachem, MD, Chair (2022)  
Glen Westall, FRACP, PhD, Vice Chair (2024)  
Cynthia Gries, MD, MSc, Past Chair (2020)  
Jason Christie, MD, Board of Directors Liaison (2019)  
Daniel Dilling, MD, Education Workforce Leader (2021)  
Erika Lease, MD, Standards and Guidelines Workforce Leader (2020)  
Jonathan Singer, MD, Quality of Life Workforce Leader  
Pablo Sanchez, MD, BSTR Council Liaison (2020)  
Joshua Mooney, MD, JFTC Liaison (2019)  
Nicole Davis, BSN, MPH, NNSAH Council Liaison (2020)

## **PAST PRESIDENTS**

1981-1982 Michael Hess, MD  
1982-1984 Jack Copeland, MD  
1984-1986 Terence English, FRCS  
1986-1988 Stuart Jamieson, MD  
1988-1990 Bruno Reichart, MD  
1990-1991 Margaret Billingham, MD  
1991-1992 Christian Cabrol, MD  
1992-1993 John O'Connell, MD  
1993-1994 Eric Rose, MD  
1994-1995 John Wallwork, FRCS  
1995-1996 Sharon Hunt, MD  
1996-1997 William Baumgartner, MD  
1997-1998 Leslie Miller, MD  
1998-1999 Alan Menkis, MD, FRCS(C)  
1999-2000 Robert L. Kormos, MD  
2000-2001 Anne Keogh, MBBS, MD  
2001-2002 James B. Young, MD  
2002-2003 Stephan Schueler, MD  
2003-2004 Jon Kobashigawa, MD  
2004-2005 Alec Patterson, MD  
2005-2006 Mark L. Barr, MD  
2006-2007 Robert C. Robbins, MD  
2007-2008 Paul A. Corris, MB FRCP  
2008-2009 Mandeep R. Mehra, MD  
2009-2010 James K. Kirklin, MD  
2010-2011 John Dark, MB, FRCS  
2011-2012 Lori J. West, MD, DPhil  
2012-2013 David O. Taylor, MD  
2013-2014 Allan R. Glanville, MBBS, MD, FRACP  
2014-2015 Hermann Reichensperner, MD, PhD  
2015-2016 Duane Davis, MD, MBA  
2016-2017 Maryl Johnson, MD  
2017-2018 Andrew Fisher, FRCP, PhD

## PAST ANNUAL MEETING PROGRAM CHAIRS

1981 San Francisco, CA, USA	Edward B. Stinson, MD and Michael L. Hess, MD
1982 Phoenix, AZ, USA	Jack Copeland, MD
1983 New Orleans, LA, USA	Jack Copeland, MD
1984 New York, NY, USA	Jack Copeland, MD
1985 Anaheim, CA, USA	Bartley Griffith, MD
1986 New York, NY, USA	Terence A. H. English
1987 New Orleans, LA, USA	John C. Baldwin, MD
1988 Los Angeles, CA, USA	John C. Baldwin, MD
1989 Munich, Germany	Joel D. Cooper, MD
1990 San Diego, CA, USA	D. Glenn Pennington, MD
1991 Paris, France	John B. O'Connell, MD
1992 San Diego, CA, USA	Eric A. Rose, MD
1993 Boca Raton, FL, USA	Maria Rosa Costanzo, MD
1994 Venice, Italy	John Wallwork, MBChB, FRCS
1995 San Francisco, CA, USA	Leslie W. Miller, MD
1996 New York, NY, USA	William A. Baumgartner, MD
1997 London, England	Stephan Schueler, MD
1998 Chicago, IL, USA	James B. Young, MD
1999 San Francisco, CA, USA	Mark L. Barr, MD
2000 Osaka, Japan	Jon Kobashigawa, MD
2001 Vancouver, Canada	David O. Taylor, MD
2002 Washington, DC, USA	Robert C. Robbins, MD
2003 Vienna, Austria	Bruce R. Rosengard, MD
2004 San Francisco, CA, USA	Mandeep R. Mehra, MD
2005 Philadelphia, PA, USA	Shaf Keshavjee, MD
2006 Madrid, Spain	John Dark, MB, FRCS
2007 San Francisco, CA, USA	Duane Davis, MD
2008 Boston, MA, USA	Lori J. West, MD, DPhil
2009 Paris, France	Randall C. Starling, MD, MPH
2010 Chicago, IL, USA	Hermann Reichenspurner, MD, PhD
2011 San Diego, CA, USA	Richard N. Pierson, III, MD
2012 Prague, Czech Republic	Stuart C. Sweet, MD, PhD
2013 Montreal, Canada	Allan R. Glanville, MBBS, MD, FRACP
2014 San Diego, CA, USA	Jason D. Christie, MD
2015 Nice, France	Andreas Zuckermann, MD
2016 Washington, DC, USA	Andrew J. Fisher, FRCP, PhD
2017 San Diego, CA, USA	Jeffrey J. Teuteberg, MD
2018 Nice, France	Christian Benden, MD, FCCP

## **PAST REGISTRY MEDICAL DIRECTORS, JOURNAL AND NEWSLETTER EDITORS**

### **Past Registry Medical Directors**

1987-1993 Michael P. Kaye, MD

1993-2001 Jeffrey D. Hosenpud, MD

2001-2012 Marshall I. Hertz, MD

2012-Present Josef Stehlik, MD, PhD

### **Past Journal of Heart and Lung Transplantation Editors**

1981-1985 Jacques G. Losman, MD

1986-1994 Michael P. Kaye, MD

1995-1999 Maria Rosa Costanzo, MD

2000-2009 James K. Kirklin, MD

### **Past Links Newsletter Editors**

2008-2011 David S. Feldman, MD, PhD

2011-2018 Vincent G. Valentine, MD

## **ISHLT AWARD RECIPIENTS**

### **OUTSTANDING ACHIEVEMENT AWARDS:**

#### **ISHLT Lifetime Achievement Award**

1996 Norman Shumway, MD  
1999 Keith Reemtsma, MD  
2004 Sir Magdi Yacoub, MD  
2010 Margaret Billingham, MD  
2012 Sharon Hunt, MD  
2014 Sir Terence English, KBE, FRCS  
2016 Adrian Kantrowitz, MD  
Jean Kantrowitz, MPH  
2018 O. Howard Frazier, MD  
2019 John Wallwork, FRCS

#### **ISHLT Lifetime Service Award**

1996 Michael P. Kaye, MD  
1997 Jacques G. Losman, MD

#### **ISHLT Pioneer Award**

2000 Christiaan Barnard, MD  
Joel D. Cooper, MD  
Norman E. Shumway, MD  
2002 Michael DeBakey, MD  
Bruce A. Reitz, MD  
2006 Leonard L. Bailey, MD  
2008 Richard E. Lower, MD  
2009 Christian E. A. Cabrol, MD  
2011 Elizabeth Hammond, MD  
2013 Jack G. Copeland, MD  
2015 Bruno Reichart, MD  
2016 Sir Roy Calne, FRCP, FRCS, FRS  
2017 Stuart Jamieson, MB, FRCS

### **EMERITUS MEMBERSHIP**

Margaret D. Allen, MD  
William Baumgartner, MD  
Christian Cabrol, MD  
Jack Copeland, MD  
Sir Terence English, KBE, FRCS  
Albert J. Guerraty, MD  
Jeffrey Hosenpud, MD  
Sharon A. Hunt, MD  
Carl V. Leier, MD  
Bruno Reichart, MD  
Marlene Rose, PhD  
John Wallwork, FRCS  
Elaine M. Winkel, MD  
Prof. Magdi Yacoub, MD

### **GRANTS AND SCHOLARSHIPS:**

#### **GRANT AWARDS:**

#### **ISHLT Norman E. Shumway Career Development Award**

2000 Gordon D. Wu, MD (supported by Roche)  
2002 Anthony Azakie, MD (supported by Roche)  
2004 Allan M. Ramirez, MD (supported by Novartis Pharma)  
2006 Dennis W. Wigle, MD, PhD (supported by Astellas Pharma)  
2008 Glen Westall, MD, PhD (supported by Roche)

- 2010 Sonja Schrepfer, MD, PhD (supported by Astellas)
- 2012 Tereza Martinu, MD, PhD
- 2014 Keshava Rajagopal, MD, PhD
- 2015 Xingan Wang, MD, PhD
- 2016 Stephen Juvet, MD, PhD, FRCPC
- 2017 Nicole Valenzuela, PhD, D(ABHI) (funded by Enduring Hearts)
- 2018 David Schibilsky, MD
- 2019 Julien Guihaire, MD, PhD

**ISHLT Joel D. Cooper Career Development Award**

- 2017 Keki Blasara, MD
- 2018 Brian Wong, PhD
- 2019 Daniel Calabrese, MD

**ISHLT/Enduring Hearts Transplant Longevity Research Award**

- 2019 Kiran Khush, MD  
Shelley Miyamoto, MD

**ISHLT Nursing Research Grant Award**

- 1997 Eileen Collins, RN, PhD
- 1998 Katherine St. Clair, RN, MSN
- 1999 Jeanne Salyer, PhD
- 2000 Nancy M. Albert, MSN, RN
- 2001 Lynn Doering, RN, DNSc
- 2002 Annette J. De Vito Dabbs, RN, MN, PhD
- 2003 Diane H. Leloudis, RN, MSN  
Janet E. Madill, PhD
- 2004 Deidre E. Logan, PhD
- 2005 Annemarie F. Kaan, MCN
- 2006 Thierry Troosters, PhD
- 2007 Mi-Kyung Song, PhD
- 2008 Stacey M. Pollock-BarZiv, PhD
- 2009 Jane MacIver, RN, MSc
- 2010 Heike Spaderna, PhD  
Gerdi Weidner, PhD
- 2011 Christiane Kugler, PhD (supported by CSL Behring)  
Hilde Bollen, RN
- 2012 Lut Berben, PhD, RN (supported by CSL Behring)  
Connie White-Williams, PhD, RN, FAAN
- 2013 Jo Wray, PhD and Jane Haines, DNP, RN, CMSRN
- 2014 Lea Ann Matura, PhD, RN
- 2015 JiYeon Choi, PhD, RN
- 2016 Mohammad Alrawashdeh, BSN, MSN
- 2016 Melissa Cousino, PhD (Jointly Funded by Enduring Hearts)
- 2017 Samantha Anthony, PhD, MSW
- 2018 Martha Abshire, PhD, RN  
Mary Amanda Dew, PhD
- 2019 Benjamin Tarrant, B.Physio  
Brittany Koons, PhD, RN

**ISHLT Research Fellowship Award**

- 1995 Frances L. Johnson, MD (supported by Ortho-Biotech)
- 1996 Tuija S. Ikonen, MD (supported by Roche)  
Andrew F. Pierre, MD (supported by Ortho-Biotech)
- 1997 Jonathan Chen, MD (supported by Roche)  
Alyssa M. Krasinskas, MD (supported by Astellas)  
Owen T. Lawrence, MD (supported by Ortho-Biotech)  
Anne K. Raisanen-Sokolowski, MD (supported by Roche)
- 1998 Kelly S.A. Blair, MD (supported by Roche)  
A.M. El Gamel, MD (supported by Roche)  
Christine L. Lau, MD (supported by Wyeth-Ayerst)  
Scott D. Ross, MD

Margaret L. Schwarze, MD (supported by Novartis)  
1999 George Juang, MD (supported by Novartis)  
Sivasai Krovvidi, PhD (supported by Roche)  
Satoshi Saito, MD (supported by Novartis)  
Donald Wong, PhD (supported by Roche)  
2000 Richard S. Lee, MD (supported by Novartis)  
Christopher H. Wigfield, FRCS (supported by Roche)  
2001 Arnar Geirsson, MD (supported by Roche)  
Matteo Vatta, PhD (supported by Roche)  
2002 Ruediger Hoebelt, MD (supported by Roche)  
2003 Ewout J. van den Bos, MD (supported by Astellas)  
Felix Fernandez, MD (supported by Roche)  
2004 Christian A. Gleissner, MD (supported by Astellas)  
Tsuyoshi Shoji, MD, PhD (supported by Actelion)  
Kendra N. Taylor, PhD (supported by Roche)  
Monica Zwierzchonieuska, MD (supported by XDX)  
2005 Ryan C. Fields, MD (supported by Chiron)  
Arne Neyrinck, MD (supported by Astellas)  
Ahmad Saad, MD (supported by Roche)  
2006 Rachel L. Anderson, MBBS (supported by Roche)  
Zhaohui Li, PhD (supported by Transmedics)  
Heather E. Merry, MD (supported by Encysive)  
Edward N. Seung, PhD (supported by XDX)  
Matthew J. Weiss, MD (supported by Novartis)  
2007 J. Raymond Fitzpatrick, III, MD (supported by Encysive)  
Howard J. Huang, MD (supported by Transmedics)  
Mylvganam Jeyakanthan, MD (supported by XDX)  
Timothy M. Millington, MD (supported by Novartis)  
Satish N. Nadig, MD (supported by Roche)  
Takeshi Oyaizu, MD, PhD (supported by Actelion)  
Sonja Schrepfer, MD (supported by Astellas)  
2008 Jonathan Choy, PhD (supported by XDX)  
Satoshi Itoh, MD (supported by Transmedics)  
Tereza Martinu, MD (supported by Novartis)  
Deepti Saini, PhD (supported by Gilead)  
Atsushi Shiozaki, MD, PhD (supported by Astellas)  
Seiichiro Sugimoto, MD, PhD (supported by Roche)  
2009 Hua Shen, MD, PhD (supported by Astellas)  
Tobias Deuse, MD, PhD (supported by Novartis)  
Masahiro Miyajima, MD, PhD (supported by XDX)  
Shin Hirayama, MD, PhD (supported by Gilead)  
2010 Esme Dijke, PhD (supported by Novartis)  
Smita Sihag, MD (supported by Genentech)  
Sumiharu Yamamoto, MD (supported by Gilead)  
Khurram Shahzad, MD (supported by United Therapeutics)  
Nina Pilat, MSc, PhD (supported by XDX)  
2011 Alejandro Bribriescio, MD (supported by Astellas)  
Alexey Dashkevich, MD (supported by XDX)  
Patricia E. de Almeida, DVM, MS, PhD  
Tiago Machuca, MD, PhD  
2012 Stephen C. Juvet, MD, FRCPC  
Maria Lucia L. Madariga, MD  
Jessica H. Spahn, PhD  
Konstantinos Malliaras, PhD  
2013 Nikolaos Diakos, MD  
Raymond Givens, MD, PhD  
Pablo Sanchez, MD, PhD  
2014 Charles Evans, MD  
Christine Lin, MD  
Stijn Verleden, PhD  
2015 Jonathan Merola, MD  
2016 Hsi-Min Hsaio, PhD

Nikolas Skartsis, MD, PhD  
Corey Tabit, MD, MBA, MPH  
2017 Ramiro Fernandez, MD  
2018 Ei Miyamoto, MD  
2019 Maria-Nieves Sanz, PhD

**ISHLT Transplant Registry Early Career Award (formerly Junior Faculty Award)**

2007 Beth D. Kaufman, MD  
2008 Cynthia Gries, MD, MSc  
Scott Halpern, MD, PhD  
Josef Stehlik, MD, MPH  
2010 Jennifer Conway, MD, FRCPC  
Kiran K. Khush, MD, MAS  
2011 Jose Nativi, MD  
2012 Erin M. Lowery, MD  
Omar E. Wever-Pinzon, MD  
2013 Chesney Castleberry, MD  
Eugene DePasquale, MD  
Aaron Healy, MD  
2014 Marian Urban, MD  
Miranda Paraskeva, MBBS  
Hrishikesh Kulkarni, MD  
Agnieszka Ciarka, MD, PhD  
2015 Livia Goldraich, MD, MSc  
Deipanjan Nandi, MD, MSc  
Evan Kransdorf, MD, PhD  
Manreet Kanwar, MD  
Natasha Loghmanpour, PhD  
Alexander Bernhardt, MD  
Jong-Chan Youn, MD, PhD  
2016 Sai Bhagra, MBBS, MRCP  
Forum Kamdar, MD  
Marco Masetti, MD, PhD  
Joshua Mooney, MD  
Edit Nagy, MD, PhD  
2017 Laith Alshwabkeh, MD, MSc  
Yuka Furuya, MD  
Christian Heim, MD  
Monique Robinson, MBBS, MRCP, DPhil  
Lorenzo Zaffiri, MD, PhD  
2018 Hakim Ali, MD  
Daniel Reichart, MD and Liesa Castro, MD  
Laneshia Tague, MD, MSCI  
Amanda Vest, MBBS, MPH  
Michael Yaoyao Yin, MD  
2019 Lauren Cooper, MD, MHS  
Michael Harhay, PhD, MPH, MS, M.Bioethics  
In-Cheol Kim, MD  
Anjan Tibrewala, MD  
Jefferson Vieira, MD, MBA, PhD

**ISHLT/Bayer Pulmonary Hypertension Research Grant Award**

2014 Benjamin Freed, MD

**ISHLT/HeartWare Award for Translational Research in MCS**

2014 Leigh Reardon, MD  
2015 Alexander Bernhard, MD

**ISHLT/O.H. Frazier Award in MCS Translational Research Sponsored by Medtronic**

2016 Todd Dardas, MD, MS  
2017 Yasuhiro Shudo, MD, PhD  
2018 Kavitha Muthiah, MBChB, PhD, FRACP



2019 Jasmin Hanke, MD

**ISHLT Branislav Radovancevic Memorial Fellowship Grant (Supported by Thoratec)**

2009 Sasa D. Borovic, MD

2010 Iki Adachi, MD

2012 Antigone Koliopoulou, MD

2014 Masahiro Ono, MD, PhD

**ISHLT International Traveling Scholarship Award**

2011 Stephanie T. Yerkovich, PhD

Sarah E. Gilpin, PhD

Kimberly M. Derkatz, BNSc

Jennifer Conway, MD, FRCPC

2012 Ramin E. Beygui, MD

Kevin C. Carney, MSN

Alexandre Souza Cauduro, MD

Esme Dijke, PhD

Ana Belen Mendez, MD

David Schibilsky, MD

Aleem Siddique, MBBS

Amparo Solé, MD, PhD

Manon Huibers, MSc

Daniel R. Goldstein, MD

Laveena Munshi, MD, FRCPC

Marco Masetti, MD

Rochelle M. Gellatly, PScPharm, ACPR, PharmD

2013 Alison Gareau, MSc

Erin Schumer, MD, MS

Bojan Vrtovec, MD, PhD

Marsha Renikunta, PhD (student)

Katie Morley, BA(Hons), RCN, MA

Ali Yeginsu, MD

Fabrizio Gandolfo, MD

Marian Urban, MD

Alexander Bernhardt, MD

Victor Rossel, MD

Mohammed Quader, MD

2014 Marny Fedrigo, MD, PhD

Zachary Kon, MD

Evgenios Neofytou, MD

Dong, Wang, MD

Stephen Clark, DM, FRCS

Caroline Patterson, BMBS, BMedSci, MRCP

Tahaunty Pena, MD

2015 Oisín O'Connell, MD, MRCPI

Lucas Van Aelst, MD, PhD

Arezu Aliabadi, MD

Timothy Sladden, MBBS, BVSc

Bao Tran, MD

L G Saptharishi, MD, DM

Allison Carroll, MD

Akshay Pendyal, MD

Stefania Paolillo, MD, PhD

Soumitra Sinha Roy, MD

2016 Lucas Van Aelst, MD, PhD

Espeed Khoshin, MB ChB, MD, FRCS

2017 Amit Adlakha, MBChB, MRCP, FFICM

In-Cheol Kim, MD, PhD

Sanjeev Kumar Khulbey, MBBS, MS, MCH

Antonios Kourliouros, PhD, FRCS (CTh)

Mrinalini Krishnan, MD

Simon Pecha, MD

Kuruswamy Prasad, MD, DM  
Ann Punnoose, MD  
Adam Putschoegl, DO  
Jong-Chan Young, MD, PhD  
2018 Greg Calligaro, MD  
Luis Garcia-Guereta Silva, MD, PhD  
Abhishek Goyal, MD, DM  
Kyung-Hee Kim, MD, PhD  
Neil Lewis, MbBS, MPhil, MD, FACC  
Anoop Mohandas, MD, DNB, DESA, FNB  
Anthony Dan Paul Salimbangon, RN, BSN, CCRN  
Loukas Tsourelis, MD  
Anh Nguyen, MD, PhD

### **ISHLT Leach-Abramson-Imhoff Links Travel Awards**

2012 Tereza Martinu, MD, Writer of the Year  
Stanley I. Martin, MD, First Runner-Up  
Luciano Potena, MD, PhD, First Runner-Up  
Nancy P. Blumenthal, CRNP, Honorable Mention  
Bronwyn J. Levvey, RN, Honorable Mention  
Javier Carbone, MD, PhD, Honorable Mention  
Stavros G. Drakos, MD, Honorable Mention  
Daniel F. Dilling, MD, Honorable Mention  
2013 Michele Estabrook, MD, Writer of the Year  
Melanie Everitt, MD, First Runner-Up  
Christina Migliore, MD, First Runner-Up  
Veronica Franco, MD, Honorable Mention  
Manreet Kanwar, MD, Honorable Mention  
Luciano Potena, MD, PhD, Honorable Mention  
Macé Schuurmans, MD, Honorable Mention  
Jeffrey J. Teuteberg, MD, Honorable Mention  
2014 Christopher R. Ensor, PharmD, BCPS-CV, Writer of the Year  
Amanda Ingemi, PharmD, First Runner-Up  
Simon Urschel, MD, Honorable Mention  
2015 Pamela S. Combs, PhD, RN, Writer of the Year  
Manreet Kanwar, MD, First Runner-Up  
Oveimar De la Cruz, MD, Honorable Mention  
Heather T. Henderson, MD, Honorable Mention  
Simon Urschel, MD, Honorable Mention  
Erin Wells, RN, BSN, CPN, Honorable Mention  
2016 Kyle Dawson, PharmD, MBA, BCPS, Writer of the Year  
Adam Cochrane, PharmD, BCPS, First Runner-Up  
Christa Kirk, PharmD, First Runner-Up  
Angela Velleca, RN, BSN, CCTC, Honorable Mention  
Erin Wells, RN, BSN, CPN, Honorable Mention  
2017 Quincy Young, PhD, RPsych, Writer of the Year  
Monica Horn, RN, First Runner-Up  
Melissa Cousino, PhD, Honorable Mention  
Erin Wells, RN, BSN, CPN, Honorable Mention  
2018 Erin Wells, RN, BSN, Writer of the Year  
Martin Schweiger, MD, First Runner-Up  
Adam Cochrane, Honorable Mention  
Pamela S. Combs, Honorable Mention  
Kyle Dawson, PharmD, MBA, BCPS, Honorable Mention  
Joshua Mooney, MD, Honorable Mention

### **ABSTRACT AWARDS:**

#### **Philip K. Caves Award**

1983 Robbin G. Cohen, MD  
1984 Hermann Reichenspurner, MD  
1985 Michael A. Breda, MD

1986 Stuart J. Knechtle, MD  
1987 Wim Van Der Bij, MD  
1988 Charles D. Fraser, Jr., MD  
1989 A.M. Wood, MD  
1990 Andres J. Duncan, MD  
1991 A. Jiminez, MD  
1992 David P. Kapelanski, MD  
1993 David Marshman, MD  
1994 Jobst Winter, MD  
Alain Chapelier, MD  
1995 Elizabeth A. Davis, MD  
1996 Moninder S. Bhabra, MD  
1997 Simon D. Eiref, MD  
1998 Carla C. Baan, MD  
1999 Joerg Koglin, MD  
2000 Michael P. Fischbein, MD  
2001 Alexander S. Krupnick, MD  
2002 Peter Blaha, MD  
2003 Sigrid Sandner, MD  
2004 M.D. Peterson, MD  
2005 Sigrid Sandner, MD  
Frank D'Ovidio, MD  
2006 Gregor Warnecke, MD  
2007 Heather E. Merry, MD  
2008 Satish N. Nadig, MD  
2009 Howard Huang, MD  
2010 Tobias Deuse, MD, PhD  
2011 Ankit Bharat, MD  
2012 Simo Syrjälä, MD  
2013 Alexey Dashkevich, MD  
2014 Jessica Spahn  
2015 Simon Pecha, MD  
2016 Corey E. Tabit, MD  
2017 Stephen Chiu, MD  
2018 Jane O, MD

#### **Nursing, Health Sciences and Allied Health Excellence in Research Award**

2005 Mary Amanda Dew, PhD  
2006 Kathleen L. Grady, PhD, RN  
2007 Christiane Kugler, PhD  
2008 Annette DeVito Dabbs, RN, PhD  
2009 Connie White-Williams, MSN  
2010 Bronwyn Levvey, RN  
2011 Samantha J. Anthony, PhD, MSW  
2012 Kate Hayes, MPhysio (Cardio)  
2013 Jane Haines, DNP, RN, CMSRN  
2014 Louise Fuller, PT  
2015 Catherine Murks, PhD, APN  
2016 Fabienne Dobbels, MSc, PhD  
2017 Maral Bakir, RN, PHN  
2018 Tara E. Miller, FNP

#### **Early Career Scientist Award**

2017 Hsi-Min Hsiao, PhD  
2018 Kenneth A. Sinclair, BSC(Hons), PhD

#### **Junior Faculty Clinical Case Dilemmas in Thoracic Transplantation Best Presentation Award**

2011 Michelle M. Kittleson, MD, PhD  
2012 Erin Albers, MD  
2013 Mustafa Ahmed, MD  
2014 Lauren Sacha  
2015 Ankit Bharat, MD

2016 Yasufumi Goda, MD  
2017 Robert Gottlieb, MD, PhD  
2018 Tiffany K. Roberts, PhD

**Branislav Radovancevic Memorial Best MCSD Paper Award (Supported by Thoratec)**

2009 Nishant Shah, MD  
2010 Jose N. Nativi, MD  
2012 Arun Raghav Mahankali Sridhar, MD, MPH  
2013 Claire Watkins, MD  
2014 Jason O. Robertson, MD

## ACCREDITATION INFORMATION / CONTINUING MEDICAL EDUCATION INFORMATION

**Accreditation Statement:** The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**Designation Statement:** ISHLT designates this live activity for a maximum of 33 AMA PRA Category 1 Credits.<sup>™</sup> Physicians should claim only the credit commensurate with the extent of their participation in the activity

### Nurses and Pharmacists



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the International Society for Heart & Lung Transplantation. Amedco LLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement - Amedco LLC designates this live activity for a maximum of 33.00 contact hours for nurses and 26.25 knowledge-based contact hours for pharmacists. Learners should

claim only the credit commensurate with the extent of their participation in the activity.

**NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.**

### Transplant Coordinators

As a designated Approved Provider by the American Board for Transplant Certification (ABTC), the International Society for Heart and Lung Transplantation's offering ISHLT 39th Annual Meeting & Scientific Sessions grants up to 33 Category 1 Continuing Education Points for Transplant Coordinators (CEPTCs) for this offering. CEPTC Provider Number: #907-00.

### Nurse Practitioners

The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit.

### Disclosure

Current guidelines state that participants in continuing medical and allied health profession education activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker's presentation. Planners, Faculty, and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

### Educational Need

Because of the rapid advances in patient health care in general and advanced heart and lung disease management in particular, professionals are in need of regular opportunities to update and maintain their knowledge of advances and changes in the field. This meeting is designed to address their needs.

### Educational Goals

The educational goals of this activity are: to enable participants to learn about current practices, emerging technologies, and medical advances related to heart and lung transplantation and advanced heart and lung disease management and to provide a forum for participants to engage in discussion, debate, and examination regarding the efficacy and applicability of these current practices, emerging technologies, and medical advances.

### Target Audience

The International Society for Heart and Lung Transplantation is a leading organization providing education for medical professionals involved in the care and treatment of patients with advanced heart or lung disease. The audience for this program includes physicians, surgeons, scientists, pharmacists, nurses, transplant coordinators and other allied health and social science professionals engaged in the management and treatment of patients with advanced heart or lung disease, basic science or clinical research related to these fields, or other specialties which cause them to become involved in the treatment of patients with advanced heart or lung disease.

### Objectives

After attending the Annual Meeting participants should have improved competence and performance in the areas of:

1. The latest information and approaches regarding transplant research, surgical techniques, medical therapies, donor management, and patient management for the treatment of patients suffering from advanced heart and lung disease.

2. The state-of-the-art treatment approaches, risk factors, risk management approaches, patient selection criteria, disease prevention strategies, outcome implications, and psychosocial management strategies for patients with advanced heart and lung failure.
3. Emerging technologies, medical advances, and the clinical applications of basic science models of advanced heart and lung disease management and prevention.

**Activity Designed to Change**

This activity is designed to change knowledge, competence, and performance.

**Learner Attributes**

Patient Care and Medical Knowledge.

**Documenting CME Credits**

The ISHLT provides CME certificates to those who have participated in an ISHLT educational activity. The ISHLT does not submit credits to regulating bodies or certifying organizations on behalf of the participant. It is the participant's responsibility to submit proof of credits on his or her own behalf.

**Disclaimer**

The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the ISHLT.

## **UNRESTRICTED EDUCATIONAL GRANTS**

The International Society for Heart and Lung Transplantation extends its heartfelt gratitude to the following companies for their unrestricted educational grants in support of the 39th Annual Meeting and Scientific Sessions:

Abbott  
Actelion  
Bayer  
Medtronic  
United Therapeutics

## **COMMERCIAL SUPPORT**

The International Society for Heart and Lung Transplantation is grateful for the support provided by the following companies for the Society and all of its endeavors in 2019:

### **TIER 1**

Medtronic

### **TIER 2**

Abbott  
Actelion  
United Therapeutics

### **TIER 3**

CareDx

### **TIER 4**

One Lambda (Thermo Fisher)  
Transmedics  
XVIVO Perfusion

### **TIER 5**

Bayer  
Gilead  
Paragonix Technologies  
TAI Diagnostics  
TandemLife | LivaNova

## ANNUAL MEETING PROGRAM HIGHLIGHTS

### Basic Science and Translational Research

This year's fascinating basic science and translational research symposia are appealing to all ISHLT attendees. In *Session 09: Refocusing the Blurry Vision: Biomarkers of Thoracic Allograft Rejection*, different biomarkers in diagnosing and monitoring thoracic graft rejection will be discussed, some of which are already in clinical use and others are investigational. *Sunrise 07: Highways to Hell: Chronic Lung Allograft Dysfunction* will bring exciting lectures about novel and interesting hypotheses involved in the pathophysiology of CLAD. In *Session 72: Seeing the Light: Antibodies in Thoracic Transplantation*, the aim is to acquire a deeper understanding of antibody-mediated mechanisms, treatments and potential downstream consequences of antibodies in transplantation. These sessions are innovating for both clinicians and researchers and will undoubtedly lead to novel insights.

### Chronic Thromboembolic Pulmonary Hypertension

Interventional options for the treatment of CTEPH are expanding with BPA recently emerging as an option, in addition to PTE surgery. Yet, how can we compare the two therapies when there are differences in patient populations, procedures performed, and variability in reporting of risks and outcomes? *Sunrise 13: A Fork in the Road: How Can We Compare Interventional Therapies in CTEPH?* will address these issues and facilitate discussion on how we can move toward more uniform reporting of outcomes. The success of PTE has improved over the years due to better understanding of the pathophysiological mechanisms leading to major complications. This knowledge has translated into better ability to prevent them, recognize them early on and manage them more appropriately. *Session 58: Resilience in the Face of Calamity: The Art of Preventing Pulmonary Thromboendarterectomy (PTE) Disasters* will review specific complications related to PTE and discuss how to manage them to achieve a successful outcome.

### Heart Failure and Transplantation

ISHLT2019 offers an exciting line-up of eight symposia that are of great interest to the contemporary advanced heart failure and transplant communities. *Session 02: Future Shock: Great Debates in Cardiogenic Shock* will feature three lively debates between leading clinicians on approaches to manage patients with cardiogenic shock, ranging from hemodynamic management to temporary mechanical circulatory support. Special heart failure populations require unique management approaches, and these will be highlighted in *Session 40: Heart Failure in Adult Congenital Heart Disease: Unique Problems Need Unique Solutions*, which will discuss controversial topics such as the timing of transplantation in ACHD patients, strategies for combined heart-liver transplantation, and use of mechanical circulatory support. The management of patients with restrictive cardio myopathies will be highlighted in the cutting-edge *Sunrise 01: In the Thick of It: Hypertrophic and Amyloid Cardiomyopathies*. Novel and sophisticated imaging techniques have been developed to better characterize and manage complex heart failure patients, and these will be explored in a joint symposium between the ISHLT and Society of Cardiac Magnetic Resonance (SCMR) entitled *Session 52: Joint ISHLT/SCMR Symposium: Cardiac MRI and the World of Heart Failure: When Two Disciplines Harmonize*. Ultimately, many of these patients will require transplantation, but the donor organ shortage continues to restrict heart transplant activity worldwide. Innovative strategies to increase donor utilization, including use of marginal donors, hepatitis C positive donors, and donors from distant locations will be explored in *Session 65: All Talk, No Action? New Strategies and Best Practices to Maximize Donor Heart Utilization*, which will culminate in an animated debate about the pros and cons of Opt Out vs Opt In policies for organ donation. Clinicians actively involved in the care of heart transplant recipients will benefit from cutting-edge talks on strategies to personalize and minimize immunosuppression in *Sunrise 14: One Size Does Not Fit All: Personalized Medicine in Heart Transplantation*, while experts in coronary imaging and pharmacology will discuss the diagnosis, prevention, and treatment of cardiac allograft vasculopathy in *Session 75: Cardiac Allograft Vasculopathy: Have Hope, Ye Who Enter*, which will end with a captivating debate on the role of revascularization and defibrillators for CAV treatment. Provocative approaches to replace heart transplantation will be presented by outstanding international leaders in the fields of cardiac 3D printing, xenotransplantation, and stem cell therapy in *Sunrise 08: Print, Replace, or Innovate: Alternative Strategies to Cardiac Transplantation*. Finally, numerous abstract presentations throughout the meeting will present the results of innovative, on-going research in the fields of advanced heart failure and cardiac transplantation.

### Infectious Diseases

Come join in the fun at ISHLT2019. In *Session 60: Joint ISHLT/ABTO Symposium: Combining Experiences to Enhance Thoracic Organ Transplantation Worldwide*, we are partnering with the Associação Brasileira de Transplante de Órgãos (ABTO) to highlight the similarities and differences in transplantation between South America and other areas across the globe. Talks on tuberculosis and Chagas' disease will be delivered by highly experienced experts. This will be of interest for ID and transplant physicians alike, especially in this age of global travel. Infections in MCS device recipients will be looked at from a new angle in *Sunrise 09: MCS Infections: New Twists in an Old Saga*, with an update on the consequences of MCS device infection and a very interesting talk on the role of biofilms in MCS device infections. In the Magic Kingdom of the Bronchoscopy, experts will discuss the evidence related to the interpretation and treatment (or not!) of positive culture results from surveillance bronchoscopies post-lung transplantation. To round out the fun on this ID rollercoaster, we will have an update on fungal infections in *Session 46: FUN and Games with FUNgal Infections in Lung Transplantation*. We will hear cutting edge talks on diagnosis, drug-drug interactions, therapeutic drug monitoring, inhalational medications and in the increasing specter of antifungal resistance.

### Lung Transplantation



Six pulmonary-focused symposia will present scientific data and expert opinions of high clinical relevance to everyone who works in the field of lung failure and lung transplantation. The ongoing scarcity of organs available for transplant remains a challenge in lung transplantation. **Session 61: Making Them Count: Enhancing Donor Utilization** aims to review strategies to optimize organ utilization by improving donor management and using organs from DCD donors, Hepatitis C donors and older donors. **Session 76: Location, Location and Allocation: World Wide Application of Broader Sharing in Lung Transplant** covers an overview of the differences in international lung allocation practices, comparing the USA, European, Canadian and Australian experiences. **Session 32: Ex-Vivo Lung Perfusion (EVLP) in 2019 – From Research to Implementation** looks at current practices and different models used as well as the ongoing clinical trials with EVLP and the rationale for using portable EVLP. **Sunrise 02: Immunobiology of the Older Lung Transplant Recipient** will address why there are significant differences in this cohort of patients who are more at risk of infection and malignancy but experience decreased rates of rejection. **Sunrise 15: Lung Transplant Candidate Selection: Challenging Cases** addresses previous contraindications which are now potentially possible leading to increased lung candidate access. Finally, the greatest challenge of all, **Session 19: Chronic Lung Allograft Dysfunction (CLAD): The End of the Beginning?** aims to review how we can make a more accurate diagnosis of the different phenotypes, i.e. obstructive versus restrictive terminology, and will cover the major risk factors for the development of CLAD using the most up to date information on this topic.

### **Mechanical Circulatory Support**

If you are looking for inspiration, cutting edge scientific content, or simply a great ride, you will get it all during ISHLT2019. Begin with leaving planet earth in **Session 63: Joint ISHLT/ICCAC Symposium: Faster, Higher, Stronger: Monitoring Exercise in Cyberspace** and you can learn how your LVAD patients can get the most out of their heart assist device. The exciting interplay of pacing technologies and durable VAD will be further explored in **Session 13: They Tell Me I Am Irregular: Why Do They Care? Arrhythmias in LVAD Recipients**. Exploring the ultimate goal of rebuilding the heart on LVAD, we provide the latest insights on recovery in **Sunrise 10: Cardiac Reverse Remodeling in MCS: State of the Art**. Surgical approaches to LVAD implantations have evolved dramatically and **Session 05: Limiting the Invasiveness of the VAD Therapy: Alternative to Limited Surgical Approaches** will update you on how the edges are cut in 2019. Two special symposia, **Sunrise 03: From Isolated to Mainstream: Evolving ECMO Strategies That Are Reshaping Outcomes** and **Session 21: Short Term Mechanical Support: Taking the Next Leap Forward** will give a comprehensive primer and expert opinion on the many developments we have witnessed over the past two years in the exciting acute support arena. Hemodynamic tailoring, hemocompatibility assessments, device and patient selection, and ECMO management strategies are just a few of the topics covered here. Lastly, before you leave, get a reality check in a symposium dedicated to serious adverse event currently limiting our abilities to broaden MCS to earlier stages of heart failure in **Session 27: Medical Management of LVAD Patients: Once the Chest is Closed, the Trouble Begins**. We hope to see you in Orlando for a great meeting!

### **Nursing, Health Sciences and Allied Health**

This year's Nursing and Allied Health sessions bring together ISHLT's various disciplines – there is something for everyone in each session! Whether a mechanical circulatory support device or a continuous infusion pump, discharging home with a device can be fraught with challenges and fears. Preparing patients and families for a successful discharge home through self-management interventions and education will be covered in **Session 14: Part of (Their) World: Discharging Patients Home with a New Device**. This session will also address issues important to patient quality of life, like bathing, drinking, sex and traveling. **Session 70: Matters of Life and Death: Palliative and End of Life Care in Transplant Medicine** aims to advance the ways in which we care for patients during another important transition: end of life. Physical, emotional and pharmacological interventions will be discussed, while also bringing attention to the importance of collaboration and cultural/religious considerations. Under recognized for much too long, the need for addressing provider burn-out in organ failure/transplant medicine will also be highlighted at the podium. **Sunrise 16: Fragility: Not Necessarily Failure** will underscore the holistic approach needed to care for a fragile community of patients with frailty, nutritional, cognitive and mental health concerns. Lastly, the advancements in organ failure/transplant medicine that we have witnessed over the years would not be possible without research. To encourage research across all disciplines in our field, **Sunrise 11: The Mission IS Possible If You Choose to Accept It: The Processes of Performing Research**, will include accomplished researchers in the field who will provide guidance for both novice and expert investigators on the processes of research, from study design and funding to the dissemination of findings.

### **Pathology**

Clinical and pathologic definitions for chronic rejection in lung transplantation – antibody-mediated rejection (AMR) and chronic lung allograft dysfunction (CLAD) – have undergone rapid changes over the past decade. **Sunrise 04: Nobody is CLAD to See AMR in Lung Transplantation** will provide an update on these two major areas of discussion over the recent years and future development. **Session 35: Bring Out Your Dead: The Postmortem Evaluation in the Thoracic Transplant Setting** will highlight the postmortem examination (“autopsy”) which is underutilized in modern medicine but provides critical information to the clinicians, families and loved ones of the decedent to help them understand the decedent's clinical course and how data obtained from autopsies may be used by hospital quality personnel, researchers, policy makers, registries and device manufacturers to improve the state of thoracic transplantation and mechanical circulatory support therapy.

### **Pediatric Thoracic Transplantation and Heart Failure**

The pediatric symposia are designed to provide a potpourri of topics in order to capture the interest of a wide range of disciplines and sub specialties. The content will bring together clinicians and researchers to share their work and to present on high impact topics that are changing how we care for our patients. **Session 36: Learning from the Children: Important Lessons from the Pediatric and**

***Congenital Heart Disease Experience*** will focus on the pre-transplant support of children and how to improve waiting list survival. Hot topics in transplantation will be addressed in ***Session 22: What Do We Do? Burning Platforms in Pediatric Thoracic Transplant. Sunrise 17: A Brand New Day: The New Normal in Pediatric Thoracic Transplantation*** will focus on lung transplant. And after they get an organ what do you do if they develop an infection? This question will be explored in the joint symposium with the International Pediatric Transplant Association (IPTA): ***Session 56: EBV and CMV are Not as Easy as 1-2-3 When Caring for Pediatric Thoracic Recipients.***


### **Pharmacy and Pharmacology**

Pharmacy and pharmacology will appeal to all areas of the ISHLT membership with four symposia highlighting pharmacotherapy needs of our patients to ensure the best outcomes. In ***Session 07: Making Co-Morbidities Great Again: Practical Updates in Co-Morbidity Management***, an expert panel will provide updates to the management of common co-morbidities pre- and post-transplant with a focus on the evidence base and novel medications. Diabetes, dyslipidemia, osteoporosis, psychiatric disorders, complimentary/alternative medicine, and immunizations/ travel medicine will all be reviewed. In ***Sunrise 06: Making Deals with the Devil: Substances of Abuse from Pre- to Post-Transplant***, our multidisciplinary panel will review substance use and abuse in transplant recipients with a focus on the evidence showing adverse effects of narcotics, anxiolytics, nicotine, marijuana, and alcohol before and after transplant. Novel approaches to assessment and cessation interventions will be discussed. In ***Sunrise 12: A Bloody Mess: Management of Hematologic Complications in Transplantation and MCS***, we will offer insights into the management of neutropenia, thrombocytopenia, and hemoglobin optimization while also discussing direct acting oral anticoagulant use and pharmacologic management of bleeding reversal in both transplant and MCS patients. Lastly, ***Sunrise 18: So Your Patient is on ECMO... Now What? Considerations for Drug Dosing and Anticoagulation in ECMO*** will discuss the hot topics of optimal dosing of anti-infective medications and anticoagulation strategies in ECMO patients, especially as the boundaries of ECMO use are expanding.

### **Pulmonary Hypertension**

**Session 57: Take These Broken Lungs and Learn to Fly: Great Debates for Patients with PAH Awaiting Transplant** will explore the complex decision making in the care of patients with end stage pulmonary hypertension awaiting lung transplantation. ***Sunrise 05: I Want to Ride My Bicycle: Cardiopulmonary Exercise Testing (CPET) for PAH and CTEPH***, will review the various aspects of exercise testing from pathophysiology to outcome prediction. ***Session 71: Breaking Bad: The Right Ventricle and Exercise Hemodynamics Rediscovered*** will provide an overview into the mechanisms, clinical diagnosis and management of chronic right heart failure in left heart disease, scleroderma, and pulmonary hypertension. In collaboration with the Pulmonary Vascular Research Institute (PVRI), ***Session 43: Changes in the World of Pulmonary Hypertension: Nice or Not Nice*** will bring in experts to focus on controversies and new proposed developments under review since the recent World Symposium on Pulmonary Hypertension.

# THE LOEWS MEETING COMPLEX





LOEWS SAPPHIRE FALLS RESORT FLOOR PLAN

LOEWS ROYAL PACIFIC RESORT FLOOR PLAN

# LOEWS ROYAL PACIFIC RESORT

## FLOOR PLAN





LOEWS  
**SAPPHIRE  
 FALLS RESORT**  
 FLOOR PLAN

## ACRONYMS

To help you navigate your way through the meeting content and find those sessions most likely to be of interest to you, we have coded each session according to the primary professional audience it was designed for.

These codes are explained as follows:

BSTR	Basic Science and Translational Research
CTEPH	Chronic Thromboembolic Pulmonary Hypertension
EEP	Economics, Ethics, Public Policy
HF/HTX	Heart Failure/Heart Transplantation
ID	Infectious Diseases
LF/LTX	Lung Failure/Lung Transplantation
MCS	Mechanical Circulatory Support
NHSAH	Nursing/Health Science/Allied Health
PATH	Pathology
PEDS	Pediatrics
PHARM	Pharmacy and Pharmacology
PH	Pulmonary Hypertension

## SCIENTIFIC COUNCIL MEETINGS & RECEPTIONS

<u>Council</u>	<u>Meeting</u>	<u>Networking Reception</u>
Basic Science and Translational Research	Wednesday, April 3 12:30 PM – 1:45 PM Pacifica 1-2	Wednesday, April 3 6:00 PM – 7:15 PM Hibiscus 1 & 2
Chronic Thromboembolic Pulmonary Hypertension	Friday, April 5 7:00 AM – 8:00 AM Oceana 3-5	Friday, April 5 6:00 PM – 7:15 PM Gardenia 2
Heart Failure & Transplantation	Friday, April 5 12:30 PM – 1:45 PM Pacifica 7	Friday, April 5 6:00 PM – 7:15 PM Hibiscus 1 & 2
Infectious Diseases	Friday, April 5 12:30 PM – 1:45 PM Pacifica 3-5	Thursday, April 4 5:45 PM – 7:00 PM Gardenia 2
Junior Faculty and Trainees	Thursday, April 4 7:00 AM – 8:00 AM Oceana 3-5	Thursday, April 4 5:45 PM – 7:00 PM Banda Sea 1 & 2
Mechanical Circulatory Support	Thursday, April 4 12:30 PM – 1:45 PM Pacifica 6	Thursday, April 4 5:45 PM – 7:00 PM Timor Sea 1 & 2
Nursing, Health Science, and Allied Health	Wednesday, April 3 12:30 PM – 1:45 PM Pacifica 3-5	Wednesday, April 3 6:00 PM – 7:15 PM Gardenia 2
Pathology	Thursday, April 4 12:30 PM – 1:45 PM Coral Sea	Wednesday, April 3 6:00 PM – 7:15 PM Hibiscus 1 & 2
Pediatric Thoracic Transplantation & Heart Failure	Thursday, April 4 12:30 PM – 1:45 PM Pacifica 3-5	Friday, April 5 6:00 PM – 7:15 PM Banda Sea 2
Pharmacy and Pharmacology	Wednesday, April 3 12:30 PM – 1:45 PM Coral Sea	Wednesday, April 3 6:00 PM – 7:15 PM Gardenia 1
Pulmonary Hypertension	Thursday, April 4 12:30 PM – 1:45 PM Pacifica 1-2	Friday, April 5 6:00 PM – 7:15 PM Gardenia 2
Pulmonary Transplantation	Friday, April 5 12:30 PM – 1:45 PM Pacifica 10-12	Friday, April 5 6:00 PM – 7:15 PM Banda Sea 1

## **SCHEDULE AT A GLANCE**

### **MONDAY, APRIL 1, 2019**

#### **8:00 AM – 12:00 PM**

ISHLT Board of Directors Meeting (Oceana 4)

#### **1:00 PM – 5:00 PM**

ISHLT Strategic Planning Meeting (Oceana 4)

#### **5:00 PM – 8:00 PM**

Academy Registration Open (Pacifica Foyer Pre-Function North)

Exhibitor Registration Open (Pacifica Foyer Pre-Function South)

Speaker Ready Room Open (Pacifica 8-9)

### **TUESDAY, APRIL 2, 2019**

#### **6:00 AM – 3:00 PM**

Academy Registration Open (Pacifica Foyer Pre-Function North)

#### **6:00 AM – 8:00 PM**

Exhibitor Registration (Pacifica Foyer Pre-Function South)

Speaker Ready Room Open (Pacifica 8-9)

#### **7:45 AM – 6:15 PM**

ISHLT ACADEMY: Core Competencies in Nursing, Health Sciences and Allied Health: Care of Patients Requiring Mechanical Circulatory Support and Transplantation (Pacifica 3-5)

#### **7:55 AM – 5:15 PM**

ISHLT ACADEMY: Core Competencies in Pediatric Heart Failure (Pacifica 1-2)

#### **8:00 AM – 5:00 PM**

ISHLT Strategic Planning Meeting (Oceana 4)

#### **8:00 AM – 1:00 PM**

ISHLT ACADEMY: Master Class in Heart Failure and Transplantation (Coral Sea and Java Sea)

ISHLT ACADEMY: Master Class in Mechanical Circulatory Support (Banda Sea and Timor Sea)

#### **11:30 AM – 1:00 PM**

Core Academy Box Lunch Pick-Up (Wantilan Pavilion)

#### **2:00 PM – 7:00 PM**

ISHLT ACADEMY: Master Class in Heart Failure and Transplantation (Coral Sea and Java Sea)

ISHLT ACADEMY: Master Class in Mechanical Circulatory Support (Banda Sea and Timor Sea)

#### **4:00 PM – 8:00 PM**

Annual Meeting Registration Open (Grand Caribbean Foyer Pre-Function North)

#### **5:00 PM – 6:00 PM**

COMMITTEE MEETING: Grants & Awards (Admiralty Boardroom)

#### **5:00 PM – 7:00 PM**

COMMITTEE MEETING: Transplant Registry (Oceana 5)

#### **6:00 PM – 7:00 PM**

COMMITTEE MEETING: International Engagement (Oceana 4)

COMMITTEE MEETING: Standards & Guidelines (Admiralty Boardroom)



## **WEDNESDAY, APRIL 3, 2019**

### **6:00 AM – 7:00 PM**

Exhibitor Registration (Pacifica Foyer Pre-Function South)  
Speaker Ready Room Open (Pacifica 8-9)

### **7:00 AM – 7:00 PM**

Annual Meeting Registration Open (Grand Caribbean Foyer Pre-Function North)

### **8:00 AM – 9:45 AM**

Poster Session 1 Mount (Timor, Banda, Gardenia, Hibiscus)

### **8:00 AM – 10:00 AM**

**OPENING PLENARY SESSION** (Grand Caribbean 1-7)

### **9:00 AM – 7:00 PM**

Press Office Open (Philippine Sea)

### **9:30 AM – 7:15 PM**

Exhibit Hall Open (Oceana 6-12)

### **10:00 AM – 10:30 AM**

Coffee Break (Oceana 6-12)

### **10:00 AM – 7:15 PM**

Industry Theater Open (Oceana 2)  
Poster Halls Open (Timor, Banda, Gardenia, Hibiscus)

### **10:30 AM – 12:15 PM**

SESSION 01 (ORAL): The Next Frontier for Thoracic Transplantation: Diagnostics and Therapies (Pacifica 1-2)  
SESSION 02 (SYMPOSIUM): Future Shock: Great Debates in Cardiogenic Shock (Pacifica 7)  
SESSION 03 (ORAL): Chronic Lung Allograft Dysfunction: Anything New? (Pacifica 10-12)  
SESSION 04 (ORAL): So Wrong It's Right: The Right Ventricle and MCS (Pacifica 6)  
SESSION 05 (SYMPOSIUM): Limiting the Invasiveness of VAD Therapy: Alternative to Limited Surgical Approaches (Grand Caribbean 1-7)  
SESSION 06 (ORAL): Pediatric Donor Utilization, MCS, Readmissions and More (Pacifica 3-5)  
SESSION 07 (SYMPOSIUM): Making Co-Morbidities Great Again: Practical Updates in Co-Morbidity Management (Coral Sea)

### **12:15 PM – 2:00 PM**

LUNCH BREAK

### **12:30 PM – 1:45 PM**

COMMITTEE MEETING: IMACS Registry (Admiralty Boardroom)  
COUNCIL MEETING: Basic Science and Translational Research (Pacifica 1-2)  
COUNCIL MEETING: Nursing, Health Sciences and Allied Health (Pacifica 3-5)  
COUNCIL MEETING: Pharmacy and Pharmacology (Coral Sea)

### **12:45 PM – 1:45 PM**

SESSION 08 (ORAL): ISHLT Spotlight: Heart Transplantation in Latin America (Pacifica 7)

### **2:00 PM – 3:45 PM**

SESSION 09 (SYMPOSIUM): Re-Focusing the Blurry Vision: Biomarkers of Thoracic Allograft Rejection (Pacifica 1-2)  
SESSION 10 (ORAL): Heart Donor Management and Allocation: Setting It Up For Success (Pacifica 7)  
SESSION 11 (ORAL): Chronic Lung Allograft Dysfunction: Overcoming the Hurdle? (Pacifica 10-12)  
SESSION 12 (ORAL): When Short-Term Becomes Long-Term: Transition from Temporary to Permanent Mechanical Support (Pacifica 6)  
SESSION 13 (SYMPOSIUM): They Tell Me I Am Irregular: Why Do They Care? Arrhythmias in LVAD Recipients (Grand Caribbean 1-7)  
SESSION 14 (SYMPOSIUM): Part of (Their) World: Discharging Patients Home with a New Device (Pacifica 3-5)  
SESSION 15 (ORAL): Pharmacotherapy in Transplantation: Reading the Tea Leaves to Improve Outcomes (Coral Sea)

**3:45 PM – 4:15 PM**

Coffee Break (Oceana 6-12)

**4:15 PM – 6:00 PM**

SESSION 16 (ORAL): Junior Faculty and Trainees Clinical Case Dilemmas: The Best of the Best (Coral Sea)

SESSION 17 (ORAL): Tolerance Is All We Need in Thoracic Transplantation (Pacifica 1-2)

SESSION 18 (ORAL): Ex-Vivo Heart Perfusion and Preservation: Some Like It Hot – or Not! (Pacifica 7)

SESSION 19 (SYMPOSIUM): Chronic Lung Allograft Dysfunction (CLAD): The End of the Beginning? (Pacifica 10-12)

SESSION 20 (ORAL): The Beat Goes On: Arrhythmias and Pacing During MCS (Pacifica 6)

SESSION 21 (SYMPOSIUM): Short Term Mechanical Support: Taking the Next Leap Forward (Grand Caribbean 1-7)

SESSION 22 (SYMPOSIUM): What Do We Do? Burning Platforms in Pediatric Thoracic Transplant (Pacifica 3-5)

**5:45 PM – 7:15 PM**

Exhibit Hall Opening Reception (Oceana 6-12)

**6:00 PM – 7:15 PM****POSTER SESSION 1:**

Basic Science & Translational Research and Pathology (Hibiscus 1 & 2)

Economics, Ethics, Public Policy (Gardenia 2)

Heart Transplantation (Adult) (Timor Sea 1 & 2)

Junior Faculty Clinical Case Reports: Mechanical Circulatory Support, Infectious Diseases, Pediatrics (Banda Sea 2)

Junior Faculty Clinical Case Reports: Mechanical Circulatory Support, Pulmonary Hypertension (Banda Sea 1)

Nursing, Health Sciences, Allied Health (Gardenia 2)

Pharmacy and Pharmacology (Gardenia 1)

**COUNCIL NETWORKING RECEPTIONS:**

Basic Science & Translational Research (Hibiscus 1 & 2)

Pathology (Hibiscus 1)

Nursing, Health Sciences, Allied Health (Gardenia 2)

Pharmacy and Pharmacology (Gardenia 1)

**6:15 PM – 7:15 PM**

MINI ORAL 01: Deciphering the Role of Antibodies and Inflammation in Thoracic Rejection (Pacifica 1-2)

MINI ORAL 02: Cardiac Donor Selection: More Than Meets the Eye (Pacifica 7)

MINI ORAL 03: Chronic Lung Allograft Dysfunction (Pacifica 10-12)

MINI ORAL 04: MCS: A Focus on Stroke (Coral Sea)

MINI ORAL 05: Do It Quick and Do It NOW: ECMO Update (Pacifica 6)

MINI ORAL 06: Pediatrics (Pacifica 3-5)

**7:15 PM – 8:15 PM**

Poster Session 1 Removal (Timor, Banda, Gardenia, Hibiscus)

## **THURSDAY, APRIL 4, 2019**

### **6:00 AM – 6:30 PM**

Annual Meeting Registration Open (Grand Caribbean Foyer Pre-Function North)

### **6:00 AM – 7:15 PM**

Speaker Ready Room Open (Pacifica 8-9)

### **7:00 AM – 9:45 AM**

Poster Session 2 Mount (Timor, Banda, Gardenia, Hibiscus)

### **7:00 AM – 8:00 AM**

COUNCIL MEETING: Junior Faculty and Trainees (Oceana 3-5)

SUNRISE 01: In the Thick of It: Hypertrophic and Amyloid Cardiomyopathies (Pacifica 7)

SUNRISE 02: Immunobiology of the Older Lung Transplant Recipient (Pacifica 10-12)

SUNRISE 03: From Isolated to Mainstream: Evolving ECMO Strategies That Are Reshaping Outcomes (Pacifica 6)

SUNRISE 04: Nobody is CLAD to See AMR in Lung Transplantation (Coral Sea)

SUNRISE 05: I Want to Ride My Bicycle: Cardiopulmonary Exercise Testing (CPET) for PAH and CTEPH (Pacifica 1-2)

SUNRISE 06: Making Deals with the Devil: Substances of Abuse from Pre- to Post-Transplant (Pacifica 3-5)

### **8:00 AM – 9:45 AM**

SESSION 23 (ORAL): Hepatitis C+ Cardiac Donors: Do They Get an A+? (Pacifica 6)

SESSION 24 (ORAL): Molecular Diagnostics in Heart Transplantation: It's All in the Genes (Pacifica 7)

SESSION 25 (SYMPOSIUM): Magic Kingdom of the Bronchoscopy: Pathogens with Real Implications and Those to Disregard (Pacifica 3-5)

SESSION 26 (ORAL): Mechanical Lung Support for Isolated Organs and Patients (Pacifica 10-12)

SESSION 27 (SYMPOSIUM): Medical Management of LVAD Patients: Once the Chest is Closed, the Trouble Begins (Grand Caribbean 1-7)

SESSION 28 (ORAL): Tissue is Not the Only Issue: Advances in Thoracic Transplant Pathology (Coral Sea)

SESSION 29 (ORAL): Pediatric Lung Transplantation: Are We Moving Forward? (Pacifica 1-2)

### **9:00 AM – 6:30 PM**

Exhibitor Registration (Pacifica Foyer Pre-Function South)

### **9:00 AM – 7:00 PM**

Press Office Open (Philippine Sea)

### **9:30 AM – 7:00 PM**

Exhibit Hall Open (Oceana 6-12)

### **9:45 AM – 10:15 AM**

Coffee Break (Oceana 6-12)

### **9:45 AM – 7:00 PM**

Industry Theater Open (Oceana 2)

Poster Halls Open (Timor, Banda, Gardenia, Hibiscus)

### **10:15 AM – 12:00 PM**

SESSION 30 (ORAL): Get up and Go! Predicting Survival in Heart Failure (Pacifica 7)

SESSION 31 (ORAL): Slaying the Dragon: Hepatitis C and Thoracic Transplantation (Pacifica 1-2)

SESSION 32 (SYMPOSIUM): Ex-Vivo Lung Perfusion (EVLP) in 2019: From Research to Implementation (Pacifica 10-12)

SESSION 33 (ORAL): Brain Attack: Strokes and MCS (Pacifica 6)

SESSION 34 (ORAL): Never Mind the Leaks: Addressing Valvular Disease with LVADs (Grand Caribbean 1-7)

SESSION 35 (SYMPOSIUM): Bring Out Your Dead: The Postmortem Evaluation in the Thoracic Transplant Setting (Coral Sea)

SESSION 36 (SYMPOSIUM): Learning from the Children: Important Lessons from the Pediatric and CHD VAD Experience (Pacifica 3-5)

### **12:00 PM – 1:45 PM**

LUNCH BREAK

### **12:30 PM – 1:45 PM**

COUNCIL MEETING: Mechanical Circulatory Support (Pacifica 6)

COUNCIL MEETING: Pathology (Coral Sea)

COUNCIL MEETING: Pediatric Thoracic Transplantation and Heart Failure (Pacifica 3-5)

COUNCIL MEETING: Pulmonary Hypertension (Pacifica 1-2)

JHLT Editorial Board Lunch Meeting (Java Sea 1)

### **1:45 PM – 3:30 PM**

SESSION 37 (SYMPOSIUM): JHLT at ISHLT: The Year in a Capsule (Pacifica 10-12)

SESSION 38 (ORAL): Early Career Scientist Award Candidate Presentations (Coral Sea)

SESSION 39 (ORAL): Walking a Tightrope: The Double-Edged Sword of Drugs after Heart Transplant (Pacifica 3-5)

SESSION 40 (SYMPOSIUM): Heart Failure in Adult Congenital Heart Disease: Unique Problems Need Unique Solutions (Pacifica 7)

SESSION 41 (ORAL): Perfecting the Graft: LVAD Pump Management, Outcomes and Medications (Pacifica 6)

SESSION 42 (ORAL): Too Much or Too Little? Obesity and Frailty in MCS (Grand Caribbean 1-7)

SESSION 43 (SYMPOSIUM): Changes in the World of Pulmonary Hypertension: Nice or Not Nice (Pacifica 1-2)

### **3:30 PM – 4:00 PM**

Coffee Break (Oceana 6-12)

### **4:00 PM – 5:45 PM**

SESSION 44 (ORAL): Philip K. Caves Award Candidate Presentations (Coral Sea)

SESSION 45 (ORAL): Acute Cardiac Rejection: New Approaches to an Old Problem (Pacifica 7)

SESSION 46 (SYMPOSIUM): FUN and Games with FUNgal Infections in Lung Transplantation (Pacifica 3-5)

SESSION 47 (ORAL): Back to the Basics: Physiological Alterations During Continuous Flow VAD Support (Pacifica 6)

SESSION 48 (SYMPOSIUM): Advances in Short- and Long-Term MCS – What's Next (Grand Caribbean 1-7)

SESSION 49 (ORAL): The Personal Connection: Psychological Issues and Care for Donor Families, Patients and Providers (Pacifica 10-12)

SESSION 50 (ORAL): PH in Translation: From Novel Biomarkers to Cutting Edge Clinical Results (Pacifica 1-2)

### **5:45 PM – 6:45 PM**

Past Presidents Meeting (Admiralty Boardroom)

### **5:45 PM – 7:00 PM**

Wine and Cheese Reception (Oceana 6-12)

### **POSTER SESSION 2:**

Infectious Diseases (Gardenia 2)

Junior Faculty Clinical Case Reports: Heart Failure/Transplantation, Lung Failure/Transplantation (Banda Sea 1 & 2)

Lung Transplantation (Adult) (Hibiscus 1 & 2)

Mechanical Circulatory Support (Adult) (Timor Sea 1 & 2)

### **COUNCIL NETWORKING RECEPTIONS:**

Junior Faculty and Trainees (Banda Sea 1 & 2)

Mechanical Circulatory Support (Timor Sea 1 & 2)

Infectious Diseases (Gardenia 2)

### **6:00 PM – 7:00 PM**

MINI ORAL 07: Basic Science and Heart Transplantation (Coral Sea)

MINI ORAL 08: Lung Donor Management and Organ Allocation (Pacifica 10-12)

MINI ORAL 09: MCS: GI Bleeding (Pacifica 6)

MINI ORAL 10 A&B: Nursing, Health Sciences, Allied Health / Pharmacy and Pharmacology (Pacifica 3-5)

MINI ORAL 11 A&B: Heart Failure (Adult) / Pediatrics (Pacifica 1-2)

MINI ORAL 12 A&B: Pulmonary Hypertension / Heart Transplantation (Pacifica 7)

### **7:00 PM – 8:00 PM**

Poster Session 2 Removal (Timor, Banda, Gardenia, Hibiscus)

## **FRIDAY, APRIL 5, 2019**

### **6:00 AM – 6:30 PM**

Annual Meeting Registration Open (Grand Caribbean Foyer Pre-Function North)

### **6:00 AM – 7:15 PM**

Speaker Ready Room Open (Pacifica 8-9)

### **7:00 AM – 10:00 AM**

Poster Session 3 Mount (Timor, Banda, Gardenia, Hibiscus)

### **7:00 AM – 8:00 AM**

COUNCIL MEETING: Chronic Thromboembolic Pulmonary Hypertension (Oceana 3-5)

SUNRISE 07: Highways to Hell: Chronic Lung Allograft Dysfunction (Pacifica 1-2)

SUNRISE 08: Print, Replace or Innovate: Alternative Strategies to Cardiac Transplantation (Pacifica 7)

SUNRISE 09: MCS Infections: New Twists in an Old Saga (Pacifica 3-5)

SUNRISE 10: Cardiac Reverse Remodeling in MCS: State of the Art (Pacifica 6)

SUNRISE 11: The Mission IS Possible If You Choose to Accept it: The Processes of Performing Research (Pacifica 10-12)

SUNRISE 12: A Bloody Mess: Management of Hematologic Complications in Transplantation and MCS (Coral Sea)

### **8:00 AM – 10:00 AM**

**PLENARY SESSION** (Grand Caribbean 1-7)

### **9:00 AM – 6:30 PM**

Exhibitor Registration (Registration South)

### **9:00 AM – 7:00 PM**

Press Office Open (Philippine Sea)

### **9:30 AM – 4:30 PM**

Exhibit Hall Open (Ocean 6-12)

### **10:00 AM – 10:30 AM**

Coffee Break (Oceana 6-12)

**Annual Business Meeting** (Grand Caribbean 1-7)

### **10:00 AM – 4:30 PM**

Industry Theater Open (Oceana 2)

### **10:00 AM – 7:15 PM**

Poster Halls Open (Timor, Banda, Gardenia, Hibiscus)

### **10:30 AM – 12:15 PM**

SESSION 51 (ORAL): Cardiac Allograft Vasculopathy: A Never-ending Story (Pacifica 6)

SESSION 52: Joint ISHLT/SCMR Symposium: Cardiac MRI and the World of Heart Failure: When Two Disciplines Harmonize (Pacifica 7)

SESSION 53 (ORAL): Chasing the Golden Snitch: Optimizing Outcomes of MCS Infections (Pacifica 1-2)

SESSION 54 (ORAL): Swipe Right or Swipe Left? Matching Donors and Recipients in Lung Transplantation (Pacifica 10-12)

SESSION 55 (ORAL): Score Now – Or Forever Hold Your Peace: Prediction and Risk in MCS (Grand Caribbean 1-7)

SESSION 56: Joint ISHLT/IPTA Symposium: EBV and CMV are Not as Easy as 1-2-3 When Caring for Ped Thoracic Tx Recipients (Pacifica 3-5)

SESSION 57 (SYMPOSIUM): Take These Broken Lungs and Learn to Fly: Great Debates for Patients with PAH Awaiting Tx (Coral Sea)

### **12:15 PM – 2:00 PM**

LUNCH BREAK

### **12:30 PM – 1:45 PM**

COMMITTEE MEETING: Registries and Databases (Admiralty Boardroom)

COUNCIL MEETING: Heart Failure and Transplantation (Pacifica 7)

COUNCIL MEETING: Infectious Diseases (Pacifica 3-5)

COUNCIL MEETING: Pulmonary Transplantation (Pacifica 10-12)

**2:00 PM – 3:45 PM**

SESSION 58 (SYMPOSIUM): Resilience in the Face of Calamity: The Art of Preventing PTE Disasters (Coral Sea)  
SESSION 59 (ORAL): Heart Transplant Short-Term Outcomes: Getting it Right From the Start (Pacifica 7)  
SESSION 60: Joint ISHLT/ABTO Symposium: Combining Experiences to Enhance Thoracic Organ Transplantation Worldwide (Pacifica 3-5)  
SESSION 61 (SYMPOSIUM): Making Them Count: Enhancing Lung Donor Utilization (Pacifica 10-12)  
SESSION 62 (ORAL): Under New Management: Novel Strategies for MCS (Grand Caribbean 1-7)  
SESSION 63: Joint ISHLT/ICCAC Symposium: Faster, Higher, Stronger: Monitoring Exercise in Cyberspace (Pacifica 6)  
SESSION 64 (ORAL): Highlights of Challenging Topics in Pediatric Heart Transplant and MCS (Pacifica 1-2)

**3:45 PM – 4:15 PM**

Coffee Break (Oceana 6-12)  
COMMITTEE MEETING: 2020 Symposium Planning (South China Sea)

**4:15 PM – 6:00 PM**

SESSION 65 (SYMPOSIUM): All Talk, No Action? New Strategies and Best Practices to Maximize Donor Heart Utilization (Pacifica 7)  
SESSION 66 (ORAL): Between the Devil and the Deep Blue Sea: Fungus or CMV? (Pacifica 1-2)  
SESSION 67 (ORAL): Diagnostics and Immunosuppression in Lung Transplantation (Pacifica 10-12)  
SESSION 68 (ORAL): LV Recovery after MCS: From Promise to Reality? (Pacifica 6)  
SESSION 69 (ORAL): Tricks of the Trade: Management Considerations with Continuous Flow LVADs (Grand Caribbean 1-7)  
SESSION 70 (SYMPOSIUM): Matters of Life and Death: Palliative and End of Life Care in Transplant Medicine (Pacifica 3-5)  
SESSION 71 (SYMPOSIUM): Breaking Bad: The Right Ventricle and Exercise Hemodynamics Rediscovered (Coral Sea)

**6:00 PM – 7:15 PM****POSTER SESSION 3:**

Heart Failure/Transplantation (Adult) (Hibiscus 1 & 2)  
Lung Failure/Transplantation (Adult) (Banda Sea 1)  
Mechanical Circulatory Support (Adult) (Timor Sea 1 & 2)  
Pediatrics (Banda Sea 2)  
Pulmonary Hypertension and CTEPH (Gardenia 2)

**COUNCIL NETWORKING RECEPTIONS**

Heart Failure and Transplantation (Hibiscus 1 & 2)  
Pulmonary Transplantation (Banda Sea 1)  
Pediatric Thoracic Transplantation and Heart Failure (Banda Sea 2)  
Pulmonary Hypertension and Chronic Thromboembolic Pulmonary Hypertension (Gardenia 2)

**6:15 PM – 7:15 PM**

MINI ORAL 13: Cardiac Donors and Recipients: Valuable Insights (Pacifica 1-2)  
MINI ORAL 14: Unique Considerations for Special Heart Transplant Populations (Pacifica 7)  
MINI ORAL 15: Infectious Diseases and Basic Science (Pacifica 3-5)  
MINI ORAL 16: Lung Transplant Outcomes (Pacifica 10-12)  
MINI ORAL 17: LVAD Physiology: Effects on End Organs (Pacifica 6)  
MINI ORAL 18: MCS: Right Heart Failure (Coral Sea)

**7:15 PM – 8:15 PM**

Poster Session 3 Removal (Timor, Banda, Gardenia, Hibiscus)

# **SATURDAY, APRIL 6, 2019**

## **6:00 AM – 12:15 PM**

Speaker Ready Room Open (Pacifica 8-9)

## **7:00 AM – 12:15 PM**

Annual Meeting Registration Open (Registration South & China Sea)

## **7:00 AM – 8:00 AM**

SUNRISE 13: A Fork in the Road: How Can We Compare Interventional Therapies in CTEPH? (Coral Sea)

SUNRISE 14: One Size Does Not Fit All: Personalized Medicine in Heart Transplantation (Pacifica 7)

SUNRISE 15: Lung Transplant Candidate Selection: Challenging Cases (Pacifica 10-12)

SUNRISE 16: Fragility: Not Necessarily Failure (Pacifica 6)

SUNRISE 17: A Brand-New Day: The New Normal in Pediatric Thoracic Transplantation (Pacifica 1-2)

SUNRISE 18: So Your Patient is on ECMO... Now What? Considerations for Drug Dosing and Anticoagulation in ECMO (Pacifica 3-5)

## **8:00 AM – 10:00 AM**

**PLENARY SESSION** (Pacifica 6)

## **10:00 AM – 10:15 AM**

Coffee Break (Pacifica Foyer)

## **10:15 AM – 12:00 PM**

SESSION 72 (SYMPOSIUM): Seeing the Light: Antibodies in Thoracic Transplantation (Pacifica 3-5)

SESSION 73 (ORAL): Life on the Cutting Edge: CTEPH and Surgical Management of Pulmonary Hypertension (Pacifica 1-2)

SESSION 74 (ORAL): Frontiers of Cost-Efficacy and Policy in Transplant and MCS (Coral Sea)

SESSION 75 (SYMPOSIUM): Cardiac Allograft Vasculopathy: Have Hope, Ye Who Enter (Pacifica 7)

SESSION 76 (SYMPOSIUM): Location, Location, and Allocation: Worldwide Application of Broader Sharing in LTX (Pacifica 10-12)

SESSION 77 (ORAL): Thicker than Water? Bleeding and LVADs (Pacifica 6)

## **12:15 PM – 2:00 PM**

SESSION 78 (ORAL): The Beginning of the End in Lung Transplantation: PGD, AMR and CLAD (Pacifica 3-5)

SESSION 79 (ORAL): Go with the Flow: Hemodynamic Guiding Therapies in Heart Failure (Pacifica 1-2)

SESSION 80 (ORAL): Heart Transplant Long-Term Outcomes: In It for the Long Haul (Pacifica 7)

SESSION 81 (ORAL): Primary Graft Dysfunction and Acute Lung Rejection (Coral Sea)

SESSION 82 (ORAL): Donor Lung Management: Can We Do Better? (Pacifica 10-12)

SESSION 83 (ORAL): What's Holding Me Back? Exercise in LVAD Patients (Pacifica 6)

## **2:00 PM**

MEETING ADJOURNS

WEDNESDAY, APRIL 3, 2019

8:00 AM - 10:00 AM

OPENING PLENARY SESSION

Room: Grand Caribbean 1-7

Target Audience: ALL

Chairs: Jeffrey J Teuteberg, MD, and Lara Danziger-Isakov, MD, MPH

- 8:00 AM**            ***Welcome/Program Chair Report***  
Lara Danziger-Isakov, MD, MPH, Children's Hospital Medical Center, Cincinnati, OH, USA
- 8:10 AM**            ***Thoracic Registry Report***  
Josef Stehlik, MD, MPH, University of Utah School of Medicine, Salt Lake City, UT, USA
- 8:20 AM**            ***IMACS Registry Report***  
Daniel J Goldstein, MD, Montefiore Medical Center, Bronx, NY, USA
- 8:30 AM**            ***Journal Editor's Report***  
Mandeep R Mehra, MD, FRCP, FACC, FESC, Brigham and Women's Hospital, Boston, MA, USA
- 8:40 AM**            ***President's Report***  
Jeffrey J Teuteberg, MD, Stanford University School of Medicine, Stanford, CA, USA
- 8:55 AM**            ***(1) Clinical Outcomes by Intended Goal of Therapy in the MOMENTUM 3 Clinical Trial: Final Analysis of the 1028 Patient Full Cohort; D. Goldstein<sup>1</sup>, M. R. Mehra<sup>2</sup>, -. MOMENTUM 3 Investigators<sup>2</sup>. <sup>1</sup>Dept of Cardiothoracic Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, <sup>2</sup>Brigham and Women's Hospital, Boston, MA***
- 9:10 AM**            ***Q&A with Interactive Discussant***  
Robert L Kormos, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
- 9:15 AM**            ***(2) INSPIRE: A Phase 3 Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of LIQ861 in Pulmonary Arterial Hypertension (PAH) (Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil NCT03399604); N. S. Hill<sup>1</sup>, J. P. Feldman<sup>2</sup>, S. Sahay<sup>3</sup>, D. J. Levine<sup>4</sup>, R. F. Roscigno<sup>5</sup>, T. A. Vaughn<sup>5</sup>, T. M. Bull<sup>6</sup>. <sup>1</sup>Tufts Medical Center, Boston, MA, <sup>2</sup>Arizona Pulmonary Specialists, Ltd, Phoenix, AZ, <sup>3</sup>Weill Cornell Medicine, Institute of Academic Medicine, Houston Methodist Lung Center, Houston Methodist, Houston, TX, <sup>4</sup>University of Texas Health Sciences Center at San Antonio, San Antonio, TX, <sup>5</sup>Liquidia Technologies, Morrisville, NC, <sup>6</sup>Anschutz Medical Campus, Univ of Colorado Denver, Aurora, CO***
- 9:30 AM**            ***Q&A with Interactive Discussant***  
Jean-Luc Vachiery, MD, Erasme University Hospital, Brussels, Belgium
- 9:35 AM**            ***Introductory Remarks to Lifetime Achievement Award Recipient***  
Keith McNeil, MD, Papworth Hospital NHS Trust, Papworth Everard, United Kingdom
- 9:40 AM**            ***Lifetime Achievement Award Recipient Lecture***  
Prof. John Wallwork, FRCS, FmedSci, CBE, Royal Papworth Hospital, Cambridge, United Kingdom



WEDNESDAY, APRIL 3, 2019

10:30 AM - 12:15 PM

**SESSION 01 (ORAL): The Next Frontier for Thoracic Transplantation: Diagnostics and Therapies**

Room: Pacifica 1-2

Target Audiences: BSTR, LTX, PEDS, PATH)

Chairs: Marilia Cascalho, MD, PhD, and Matthew G Hartwig, MD

- 10:30 AM** (5) *Early Detection of Post-Transplant Lymphoproliferative Disorder Using Circulating Tumor DNA*; J. Soo, J. Schroers-Martin, A. Garofalo, D. Kurtz, N. D'Emilio, H. Luikart, A. Alizadeh, K. Khush. *Stanford University, Stanford, CA*
- 10:45 AM** (6) *Distinct Heart Failure Phenotypes Identified by Myocardial Transcriptome Sequencing: Targets for Reverse Remodeling*; P. Shah<sup>1</sup>, W. Zhu<sup>2</sup>, S. Navankasattusas<sup>3</sup>, D. K. Ramadurai<sup>3</sup>, S. S. Desai<sup>1</sup>, I. Taleb<sup>3</sup>, I. Efimov<sup>4</sup>, R. Singh<sup>5</sup>, N. Aliyev<sup>3</sup>, R. K. Iyer<sup>2</sup>, O. Wever-Pinzon<sup>6</sup>, S. McKellar<sup>7</sup>, W. T. Caine<sup>8</sup>, C. R. deFilippi<sup>9</sup>, J. Zhu<sup>10</sup>, S. Drakos<sup>6</sup>. <sup>1</sup>*Heart Failure and Transplantation, Inova Heart and Vascular Institute, Falls Church, VA*, <sup>2</sup>*Inova Translational Medicine Institute, Falls Church, VA*, <sup>3</sup>*University of Utah, Salt Lake City, UT*, <sup>4</sup>*George Washington University, Washington, DC*, <sup>5</sup>*Cardiac Surgery, Inova Heart and Vascular Institute, Falls Church, VA*, <sup>6</sup>*Heart Failure and Transplantation, University of Utah, Salt Lake City, UT*, <sup>7</sup>*Cardiac Surgery, University of Utah, Salt Lake City, UT*, <sup>8</sup>*Cardiac Surgery, Intermountain Medical Center, Salt Lake City, UT*, <sup>9</sup>*Inova Heart and Vascular Institute, Falls Church, VA*, <sup>10</sup>*Mokobio, Rockville, MD*
- 11:00 AM** (315) *Exosome Proteomics and Machine Learning Identify Novel Biomarkers of Primary Graft Dysfunction*; N. Giangreco<sup>1</sup>, G. Lebreton<sup>2</sup>, S. Restaino<sup>3</sup>, M. Farr<sup>3</sup>, P. C. Colombo<sup>3</sup>, E. Zorn<sup>4</sup>, N. Tatonetti<sup>1</sup>, P. Leprince<sup>2</sup>, J. Kobashigawa<sup>5</sup>, B. Fine<sup>3</sup>. <sup>1</sup>*Biomedical Informatics, Columbia University, New York, NY*, <sup>2</sup>*Chirurgie Thoracique et Cardiovasculaire, Pitié-Salpêtrière University Hospital, Paris, France*, <sup>3</sup>*Division of Cardiology, Columbia University, New York, NY*, <sup>4</sup>*Center for Translational Immunology, Columbia University, New York, NY*, <sup>5</sup>*Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA*
- 11:15 AM** (8) *Engineered Mesenchymal Stromal Cell Therapy during Pig Ex Vivo Lung Perfusion and Transplant*; A. I. Nykanen<sup>1</sup>, A. Mariscal<sup>1</sup>, M. Takahashi<sup>1</sup>, A. Duong<sup>1</sup>, A. Ali<sup>1</sup>, M. Chen<sup>1</sup>, A. Takahagi<sup>1</sup>, H. Gokhale<sup>1</sup>, C. Estrada<sup>2</sup>, T. Martinu<sup>1</sup>, S. Juvet<sup>1</sup>, J. Yeung<sup>1</sup>, T. K. Waddell<sup>1</sup>, M. Cypel<sup>1</sup>, M. Liu<sup>1</sup>, J. E. Davies<sup>3</sup>, S. Keshavjee<sup>1</sup>. <sup>1</sup>*Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada*, <sup>2</sup>*Tissue Regeneration Therapeutics, Toronto, ON, Canada*, <sup>3</sup>*Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON, Canada*
- 11:30 AM** (9) *Hydrogen-Rich Preservation Solution Attenuates Lung Ischemia-Reperfusion Injury after Prolonged Cold Ischemia in a Canine Left Lung Transplant Model*; H. Kayawake<sup>1</sup>, T. F. Chen-Yoshikawa<sup>1</sup>, M. Saito<sup>1</sup>, S. Hirano<sup>2</sup>, R. Kurokawa<sup>2</sup>, H. Yamagishi<sup>1</sup>, R. Okabe<sup>1</sup>, F. Gochi<sup>1</sup>, J. Tokuno<sup>1</sup>, S. Ueda<sup>1</sup>, Y. Yokoyama<sup>1</sup>, M. Ikeda<sup>1</sup>, H. Oda<sup>1</sup>, Y. Yamada<sup>1</sup>, Y. Yutaka<sup>1</sup>, D. Nakajima<sup>1</sup>, A. Ohsumi<sup>1</sup>, M. Hamaji<sup>1</sup>, H. Date<sup>1</sup>. <sup>1</sup>*Department of Thoracic Surgery, Kyoto University, Kyoto, Japan*, <sup>2</sup>*MiZ Company Limited, Kamakura, Japan*
- 11:45 AM** (10) *Atorvastatin Preserves Cardiac Contractility via Reducing Matrix Metalloproteinase-2 Isoforms Expression in a Diabetic Heart Model*; H. Lee<sup>1</sup>, S. Lee<sup>1</sup>, S. Song<sup>2</sup>, S. Bae<sup>3</sup>, S. Kim<sup>4</sup>, J. Choi<sup>5</sup>. <sup>1</sup>*Cardiology Department, Pusan National University Hospital, Busan, Korea, Republic of*, <sup>2</sup>*Nephrology Department, Pusan National University Hospital, Busan, Korea, Republic of*, <sup>3</sup>*MRC for Ischemic Tissue Regeneration and Department of Pharmacology, Medical Research Institute, Pusan National University Hospital, Busan, Korea, Republic of*, <sup>4</sup>*Endocrinology Department, Pusan National University Hospital, Busan, Korea, Republic of*, <sup>5</sup>*Department of Cardiology, Pusan National University Hospital, Busan, Korea, Republic of*
- 12:00 PM** (11) *Triptolide Attenuates Graft Inflammation During Ex Vivo Lung Perfusion*; S. Burki, K. Noda, B. Philips, P. G. Sanchez, A. Kumar, J. D'Cunha. *Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA*

**WEDNESDAY, APRIL 3, 2019**

**10:30 AM - 12:15 PM**

**SESSION 02 (SYMPOSIUM): Future Shock: Great Debates in Cardiogenic Shock**

**Room: Pacifica 7**

**Target Audiences: HF/HTX, MCS**

**Chairs:** Teresa De Marco, MD, and Richard Cheng, MD

**Session Summary:** The incidence of cardiogenic shock is increasing, leading to an emerging focus on refining our approach to shock. This symposium will provide a framework for understanding goals of treatment, defining phenotypes and profiles of shock, exploring geographical differences in management, and reviewing trends in use of temporary MCS. A 10-min panel discussion with all speakers will conclude this session.

- 10:30 AM**            ***CASE PRESENTATION: 'Gimme Gimme Shock Treatment': Acute cardiogenic shock patient transferred for advanced heart failure therapy***  
Adriana Torres, MD, LosCobos Medical Center, Bogota, Colombia
- 10:35 AM**            ***DEBATE 1: 'Culture Shock': Tissue Perfusion is More Important than Hemodynamics in Managing Cardiogenic Shock (PRO)***  
Daniel J Goldstein, MD, Montefiore Medical Center, Bronx, NY, USA
- 10:50 AM**            ***DEBATE 1: 'Culture Shock': Tissue Perfusion is More Important than Hemodynamics in Managing Cardiogenic Shock (CON)***  
Jennifer Cowger, MD, MS, Henry Ford Hospitals, Detroit, MI, USA
- 11:05 AM**            ***DEBATE 2: 'Shock Rock': One Treatment Fits All in Cardiogenic Shock (PRO)***  
Shelley Hall, MD, Baylor University Medical Center, Dallas, TX, USA
- 11:20 AM**            ***DEBATE 2: 'Shock Rock': One Treatment Fits All in Cardiogenic Shock (CON)***  
Rebecca Cogswell, MD, University of Minnesota, Minneapolis, MN, USA
- 11:35 AM**            ***DEBATE 3: 'Shock Treatment': All Patients Should Receive Temporary MCS in Cardiogenic Shock to Maximize Survival (PRO)***  
Pascal Leprince, MD, Hôpital de La Petie Salpetriere, Paris, France
- 11:50 AM**            ***DEBATE 3: 'Shock Treatment': All Patients Should Receive Temporary MCS in Cardiogenic Shock to Maximize Survival (CON)***  
David A Baran, MD, Sentara Heart Hospital, Norfolk, VA, USA
- 12:05 PM**            ***10-min Panel Discussion***

WEDNESDAY, APRIL 3, 2019

10:30 AM - 12:15 PM

**SESSION 03 (ORAL): Chronic Lung Allograft Dysfunction: Anything New?**

**Room: Pacifica 10-12**

**Target Audiences: LTX, BSTR, PATH**

**Chairs:** Selim M. Arcasoy, MD, MPH, and Mark Greer, MB Bch

- 10:30 AM**            **(12) *Diffusing Capacity for Carbon Monoxide (DLCO): A Predictor of CLAD and Death after Lung Transplantation in a 20-Year Longitudinal Study***; D. R. Darley<sup>1</sup>, J. Ma<sup>2</sup>, E. Huszti<sup>2</sup>, R. Ghany<sup>1</sup>, M. Hutcheon<sup>1</sup>, C. Chow<sup>1</sup>, J. Tikkanen<sup>1</sup>, S. Keshavjee<sup>1</sup>, L. G. Singer<sup>1</sup>, T. Martinu<sup>1</sup>. <sup>1</sup>Toronto Lung Transplant Program, Toronto General Hospital, University of Toronto, Toronto, ON, Canada, <sup>2</sup>Biostatistics Research Unit, University Health Network, Toronto, ON, Canada
- 10:45 AM**            **(13) *Molecular Analysis of Transbronchial and Mucosal Biopsies in Patients with CLAD***; M. Parkes<sup>1</sup>, P. F. Halloran<sup>1</sup>, J. Chang<sup>1</sup>, K. S. Famulski<sup>1</sup>, J. Reeve<sup>1</sup>, R. Hachem<sup>2</sup>, P. Jaksch<sup>3</sup>, S. Juvet<sup>4</sup>, W. Klepetko<sup>3</sup>, S. Keshavjee<sup>4</sup>, D. Kreisel<sup>2</sup>, A. Roux<sup>5</sup>, G. I. Snell<sup>6</sup>, E. Trulock<sup>2</sup>, I. L. Timofte<sup>7</sup>, G. P. Westall<sup>6</sup>, K. M. Halloran<sup>1</sup>. <sup>1</sup>University of Alberta, Edmonton, AB, Canada, <sup>2</sup>Washington University School of Medicine, St. Louis, MO, <sup>3</sup>Medical University of Vienna, Vienna, Austria, <sup>4</sup>University Health Network, Toronto, ON, Canada, <sup>5</sup>Hôpital Foch, Suresnes, France, <sup>6</sup>Monash University, Melbourne, Australia, <sup>7</sup>University of Maryland, Baltimore, MD
- 11:00 AM**            **(14) *Predictive Biomarkers for Bronchiolitis Obliterans***; V. Kaza<sup>1</sup>, C. Zhu<sup>1</sup>, L. Feng<sup>1</sup>, A. Reddy<sup>2</sup>, C. Lacelle<sup>3</sup>, L. Terada<sup>1</sup>, M. Manish<sup>1</sup>, S. Bollineni<sup>1</sup>, A. Banga<sup>1</sup>, F. Torres<sup>1</sup>, J. Mullins<sup>1</sup>, Q. Li<sup>4</sup>. <sup>1</sup>UT SW Med Ctr, Dallas, TX, <sup>2</sup>Southwest Pulmonary Associates, Dallas, TX, <sup>3</sup>UT Southwestern Medical Center, Dallas, TX, <sup>4</sup>Ut SW Med Ctr, Dallas, TX
- 11:15 AM**            **(15) *Chest CT Has Prognostic Value at BOS Diagnosis after Lung Transplantation***; A. Van Herck<sup>1</sup>, A. Sacreas<sup>1</sup>, T. Heigl<sup>1</sup>, J. Kaes<sup>1</sup>, A. Vanstapel<sup>1</sup>, S. E. Verleden<sup>1</sup>, B. M. Vanaudenaerde<sup>1</sup>, W. De Wever<sup>2</sup>, G. M. Verleden<sup>1</sup>, R. Vos<sup>1</sup>. <sup>1</sup>Lung Transplant Unit, Department of Chronic Diseases, Metabolism & Ageing, University of Leuven, Leuven, Belgium, <sup>2</sup>Department of Radiology, University Hospitals Leuven, Leuven, Belgium
- 11:30 AM**            **(16) *Regulatory T Cells in Asymptomatic ISHLT Grade A1 Rejection and the Risk of Chronic Lung Allograft Dysfunction***; M. White, L. Levy, S. Moshkelgosha, G. Zehong, S. Keshavjee, T. Martinu, S. Juvet. Toronto Lung Transplant Program, Toronto General Research Institute, Toronto, ON, Canada
- 11:45 AM**            **(17) *Emergence of a Specific Intrapulmonary CD4+ T Cell Subset Prior to the Onset of Lung Allograft Dysfunction***; S. Moshkelgosha<sup>1</sup>, L. Levy<sup>1</sup>, T. Martinu<sup>1</sup>, R. Zamel<sup>1</sup>, C. Guidos<sup>2</sup>, S. Keshavjee<sup>1</sup>, J. Yeung<sup>1</sup>, S. C. Juvet<sup>1</sup>. <sup>1</sup>Toronto Lung Transplant Program, Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada, <sup>2</sup>The Hospital for Sick Children (SickKids), Toronto, ON, Canada
- 12:00 PM**            **(18) *Increased Hazard of Chronic Lung Allograft Dysfunction in the Presence of Persistent and Complement Fixing Donor-Specific Antibodies***; C. J. Iasella<sup>1</sup>, C. R. Ensor<sup>2</sup>, M. Marrari<sup>3</sup>, M. Mangiola<sup>3</sup>, C. A. Moore<sup>4</sup>, M. R. Morrell<sup>5</sup>, J. M. Pilewski<sup>5</sup>, J. D'Cunha<sup>6</sup>, P. Sanchez<sup>6</sup>, J. F. McDyer<sup>5</sup>, A. Zeevi<sup>3</sup>. <sup>1</sup>Department of Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>Department of Pharmacy, Florida Hospital, Orlando, FL, <sup>3</sup>Department of Pathology, University of Pittsburgh, Pittsburgh, PA, <sup>4</sup>Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>5</sup>Department of Medicine, University of Pittsburgh, Pittsburgh, PA, <sup>6</sup>Department of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA

WEDNESDAY, APRIL 3, 2019  
10:30 AM - 12:15 PM

**SESSION 04 (ORAL): So Wrong It's Right: The Right Ventricle and MCS**

**Room: Pacifica 6**

**Target Audiences: MCS, PH, PHARM**

**Chairs:** Bastian Schmack, MD, and Brent Lampert, MD

- 10:30 AM** (19) *Right Ventricular Strain as a Predictor of Post-LVAD Early Right Ventricular Failure*; L. W. Liang, E. Y. Birati, C. Justice, Y. Han. *Hospital of the University of Pennsylvania, Philadelphia, PA*
- 10:45 AM** (20) *Serial Assessment of Pulmonary Artery Pulsatility Index Provides Incremental Risk Assessment for Early Right Ventricular Failure after Left Ventricular Assist Device Implantation*; M. H. Gonzalez<sup>1</sup>, J. Wagener<sup>1</sup>, A. Aggarwal<sup>2</sup>, T. Buda<sup>1</sup>, V. Menon<sup>1</sup>, M. Jacob<sup>1</sup>, W. Tang<sup>1</sup>, E. Hsich<sup>1</sup>, M. Tong<sup>3</sup>, E. Soltesz<sup>3</sup>, R. Starling<sup>1</sup>, J. Estep<sup>1</sup>, E. Joyce<sup>1</sup>. <sup>1</sup>*Cardiology, Cleveland Clinic Foundation, Cleveland, OH*, <sup>2</sup>*Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH*, <sup>3</sup>*Cardiothoracic Surgery, Cleveland Clinic Foundation, Cleveland, OH*
- 11:00 AM** (21) *Bridging Biventricular Failure to Successful Heart Transplants: HVAD BiVAD versus TAH*; A. Salimbangon<sup>1</sup>, R. Chand<sup>1</sup>, C. Lum<sup>1</sup>, D. Vucicevic<sup>2</sup>, E. DePasquale<sup>1</sup>. <sup>1</sup>*UCLA, Los Angeles, CA*, <sup>2</sup>*Newark Beth Israel, Newark, NJ*
- 11:15 AM** (22) *New Insights into Right Ventricular Function among Patients with Left Ventricular Assist Devices Using High Fidelity Conductance Catheters to Generate Real Time Pressure Volume Loops*; W. K. Cornwell<sup>1</sup>, G. Coe<sup>2</sup>, A. Levy<sup>2</sup>, T. Tran<sup>2</sup>, M. Bradley<sup>2</sup>, K. O'Gean<sup>2</sup>, M. Ostertag<sup>2</sup>, M. Spotts<sup>3</sup>, S. Laing<sup>2</sup>, J. Lawley<sup>4</sup>, C. DeSouza<sup>5</sup>, B. Stauffer<sup>2</sup>, A. Ambardekar<sup>2</sup>, J. Pal<sup>2</sup>, G. Wolfel<sup>2</sup>, W. Kohrt<sup>2</sup>. <sup>1</sup>*University of Colorado, Denver, CO*, <sup>2</sup>*University of Colorado, Aurora, CO*, <sup>3</sup>*Aurora, University of Colorado, Denver, CO*, <sup>4</sup>*University of Innsbruck, Innsbruck, Austria*, <sup>5</sup>*University of Colorado, Boulder, CO*
- 11:30 AM** (23) *Early and Late Right Heart Failure Following LVAD Implantation: Epidemiology, Natural History and Outcomes. An Analysis of the STS INTERMACS Database*; C. J. Kapelios<sup>1</sup>, L. H. Lund<sup>2</sup>, C. H. Selzman<sup>3</sup>, S. L. Meyers<sup>4</sup>, A. Koliopoulou<sup>3</sup>, J. Stehlik<sup>3</sup>, O. Wever-Pinzon<sup>3</sup>, A. G. Kfoury<sup>5</sup>, J. C. Fang<sup>3</sup>, J. K. Kirklin<sup>4</sup>, S. G. Drakos<sup>3</sup>. <sup>1</sup>*National and Kapodestrian University of Athens, Athens, Greece*, <sup>2</sup>*Karolinska University Hospital, Stockholm, Sweden*, <sup>3</sup>*University of Utah Health & School of Medicine, Salt Lake City, UT*, <sup>4</sup>*Kirklin Institute for Research in Surgical Outcomes, University of Alabama at Birmingham, Birmingham, AL*, <sup>5</sup>*Intermountain Medical Center, Salt Lake City, UT*
- 11:45 AM** (24) *Pectoralis Muscle Attenuation Improves the Prediction of Right Ventricular Failure after LVAD Implantation*; H. Shah<sup>1</sup>, T. Murray<sup>2</sup>, J. Estep<sup>3</sup>, R. Araujo<sup>4</sup>, A. El Rafei<sup>5</sup>, B. Trachtenberg<sup>4</sup>, L. Teigen<sup>6</sup>, J. Schultz<sup>1</sup>, R. John<sup>7</sup>, C. Martin<sup>1</sup>, R. Cogswell<sup>1</sup>. <sup>1</sup>*Cardiology, University of Minnesota, Minneapolis, MN*, <sup>2</sup>*Biostatistics, University of Minnesota, Minneapolis, MN*, <sup>3</sup>*Cardiology, Cleveland Clinic, Cleveland, OH*, <sup>4</sup>*Cardiology, Houston Methodist, Houston, TX*, <sup>5</sup>*Internal Medicine, University of Minnesota, Minneapolis, MN*, <sup>6</sup>*Gastroenterology Hepatology and Nutrition, University of Minnesota, Minneapolis, MN*, <sup>7</sup>*Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN*
- 12:00 PM** (25) *Oral Milrinone for the Treatment of Right Ventricular Failure in LVAD Patients*; N. Uriel<sup>1</sup>, D. Burkhoff<sup>2</sup>, G. Kim<sup>1</sup>, T. Silverstein<sup>1</sup>, J. Raikhelkar<sup>1</sup>, B. Smith<sup>1</sup>, C. Juricek<sup>1</sup>, V. Jeevanandam<sup>1</sup>, R. M. Lang<sup>3</sup>, G. Sayer<sup>1</sup>. <sup>1</sup>*University of Chicago, Chicago, IL*, <sup>2</sup>*Columbia University, New York, NY*, <sup>3</sup>*University of Chicago Medicine, Chicago, IL*

**WEDNESDAY, APRIL 3, 2019**  
**10:30 AM - 12:15 PM**

**SESSION 05 (SYMPOSIUM): Limiting the Invasiveness of the VAD Therapy: Alternative to Limited Surgical Approaches**  
**Room: Grand Caribbean 1-7**  
**Target Audience: MCS**

**Chairs:** George M. Wieselthaler, MD, and Marian Urban, MD

**Session Summary:** The ISHLT 2018 Annual Meeting included the highest number of abstracts on less invasive VAD implantation approach. This symposium will evaluate the potential advantages of minimal invasive approaches for VAD implantation, the usage of ECMO instead of CPB, and the feasibility and advantages of adding minimal invasive and off-pump techniques.

- 10:30 AM**            ***Influence of the Surgical Technique on Post-Operative Outcome: Is Minimal Invasive Approach the Way to Go?***  
Victor Pretorius, MD, UCSD Medical Center, La Jolla, CA, USA
- 10:45 AM**            ***Q&A***
- 10:50 AM**            ***The Alternative Approach: Should We Be Using ECMO Instead of CPB?***  
Julia Riebandt, MD, Medical University of Vienna, Vienna, Austria
- 11:05 AM**            ***Q&A***
- 11:10 AM**            ***Going 'Off-Pump': Does It Make a Difference?***  
Diyar Saeed, MD, PhD, Leipzig Heart Center, Leipzig, Germany
- 11:25 AM**            ***Q&A***
- 11:30 AM**            ***Going 'BIVAD': Acute Pitfalls and Long-Term Threats***  
Evgenij V Potapov, MD, PhD, Deutsches Herzzentrum, Berlin, Germany
- 11:45 AM**            ***Q&A***
- 11:50 AM**            ***Out with the Old: Pump Replacement/Upgrade Decommissioning Explant***  
Carmelo A Milano, MD, Duke University Medical Center, Durham, NC, USA
- 12:05 PM**            ***Q&A***

WEDNESDAY, APRIL 3, 2019

10:30 AM - 12:15 PM

**SESSION 06 (ORAL): Pediatric Donor Utilization, MCS, Readmissions and More**

**Room: Pacifica 3-5**

**Target Audiences: PEDS, HF, HTX, MCS**

**Chairs:** Jonathan N Johnson, MD, and Francesco Parisi, MD

- 10:30 AM** (26) *Donor Utilization in the Australian National Paediatric Heart Transplant Program: Stretching the Limits*; J. Wacker<sup>1</sup>, A. Shipp<sup>1</sup>, I. Konstantinov<sup>2</sup>, J. Brink<sup>2</sup>, R. Weintraub<sup>1</sup>, J. Mathew<sup>1</sup>. <sup>1</sup>Cardiology, The Royal Children's Hospital Melbourne, Parkville, Australia, <sup>2</sup>Cardiac Surgery, The Royal Children's Hospital Melbourne, Parkville, Australia
- 10:45 AM** (27) *Regional Variation in Donor Refusal Rates Correlates with Poor Wait List Outcomes*; R. R. Davies<sup>1</sup>, R. Butts<sup>2</sup>, M. Bano<sup>2</sup>, R. D. Jaquiss<sup>1</sup>, R. C. Kirk<sup>1</sup>. <sup>1</sup>Pediatric Cardiothoracic Surgery, UT Southwestern - Children's Health Dallas, Dallas, TX, <sup>2</sup>Pediatrics (Cardiology), UT Southwestern - Children's Health Dallas, Dallas, TX
- 11:00 AM** (417) *Toward a New Strategy for Pediatric Heart Allocation: High Risk Organs for Less Ill Patients?*; A. K. Morrison<sup>1</sup>, C. Gowda<sup>2</sup>, R. Gajarski<sup>1</sup>, D. Nandi<sup>1</sup>. <sup>1</sup>The Heart Center, Nationwide Children's Hospital, Columbus, OH, <sup>2</sup>Department of Pediatrics, Division of Infectious Diseases, Nationwide Children's Hospital, Columbus, OH
- 11:15 AM** (29) *Anti-Coagulation Management in Pediatric Ventricular Assist Device: A Quality Improvement Target*; C. VanderPluym<sup>1</sup>, M. O'Connor<sup>2</sup>, A. Lorts<sup>3</sup>, M. Ploutz<sup>4</sup>, D. Peng<sup>5</sup>, S. Law<sup>6</sup>, M. Zinn<sup>7</sup>, R. Niebler<sup>8</sup>, D. Rosenthal<sup>9</sup>, J. Conway<sup>10</sup>, S. Auerbach<sup>11</sup>, D. Sutcliffe<sup>12</sup>, M. Mehegan<sup>13</sup>. <sup>1</sup>Boston Children's Hospital, Boston, MA, <sup>2</sup>Children's Hospital of Philadelphia, Philadelphia, PA, <sup>3</sup>Cincinnati Children's Hospital, Cincinnati, OH, <sup>4</sup>Phoenix Children's Hospital, Phoenix, AZ, <sup>5</sup>C.S. Mott Children's Hospital, Ann Arbor, MI, <sup>6</sup>Morgan Stanley Children's Hospital of New York Presbyterian, New York, NY, <sup>7</sup>Children's Hospital of Pittsburgh, Pittsburgh, PA, <sup>8</sup>Children's Hospital of Wisconsin, Milwaukee, WI, <sup>9</sup>Lucile Packard Children's Hospital, Palo Alto, CA, <sup>10</sup>Stollery Children's Hospital, Edmonton, AB, Canada, <sup>11</sup>Children's Hospital Colorado, Aurora, CO, <sup>12</sup>Children's Health Dallas, Dallas, TX, <sup>13</sup>Children's Hospital St. Louis, St. Louis, MO
- 11:30 AM** (30) *Role of ECMO as Bridge to VAD Therapy in Critically Ill Pediatric Patients - An Analysis of the STS Pedimacs Database*; S. M. Peer<sup>1</sup>, D. A. Koehl<sup>2</sup>, R. S. Cantor<sup>2</sup>, R. A. Jonas<sup>1</sup>, P. Sinha<sup>1</sup>. <sup>1</sup>Cardiac Surgery, Children's National Health System, Washington, DC, <sup>2</sup>Kirklin Institute for Research in Surgical Outcomes, University of Alabama at Birmingham, Birmingham, AL
- 11:45 AM** (31) *Hospital Readmission Following Pediatric Heart Transplantation*; W. T. Mahle<sup>1</sup>, K. Mason<sup>2</sup>, A. Dipchand<sup>3</sup>, M. Richmond<sup>4</sup>, C. Canter<sup>5</sup>, D. Hsu<sup>6</sup>, T. P. Singh<sup>7</sup>, R. Shaddy<sup>8</sup>, B. Armstrong<sup>2</sup>, A. Zeevi<sup>9</sup>, D. Ikle<sup>2</sup>, H. Diop<sup>10</sup>, J. Odum<sup>10</sup>, S. Webber<sup>11</sup>. <sup>1</sup>Children's Healthcare of Atlanta, Atlanta, GA, <sup>2</sup>Rho, Chapel Hill, NC, <sup>3</sup>Hospital for Sick Children, Toronto, ON, Canada, <sup>4</sup>Columbia Presbyterian, New York, NY, <sup>5</sup>St. Louis Children's, St. Louis, MO, <sup>6</sup>Montefiore Children's Hospital, New York, NY, <sup>7</sup>Boston Children's Hospital, Boston, MA, <sup>8</sup>Los Angeles Children's Hospital, Los Angeles, CA, <sup>9</sup>Children's Hospital of Pittsburgh, Pittsburgh, PA, <sup>10</sup>NIH, Bethesda, MD, <sup>11</sup>Vanderbilt University School of Medicine, Nashville, TN
- 12:00 PM** (32) *Slowed Progression of Maximal Intimal Thickening by Intravascular Ultrasound after Initiation of Sirolimus*; A. Putschoggl<sup>1</sup>, L. Pyle<sup>1</sup>, M. Everitt<sup>1</sup>, S. Miyamoto<sup>1</sup>, B. Pietra<sup>2</sup>, S. Auerbach<sup>1</sup>. <sup>1</sup>Children's Hospital Colorado, Aurora, CO, <sup>2</sup>University of Florida Health, Gainesville, FL

**WEDNESDAY, APRIL 3, 2019**  
**10:30 AM - 12:15 PM**

**SESSION 07 (SYMPOSIUM): Making Co-Morbidities Great Again: Practical Updates in Co-Morbidity Management**  
**Room: Coral Sea**  
**Target Audiences: PHARM, HF/HTX, LF/LTX**

**Chairs:** Patricia Ging, PharmD, and Nicole L Casciello, PharmD, MBA

**Session Summary:** This symposium will review management of comorbidities and primary care needs that affect heart and lung transplant recipients before and after transplant including diabetes, dyslipidemia, osteoporosis, psychiatric disorders, complimentary/alternative medicine, and immunizations/travel. Best practices and recent guideline recommendations will be presented for each topic. New and novel medications available and any pros or cons for use in the transplant population will be discussed. A 15-min panel discussion with all speakers will conclude this session.

**10:30 AM**                    *What to Do When the A1C is 'BIGLY': An Update on the Management of Post-Transplant Diabetes*  
Jennifer L Day, PharmD, Baptist Health Heart Failure and Transplant Institute, Little Rock, AR, USA

**10:45 AM**                    *Good Lipoproteins on Both Sides: Optimizing Treatment of Dyslipidemia and Obesity*  
Jill C Krisl, PharmD, Houston Methodist Hospital, Houston, TX, USA

**11:00 AM**                    *'Skeletons in the Closet': Diagnosis, Prevention and Treatment of Osteoporosis*  
David Iturbe, MD, Hospital Universitario Marques de Valdecilla, Santander, Spain

**11:15 AM**                    *'Stable Genius': Managing Mental Health After Transplant*  
Melissa Sanchez, BSc Hons, Royal Brompton & Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom

**11:30 AM**                    *Combating 'Alternative Facts': Complementary and Alternative Medicine in Transplant*  
Teena Sam, PharmD, Baylor University Medical Center, Dallas, TX, USA

**11:45 AM**                    *'Fake News': Immunization Practices and Travel Prophylaxis*  
Michele Estabrook, MD, St. Louis Children's Hosp, St Louis, MO, USA

**12:00 PM**                    *15-min Panel Discussion*

WEDNESDAY, APRIL 3, 2019

12:45 PM - 1:45 PM

SESSION 08 (ORAL): ISHLT Spotlight: Heart Transplantation in Latin America

Room: Pacifica 7

Target Audiences: HF/HTX, EEP, ID, PATH

Chairs: Are M Holm, MD, PhD, Howard Eisen, MD, and Victor Rossel, MD

- 12:45 PM      **(33) Sequential Measurement of Trypanosoma cruzi Parasitic Load in Endomyocardial Biopsies for Early Detection and Follow-up of Chagas Disease Reactivation After Heart Transplantation;** L. A. Benvenuti<sup>1</sup>, A. Roggério<sup>1</sup>, A. S. Nishiya<sup>2</sup>, S. Mangini<sup>1</sup>, J. E. Levi<sup>2</sup>. <sup>1</sup>Heart Institute (InCor), Hospital das Clínicas da FMUSP, São Paulo, Brazil, <sup>2</sup>Fundação Pró-Sangue, Hospital das Clínicas da FMUSP, São Paulo, Brazil
- 12:57 PM      **(34) The Paradigm of Gender: Mismatch and Its Influence on Short and Long-Term Outcomes after Heart Transplantation;** M. D. Gilbert<sup>1</sup>, P. A. Morejón<sup>2</sup>, M. F. Renedo<sup>2</sup>, E. F. Giordanino<sup>2</sup>, L. E. Favalaro<sup>2</sup>, R. D. Ratto<sup>2</sup>, D. O. Absi<sup>1</sup>, R. R. Favalaro<sup>1</sup>, A. M. Bertolotti<sup>1</sup>. <sup>1</sup>Cardiovascular, Thoracic Surgery, and Intrathoracic Transplantation, Hospital Universitario Fundación Favalaro, Buenos Aires, Argentina, <sup>2</sup>Heart Failure and Heart Transplantation, Hospital Universitario Fundación Favalaro, Buenos Aires, Argentina
- 1:09 PM      **(35) Incidence of Right Ventricular Dysfunction in Adult Patients Submitted to Heart Transplantation According to the Presence of Pre-Transplant Pulmonary Hypertension;** M. M. Lensi, A. S. Ramos, J. Xavier Junior, L. B. Seguro, S. Mangini, M. S. Avila, I. W. Campos, A. P. Duque, F. Gaiotto, S. P. Steffen, F. Bacal, F. G. Marcondes-Braga. Heart Transplant Department, Heart Institute - InCor HC FMUSP, São Paulo, Brazil
- 1:21 PM      **(36) The Effect of Donor-Recipient Heart Mass and Size Matching in Primary Graft Dysfunction Development after Heart Transplantation;** M. D. Gilbert<sup>1</sup>, P. A. Morejón<sup>2</sup>, M. F. Renedo<sup>2</sup>, E. F. Giordanino<sup>2</sup>, L. E. Favalaro<sup>2</sup>, R. D. Ratto<sup>2</sup>, D. O. Absi<sup>1</sup>, R. R. Favalaro<sup>1</sup>, A. M. Bertolotti<sup>1</sup>. <sup>1</sup>Cardiovascular, Thoracic Surgery, and Intrathoracic Transplantation, Hospital Universitario Fundación Favalaro, Buenos Aires, Argentina, <sup>2</sup>Heart Failure and Heart Transplantation, Hospital Universitario Fundación Favalaro, Buenos Aires, Argentina
- 1:33 PM      **(37) Endomyocardial Biopsy after Heart Transplantation. When is Too Late?;** L. M. Guerrero Cepeda, F. G. Marcondes-Braga, D. M. Costa, R. M. Mendes, S. Duarte, J. C. Oliveira, I. Wosniack, L. F. Seguro, S. Mangini, F. Gaiotto, R. H. Santos, M. S. Avila, F. Bacal. Heart Transplantation, Instituto do Coração INCOR, São Paulo, Brazil



**WEDNESDAY, APRIL 3, 2019**

**2:00 PM - 3:45 PM**

**SESSION 09 (SYMPOSIUM): Re-Focusing the Blurry Vision: Biomarkers of Thoracic Allograft Rejection**

**Room: Pacifica 1-2**

**Target Audiences: BSTR, HF/HTX, LF/LTX**

**Chairs:** Daniel Kreisel, MD, PhD, and Tereza Martinu, MD

**Session Summary:** The goal of this symposium is to review advances in molecular diagnostic assessments and novel biomarkers in thoracic (both heart and lung) organ transplantation. This will include approaches that are being applied clinically and others that are investigational but that can provide greater insight into the pathophysiology and immunology of allograft rejection.

**2:00 PM**

***Donor-Derived Cell Free DNA as a Marker of Allograft Injury***

Hannah Valentine, MD, National Institutes of Health, Bethesda, MD, USA

**2:15 PM**

***Q&A***

**2:20 PM**

***Monitoring Immune Responses***

Glen Westall, MD, PhD, Alfred Hospital, Melbourne, Australia

**2:35 PM**

***Q&A***

**2:40 PM**

***MicroRNA and Exosomes***

P. Christian Schulze, MD, PhD, University Hospital, Jena, Germany

**2:55 PM**

***Q&A***

**3:00 PM**

***Through the Looking Glass: Advances in Histology***

Martin J Goddard, FRCS MRCPa, Papworth Hospital, Cambridge, United Kingdom

**3:15 PM**

***Q&A***

**3:20 PM**

***Gene Expression Signatures to Monitor Graft Rejection***

Jean-Paul Duong Van Huyen, MD, Hospital Necker, Paris, France

**3:35 PM**

***Q&A***

WEDNESDAY, APRIL 3, 2019

2:00 PM - 3:45 PM

**SESSION 10 (ORAL): Heart Donor Management and Allocation: Setting It Up For Success**

**Room: Pacifica 7**

**Target Audiences: HTX, HF**

**Chairs:** Victor Rossel, MD, and Jamila Kremer, MD

- 2:00 PM**            **(38) *Non Ischemic Heart Preservation – Results from the Safety Study***; J. Nilsson<sup>1</sup>, V. Jernryd<sup>2</sup>, G. Qin<sup>3</sup>, A. Paskevicius<sup>3</sup>, T. Sjöberg<sup>3</sup>, P. Höglund<sup>4</sup>, S. Steen<sup>3</sup>. <sup>1</sup>Skanes University Hospital Cardiothoracic Surgery, Lund, Sweden, <sup>2</sup>Clinical Sciences Lund, Cardiothoracic Surgery, Lund University, Skane University Hospital, Lund, Sweden, <sup>3</sup>Clinical Sciences Lund, Cardiothoracic Surgery, Lund University and Skane University Hospital, Lund, Sweden, <sup>4</sup>Laboratory Medicine, Lund, Clinical Chemistry and Pharmacology, Lund University and Skane University Hospital, Lund, Sweden
- 2:15 PM**            **(39) *Donation after Circulatory Death in Heart Transplantation May Increase the Donor Pool by 20% in the U.S***; O. K. Jawitz<sup>1</sup>, V. Raman<sup>1</sup>, A. Devore<sup>2</sup>, R. Mentz<sup>2</sup>, C. B. Patel<sup>2</sup>, M. Hartwig<sup>1</sup>, M. Daneshmand<sup>1</sup>, J. Schroder<sup>1</sup>, C. Milano<sup>1</sup>. <sup>1</sup>Department of Surgery, Duke University School of Medicine, Durham, NC, <sup>2</sup>Department of Medicine, Duke University School of Medicine, Durham, NC
- 2:30 PM**            **(40) *DCD Donor Hearts Recipients Compared to DBD Donor Heart Recipients Present with Comparable Systolic Left Ventricular Function and Better Myocardial Strain at 1 Year Follow Up***; A. Ciarka<sup>1</sup>, A. Page<sup>2</sup>, S. Messer<sup>2</sup>, E. Pavlushkov<sup>2</sup>, S. Colah<sup>2</sup>, R. Axell<sup>2</sup>, B. Parizkova<sup>2</sup>, S. Tsui<sup>2</sup>, J. Parameshwar<sup>2</sup>, S. Large<sup>2</sup>. <sup>1</sup>Cardiovascular Diseases, Catholic University of Leuven, Leuven, Belgium, <sup>2</sup>of Transplantation, Papworth Hospital, NHS Foundation Trust, Cambridge, United Kingdom
- 2:45 PM**            **(41) *A Data-Driven Framework for Monitoring and Improving Organ Donation Awareness among Minorities Using Optimal Social Network Intervention***; D. Pinheiro<sup>1</sup>, M. Murphy<sup>2</sup>, R. Iyengar<sup>2</sup>, J. Lazareff<sup>3</sup>, J. Choi<sup>4</sup>, R. Menezes<sup>5</sup>, M. Cadeiras<sup>1</sup>. <sup>1</sup>Department of Internal Medicine, University of California, Davis, Sacramento, CA, <sup>2</sup>Department of Medicine, University of California, Los Angeles, Los Angeles, CA, <sup>3</sup>Center for World Health, University of California, Los Angeles, Los Angeles, CA, <sup>4</sup>Department of Sociology, State University of San Diego, San Diego, CA, <sup>5</sup>Department of Computer Science, University of California, Davis, Exeter, United Kingdom
- 3:00 PM**            **(42) *The Impact of DCD Heart Transplantation on the Waiting List: A Single Centre Experience***; A. Page, R. Duehmke, S. Messer, S. Barra, M. Berman, S. Bhagra, J. Parameshwar, S. Tsui, P. Catarino, S. Pettit, S. Large. Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom
- 3:15 PM**            **(43) *The Benefit of Heart Transplant Among Candidates Assigned Lower Priority in the New 6-Status US Heart Allocation System***; W. F. Parker<sup>1</sup>, E. S. Huang<sup>1</sup>, R. D. Gibbons<sup>2</sup>, A. S. Anderson<sup>3</sup>, M. M. Churpek<sup>1</sup>. <sup>1</sup>University of Chicago Medicine, Chicago, IL, <sup>2</sup>Public Health Sciences, University of Chicago Medicine, Chicago, IL, <sup>3</sup>Northwestern Medicine, Chicago, IL
- 3:30 PM**            **(44) *Clinical Factors Associated with Left Ventricular Recovery in Brain Dead Cardiac Donors***; J. R. Peacock, J. Ji, A. Bhatia, J. C. Hartupee, G. A. Ewald. Washington University in St. Louis, St. Louis, MO

WEDNESDAY, APRIL 3, 2019

2:00 PM - 3:45 PM

**SESSION 11 (ORAL): Chronic Lung Allograft Dysfunction: Overcoming the Hurdle?**

Room: Pacifica 10-12

Target Audiences: LF/LTX, BSTR, PATH

Chairs: Edward R Garrity, MD, and Cynthia J. Gries, MD, MSc

- 2:00 PM**            **(45) Increased Frequency Of regulatory CD127<sup>low</sup> T Cells and of IL2<sup>+</sup> T Cells Early after Lung Transplant is Associated with Improved Graft Survival;** F. Ius<sup>1</sup>, J. Salman<sup>1</sup>, A. Knöfel<sup>1</sup>, T. Nakagiri<sup>1</sup>, W. Sommer<sup>1</sup>, T. Siemeni<sup>1</sup>, C. Kühn<sup>1</sup>, T. Welte<sup>2</sup>, C. S. Falk<sup>3</sup>, A. Haverich<sup>1</sup>, I. Tudorache<sup>1</sup>, G. Warnecke<sup>1</sup>. <sup>1</sup>Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, <sup>2</sup>Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany, <sup>3</sup>Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany
- 2:15 PM**            **(46) Prognostic Significance of Mesenchymal Cell Colony Forming Units in Bronchoalveolar Lavage Fluid for Restrictive Chronic Lung Allograft Dysfunction;** M. P. Combs<sup>1</sup>, M. Xia<sup>2</sup>, D. S. Wheeler<sup>1</sup>, E. A. Belloli<sup>1</sup>, D. M. Lyu<sup>1</sup>, N. M. Walker<sup>1</sup>, S. Murray<sup>2</sup>, V. N. Lama<sup>1</sup>. <sup>1</sup>Department of Medicine, University of Michigan, Ann Arbor, MI, <sup>2</sup>Department of Biostatistics, University of Michigan, Ann Arbor, MI
- 2:30 PM**            **(47) Intra-graft IgG Levels and Donor-Specific anti-HLA Antibodies in Different Phenotypes of Chronic Lung Allograft Dysfunction;** A. Sacreas<sup>1</sup>, J. Taupin<sup>2</sup>, A. Van Herck<sup>1</sup>, J. Kaes<sup>1</sup>, T. Heigl<sup>1</sup>, A. Vanstapel<sup>1</sup>, M. Emonds<sup>3</sup>, L. Daniëls<sup>3</sup>, R. Vos<sup>1</sup>, G. M. Verleden<sup>1</sup>, B. M. Vanaudenaerde<sup>1</sup>, A. Roux<sup>4</sup>, S. E. Verleden<sup>1</sup>. <sup>1</sup>Leuven Lung Transplant Unit, Department of Chronic Diseases, Metabolism, and Ageing (CHROMETA), KU Leuven, Leuven, Belgium, <sup>2</sup>Laboratoire d'Immunologie et Histocompatibilité, Saint-Louis Hospital, Paris, France, <sup>3</sup>Histocompatibility and Immunogenetics Laboratory, Belgian Red Cross-Flanders, Mechelen, Belgium, <sup>4</sup>Service de Transplantation Pulmonaire, Foch Hospital, Suresnes, France
- 2:45 PM**            **(48) Airway Transcriptome Analysis and Immune Proteome Profiling of the Lung Allograft Reveals Novel Immune Signatures in Chronic Lung Allograft Dysfunction;** C. J. Iasella<sup>1</sup>, A. Hoji<sup>2</sup>, Y. Zhang<sup>2</sup>, W. Xu<sup>2</sup>, K. Chen<sup>2</sup>, M. Brown<sup>2</sup>, E. Lendermon<sup>2</sup>, B. A. Johnson<sup>2</sup>, S. Kilaru<sup>2</sup>, M. R. Morrell<sup>2</sup>, J. M. Pilewski<sup>2</sup>, J. F. McDyer<sup>2</sup>. <sup>1</sup>Department of Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>Department of Medicine, University of Pittsburgh, Pittsburgh, PA
- 3:00 PM**            **(49) Host miRNA Profile of Aspergillus Colonization Resulting in CLAD in Lung Transplant Recipients;** W. Gohir<sup>1</sup>, W. Klement<sup>2</sup>, L. G. Singer<sup>3</sup>, S. M. Palmer<sup>4</sup>, S. Keshavjee<sup>3</sup>, S. Husain<sup>1</sup>. <sup>1</sup>Multi Organ Transplant Unit, Division of Infectious Diseases, University Health Network, Toronto, ON, Canada, <sup>2</sup>Organ Donation and Transplantation, Canadian Blood Services, Ottawa, ON, Canada, <sup>3</sup>Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada, <sup>4</sup>Division of Pulmonary and Critical Care Medicine, Duke University, Durham, NC
- 3:15 PM**            **(50) Identification and Characterization of Patients With a Mixed Phenotype of CLAD;** S. E. Verleden<sup>1</sup>, J. Von der Thusen<sup>2</sup>, A. Van Herck<sup>1</sup>, B. Weynand<sup>1</sup>, E. Verbeke<sup>1</sup>, J. Verschakelen<sup>1</sup>, A. Dubbeldam<sup>1</sup>, B. Vanaudenaerde<sup>1</sup>, D. Van Raemdonck<sup>1</sup>, R. Vos<sup>1</sup>, G. Verleden<sup>1</sup>. <sup>1</sup>KU Leuven, Leuven, Belgium, <sup>2</sup>Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
- 3:30 PM**            **(51) Exploring Chronic Lung Transplant (LTx) Allograft Dysfunction (CLAD): The Potential Clinical Prognostic Relevance of Single Bite Transbronchial Biopsy (TBB) Microarray;** G. I. Snell<sup>1</sup>, G. Westall<sup>1</sup>, Y. Cristiano<sup>1</sup>, B. J. Levvey<sup>1</sup>, L. Sullivan<sup>1</sup>, K. Halloran<sup>2</sup>, P. Halloran<sup>3</sup>. <sup>1</sup>Lung Transplant Service, Alfred Hospital, Melbourne, Australia, <sup>2</sup>Lung Transplant and Pulmonary Medicine, University of Alberta, Edmonton, AB, Canada, <sup>3</sup>Department of Medicine, University of Alberta, Edmonton, AB, Canada

WEDNESDAY, APRIL 3, 2019

2:00 PM - 3:45 PM

**SESSION 12 (ORAL): When Short-Term Becomes Long-Term: Transition from Temporary to Permanent Mechanical Support**

**Room: Pacifica 6**

**Target Audience: MCS**

**Chairs:** Maria M. Mountis, DO, and Christopher T Salerno, MD

- 2:00 PM** (52) *Outcomes of Patients Supported with ECMO as a Bridge to Durable Mechanical Circulatory Support: An Analysis of the STS Intermacs Database*; R. Y. Loyaga-Rendon<sup>1</sup>, T. Boeve<sup>2</sup>, J. Tallaj<sup>3</sup>, S. Lee<sup>1</sup>, M. Leacche<sup>2</sup>, D. A. Koehl<sup>4</sup>, R. S. Cantor<sup>4</sup>, K. Lotun<sup>5</sup>, D. Acharya<sup>5</sup>. <sup>1</sup>Cardiology Division, Spectrum Health, Grand Rapids, MI, <sup>2</sup>Cardiothoracic Surgery Division, Spectrum Health, Grand Rapids, MI, <sup>3</sup>Cardiovascular Division, University of Alabama at Birmingham, Birmingham, AL, <sup>4</sup>Kirklin Institute for Research in Surgical Outcomes, University of Alabama at Birmingham, Birmingham, AL, <sup>5</sup>Cardiovascular Diseases Division, University of Arizona Sarver Heart Center, Tucson, AZ
- 2:15 PM** (53) *Comparison of ECMO Patients Bridged to LVAD vs Bridged to Transplantation*; C. Lui, C. D. Fraser, A. Suarez-Pierre, X. Zhou, K. J. Zehr, C. W. Choi, A. Kilic. Johns Hopkins University, Baltimore, MD
- 2:30 PM** (54) *Short and Long-Term Adverse Events in Patients on Temporary Circulatory Support before LVAD: An IMACS Registry Analysis*; V. Ton<sup>1</sup>, J. A. Hernandez-Montfort<sup>2</sup>, R. Xie<sup>3</sup>, B. P. Meyns<sup>4</sup>, T. Nakatani<sup>5</sup>, M. Yanase<sup>6</sup>, S. Shaw<sup>7</sup>, S. Pettit<sup>8</sup>, I. Netuka<sup>9</sup>, J. Kirklin<sup>10</sup>, D. J. Goldstein<sup>11</sup>, J. Cowger<sup>12</sup>. <sup>1</sup>University of Maryland School of Medicine, Baltimore, MD, <sup>2</sup>The University of Texas Medical Branch-Galveston, Galveston, TX, <sup>3</sup>The University of Alabama at Birmingham, Birmingham, AL, <sup>4</sup>Gasthuisberg University Hospital, Leuven, Belgium, <sup>5</sup>National Cardiovascular Center, Osaka, Japan, <sup>6</sup>National Cerebral and Cardiovascular Center, Osaka, Japan, <sup>7</sup>Wythenshawe Hospital, Manchester, United Kingdom, <sup>8</sup>Royal Papworth Hospital, Cambridge, United Kingdom, <sup>9</sup>IKEM - Institute for Clinical and Experimental Medicine, Prague, Czech Republic, <sup>10</sup>University of Alabama at Birmingham, Birmingham, AL, <sup>11</sup>Montefiore Medical Center, New York, NY, <sup>12</sup>Henry Ford Health System, Detroit, MI
- 2:45 PM** (55) *Longitudinal Impact of Temporary Mechanical Circulatory Support on Durable Left Ventricular Assist Device Outcomes: An IMACS Registry Analysis*; J. A. Hernandez-Montfort<sup>1</sup>, V. Khue Ton<sup>2</sup>, R. Xie<sup>3</sup>, A. Fisher<sup>4</sup>, B. Meyns<sup>5</sup>, T. Nakatani<sup>6</sup>, I. Netuka<sup>7</sup>, S. Pettit<sup>8</sup>, S. Shaw<sup>9</sup>, M. Yanase<sup>10</sup>, J. K. Kirklin<sup>11</sup>, A. Rowe<sup>12</sup>, D. J. Goldstein<sup>13</sup>, J. Cowger<sup>14</sup>. <sup>1</sup>The University of Texas Medical Branch - Galveston, Galveston, TX, <sup>2</sup>University of Maryland, Baltimore, MD, <sup>3</sup>IMACS, Birmingham, AL, <sup>4</sup>Newcastle University, Newcastle, United Kingdom, <sup>5</sup>UZ Leuven, Leuven, Belgium, <sup>6</sup>Maki Hospital, Osaka, Japan, <sup>7</sup>Institut Clinical and Experimental Medicine, Prague, Czech Republic, <sup>8</sup>Papworth, Cambridge, United Kingdom, <sup>9</sup>Manchester University NHS Foundation Trust, Manchester, United Kingdom, <sup>10</sup>National Cerebral and Cardiovascular Center, Osaka, Japan, <sup>11</sup>University of Alabama- Birmingham, Birmingham, AL, <sup>12</sup>ISHLT Headquarters, Addison, TX, <sup>13</sup>Montefiore, Bronx, NY, <sup>14</sup>Cardiology, Henry Ford Hospital, Detroit, MI
- 3:00 PM** (56) *Transition from Short-Term to Durable Mechanical Circulatory Support Systems. Outcome and Patient Selection. On Behalf of ECMO-VAD Study Group*; D. Saeed<sup>1</sup>, E. Potapov<sup>2</sup>, A. Loforte<sup>3</sup>, M. Morchius<sup>4</sup>, D. Schibilsky<sup>5</sup>, D. Zimpfer<sup>6</sup>, J. Riebandt<sup>6</sup>, F. Pappalardo<sup>7</sup>, M. Attisani<sup>8</sup>, A. Haneya<sup>9</sup>, F. Ramjankhan<sup>10</sup>, D. Donker<sup>10</sup>, U. Jorde<sup>11</sup>, R. Wieloch<sup>1</sup>, R. Ayala<sup>12</sup>, D. Tsyganenko<sup>2</sup>, J. Cremer<sup>9</sup>, A. Lichtenberg<sup>1</sup>, J. Gummert<sup>4</sup>. <sup>1</sup>Cardiovascular Surgery, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany, <sup>2</sup>Deutsches Herzzentrum Berlin, Berlin, Germany, <sup>3</sup>Bologna University, Bologna, Italy, <sup>4</sup>Herz und Diabetes Zentrum NRW, Bad Oeynhausen, Germany, <sup>5</sup>Cardiovascular Surgery, Freiburg University, Freiburg, Germany, <sup>6</sup>Medical University Vienna, Vienna, Austria, <sup>7</sup>Cardiovascular Surgery, San Raffaele Hospital, Milan, Italy, <sup>8</sup>Cardiovascular Surgery, University of Turin, Turin, Italy, <sup>9</sup>Cardiovascular Surgery, University Hospital Schleswig Holstein, Kiel, Germany, <sup>10</sup>Cardiovascular Surgery, University Medical Center Utrecht, Utrecht, Netherlands, <sup>11</sup>Montefiore Medical Center, Bronx, NY, <sup>12</sup>Freiburg University, Freiburg, Germany
- 3:15 PM** (57) *Risk Factors for Bleeding and Thrombosis Events on Venous-Arterial Extracorporeal Life Support: An ELSO Analysis*; F. R. Cabezas<sup>1</sup>, E. W. Grandin<sup>1</sup>, R. Kociol<sup>1</sup>, M. R. Mehra<sup>2</sup>. <sup>1</sup>Beth Israel Deaconess Medical Center, Boston, MA, <sup>2</sup>Advanced Heart Failure, Brigham and Women's Hospital, Boston, MA
- 3:30 PM** (58) *Impact of Temporary Mechanical Circulatory Support Prior to Implantation of a Ventricular Assist Device with a Follow-Up of 1 Year- A EUROMACS Analysis*; D. Schibilsky<sup>1</sup>, T. de By<sup>2</sup>, J. Gummert<sup>3</sup>, F. Ramjankhan<sup>4</sup>, J. Wolfinger<sup>1</sup>, E. Potapov<sup>5</sup>, I. Netuka<sup>6</sup>, F. Beyersdorf<sup>1</sup>, M. Siepe<sup>1</sup>. <sup>1</sup>Department of Cardiovascular

*Surgery, University Heart Center Freiburg • Bad Krozingen, Freiburg Germany and Medical Faculty of the Albert-Ludwigs-University Freiburg, Germany, Freiburg, Germany, <sup>2</sup>EUROMACS, Windsor, Germany, <sup>3</sup>Department of Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany, <sup>4</sup>Department of Cardiovascular Surgery, University Medical Center Utrecht, Utrecht, Germany, <sup>5</sup>Department of Cardiothoracic and Vascular Surgery, German Heart Institute Berlin, Berlin, Germany, <sup>6</sup>Department of Cardiac Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic*

**WEDNESDAY, APRIL 3, 2019**

**2:00 PM - 3:45 PM**

**SESSION 13 (SYMPOSIUM): They Tell Me I Am Irregular: Why Do They Care? Arrhythmias in LVAD Recipients**

**Room: Grand Caribbean 1-7**

**Target Audience: MCS**

**Chairs:** Michael M. Givertz, MD, and Stephan Schueler, MD, PhD, FRCS

**Session Summary:** CF-LVAD patients are living longer, and cardiac implantable electronic devices and arrhythmia management have assumed a significant role. More data is available to guide management, and expert speakers including MCS and EP specialists will discuss existing data & provide recommendations regarding appropriate management of ICD/CRT and arrhythmias in LVAD recipients.

**2:00 PM**

***Atrial Fibrillation and Flutter in LVAD Patients: Incidence, Significance and Management***

Sean P Pinney, MD, Mount Sinai Medical Center, New York, NY, USA

**2:15 PM**

***Q&A***

**2:20 PM**

***Optimal Device Programming and Role of Catheter and Surgical Ablation in Arrhythmia Management Post-LVAD***

Joshua D Moss, MD, UCSF Medical Center, San Francisco, CA, USA

**2:35 PM**

***Q&A***

**2:40 PM**

***DEBATE: All VAD Patients Should Have ICD and All VT Should Be Ablated (PRO)***

Anique Ducharme, MD, MSC, Montreal Heart Institute, Montreal, QC, Canada

**2:55 PM**

***DEBATE: All VAD Patients Should Have ICD and All VT Should Be Ablated (CON)***

Shashank S Desai, MD, Inova Fairfax Hospital, Falls Church, VA, USA

**3:10 PM**

***DEBATE: BiV Pacing Improves Outcomes in LVAD Patients (PRO)***

Gabriel Sayer, MD, University of Chicago, Chicago, IL, USA

**3:25 PM**

***DEBATE: BiV Pacing Improves Outcomes in LVAD Patients (CON)***

Jens Garbade, MD, University of Leipzig Medical Center, Leipzig, Germany

**WEDNESDAY, APRIL 3, 2019**

**2:00 PM - 3:45 PM**

**SESSION 14 (SYMPOSIUM): Part of (Their) World: Discharging Patients Home with a New Device**

**Room: Pacifica 3-5**

**Target Audiences: NHSAH, MCS, PEDS**

**Chairs:** Sarah E Schroeder, ACNP-BC, MSN, RN, AACC, and Mark E Puhlman, DNP, ANP-C

**Session Summary:** A successful discharge for patients with VAD or other supportive therapies (continuous infusions for pulmonary hypertension and heart failure patients) requires thoughtful planning and education. This symposium addresses topics geared towards helping patients successfully discharge to (and remain) home, including self-management/self-efficacy, discharge medications, avoiding readmission, preparing caregivers of patients with devices, and addressing the issues most important to patients: driving, showering, drinking, sex and traveling.

- 2:00 PM**            *I Can Go the Distance: Building Self Care and Self-Empowerment in Patients*  
Jesus Casida, PhD, RN, Johns Hopkins University, Baltimore, MD, USA
- 2:15 PM**            *Q&A*
- 2:20 PM**            *You've Got a Friend in Me: Preparing Caregivers*  
Jodie Lantz, MSN, RN, PCNS-BC, Children's Health Dallas, Richardson, TX, USA
- 2:35 PM**            *Q&A*
- 2:40 PM**            *A Spoonful of Sugar Makes the Discharge Medications Go Down*  
Cassandra Vale, PharmD, The Prince Charles Hospital, Queensland, Australia
- 2:55 PM**            *Q&A*
- 3:00 PM**            *How Far I'll Go: Preventing Returns to the Hospital*  
Nicola Robinson Smith, RN, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
- 3:15 PM**            *Q&A*
- 3:20 PM**            *The Bare Necessities: The Do's and Don'ts of Living with a New Device*  
Wendy Gin-Sing, CNS, Hammersmith Hospital, London, United Kingdom
- 3:35 PM**            *Q&A*

WEDNESDAY, APRIL 3, 2019

2:00 PM - 3:45 PM

**SESSION 15 (ORAL): Pharmacotherapy in Transplantation: Reading the Tea Leaves to Improve Outcomes**

Room: Coral Sea

Target Audiences: PHARM, HF/HTX, MCS

Chairs: Adam B Cochrane, PharmD, and Keyur B. Shah, MD

- 2:00 PM** (59) *Omega-3 Suppresses Gastrointestinal Bleeding by Reducing Angiotensin-2 Expression in LVAD Patients*; T. Imamura, A. Nguyen, D. Nitta, S. Kalantari, B. Smith, J. Raikhelkar, N. Narang, B. Chung, I. Ebong, L. Holzhauser, T. Fujino, C. Juricek, P. Combs, D. Onsager, T. Song, T. Ota, V. Jeevanandam, G. Sayer, G. Kim, N. Uriel. *University of Chicago, Chicago, IL*
- 2:15 PM** (60) *Effect of Methylene Blue Administration on Vasoplegia Following Left Ventricular Assist Device Implantation*; A. Saha<sup>1</sup>, D. L. Jennings<sup>2</sup>, J. Sanchez<sup>1</sup>, A. Melehy<sup>1</sup>, M. Yuzefpolskaya<sup>3</sup>, P. C. Colombo<sup>3</sup>, M. A. Farr<sup>3</sup>, H. Takayama<sup>4</sup>, Y. Naka<sup>4</sup>, K. Takeda<sup>4</sup>. <sup>1</sup>*Columbia University Vagelos College of Physicians and Surgeons, New York, NY*, <sup>2</sup>*Department of Pharmacy, Columbia University Irving Medical Center, New York, NY*, <sup>3</sup>*Department of Medicine, Division of Cardiology, Columbia University Irving Medical Center, New York, NY*, <sup>4</sup>*Department of Surgery, Division of Cardiac, Thoracic & Vascular Surgery, Columbia University Irving Medical Center, New York, NY*
- 2:30 PM** (61) *Comparative Efficacy of Bortezomib and Carfilzomib Desensitization Protocols in Highly Sensitized Cardiac Transplant Candidates*; M. Sobhanian<sup>1</sup>, J. Saltarrelli<sup>2</sup>, P. Weeks<sup>1</sup>, S. Nathan<sup>2</sup>, R. Radovancevic<sup>2</sup>, B. Kar<sup>2</sup>, I. Gregoric<sup>2</sup>. <sup>1</sup>*Memorial Hermann Hospital - Texas Medical Center, Houston, TX*, <sup>2</sup>*The University of Texas Health Science Center at Houston, Houston, TX*
- 2:45 PM** (62) *Mycophenolic Acid Area under the Curve Monitoring via Limited Sampling Strategy in Pediatric Heart Transplant Recipients*; S. A. Crow, S. H. Dahl, J. N. Johnson. *Mayo Clinic, Rochester, MN*
- 3:00 PM** (63) *Association between Cumulative Pre-Transplant Amiodarone Dose and Post-Transplant Outcomes after Heart Transplantation*; L. M. Lourenco<sup>1</sup>, K. Lang<sup>1</sup>, P. Simone<sup>1</sup>, S. Patel<sup>1</sup>, J. Powers<sup>2</sup>, T. Riley<sup>2</sup>, C. Murks<sup>2</sup>, B. Smith<sup>2</sup>, S. Kalantari<sup>2</sup>, J. Raikhelkar<sup>2</sup>, N. Sarswat<sup>2</sup>, G. Kim<sup>2</sup>, G. Sayer<sup>2</sup>, N. Uriel<sup>2</sup>. <sup>1</sup>*Pharmacy Services, University of Chicago Medicine, Chicago, IL*, <sup>2</sup>*Cardiology, University of Chicago Medicine, Chicago, IL*
- 3:15 PM** (64) *Retrospective Nested Case Control Study of the Impact of Immunosuppression on Post Transplant Malignancy among Adult Heart Transplant Patients*; S. A. Crow, R. J. Bubik, N. L. Pereira, K. C. Mara, R. A. Dierkhising, S. S. Kushwaha. *Mayo Clinic, Rochester, MN*
- 3:30 PM** (65) *Past is Not Prologue - Immune Function Assay Results as a Predictor of Malignancy Post-Heart Transplant (HT)*; T. Khuu<sup>1</sup>, M. Kamath<sup>2</sup>, M. Moore<sup>1</sup>, A. Salimbangon<sup>1</sup>, T. Daun<sup>1</sup>, A. Chang<sup>1</sup>, L. Sweet<sup>1</sup>, E. DePasquale<sup>2</sup>, A. Nsair<sup>2</sup>, R. Ardehali<sup>2</sup>, A. Baas<sup>2</sup>, M. Deng<sup>2</sup>, M. Cadeiras<sup>3</sup>, A. Ardehali<sup>4</sup>. <sup>1</sup>*Transplant Services, UCLA, Los Angeles, CA*, <sup>2</sup>*Medicine, Cardiology, UCLA, Los Angeles, CA*, <sup>3</sup>*Medicine, Cardiology, UC Davis, Davis, CA*, <sup>4</sup>*Surgery, UCLA, Los Angeles, CA*



WEDNESDAY, APRIL 3, 2019

4:15 PM - 6:00 PM

**SESSION 16 (ORAL): Junior Faculty and Trainees Clinical Case Dilemmas: The Best of the Best**

**Room:** Coral Sea

**Target Audience:** ALL

**Chairs:** Ryan Butts, MD, and Lavanya Bellumkonda, MD

- 4:15 PM** (66) *Stop the Leak! Transcatheter Aortic Valve Replacement in Pediatric VAD Patient*; H. P. Tunuguntla<sup>1</sup>, I. Adachi<sup>2</sup>, A. Khan<sup>1</sup>, B. A. Elias<sup>2</sup>, S. Choudhry<sup>1</sup>, A. G. Cabrera<sup>1</sup>, J. F. Price<sup>1</sup>, W. J. Dreyer<sup>1</sup>, S. W. Denfield<sup>1</sup>, J. A. Spinner<sup>1</sup>, A. Jeewa<sup>3</sup>, A. M. Qureshi<sup>1</sup>. <sup>1</sup>*Pediatric Cardiology, Texas Children's Hospital, Houston, TX*, <sup>2</sup>*Congenital Heart Surgery, Texas Children's Hospital, Houston, TX*, <sup>3</sup>*Pediatric Cardiology, The Hospital for Sick Children, Toronto, ON, Canada*
- 4:20 PM** **Expert Discussant**, Christopher Almond, MD, Stanford University, Stanford, CA, USA
- 4:25 PM** **Discussion**
- 4:32 PM** (67) *The Utility of CardioMEMS Implantable Hemodynamic Monitoring Device in Heartware HVAD Patient with Recurrent Gastrointestinal Bleeding*; H. Singh<sup>1</sup>, V. Kittipibul<sup>2</sup>, R. Flowers<sup>2</sup>, S. V. Chaparro<sup>3</sup>. <sup>1</sup>*University of Miami Miller School of Medicine, Miami, FL*, <sup>2</sup>*Department of Medicine, University of Miami Miller School of Medicine, Miami, FL*, <sup>3</sup>*Cardiovascular Medicine Division, University of Miami Miller School of Medicine, Miami, FL*
- 4:37 PM** **Expert Discussant**, Robert L. Kormos, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
- 4:42 PM** **Discussion**
- 4:49 PM** (68) *Inverted Lung Transplantation: Interposition of Pericardial Conduit for Pulmonary Venous Anastomosis*; H. Yamamoto<sup>1</sup>, K. Miyoshi<sup>2</sup>, T. Kurosaki<sup>1</sup>, S. Otani<sup>1</sup>, M. Okazaki<sup>1</sup>, S. Sugimoto<sup>1</sup>, M. Yamane<sup>1</sup>, S. Toyooka<sup>1</sup>, T. Oto<sup>1</sup>. <sup>1</sup>*General Thoracic Surgery, Organ Transplant Center, Okayama University Hospital, Okayama, Japan*, <sup>2</sup>*General Thoracic Surgery, Okayama Medical Center, Okayama, Japan*
- 4:54 PM** **Expert Discussant**, Christopher H. Wigfield, MD, FRCS, Advocate Christ Medical Center, Chicago, IL, USA
- 4:59 PM** **Discussion**
- 5:06 PM** (69) *Successful Bacteriophage Therapy for Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infection in a Cystic Fibrosis Patient*; N. Law<sup>1</sup>, C. Logan<sup>1</sup>, C. Furr<sup>2</sup>, S. Lehman<sup>2</sup>, S. Morales<sup>2</sup>, F. Rosas<sup>2</sup>, A. Gaidamaka<sup>2</sup>, I. Bilinsky<sup>2</sup>, P. Grint<sup>2</sup>, R. Schooley<sup>1</sup>, S. Aslam<sup>1</sup>. <sup>1</sup>*University of California, San Diego, San Diego, CA*, <sup>2</sup>*AmpliPhi Biosciences Inc, San Diego, CA*
- 5:11 PM** **Expert Discussant**, Nicolas Mueller, MD., University Hospital Zurich, Zurich, Switzerland
- 5:16 PM** **Discussion**
- 5:23 PM** (70) *Tocilizumab for Antibody-Mediated Rejection in the Setting of Cardiac Allograft Vasculopathy*; S. January<sup>1</sup>, A. Pottebaum<sup>1</sup>, D. Raymer<sup>1</sup>, K. Lavine<sup>2</sup>. <sup>1</sup>*Barnes-Jewish Hospital, St Louis, MO*, <sup>2</sup>*Washington University School of Medicine, St Louis, MO*
- 5:28 PM** **Expert Discussant**, Jon A. Kobashigawa, MD, Cedars-Sinai Heart Institute, Los Angeles, CA, USA
- 5:33 PM** **Discussion**
- 5:40 PM** (71) *Expanding Benefits from Cardiac Resynchronization Therapy to Exercise-Induced Left Bundle Branch Block in the Setting of Advanced Heart Failure: A Case Report*; F. L. Scolari, W. R. Menegazzo, A. D. Silveira, A. C. Mendes, M. Pimentel, N. Clausell, L. Goldraich. *Hospital de Clínicas Porto Alegre, Porto Alegre, Brazil*
- 5:45 PM** **Expert Discussant**, Sharon A. Hunt, MD, Stanford University Medical Center, Stanford, CA, USA
- 5:50 PM** **Discussion**

WEDNESDAY, APRIL 3, 2019

4:15 PM - 6:00 PM

**SESSION 17 (ORAL): Tolerance Is All We Need in Thoracic Transplantation**

**Room: Pacifica 1-2**

**Target Audiences: BSTR, HTX, LTX, PATH**

**Chairs:** Fabio Ius, MD, and Thalachallour Mohanakumar, PhD

- 4:15 PM** (72) *31 Day Xenograft Lung Recipient Survival - Progress towards the Clinic*; L. Burdorf<sup>1</sup>, C. Laird<sup>2</sup>, S. Sendil<sup>2</sup>, N. O'Neill<sup>2</sup>, T. Zhang<sup>2</sup>, D. Parsell<sup>2</sup>, I. Tatarov<sup>3</sup>, Z. Abady<sup>1</sup>, B. M. Cerel<sup>1</sup>, S. Pratts<sup>1</sup>, C. J. Phelps<sup>4</sup>, D. L. Ayares<sup>4</sup>, A. M. Azimzadeh<sup>1</sup>, R. N. Pierson III<sup>1</sup>. <sup>1</sup>*Surgery, Center for Transplantation Sciences, MGH, Charlestown, MA*, <sup>2</sup>*Surgery, University of Maryland, Baltimore, MD*, <sup>3</sup>*Surgery, University of Maryland, Baltimore, MA*, <sup>4</sup>*Revivacor, Blacksburg, VA*
- 4:30 PM** (73) *Tolerance Induction by Myeloid Progenitor Cells Does Not Require Lethal Preconditioning or Hematopoietic Stem Cell Transplantation*; Y. Li<sup>1</sup>, A. Sedello<sup>2</sup>, J. Domen<sup>1</sup>. <sup>1</sup>*Ward Family Heart Center, Children's Mercy Hospital and Clinics, Kansas City, MO*, <sup>2</sup>*Cellerant Therapeutics, San Carlos, CA*
- 4:45 PM** (74) *IL-22 Regulates Induction of Foxp3-Rich Tertiary Lymphoid Organs in Tolerant Lung Allografts*; S. Tanaka<sup>1</sup>, J. M. Gauthier<sup>1</sup>, A. Fuchs<sup>1</sup>, W. Li<sup>1</sup>, R. Higashikubo<sup>1</sup>, A. Y. Tong<sup>1</sup>, A. S. Krupnick<sup>2</sup>, A. E. Gelman<sup>1</sup>, D. Kreisel<sup>1</sup>. <sup>1</sup>*Department of Surgery, Washington University in St. Louis, St. Louis, MO*, <sup>2</sup>*Department of Surgery, The University of Virginia, Charlottesville, VA*
- 5:00 PM** (75) *Intrapulmonary Immune Regulation by Pre-Transplant Infusion of Recipient-Derived Regulatory T Cells in a Rat Model of Ex Vivo Lung Perfusion Followed by Transplantation*; E. Miyamoto, T. Martinu, D. Hwang, A. Ohsumi, K. Boonstra, B. Joe, M. Umana, M. Liu, M. Cypel, S. Keshavjee, S. Juvet. *Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada*
- 5:15 PM** (76) *PI3-Kinase Inhibition Promotes Tolerogenic CD8+ T Cell Function in Lung Transplant Recipients with a History of Cigarette Smoke Exposure*; K. J. Patel<sup>1</sup>, Q. Cheng<sup>2</sup>, D. P. Allen<sup>1</sup>, C. Li<sup>1</sup>, C. Wallace<sup>1</sup>, A. Alawieh<sup>1</sup>, L. Cardenas<sup>3</sup>, J. Kilkenny<sup>1</sup>, S. N. Nadig<sup>1</sup>, M. Goddard<sup>4</sup>, J. Christie<sup>5</sup>, C. Krieger<sup>3</sup>, C. Atkinson<sup>1</sup>. <sup>1</sup>*Surgery, Medical University of South Carolina, Charleston, SC*, <sup>2</sup>*Department of Surgery, Tongji Hospital, Wuhan, China*, <sup>3</sup>*Microbiology and Immunology, Medical University of South Carolina, Charleston, SC*, <sup>4</sup>*Pathology, Royal Papworth Hospital NHS Trust, Cambridgeshire, United Kingdom*, <sup>5</sup>*Division of Pulmonary and Critical Care Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA*
- 5:30 PM** (77) *Donor T and NK Cells are Derived from the Donor Lung Parenchyma and Represent Tissue-Resident Memory Cells - An Important Feature for Tolerance Development*; R. Bellmàs Sanz<sup>1</sup>, A. Hitz<sup>1</sup>, B. Wiegmann<sup>2</sup>, K. Bläsing<sup>1</sup>, F. Ius<sup>2</sup>, A. Knöfel<sup>2</sup>, I. Tudorache<sup>2</sup>, M. Avsar<sup>2</sup>, D. Jonigk<sup>3</sup>, A. Haverich<sup>2</sup>, G. Warnecke<sup>2</sup>, C. Falk<sup>1</sup>. <sup>1</sup>*Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany*, <sup>2</sup>*Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany*, <sup>3</sup>*Institute of Pathology, Hannover Medical School, Hannover, Germany*
- 5:45 PM** (78) *Cardiac Allograft Vasculopathy is Linked to Impaired Generation of Regulatory M2 Macrophages*; L. Holzhauser, T. Imamura, K. A. Arnold, A. Schroeder, C. Murks, J. Powers, T. Riley, G. Kim, J. Raikhelkar, B. Smith, A. Nguyen, S. Nathan, B. Chung, V. Jeevanandam, N. Narang, I. Ebong, G. Sayer, N. Uriel, A. Francis. *University of Chicago, Chicago, IL*

WEDNESDAY, APRIL 3, 2019

4:15 PM - 6:00 PM

**SESSION 18 (ORAL): Ex-Vivo Heart Perfusion and Preservation: Some Like It Hot - or Not!**

Room: Pacifica 7

Target Audiences: HTX, HF

Chairs: Luanda P Grazette, MD, and Maryl R Johnson, MD

- 4:15 PM** (79) *Successful Utilization of Extended Criteria Donor (ECD) Hearts for Transplantation - Results of the OCS™ Heart EXPAND Trial to Evaluate the Effectiveness and Safety of the OCS Heart System to Preserve and Assess ECD Hearts for Transplantation*; J. N. Schroder<sup>1</sup>, D. D'Alessandro<sup>2</sup>, F. Esmailian<sup>3</sup>, T. Boeve<sup>4</sup>, P. Tang<sup>5</sup>, K. Liao<sup>6</sup>, I. Wang<sup>7</sup>, A. Anyanwu<sup>8</sup>, A. Shah<sup>9</sup>, K. Mudy<sup>10</sup>, E. Soltesz<sup>11</sup>, J. W. Smith<sup>12</sup>. <sup>1</sup>Duke University Medical Center, Durham, NC, <sup>2</sup>Massachusetts General Hospital, Boston, MA, <sup>3</sup>Cedars-Sinai Medical Center, Los Angeles, CA, <sup>4</sup>Spectrum Health, Grand Rapids, MI, <sup>5</sup>University of Michigan, Ann Arbor, MI, <sup>6</sup>University of Minnesota, Minneapolis, MN, <sup>7</sup>Indiana University, Indianapolis, IN, <sup>8</sup>Mount Sinai, New York, NY, <sup>9</sup>Vanderbilt University, Nashville, TN, <sup>10</sup>Minneapolis Heart Institute, Minneapolis, MN, <sup>11</sup>Cleveland Clinic Foundation, Cleveland, OH, <sup>12</sup>University of Washington, Seattle, WA
- 4:30 PM** (80) *Ex-vivo Perfusion on Marginal Donors in Heart Transplantation: Clinical Results and Pathological Findings*; S. Sponga<sup>1</sup>, V. Ferrara<sup>1</sup>, A. P. Beltrami<sup>2</sup>, A. Bonetti<sup>2</sup>, C. Cantarutti<sup>2</sup>, A. Caragnano<sup>2</sup>, F. Ortolani<sup>2</sup>, A. Lechiancole<sup>1</sup>, R. Esposito<sup>1</sup>, C. Di Nora<sup>1</sup>, V. Tursi<sup>3</sup>, C. Nalli<sup>1</sup>, U. Livi<sup>1</sup>. <sup>1</sup>Cardiothoracic Department, Udine University Hospital, Udine, Italy, <sup>2</sup>Medical Area Department (DAME), Udine University Hospital, Udine, Italy, <sup>3</sup>Udine University Hospital, Udine, Italy
- 4:45 PM** (81) *First to 50: Early Outcomes Following Heart Transplantation at Royal Papworth Hospital from Donation after Circulatory Determined Death (DCD) Donors*; S. Messer, A. Page, M. Berman, S. Colah, J. Dunning, E. Pavlushkov, P. Kaul, J. Parameshwar, Y. Abu-Omar, S. Pettit, C. Lewis, A. Kydd, S. Bhagra, A. Cockell, R. Quigley, J. Baxter, C. Ellis, D. Jenkins, C. Sudarshan, A. Ali, S. Tsui, P. Catarino, S. Large. *Transplant Surgery, Royal Papworth Hospital, Cambridgeshire, United Kingdom*
- 5:00 PM** (82) *Cardiac Transplantation in Higher Risk Patients: Is Ex Vivo Heart Perfusion a Safe Preservation Technique? A Two Center Experience*; S. V. Rojas<sup>1</sup>, F. Ius<sup>1</sup>, D. Schibilsky<sup>2</sup>, T. Kaufeld<sup>1</sup>, W. Sommer<sup>1</sup>, C. Benk<sup>2</sup>, T. Goecke<sup>1</sup>, T. Siemeni<sup>1</sup>, R. Poyanmehr<sup>1</sup>, S. Rümke<sup>1</sup>, A. Mogaldea<sup>1</sup>, D. Bobylev<sup>1</sup>, J. Salman<sup>1</sup>, M. Avsar<sup>1</sup>, I. Tudorache<sup>1</sup>, C. Bara<sup>1</sup>, F. Beyersdorf<sup>2</sup>, A. Haverich<sup>1</sup>, M. Siepe<sup>2</sup>, G. Warnecke<sup>1</sup>. <sup>1</sup>Department of Cardiothoracic-, Transplantation- and Vascular Surgery, Hannover Medical School, Hannover, Germany, <sup>2</sup>Department of Thoracic and Cardiovascular Surgery, University of Freiburg, Freiburg, Germany
- 5:15 PM** (83) *Keeping It Cool: Extended Myocardial Protection with Topical Cooling to Reduce PGD*; S. Avtaar Singh<sup>1</sup>, S. Das De<sup>1</sup>, K. Morcos<sup>1</sup>, Y. Hegazy<sup>1</sup>, H. Al-Haideri<sup>1</sup>, S. Nair<sup>1</sup>, J. Dalzell<sup>2</sup>, H. Doshi<sup>1</sup>, N. Al-Attar<sup>1</sup>, P. Curry<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, Golden Jubilee National Hospital, Glasgow, United Kingdom, <sup>2</sup>Scottish National Advanced Heart Failure Service, Golden Jubilee National Hospital, Glasgow, United Kingdom
- 5:30 PM** (84) *The First Clinical Use of a Novel Cold Storage System of Donor Hearts*; N. Naito<sup>1</sup>, M. Funamoto<sup>1</sup>, R. Pierson<sup>1</sup>, M. Villavicencio<sup>1</sup>, W. Riley<sup>2</sup>, G. Lewis<sup>3</sup>, D. D'Alessandro<sup>1</sup>. <sup>1</sup>Cardiac Surgery, Massachusetts General Hospital, Boston, MA, <sup>2</sup>Perfusion Services, Massachusetts General Hospital, Boston, MA, <sup>3</sup>Cardiology, Massachusetts General Hospital, Boston, MA
- 5:45 PM** (85) *Heart Ablation Avoiding Asystolia with an Always- Beating Heart*; I. G. Berra<sup>1</sup>, M. L. Berra<sup>2</sup>, M. A. Lewis<sup>3</sup>, S. Berra<sup>4</sup>, A. O. Irusta<sup>5</sup>, G. Berra<sup>6</sup>, P. A. Takeuchi<sup>5</sup>. <sup>1</sup>Heart, Lung and Kidney Transplant Team, Hospital Nacional de Pediatría JP Garrahan, Moron, Argentina, <sup>2</sup>Clinica Medica, Hospital Nacional Alejandro Posadas, Morón, Argentina, <sup>3</sup>Vice President, Lew Insumos e Innovaciones, Moron, Argentina, <sup>4</sup>Facultad de Ingeniería, Universidad de Buenos Aires, Buenos Aires, Argentina, <sup>5</sup>Design Team, Lew Insumos e Innovaciones, Moron, Argentina, <sup>6</sup>President, Lew Insumos e Innovaciones, Moron, Argentina

**WEDNESDAY, APRIL 3, 2019**

**4:15 PM - 6:00 PM**

**SESSION 19 (SYMPOSIUM): Chronic Lung Allograft Dysfunction (CLAD): The End of the Beginning?**

**Room: Pacifica 10-12**

**Target Audiences: LF/LTX, BSTR, PATH**

**Chairs:** Christian Benden, MD, and Sofya Tokman, MD

**Session Summary:** The recognition that not all cases of lung allograft dysfunction could be described accurately within the bronchiolitis obliterans syndrome (BOS) terminology led to the development of a new overarching descriptor (CLAD) to embrace both obstructive and restrictive allograft dysfunction. How to detect, diagnose, and manage suspected cases is described based on sound physiological and radiological principles. Exclusion criteria are discussed as well as special circumstances. A 15-min panel discussion with all speakers will conclude this session.

**4:15 PM**

***CLAD: Definition and Beyond***

Geert Verleden, MD, Univ Hospital Gasthuisberg, Belgium, Belgium

**4:30 PM**

***CLAD Phenotypes: Why Split?***

Jamie Todd, MD, Duke University, Durham, NC, USA

**4:45 PM**

***Restrictive Allograft Syndrome: Definition and Diagnosis***

Masaaki Sato, MD, University of Tokyo, Tokyo, Japan

**5:00 PM**

***Restrictive Allograft Syndrome: Pathology***

Jan H von der Thüsen, MD PhD, Erasmus Medical Center, Rotterdam, Netherlands

**5:15 PM**

***Risk Factors and Prognosis of Restrictive Allograft Syndrome***

Gregory I. Snell, MBBS, FRACP, MD, Alfred Hospital, Melbourne, Australia

**5:30 PM**

***CLAD Treatment: The Kingdom of the Near Dead?***

Lianne G. Singer, MD, FRCPC, Toronto General Hospital, Toronto, ON, Canada

**5:45 PM**

***15-min Panel Discussion***

WEDNESDAY, APRIL 3, 2019

4:15 PM - 6:00 PM

SESSION 20 (ORAL): The Beat Goes On: Arrhythmias and Pacing During MCS

Room: Pacifica 6

Target Audiences: MCS, NNSAH

Chairs: Melana Yuzefpolskaya, MD, and Joseph Rogers, MD

- 4:15 PM** (86) *Atrial Fibrillation is a Predictor of Poor Physical Capacity 6 Months after Implantation of a Full Magnetically Levitated Left Ventricular Assist Device: An Analysis from ELEVATE*; K. K. Mirza<sup>1</sup>, F. Gustafsson<sup>1</sup>, Y. Pya<sup>2</sup>, S. Shaw<sup>3</sup>, A. Diegeler<sup>1</sup>, I. Netuka<sup>4</sup>, J. Lavee<sup>5</sup>, J. Garbade<sup>6</sup>, M. Morshuis<sup>7</sup>, J. Heatley<sup>8</sup>, D. Saeed<sup>9</sup>, E. V. Potapov<sup>10</sup>, J. Schmitto<sup>11</sup>, D. Zimpfer<sup>12</sup>. <sup>1</sup>Department of Cardiology, Rigshospitalet, Copenhagen, Denmark, <sup>2</sup>National Research Center for Cardiac Surgery, Astana, Kazakhstan, <sup>3</sup>Southmoor Road, M23 9LT, Manchester University NHS Foundation Trust, Manchester, United Kingdom, <sup>4</sup>Institute for Clinical and Experimental Medicine, Prague, Czech Republic, <sup>5</sup>Heart Transplantation Unit, Leviev Heart Center, Sheba Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, <sup>6</sup>Struempellstr. 39, 4289, Department of Cardiac Surgery, Heart Center Leipzig, University of Leipzig, Leipzig, Germany, <sup>7</sup>Georgstrasse 11, 32545, Department of Cardiothoracic Surgery, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Germany, <sup>8</sup>Abbott, Chicago, IL, <sup>9</sup>Strümpellstrasse 39, 04289, University Department for Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany, <sup>10</sup>Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin; DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany, <sup>11</sup>Department of Cardiothoracic, Transplantation and Vascular Surgery, Medizinische Hochschule Hannover, Hannover, Germany, <sup>12</sup>Department of Surgery, Waehringer Guertel 18–20, Division of Cardiac Surgery, Medical University of Vienna, Vienna, Austria
- 4:30 PM** (87) *Impact of Atrial Fibrillation on Mortality and Thromboembolic Complications after Left Ventricular Assist Device Implantation*; V. Blumer<sup>1</sup>, M. Ortiz<sup>2</sup>, G. Hernandez<sup>3</sup>, V. Kittipibul<sup>1</sup>, A. Gage<sup>4</sup>, E. Joyce<sup>5</sup>, S. Chaparro<sup>1</sup>. <sup>1</sup>University of Miami, Miami, FL, <sup>2</sup>University of Iowa, Iowa City, IA, <sup>3</sup>Univ. of Miami, Miami, FL, <sup>4</sup>Cleveland Clinic, Cleveland, OH, <sup>5</sup>Mater Misericordiae University Hospital, Dublin, Ireland
- 4:45 PM** (88) *Peak Left Atrial Appendage Emptying Velocity Remains Reduced in Atrial Fibrillation during Continuous Flow Left Ventricular Assist Device Support*; A. Rahman<sup>1</sup>, E. Tam<sup>1</sup>, L. ZHeng<sup>1</sup>, J. Fontes<sup>1</sup>, S. Forest<sup>2</sup>, S. Vukelic<sup>1</sup>, D. Sims<sup>1</sup>, J. Shin<sup>1</sup>, S. Patel<sup>1</sup>, D. J. Goldstein<sup>2</sup>, U. P. Jorde<sup>1</sup>, O. Saeed<sup>1</sup>. <sup>1</sup>Medicine (Cardiology), Montefiore Medical Center, Bronx, NY, <sup>2</sup>Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY
- 5:00 PM** (89) *Comparison of Amiodarone and Beta Blockers to Suppress Tachyarrhythmias in Patients with Left Ventricular Assist Devices*; B. El-Sabawi<sup>1</sup>, J. V. Hull<sup>2</sup>, H. Tun<sup>3</sup>, A. S. Vaidya<sup>3</sup>, J. E. Rahman<sup>3</sup>, K. A. Pandya<sup>3</sup>, L. Grazette<sup>3</sup>, M. W. Fong<sup>3</sup>. <sup>1</sup>Department of Medicine, Mayo Clinic, Rochester, MN, <sup>2</sup>Keck School of Medicine of the University of Southern California, Los Angeles, CA, <sup>3</sup>Division of Cardiology, Keck School of Medicine of the University of Southern California, Los Angeles, CA
- 5:15 PM** (90) *Functional Status, Quality of Life and Ventricular Tachyarrhythmias Improve with Right Ventricular Pacing Compared to Biventricular Pacing in LVAD Patients*; B. Chung<sup>1</sup>, J. Grinstein<sup>2</sup>, S. Weatherford<sup>1</sup>, S. Tayazime<sup>1</sup>, D. Rodgers<sup>1</sup>, A. Nguyen<sup>1</sup>, N. Narang<sup>1</sup>, G. Kim<sup>1</sup>, J. Raikhelkar<sup>1</sup>, U. Jorde<sup>3</sup>, C. LaBuhn<sup>1</sup>, V. Jeevanandam<sup>1</sup>, G. Sayer<sup>1</sup>, N. Uriel<sup>1</sup>. <sup>1</sup>University of Chicago, Chicago, IL, <sup>2</sup>MedStar Health, Washington, DC, DC, <sup>3</sup>Montefiore Medical Center, New York City, NY
- 5:30 PM** (91) *Acute Hemodynamic Effects of Different Pacing Strategies in LVAD Recipients*; G. Gulati<sup>1</sup>, M. Brisco-Bacik<sup>2</sup>, C. Madias<sup>1</sup>, S. Joseph<sup>3</sup>, A. Kilic<sup>4</sup>, J. Rich<sup>5</sup>, I. Gosev<sup>6</sup>, M. Kiernan<sup>1</sup>. <sup>1</sup>Cardiology, Tufts Medical Center, Boston, MA, <sup>2</sup>Cardiology, Temple University Hospital, Philadelphia, PA, <sup>3</sup>Cardiology, Baylor University Medical Center, Dallas, TX, <sup>4</sup>Surgery, Johns Hopkins Medical Institutions, Baltimore, MD, <sup>5</sup>Cardiology, Northwestern University, Chicago, IL, <sup>6</sup>Surgery, University of Rochester, Rochester, NY
- 5:45 PM** (92) *Ventricular Arrhythmias in Patients with Biventricular Assist Devices*; A. Lin, H. Tran, J. Hsu, K. Hoffmayer, G. Feld, E. Adler, V. Pretorius, D. Krummen, G. Ho. University of California San Diego, San Diego, CA

**WEDNESDAY, APRIL 3, 2019**

**4:15 PM - 6:00 PM**

**SESSION 21 (SYMPOSIUM): Short Term Mechanical Support: Taking the Next Leap Forward**

**Room: Grand Caribbean 1-7**

**Target Audiences: MCS, HF/HTX**

**Chairs:** Bart Meyns, MD, PhD, and Luciano Potena, MD, PhD

**Session Summary:** This symposium will focus on short term mechanical support with a view to optimizing results, whether as a bridge to recovery, long term mechanical support or transplant. Current and future management trends will be discussed to identify best practices for these complex patients.

- 4:15 PM**            *IABPs Work, But in Whom?*  
Jerry D Estep, MD, Cleveland Clinic, Cleveland, OH, USA
- 4:30 PM**            *Q&A*
- 4:35 PM**            *In It for the Long Haul? What is the Role of ECMO in Short-Term Support?*  
Martin Strueber, MD, Beth Israel Medical Center, Newark, NJ, USA
- 4:50 PM**            *Q&A*
- 4:55 PM**            *DEBATE: Six Months After the Change in the US Allocation System: It Still Makes Sense to Transplant Patients Off ECMO (PRO)*  
Danny Ramzy, MD, PhD, Cedars-Sinai Med Ctr, Los Angeles, CA, USA
- 5:10 PM**            *DEBATE: Six Months After the Change in the US Allocation System: It Still Makes Sense to Transplant Patients Off ECMO (CON)*  
Jose Gonzalez-Costello, MD, Belvitge Hospital, Barcelona, Spain
- 5:25 PM**            *Debate Rebuttal (PRO)*  
Danny Ramzy, MD, PhD, Cedars-Sinai Med Ctr, Los Angeles, CA, USA
- 5:30 PM**            *Debate Rebuttal (CON)*  
Jose Gonzalez-Costello, MD, Belvitge Hospital, Barcelona, Spain
- 5:35 PM**            *Do All Roads Lead to Rome? Access Strategies for Temporary Percutaneous Mechanical Support*  
Jennifer A Cowger, MD, MS, Henry Ford Hospitals, Detroit, MI, USA
- 5:50 PM**            *Q&A*

**WEDNESDAY, APRIL 3, 2019**

**4:15 PM - 6:00 PM**

**SESSION 22 (SYMPOSIUM): What Do We Do? Burning Platforms in Pediatric Thoracic Transplant**

**Room: Pacifica 3-5**

**Target Audiences: PEDS, HF/HTX, NHSAH**

**Chairs:** Melanie D Everitt, MD, and Tajinder P Singh, MD, MSc

**Session Summary:** The goal of the symposium is to address the challenges we are currently facing within the field of pediatric thoracic transplant. From donor selection to indications for transplant in the failing Fontan population, a potpourri of topics will be covered. A 15-min panel discussion with all speakers will conclude this session.

- 4:15 PM**            *Pediatric Heart Donors with Low Ejection Fraction - How Low Can You Go?*  
Claire A Irving, MBChB, MRCPCH, MD, Children's Hospital Westmead, Sydney, Australia
- 4:30 PM**            *But It's Legal Here: Addressing Legalized Marijuana and Illicit Drug Use with Thoracic Transplant Patients*  
Carol K Conrad, MD, Lucille Packard Children's Hospital, Palo Alto, CA, USA
- 4:45 PM**            *How Low Should We Go? Outcomes of Infant VAD and Transplant*  
Kathleen Simpson, MD, Washington University/St. Louis Children's Hospital, St. Louis, MO, USA
- 5:00 PM**            *Practical Strategies for Transitioning Our GenZ Patients*  
Jo Wray, PhD, Great Ormond Street Hospital, London, United Kingdom
- 5:15 PM**            *Routine Use of mTOR inhibitors in Pediatric Thoracic Transplant Recipients: Show Me the Evidence*  
Kevin P Daly, MD, Boston Children's Hospital, Boston, MA, USA
- 5:30 PM**            *When to Refer: Advanced Cardiac Support for the Failing Fontan*  
Kurt R Schumacher, MD, CS Mott Children's Hospital, Ann Arbor, MI, USA
- 5:45 PM**            *15-min Panel Discussion*

WEDNESDAY, APRIL 3, 2019

6:15 PM - 7:15 PM

**MINI ORAL 01: Deciphering the Role of Antibodies and Inflammation in Thoracic Rejection**

Room: Pacifica 1-2

Target Audiences: BSTR, HTX, LTX, PATH

Chairs: Yoshito Yamada, MD, PhD, and Sebastian G A Michel, MD

- 6:15 PM** (357) *Downregulation of Alloimmunity in Lung Allograft by Eosinophils is Orchestrated by PD-L1 Dependent Contact with CD8+ T Cells*; O. O. Onyema<sup>1</sup>, Y. Guo<sup>1</sup>, B. Mahgoub<sup>1</sup>, A. Manafi<sup>1</sup>, Q. Wang<sup>1</sup>, S. Criswell<sup>2</sup>, J. Lannigan<sup>3</sup>, E. A. Jacobsen<sup>4</sup>, A. E. Gelman<sup>5</sup>, D. Kreisel<sup>5</sup>, A. S. Krupnick<sup>1</sup>. <sup>1</sup>Department of Surgery and Carter Immunology Center, University of Virginia, Charlottesville, VA, <sup>2</sup>Department of Cell Biology and Advanced Microscopy Core Laboratory, University of Virginia, Charlottesville, VA, <sup>3</sup>Flow Cytometry Core Facility, University of Virginia, Charlottesville, VA, <sup>4</sup>Department of Biochemistry and Molecular Biology, Mayo Clinic, Scottsdale, AZ, <sup>5</sup>Department of Surgery, Washington University, St Louis, MO
- 6:20 PM** (358) *Donor-Derived Factors Influence NK Cell Effector Activity in a Model of Antibody-Mediated Chronic Rejection*; C. M. Lin<sup>1</sup>, B. Mehrad<sup>1</sup>, R. G. Gill<sup>2</sup>. <sup>1</sup>Medicine, University of Florida, Gainesville, FL, <sup>2</sup>Surgery, University of Colorado, Aurora, CO
- 6:25 PM** (359) *Proteomic Profiling of Extracellular Vesicles during Acute Cellular Rejection*; O. Gidlöf, I. Sukma Dewi, J. Öhman, M. Evander, T. Laurell, G. Smith. Lund University, Lund, Sweden
- 6:30 PM** (360) *Recipient CD103+ Classical Dendritic Cells Enhance Acute Rejection in Response to Airway Inflammation after Mouse Lung Transplantation*; T. Watanabe, T. Martinu, K. Boonstra, J. M. Umana, M. Horie, Z. Guan, D. Hwang, M. Liu, S. Keshavjee, S. Juvet. University Health Network, Toronto, ON, Canada
- 6:35 PM** (361) *Development of Novel Murine Antibody Mediated Rejection Model after Orthotopic Lung Transplant*; Y. Shiina, H. Suzuki, T. Kaiho, A. Hata, T. Yamamoto, J. Morimoto, Y. Sakairi, H. Wada, T. Nakajima, I. Yoshino. Department of General Thoracic Surgery, Chiba University Graduate School of Medicine, Chiba, Japan
- 6:40 PM** (362) *Recipient HLA-G Single Nucleotide Polymorphisms Predict Post-Lung Development of Donor Specific Antibodies*; D. C. Birriel, A. Ulahannan, J. Ma, J. Lazarte, T. Martinu, L. Singer, V. Rao, S. Keshavjee, D. Delgado, J. Tikkanen, S. Juvet. UHN, Toronto, ON, Canada
- 6:45 PM** (363) *Alpha1-Antitrypsin Therapy Suppresses Acute Rejection in an Orthotopic Murine Lung Transplantation Model*; T. Nakagiri<sup>1</sup>, A. Knöfel<sup>1</sup>, S. Janciauskiene<sup>2</sup>, P. Zardo<sup>1</sup>, S. Wrenger<sup>2</sup>, T. Welte<sup>2</sup>, A. Haverich<sup>1</sup>, G. Warnecke<sup>1</sup>. <sup>1</sup>Cardiothoracic, Transplantation, and Vascular Surgery, Hannover Medical School, Hannover, Germany, <sup>2</sup>Respiratory Medicine, Hannover Medical School, Hannover, Germany
- 6:50 PM** (364) *Circulating Exosomes with Lung Self-Antigens, Ka1Tubulin and Collagen V, and Immune Responses to Lung Self-Antigens Precedes Histological Evidence of Chronic Rejection Following Orthotopic Murine Lung Transplantation*; M. Rahman, M. Sharma, W. Liu, M. A. Smith, R. M. Bremner, T. Mohanakumar. Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ
- 6:55 PM** (365) *Reconstruction of Transcriptional Programs of Monocyte to Macrophage Sequential Cell Fate Transition Using Single Cell RNA Sequencing in Sex Mis-Matched Lung Transplantation*; B. O'Sullivan<sup>1</sup>, J. Powell<sup>2</sup>, S. Lukowski<sup>3</sup>, M. Tan<sup>1</sup>, P. Hopkins<sup>1</sup>, D. Chambers<sup>1</sup>. <sup>1</sup>Queensland Lung Transplant Research, Brisbane, Australia, <sup>2</sup>Garvan Institute, Sydney, Australia, <sup>3</sup>Institute for Molecular Bioscience, Brisbane, Australia
- 7:00 PM** (366) *Clonal Composition and Single-Cell Characterization of T-Cell Infiltrates in Cardiac Allograft Vasculopathy*; M. V. Habal<sup>1</sup>, A. Myung<sup>2</sup>, S. Rao<sup>2</sup>, S. See<sup>2</sup>, R. R. Shihab<sup>2</sup>, P. Roy<sup>2</sup>, C. Marboe<sup>3</sup>, S. Restaino<sup>1</sup>, A. S. Han<sup>2</sup>, M. Givertz<sup>4</sup>, J. C. Madsen<sup>5</sup>, L. J. Addonizio<sup>6</sup>, M. Farr<sup>1</sup>, E. Zorn<sup>2</sup>. <sup>1</sup>Cardiology, Columbia University, New York, NY, <sup>2</sup>Columbia Center for Translational Immunology, Columbia University, New York, NY, <sup>3</sup>Pathology & Cell Biology, Columbia University, New York, NY, <sup>4</sup>Cardiology, Brigham and Women's Hospital, Boston, MA, <sup>5</sup>Surgery, Massachusetts General Hospital, Boston, MA, <sup>6</sup>Pediatric Cardiology, Columbia University, New York, NY



7:05 PM

**(367) *The Frequency of Tissue-Resident Donor T and NK Cells in Peripheral Blood after Lung Transplantation is Modulated by Normothermic Ex Vivo Lung***; C. Falk<sup>1</sup>, B. Wiegmann<sup>2</sup>, A. Hitz<sup>1</sup>, R. Bellmas-Sanz<sup>1</sup>, K. Bläsing<sup>1</sup>, F. Ius<sup>2</sup>, C. Kühn<sup>2</sup>, M. Avsar<sup>2</sup>, I. Tudorache<sup>2</sup>, A. Haverich<sup>2</sup>, G. Warnecke<sup>2</sup>. <sup>1</sup>*Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany*, <sup>2</sup>*Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany*

7:10 PM

**(368) *Persisting Donor Alveolar Macrophages Have Increased Expression of Scavenger Receptor CD206 Compared to Graft-Infiltrating Recipient-Derived Macrophages Following Lung Transplantation***; M. E. Snyder<sup>1</sup>, S. P. Weisberg<sup>2</sup>, T. Connors<sup>3</sup>, L. Benvenuto<sup>4</sup>, L. Shah<sup>4</sup>, H. J. Robbins<sup>4</sup>, J. L. Hook<sup>4</sup>, F. D'Ovidio<sup>5</sup>, J. Sonett<sup>5</sup>, S. Arcasoy<sup>4</sup>, D. L. Farber<sup>5</sup>. <sup>1</sup>*Medicine, University of Pittsburgh, Pittsburgh, PA*, <sup>2</sup>*Pathology, Columbia University, New York, NY*, <sup>3</sup>*Pediatrics, Columbia University, New York, NY*, <sup>4</sup>*Medicine, Columbia University, New York, NY*, <sup>5</sup>*Surgery, Columbia University, New York, NY*

WEDNESDAY, APRIL 3, 2019

6:15 PM - 7:15 PM

**MINI ORAL 02: Cardiac Donor Selection: More Than Meets the Eye**

**Room: Pacifica 7**

**Target Audiences: HF/HTX, MCS**

**Chairs:** Steven SL Tsui, MD, FRCS, and Alanna A Morris, MD

- 6:15 PM** (369) *How Big is Too Big? An Analysis of Morbidly Obese Heart Donors in the UNOS Database*; E. D. Krebs, J. P. Beller, J. H. Mehaffey, N. R. Teman, J. L. Kennedy, G. Ailawadi, L. T. Yarboro. *University of Virginia, Charlottesville, VA*
- 6:20 PM** (370) *Label-Free Proteomics Approach Characterizes Plasma Protein Signature of Donor Brain Death*; J. Lukac<sup>1</sup>, M. Saraswata<sup>2</sup>, S. Joenväärää<sup>2</sup>, E. Holmström<sup>1</sup>, K. Dhaygude<sup>3</sup>, R. Krebs<sup>1</sup>, A. Nykänen<sup>1</sup>, R. Renkonen<sup>2</sup>, K. Lemström<sup>1</sup>. <sup>1</sup>*Cardiopulmonary Research Group, Transplantation Laboratory University of Helsinki, Helsinki, Finland*, <sup>2</sup>*Mass Spectrometry Group, Transplantation Laboratory University of Helsinki, Helsinki, Finland*, <sup>3</sup>*Cardiovascular Research Group, Transplantation Laboratory, University of Helsinki, Helsinki, Finland*
- 6:25 PM** (371) *Donor Hormonal Thyroid Therapy is Associated with Increased Risk of Primary Graft Dysfunction after Heart Transplantation*; Y. Peled, J. Lavee, E. Nachum, Y. Kassif, M. Arad, A. Kogan, D. Freimark, E. Ram. *Sheba Medical Center Tel Hashomer and Tel-Aviv University, Ramat Gan, Israel*
- 6:30 PM** (372) *Matchmaking Just Got Easier: Impact of Phenotypic Donor-Recipient Likeness in Open Heart Transplantation*; B. D. Lo, A. Suarez-Pierre, X. Zhou, C. Lui, M. F. Hunt, G. J. Whitman, C. W. Choi, A. Kilic. *Division of Cardiac Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD*
- 6:35 PM** (373) *Oversizing Donors - Is It Necessary for ACHD Patients?: An Analysis of the United Network for Organ Sharing Registry*; D. E. Clark<sup>1</sup>, R. D. Byrne<sup>2</sup>, D. S. Burnstein<sup>3</sup>, M. R. Danter<sup>4</sup>, R. Fowler<sup>1</sup>, B. P. Frischhertz<sup>1</sup>, J. Lindenfeld<sup>1</sup>, J. A. Mazurek<sup>5</sup>, B. A. Mettler<sup>6</sup>, A. Opatowsky<sup>7</sup>, T. L. Richardson<sup>2</sup>, E. M. Sandhuas<sup>1</sup>, K. H. Schlendorf<sup>1</sup>, J. Schmeckpeper<sup>1</sup>, A. S. Shah<sup>4</sup>, A. J. Weingarten<sup>8</sup>, S. Zalawadiya<sup>1</sup>, J. N. Menachem<sup>1</sup>. <sup>1</sup>*Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN*, <sup>2</sup>*Internal Medicine-Pediatrics, Vanderbilt University Medical Center, Nashville, TN*, <sup>3</sup>*Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA*, <sup>4</sup>*Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN*, <sup>5</sup>*Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA*, <sup>6</sup>*Pediatric Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN*, <sup>7</sup>*Cardiology, Harvard Medical School, Boston, MA*, <sup>8</sup>*Cardiovascular Medicine, Vanderbilt University, Nashville, TN*
- 6:40 PM** (374) *Mitigating the Impact of Gender Mismatch in Heart Transplantation Using BMI and BSA Ratios*; Y. D. Barac, O. Jawitz, V. Raman, M. Hartwig, J. Klapper, J. Schroder, M. Daneshmand, C. Patel, C. Milano. *Duke University Medical Center, Durham, NC*
- 6:45 PM** (375) *Characteristics and Short-Term Outcomes of Hepatitis C Antibody Positive Organs for Heart Transplantation: UNOS Analysis*; E. M. DeFilippis, R. C. Givens, A. R. Garan, F. Latif, S. W. Restaino, Y. Naka, K. Takeda, H. Takayama, P. C. Colombo, M. A. Farr, V. K. Topkara. *Columbia University Medical Center, New York, NY*
- 6:50 PM** (376) *Heart Transplant Recipient and Donor Age: Should the Younger Recipient Be Matched with the Younger Donor?*; Y. Ravi<sup>1</sup>, N. Srikanth<sup>2</sup>, I. W. Paul<sup>3</sup>, B. A. Whitson<sup>4</sup>, S. Emani<sup>5</sup>, C. B. Sai-Sudhakar<sup>1</sup>. <sup>1</sup>*Cardiac Surgery, Scott & White, Texas A&M, Temple, TX*, <sup>2</sup>*Medical Student, Saveetha Institute of Medical Sciences, Chennai, India*, <sup>3</sup>*Medical Student, Sree Mookambika Institute of Medical Sciences, Kulasekaram, India*, <sup>4</sup>*Cardiac Surgery, The Ohio State University, Columbus, OH*, <sup>5</sup>*Internal Medicine, The Ohio State University, Columbus, OH*
- 6:55 PM** (377) *Impact of Donor to Recipient Size Match on Survival after Heart Transplant Bridged with Continuous Flow Left Ventricular Assist Device*; R. Yanagida<sup>1</sup>, A. Okoh<sup>2</sup>, S. Fugar<sup>3</sup>, M. Camacho<sup>4</sup>, M. Strueber<sup>4</sup>, M. J. Zucker<sup>2</sup>. <sup>1</sup>*Newark Beth Israel Medical Center, Newark, NJ*, <sup>2</sup>*Department of Medicine, Newark Beth Israel Medical Center, Newark, NJ*, <sup>3</sup>*Department of Medicine, Rush University Medical Center, Chicago, IL*, <sup>4</sup>*Department of Cardiothoracic Surgery, Newark Beth Israel Medical Center, Newark, NJ*

7:00 PM

**(378) Older Donors Portend Worse Survival in Older and Younger Recipients after Heart Transplant: A UNOS Database Analysis;** V. Raman, O. K. Jawitz, C. White, M. Daneshmand, J. Schroder, C. Milano, M. Hartwig. *Duke University Medical Center, Durham, NC*

7:05 PM

**(379) Cardiac Allografts from Overdosed Donors: An Underutilized Resource?;** N. K. Ranganath<sup>1</sup>, K. G. Phillips<sup>1</sup>, J. Malas<sup>1</sup>, B. E. Lonze<sup>2</sup>, D. E. Smith<sup>1</sup>, Z. N. Kon<sup>1</sup>, C. G. Gidea<sup>3</sup>, A. Reventovich<sup>3</sup>, N. Moazami<sup>1</sup>. <sup>1</sup>*Cardiothoracic Surgery, NYU Langone Health, New York, NY*, <sup>2</sup>*Surgery, NYU Langone Health, New York, NY*, <sup>3</sup>*Medicine, NYU Langone Health, New York, NY*

7:10 PM

**(380) Donors after Circulatory Death at the Medical College of Wisconsin and Potential for Increased Volume in Cardiac Transplantation;** A. Cole<sup>1</sup>, A. Mohammed<sup>2</sup>, L. Durham<sup>1</sup>, N. Gaglianello<sup>2</sup>, D. Ishizawa<sup>2</sup>, L. Joyce<sup>1</sup>, R. Kursel<sup>2</sup>, M. Saltzberg<sup>2</sup>, D. Joyce<sup>1</sup>. <sup>1</sup>*Cardiothoracic Surgery, Medical College of Wisconsin, Milwaukee, WI*, <sup>2</sup>*Advanced Heart Failure, Medical College of Wisconsin, Milwaukee, WI*

WEDNESDAY, APRIL 3, 2019

6:15 PM - 7:15 PM

**MINI ORAL 03: Chronic Lung Allograft Dysfunction**

Room: Pacifica 10-12

Target Audiences: LF/LTX, BSTR, PATH, PHARM

Chairs: Joshua Mooney, MD, and Tanya J. McWilliams, MD, PhD

- 6:15 PM** (1030) *Early Shift of Lung Perfusion to the Unilateral Lung Predicts the Development of Unilateral Chronic Lung Allograft Dysfunction after Bilateral Living-Donor Lobar Lung Transplantation*; H. Yamamoto<sup>1</sup>, S. Sugimoto, T. Kurosaki, S. Otani, M. Okazaki, M. Yamane, S. Toyooka, T. Oto. *General Thoracic Surgery, Organ Transplant Center, Okayama University Hospital, Okayama, Japan*
- 6:20 PM** (382) *Bronchoalveolar Lavage Pentraxin 3 Levels during Clinically-Stable Minimal Acute Rejection are Associated with CLAD and Death Risk*; L. Levy<sup>1</sup>, E. Huszti<sup>2</sup>, R. Ghany<sup>1</sup>, M. Ahmed<sup>1</sup>, S. Hunter<sup>1</sup>, K. Zhang<sup>1</sup>, K. Boonstra<sup>1</sup>, W. Klement<sup>1</sup>, S. Moshkelgosha<sup>1</sup>, J. Tikkanen<sup>1</sup>, L. Singer<sup>1</sup>, S. Keshavjee<sup>1</sup>, S. Juvet<sup>1</sup>, T. Martinu<sup>1</sup>. <sup>1</sup>Toronto Lung Transplant Program, Toronto, ON, Canada, <sup>2</sup>BioStatistics Research Unit, University Health Network, University of Toronto, Toronto, ON, Canada
- 6:25 PM** (383) *Impact of mir21 Expression in Chronic Lung Allograft Dysfunction after Lung Transplantation*; N. Miyahara<sup>1</sup>, A. Benazzo<sup>1</sup>, F. Oberndorfer<sup>2</sup>, P. Jaksch<sup>1</sup>, W. Klepetko<sup>1</sup>, K. Hoetzenecker<sup>1</sup>. <sup>1</sup>Thoracic Surgery, Medical University of Vienna, Vienna, Austria, <sup>2</sup>Pathology, Medical University of Vienna, Vienna, Austria
- 6:30 PM** (384) *Quantiferon®-Monitor: A Potential Biomarker of Immunosuppression in Lung Transplantation*; B. J. Gardiner<sup>1</sup>, Y. Cristiano<sup>2</sup>, B. J. Levvey<sup>2</sup>, G. I. Snell<sup>2</sup>, A. Y. Peleg<sup>1</sup>, G. P. Westall<sup>2</sup>. <sup>1</sup>Infectious Diseases, Alfred Hospital & Monash University, Melbourne, Australia, <sup>2</sup>Respiratory Medicine & Lung Transplantation, Alfred Hospital & Monash University, Melbourne, Australia
- 6:35 PM** (385) *Lung Bacterial Burden is Increased Following the Onset of Chronic Rejection*; M. P. Combs, D. S. Wheeler, J. Luth, N. M. Walker, R. P. Dickson, V. N. Lama. *Department of Medicine, University of Michigan, Ann Arbor, MI*
- 6:40 PM** (386) *The Impact of Pharmacogenomics on Tacrolimus Dosing and Levels among Lung Transplant Recipients*; A. W. Brown<sup>1</sup>, J. Peterson<sup>1</sup>, M. Fregoso<sup>1</sup>, M. Nayyar<sup>1</sup>, A. Cochrane<sup>1</sup>, J. Pluhacek<sup>1</sup>, M. Lemma<sup>1</sup>, S. Aryal<sup>1</sup>, O. A. Shlobin<sup>1</sup>, C. S. King<sup>1</sup>, R. Iyer<sup>2</sup>, J. F. Deeken<sup>2</sup>, S. D. Nathan<sup>1</sup>. <sup>1</sup>Inova Advanced Lung Disease & Transplant, Fairfax, VA, <sup>2</sup>Inova Translational Medicine Institute, Fairfax, VA
- 6:45 PM** (387) *Extracorporeal Photopheresis (ECP) in the Management of Chronic Lung Allograft Dysfunction*; Y. Furuya<sup>1</sup>, C. Witt<sup>1</sup>, E. P. Trulock<sup>1</sup>, D. Byers<sup>1</sup>, H. Kulkarni<sup>1</sup>, L. K. Tague<sup>1</sup>, P. Aguilar<sup>1</sup>, D. Kreisel<sup>2</sup>, V. Puri<sup>2</sup>, A. Gelman<sup>2</sup>, R. Hachem<sup>1</sup>. <sup>1</sup>Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, Saint Louis, MO, <sup>2</sup>Division of Cardiothoracic Surgery, Washington University School of Medicine, Saint Louis, MO
- 6:50 PM** (388) *Five-Year Results of an IgA and IgM-Enriched Human Immunoglobulin G-Based Therapy for Early Anti-HLA Donor Specific Antibodies in 158 Lung-Transplanted Patients*; F. Ius<sup>1</sup>, M. Verboom<sup>2</sup>, W. Sommer<sup>1</sup>, C. Müller<sup>3</sup>, M. Hallensleben<sup>2</sup>, J. Salman<sup>1</sup>, T. Siemeni<sup>1</sup>, C. Kühn<sup>1</sup>, M. Avsar<sup>1</sup>, D. Bobylev<sup>1</sup>, N. Schwerk<sup>3</sup>, A. Haverich<sup>1</sup>, I. Tudorache<sup>1</sup>, G. Warnecke<sup>1</sup>. <sup>1</sup>Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, <sup>2</sup>Department of Transfusion Medicine, Hannover Medical School, Hannover, Germany, <sup>3</sup>Department of Paediatrics, Hannover Medical School, Hannover, Germany
- 6:55 PM** (389) *Donor-Specific Antibodies and Antibody-Mediated Rejection after Alemtuzumab Induction Therapy: A Retrospective Analysis of a High-Volume Lung Transplant Center*; A. Benazzo<sup>1</sup>, S. Schwarz<sup>1</sup>, S. Geleff<sup>2</sup>, D. Weber<sup>3</sup>, G. Murakozy<sup>1</sup>, C. Lambers<sup>3</sup>, B. Moser<sup>1</sup>, J. Matilla<sup>1</sup>, G. Lang<sup>3</sup>, S. Taghavi<sup>1</sup>, W. Klepetko<sup>1</sup>, K. Hoetzenecker<sup>1</sup>, P. Jaksch<sup>1</sup>. <sup>1</sup>Thoracic Surgery, Medical University of Vienna, Vienna, Austria, <sup>2</sup>Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria, <sup>3</sup>Division of Thoracic Surgery, Medical University of Vienna, Vienna, Austria
- 7:00 PM** (390) *Extravascular Lung Water Quantification in Donor Lungs*; K. S. Ayyat<sup>1</sup>, T. Okamoto<sup>1</sup>, H. Niikawa<sup>1</sup>, Y. Itoda<sup>1</sup>, S. Dugar<sup>1</sup>, S. Q. Latifi<sup>1</sup>, D. J. Lebovitz<sup>2</sup>, A. Moghekar<sup>1</sup>, K. R. McCurry<sup>1</sup>. <sup>1</sup>Cleveland Clinic, Cleveland, OH, <sup>2</sup>Lifebanc, Cleveland, OH

7:05 PM

**(391) Precision Proteomics as Protein Biomarker Discovery in Detecting Chronic Lung Allograft Dysfunction;** H. Ghaidar, M. Fakhro, S. Lindstedt. *Cardiothoracic Surgery, Lund University Hospital, Lund, LUND, Sweden*

7:10 PM

**(392) Mid-Term Results of Lung Transplantation (LTx) after Bridging with Extracorporeal Membrane Oxygenation - Influence of Concomitant Invasive Mechanical Ventilation (iMV);** M. Monteagudo Vela<sup>1</sup>, D. Garcia Saez<sup>1</sup>, P. Mohite<sup>1</sup>, A. Reed<sup>2</sup>, F. De Robertis<sup>1</sup>, U. Stock<sup>1</sup>, B. Mahesh<sup>1</sup>, M. Carby<sup>2</sup>, A. Simon<sup>1</sup>, B. Zych<sup>1</sup>. <sup>1</sup>*Cardiothoracic Transplantation and Mechanical Circulatory Support, Harefield Hospital, London, United Kingdom*, <sup>2</sup>*Respiratory Medicine, Harefield Hospital, London, United Kingdom*

WEDNESDAY, APRIL 3, 2019

6:15 PM - 7:15 PM

**MINI ORAL 04: MCS: A Focus on Stroke**

Room: Coral Sea

Target Audience: MCS

Chairs: Paolo C Colombo, MD, and Anique Ducharme, MD, MSC

- 6:15 PM** (393) *Pulmonary Effective Arterial Elastance and Pulmonary Artery Capacitance after Left Ventricular Assist Device Implantation is Associated with Hemocompatibility-Related Adverse Events*; D. Nitta, T. Imamura, T. Fujino, A. Nguyen, B. Chung, D. Rodgers, J. Raikhelkar, B. Smith, L. Holzhauser, N. Narang, I. Ebong, C. Juricek, V. Jeevanandam, G. Kim, G. Sayer, N. Uriel. *University of Chicago, Chicago, IL*
- 6:20 PM** (394) *Decoupling between Pulmonary Artery and Wedge Pressure is Associated with Hemocompatibility-Related Adverse Events Following LVAD Implantation*; T. Imamura, S. Kalantari, B. Smith, D. Rodgers, J. Raikhelkar, G. Kim, A. Nguyen, N. Narang, B. Chung, I. Ebong, L. Holzhauser, D. Nitta, T. Fujino, C. Juricek, P. Combs, D. Onsager, T. Song, T. Ota, V. Jeevanandam, G. Sayer, N. Uriel. *University of Chicago, Chicago, IL*
- 6:25 PM** (395) *Hemocompatibility in HeartMate III: Is Anticoagulation Alone a Safe Strategy?*; V. Tarzia<sup>1</sup>, C. Tessari<sup>2</sup>, A. Fabozzo<sup>3</sup>, C. Cavalli<sup>1</sup>, T. Bocca<sup>1</sup>, C. Pagnin<sup>4</sup>, B. Volpe<sup>5</sup>, T. Bottio<sup>6</sup>, G. Gerosa<sup>7</sup>. <sup>1</sup>Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Cardiac Surgery, Padova, Italy, <sup>2</sup>Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Chiara Tessari, Padova, Italy, <sup>3</sup>Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Assunta Fabozzo, Padova, Italy, <sup>4</sup>Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Chiara Pagnin, Padova, Italy, <sup>5</sup>Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Biancarosa Volpe, Padova, Italy, <sup>6</sup>Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Tomaso Bottio, Padova, Italy, <sup>7</sup>Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Gino Gerosa, Padova, Italy
- 6:30 PM** (396) *Hemocompatibility-Related Adverse Events: Is the Burden Different among Available Centrifugal Flow Pumps?*; K. A. Holst<sup>1</sup>, M. P. Weber<sup>2</sup>, V. Tchanchaleishvili<sup>2</sup>, S. Dunlay<sup>1</sup>, S. Maltais<sup>1</sup>, R. Daly<sup>1</sup>, J. Stulak<sup>1</sup>. <sup>1</sup>Mayo Clinic, Rochester, MN, <sup>2</sup>Thomas Jefferson University, Philadelphia, PA
- 6:35 PM** (397) *Digoxin is Associated with Decreased Survival Free from Hemocompatibility-Related Adverse Events in LVAD Patients - A Propensity Score Matched Analysis*; A. Pinsino<sup>1</sup>, A. Gaudig<sup>2</sup>, K. L. Hoffman<sup>3</sup>, D. D'Angelo<sup>3</sup>, E. A. Royzman<sup>2</sup>, G. M. Mondellini<sup>2</sup>, F. Castagna<sup>2</sup>, A. M. Zuver<sup>2</sup>, A. R. Garan<sup>2</sup>, H. Takayama<sup>4</sup>, K. Takeda<sup>4</sup>, Y. Naka<sup>4</sup>, R. T. Demmer<sup>5</sup>, M. Yuzefpolskaya<sup>2</sup>, P. C. Colombo<sup>2</sup>. <sup>1</sup>Jacobi - Albert Einstein College of Medicine, Bronx, NY, <sup>2</sup>Department of Medicine, Columbia University Medical Center, New York, NY, <sup>3</sup>Healthcare Policy and Research, Weill Cornell Medicine, New York, NY, <sup>4</sup>Department of Surgery, Columbia University Medical Center, New York, NY, <sup>5</sup>Epidemiology and Community Health, University of Minnesota, Minneapolis, MN
- 6:40 PM** (398) *Influence of Device Type on Stroke Risk in Women Undergoing LVAD Implantation*; R. J. Vela<sup>1</sup>, J. Pruszynski<sup>1</sup>, A. Amin<sup>2</sup>, M. Drazner<sup>2</sup>, L. C. Huffman<sup>1</sup>, M. Peltz<sup>1</sup>. <sup>1</sup>Cardiovascular & Thoracic Surgery, UT Southwestern Medical Center, Dallas, TX, <sup>2</sup>Internal Medicine, UT Southwestern Medical Center, Dallas, TX
- 6:45 PM** (399) *Concentrated Factor Administration and Subsequent Stroke Rates on HeartMate II LVAD Support*; J. Schultz<sup>1</sup>, A. Shaffer<sup>2</sup>, J. Misialek<sup>1</sup>, H. Shah<sup>1</sup>, R. John<sup>2</sup>, C. Martin<sup>1</sup>, T. Thenappan<sup>1</sup>, T. Alexy<sup>1</sup>, F. Kamdar<sup>1</sup>, R. Cogswell<sup>1</sup>. <sup>1</sup>Department of Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN, <sup>2</sup>Department of Surgery, Division of Cardiovascular Surgery, University of Minnesota, Minneapolis, MN
- 6:50 PM** (400) *Current Smoking and Increased Risk of Stroke in Patients with Left Ventricular Assist Device*; S. Sherazi<sup>1</sup>, I. Goldenberg<sup>1</sup>, S. McNitt<sup>1</sup>, V. Kutiyifa<sup>1</sup>, I. Gosev<sup>2</sup>, K. Wood<sup>2</sup>, L. Chen<sup>1</sup>, S. Polonsky<sup>1</sup>, H. Vidula<sup>1</sup>, J. Alexis<sup>1</sup>. <sup>1</sup>Cardiology, University of Rochester Medical Center, Rochester, NY, <sup>2</sup>Cardiothoracic Surgery, University of Rochester Medical Center, Rochester, NY
- 6:55 PM** (401) *Carotid Artery Blood Flow and Its Association with Stroke during Left Ventricular Assist Device Support*; M. E. Kiyatkin<sup>1</sup>, A. M. Zuver<sup>1</sup>, A. Gaudig<sup>2</sup>, M. Tiburcio<sup>1</sup>, B. J. McDonnell<sup>3</sup>, M. Yuzefpolskaya<sup>1</sup>, P. C. Colombo<sup>1</sup>, E. J. Stöhr<sup>4</sup>, J. Z. Willey<sup>1</sup>. <sup>1</sup>Columbia University Irving Medical Center, New York, NY, <sup>2</sup>University of Münster, Münster, Germany, <sup>3</sup>Cardiff Metropolitan University, Cardiff, United Kingdom, <sup>4</sup>Cardiff Metropolitan University, Cardiff, United Kingdom

7:00 PM

**(402) Different Risk Factors for Ischemic and Hemorrhagic Stroke on Continuous Flow Left Ventricular Assist Device Support;** H. K. Lamba<sup>1</sup>, M. Kim<sup>1</sup>, L. Hart<sup>1</sup>, B. Chou<sup>1</sup>, C. Rao<sup>1</sup>, S. Chatterjee<sup>1</sup>, S. Sattee<sup>2</sup>, F. Cheema<sup>1</sup>, A. Civitello<sup>1</sup>, R. Delgado<sup>1</sup>, A. Nair<sup>1</sup>, A. Shafii<sup>1</sup>, G. Loor<sup>1</sup>, T. Rosengart<sup>1</sup>, O. Frazier<sup>1</sup>, J. Morgan<sup>3</sup>.  
<sup>1</sup>Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, TX, <sup>2</sup>Baylor College of Medicine, Houston, TX, <sup>3</sup>Texas Heart Institute at Baylor College of Medicine, Houston, TX

7:05 PM

**(403) Strokes in LVADS. Insights from Modelling Flow in the Circle of Willis;** K. Balakrishnan<sup>1</sup>, R. Krishnakumar<sup>2</sup>, S. Krishna<sup>2</sup>. <sup>1</sup>Fortis Malar Hospital, Chennai, India, <sup>2</sup>Engineering Design, Indian Institute of Technology, Madras, Chennai, India

7:10 PM

**(404) Does Left Atrial Appendage Occlusion in LVAD Patients Impact Outcomes: A Single Centre Study;** E. Yu<sup>1</sup>, J. Alvarez<sup>1</sup>, R. Ribeiro<sup>1</sup>, M. B. Adamson<sup>1</sup>, F. Amin<sup>1</sup>, M. Degen<sup>1</sup>, F. Foroutan<sup>2</sup>, J. Duero Posada<sup>2</sup>, T. Yau<sup>1</sup>, R. Cusimano<sup>1</sup>, F. Billia<sup>2</sup>, C. Alba<sup>2</sup>, M. Badiwala<sup>1</sup>, V. Rao<sup>1</sup>. <sup>1</sup>Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada, <sup>2</sup>Cardiology, Toronto General Hospital, Toronto, ON, Canada

WEDNESDAY, APRIL 3, 2019

6:15 PM - 7:15 PM

**MINI ORAL 05: Do It Quick and Do It NOW: ECMO Update**

Room: Pacifica 6

Target Audience: MCS

Chairs: Hiroo Takayama, MD, and Alastair Proudfoot, MBChB

- 6:15 PM** (405) *Use of Extracorporeal Membrane Oxygenation (ECMO) in Acute Myocarditis - Insights from a National Inpatient Database*; M. S. Panhwar<sup>1</sup>, A. Karim<sup>1</sup>, M. Ginwalla<sup>2</sup>. <sup>1</sup>Internal Medicine, Case Western Reserve Univ/Univ Hospitals of Cleveland, Cleveland, OH, <sup>2</sup>Division of Cardiology, Case Western Reserve Univ/Univ Hospitals of Cleveland, Cleveland, OH
- 6:20 PM** (406) *Assessing Left Ventricular Unloading and Wall Tension to Predict the Need for Durable Mechanical Circulatory Support after Peripheral VA-ECMO*; A. Prasad<sup>1</sup>, C. E. Brehm<sup>2</sup>, M. Goldenberg<sup>3</sup>, A. Ghodsizad<sup>4</sup>, M. M. Koerner<sup>5</sup>, A. El Banayosy<sup>5</sup>, K. Singbartl<sup>6</sup>. <sup>1</sup>Anesthesiology and Perioperative Medicine, PennState Health, Hershey, PA, <sup>2</sup>Heart and Vascular Institute, PennState Health, Hershey, PA, <sup>3</sup>PennState College of Medicine, Hershey, PA, <sup>4</sup>Miami Transplant Institute, University of Miami, Miami, FL, <sup>5</sup>Advanced Cardiac Care and Transplant Institute, INTEGRIS Baptist Medical Center, Oklahoma City, OK, <sup>6</sup>Critical Care Medicine, Mayo Clinic, Phoenix, AZ
- 6:25 PM** (407) *Bridging VA ECMO to Durable MCS: Keys to Success*; A. M. El Banayosy, M. M. Koerner, D. A. Horstmanshof, A. Phanco, B. V. Jassman, C. Elkins, J. W. Long, A. El Banayosy. *INTEGRIS Baptist Medical Center, Oklahoma City, OK*
- 6:30 PM** (408) *Hematological Complications of Impella as an Unloading Device in Patients with Cardiogenic Shock and Venous-Arterial ECMO. A Systematic Review and Meta-analysis*; J. E. Pino<sup>1</sup>, E. Grajeda<sup>1</sup>, F. Ramos-Tuarez<sup>1</sup>, S. Sundaravel<sup>1</sup>, S. Sehatbakhsh<sup>2</sup>, E. Donath<sup>1</sup>, R. Chait<sup>2</sup>. <sup>1</sup>Medicine, University of Miami/JFK Medical Center, West Palm Beach, FL, <sup>2</sup>Medicine, University of Miami/JFK Medical Center, Atlantis, FL
- 6:35 PM** (409) *Lactate Predicts Mortality 12 Hours after VA ECMO Initiation*; A. Melvin, B. C. Ayers, K. Wood, S. Prasad, B. Barrus, I. Gosev. *University of Rochester, Rochester, NY*
- 6:40 PM** (410) *Prognostic Value of Neutrophil Lymphocyte Ratio for Early Renal Failure in ECMO Patients*; M. Sargin, M. T. Mete, S. B. Erdogan, H. Kuplay, M. Bastopcu, S. Akansel, M. Acarel, S. A. Aka. *Cardiovascular Surgery, Siyami Ersek Hospital, Istanbul, Turkey*
- 6:45 PM** (411) *Differences in Post-Thoracotomy Outcomes in Patients Implanted off ECMO*; J. D. Schmitto<sup>1</sup>, M. Ozbaran<sup>2</sup>, C. Engin<sup>2</sup>, A. Simon<sup>3</sup>, V. Horvath<sup>4</sup>, J. Roussel<sup>5</sup>, M. Pac<sup>6</sup>, U. Kervan<sup>6</sup>, S. Klotz<sup>7</sup>, F. Wagner<sup>8</sup>, T. Schloeglhofer<sup>9</sup>, D. Zimpfer<sup>9</sup>. <sup>1</sup>Cardiac Surgery, Hannover Medical School, Hannover, Germany, <sup>2</sup>Cardiac Surgery, Ege University Medical Center, Izmir, Turkey, <sup>3</sup>Cardiac Surgery, Royal Brompton and Harefield Hospital, London, United Kingdom, <sup>4</sup>Cardiac Surgery, Center for Cardiovascular and Transplant Surgery, Brno, Czech Republic, <sup>5</sup>Cardiac Surgery, University of Nantes, Nantes, France, <sup>6</sup>Cardiac Surgery, Turkiye Yuksek Ihtisas Education & Research Hospital, Ankara, Turkey, <sup>7</sup>Cardiac Surgery, University Hospital Luebeck, Luebeck, Germany, <sup>8</sup>Cardiac Surgery, Uniklinik Hamburg Eppendorf, Hamburg, Germany, <sup>9</sup>Cardiac Surgery, Medical University Vienna, Vienna, Austria
- 6:50 PM** (412) *Mid Term Survival after VA ECMO Weaning*; A. Vincentelli<sup>1</sup>, N. Rouse<sup>1</sup>, V. Loobuyck<sup>1</sup>, M. Moussa<sup>2</sup>, A. Mugnier<sup>1</sup>, J. Soquet<sup>1</sup>, E. Robin<sup>2</sup>, F. Juthier<sup>1</sup>, C. Goeminne<sup>1</sup>, C. Banfi<sup>1</sup>. <sup>1</sup>Cardiac Surgery, Centre Hospitalier Universitaire Regional de Lille, Lille, France, <sup>2</sup>Cardiac Surgery, Anesthesiology, Centre Hospitalier Universitaire Regional de Lille, Lille, France
- 6:55 PM** (413) *Does Transport Time or Distance from Hospital Affect Survival in Extracorporeal Membrane Oxygenation (ECMO) Patients?*; J. S. Nelson, A. Eisenbeiss, E. Stauder, K. Graham, R. Alharethi, W. Caine, H. Smith, B. Reid, M. McCulloch, B. Rasmusson, V. Hebl, B. Kfoury. *Intermountain Medical Center, Murray, UT*
- 7:00 PM** (414) *Predictors of Survival to Discharge and Ventricular Recovery after VA-ECMO Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock*; J. A. Fried<sup>1</sup>, M. Cevasco<sup>2</sup>, L. Witer<sup>2</sup>, A. Masoumi<sup>1</sup>, D. Brodie<sup>3</sup>, J. Griffith<sup>1</sup>, V. Topkara<sup>1</sup>, K. Clerkin<sup>1</sup>, A. Zuver<sup>1</sup>, D. Karpaliotis<sup>1</sup>, A. Kirtane<sup>1</sup>, H. Takayama<sup>2</sup>, M. Yuzefpolskaya<sup>1</sup>, Y. Naka<sup>2</sup>, P. Colombo<sup>1</sup>, K. Takeda<sup>2</sup>, A. R. Garan<sup>1</sup>. <sup>1</sup>Cardiology, Columbia University Medical



Center, New York, NY, <sup>2</sup>Cardiothoracic Surgery, Columbia University Medical Center, New York, NY,  
<sup>3</sup>Pulmonary and Critical Care Medicine, Columbia University Medical Center, New York, NY

**7:05 PM**

**(415) Effect of Time from Cardiogenic Shock to Initiation of Complete Cardiovascular Support on Survival: “Shock to Support Time”;** A. Scatola<sup>1</sup>, A. Singh<sup>1</sup>, K. Singh<sup>2</sup>, N. Singh<sup>2</sup>, P. Meraj<sup>1</sup>. <sup>1</sup>Cardiology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, <sup>2</sup>New York Institute of Technology, New York, NY

**7:10 PM**

**(416) Risk and Causes of 30-Day Readmissions Following Extracorporeal Membrane Oxygenation Support for Cardiogenic Shock;** N. Tashtish<sup>1</sup>, S. Al-Kindi<sup>2</sup>, M. Karnib<sup>1</sup>, C. Di Felice<sup>3</sup>, E. Zanath<sup>4</sup>, G. Oliveira<sup>2</sup>, F. Lytle<sup>4</sup>, C. Elamm<sup>2</sup>. <sup>1</sup>Internal Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, <sup>2</sup>Cardiovascular Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, <sup>3</sup>Pulmonary and Critical Care, University Hospitals Cleveland Medical Center, Cleveland, OH, <sup>4</sup>Department of Anesthesia, University Hospitals Cleveland Medical Center, Cleveland, OH

WEDNESDAY, APRIL 3, 2019

6:15 PM - 7:15 PM

**MINI ORAL 06: Pediatrics**

**Room: Pacifica 3-5**

**Target Audiences: PEDS, HTX, MCS**

**Chairs:** Jacob Mathew, MD, and Beth Kaufman, MD

- 6:15 PM** (1203) *Expanding the Donor Pool for Transplant Candidates with Congenital Heart Disease: Use of Recipient Total Cardiac Volumes*; S. B. Shugh<sup>1</sup>, N. A. Szugye<sup>1</sup>, C. R. Villa<sup>1</sup>, F. Zafar<sup>2</sup>, R. Bryant III<sup>2</sup>, A. Lorts<sup>1</sup>, D. L. Morales<sup>2</sup>, R. A. Moore<sup>1</sup>. <sup>1</sup>*Pediatric Cardiology, The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH*, <sup>2</sup>*Cardiothoracic Surgery, The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH*
- 6:20 PM** (418) *Transplant Center Refusal Rate and Waitlist Outcomes in Pediatric Heart Transplantation*; N. Baez, R. Davies, R. Kirk, M. Bano, D. Sutcliffe, R. Jaquiss, R. Butts. *University of Texas Southwestern Medical Center, Dallas, TX*
- 6:25 PM** (419) *Pediatric Heart Transplant Recipients Bridged with Biventricular Assist Device Have Worse One-Year Graft Survival: An Analysis of the United Network of Organ Sharing Database*; K. Watanabe<sup>1</sup>, A. Joong<sup>1</sup>, P. T. Thrush<sup>1</sup>, N. Srdanovic<sup>2</sup>, M. C. Monge<sup>1</sup>, E. Pahl<sup>1</sup>. <sup>1</sup>*Ann and Robert Lurie Children's Hospital, Northwestern University Feinberg School of Medicine, Chicago, IL*, <sup>2</sup>*Biostatistics Collaboration Center, Northwestern University Feinberg School of Medicine, Chicago, IL*
- 6:30 PM** (420) *Variability in Donor Selection among Pediatric Heart Transplant Providers - Results from an International Survey*; J. Godown<sup>1</sup>, R. Kirk<sup>2</sup>, A. Joong<sup>3</sup>, A. Lal<sup>4</sup>, M. McCulloch<sup>5</sup>, D. M. Peng<sup>6</sup>, J. Scheel<sup>7</sup>, R. Davies<sup>8</sup>, A. I. Dipchand<sup>9</sup>, O. Miera<sup>10</sup>, J. G. Gossett<sup>11</sup>. <sup>1</sup>*Pediatric Cardiology, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN*, <sup>2</sup>*Pediatric Cardiology, University of Texas Southwestern Medical Center, Dallas, TX*, <sup>3</sup>*Pediatric Cardiology, Ann and Robert H Lurie Children's Hospital of Chicago, Chicago, IL*, <sup>4</sup>*Pediatric Cardiology, Primary Children's Hospital, University of Utah, Salt Lake City, UT*, <sup>5</sup>*Pediatric Cardiology, University of Virginia Children's Hospital, Charlottesville, VA*, <sup>6</sup>*Pediatric Cardiology, C.S. Mott Children's Hospital, Ann Arbor, MI*, <sup>7</sup>*Pediatric Cardiology, St. Louis Children's Hospital, St. Louis, MO*, <sup>8</sup>*Pediatric Cardiothoracic Surgery, University of Texas Southwestern Medical Center, Dallas, TX*, <sup>9</sup>*Pediatric Cardiology, The Hospital for Sick Children, Toronto, ON, Canada*, <sup>10</sup>*Deutsches Herzzentrum Berlin, Berlin, Germany*, <sup>11</sup>*UCSF Benioff Children's Hospitals, San Francisco, CA*
- 6:35 PM** (421) *Non-Infant, Single Ventricle Patients Enjoy the Same Post-Transplant Survival as Other Congenital Heart Patients*; K. W. Riggs<sup>1</sup>, J. T. Broderick<sup>1</sup>, F. Zafar<sup>1</sup>, C. Chin<sup>2</sup>, R. Bryant III<sup>1</sup>, D. L. Morales<sup>1</sup>. <sup>1</sup>*Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, OH*, <sup>2</sup>*Pediatric Cardiology, Cincinnati Children's Hospital, Cincinnati, OH*
- 6:40 PM** (422) *Lifetime Achievement and Quality of Life in Adult Survivors of Pediatric Heart Transplant*; N. T. Stanford<sup>1</sup>, J. McAllister<sup>2</sup>, L. Addonizio<sup>2</sup>, M. Richmond<sup>2</sup>, S. Law<sup>2</sup>, T. Lee<sup>2</sup>, M. Farr<sup>3</sup>, M. Gibbons<sup>2</sup>, K. Jensen<sup>2</sup>, H. Lee<sup>2</sup>, A. Rothkopf<sup>2</sup>, R. Jackson<sup>3</sup>, W. Zuckerman<sup>2</sup>. <sup>1</sup>*Department of Pediatrics, Columbia University Medical Center, New York, NY*, <sup>2</sup>*Division of Pediatric Cardiology, Columbia University Medical Center, New York, NY*, <sup>3</sup>*Division of Cardiology, Columbia University Medical Center, New York, NY*
- 6:45 PM** (423) *De Novo Development of Antibodies to Cardiac Myosin and Vimentin in Pediatric Heart Transplant Recipients: A Single Center Pilot Study*; S. Zangwill<sup>1</sup>, M. Ploutz<sup>1</sup>, S. Bansal<sup>2</sup>, T. Mohanakumar<sup>2</sup>. <sup>1</sup>*Cardiology, Phoenix Children's Hospital, Phoenix, AZ*, <sup>2</sup>*Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ*
- 6:50 PM** (1185) *Antithymocyte Globulin Induction is Associated with Complement Deposition in Pediatric Cardiac Transplant Biopsies*; S. Ghaleb<sup>1</sup>, H. Martinez<sup>1</sup>, S. Wittekind<sup>1</sup>, D. Witte<sup>2</sup>, T. Hengehold<sup>3</sup>, C. Chin<sup>1</sup>. <sup>1</sup>*Pediatric Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH*, <sup>2</sup>*Department of Pathology and Laboratory Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH*, <sup>3</sup>*University of Cincinnati College of Medicine, Cincinnati, OH*
- 6:55 PM** (425) *Retransplantation: An Underutilized Resource or Only for a Select Few?*; M. Vazquez Alvarez<sup>1</sup>, E. Pruitt<sup>2</sup>, D. Nandi<sup>3</sup>, M. S. Kemna<sup>4</sup>, S. Urschel<sup>5</sup>, S. C. West<sup>6</sup>, K. Y. Lin<sup>7</sup>, H. M. Lim<sup>8</sup>, T. Allain-Rooney<sup>1</sup>, A. I. Dipchand<sup>1</sup>. <sup>1</sup>*Labatt Family Heart Center, Hospital for the Sick Children, Toronto, ON, Canada*, <sup>2</sup>*University of*

Alabama at Birmingham, Birmingham, AL, <sup>3</sup>The Heart Center, Nationwide Children's Hospital, Columbus, OH, <sup>4</sup>Seattle Children's Hospital, Seattle, WA, <sup>5</sup>Stollery Children's Hospital, Edmonton, AB, Canada, <sup>6</sup>UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, <sup>7</sup>Children's Hospital of Philadelphia, Philadelphia, PA, <sup>8</sup>C.S. Mott Children's Hospital, Ann Arbor, MI

7:00 PM

**(426) First Clinical Experience of Jarvik 2015 in North America: The New Era of Pediatric-Specific VAD Support;** I. Adachi<sup>1</sup>, J. A. Spinner<sup>2</sup>, Z. Spigel<sup>1</sup>, H. Tunuguntla<sup>3</sup>, B. Elias<sup>1</sup>, E. O. McCullum<sup>1</sup>, A. G. Cabrera<sup>3</sup>, S. Tume<sup>4</sup>, W. J. Dreyer<sup>3</sup>, H. Justino<sup>3</sup>, J. S. Heine<sup>1</sup>, C. A. Caldarone<sup>1</sup>. <sup>1</sup>Congenital Heart Surgery, Texas Children's Hospital, Houston, TX, <sup>2</sup>Pediatrics, Baylor College of Medicine, Houston, TX, <sup>3</sup>Pediatric Cardiology, Texas Children's Hospital, Houston, TX, <sup>4</sup>Critical Care, Texas Children's Hospital, Houston, TX

7:05 PM

**(1204) Heterogeneous Outcomes of Liver Disease after Heart Transplantation for a Failed Fontan Procedure;** A. M. Ybarra<sup>1</sup>, G. Khanna<sup>2</sup>, Y. P. Turmelle<sup>1</sup>, J. M. Stoll<sup>1</sup>, C. D. Castleberry<sup>1</sup>, J. N. Scheel<sup>1</sup>, V. Exil<sup>3</sup>, R. Ameduri<sup>4</sup>, C. E. Canter<sup>1</sup>, K. E. Simpson<sup>1</sup>. <sup>1</sup>Pediatrics, Washington University in Saint Louis School of Medicine, St Louis, MO, <sup>2</sup>Radiology, Washington University in Saint Louis School of Medicine, St Louis, MO, <sup>3</sup>Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA, <sup>4</sup>Pediatrics, University of Minnesota School of Medicine, Minneapolis, MN

7:10 PM

**(428) Real World Data from the ACTION Quality Improvement Network - Preliminary Experience with a Magnetically Levitated Ventricular Assist Device in US Pediatric Centers;** M. J. O'Connor<sup>1</sup>, A. Lorts<sup>2</sup>, C. Mascio<sup>3</sup>, D. Sutcliffe<sup>4</sup>, R. Davies<sup>4</sup>, S. Law<sup>5</sup>, P. Chai<sup>5</sup>, D. Rosenthal<sup>6</sup>, K. Maeda<sup>6</sup>, D. Nandi<sup>7</sup>, P. McConnell<sup>7</sup>, D. Morales<sup>2</sup>. <sup>1</sup>Division of Cardiology, The Children's Hospital of Philadelphia, Philadelphia, PA, <sup>2</sup>Cincinnati Children's Hospital, Cincinnati, OH, <sup>3</sup>The Children's Hospital of Philadelphia, Philadelphia, PA, <sup>4</sup>Children's Medical Center Dallas, Dallas, TX, <sup>5</sup>Morgan Stanley Children's Hospital, New York, NY, <sup>6</sup>Lucile Packard Children's Hospital Stanford, Palo Alto, CA, <sup>7</sup>Nationwide Children's Hospital, Columbus, OH

**THURSDAY, APRIL 4, 2019**

**7:00 AM - 8:00 AM**

**SUNRISE SYMPOSIUM 01: In the Thick of It: Hypertrophic and Amyloid Cardiomyopathies**

**Room: Pacifica 7**

**Target Audience: HF/HTX**

**Chairs:** Jignesh K. Patel, MD, PhD, and Marta Farrero Torres, MD

**Session Summary:** Hypertrophic and infiltrative cardiomyopathies are often underrecognized. There has been increasing understanding of HCM and cardiac amyloidosis with rapid development of diagnostic modalities and treatment strategies. This symposium will begin with a case and then review recent advances, highlighting key therapeutics that are available and being developed. The role of heart transplant and advanced therapies in these entities will be outlined. A 10-min panel discussion with all speakers will conclude this session.

- 7:00 AM**                    ***CASE PRESENTATION of HCM: Gasping and Dizzy - Please Help!***  
Imad Hussain, MD, Houston Methodist Hosp, Houston, TX, USA
- 7:05 AM**                    ***Veni, Vidi, Vici: Pathophysiology and Therapeutic Options in Hypertrophic Cardiomyopathy***  
Eulalia Roig, MD, Hospital Sant Pau, Barcelona, Spain
- 7:25 AM**                    ***CASE PRESENTATION of Cardiac Amyloidosis: I Can't Breathe and My Tongue is Too Big!***  
Song Li, MD, University of Washington, Seattle, WA, USA
- 7:30 AM**                    ***Double Double Toil and Trouble: Physiology and Therapeutic Options for Cardiac Amyloidosis***  
Margot Davis, MD, University of British Columbia, Vancouver, BC, Canada
- 7:50 AM**                    ***10-min Panel Discussion***

**THURSDAY, APRIL 4, 2019**

**7:00 AM - 8:00 AM**

**SUNRISE SYMPOSIUM 02: Immunobiology of the Older Lung Transplant Recipient**

**Room: Pacifica 10-12**

**Target Audiences: LF/LTX, BSTR, PHARM**

**Chairs:** Jonathan P. Singer, MD, MS, and Hanneke Kwakkel-van Erp, MD, PhD

**Session Summary:** As the number of older transplant patients continues to grow it becomes more important to understand age-associated immune changes, which may influence the impact of immunosuppression. Older lung transplant patients experience increased rates of infection, malignancy, and death, but decreased rates of rejection, suggesting over immune suppression. Yet at the same time, older transplant recipients experience increased levels of inflammation.

**7:00 AM**                    *Frailty and Pro-Inflammatory Cytokines: Potential Biomarkers for Poor Outcomes?*  
Joshua Diamond, MD, University of Pennsylvania, Philadelphia, PA, USA

**7:15 AM**                    *Q&A*

**7:20 AM**                    *Immune Senescence and Transplantation: Balance Between Infection and Rejection*  
Joanna M. Schaenman, MD, PhD, UCLA School of Medicine, Los Angeles, CA, USA

**7:35 AM**                    *Q&A*

**7:40 AM**                    *Challenges in Medication Administration in Older Transplant Patients*  
Patricia Ging, PharmD, Mater Misericordiae University Hospital, Dublin, Ireland

**7:55 AM**                    *Q&A*

**THURSDAY, APRIL 4, 2019**

**7:00 AM - 8:00 AM**

**SUNRISE SYMPOSIUM 03: From Isolated to Mainstream: Evolving ECMO Strategies That Are Reshaping Outcomes**

**Room: Pacifica 6**

**Target Audiences: MCS, HF/HTX**

**Chairs:** Feras Khaliel, MD, PhD, and Ivan Knezevic, MD

**Session Summary:** The aim of this symposium is to update attendees on cutting edge techniques and experiences in the realm of ECMO, related both to BTT and non-BTT populations. Therapies and strategies that used to seem very isolated (mobilizing on ECMO, etc.) are likely more mainstream than previously thought. An understanding of the data and outcomes may lead to expanded international adoption of some useful practices.

**7:00 AM**                    *Pressure Volume Loops: What Insight Can They Give Us on Device Strategy?*  
Jiri Maly, MD, PhD, IKEM, Prague, Czech Republic

**7:15 AM**                    *Q&A*

**7:20 AM**                    *The Future of ECMO: It's All About Hemocompatibility*  
Omar Saeed, MD, Montefiore Medical Center, Bronx, NY, USA

**7:35 AM**                    *Q&A*

**7:40 AM**                    *When the Bridge Has Termites: The Impact of ECMO-Related Infections on Post-Transplant Outcomes in Bridged Patients*  
Priya Nair, MD, St Vincent's Hospital, Sydney, Australia

**7:55 AM**                    *Q&A*

**THURSDAY, APRIL 4, 2019**

**7:00 AM - 8:00 AM**

**SUNRISE SYMPOSIUM 04: Nobody is CLAD to See AMR in Lung Transplantation**

**Room: Coral Sea**

**Target Audiences: PATH, BSTR, LF/LTX, PEDS**

**Chairs:** Monique Malouf, MD, and Desley Neil, FRCPath

**Session Summary:** Clinical and pathologic definitions for chronic rejection in lung transplantation - antibody-mediated rejection (AMR) and chronic lung allograft dysfunction (CLAD) - have undergone rapid changes over the past decade. This session will provide an update on the two major areas of discussion and acquisition over the recent years (AMR, CLAD) and potential areas for future development.

**7:00 AM**                    *Clinical Review of Antibody Mediated Rejection and Chronic Lung Allograft Dysfunction*  
Angela Koutsokera, MD, PhD, Lausanne University Hospital, Lausanne, Switzerland

**7:15 AM**                    *Pathology of Antibody Mediated Rejection*  
Fiorella Calabrese, MD, University of Padua, Padua, Italy

**7:30 AM**                    *Pathology of Chronic Lung Allograft Dysfunction*  
David M. Hwang, MD, PhD, Toronto General Hospital, Toronto, ON, Canada

**7:45 AM**                    *15-min Panel Discussion*

**THURSDAY, APRIL 4, 2019**

**7:00 AM - 8:00 AM**

**SUNRISE SYMPOSIUM 05: I Want to Ride My Bicycle: Cardiopulmonary Exercise Testing (CPET) for PAH and CTEPH**

**Room: Pacifica 1-2**

**Target Audiences: PH, CTEPH**

**Chairs:** Marco Guazzi, MD, PhD, and William Auger, MD

**Session Summary:** Exercise testing plays a key role in the management of PAH and CTEPH, diseases with exercise-induced symptoms. In contrast with 6MWD, CPET provides unique insights in the pathophysiology of PAH and CTEPH. In addition, the role of key variables derived from CPET on outcome may be useful in assessing treatment efficacy in clinical practice and maybe clinical trials. This symposium will review the various aspects of this technique, from pathophysiology to outcome prediction. A 15-min panel discussion with all speakers will conclude this session.

**7:00 AM**

***Bicycle Race: Basic Principles of CPET***

Lisa Mielniczuk, MD, Univ of Ottawa Heart Institute, Ottawa, ON, Canada

**7:15 AM**

***Under Pressure: CPET in PAH and CTEPH***

Marco Guazzi, MD, PhD, IRCCS Pol San Donato, Milan, Italy

**7:30 AM**

***Don't Stop Me Now: CPET to Predict Outcome in PAH - Time for a Change!***

Jean-Luc Vachiery, MD, Erasme University Hospital, Brussels, Belgium

**7:45 AM**

***15-min Panel Discussion***



**THURSDAY, APRIL 4, 2019**

**7:00 AM - 8:00 AM**

**SUNRISE SYMPOSIUM 06: Making Deals with the Devil: Substances of Abuse from Pre- to Post-Transplant**

**Room: Pacifica 3-5**

**Target Audiences: PHARM, HF/HTX, LF/LTX, NNSAH**

**Chairs:** Martin Zamora, MD, and Vincent G. Valentine, MD

**Session Summary:** The purpose of this symposium is to review substances of abuse pre- and post-transplant. The symposium will focus on use of medications for pain and anxiety, smoking (nicotine and marijuana), and alcohol use. Speakers will present available evidence describing why these substances are harmful when used before and after transplant and offer guidance for cessation or therapeutic alternatives.

**7:00 AM**

***'Hurts So Good': Analgesia Beyond Opioids***

Amanda Ingemi, PharmD, Sentara Norfolk General Hospital, Norfolk, VA, USA

**7:15 AM**

***Q&A***

**7:20 AM**

***So, Light 'em if You've Got 'em - or Don't! Smoking Pre- and Post-Transplant***

Erik Verschuuren, MD, PhD, University Medical Centre Groningen, Groningen, Netherlands

**7:35 AM**

***Q&A***

**7:40 AM**

***How Much is Too Much? Alcohol Use and Cessation Pre- and Post-Transplant***

Mary Amanda Dew, PhD, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

**7:55 AM**

***Q&A***

THURSDAY, APRIL 4, 2019

8:00 AM - 9:45 AM

**SESSION 23 (ORAL): Hepatitis C+ Cardiac Donors: Do They Get an A+?**

**Room: Pacifica 6**

**Target Audiences: HTX, ID**

**Chairs:** JoAnn Lindenfeld, MD, and Sanjeet Singh Avtaar Singh, MRCS, MSc

- 8:00 AM** (93) *Early Utilization Trends and Outcomes of Hepatitis C Donor Hearts in the Era of Nucleic Acid Amplification Testing (NAT) and Direct Acting Antivirals (DAAs)*; S. Madan, S. R. Patel, O. Saeed, S. Forest, J. J. Shin, D. B. Sims, D. J. Goldstein, U. P. Jorde. *Montefiore Medical Center, Bronx, NY*
- 8:15 AM** (94) *Use of Donor HCV NAT Positive Hearts: Expanding the Donor Pool?*; E. C. DePasquale<sup>1</sup>, C. J. Lum<sup>1</sup>, R. Chand<sup>1</sup>, W. Ragalic<sup>1</sup>, A. Chang<sup>1</sup>, A. Salimbangon<sup>1</sup>, M. Deng<sup>1</sup>, M. Cadeiras<sup>2</sup>, T. Khuu<sup>1</sup>, D. Vucicevic<sup>3</sup>, K. Pandya<sup>4</sup>, A. Ardehali<sup>1</sup>. <sup>1</sup>UCLA, Los Angeles, CA, <sup>2</sup>UC Davis, Sacramento, CA, <sup>3</sup>Newark Beth Israel, Newark, NJ, <sup>4</sup>USC, Los Angeles, CA
- 8:30 AM** (95) *Clinical Experience with Heart Transplantation from Hepatitis C Positive Donors*; A. Reyentovich<sup>1</sup>, C. Gidea<sup>1</sup>, D. Smith<sup>2</sup>, B. Lonze<sup>3</sup>, J. Pavone<sup>1</sup>, S. Katz<sup>1</sup>, S. Pan<sup>1</sup>, S. Rao<sup>1</sup>, T. Saraon<sup>1</sup>, N. Moazami<sup>4</sup>. <sup>1</sup>Heart Transplant, NYU Langone Medical Center, New York, NY, <sup>2</sup>CardioThoracic Surgery, NYU Langone Medical Center, New York, NY, <sup>3</sup>Transplant Surgery, NYU Langone Medical Center, New York, NY, <sup>4</sup>Cardiothoracic Surgery, NYU Langone Medical Center, New York, NY
- 8:45 AM** (96) *Successful Transplantation of 58 Hepatitis C-Exposed Donor Hearts in the Era of Direct-Acting Antiviral Therapies*; K. Schlendorf, S. Zalawadiya, A. Shah, M. Wigger, R. Perri, M. Danter, M. Brinkley, J. Menachem, S. Brown Sacks, H. Ooi, L. Punnoose, K. Balsara, L. Stevenson, J. Awad, R. Fowler, H. O'dell, S. Ruzevich-Scholl, J. Lindenfeld. *Vanderbilt University Medical Center, Nashville, TN*
- 9:00 AM** (97) *Regional Variation in Utilization of Hepatitis C-Positive Organs for Heart Transplantation in the United States*; E. M. DeFilippis<sup>1</sup>, A. R. Garan<sup>1</sup>, R. C. Givens<sup>1</sup>, L. K. Truby<sup>2</sup>, F. Latif<sup>1</sup>, S. W. Restaino<sup>1</sup>, K. Takeda<sup>1</sup>, H. Takayama<sup>1</sup>, Y. Naka<sup>1</sup>, P. C. Colombo<sup>1</sup>, M. A. Farr<sup>1</sup>, V. K. Topkara<sup>1</sup>. <sup>1</sup>Columbia University Medical Center, New York, NY, <sup>2</sup>Duke University Medical Center, Durham, NC
- 9:15 AM** (98) *Trends in Renal Function among Heart-Transplant Recipients of Donor-Derived Hepatitis C Virus*; S. Zalawadiya<sup>1</sup>, J. Lindenfeld<sup>1</sup>, A. Shah<sup>2</sup>, M. Wigger<sup>1</sup>, M. Danter<sup>2</sup>, D. Brinkley<sup>1</sup>, J. Menachem<sup>1</sup>, L. Punnoose<sup>1</sup>, S. Brown Sacks<sup>1</sup>, H. Ooi<sup>1</sup>, K. Balsara<sup>2</sup>, R. Perri<sup>3</sup>, J. Awad<sup>3</sup>, S. Smith<sup>1</sup>, R. Fowler<sup>1</sup>, H. O'Dell<sup>3</sup>, C. Darragh<sup>3</sup>, S. Ruzevich-Scholl<sup>1</sup>, K. Schlendorf<sup>1</sup>. <sup>1</sup>Heart Failure and Transplantation, Vanderbilt University Medical Center, Nashville, TN, <sup>2</sup>Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN, <sup>3</sup>Gastroenterology and Hepatology, Vanderbilt University Medical Center, Nashville, TN
- 9:30 AM** (99) *Acceptance of HCV-Positive Donor Hearts Improves Organ Acceptance Selectivity: Single Center Experience*; K. J. Gaj<sup>1</sup>, D. A. D'Alessandro<sup>2</sup>, E. D. Bethea<sup>3</sup>, J. L. Gustafson<sup>3</sup>, M. A. Villavicencio-Theoduloz<sup>2</sup>, R. T. Chung<sup>3</sup>, G. D. Lewis<sup>4</sup>. <sup>1</sup>Cardiac Transplantation, Massachusetts General Hospital, Boston, MA, <sup>2</sup>Cardiothoracic Surgery, Massachusetts General Hospital, Boston, MA, <sup>3</sup>Liver Center and Gastrointestinal Division, Massachusetts General Hospital, Boston, MA, <sup>4</sup>Advanced Heart Disease, Massachusetts General Hospital, Boston, MA

THURSDAY, APRIL 4, 2019

8:00 AM - 9:45 AM

SESSION 24 (ORAL): Molecular Diagnostics in Heart Transplantation: It's All in the Genes

Room: Pacifica 7

Target Audiences: HTX, BSTR, PATH

Chairs: Pradeep P.A. Mammen, MD, FACC, FAHA, and Markus Johannes Barten, MD, PhD

- 8:00 AM** **(100) Increase in Donor Fraction Cell-Free DNA Correlates with Cellular and Antibody Mediated Rejection (ACR/AMR) in Adult and Pediatric Heart Transplant Recipients: DNA Based Transplant Rejection Test (DTRT)-A Prospective Blinded Multicenter NIH/NHLBI Funded Clinical Study;** M. E. Richmond<sup>1</sup>, S. J. Kindel<sup>2</sup>, J. N. Schroder<sup>3</sup>, S. R. Deshpande<sup>4</sup>, D. P. Bichell<sup>5</sup>, M. A. Wigger<sup>6</sup>, K. R. Knecht<sup>7</sup>, E. Pahl<sup>8</sup>, N. A. Gaglianella<sup>9</sup>, P. M. Simpson<sup>10</sup>, W. T. Mahle<sup>11</sup>, A. T. Mitchell<sup>12</sup>, S. D. Zangwill<sup>13</sup>, M. E. Mitchell<sup>14</sup>. <sup>1</sup>Pediatrics, Columbia University, New York, NY, <sup>2</sup>Pediatrics, Children's Hospital of Wisconsin, Milwaukee, WI, <sup>3</sup>Surgery, Duke University, Durham, NC, <sup>4</sup>Children's National, Washington, DC, <sup>5</sup>Surgery, Vanderbilt University, Nashville, TN, <sup>6</sup>Medicine, Vanderbilt University, Nashville, TN, <sup>7</sup>Pediatrics, Arkansas Children's Hospital, Little Rock, AR, <sup>8</sup>Pediatrics, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, <sup>9</sup>Medicine, Medical College of Wisconsin, Milwaukee, WI, <sup>10</sup>Pediatrics, Medical College of Wisconsin, Milwaukee, WI, <sup>11</sup>Emory University, Atlanta, GA, <sup>12</sup>Surgery and Biomedical Engineering, Medical College of Wisconsin and Children's Hospital of Wisconsin, Milwaukee, WI, <sup>13</sup>Pediatrics, Phoenix Children's Hospital, Phoenix, AZ, <sup>14</sup>Surgery, Pediatric Cardiothoracic Surgery, Children's Hospital of Wisconsin, Milwaukee, WI
- 8:15 AM** **(101) Increase in Total Cell-Free DNA Correlates with Death in Adult and Pediatric Heart Transplant Recipients: DNA Based Transplant Rejection Test (DTRT)-A Prospective Blinded Multicenter NIH/NHLBI Funded Clinical Study;** S. D. Zangwill<sup>1</sup>, S. J. Kindel<sup>2</sup>, J. N. Schroder<sup>3</sup>, D. P. Bichell<sup>4</sup>, S. R. Deshpande<sup>5</sup>, M. A. Wigger<sup>6</sup>, M. E. Richmond<sup>7</sup>, K. R. Knecht<sup>8</sup>, N. A. Gaglianella<sup>9</sup>, E. Pahl<sup>10</sup>, P. M. Simpson<sup>11</sup>, W. T. Mahle<sup>12</sup>, A. T. Mitchell<sup>13</sup>, M. E. Mitchell<sup>14</sup>. <sup>1</sup>Pediatrics, Phoenix Children's Hospital, Phoenix, AZ, <sup>2</sup>Pediatrics, Children's Hospital of Wisconsin, Milwaukee, WI, <sup>3</sup>Surgery, Duke University, Durham, NC, <sup>4</sup>Surgery, Vanderbilt University, Nashville, TN, <sup>5</sup>National Children's Hospital, Washington, DC, <sup>6</sup>Medicine, Vanderbilt University, Nashville, TN, <sup>7</sup>Pediatrics, Columbia University, New York, NY, <sup>8</sup>Pediatrics, Arkansas Children's Hospital, Little Rock, AR, <sup>9</sup>Medicine, Medical College of Wisconsin, Milwaukee, WI, <sup>10</sup>Pediatrics, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, <sup>11</sup>Pediatrics, Medical College of Wisconsin, Milwaukee, WI, <sup>12</sup>Pediatrics, Emory University, Atlanta, GA, <sup>13</sup>Surgery, Medical College of Wisconsin and Children's Hospital of Wisconsin, Milwaukee, WI, <sup>14</sup>Surgery, Pediatric Cardiothoracic Surgery, Medical College of Wisconsin and Children's Hospital of Wisconsin, Milwaukee, WI
- 8:30 AM** **(102) Correlation of Human Myocardial Apoptosis with Pathology Rejection Grade and Levels of Donor-Derived Cell-Free DNA in Heart Transplantation;** S. Pattar<sup>1</sup>, F. Iqbal<sup>2</sup>, D. Isaac<sup>3</sup>, N. Fine<sup>3</sup>, S. C. Greenway<sup>4</sup>. <sup>1</sup>Biochemistry & Molecular Biology, University of Calgary, Calgary, AB, Canada, <sup>2</sup>Health Sciences, University of Calgary, Calgary, AB, Canada, <sup>3</sup>Libin Cardiovascular Institute of Alberta, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, <sup>4</sup>Pediatrics, Cardiac Sciences, Biochem. & Molecular Bio/Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada
- 8:45 AM** **(103) Distinct Patterns of Gene Expression Identified Longitudinally and within AlloMap Score Ranges are Associated with Clinical Outcomes;** A. Loupy<sup>1</sup>, R. N. Woodward<sup>2</sup>, M. Machrus<sup>2</sup>, S. P. Pinney<sup>3</sup>, J. A. Kobashigawa<sup>4</sup>. <sup>1</sup>Hospital Necker, Paris, France, <sup>2</sup>CareDx, Brisbane, CA, <sup>3</sup>Mt Sinai Health System, New York, NY, <sup>4</sup>Cedars-Sinai Heart Institute, Los Angeles, CA
- 9:00 AM** **(104) Molecular Microscope Determinants of Graft Survival in the INTERHEART Study;** J. Reeve<sup>1</sup>, D. H. Kim<sup>1</sup>, M. G. Crespo-Leiro<sup>2</sup>, J. Kobashigawa<sup>3</sup>, L. Potena<sup>4</sup>, M. Deng<sup>5</sup>, M. Cadeiras<sup>5</sup>, E. C. Depasquale<sup>5</sup>, A. Loupy<sup>6</sup>, P. Macdonald<sup>7</sup>, A. Zuckermann<sup>8</sup>, A. Z. Aliabadi<sup>8</sup>, J. Goekler<sup>8</sup>, M. Parkes<sup>1</sup>, P. F. Halloran<sup>1</sup>. <sup>1</sup>University of Alberta, Edmonton, AB, Canada, <sup>2</sup>Complexo Hospitalario Universitario A Coruña, A Coruña, Spain, <sup>3</sup>Cedars-Sinai Medical Center, Los Angeles, CA, <sup>4</sup>University of Bologna, Bologna, Italy, <sup>5</sup>Ronald Reagan UCLA Medical Center, Los Angeles, CA, <sup>6</sup>Hôpital Necker, Paris, France, <sup>7</sup>The Victor Chang Cardiac Research Institute, Sydney, Australia, <sup>8</sup>Medical University of Vienna, Vienna, Austria
- 9:15 AM** **(105) miR-208a-5p and miR-135a-5p in Formalin Fixed Paraffin Embedded Endo-Myocardial Monitoring Biopsies Discriminate Rejection from Cardiac Infection;** A. Di Francesco<sup>1</sup>, M. Fedrigo<sup>1</sup>, C. Castellani<sup>1</sup>, D. Gregori<sup>1</sup>, D. Santovito<sup>2</sup>, L. Ntarelli<sup>2</sup>, G. Toscano<sup>1</sup>, T. Bottio<sup>1</sup>, G. Thiene<sup>1</sup>, M. Valente<sup>1</sup>, M. Valente<sup>1</sup>, A. Schober<sup>2</sup>, C. Basso<sup>1</sup>, G. Gerosa<sup>1</sup>, A. Angelini<sup>1</sup>. <sup>1</sup>Department of Cardiac, Thoracic, Vascular Sciences and

*Public Health, University of Padova, Padova, Italy, <sup>2</sup>Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians University (LMU), Munich, Germany*

**9:30 AM**

**(106) *Circulating, Cell-Free, MicroRNA Sequencing to Diagnose Cardiac Allograft Rejection and Distinguish Rejection Subtype***; P. Shah<sup>1</sup>, S. Agbor-Enoh<sup>2</sup>, W. Zhu<sup>3</sup>, M. Harpole<sup>3</sup>, Y. Wakabayashi<sup>4</sup>, K. Bhatti<sup>2</sup>, P. Kothiyal<sup>3</sup>, U. Fideli<sup>2</sup>, S. Hsu<sup>5</sup>, M. E. Rodrigo<sup>6</sup>, E. Feller<sup>7</sup>, K. B. Shah<sup>8</sup>, R. K. Iyer<sup>3</sup>, J. Zhu<sup>4</sup>, H. Valantine<sup>2</sup>.  
<sup>1</sup>*Heart Failure and Transplantation, Inova Heart and Vascular Institute, Falls Church, VA, <sup>2</sup>National Heart, Lung and Blood Institute, Bethesda, MD, <sup>3</sup>Inova Translational Medicine Institute, Falls Church, VA, <sup>4</sup>Mokobio, Rockville, MD, <sup>5</sup>Heart Failure and Transplantation, Johns Hopkins University, Baltimore, MD, <sup>6</sup>Heart Failure and Transplantation, Washington Hospital Center, DC, DC, <sup>7</sup>Heart Failure and Transplantation, University of Maryland, Baltimore, MD, <sup>8</sup>Heart Failure and Transplantation, Virginia Commonwealth University, Richmond, VA*

**THURSDAY, APRIL 4, 2019**  
**8:00 AM - 9:45 AM**

**SESSION 25 (SYMPOSIUM): The Magic Kingdom of the Bronchoscopy: Pathogens with Real Implications and Those to Disregard**  
**Room: Pacifica 3-5**  
**Target Audiences: ID, LF/LTX, PATH**

**Chairs:** Are Holm, MD, and Stephanie M Pouch, MD

**Session Summary:** This symposium will review the evidence and discuss the utility of detection of pathogens from surveillance bronchoscopies after lung transplantation. Evidence will be presented regarding the interpretation and treatment of positive culture results from surveillance bronchoscopy. We will review and analyze the management/treatment of bacteria, fungi, atypical mycobacteria and CMV in asymptomatic patients.

- 8:00 AM**                    ***‘Critter Country’: Treatment and Eradication of Bacteria and Bacterial Biome***  
Nicolas Mueller, MD, University Hospital Zurich, Zurich, Switzerland
- 8:15 AM**                    ***Q&A***
- 8:20 AM**                    ***‘Fungal Frontierland’: Pathogens or Colonizers?***  
Me-Linh Luong, MD, St. Luc Hospital, Montréal, QC, Canada
- 8:35 AM**                    ***Q&A***
- 8:40 AM**                    ***‘Off Main Street’: Atypical Mycobacteria - What, When and How to Manage***  
Fernanda Silveira, MD, University of Pittsburgh, Pittsburgh, PA, USA
- 8:55 AM**                    ***Q&A***
- 9:00 AM**                    ***‘CMV Square’: Lung Transplant Recipients with CMV Positivity in a Bronchoscopy without CMV DNAemia***  
Jutta K Preiksaitis, MD, University of Alberta, Edmonton, AB, Canada
- 9:15 AM**                    ***Q&A***
- 9:20 AM**                    ***‘Tomorrowland’: A Case-Based Approach to Managing Bronchoscopy Results***  
Shalika B Katugaha, MD, InovaFairfax Hospital, Annandale, VA, USA
- 9:40 AM**                    ***Q&A***

THURSDAY, APRIL 4, 2019

8:00 AM - 9:45 AM

**SESSION 26 (ORAL): Mechanical Lung Support for Isolated Organs and Patients**

Room: Pacifica 10-12

Target Audience: LF/LTX

Chairs: Alexis Slama, MD, and Daniel F Dilling, MD

- 8:00 AM** (107) *Validation of an EVLP Perfusate Diagnostic Test for the Prediction of Lung Transplant Outcomes*; A. T. Sage<sup>1</sup>, M. Richard-Greenblatt<sup>2</sup>, K. J. Zhong<sup>2</sup>, M. B. Snow<sup>1</sup>, M. Babits<sup>1</sup>, M. Chen<sup>1</sup>, H. Gokhale<sup>1</sup>, M. Galasso<sup>1</sup>, H. Shan<sup>1</sup>, M. Cypel<sup>1</sup>, M. Liu<sup>1</sup>, K. C. Kain<sup>2</sup>, S. Keshavjee<sup>1</sup>. <sup>1</sup>Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada, <sup>2</sup>University Health Network, Toronto, ON, Canada
- 8:15 AM** (108) *A Clinical Trial Evaluating the Effects of Ultra-Violet C treatment (UVC) during Ex Vivo Lung Perfusion (EVLP) as a Method of Inactivating Hepatitis C Infection in Donor Lungs*; M. Cypel<sup>1</sup>, M. Galasso<sup>1</sup>, R. Ribeiro<sup>1</sup>, B. Wilson<sup>1</sup>, V. Bagnato<sup>2</sup>, C. Kurachi<sup>2</sup>, M. Chen<sup>1</sup>, D. Kumar<sup>1</sup>, T. K. Waddell<sup>1</sup>, L. G. Singer<sup>1</sup>, S. Keshavjee<sup>1</sup>, A. Humar<sup>1</sup>, J. Feld<sup>1</sup>. <sup>1</sup>Toronto General Hospital, Toronto, ON, Canada, <sup>2</sup>Sao Paulo University, Sao Carlos, Brazil
- 8:30 AM** (109) *Stratification Risk Analysis in Bridging Patients to Lung Transplant on ECMO: The STABLE Recipient Risk Score*; A. Habberthuer, T. Richards, F. Sertic, M. Crespo, M. Molina, P. Vallabhajosyula, E. Cantu, Y. Suzuki, D. Diagne, C. Bermudez. *Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA*
- 8:45 AM** (110) *Ex-Vivo Lung Perfusion Mediated Delivery of Rituximab to Clear Latent Epstein-Barr Virus*; T. J. Ku<sup>1</sup>, M. Cypel<sup>2</sup>, R. V. Ribeiro<sup>2</sup>, V. H. Ferreira<sup>1</sup>, D. Kumar<sup>1</sup>, A. Humar<sup>1</sup>. <sup>1</sup>Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada, <sup>2</sup>Latner Thoracic Surgery Laboratories, University Health Network, Toronto, ON, Canada
- 9:00 AM** (111) *Early Outcomes with the Use of ExtraCorporeal Membrane Oxygenation as a Bridge to Combined Heart and Lung Transplant*; F. Sertic, M. M. Crespo, A. Habberthuer, D. Diagne, L. Chavez, T. Richards, M. Molina, Y. Suzuki, E. Rame, J. Wald, E. Cantu, C. Bermudez. *University of Pennsylvania, Philadelphia, PA*
- 9:15 AM** (112) *Increasing Use of EVLP in the United States: Data from the OPTN/UNOS*; R. R. Lehman<sup>1</sup>, K. Uccellini<sup>1</sup>, E. Lease<sup>2</sup>, R. Daly<sup>3</sup>, K. M. Chan<sup>4</sup>. <sup>1</sup>United Network for Organ Sharing, Richmond, VA, <sup>2</sup>University of Washington, Seattle, WA, <sup>3</sup>Mayo Clinic, Rochester, MN, <sup>4</sup>University of Michigan, Ann Arbor, MI
- 9:30 AM** (113) *Central Ambulatory Venous-Arterial Extracorporeal Membrane Oxygenation in Lung Transplantation*; P. Downey<sup>1</sup>, W. Ragalic<sup>1</sup>, D. Ross<sup>2</sup>, A. Ardehali<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, UCLA, Los Angeles, CA, <sup>2</sup>Pulmonary and Critical Care Medicine, UCLA, Los Angeles, CA

**THURSDAY, APRIL 4, 2019**

**8:00 AM - 9:45 AM**

**SESSION 27 (SYMPOSIUM): Medical Management of LVAD Patients: Once the Chest is Closed, the Trouble Begins**

**Room: Grand Caribbean 1-7**

**Target Audience: MCS**

**Chairs:** Marco Masetti, MD, PhD, and Garrick C. Stewart, MD

**Session Summary:** This symposium will examine state of the art knowledge on device programming and medical management of LVAD patients. Current controversies such as the utility of platelet function monitoring and invasive hemodynamic testing will be reviewed and debated. A 10-min panel discussion with all speakers will conclude this session.

- 8:00 AM**            *What are We Treating with Heart Failure Therapy after MCS: the LV, the RV, the Periphery or Ourselves?*  
Gabriella Masciocco, MD, Niguarda Hospital, Milan, Italy
- 8:20 AM**            *Antiplatelet Therapy: Fixed Dose or Functional Assays?*  
Jeffrey J Teuteberg, MD, Stanford University School of Medicine, Stanford, CA, USA
- 8:35 AM**            *Time in Therapeutic Range: Is There an Optimal Way to Manage INR?*  
Douglas L Jennings, PharmD, New York-Presbyterian Hospital, New York, NY, USA
- 8:50 AM**            *Pump Data: Do We Need It to Decide Changes in Therapy?*  
Thomas Schloglhofer, MSc, Medical University of Vienna, Vienna, Austria
- 9:05 AM**            *DEBATE: You Need Information From Invasive Hemodynamics to Properly Manage an LVAD (PRO)*  
Nir Uriel, MD, University of Chicago, Chicago, IL, USA
- 9:20 AM**            *DEBATE: You Need Information From Invasive Hemodynamics to Properly Manage an LVAD (CON)*  
Emma Birks, MD, PhD, University of Louisville, Louisville, KY, USA
- 9:35 AM**            *10-min Panel Discussion*

THURSDAY, APRIL 4, 2019

8:00 AM - 9:45 AM

**SESSION 28 (ORAL): Tissue is Not the Only Issue: Advances in Thoracic Transplant Pathology**

**Room: Coral Sea**

**Target Audiences: PATH, BSTR, HTX, LTX, PEDS**

**Chairs:** Patrick Bruneval, MD, and Brandon T Larsen, MD, PhD

- 8:00 AM** (114) *Gene Expression in Formalin-Fixed Paraffin-Embedded Lung Transplant Biopsies: Correlation between Molecular and Histologic Phenotypes*; B. Adam, K. Du, S. Rotich, M. Mengel. *Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada*
- 8:15 AM** (115) *Occurrence and Risk Factors for Acute Lung Injury (ALI) and Organizing Pneumonia (OP) after Lung Transplant*; E. N. Pavlisko<sup>1</sup>, M. L. Neely<sup>1</sup>, H. Kopetskie<sup>2</sup>, D. Hwang<sup>3</sup>, C. F. Farver<sup>4</sup>, A. V. Arrossi<sup>4</sup>, W. D. Wallace<sup>5</sup>, P. Illei<sup>6</sup>, M. Sever<sup>7</sup>, J. Kirchner<sup>1</sup>, C. W. Frankel<sup>1</sup>, L. D. Snyder<sup>1</sup>, T. Martinu<sup>8</sup>, M. Y. Shino<sup>9</sup>, N. Williams<sup>10</sup>, M. A. Robien<sup>11</sup>, L. G. Singer<sup>8</sup>, M. Budev<sup>4</sup>, W. Tsuang<sup>4</sup>, P. D. Shah<sup>6</sup>, J. M. Reynolds<sup>1</sup>, S. Weigt<sup>9</sup>, J. A. Belperio<sup>9</sup>, S. M. Palmer<sup>1</sup>, J. L. Todd<sup>1</sup>. <sup>1</sup>Duke University Medical Center, Durham, NC, <sup>2</sup>Rho Federal Systems Division, Chapel Hill, NC, <sup>3</sup>Sunnybrook Health Sciences Center, Toronto, ON, Canada, <sup>4</sup>Cleveland Clinic, Cleveland, OH, <sup>5</sup>University of California, Los Angeles, CA, <sup>6</sup>Johns Hopkins University, Baltimore, MD, <sup>7</sup>Rho Federal Systems Division, Chapel Hill, NC, <sup>8</sup>University of Toronto, Toronto, ON, Canada, <sup>9</sup>University of California Los Angeles, Los Angeles, CA, <sup>10</sup>National Institute of Allergy and Infectious Disease, Bethesda, MD, <sup>11</sup>National Institute of Allergy and Infectious Disease, Bethesda, MD
- 8:30 AM** (116) *The Prognostic Value of Fibrin and Organizing Pneumonia in Transbronchial Biopsies from Lung Transplant Patients*; A. Vanstapel<sup>1</sup>, S. E. Verleden<sup>1</sup>, A. Van Herck<sup>1</sup>, J. Kaes<sup>1</sup>, T. Heigl<sup>1</sup>, A. Sacreas<sup>1</sup>, E. Verbeken<sup>2</sup>, B. Weynand<sup>2</sup>, B. M. Vanaudenaerde<sup>1</sup>, G. M. Verleden<sup>1</sup>, R. Vos<sup>1</sup>. <sup>1</sup>Leuven Lung Transplant Unit, KU Leuven - UH Leuven, Leuven, Belgium, <sup>2</sup>Department of Imaging and Pathology, KU Leuven - UH Leuven, Leuven, Belgium
- 8:45 AM** (117) *Sarcoidosis Associated Pulmonary Hypertension: Correlation of Vascular Morphologic Changes with Hemodynamic Data in Explanted Lungs*; P. Chung, K. Warrior, M. Reid, R. Nigdelioglu, S. Boyes, V. Ananthanarayanan, S. Quddus. *Pulmonary and Critical Care, Loyola University Medical Center, Maywood, IL*
- 9:00 AM** (118) *What are the Histopathologic Findings in Pulmonary Allografts with Graft Failure?*; R. E. White, A. P. Burke. *Pathology, University of Maryland, Baltimore, MD*
- 9:15 AM** (119) *Endomyocardial Biopsy Findings in Pediatric Heart Transplants Recipients with Positive HLA Associated Antibodies: Review of a Cohort with Poor Outcomes*; A. Shenoy<sup>1</sup>, A. K. Eshakula<sup>2</sup>, S. S. Goldstein<sup>2</sup>, B. A. Pietra<sup>3</sup>, M. S. Bleiweis<sup>3</sup>, F. J. Fricker<sup>3</sup>, D. Gupta<sup>3</sup>. <sup>1</sup>Departments of Pathology, Immunology and Laboratory Medicine & Pediatrics, University of Florida, Gainesville, FL, <sup>2</sup>Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL, <sup>3</sup>Congenital Heart Center, University of Florida, Gainesville, FL
- 9:30 AM** (120) *Accelerated Cardiac Allograft Vasculopathy: A Clinical and Pathologic Correlation Study*; D. V. Miller<sup>1</sup>, M. Revelo<sup>1</sup>, E. Hammond<sup>1</sup>, B. Kfoury<sup>2</sup>, K. Afshar<sup>2</sup>, K. Molina<sup>3</sup>, R. Alharethi<sup>2</sup>. <sup>1</sup>Pathology, UTAH Cardiac Transplant Program, Salt Lake City, UT, <sup>2</sup>Cardiology, UTAH Cardiac Transplant Program, Salt Lake City, UT, <sup>3</sup>Pediatric Cardiology, UTAH Cardiac Transplant Program, Salt Lake City, UT



THURSDAY, APRIL 4, 2019

8:00 AM - 9:45 AM

**SESSION 29 (ORAL): Pediatric Lung Transplantation: Are We Moving Forward?**

Room: Pacifica 1-2

Target Audiences: PEDS, LTX

Chairs: Ernestina Melicoff-Portillo, MD, and Brigitte W Willemse, MD, PhD

- 8:00 AM** (121) *Pediatric Patients with Pulmonary Vascular and Restrictive Lung Disease Suffer Disproportionately High Waitlist Mortality*; K. W. Riggs<sup>1</sup>, D. B. Colohan<sup>1</sup>, R. Rizwan<sup>1</sup>, C. Towe<sup>2</sup>, M. Schechter<sup>2</sup>, F. Zafar<sup>1</sup>, D. L. Morales<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, OH, <sup>2</sup>Pulmonary Medicine, Cincinnati Children's Hospital, Cincinnati, OH
- 8:15 AM** (122) *Outcomes of Cystic Fibrosis and Non-Cystic Fibrosis Pediatric Lung Transplants: An ISHLT Registry Study*; J. S. Nelson<sup>1</sup>, T. M. Maul<sup>1</sup>, C. G. Hurtado<sup>2</sup>, P. D. Wearden<sup>1</sup>. <sup>1</sup>Cardiovascular Services, Nemours Children's Hospital, Orlando, FL, <sup>2</sup>University of Central Florida College of Medicine, Orlando, FL
- 8:30 AM** (123) *Pediatric Lung Transplantation: Fit for Split?*; T. Martens<sup>1</sup>, M. Kanakis<sup>2</sup>, H. Spencer<sup>3</sup>, N. Muthialu<sup>4</sup>. <sup>1</sup>Cardiothoracic Surgery, University Hospital, Ghent, Belgium, <sup>2</sup>Cardiothoracic Surgery, Onassis Cardiothoracic Surgery Centre, Athens, Greece, <sup>3</sup>Transplantation, Great Ormond Street Hospital, London, United Kingdom, <sup>4</sup>Cardiothoracic Surgery, Great Ormond Street Hospital, London, United Kingdom
- 8:45 AM** (124) *Etiology of Failure Predicts Heart-Lung Transplant Candidate's Waitlist Survival*; K. W. Riggs<sup>1</sup>, J. L. Chapman<sup>1</sup>, M. Schechter<sup>2</sup>, C. Towe<sup>2</sup>, R. Bryant<sup>1</sup>, F. Zafar<sup>1</sup>, D. L. Morales<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, OH, <sup>2</sup>Pulmonary Medicine, Cincinnati Children's Hospital, Cincinnati, OH
- 9:00 AM** (125) *Is the Current Era Better for Pediatric Heart-Lung Transplantation?*; K. W. Riggs<sup>1</sup>, J. L. Chapman<sup>1</sup>, M. Schechter<sup>2</sup>, C. Towe<sup>2</sup>, R. Bryant<sup>1</sup>, F. Zafar<sup>1</sup>, D. L. Morales<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, OH, <sup>2</sup>Pulmonary Medicine, Cincinnati Children's Hospital, Cincinnati, OH
- 9:15 AM** (126) *Proinflammatory Cytokines as Biomarkers for BOS, Death, or Retransplantation after Lung Transplantation*; C. K. Conrad. Pediatrics, Lucile Packard Children's Hospital, Palo Alto, CA
- 9:30 AM** (127) *Five-Year Experience with Treatment of Early Donor Specific Anti-HLA Antibodies in Pediatric Lung Transplant Recipients*; F. Ius<sup>1</sup>, N. Schwerk<sup>2</sup>, C. Müller<sup>2</sup>, W. Sommer<sup>1</sup>, M. Verboom<sup>3</sup>, M. Hallensleben<sup>3</sup>, J. Salman<sup>1</sup>, T. Siemeni<sup>1</sup>, C. Kühn<sup>1</sup>, M. Avsar<sup>1</sup>, D. Bobylev<sup>1</sup>, J. Carlens<sup>2</sup>, L. Bayir<sup>2</sup>, G. Hansen<sup>2</sup>, R. Blasczyk<sup>3</sup>, A. Haverich<sup>1</sup>, I. Tudorache<sup>1</sup>, G. Warnecke<sup>1</sup>. <sup>1</sup>Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, <sup>2</sup>Department of Paediatric Pulmonology, Allergology, and Neonatology, Hannover Medical School, Hannover, Germany, <sup>3</sup>Department of Transfusion Medicine, Hannover Medical School, Hannover, Germany

THURSDAY, APRIL 4, 2019  
10:15 AM - 12:00 PM

**SESSION 30 (ORAL): Get Up and Go! Predicting Survival in Heart Failure**

**Room: Pacifica 7**

**Target Audiences: HF, HTX, NNSAH**

**Chairs:** George G Sokos, DO, and Wandy Chan, PhD, FRACP

- 10:15 AM** (128) **Genomic Prediction of One Year Survival Status Related to Functional Recovery Potential in Advanced Heart Failure Patients Undergoing Mechanical Circulatory Support;** G. Bondar<sup>1</sup>, T. Bao<sup>1</sup>, M. Kurani<sup>1</sup>, D. L. Bhaskar<sup>1</sup>, A. Le<sup>1</sup>, R. Dod<sup>1</sup>, Y. Khachatourian<sup>1</sup>, A. Aliyari<sup>1</sup>, E. Higuchi<sup>1</sup>, E. Oh<sup>1</sup>, K. Patel<sup>1</sup>, M. Cadeiras<sup>2</sup>, J. Schaenman<sup>1</sup>, L. Masukawa<sup>1</sup>, S. Kupiec-Weglinski<sup>3</sup>, V. Groysberg<sup>1</sup>, M. Bakir<sup>1</sup>, E. Depasquale<sup>1</sup>, M. Kamath<sup>1</sup>, D. Liem<sup>1</sup>, J. Meltzer<sup>1</sup>, M. Kwon<sup>1</sup>, M. Rossetti<sup>1</sup>, D. Elashoff<sup>1</sup>, X. Li<sup>1</sup>, E. Reed<sup>1</sup>, P. Ping<sup>1</sup>, M. C. Deng<sup>1</sup>. <sup>1</sup>David-Geffen Sch Med, Los Angeles, CA, <sup>2</sup>University of California Davis School of Medicine, Sacramento, CA, <sup>3</sup>Cornell University, Ithaca, NY
- 10:30 AM** (129) **Impact of Frailty on Health-Related Quality of Life from before to 6 Months after Surgery: Findings from the Sustaining Quality of Life of the Aged: Transplant or Mechanical Support (SUSTAIN-IT) Study;** K. Ghafourian<sup>1</sup>, A. C. Andrei<sup>2</sup>, Y. Xu<sup>2</sup>, C. W. Yancy<sup>1</sup>, H. Adam<sup>2</sup>, D. T. Pham<sup>2</sup>, K. L. Grady<sup>2</sup>. <sup>1</sup>Cardiology, Northwestern University, Chicago, IL, <sup>2</sup>Surgery, Northwestern University, Chicago, IL
- 10:45 AM** (130) **Leg Muscle Strength Independently Predicts Clinical Outcome in Patients with Acute Decompensated Heart Failure;** J. Youn<sup>1</sup>, E. Yoon<sup>1</sup>, H. Choi<sup>2</sup>, I. Kim<sup>3</sup>, J. Lee<sup>1</sup>, S. Lee<sup>1</sup>, S. Han<sup>1</sup>, S. Kang<sup>4</sup>. <sup>1</sup>Dongtan Sacred Heart Hospital, Hallym University, Hwaseong, Korea, Republic of, <sup>2</sup>Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of, <sup>3</sup>Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of, <sup>4</sup>Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
- 11:00 AM** (131) **Comparison of Percutaneous Ventricular Assist Device and Intra-Aortic Balloon Pump for Cardiogenic Shock;** A. Y. Lee<sup>1</sup>, C. Y. Guerrero-Miranda<sup>1</sup>, T. Nisar<sup>2</sup>, A. K. Jamil<sup>2</sup>, A. Perez<sup>1</sup>, D. Tangellamundi<sup>1</sup>, J. Feliuss<sup>2</sup>, S. A. Hall<sup>1</sup>, D. Wencker<sup>1</sup>. <sup>1</sup>Baylor University Medical Center, Dallas, TX, <sup>2</sup>Baylor Scott & White Research Institute, Dallas, TX
- 11:15 AM** (132) **Characteristics and Outcomes of Patients with Cardiogenic Shock Complicated by Acute Kidney Injury Requiring Hemodialysis;** C. Inampudi<sup>1</sup>, O. Adegbala<sup>2</sup>, E. Akintoye<sup>1</sup>, P. Alvarez<sup>1</sup>, A. Briasoulis<sup>1</sup>. <sup>1</sup>Internal Medicine - Cardiology, Univ of Iowa Hospital, Iowa City, IA, <sup>2</sup>Internal Medicine, Englewood Hospital and Medical Center, Seton Hall University-Hackensack Meridian School of Medicine, Englewood, New Jersey, NJ
- 11:30 AM** (133) **LVAD Survival May Be Predicted by Preoperative Lymphopenia;** K. Stawiarski<sup>1</sup>, O. Agboola<sup>2</sup>, D. Jacoby<sup>3</sup>, L. Bellumkonda<sup>3</sup>, L. Sugeng<sup>3</sup>, T. Ahmad<sup>3</sup>, M. Chen<sup>3</sup>, G. McCloskey<sup>2</sup>, A. Geirsson<sup>2</sup>, M. Anwar<sup>2</sup>, P. Bonde<sup>2</sup>. <sup>1</sup>Yale New Haven Health Bridgeport Hospital, Bridgeport, CT, <sup>2</sup>Yale School of Medicine, New Haven, CT, <sup>3</sup>Yale School of Medicine, Bridgeport, CT
- 11:45 AM** (134) **Differences in Health-Related Quality of Life by Socio-Demographic Characteristics: Findings from the Sustaining Quality of Life of the Aged: Transplant or Mechanical Support (SUSTAIN-IT) Study;** L. Uppalapati<sup>1</sup>, A. Andrei<sup>2</sup>, C. Yancy<sup>3</sup>, Y. Xu<sup>2</sup>, H. Adam<sup>2</sup>, D. Pham<sup>2</sup>, K. L. Grady<sup>2</sup>. <sup>1</sup>Northwestern University, Chicago, IL, <sup>2</sup>Surgery / Cardiac Surgery, Northwestern University, Chicago, IL, <sup>3</sup>Medicine, Northwestern University, Chicago, IL

THURSDAY, APRIL 4, 2019  
10:15 AM - 12:00 PM

**SESSION 31 (ORAL): Slaying the Dragon: Hepatitis C and Thoracic Transplantation**

**Room: Pacifica 1-2**

**Target Audiences: ID, HTX, LTX, PEDS**

**Chairs:** Valentina Stosor, MD, and Saima Aslam, MD, MS

- 10:15 AM** (135) *Routine Utilization of NAT Negative PHS Increased Risk Thoracic Organs Appears Safe and Effective in Increasing Organ Supply for Transplantation*; K. J. Gaj<sup>1</sup>, L. Irwin<sup>1</sup>, A. Leifer<sup>1</sup>, M. A. Villavicencio-Theoduloz<sup>2</sup>, K. Turvey<sup>1</sup>, G. D. Lewis<sup>3</sup>, C. Kotton<sup>4</sup>, D. A. D'Alessandro<sup>1</sup>. <sup>1</sup>Transplant Surgery, Massachusetts General Hospital, Boston, MA, <sup>2</sup>Transplant Surgery, Massachusetts General Hospital, Boston, MA, <sup>3</sup>Advanced Heart Disease, Massachusetts General Hospital, Boston, MA, <sup>4</sup>Infectious Disease Division, Massachusetts General Hospital, Boston, MA
- 10:30 AM** (136) *Transplantation of NAT+HCV Donor Lungs into Non-Infected Recipients Followed by Treatment with Sofosbuvir/Velpatasvir (S/V)*; M. Cypel, J. Feld, L. G. Singer, N. Marks, I. Bahinskaya, M. Kuczynski, D. Kumar, M. Galasso, R. Ribeiro, J. Yeung, L. Donahoe, A. Pierre, M. de Perrot, K. Yasufuku, T. K. Waddell, S. Keshavjee, A. Humar, A. Humar. Toronto General Hospital, Toronto, ON, Canada
- 10:45 AM** (137) *Preemptive Pan-Genotypic Direct Acting Antiviral Therapy in Donor HCV-Positive to Recipient HCV-Negative Cardiac Transplantation Produces Viral Clearance and is Associated with Favorable Outcomes*; G. D. Lewis, E. D. Bethea, K. Gaj, J. Gustafson, A. Dugal, K. Turvey, E. Coglianese, S. S. Thomas, C. Newton-Cheh, N. E. Ibrahim, W. D. Carlson, R. V. Shah, R. V. Shah, J. E. Ho, M. Nayor, J. K. Steiner, M. E. Afari, T. Lebeis, J. C. Madsen, M. A. Villavicencio-Theoduloz, R. T. Chung, D. A. D'Alessandro. Massachusetts General Hospital, Boston, MA
- 11:00 AM** (138) *Magnitude of Recipient Viremia after Heart Transplantation from HCV Viremic Donors and Time to Clearance with Therapy*; C. G. Gidea<sup>1</sup>, A. Reyentovich<sup>1</sup>, D. Smith<sup>2</sup>, J. Pavone<sup>1</sup>, S. Katz<sup>1</sup>, S. Pan<sup>1</sup>, S. Rao<sup>1</sup>, T. Saraon<sup>1</sup>, N. Moazami<sup>2</sup>. <sup>1</sup>Heart Transplant, NYU Langone Medical Center, New York, NY, <sup>2</sup>Cardiothoracic Surgery, NYU Langone Medical Center, New York, NY
- 11:15 AM** (139) *The Impact of Utilizing Hepatitis C Virus Nucleic Acid Test-Positive Donor Heart on Heart Transplant Waitlist Time*; Y. K. Gernhofer<sup>1</sup>, M. Brambatti<sup>2</sup>, B. H. Greenberg<sup>2</sup>, E. Adler<sup>2</sup>, S. Aslam<sup>3</sup>, V. Pretorius<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, UC San Diego, San Diego, CA, <sup>2</sup>Cardiology, UC San Diego, San Diego, CA, <sup>3</sup>Infectious Diseases, UC San Diego, San Diego, CA
- 11:30 AM** (140) *The Impact of HCV Viremia in Heart Transplant Recipients from Donors with HCV Infection on Acute and Humoral Cellular Rejection*; C. G. Gidea<sup>1</sup>, N. Narula<sup>2</sup>, A. Reyentovich<sup>1</sup>, D. Smith<sup>3</sup>, J. Pavone<sup>1</sup>, S. Katz<sup>1</sup>, S. Pan<sup>1</sup>, S. Rao<sup>1</sup>, T. Saraon<sup>1</sup>, N. Moazami<sup>3</sup>. <sup>1</sup>Heart Transplant, NYU Langone Medical Center, New York, NY, <sup>2</sup>Pathology, NYU Langone Medical Center, New York, NY, <sup>3</sup>Cardiothoracic Surgery, NYU Langone Medical Center, New York, NY
- 11:45 AM** (141) *Outcomes of Heart and Heart-Kidney Transplantation from Hepatitis C Virus (HCV) Positive Donors into HCV Negative Recipients*; S. Aslam<sup>1</sup>, I. Yumul<sup>2</sup>, M. Mariski<sup>1</sup>, V. Pretorius<sup>1</sup>, E. Adler<sup>1</sup>. <sup>1</sup>University of California, San Diego, San Diego, CA, <sup>2</sup>University of Iowa, Iowa City, IA

**THURSDAY, APRIL 4, 2019**  
**10:15 AM - 12:00 PM**

**SESSION 32 (SYMPOSIUM): Ex-Vivo Lung Perfusion (EVLP) in 2019: From Research to Implementation**  
**Room: Pacifica 10-12**  
**Target Audiences: LF/LTX, MCS**

**Chairs:** John Dark, MB, FRCS, and Tiago Machuca, MD, PhD

**Session Summary:** This symposium will bring experts in Ex-Vivo Lung Perfusion and donor lung management from all over the world. Current practices, different models, ongoing clinical trials with EVLP and added therapeutics will be discussed. The attendee will increase his or her understanding of the technique, its applications and future directions. A 15-min panel discussion with all speakers will conclude this session.

- 10:15 AM**            *Implementation of High Volume Clinical EVLP: The Toronto Model*  
Shaf Keshavjee, MD, FRCSC, Toronto General Hospital, Toronto, ON, Canada
- 10:30 AM**            *Rationale for Portable EVLP*  
Wiebke Sommer, MD, Hannover Medical School, Hannover, Germany
- 10:45 AM**            *Benefits and Barriers of a Do-It-Yourself EVLP Program*  
Peter Hopkins, FRACP, The Prince Charles Hospital, Brisbane, Australia
- 11:00 AM**            *Organ Procurement Organization-Based EVLP Program*  
Duane Davis, MD, MBA, Florida Hospital, Orlando, FL, USA
- 11:15 AM**            *Experience with a Third-Party EVLP Program*  
Kenneth R. McCurry, MD, FACS, Cleveland Clinic, Cleveland, OH, USA
- 11:30 AM**            *The Role of Biomarkers in EVLP*  
Andrew J Fisher, FRCP, PhD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
- 11:45 AM**            *15-min Panel Discussion*

THURSDAY, APRIL 4, 2019  
10:15 AM - 12:00 PM

SESSION 33 (ORAL): Brain Attack: Strokes and MCS  
Room: Pacifica 6  
Target Audience: MCS

Chairs: Sai Bhagra, MBBS, and Erin Coglianese, MD

- 10:15 AM** (142) *Understanding Risk Factors for Stroke Subtypes in the ENDURANCE Trials*; S. Cho<sup>1</sup>, R. Starling<sup>2</sup>, J. Teuteberg<sup>3</sup>, J. Rogers<sup>4</sup>, F. Pagani<sup>5</sup>, P. Shah<sup>6</sup>, K. Uchino<sup>7</sup>, T. Vassiliades<sup>8</sup>. <sup>1</sup>John Hopkins University, Baltimore, MD, <sup>2</sup>Cardiology, Cleveland Clinic, Cleveland, OH, <sup>3</sup>Cardiology, Stanford University, Stanford, CA, <sup>4</sup>Duke University, Durham, NC, <sup>5</sup>University of Michigan, Ann Arbor, MI, <sup>6</sup>Cardiology, Inova Fairfax, Falls Church, VA, <sup>7</sup>Cleveland Clinic, Cleveland, OH, <sup>8</sup>Medtronic, Framingham, MA
- 10:30 AM** (143) *Long-Term Burden of Hemocompatibility Related Adverse Events in the MOMENTUM 3 Trial: Final Analysis of the 1028 Patient Cohort*; N. Uriel<sup>1</sup>, M. Mehra<sup>2</sup>. <sup>1</sup>University of Chicago, Chicago, IL, <sup>2</sup>Brigham and Women's Hospital and Harvard Medical School, Boston, MA
- 10:45 AM** (144) *Two-Year Outcomes in Real World Patients Treated with Heartmate 3™ Left Ventricular Assist Device for Advanced Heart Failure: Data from the ELEVATE Registry*; D. Saeed<sup>1</sup>, J. Garbade<sup>1</sup>, F. Gustafsson<sup>2</sup>, J. Lavee<sup>3</sup>, M. Morshuis<sup>4</sup>, D. Zimpfer<sup>5</sup>, E. Potapov<sup>6</sup>, Y. Pya<sup>7</sup>, J. Schmitto<sup>8</sup>, S. M. Shaw<sup>9</sup>. <sup>1</sup>Department for Cardiac Surgery, Leipzig Heart Centre, Leipzig, Germany, <sup>2</sup>The Heart Centre, Rigshospitalet, Copenhagen, Denmark, <sup>3</sup>Heart Transplantation Unit, Leviev Heart Center, Tel Aviv, Israel, <sup>4</sup>Department of Cardiothoracic Surgery, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Germany, <sup>5</sup>Department of Surgery, Medical University of Vienna, Vienna, Austria, <sup>6</sup>Deutsches Herzzentrum Berlin, Berlin, Germany, <sup>7</sup>National Research Center for Cardiac Surgery, Astana, Kazakhstan, <sup>8</sup>Medizinische Hochschule Hannover, Hannover, Germany, <sup>9</sup>Heart and Lung Transplant Centre, Manchester University NHS Foundation Trust, Manchester, United Kingdom
- 11:00 AM** (145) *Impact of Stroke Onset Severity on 2-Year Survival in Destination Therapy Patients Supported by Centrifugal Flow versus Axial Flow Ventricular Assist Devices*; P. Shah<sup>1</sup>, C. Mahr<sup>2</sup>, J. Rogers<sup>3</sup>, M. Kiernan<sup>4</sup>, S. Boyce<sup>5</sup>, N. A. Mokadam<sup>6</sup>, F. Pagani<sup>7</sup>, T. Vassiliades<sup>8</sup>, J. Teuteberg<sup>9</sup>. <sup>1</sup>Cardiology, Inova Fairfax, Falls Church, VA, <sup>2</sup>Cardiology, University of Washington, Seattle, WA, <sup>3</sup>Cardiology, Duke University, Durham, NC, <sup>4</sup>Cardiology, Tufts University, Boston, MA, <sup>5</sup>Cardiac Surgery, Washington Hospital Center, Washington, DC, <sup>6</sup>Cardiac Surgery, University of Washington, Seattle, WA, <sup>7</sup>Cardiac Surgery, University of Michigan, Ann Arbor, MI, <sup>8</sup>Medtronic, Framingham, MA, <sup>9</sup>Cardiology, Stanford University, Stanford, CA
- 11:15 AM** (146) *Apixaban in HVAD Patients Non-Compliant to Standard Vitamin-K-Antagonism*; S. Schulte-Eistrup<sup>1</sup>, N. Mayer-Wingert<sup>1</sup>, N. Reiss<sup>2</sup>, J. Sindermann<sup>3</sup>, H. Warnecke<sup>1</sup>. <sup>1</sup>Cardiac Surgery, Schuechtermann Klinik, Bad Rothenfelde, Germany, <sup>2</sup>Clinical Research, Schuechtermann Klinik, Bad Rothenfelde, Germany, <sup>3</sup>Rehabilitation, Schuechtermann Klinik, Bad Rothenfelde, Germany
- 11:30 AM** (147) *Presence of Left Atrial or Left Ventricular Thrombus at the Time of CF-LVAD Implantation is Associated with Increased Post-Operative Risk of Stroke or Death*; J. A. Fried<sup>1</sup>, H. Lumish<sup>1</sup>, A. M. Zuver<sup>1</sup>, A. R. Garan<sup>1</sup>, V. K. Topkara<sup>1</sup>, B. Cagliostro<sup>1</sup>, G. Parkis<sup>2</sup>, M. Cevasco<sup>2</sup>, M. T. Pineda<sup>2</sup>, G. M. Mondellini<sup>1</sup>, K. Ross<sup>2</sup>, L. Witer<sup>2</sup>, H. Takayama<sup>2</sup>, K. Takeda<sup>2</sup>, Y. Naka<sup>2</sup>, M. Yuzefpolskaya<sup>1</sup>, R. T. Demmer<sup>3</sup>, P. C. Colombo<sup>1</sup>. <sup>1</sup>Cardiology, Columbia University Medical Center, New York, NY, <sup>2</sup>Department of Surgery, Columbia University Medical Center, New York, NY, <sup>3</sup>Epidemiology and Community Health, University of Minnesota, Minneapolis, MN
- 11:45 AM** (148) *Occurrence and Clinical Patterns of Stroke Based on Arterial Cannulation Strategy during Venous-Arterial Extracorporeal Membrane Oxygenation Support*; M. Nishikawa, J. Willey, A. R. Garan, M. Cevasco, L. Witer, J. Sanchez, P. Kurlansky, A. Kirtane, D. Brodie, M. Yuzefpolskaya, P. Colombo, H. Takayama, Y. Naka, K. Takeda. Columbia University Irving Medical Center, New York, NY

THURSDAY, APRIL 4, 2019  
10:15 AM - 12:00 PM

**SESSION 34 (ORAL): Never Mind the Leaks: Addressing Valvular Disease with LVADs**

**Room: Grand Caribbean 1-7**

**Target Audience: MCS**

**Chairs:** William Hiesinger, MD, and J. Eduardo Rame, MD

- 10:15 AM** (149) *Course and Clinical Impact of Tricuspid Regurgitation after LVAD Implantation: An Analysis of the EUROMACS Registry*; K. Veen<sup>1</sup>, M. M. Mokhles<sup>1</sup>, O. I. Soliman<sup>1</sup>, T. M. de By<sup>2</sup>, P. Mohacsi<sup>3</sup>, F. Schoenrath<sup>4</sup>, L. Paluszkiwicz<sup>5</sup>, A. J. Bogers<sup>1</sup>, J. J. Takkenberg<sup>1</sup>, K. Caliskan<sup>1</sup>. <sup>1</sup>Erasmus MC, Rotterdam, Netherlands, <sup>2</sup>EUROMACS Registry, Windsor, United Kingdom, <sup>3</sup>University Hospital Zurich, Zurich, Switzerland, <sup>4</sup>German Heart Centre Berlin, Berlin, Germany, <sup>5</sup>Heart and Diabetes Centre NRW, Bad Oeynhausen, Germany
- 10:30 AM** (150) *Aortic Insufficiency is Associated with Hemocompatibility-Related Adverse Events in LVAD Patients*; T. Imamura, J. Raikhelkar, G. Kim, B. Smith, S. Kalantari, A. Nguyen, N. Narang, B. Chung, I. Ebong, L. Holzhauser, J. Grinstein, D. Nitta, T. Fujino, C. Juricek, D. Rodgers, P. Combs, T. Song, T. Ota, V. Jeevanandam, G. Sayer, N. Uriel. *University of Chicago, Chicago, IL*
- 10:45 AM** (151) *Impact of Pre-Op Mitral Regurgitation Following Left Ventricular Assist Device Implant*; G. N. Cohan<sup>1</sup>, B. Pierce<sup>2</sup>, Z. Rhinehart<sup>2</sup>, F. Thoma<sup>3</sup>, W. Katz<sup>2</sup>, A. Kilic<sup>1</sup>, R. Kormos<sup>1</sup>, C. M. Sciortino<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>Cardiology, University of Pittsburgh, Pittsburgh, PA, <sup>3</sup>Heart and Vascular Institute, University of Pittsburgh, Pittsburgh, PA
- 11:00 AM** (152) *Longitudinal Trend of Tricuspid Regurgitation Following Left Ventricular Assist Device Implantation*; T. Fujino, T. Imamura, D. Nitta, D. Rodgers, A. Nguyen, B. Chung, J. Raikhelkar, B. Smith, I. Ebong, N. Narang, L. Holzhauser, T. Ota, V. Jeevanandam, G. Kim, G. Sayer, N. Uriel. *University of Chicago, Chicago, IL*
- 11:15 AM** (153) *TAVI in LVAD Patients with Aortic Insufficiency*; M. N. Belkin, T. Imamura, A. J. Kanelidis, L. Holzhauser, I. Ebong, N. Narang, J. E. Blair, S. Nathan, J. D. Paul, A. P. Shah, B. Chung, A. Nguyen, B. Smith, S. Kalantari, J. Raikhelkar, N. Sarswat, G. Kim, G. Sayer, N. Uriel. *University of Chicago, Chicago, IL*
- 11:30 AM** (154) *Increased Incidence of De Novo Aortic Incompetence in Patients Supported with Impella Prior to LVAD Implantation*; S. D. Rao, B. Johnson, V. Medina, E. Rame, L. Goldberg, J. Wald, P. Atluri, C. Bermudez, M. Acker, E. Y. Birati. *University of Pennsylvania, Philadelphia, PA*
- 11:45 AM** (155) *Impact of Concomitant Valvular Surgery on Patients Undergoing LVAD Implantation*; K. Y. Mulumba<sup>1</sup>, P. Kasinpila<sup>1</sup>, R. Fong<sup>1</sup>, S. Kong<sup>1</sup>, L. Hecker<sup>1</sup>, R. Nissan<sup>1</sup>, D. Banerjee<sup>2</sup>, J. Teuteberg<sup>2</sup>, Y. Shudo<sup>1</sup>, Y. Woo<sup>1</sup>, W. Hiesinger<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, Stanford University, Palo Alto, CA, <sup>2</sup>Cardiology, Stanford University, Palo Alto, CA

**THURSDAY, APRIL 4, 2019**  
**10:15 AM - 12:00 PM**

**SESSION 35 (SYMPOSIUM): Bring Out Your Dead: The Postmortem Evaluation in the Thoracic Transplant Setting**  
**Room: Coral Sea**  
**Target Audiences: PATH, HF/HTX, LF/LTX**

**Chairs:** Lorriana E Leard, MD, and Carmela D Tan, MD

**Session Summary:** The postmortem examination ("autopsy") is underutilized in modern medicine, but provides critical information to the clinicians, families and loved ones of the decedent to help them understand the decedent's clinical course. Data obtained from autopsies may be used by hospital quality personnel, researchers, policy makers, registries and device manufacturers to improve the state of thoracic transplantation and mechanical circulatory support therapy. A 15-min panel discussion with all speakers will conclude this session.

**10:15 AM**            *The Autopsy in the Modern Era: What the Clinician Still Would Like to Gain from an Autopsy*  
Stephen C Clark, MD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

**10:30 AM**            *What the Pathologist Can Tell: More Than Just Cause of Death*  
Anja C Roden, MD, Mayo Clinic, Rochester, MN, USA

**10:45 AM**            *How is a Postmortem Examination Performed: Frequently Asked Questions*  
Billie S. Fyfe-Kirschner, MD, Robert Wood Johnson School of Medicine, New Brunswick, NJ, USA

**11:00 AM**            *The Autopsy in the Mechanical Circulatory Support Patient*  
Robert F. Padera, MD, PhD, Brigham & Women's Hospital, Boston, MA, USA

**11:15 AM**            *The Autopsy in the Thoracic Transplant Patient*  
Ornella Leone, MD, S. Orsola Hospital, Bologna, Italy

**11:30 AM**            *The 'Rapid Autopsy': A Tool for Scientific Inquiry*  
Dylan V. Miller, MD, Intermountain Central Lab, Murray, UT, USA

**11:45 AM**            *15-min Panel Discussion*

**THURSDAY, APRIL 4, 2019**  
**10:15 AM - 12:00 PM**

**SESSION 36 (SYMPOSIUM): Learning from the Children: Important Lessons from the Pediatric and Congenital Heart Disease VAD Experience**  
**Room: Pacifica 3-5**  
**Target Audiences: PEDS, HTX, MCS**

**Chairs:** Angela Lorts, MD, and Ulrich Jorde, MD

**Session Summary:** Pediatric and congenital heart disease VAD support is a challenge because the population is heterogenous, VADs were not designed for complex anatomy and physiology, and compared with adults, the numbers, data and collective experience are extremely limited. Despite these challenges, pediatric centers have successfully adapted and utilized VADs to improve outcomes. This symposium will provide an opportunity for the pediatric community to share their experience with the broader MCS community. A 15-min panel discussion with all speakers will conclude this session.

- 10:15 AM**            *Not Just Small Adults: Outcomes of Pediatric Patients with Continuous Flow Devices*  
Christina J VanderPluym, MD, Boston Children's Hospital, Boston, MA, USA
- 10:30 AM**            *Not Just Small Adults: Novel Antithrombosis Strategies Used in Pediatric VADs*  
Oliver Miera, MD, Deutsches Herzzentrum Berlin, Berlin, Germany
- 10:45 AM**            *Not-So Temporary Circulatory Support*  
Aamir Jeewa, MD, Hospital for Sick Children, Toronto, ON, Canada
- 11:00 AM**            *Optimizing Hemodynamics of Continuous Flow VADS for Small Patients*  
Lucas Eastaugh, MBBS, Royal Children's Hospital, Melbourne, Australia
- 11:15 AM**            *One Size Fits All? Strategies for Using Implantable VADs in Small Patients*  
Antonio Amodeo, MD, Bambino Gesu Ped Hosp, Rome, Italy
- 11:30 AM**            *Building Bridges: Collaborative Learning to Improve Outcomes in VAD Care*  
David M Peng, MD, University of Michigan, Ann Arbor, MI, USA
- 11:45 AM**            *15 min Panel Discussion*



**THURSDAY, APRIL 4, 2019**

**1:45 PM - 3:30 PM**

**SESSION 37 (SYMPOSIUM): JHLT at ISHLT: The Year in a Capsule**

**Room: Pacifica 10-12**

**Target Audiences: HF/HTX, ID, LF/LTX, MCS, PEDS, PH**

**Chairs:** Manreet Kanwar, MD, and Martin Schweiger, MD

**Session Summary:** This symposium will highlight the most exciting publications in JHLT over the past year, each paper followed by a discussion by one of the senior editorial consultants of the journal to relate the presented articles to the greater body of published literature and discuss how they advance our understanding in the field.

- 1:45 PM**                    *JHLT Best Papers of 2018*  
Patricia A. Uber, PharmD, Virginia Commonwealth University, Richmond, VA, USA
- 1:50 PM**                    *Highlights of Heart Transplantation and MCS*  
Simon Pecha, MD, University Hospital Hamburg, Hamburg, Germany
- 2:05 PM**                    *Invited Discussant in Heart Transplantation and MCS*  
Francis D Pagani, MD, PhD, University of Michigan, Ann Arbor, MI, USA
- 2:15 PM**                    *Highlights of Lung Transplantation and Pulmonary Hypertension*  
Peter Riddell, MBBS, Mater Misericordiae University Hospital, Dublin, Ireland
- 2:30 PM**                    *Invited Discussant in Lung Transplantation and Pulmonary Hypertension*  
Jason D Christie, MD, University of Pennsylvania, Philadelphia, PA, USA
- 2:40 PM**                    *Highlights of Pediatric Heart and Lung Transplantation*  
Ann R Punnoose, MD, Children's Hospital of Wisconsin, Milwaukee, WI, USA
- 2:55 PM**                    *Invited Discussant in Pediatric Heart and Lung Transplantation*  
Stuart C Sweet, MD, PhD, St. Louis Children's Hospital, St. Louis, MO, USA
- 3:05 PM**                    *Highlights of Infectious Disease*  
Jonathan M Hand, MD, Ochsner Medical Center, New Orleans, LA, USA
- 3:20 PM**                    *Invited Discussant in Infectious Diseases*  
Emily A Blumberg, MD, University of Pennsylvania, Philadelphia, PA, USA

THURSDAY, APRIL 4, 2019  
1:45 PM - 3:30 PM

**SESSION 38 (ORAL): Early Career Scientist Award Candidate Presentations**

**Room:** Coral Sea

**Target Audiences:** BSTR, HTX, LTX, PATH

**Chairs:** Andrew E Gelman, PhD, and Frank D'Ovidio, MD, PhD

- 1:45 PM**            **(156) Mitochondrial DNA Mismatches in Thoracic Transplantation: Potential Triggers of Allograft Immunogenicity;** A. Marishta<sup>1</sup>, Y. Yang<sup>1</sup>, X. Hu<sup>2</sup>, M. Jang<sup>1</sup>, K. Cuttin<sup>1</sup>, A. Jackson<sup>3</sup>, H. Luikart<sup>4</sup>, K. Bhatti<sup>1</sup>, U. Fideli<sup>1</sup>, T. Deuse<sup>2</sup>, K. Khush<sup>4</sup>, S. Schrepfer<sup>2</sup>, S. Agbor-Enoh<sup>1</sup>, H. Valantine<sup>1</sup>. <sup>1</sup>Genomic Research Alliance for Transplantation (GRAfT), Laboratory of Transplantation Genomics, National Heart, Lung, and Blood Institute, Bethesda, MD, <sup>2</sup>Department of Surgery, Transplant and Stem Cell Immunobiology (TSI)-Lab, University of California San Francisco (UCSF), San Francisco, CA, <sup>3</sup>Pulmonary and Critical Care Medicine, The Johns Hopkins School of Medicine, Baltimore, MD, <sup>4</sup>Department of Medicine, Stanford University School of Medicine, Palo Alto, CA
- 2:05 PM**            **(157) Effects of Nissen Fundoplication on Markers of Microaspiration and Inflammation after Lung Transplantation;** K. C. Zhang<sup>1</sup>, S. E. Hunter<sup>1</sup>, E. Huszti<sup>2</sup>, M. Ahmed<sup>1</sup>, L. Levy<sup>1</sup>, K. M. Boonstra<sup>1</sup>, A. T. Sage<sup>1</sup>, S. Azad<sup>1</sup>, R. Zamel<sup>1</sup>, C. Frankel<sup>3</sup>, M. Budev<sup>4</sup>, P. Shah<sup>5</sup>, L. D. Snyder<sup>3</sup>, J. Belperio<sup>6</sup>, L. G. Singer<sup>1</sup>, S. S. Weigt<sup>6</sup>, J. L. Todd<sup>3</sup>, S. Keshavjee<sup>1</sup>, S. M. Palmer<sup>3</sup>, T. Martinu<sup>1</sup>, \*. for the CTOT-20 Investigators<sup>1</sup>. <sup>1</sup>Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada, <sup>2</sup>Biostatistics Research Unit, University Health Network, Toronto, ON, Canada, <sup>3</sup>Duke University Medical Center, Durham, NC, <sup>4</sup>Cleveland Clinic, Cleveland, OH, <sup>5</sup>Johns Hopkins University Hospital, Baltimore, MD, <sup>6</sup>UCLA Medical Center, Los Angeles, CA
- 2:25 PM**            **(158) ABO Tolerance Following Treatment of Infant Mice with A-Expressing MHC-Identical Erythrocytes;** J. Fersovich<sup>1</sup>, B. Motyka<sup>1</sup>, I. Adam<sup>1</sup>, J. Pearcey<sup>1</sup>, K. Tao<sup>1</sup>, C. W. Cairo<sup>2</sup>, P. J. Cowan<sup>3</sup>, L. J. West<sup>1</sup>. <sup>1</sup>Dept Pediatrics, Alberta Transplant Institute, Canadian National Transplant Research Program, University of Alberta, Edmonton, AB, Canada, <sup>2</sup>Dept Chemistry, University of Alberta, Edmonton, AB, Canada, <sup>3</sup>Immunology Research Centre, St Vincent's Hospital, Melbourne, Australia
- 2:45 PM**            **(159) Modulating Mitochondrial Fusion/Fission Induces Immunoprotective Effects in Models of Cardiac Transplantation;** D. T. Tran<sup>1</sup>, Z. Tu<sup>2</sup>, C. Atkinson<sup>1</sup>, S. N. Nadig<sup>1</sup>. <sup>1</sup>Microbiology & Immunology, Surgery, Medical University of South Carolina, Charleston, SC, <sup>2</sup>Microbiology & Immunology, Medical University of South Carolina, Charleston, SC
- 3:05 PM**            **(160) The Evaluation of Coronary Artery Function during Normothermic Ex Situ Heart Perfusion;** X. Qi, S. Hatami, B. Tkachuk, M. Buchko, S. Bozso, D. He, S. Himmat, C. W. White, J. Nagendran, D. H. Freed. *Surgery, University of Alberta, Edmonton, AB, Canada*

THURSDAY, APRIL 4, 2019

1:45 PM - 3:30 PM

**SESSION 39 (ORAL): Walking a Tightrope: The Double-Edged Sword of Drugs after Heart Transplant**

Room: Pacifica 3-5

Target Audiences: HTX, ID, PHARM

Chairs: Darko Vucicevic, MD, and Monica Colvin, MD

- 1:45 PM** (161) *Late-Breaking Clinical Trial: 10-Year Follow-Up of the Everolimus versus Azathioprine Multi-National Study*; J. A. Kobashigawa<sup>1</sup>, R. Starling<sup>2</sup>, E. Passano<sup>1</sup>, P. Bernhardt<sup>3</sup>, B. Azarbal<sup>1</sup>, R. Cheng<sup>1</sup>, F. Esmailian<sup>1</sup>, K. Khush<sup>4</sup>, D. Mancini<sup>5</sup>, J. Patel<sup>1</sup>, T. Sato<sup>1</sup>, S. Varnous<sup>6</sup>. <sup>1</sup>Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA, <sup>2</sup>Cleveland Clinic, Cleveland, OH, <sup>3</sup>Novartis Pharmaceuticals, Basel, Switzerland, <sup>4</sup>Stanford University, Palo Alto, CA, <sup>5</sup>Mount Sinai, New York, NY, <sup>6</sup>APHP, Pitié-Salpêtrière, Sorbonne University, Paris, France
- 2:00 PM** (162) *Effect of Donor Simvastatin Treatment on Gene Expression Profiles in Human Cardiac Allografts during Ischemia-Reperfusion Injury*; R. Krebs<sup>1</sup>, M. Kankainen<sup>2</sup>, E. Holmström<sup>1</sup>, K. Dhaygude<sup>1</sup>, J. Lukac<sup>1</sup>, T. Ojala<sup>2</sup>, P. Mattila<sup>2</sup>, A. Nykänen<sup>1</sup>, K. Lemström<sup>1</sup>. <sup>1</sup>Transplantation Laboratory, University of Helsinki, Helsinki, Finland, <sup>2</sup>Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland
- 2:15 PM** (163) *Higher Intensity Statin Therapy Reduces Clinical Endpoints after Heart Transplantation Independent of Lipid Levels*; J. R. Golbus<sup>1</sup>, S. Adie<sup>1</sup>, S. Hanigan<sup>1</sup>, M. Dorsch<sup>1</sup>, B. Rooks<sup>2</sup>, K. D. Aaronson<sup>1</sup>, M. C. Konerman<sup>1</sup>. <sup>1</sup>Internal Medicine, University of Michigan, Ann Arbor, MI, <sup>2</sup>University of Michigan, Ann Arbor, MI
- 2:30 PM** (164) *Everolimus in the Prevention of Calcineurin-Inhibitor-Induced Left Ventricular Hypertrophy in Heart Transplantation (RAD-TAC Study)*; C. Anthony, M. Imran, S. Emmanuel, J. Iliff, E. Kotlyar, K. Muthiah, A. M. Keogh, C. S. Hayward, P. S. Macdonald, A. Jabbour. *Heart and Lung Transplant, St Vincent's Hospital Sydney, Sydney, Australia*
- 2:45 PM** (165) *Gut Microbial Diversity, Inflammation and Oxidative Stress is Associated with Tacrolimus Dosing Requirements Early after Heart Transplant*; D. L. Jennings<sup>1</sup>, B. Bohn Damasceno Ferreira<sup>2</sup>, A. Zuver<sup>2</sup>, O. Drew<sup>3</sup>, M. Gaine<sup>3</sup>, E. Royzman<sup>3</sup>, J. Hupf<sup>3</sup>, M. Farr<sup>3</sup>, F. Latif<sup>3</sup>, S. Restaino<sup>3</sup>, A. R. Garan<sup>3</sup>, H. Takayama<sup>4</sup>, K. Takeda<sup>4</sup>, Y. Naka<sup>4</sup>, P. C. Colombo<sup>3</sup>, R. Demmer<sup>5</sup>, M. Yuzeffpolskaya<sup>3</sup>. <sup>1</sup>Pharmacy, NewYork-Presbyterian Hospital, New York, NY, <sup>2</sup>Public Health, Columbia University, New York, NY, <sup>3</sup>Medical Cardiology, Columbia University, New York, NY, <sup>4</sup>Cardiothoracic Surgery, Columbia University, New York, NY, <sup>5</sup>Public Health, University of Minnesota, Minneapolis, MN
- 3:00 PM** (166) *Early Infection Risk Associated with Induction Immunosuppression after Cardiac Transplant in Patients with Left Ventricular Assist Devices*; J. Batra<sup>1</sup>, D. L. Jennings<sup>1</sup>, A. R. Garan<sup>1</sup>, L. K. Truby<sup>1</sup>, K. Takeda<sup>2</sup>, H. Takayama<sup>2</sup>, S. Restaino<sup>1</sup>, F. Latif<sup>1</sup>, J. Haythe<sup>1</sup>, M. Yuzeffpolskaya<sup>1</sup>, P. C. Colombo<sup>1</sup>, Y. Naka<sup>2</sup>, M. A. Farr<sup>1</sup>, V. K. Topkara<sup>1</sup>. <sup>1</sup>Medicine, Columbia University, New York, NY, <sup>2</sup>Surgery, Columbia University, New York, NY
- 3:15 PM** (167) *Specific Immune Tolerance Response Triggered by Extracorporeal Photopheresis after Heart Transplantation*; K. Klaeske<sup>1</sup>, M. Dieterlen<sup>1</sup>, J. Wittke<sup>1</sup>, M. Borger<sup>1</sup>, J. Garbade<sup>1</sup>, S. Lehmann<sup>1</sup>, H. Reichenspurner<sup>2</sup>, M. Barten<sup>2</sup>. <sup>1</sup>Clinic for Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany, <sup>2</sup>University Heart Center Hamburg, Hamburg, Germany

**THURSDAY, APRIL 4, 2019**  
**1:45 PM - 3:30 PM**

**SESSION 40 (SYMPOSIUM): Heart Failure in Adult Congenital Heart Disease: Unique Problems Need Unique Solutions**  
**Room: Pacifica 7**  
**Target Audiences: HF/HTX, MCS, PEDS**

**Chairs:** Maryjane Farr, MD, and Heather J. Ross, MD, MHSc, FRCPC

**Session Summary:** The aim of this symposium is to describe the pathophysiology and management of heart failure syndromes that are unique to ACHD patients.

- 1:45 PM**            *Too Sick to Live, Too Well to Die: When Do You Transplant a Failing ACHD Patient?*  
Daphne Hsu, MD, Children's Hospital Montefiore, Bronx, NY, USA
- 2:00 PM**            *Q&A*
- 2:05 PM**            *Is Two Really Better Than One? Heart-Liver Transplantation in ACHD*  
Clive J Lewis, MB BChir PhD FRCP, Papworth Hospital, Cambridge, United Kingdom
- 2:20 PM**            *Q&A*
- 2:25 PM**            *Under Pressure: Managing Pulmonary Hypertension in ACHD*  
Robert Weintraub, MD, Royal Children's Hospital, Parkville, Australia
- 2:40 PM**            *Q&A*
- 2:45 PM**            *I've Got Options: VADs in Patients with ACHD*  
David Morales, MD, Cincinnati Children's Hospital, Cincinnati, OH, USA
- 3:00 PM**            *Q&A*
- 3:05 PM**            *The Failing Sub-Pulmonic RV in Congenital Heart Disease: Forgotten, But Not Gone*  
Wendy M Book, MD, Emory University, Atlanta, GA, USA
- 3:20 PM**            *Q&A*

THURSDAY, APRIL 4, 2019  
1:45 PM - 3:30 PM

**SESSION 41 (ORAL): Perfecting the Graft: LVAD Pump Management, Outcomes and Medications**

**Room: Pacifica 6**

**Target Audience: MCS**

**Chairs:** Nader Moazami, MD, and Emma Birks, MD, PhD

- 1:45 PM** (168) *Impact of Hemodynamic Ramp Test-Guided HVAD RPM and Medication Adjustments on Exercise Tolerance and Quality of Life: The RAMP-IT-UP Multicenter Study*; N. Uriel<sup>1</sup>, D. Burkhoff<sup>2</sup>, J. Rich<sup>3</sup>, S. Drakos<sup>4</sup>, D. Banerjee<sup>5</sup>, J. Teuteberg<sup>5</sup>, G. Sayer<sup>1</sup>. <sup>1</sup>University of Chicago, Chicago, IL, <sup>2</sup>Columbia University, New York, NY, <sup>3</sup>Northwestern University, Chicago, IL, <sup>4</sup>University of Utah, Salt Lake City, UT, <sup>5</sup>Stanford University, Palo Alto, CA
- 2:00 PM** (169) *HeartMate 3 Surgical Implant Technique and Outcomes in the MOMENTUM 3 Trial*; C. Salerno<sup>1</sup>, Y. Naka<sup>2</sup>, S. C. Silvestry<sup>3</sup>, D. J. Goldstein<sup>4</sup>, J. C. Cleveland<sup>5</sup>, A. Bansal<sup>6</sup>, N. A. Mokadam<sup>7</sup>, J. N. Schroder<sup>8</sup>, V. Jeevanandam<sup>9</sup>, A. J. Tautoles<sup>10</sup>, J. Chuang<sup>11</sup>, J. W. Long<sup>12</sup>. <sup>1</sup>St. Vincent Heart Center, Indianapolis, IN, <sup>2</sup>Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York, NY, <sup>3</sup>Florida Hospital, Orlando, FL, <sup>4</sup>Montefiore Einstein Center for Heart and Vascular Care, New York, NY, <sup>5</sup>University of Colorado School of Medicine, Aurora, CO, <sup>6</sup>Ochsner Clinic Foundation, New Orleans, LA, <sup>7</sup>Ohio State University Medical Center, Columbus, OH, <sup>8</sup>Duke University Medical Center, Durham, NC, <sup>9</sup>University of Chicago School of Medicine and Medical Center, Chicago, IL, <sup>10</sup>Advocate Christ Medical Center, Oak Lawn, IL, <sup>11</sup>Abbott, Abbott Park, IL, <sup>12</sup>Integris Baptist Medical Center, Oklahoma City, OK
- 2:15 PM** (170) *Poor Left Ventricular Unloading is Associated with Increased Mortality after Continuous Flow Left Ventricular Assist Device Implantation*; V. Maharaj<sup>1</sup>, R. Cogswell<sup>1</sup>, J. Schultz<sup>1</sup>, R. John<sup>2</sup>, C. Martin<sup>1</sup>, T. Thenappan<sup>1</sup>, T. Alexy<sup>1</sup>. <sup>1</sup>Division of Cardiology, University of Minnesota Medical Center, Minneapolis, MN, <sup>2</sup>Division of Cardiothoracic Surgery, University of Minnesota Medical Center, Minneapolis, MN
- 2:30 PM** (171) *Effect of Anesthesia on Cardiac Hemodynamics in patients undergoing durable LVAD Implantation: The EACH LVAD Study*; T. C. Hanff<sup>1</sup>, P. A. Patel<sup>2</sup>, K. L. Kurcik<sup>1</sup>, S. Rao<sup>1</sup>, S. E. Kimmel<sup>3</sup>, M. E. Putt<sup>3</sup>, P. Atluri<sup>4</sup>, C. A. Bermudez<sup>4</sup>, M. A. Acker<sup>4</sup>, E. Y. Birati<sup>1</sup>, J. E. Rame<sup>1</sup>, J. W. Wald<sup>1</sup>. <sup>1</sup>Division of Cardiology, University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Department of Anesthesiology and Critical Care, University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, <sup>4</sup>Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA
- 2:45 PM** (172) *Evaluation of Anticoagulation Bridging Strategies in LVAD Patients*; A. D. Rabon<sup>1</sup>, D. J. Taber<sup>2</sup>, W. E. Uber<sup>1</sup>, B. A. Houston<sup>3</sup>, H. Meadows<sup>1</sup>. <sup>1</sup>Department of Pharmacy Services, Medical University of South Carolina, Charleston, SC, <sup>2</sup>Department of Surgery, Medical University of South Carolina, Charleston, SC, <sup>3</sup>Division of Cardiology, Medical University of South Carolina, Charleston, SC
- 3:00 PM** (173) *Concentrated Factor Administration and Subsequent Pump Thrombosis on HeartMate II LVAD Support*; H. Shah<sup>1</sup>, R. Cogswell<sup>1</sup>, J. Misialek<sup>2</sup>, J. Schultz<sup>1</sup>, A. Nitzkowski<sup>3</sup>, R. John<sup>4</sup>, C. Martin<sup>1</sup>, M. Pritzker<sup>1</sup>, A. Shaffer<sup>4</sup>. <sup>1</sup>Cardiology, University of Minnesota, Minneapolis, MN, <sup>2</sup>Epidemiology & Community Health, University of Minnesota, Minneapolis, MN, <sup>3</sup>Pharmacology, University of Minnesota, Minneapolis, MN, <sup>4</sup>Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN
- 3:15 PM** (174) *Regional Outcomes after Continuous-Flow Left Ventricular Assist Device: An IMACS Analysis*; K. K. Mirza<sup>1</sup>, R. Rongbing Xie<sup>2</sup>, J. K. Kirklin<sup>2</sup>, B. Meyns<sup>3</sup>, J. A. Cowger<sup>4</sup>, J. Pennington<sup>2</sup>, F. Gustafsson<sup>1</sup>, D. Goldstein<sup>5</sup>. <sup>1</sup>Department of Cardiology, Rigshospitalet, Copenhagen, Denmark, <sup>2</sup>Department of Surgery, University of Alabama, Birmingham, AL, <sup>3</sup>Katholieke Universiteit Leuven, Leuven, Belgium, <sup>4</sup>Henry Ford Hospital, Detroit, MI, <sup>5</sup>Department of Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY

THURSDAY, APRIL 4, 2019

1:45 PM - 3:30 PM

SESSION 42 (ORAL): Too Much or Two Little? Obesity and Frailty in MCS

Room: Grand Caribbean 1-7

Target Audiences: MCS, NNSAH

Chairs: Gene H Kim, MD, and Mary E Keebler, MD

- 1:45 PM** (175) *Complete Sternal-Sparing LVAD Implantation is a Safe and Effective Technique for Obese Patients*; K. Wood, B. C. Ayers, H. Vidula, J. Alexis, B. Barrus, S. Prasad, I. Gosev. *University of Rochester, Rochester, NY*
- 2:00 PM** (176) *Continuous-Flow Left Ventricular Assist Devices and Bariatric Surgery in Patients with Morbid Obesity and Heart Failure - A Systematic Review*; J. Challapalli<sup>1</sup>, D. Cross<sup>2</sup>, M. P. Weber<sup>2</sup>, J. Choi<sup>2</sup>, E. J. Maynes<sup>2</sup>, R. Aggarwal<sup>3</sup>, A. J. Boyle<sup>4</sup>, J. W. Entwistle<sup>2</sup>, H. T. Massey<sup>2</sup>, R. J. Morris<sup>2</sup>, V. Tchanchaleishvili<sup>2</sup>. <sup>1</sup>College of Medicine, Drexel University, Philadelphia, PA, <sup>2</sup>Division of Cardiac Surgery, Thomas Jefferson University, Philadelphia, PA, <sup>3</sup>Department of Surgery, Thomas Jefferson University, Philadelphia, PA, <sup>4</sup>Division of Cardiology, Thomas Jefferson University, Philadelphia, PA
- 2:15 PM** (177) *Impact of Diabetes Mellitus on Mortality and In-Hospital Outcomes after Left Ventricular Assist Device Implantation*; V. Blumer<sup>1</sup>, M. Ortiz<sup>2</sup>, G. Hernandez<sup>3</sup>, S. Chaparro<sup>1</sup>, A. Vest<sup>4</sup>. <sup>1</sup>University of Miami, Miami, FL, <sup>2</sup>University of Iowa, Iowa, IA, <sup>3</sup>Univ. of Miami, Miami, FL, <sup>4</sup>Tufts Medical Center, Boston, MA
- 2:30 PM** (178) *The Combination of Left Ventricular Assist Device and Laparoscopic Sleeve Gastrectomy May Promote Myocardial Recovery in Obese Advanced Chronic Heart Failure Patients*; G. Poglajen<sup>1</sup>, S. Kumar<sup>1</sup>, B. Akkanti<sup>1</sup>, R. Radovancevic<sup>1</sup>, S. Nathan<sup>1</sup>, M. Jumean<sup>1</sup>, M. H. Akay<sup>1</sup>, M. Patel<sup>1</sup>, B. Vrtovec<sup>2</sup>, B. Kar<sup>1</sup>, I. D. Gregoric<sup>1</sup>. <sup>1</sup>Department of Advanced Cardiopulmonary Therapies and Transplantation, The Univ. of Texas Health Science Center-Houston, Houston, TX, <sup>2</sup>Advanced Heart Failure and Transplantation Center, University Medical Center Ljubljana, Ljubljana, Slovenia
- 2:45 PM** (179) *Comprehensive Nutrition Assessment before Left Ventricular Assist Device Implantation in Chronically Ill Hospitalized Patients*; A. Melehy, D. Seres, H. Mullen, J. Sanchez, P. Kurlanksy, R. Garan, V. Topkara, M. Yuzefpolskaya, P. C. Colombo, H. Takayama, Y. Naka, K. Takeda. *Columbia University Medical Center, New York, NY*
- 3:00 PM** (180) *The Impact of Frailty on Survival in Patients Undergoing Advanced Therapies for Heart Failure*; M. Stein<sup>1</sup>, K. T. O'Brien<sup>1</sup>, F. Foroutan<sup>1</sup>, V. Rao<sup>1</sup>, H. J. Ross<sup>1</sup>, A. C. Alba<sup>2</sup>. <sup>1</sup>Toronto General Hospital, University Health Network, Toronto, ON, Canada, <sup>2</sup>Toronto General Hospital, University Health Network, Toronto, ON, Canada
- 3:15 PM** (181) *Frailty and Clinical Outcomes Following Left Ventricular Assist Device Implantation*; H. G. Uzun<sup>1</sup>, E. Demir<sup>2</sup>, E. Simsek<sup>2</sup>, T. Capanoglu<sup>3</sup>, H. Karapolat<sup>3</sup>, C. Engin<sup>4</sup>, T. Yagdi<sup>4</sup>, P. Ozturk<sup>4</sup>, M. Ozbaran<sup>4</sup>, S. Nalbantgil<sup>2</sup>. <sup>1</sup>Cardiology, Can State Hospital, Canakkale, Turkey, <sup>2</sup>Cardiology, Ege University, Izmir, Turkey, <sup>3</sup>Physical Medicine and Rehabilitation, Ege University, Izmir, Turkey, <sup>4</sup>Cardiovascular Surgery, Ege University, Izmir, Turkey

**THURSDAY, APRIL 4, 2019**

**1:45 PM - 3:30 PM**

**SESSION 43 (SYMPOSIUM): Changes in the World of Pulmonary Hypertension: Nice or Not Nice**

**Room: Pacifica 1-2**

**Target Audiences: PH, CTEPH, PATH**

**Chairs:** Colin Church, MD PhD, and Marc A. Simon, MD

**Session Summary:** This symposium, in collaboration with the Pulmonary Vascular Research Institute (PVRI), will focus on controversies and new proposed developments under review since the recent World Symposium on Pulmonary Hypertension, exploring the concept of changing the definition to mean pulmonary artery pressure of 20mmHg and the implications for future management of patients, risk stratification of patients with PAH and best approach, and which best clinical trial endpoint should be adopted.

- 1:45 PM**                    *Feeling the Pressure: New Hemodynamic Classification of Pulmonary Vascular Disease*  
Robert P. Frantz, MD, Mayo Clinic, Rochester, MN, USA
- 2:00 PM**                    *Q&A*
- 2:05 PM**                    *The Drugs Don't (or might not) Work Anymore! Implications for Treatments in PAH with the New Hemodynamic Definition*  
Mardi Gomberg-Maitland, MD, Inova Fairfax Hospital, Falls Church, VA, USA
- 2:20 PM**                    *Q&A*
- 2:25 PM**                    *Too Risky for PAH? Patient Stratification and Implications for Treatment*  
Paul Hassoun, MD, Johns Hopkins University, Baltimore, MD, USA
- 2:40 PM**                    *Q&A*
- 2:45 PM**                    *DEBATE: Quality Over Quantity? Future Trial Primary Endpoints Should Be QOL Focused (PRO)*  
Ioana R Preston, MD, Tufts Medical Center, Boston, MA, USA
- 3:00 PM**                    *DEBATE: Quality over Quantity? Future Trial Primary Endpoints Should be QOL Focused (CON)*  
Paul Corris, MB FRCP, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
- 3:15 PM**                    *Debate Rebuttal (PRO)*  
Ioana R Preston, MD, Tufts Medical Center, Boston, MA, USA
- 3:20 PM**                    *Debate Rebuttal (CON)*  
Paul Corris, MB FRCP, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

THURSDAY, APRIL 4, 2019

4:00 PM - 5:45 PM

**SESSION 44 (ORAL): Philip K. Caves Award Candidate Presentations**

**Room: Coral Sea**

**Target Audience: ALL**

**Chairs:** Hermann Reichenspurner, MD, PhD, and Christopher H Wigfield, MD, FRCS

- 4:00 PM** (182) *B Cells Drive Chronic Lung Allograft Rejection after Ischemia-Reperfusion Injury in Mouse Lung Transplantation*; T. Watanabe, T. Martinu, K. Boonstra, M. Horie, Z. Guan, B. Joe, K. Bei, A. Chruscinski, D. Hwang, M. Liu, S. Keshavjee, S. Juvet. *University Health Network, Toronto, ON, Canada*
- 4:15 PM** (183) *Microbiome Dependent Regulatory T Cell Generation Correlates with Acute and Chronic Lung Allograft Rejection in a Murine Model*; Y. Guo<sup>1</sup>, Q. Wang<sup>1</sup>, D. Li<sup>1</sup>, A. Manafi<sup>1</sup>, Z. Mei<sup>1</sup>, O. Onyema<sup>1</sup>, A. E. Gelman<sup>2</sup>, D. Kreisel<sup>2</sup>, A. S. Krupnick<sup>1</sup>. <sup>1</sup>*Surgery, University of Virginia, Charlottesville, VA*, <sup>2</sup>*Surgery, Washington University in St. Louis, St. Louis, MO*
- 4:30 PM** (184) *Right Ventricular Dysfunction Correlates with Decreased Endothelial Progenitor Cell Mobilisation and Impaired Angiogenesis in Patients with Dilated Cardiomyopathy*; S. Frljak<sup>1</sup>, M. Jaklic<sup>1</sup>, G. Zemljic<sup>1</sup>, A. Cerar<sup>1</sup>, G. Poglajen<sup>1</sup>, F. Haddad<sup>2</sup>, B. Vrtovec<sup>1</sup>. <sup>1</sup>*Advanced Heart Failure and Transplantation Center, UMC Ljubljana, Ljubljana, Slovenia*, <sup>2</sup>*Stanford Cardiovascular Institute, Stanford, CA*
- 4:45 PM** (185) *Host miRNA Profile of Invasive Aspergillosis in Lung Transplant Recipients*; W. Gohir<sup>1</sup>, W. Klement<sup>2</sup>, L. G. Singer<sup>3</sup>, S. M. Palmer<sup>4</sup>, S. Keshavjee<sup>3</sup>, S. Husain<sup>1</sup>. <sup>1</sup>*Multi Organ Transplant Unit, Division of Infectious Diseases, University Health Network, Toronto, ON, Canada*, <sup>2</sup>*Organ Donation and Transplantation, Canadian Blood Services, Ottawa, ON, Canada*, <sup>3</sup>*Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada*, <sup>4</sup>*Division of Pulmonary and Critical Care Medicine, Duke University, Durham, NC*
- 5:00 PM** (186) *Estimation of Pulmonary Capillary Wedge Pressure from the HVAD Waveform and Its Prognostic Implications*; T. Imamura, D. Nitta, D. Rodgers, J. Grinstein, S. Kalantari, B. Smith, J. Raikhelkar, G. Kim, A. Nguyen, N. Narang, B. Chung, I. Ebong, L. Holzhauser, T. Fujino, C. Juricek, P. Combs, T. Song, T. Ota, V. Jeevanandam, G. Sayer, N. Uriel. *University of Chicago, Chicago, IL*
- 5:15 PM** (187) *Hemodynamic Parameters That Predict Success with an Ambulatory Counterpulsation Heart Assist System in Advanced Congestive Heart Failure*; T. Symalla<sup>1</sup>, T. Song<sup>1</sup>, D. Onsager<sup>1</sup>, T. Ota<sup>1</sup>, C. LaBuhn<sup>1</sup>, P. Combs<sup>1</sup>, T. Lammy<sup>1</sup>, S. Patel-Raman<sup>2</sup>, G. Sayer<sup>3</sup>, G. Kim<sup>3</sup>, J. Raikhelkar<sup>3</sup>, N. Uriel<sup>3</sup>, V. Jeevanandam<sup>1</sup>. <sup>1</sup>*Cardiac Surgery, University of Chicago, Chicago, IL*, <sup>2</sup>*NuPulseCV, NuPulseCV, Chicago, IL*, <sup>3</sup>*Cardiology, University of Chicago, Chicago, IL*
- 5:30 PM** (188) *A Novel Tool to Quantify Immune Suppression after Pediatric Transplantation: Flow Cytometric Activation Assays*; R. E. Penner<sup>1</sup>, L. Ionescu<sup>1</sup>, S. Mital<sup>2</sup>, B. Foster<sup>3</sup>, P. Birk<sup>4</sup>, V. Phan<sup>5</sup>, T. Blydt-Hansen<sup>6</sup>, U. Allen<sup>2</sup>, L. Hamiwka<sup>7</sup>, C. Morgan<sup>1</sup>, S. Urschel<sup>1</sup>. <sup>1</sup>*University of Alberta, Edmonton, AB, Canada*, <sup>2</sup>*Hospital for Sick Children, Toronto, ON, Canada*, <sup>3</sup>*McGill University, Montreal, QC, Canada*, <sup>4</sup>*University of Manitoba, Winnipeg, MB, Canada*, <sup>5</sup>*CHU Sainte-Justine, Montreal, QC, Canada*, <sup>6</sup>*BC Children's Hospital, Vancouver, BC, Canada*, <sup>7</sup>*Alberta Children's Hospital, Calgary, AB, Canada*



THURSDAY, APRIL 4, 2019

4:00 PM - 5:45 PM

**SESSION 45 (ORAL): Acute Cardiac Rejection: New Approaches to an Old Problem**

Room: Pacifica 7

Target Audiences: HTX, BSTR, PATH

Chairs: David Schibilsky, MD, and Ravikumar Ratnagiri, MD

- 4:00 PM** (189) *Clinical and Pathological Insights of Myocardial Molecular Profiling: Time to Revise ISHLT Grading System?*; L. Potena<sup>1</sup>, V. Agostini<sup>1</sup>, L. Borgese<sup>1</sup>, E. Rinaldi<sup>1</sup>, L. Giovannini<sup>1</sup>, J. Reeve<sup>2</sup>, M. Parkes<sup>2</sup>, M. Masetti<sup>1</sup>, A. Russo<sup>1</sup>, O. Leone<sup>1</sup>, P. Halloran<sup>2</sup>. <sup>1</sup>Bologna University Hospital, Bologna, Italy, <sup>2</sup>University of Alberta, Edmonton, AB, Canada
- 4:15 PM** (190) *HLA Epitope Mismatching is Associated with Rejection and Worsened Graft Survival in Heart Transplant Recipients*; E. Osorio-Jaramillo<sup>1</sup>, G. W. Haasnoot<sup>2</sup>, A. Kaider<sup>3</sup>, A. Zuckermann<sup>1</sup>, A. Schaefer<sup>1</sup>, T. Haberl<sup>1</sup>, J. Goekler<sup>1</sup>, P. Angleitner<sup>1</sup>, R. Moayedifar<sup>1</sup>, G. F. Fischer<sup>4</sup>, G. Laufer<sup>1</sup>, F. H. Claas<sup>2</sup>, A. Z. Aliabadi-Zuckermann<sup>1</sup>. <sup>1</sup>Division of Cardiac Surgery, Medical University of Vienna, Vienna, Austria, <sup>2</sup>Department of Immunhematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands, <sup>3</sup>Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria, <sup>4</sup>Department for Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria
- 4:30 PM** (191) *Non-HLA Antibodies as a Cause for Biopsy Negative Rejection: Is It Worth Testing for Them?*; J. A. Kobashigawa<sup>1</sup>, J. Patel<sup>1</sup>, M. Kittleson<sup>1</sup>, E. Kransdorf<sup>1</sup>, S. Dimbil<sup>1</sup>, R. Levine<sup>1</sup>, G. Esmailian<sup>1</sup>, C. Kawata<sup>1</sup>, L. Czer<sup>1</sup>, M. Hamilton<sup>1</sup>, D. Ramzy<sup>1</sup>, X. Zhang<sup>2</sup>. <sup>1</sup>Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA, <sup>2</sup>Cedars-Sinai Medical Center, Los Angeles, CA
- 4:45 PM** (704) *Heart Transplant Patients with Histologic Normal and Molecular Microscope Abnormal Biopsies: An Exploratory Analysis*; K. Shah<sup>1</sup>, J. A. Kobashigawa<sup>1</sup>, J. Patel<sup>1</sup>, M. Kittleson<sup>1</sup>, D. H. Chang<sup>1</sup>, S. Dimbil<sup>1</sup>, R. Levine<sup>1</sup>, S. Sana<sup>1</sup>, L. Czer<sup>1</sup>, B. Azarbal<sup>1</sup>, F. Esmailian<sup>1</sup>, P. Halloran<sup>2</sup>. <sup>1</sup>Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, <sup>2</sup>University of Alberta, Alberta, AB, Canada
- 5:00 PM** (193) *Racial Differences in Risk of Acute Rejection after Cardiac Transplantation*; R. C. Patel<sup>1</sup>, L. B. Cooper<sup>2</sup>, R. T. Cole<sup>3</sup>, S. Sinha<sup>2</sup>, L. J. Bogar<sup>4</sup>, S. D. Barnett<sup>2</sup>, A. Cochrane<sup>2</sup>, M. Psocka<sup>2</sup>, P. Shah<sup>2</sup>. <sup>1</sup>Virginia Commonwealth University School of Medicine, Richmond, VA, <sup>2</sup>Department of Heart Failure and Transplant, Inova Heart and Vascular Institute, Falls Church, VA, <sup>3</sup>Department of Heart Failure and Transplant, Emory University, Atlanta, GA, <sup>4</sup>Department of Cardiac Surgery, Inova Heart and Vascular Institute, Falls Church, VA
- 5:15 PM** (194) *Crossing Low Level Donor-Specific Antibody at the Time of Heart Transplantation May Save Lives*; J. A. Kobashigawa<sup>1</sup>, M. Kittleson<sup>1</sup>, D. H. Chang<sup>1</sup>, E. Kransdorf<sup>1</sup>, S. Dimbil<sup>1</sup>, R. Levine<sup>1</sup>, C. Kawata<sup>1</sup>, M. Olymbios<sup>1</sup>, A. Velleca<sup>1</sup>, L. Czer<sup>1</sup>, X. Zhang<sup>2</sup>, D. Ramzy<sup>1</sup>, J. Patel<sup>1</sup>. <sup>1</sup>Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, <sup>2</sup>Cedars-Sinai Medical Center, Los Angeles, CA
- 5:30 PM** (195) *Identification of Risk Factors for Biopsy-Proven Rejection during the First Year Post Heart Transplantation*; G. Coutance<sup>1</sup>, G. Bonnet<sup>2</sup>, J. Van Keer<sup>3</sup>, M. Racapé<sup>3</sup>, P. Bruneval<sup>2</sup>, J. Duong Van Huyen<sup>3</sup>, J. Taupin<sup>4</sup>, S. Varnous<sup>5</sup>, L. Lecuyer<sup>6</sup>, P. Rouvier<sup>5</sup>, X. Jouven<sup>2</sup>, A. Loupy<sup>3</sup>. <sup>1</sup>Paris Transplant Group, Pitié-Salpêtrière Hospital, Paris, France, <sup>2</sup>Paris Transplant Group, Hôpital Européen Georges Pompidou, Paris, France, <sup>3</sup>Paris Transplant Group, Paris, France, <sup>4</sup>Saint Louis Hospital, Paris, France, <sup>5</sup>Groupe Hospitalier Pitié-Salpêtrière, Paris, France, <sup>6</sup>Hôpital Européen Georges Pompidou, Paris, France

**THURSDAY, APRIL 4, 2019**

**4:00 PM - 5:45 PM**

**SESSION 46 (SYMPOSIUM): FUN and Games with FUNgal Infections in Lung Transplantation**

**Room: Pacifica 3-5**

**Target Audiences: ID, LF/LTX, PATH, PHARM**

**Chairs:** Orla Morrissey, MD, and Gregory A Fishbein, MD

**Session Summary:** Fungal infections after thoracic transplantation are associated with high mortality. Prophylaxis and treatment come with various complications including drug-drug interactions, toxicities, treatment failure and emerging resistance. This symposium will provide insights regarding the epidemiology, prevention, diagnosis and treatment approaches to take when faced with the challenges of fungal infections in thoracic transplantation. A 15-min panel discussion with all speakers will conclude this session.

**4:00 PM**

***Defining Fungal Infection: Not a TRIVIAL PURSUIT***

Erika D Lease, MD, University of Washington, Seattle, WA, USA

**4:15 PM**

***DEBATE: Every Patient Should Receive Antifungal Prophylaxis After Lung Transplantation (PRO)***

John W Baddley, MD, MSPH, University of Alabama at Birmingham, Birmingham, AL, USA

**4:30 PM**

***DEBATE: Every Patient Should Receive Antifungal Prophylaxis After Lung Transplantation (CON)***

Shahid Husain, MD, MS, University Health Network, Toronto, ON, Canada

**4:45 PM**

***Don't Be SORRY! Tips and Tricks for Managing Azole Antifungal Agents***

Tara Veasey, PharmD, BCPS, Allegheny General Hospital, Pittsburgh, PA, USA

**5:00 PM**

***Not a MONOPOLY: Antifungal Drug Administration Via the Inhaled Route***

Antonio B Roman, MD, PhD, Hospital General Vall D'Hebron, Barcelona, Spain

**5:15 PM**

***Are We in TROUBLE? Emergence of Azole-Resistant Molds***

Minh-Hong Nguyen, MD, University of Pittsburgh, Pittsburgh, PA, USA

**5:30 PM**

***15 minute Panel Discussion***

THURSDAY, APRIL 4, 2019

4:00 PM - 5:45 PM

SESSION 47 (ORAL): Back to the Basics: Physiological Alterations During Continuous Flow VAD Support

Room: Pacifica 6

Target Audiences: MCS, BSTR, PATH

Chairs: Ahmet Kilic, MD, and Carlo Banfi, MD, PhD, FCCP

- 4:00 PM** (196) *Evaluation of the Effect of Artificial Pulsatility in Continuous Flow Assist Device on Peripheral Vascular Reactivity*; P. Ivak<sup>1</sup>, J. Pi<sup>1</sup>, P. Wohlfahrt<sup>2</sup>, I. Kralova-Lesna<sup>2</sup>, V. Lanska<sup>3</sup>, Z. Tucanova<sup>1</sup>, M. Konarik<sup>1</sup>, I. Netuka<sup>1</sup>. <sup>1</sup>Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, <sup>2</sup>Laboratory for Atherosclerosis Research, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, <sup>3</sup>Department of Data Analysis and Statistics, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 4:15 PM** (197) *Long-Term Changes in Kidney Function after Left Ventricular Assist Device Implant: An Analysis of the STS Intermacs Database*; D. D. Franz<sup>1</sup>, M. R. Stedman<sup>1</sup>, S. L. Myers<sup>2</sup>, D. C. Naftel<sup>2</sup>, S. A. Silver<sup>3</sup>, D. Banerjee<sup>1</sup>, T. I. Chang<sup>1</sup>. <sup>1</sup>Medicine, Stanford University, Palo Alto, CA, <sup>2</sup>University of Alabama at Birmingham, Birmingham, AL, <sup>3</sup>Kingston General Hospital, Kingston, ON, Canada
- 4:30 PM** (198) *Functional Assessment of Decellularized Extracellular Matrix in Patients Undergoing LVAD Implantation*; D. Yu<sup>1</sup>, M. Vaicik<sup>2</sup>, A. Nguyen<sup>1</sup>, D. Rodgers<sup>1</sup>, N. Narang<sup>1</sup>, H. Holzhauser<sup>1</sup>, I. Ebong<sup>1</sup>, A. Kanelidis<sup>1</sup>, G. Sayer<sup>1</sup>, J. Raikhelkar<sup>1</sup>, N. Sarswat<sup>1</sup>, B. Smith<sup>1</sup>, S. Kalantari<sup>1</sup>, B. Chung<sup>1</sup>, J. Georgiadis<sup>2</sup>, N. Uriel<sup>1</sup>, G. H. Kim<sup>1</sup>. <sup>1</sup>Department of Medicine, Section of Cardiology, University of Chicago, Chicago, IL, <sup>2</sup>College of Engineering, Illinois Institute of Technology, Chicago, IL
- 4:45 PM** (199) *Platelet Transcriptomics Following Mechanical Unloading*; A. Koliopoulou, C. Frey, E. Montenont, J. W. Rowley, S. H. McKellar, S. G. Drakos, M. T. Rondina, C. H. Selzman. University of Utah, Salt Lake City, UT
- 5:00 PM** (200) *A Comparison of Middle Cerebral Artery and Central Retinal Artery Hemodynamics in HM II Patients*; E. J. Stöhr<sup>1</sup>, R. Ji<sup>2</sup>, K. Akiyama<sup>3</sup>, F. Castagna<sup>2</sup>, A. Pinsino<sup>2</sup>, J. R. Cockcroft<sup>1</sup>, M. Yuzefpolskaya<sup>2</sup>, A. R. Garan<sup>2</sup>, V. K. Topkara<sup>2</sup>, R. T. Te-Frey<sup>3</sup>, H. Takayama<sup>3</sup>, K. Takeda<sup>3</sup>, Y. Naka<sup>3</sup>, P. C. Colombo<sup>2</sup>, J. Z. Willey<sup>4</sup>, B. J. McDonnell<sup>1</sup>. <sup>1</sup>Physiology & Health, Cardiff Metropolitan University, Cardiff, United Kingdom, <sup>2</sup>Medicine, Columbia University Medical Center, New York, NY, <sup>3</sup>Cardiothoracic Surgery, Columbia University Medical Center, New York, NY, <sup>4</sup>Neurology Stroke, Columbia University Medical Center, New York, NY
- 5:15 PM** (201) *Risk of dnDSA with Various MCS Devices as Bridge-to-Transplant*; R. T. Cole<sup>1</sup>, M. Flattery<sup>2</sup>, J. Minto<sup>3</sup>, A. Parikh<sup>4</sup>, T. Dong<sup>1</sup>, R. Roy<sup>1</sup>, L. Bogar<sup>5</sup>, A. Smith<sup>1</sup>, J. Vega<sup>1</sup>, A. Morris<sup>1</sup>, S. Laskar<sup>6</sup>, K. Bhatt<sup>1</sup>, D. Gupta<sup>1</sup>, A. Lala<sup>7</sup>, K. Shah<sup>8</sup>, P. Shah<sup>9</sup>. <sup>1</sup>Cardiology, Emory Univ Sch of Med, Atlanta, GA, <sup>2</sup>Cardiology, Virginia Commonwealth University, Richmond, VA, <sup>3</sup>George Washington University School of Medicine, Washington, D.C., DC, <sup>4</sup>Cardiology, Mount Sinai Hospital, New York, NY, <sup>5</sup>Department of Cardiac Surgery, Inova Heart and Vascular Institute, Falls Church, VA, <sup>6</sup>Cardiology, Emory University School of Medicine, Atlanta, GA, <sup>7</sup>Mount Sinai Hospital, New York, NY, <sup>8</sup>Virginia Commonwealth University, Richmond, VA, <sup>9</sup>Inova Heart and Vascular Institute, Falls Church, VA
- 5:30 PM** (202) *Associations among Biomarkers of Congestion, Inflammation and Oxidative Stress in Heart Failure, LVAD and Heart Transplant*; E. A. Royzman<sup>1</sup>, G. M. Mondellini<sup>1</sup>, A. M. Zuver<sup>1</sup>, C. A. Bravo<sup>2</sup>, D. L. Brunjes<sup>1</sup>, D. Onat<sup>1</sup>, M. Mabasa<sup>1</sup>, J. C. Hupf<sup>1</sup>, A. R. Garan<sup>1</sup>, H. Takayama<sup>3</sup>, K. Takeda<sup>3</sup>, Y. Naka<sup>3</sup>, R. T. Demmer<sup>4</sup>, P. C. Colombo<sup>1</sup>, M. Yuzefpolskaya<sup>1</sup>. <sup>1</sup>Department of Medicine, Columbia University Medical Center, New York, NY, <sup>2</sup>Department of Medicine, Montefiore Medical Center, Bronx, NY, <sup>3</sup>Department of Surgery, Columbia University Medical Center, New York, NY, <sup>4</sup>Epidemiology and Community Health, University of Minnesota, Minneapolis, MN

**THURSDAY, APRIL 4, 2019**

**4:00 PM - 5:45 PM**

**SESSION 48 (SYMPOSIUM): Advances in Short- and Long-Term Mechanical Circulatory Support - What's Next**

**Room: Grand Caribbean 1-7**

**Target Audience: MCS**

**Chairs:** Ulrich Jorde, MD, and Simon Maltais, MD PhD

**Session Summary:** Following a brief update on the state of the art of short and long term MCS, this symposium will focus on innovation and improvement opportunities. Specifically, issues of device size, deployment / implantation, hemodynamic properties and hemocompatibility will be reviewed. Presenters will discuss current capabilities as well as ongoing research and development efforts with 2- and 5-year targets. This symposium is not CME accredited.

- 4:00 PM**                    ***STATE OF THE ART Durable MCS and Unmet Needs***  
Joseph G Rogers, MD, Duke University Medical Center, Durham, NC, USA
- 4:05 PM**                    ***The Future of Durable MCS - Medtronic Perspective***  
Eric Corndorf, PhD, Medtronic, Framingham, MA, USA
- 4:20 PM**                    ***The Future of Durable MCS - Abbott Perspective***  
Kevin Bourque, DVP, Abbott, Burlington, MA, USA
- 4:35 PM**                    ***STATE OF THE ART and Unmet Needs Total Heart Replacement (THR)***  
Julia Riebandt, MD, Medical University of Vienna, Vienna, Austria
- 4:40 PM**                    ***The Future of THR - Syncardia Perspective***  
Steven R. Langford, BSEE, SynCardia Systems, Tucson, AZ, USA
- 4:55 PM**                    ***The Future of THR - CarMat Perspective***  
Piet G. Jansen, MD, PhD, Carmat SA, Velizy-Villacoublay Cedex, France
- 5:10 PM**                    ***STATE OF THE ART Acute MCS and Unmet Needs***  
Shelley Hall, MD, Baylor University Medical Center, Dallas, TX, USA
- 5:15 PM**                    ***The Future of Acute MCS - Abiomed Perspective***  
Daniel H. Raess, MD, FACC, FACS, Abiomed, Danvers, MA, USA
- 5:30 PM**                    ***15-min Panel Discussion***

THURSDAY, APRIL 4, 2019

4:00 PM - 5:45 PM

SESSION 49 (ORAL): The Personal Connection: Psychological Issues and Care for Donor Families, Patients and Providers

Room: Pacifica 10-12

Target Audiences: NHSAH, HTX, LTX, PEDS, PHARM

Chairs: Flavio R Epstein, PhD, and Melissa Sanchez, BScHons, PGDip, MSc, DClinPSy

- 4:00 PM** (203) *Intravenous Methamphetamine Does Not Appear to Be a Contraindication for Heart Donation in Heart Transplantation*; A. Velleca, T. Kao, B. Kearney, J. Patel, M. Kittleson, R. Levine, S. Dimbil, S. Mersola, M. Hamilton, F. Esmailian, J. Kobashigawa. *Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA*
- 4:15 PM** (204) *Donor Family and Recipient Anonymity: Time for Change*; J. Poole<sup>1</sup>, M. Shildrick<sup>2</sup>, S. Abbey<sup>3</sup>, I. Bachmann<sup>4</sup>, A. Carnie<sup>5</sup>, D. Dal Bo<sup>4</sup>, E. De Luca<sup>6</sup>, T. El-Sheikh<sup>7</sup>, E. Jan<sup>4</sup>, P. McKeever<sup>8</sup>, A. Wright<sup>9</sup>, H. Ross<sup>6</sup>. <sup>1</sup>*Faculty of Community Services, School of Social Work, Ryerson University, Toronto, ON, Canada*, <sup>2</sup>*Tema Genus, Tema Institute, Linkopings Universitet, Linkopings, Sweden*, <sup>3</sup>*Department of Psychiatry, University Health Network, Toronto, ON, Canada*, <sup>4</sup>*Department of Studio Arts, Faculty of Fine Arts, Concordia University, Montreal, QC, Canada*, <sup>5</sup>*Winchester School of Art, Southampton University, Winchester, United Kingdom*, <sup>6</sup>*Department of Cardiology, University Health Network, Toronto, ON, Canada*, <sup>7</sup>*Department of Art History, Faculty of Fine Arts, Concordia University, Montreal, QC, Canada*, <sup>8</sup>*Bloorview Research Institute, Holland Bloorview Kids Rehabilitation Hospital, Toronto, ON, Canada*, <sup>9</sup>*Department of English, Linguistics and Cultural Studies, University of Westminster, London, United Kingdom*
- 4:30 PM** (205) *Universal Depression Screen of Ambulatory Cardiac Transplant Recipients is Feasible and Identifies a Subset of Patients That May Benefit from Mental Health Intervention*; L. Peters, L. Rosenthal, H. Monroe, M. Dierks, A. Ambardekar, C. McIlvennan. *University of Colorado, Aurora, CO*
- 4:45 PM** (206) *Depressive Symptoms, Physical Activity, and Post-Transplant Outcomes: The ADAPT Prospective Study*; P. J. Smith, C. Frankel, D. Bacon, E. Bush, L. Snyder. *Duke University Medical Center, Durham, NC*
- 5:00 PM** (207) *PTSD in Tx ICU Nurses*; M. Sanchez<sup>1</sup>, A. Simon<sup>2</sup>, D. Ford<sup>1</sup>. <sup>1</sup>*Psychological Medicine, Royal Brompton & Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom*, <sup>2</sup>*MCS and Cardiothoracic Transplantation, Royal Brompton & Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom*
- 5:15 PM** (208) *Illness Specific Anxiety Following Pediatric Heart Transplant*; A. D. McCormick, K. R. Schumacher, M. Zamberlan, K. Uzark, S. Yu, R. Lowery, N. Rottach, M. K. Cousino. *Department of Pediatrics, Michigan Medicine, Ann Arbor, MI*
- 5:30 PM** (209) *The Value of Licensed Clinical Social Worker Pre-Implant Assessment in Predicting Non-Compliance in Durable Mechanical Circulatory Support Device Patients*; H. Barone<sup>1</sup>, M. Olman<sup>2</sup>, A. Fishman<sup>2</sup>, L. Olanisa<sup>2</sup>, C. Runyan<sup>1</sup>, J. Hajj<sup>1</sup>, N. Huie<sup>1</sup>, M. Lindsay<sup>1</sup>, E. Passano<sup>1</sup>, J. Kobashigawa<sup>1</sup>, J. Moriguchi<sup>1</sup>, R. Cole<sup>1</sup>, F. Esmailian<sup>1</sup>, J. Chung<sup>1</sup>, D. Ramzy<sup>1</sup>. <sup>1</sup>*Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA*, <sup>2</sup>*Cedars-Sinai Medical Center, Los Angeles, CA*

THURSDAY, APRIL 4, 2019

4:00 PM - 5:45 PM

SESSION 50 (ORAL): Pulmonary Hypertension in Translation: From Novel Biomarkers to Cutting Edge Clinical Results

Room: Pacifica 1-2

Target Audiences: PH, PHARM

Chairs: C. Dario Vizza, MD, and Amresh Raina, MD

- 4:00 PM** (210) *Treatment with Oral Treprostinil Delays Time to Clinical Worsening in Patients with Pulmonary Arterial Hypertension - Results from FREEDOM-EV*; V. F. Tapson<sup>1</sup>, C. J. Sanchez Diaz<sup>2</sup>, G. M. Bohns Meyer<sup>3</sup>, T. Pulido<sup>4</sup>, P. Sepulveda<sup>5</sup>, K. Y. Wang<sup>6</sup>, C. Q. Deng<sup>7</sup>, R. Grover<sup>7</sup>, D. Solum<sup>7</sup>, A. Ousmanou<sup>7</sup>, R. J. White<sup>8</sup>. <sup>1</sup>Cedars Sinai, Los Angeles, CA, <sup>2</sup>Unidad De Inv Clinica En Medicina, Monterrey, Mexico, <sup>3</sup>Complexo Hospitalar Santa Casa de Porto Alegre, Porto Alegre, Brazil, <sup>4</sup>Instituto Nacional de Cardiologia Ignacio Chávez, Mexico City, Mexico, <sup>5</sup>Hospital San Juan De Dios, University of Chile, Santiago, Chile, <sup>6</sup>Taichung Veterans General Hospital, Taichung, Taiwan, <sup>7</sup>United Therapeutics, Research Triangle Park, NC, <sup>8</sup>University of Rochester Medical Center, Rochester, NY
- 4:15 PM** (211) *Risk Assessment in Functional Class (FC) II Pulmonary Arterial Hypertension (PAH) Patients: Comparison of Physician Gestalt with ESC/ERS-Guidelines and REVEAL 2.0*; S. Sahay<sup>1</sup>, A. Tonelli<sup>2</sup>, T. Kung<sup>3</sup>, Z. Watson<sup>4</sup>, R. L. Benza<sup>5</sup>. <sup>1</sup>Houston Methodist Hospital, Houston, TX, <sup>2</sup>Cleveland Clinic, Cleveland, OH, <sup>3</sup>Actelion Pharmaceuticals US, Inc., South San Francisco, CA, <sup>4</sup>Putnam Associates, Boston, MA, <sup>5</sup>Allegheny General Hospital, Pittsburgh, PA
- 4:30 PM** (212) *Clinical Surrogates of Right Ventricular-Pulmonary Arterial Uncoupling*; C. G. Ireland<sup>1</sup>, R. L. Damico<sup>1</sup>, T. M. Kolb<sup>1</sup>, S. Mathai<sup>1</sup>, S. Zimmerman<sup>1</sup>, A. A. Shah<sup>1</sup>, M. Mukherjee<sup>1</sup>, F. Wigley<sup>1</sup>, P. M. Hassoun<sup>1</sup>, D. A. Kass<sup>1</sup>, R. J. Tedford<sup>2</sup>, S. Hsu<sup>1</sup>. <sup>1</sup>The Johns Hopkins Hospital, Baltimore, MD, <sup>2</sup>Medical University of South Carolina, Charleston, SC
- 4:45 PM** (213) *Relationship between Race/Ethnicity and Survival in Patients with Pulmonary Arterial Hypertension (PAH)*; S. Medrek<sup>1</sup>, S. Sahay<sup>2</sup>, T. Kung<sup>3</sup>, C. Zhao<sup>3</sup>, A. E. Frost<sup>2</sup>. <sup>1</sup>Division of Pulmonary and Critical Care Medicine, University of New Mexico, Albuquerque, NM, <sup>2</sup>Houston Methodist Hospital, Houston, TX, <sup>3</sup>Actelion, South San Francisco, CA
- 5:00 PM** (214) *Suppressor of Tumorigenicity 2 as a Biomarker in Pulmonary Arterial Hypertension and its Association with REVEAL Risk Score in Riociguat-Treated Patients in the RESPITE Study*; R. L. Benza<sup>1</sup>, J. R. Klinger<sup>2</sup>, H. A. Ghofrani<sup>3</sup>, P. Jansa<sup>4</sup>, E. Grünig<sup>5</sup>, D. Vizza<sup>6</sup>, M. M. Hoepfer<sup>7</sup>. <sup>1</sup>The Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA, <sup>2</sup>Division of Pulmonary, Sleep, and Critical Care Medicine, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI, <sup>3</sup>University of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen, Germany, <sup>4</sup>Clinical Department of Cardiology and Angiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, <sup>5</sup>Centre for Pulmonary Hypertension, Thorax Clinic at the University Hospital, Heidelberg, Germany, <sup>6</sup>Pulmonary Hypertension Unit, Department of Cardiovascular and Respiratory Disease, La Sapienza University of Rome, Rome, Italy, <sup>7</sup>Clinic for Respiratory Medicine, Hannover Medical School, Member of the German Center for Lung Research (DZL), Hannover, Germany
- 5:15 PM** (215) *Long-Term Outcomes in Pulmonary Arterial Hypertension by Functional Class: A Meta-Analysis of Randomized Controlled Trials and Observational Registries*; N. H. Kim<sup>1</sup>, M. Fisher<sup>2</sup>, D. S. Poch<sup>1</sup>, C. Zhao<sup>3</sup>, M. Shah<sup>3</sup>, S. Bartolome<sup>4</sup>. <sup>1</sup>University of California, San Diego, La Jolla, CA, <sup>2</sup>Emory School of Medicine, Atlanta, GA, <sup>3</sup>Actelion, South San Francisco, CA, <sup>4</sup>University of Texas, Southwestern Medical Center, Dallas, TX
- 5:30 PM** (216) *Beta Receptor Blockade Fails to Recover Ventricular Function Despite Increased Pre-Synaptic Sympathetic Nervous System Function in Experimental Pulmonary Arterial Hypertension*; J. Zelt, A. Ahmadi, J. Renaud, R. deKemp, R. Beanlands, L. Mielniczuk. University of Ottawa Heart Institute, Ottawa, ON, Canada

THURSDAY, APRIL 4, 2019

6:00 PM - 7:00 PM

**MINI ORAL 07A & 07b: Basic Science and Translational Research / Heart Transplantation (Adult)**

Room: Coral Sea

Target Audiences: BSTR, HTX, PATH, PEDS

Chairs: Alexander M Bernhardt, MD, and Karl B Lemstrom, MD, PhD

- 6:00 PM** (429) *Functional Assessment of DCD Hearts Following Normothermic Regional Perfusion Can Predict Post-Transplantation Contractility*; R. Ribeiro, J. S. Alvarez, E. Paradiso, F. Yu, M. B. Adamson, F. Foroutan, V. Bissoondath, M. Meineri, V. Rao, M. V. Badiwala. *Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada*
- 6:05 PM** (430) *Hi1a, an ASIC1a Inhibitor, Significantly Improves the Tolerance of Donor Allografts to Ischaemia in a Rodent Model of DCD Heart Transplantation*; S. E. Scheuer<sup>1</sup>, L. Gao<sup>2</sup>, M. Hicks<sup>1</sup>, H. Chew<sup>1</sup>, A. Doyle<sup>2</sup>, J. Villanueva<sup>2</sup>, A. Jabbour<sup>1</sup>, G. King<sup>3</sup>, P. Macdonald<sup>1</sup>, K. Dhital<sup>1</sup>. <sup>1</sup>*St Vincent's Hospital, Darlinghurst, Australia*, <sup>2</sup>*Victor Chang Cardiac Research Institute, Darlinghurst, Australia*, <sup>3</sup>*Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia*
- 6:10 PM** (431) *In Vivo Resuscitation, Perfusion and Transplantation of a Porcine Cardiac Allograft Donated after Cardiac Death*; A. Grant<sup>1</sup>, R. R. Gonzalez<sup>2</sup>, A. Klima<sup>1</sup>, A. Badiye<sup>3</sup>, A. Gardiner<sup>4</sup>, M. Thomas<sup>5</sup>, I. Hernandez Schulman<sup>6</sup>, J. Hare<sup>7</sup>, A. Ghodsizad<sup>2</sup>, M. Loebe<sup>2</sup>. <sup>1</sup>*Miami Transplant Institute University of Miami, Miami, FL*, <sup>2</sup>*Surgery, Miami Transplant Institute University of Miami, Miami, FL*, <sup>3</sup>*Cardiology, Miami Transplant Institute University of Miami, Miami, FL*, <sup>4</sup>*Veterinary Resources, University of Miami, Miami, FL*, <sup>5</sup>*Department Veterinary Resources, University of Miami, Miami, FL*, <sup>6</sup>*Interdisciplinary Stem Cell Institute, Department of Medicine, Division of Nephrology, Katz Family Division of Nephrology and Hypertension, University of Miami Leonard M Miller School of Medicine, Miami, FL*, <sup>7</sup>*Interdisciplinary Stem Cell Institute, Cardiovascular Division, University of Miami Leonard M Miller School of Medicine, Miami, FL*
- 6:15 PM** (432) *Conditioned Medium from Mesenchymal Stem Cells Protects Vascular Grafts of Brain-Dead Rats against In Vitro Ischemia/Reperfusion Injury*; S. Korkmaz-Icöz<sup>1</sup>, P. Zhou<sup>1</sup>, Y. Guo<sup>1</sup>, S. Loganathan<sup>1</sup>, P. Brlecic<sup>1</sup>, T. Radovits<sup>2</sup>, M. Ruppert<sup>1</sup>, A. A. Sayour<sup>1</sup>, M. Karck<sup>1</sup>, G. Szabó<sup>1</sup>. <sup>1</sup>*Cardiac Surgery, Heidelberg University Hospital, Heidelberg, Germany*, <sup>2</sup>*Heart and Vascular Center, Semmelweis University, Budapest, Hungary*
- 6:20 PM** (433) *Gene Expression in Ex Vivo Perfused Porcine Hearts: Identification of a Molecular Injury-Repair Response*; S. Rotich<sup>1</sup>, N. Herbers<sup>1</sup>, S. Hatami<sup>2</sup>, M. Mengel<sup>1</sup>, J. Nagendran<sup>2</sup>, D. H. Freed<sup>2</sup>, B. Adam<sup>1</sup>. <sup>1</sup>*Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada*, <sup>2</sup>*Department of Surgery, University of Alberta, Edmonton, AB, Canada*
- 6:25 PM** (434) *Ghrelin, a Novel Growth Hormone-Releasing Peptide, Inhibits Inflammatory Response and Apoptosis during Ischemic Reperfusion Injury Following Murine Heart Transplantation*; N. Fukunaga<sup>1</sup>, R. V. Ribeiro<sup>1</sup>, V. Bissoondath<sup>1</sup>, F. Billia<sup>2</sup>, M. V. Badiwala<sup>1</sup>, V. Rao<sup>1</sup>. <sup>1</sup>*Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada*, <sup>2</sup>*Cardiology, Toronto General Hospital, Toronto, ON, Canada*
- 6:30 PM** (435) *Survival Outcomes in Heart Transplant Patients; Specific Focus on ACHD Patients and Their Outcomes as Compared to Dilated and Ischemic Cardiomyopathy Patients*; A. Kinsella<sup>1</sup>, V. Rao<sup>1</sup>, C. Fan<sup>2</sup>, C. Manlhiot<sup>2</sup>, J. Stehlik<sup>2</sup>, H. Ross<sup>2</sup>, A. C. Alba<sup>2</sup>. <sup>1</sup>*Cardiac Surgery, Toronto General Hospital, Toronto, ON, Canada*, <sup>2</sup>*Peter Munk Cardiac Centre, Toronto General Hospital, Toronto, ON, Canada*
- 6:35 PM** (436) *Candidate Selection and the Survival Benefit of Heart Transplantation in the United States*; W. F. Parker<sup>1</sup>, E. S. Huang<sup>1</sup>, R. D. Gibbons<sup>2</sup>, A. S. Anderson<sup>3</sup>, M. M. Churpek<sup>1</sup>. <sup>1</sup>*University of Chicago Medicine, Chicago, IL*, <sup>2</sup>*Public Health Sciences, University of Chicago Medicine, Chicago, IL*, <sup>3</sup>*Northwestern Medicine, Chicago, IL*
- 6:40 PM** (437) *Does Pre-Existing Donor Heart Coronary Artery Disease Impact Survival after Orthotopic Heart Transplantation?*; J. Jahanyar<sup>1</sup>, J. M. Liao<sup>2</sup>, N. Zhang<sup>3</sup>, R. J. Butterfield III<sup>4</sup>, B. W. Hardaway<sup>5</sup>, R. L. Scott<sup>5</sup>, E. D. Steidley<sup>5</sup>. <sup>1</sup>*Cardiothoracic Surgery, Mayo Clinic, Phoenix, AZ*, <sup>2</sup>*Medicine, University of Washington, Seattle, WA*, <sup>3</sup>*Health Sciences Research, Mayo Clinic, Phoenix, AZ*, <sup>4</sup>*Biostatistics, Mayo Clinic, Phoenix, AZ*, <sup>5</sup>*Cardiology, Mayo Clinic, Phoenix, AZ*

6:45 PM

**(438) Long-Term Survival after Heart Transplantation: Interaction between Donor and Recipient Age;** A. Lechiancole, S. Sponga, V. Ferrara, C. Nalli, C. Di Nora, G. Guzzi, D. Piani, M. Meneguzzi, G. Benedetti, V. Tursi, U. Livi. *Cardio-Thoracic Surgery of Udine, ASUIUD, Udine, Italy*

6:50 PM

**(982) Heart Transplantation with ECMO Bridging: Survival Differences in the Era of the New Heart Allocation Policy;** J. Jahanyar<sup>1</sup>, J. M. Liao<sup>2</sup>, N. Zhang<sup>3</sup>, R. J. Butterfield III<sup>4</sup>, B. W. Hardaway<sup>5</sup>, R. L. Scott<sup>5</sup>, E. D. Steidley<sup>5</sup>. <sup>1</sup>*Cardiothoracic Surgery, Mayo Clinic, Phoenix, AZ*, <sup>2</sup>*Medicine, University of Washington, Seattle, WA*, <sup>3</sup>*Health Sciences Research, Mayo Clinic, Phoenix, AZ*, <sup>4</sup>*Biostatistics, Mayo Clinic, Phoenix, AZ*, <sup>5</sup>*Cardiology, Mayo Clinic, Phoenix, AZ*

6:55 PM

**(440) Survival after Primary Graft Dysfunction in Heart Transplantation: Outcomes of the National UK Data;** S. Avtaar Singh<sup>1</sup>, S. Das De<sup>1</sup>, S. Rushton<sup>2</sup>, N. Banner<sup>3</sup>, C. Berry<sup>4</sup>, N. Al-Attar<sup>1</sup>. <sup>1</sup>*Cardiothoracic Surgery, Golden Jubilee National Hospital, Glasgow, United Kingdom*, <sup>2</sup>*Statistics, National Health Service Blood and Transplant, Bristol, United Kingdom*, <sup>3</sup>*Advanced Heart Failure and Transplantation, Harefield Hospital, London, United Kingdom*, <sup>4</sup>*Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom*



THURSDAY, APRIL 4, 2019

6:00 PM - 7:00 PM

**MINI ORAL 08: Lung Donor Management and Organ Allocation**

Room: Pacifica 10-12

Target Audiences: LF/LTX

Chairs: David R Darley, MBBS BSc (Hons II) and Erika D. Lease, MD

- 6:00 PM** (441) *The Accuracy of LAS in Predicting Post-Transplant Risk of ECMO Recipients*; J. Katsis, W. F. Parker, M. Churpek, E. Garrity. *Pulmonary and Critical Care, University of Chicago, Chicago, IL*
- 6:05 PM** (442) *The Protective Effect of Prone Positioning on Human Rejected Donor Lungs during Cellular Ex Vivo Lung Perfusion*; H. Niikawa<sup>1</sup>, T. Okamoto<sup>1</sup>, K. S. Ayyat<sup>1</sup>, Y. Itoda<sup>1</sup>, C. F. Farver<sup>2</sup>, K. R. McCurry<sup>1</sup>. <sup>1</sup>*Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH*, <sup>2</sup>*Anatomic Pathology, Cleveland Clinic, Cleveland, OH*
- 6:10 PM** (443) *Evaluation of the Effects of the Correction of Hydroelectrolytic Disorders during Prolonged Ex-Vivo Lung Perfusion*; J. Issard, B. Decante, J. Guihaire, D. Mitilian, D. Boulate, S. Mussot, D. Fabre, E. Fadel, O. Mercier. *Thoracic and Vascular Surgery, Hopital Marie Lannelongue, Paris, France*
- 6:15 PM** (444) *Donor Lung Weight at Lung Procurement; Predictive Value for Transplant Suitability during Ex Vivo Lung Perfusion*; T. Okamoto, H. Niikawa, D. Wheeler, B. Soliman, K. S. Ayyat, Y. Itoda, K. R. McCurry. *Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH*
- 6:20 PM** (445) *Impact of Lung Allograft Oversizing on Pleural Cavity Expansion in Transplant Recipients with Idiopathic Pulmonary Fibrosis*; S. H. Roberts<sup>1</sup>, S. L. Miter<sup>1</sup>, B. Shukrullah<sup>2</sup>, B. C. Keller<sup>1</sup>, M. E. Lee<sup>1</sup>, T. Yurjevic<sup>1</sup>, S. Carter<sup>1</sup>, A. Pope-Harman<sup>1</sup>, P. Lee<sup>1</sup>, B. A. Whitson<sup>1</sup>. <sup>1</sup>*The Ohio State University Wexner Medical Center, Columbus, OH*, <sup>2</sup>*Minneapolis Heart Institute, Minneapolis, MN*
- 6:25 PM** (446) *Single Lung Transplant Compared with Double Lung Transplant in Older Adults with Interstitial Lung Disease*; L. J. Benvenuto<sup>1</sup>, M. Aversa<sup>1</sup>, L. Shah<sup>1</sup>, M. Carroll<sup>1</sup>, F. D'Ovidio<sup>2</sup>, B. P. Stanifer<sup>2</sup>, J. R. Sonett<sup>2</sup>, H. Y. Robbins<sup>1</sup>, S. Arcasoy<sup>1</sup>. <sup>1</sup>*Medicine, Columbia University Medical Center, New York, NY*, <sup>2</sup>*Surgery, Columbia University Medical Center, New York, NY*
- 6:30 PM** (447) *Right Single and Double Lung Transplant Outperform Left Single Lung Transplant in Chronic Obstructive Pulmonary Disease: A UNOS Analysis*; L. J. Benvenuto<sup>1</sup>, J. Costa<sup>2</sup>, D. Piloni<sup>2</sup>, M. Aversa<sup>1</sup>, H. Y. Robbins<sup>1</sup>, L. Shah<sup>1</sup>, B. P. Stanifer<sup>2</sup>, S. Arcasoy<sup>1</sup>, J. R. Sonett<sup>2</sup>, F. D'Ovidio<sup>2</sup>. <sup>1</sup>*Medicine, Columbia University Medical Center, New York, NY*, <sup>2</sup>*Surgery, Columbia University Medical Center, New York, NY*
- 6:35 PM** (448) *Initial Experience with Non-Perfused Organ Donors for Lung Transplantation*; Y. Watanabe<sup>1</sup>, A. Healey<sup>2</sup>, M. Scott<sup>2</sup>, S. Lavery<sup>2</sup>, K. Johnson<sup>2</sup>, C. Mills<sup>2</sup>, M. Galasso<sup>1</sup>, M. Chen<sup>1</sup>, J. Yeung<sup>1</sup>, L. Donahoe<sup>1</sup>, A. Pierre<sup>1</sup>, M. de Perrot<sup>1</sup>, K. Yasufuku<sup>1</sup>, T. K. Waddell<sup>1</sup>, S. Keshavjee<sup>1</sup>, M. Cypel<sup>1</sup>. <sup>1</sup>*Toronto Lung Transplant Program, Toronto General Hospital, Toronto, ON, Canada*, <sup>2</sup>*Trillium Gift of Life Network, Toronto, ON, Canada*
- 6:40 PM** (449) *Time from Lung Transplant Donor Brain Death to Cross Clamp: An Analysis of the UNOS Registry*; O. K. Jawitz, V. Raman, Y. Barac, M. Mulvihill, C. Moore, A. Choi, M. Hartwig, J. Klapper. *Department of Surgery, Duke University School of Medicine, Durham, NC*
- 6:45 PM** (450) *Living-Donor Lobar Lung Transplantation with Undersized Lobar Grafts Can Provide Comparable Long-Term Pulmonary Function and Exercise Capacity to Cadaveric Lung Transplantation*; D. Nakajima, T. F. Chen-Yoshikawa, T. Menju, T. Sato, M. Sonobe, Y. Yamada, Y. Yutaka, A. Ohsumi, M. Hamaji, H. Date. *Thoracic Surgery, Kyoto University, Kyoto, Japan*
- 6:50 PM** (451) *Predicted Total Lung Capacity Ratio between Donors and Recipients Does Not Predict Outcomes in Non-Volume Reduced Lung Transplantation*; R. Poyanmehr<sup>1</sup>, W. Sommer<sup>1</sup>, F. Ius<sup>1</sup>, J. Salman<sup>1</sup>, T. Siemeni<sup>1</sup>, M. Avsar<sup>1</sup>, C. Kühn<sup>1</sup>, M. Greer<sup>2</sup>, J. Gottlieb<sup>2</sup>, T. Welte<sup>2</sup>, A. Haverich<sup>1</sup>, I. Tudorache<sup>1</sup>, G. Warnecke<sup>1</sup>. <sup>1</sup>*Departement of Cardiothoracic Surgery, Medizinische Hochschule Hannover, Hannover, Germany*, <sup>2</sup>*Departement of Pneumology, Medizinische Hochschule Hannover, Hannover, Germany*

6:55 PM

**(452) Human (Mesenchymal Stem Cells) SC Loaded Single Lung Allograft;** A. Grant<sup>1</sup>, R. R. Gonzalez<sup>2</sup>, N. Sinha<sup>3</sup>, B. Forsberg<sup>4</sup>, A. Klima<sup>4</sup>, A. Patel<sup>5</sup>, C. Piechazek<sup>6</sup>, R. Vianna<sup>7</sup>, M. Mirsaedi<sup>8</sup>, M. Loebe<sup>9</sup>, A. Ghodsizad<sup>10</sup>. <sup>1</sup>Department of Surgery, Trauma and Surgical Critical Care Grady Memorial Hospital Emory University School of Medicine, Atlanta, GA, <sup>2</sup>Surgery, Miami Transplant Institute University of Miami, Miami, FL, <sup>3</sup>Miami Transplant Institute, Memorial Jackson Health System, University of Miami Leonard M Miller School of Medicine, Miami, FL, <sup>4</sup>Comprehensive Care Services, Inc., Livonia, MI, <sup>5</sup>Dewitt Daughtry Family Department of Surgery, Division of Cardiothoracic Surgery, University of Miami Leonard M Miller School of Medicine, Miami, FL, <sup>6</sup>Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, <sup>7</sup>Department of Surgery, Liver, Intestinal and Multivisceral Transplant, Miami Transplant Institute, Dewitt Daughtry Family Department of Surgery, University of Miami Leonard M Miller School of Medicine, Miami, FL, <sup>8</sup>Division of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine, University of Miami Leonard M Miller School of Medicine, Miami, FL, <sup>9</sup>Division of Heart and Lung Transplant and Mechanical Support, Miami Transplant Institute, Dewitt Daughtry Family Department of Surgery, Division of Cardiothoracic Surgery, University of Miami Leonard M Miller School of Medicine, Miami, FL, <sup>10</sup>Division of Heart and Lung Transplant and Mechanical Support, Miami Transplant Institute, Dewitt Daughtry Family Department of Surgery, Division of Cardiothoracic Surgery, University of Miami Leonard M Miller School of Medicine, Miami, FL

THURSDAY, APRIL 4, 2019  
6:00 PM - 7:00 PM

**MINI ORAL 09: MCS: GI Bleeding**

**Room: Pacifica 6**

**Target Audience: MCS**

**Chairs:** Antonio Loforte, MD, and Sanem Nalbantgil, MD

- 6:00 PM** (453) *Early Anticoagulation Bridging to Therapeutic International Normalized Ratio after Left Ventricular Assist Device Implantation is Not Associated with Thromboembolic and Bleeding Complications: A Systematic Review and Meta-Analysis*; V. Kittipibul<sup>1</sup>, N. Angsubhakorn<sup>2</sup>, J. Kewchareon<sup>3</sup>, N. Prasitlumkum<sup>3</sup>, P. Rattanawong<sup>3</sup>. <sup>1</sup>Department of Internal Medicine, University of Miami Miller School of Medicine, Miami, FL, <sup>2</sup>Department of Internal Medicine, University of Minnesota, Minneapolis, MN, <sup>3</sup>Department of Internal Medicine, University of Hawaii, Honolulu, HI
- 6:05 PM** (454) *Thalidomide Use Reduces Risk of Refractory Gastrointestinal Bleeding in Patients with Continuous Flow Left Ventricular Assist Devices*; P. Namdaran<sup>1</sup>, T. A. Zikos<sup>2</sup>, J. Y. Pan<sup>2</sup>, D. Banerjee<sup>3</sup>. <sup>1</sup>Division of Cardiovascular Medicine, University of Utah, Salt Lake City, UT, <sup>2</sup>Division of Gastroenterology and Hepatology, Stanford University, Stanford, CA, <sup>3</sup>Division of Cardiovascular Medicine, Stanford University, Stanford, CA
- 6:10 PM** (917) *HVAD Cannula Positioning is Associated with Higher GI Bleed Rates*; T. Imamura, G. Kim, J. Raikhelkar, B. Smith, A. Nguyen, N. Narang, B. Chung, I. Ebong, L. Holzhauser, D. Nitta, T. Fujino, C. Juricek, P. Combs, T. Song, T. Ota, V. Jeevanandam, G. Sayer, N. Uriel. *University of Chicago, Chicago, IL*
- 6:15 PM** (456) *Diagnostic Yield of Endoscopy Procedures in the Management of Left Ventricular Assist Device Recipients Presenting with Gastrointestinal Bleeding*; A. Y. Lee<sup>1</sup>, K. M. Tecson<sup>2</sup>, H. E. Sheffield<sup>3</sup>, M. E. Marcom<sup>3</sup>, A. Z. Jacob<sup>3</sup>, S. Patlolla<sup>4</sup>, N. H. Kwak<sup>5</sup>, B. L. Da<sup>6</sup>, J. Felius<sup>7</sup>, S. A. Hall<sup>8</sup>, H. Kale<sup>9</sup>, P. Kale<sup>8</sup>. <sup>1</sup>Baylor Heart and Vascular Hospital, Dallas, TX, <sup>2</sup>Baylor Heart and Vascular Institute, Baylor Scott & White Research Institute, Dallas, TX, <sup>3</sup>College of Medicine, Texas A&M Health Science Center, Dallas, TX, <sup>4</sup>Department of Internal Medicine, Baylor Scott and White, Dallas, TX, <sup>5</sup>Department of Gastroenterology, SUNY Health Science Center, Brooklyn, NY, <sup>6</sup>National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Bethesda, MD, <sup>7</sup>Annette C. and Harold C. Simmons Transplant Institute, Baylor Scott & White Research Institute, Dallas, TX, <sup>8</sup>Annette C. and Harold C. Simmons Transplant Institute, Baylor Scott and White, Dallas, TX, <sup>9</sup>Digestive Health Associates of Texas, Baylor Scott and White, Dallas, TX
- 6:20 PM** (457) *Serotonergic Antidepressants and Hospitalization for Bleeding in Patients with LVAD*; K. Behrend<sup>1</sup>, M. P. Lillyblad<sup>1</sup>, P. Skelton<sup>1</sup>, R. F. Gaberich<sup>2</sup>, K. Wilson<sup>2</sup>, P. M. Eckman<sup>3</sup>, B. Sun<sup>3</sup>, K. Hryniewicz<sup>3</sup>. <sup>1</sup>Abbott Northwestern Hospital, Minneapolis, MN, <sup>2</sup>Minneapolis Heart Institute Foundation, Minneapolis, MN, <sup>3</sup>Minneapolis Heart Institute, Minneapolis, MN
- 6:25 PM** (458) *Correlation of Thromboelastography Parameters with Bleeding Episodes of Post-LVAD Surgery*; P. Tanrachoti, P. Pachariyanon, W. Vutthikraivit, B. Hirsch, N. Nair. *Texas Tech University Health Sciences Center, Lubbock, TX*
- 6:30 PM** (459) *Safety and Performance of a Self-Assembling Peptide Haemostat for the Management of Bleeding after Left Ventricular Assist Device Implantation: Outcomes of a Post Market Clinical Follow-Up Study*; M. Morshuis, M. Schönbrodt, J. Gummert. *Cardiac Surgery, HDZ-NRW.de, Bad Oeynhausen, Germany*
- 6:35 PM** (460) *Pre-Operative Ventilatory Inefficiency is Associated with Gastrointestinal Bleeding in Patients with Continuous-Flow Left Ventricular Assist Devices*; M. D. Yu<sup>1</sup>, J. Newman<sup>1</sup>, Y. Brailovsky<sup>1</sup>, M. Liebo<sup>1</sup>, R. Zolty<sup>2</sup>, B. Lowes<sup>2</sup>, A. Heroux<sup>1</sup>, E. Raichlin<sup>1</sup>. <sup>1</sup>Loyola University Medical Center, Maywood, IL, <sup>2</sup>University of Nebraska Medical Center, Omaha, NE
- 6:40 PM** (461) *Pulmonary Artery Pulsatile Index (PAPi) Score May Predict Risk of Gastrointestinal Bleeding in Patients with Left Ventricular Assist Device*; L. Cunningham, S. George, A. M. El Banayosy, D. Horstmanshof. *Advanced Heart Failure and Transplant Cardiology, Integris Baptist Medical Center, Oklahoma City, OK*
- 6:45 PM** (462) *Gastrointestinal Hemorrhage among LVAD Recipients. A Nationwide Inpatient Sample Study*; D. C. Voruganti<sup>1</sup>, G. P. Shantha<sup>2</sup>, C. Inampudi<sup>3</sup>, P. Alvarez<sup>3</sup>, M. C. Giudici<sup>3</sup>, A. Briasoulis<sup>3</sup>. <sup>1</sup>Internal Medicine,

*University of Iowa Hospitals and Clinics, Iowa City, IA, <sup>2</sup>Cardiovascular Diseases, University of Michigan, Ann Arbor, MI, <sup>3</sup>Cardiovascular Diseases, University of Iowa Hospitals and Clinics, Iowa City, IA*

**6:50 PM**

**(463) Microbiome-Derived TMAO Exhibits No Protective Effect against GIB in LVAD Patients;** A. M. Zuver<sup>1</sup>, K. L. Hoffman<sup>2</sup>, D. D'Angelo<sup>2</sup>, D. Onat<sup>1</sup>, E. A. Royzman<sup>1</sup>, J. C. Hupf<sup>1</sup>, D. L. Brunjes<sup>1</sup>, G. M. Mondellini<sup>1</sup>, C. A. Bravo<sup>3</sup>, M. Tiburcio<sup>4</sup>, A. R. Garan<sup>1</sup>, H. Takayama<sup>4</sup>, K. Takeda<sup>4</sup>, Y. Naka<sup>4</sup>, P. C. Colombo<sup>1</sup>, R. T. Demmer<sup>5</sup>, M. Yuzefpolskaya<sup>1</sup>. <sup>1</sup>*Department of Medicine, Columbia University Medical Center, New York, NY, <sup>2</sup>Healthcare Policy and Research, Weill Cornell Medicine, New York, NY, <sup>3</sup>Department of Medicine, Montefiore Medical Center, Bronx, NY, <sup>4</sup>Department of Surgery, Columbia University Medical Center, New York, NY, <sup>5</sup>Epidemiology and Community Health, University of Minnesota, Minneapolis, MN*

**6:55 PM**

**(464) Gastrointestinal Bleeding Ceases after Heart Transplantation in Patients Bridged on Continuous-Flow LVAD Support;** A. Critsinelis<sup>1</sup>, J. Kraus<sup>2</sup>, H. Lamba<sup>1</sup>, F. Cheema<sup>1</sup>, A. Civitello<sup>1</sup>, R. Delgado<sup>1</sup>, A. Nair<sup>1</sup>, A. Shafii<sup>1</sup>, G. Loor<sup>1</sup>, T. Rosengart<sup>1</sup>, O. Frazier<sup>1</sup>, J. Morgan<sup>1</sup>. <sup>1</sup>*Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, TX, <sup>2</sup>Baylor College of Medicine, Houston, TX*

THURSDAY, APRIL 4, 2019

6:00 PM - 7:00 PM

MINI ORAL 10A & 10B: Nursing, Health Sciences, Allied Health / Pharmacy and Pharmacology

Room: Pacifica 3-5

Target Audiences: NHSAH, PHARM, HTX, LTX, MCS, PEDS

Chairs: Donna Hickling, and Kyle L Dawson, PharmD, MBA, BCPS

- 6:00 PM** (465) *Associations between Self-Reported Physical Function and Exercise Capacity in De Novo Heart Transplant Recipients*; K. Rolid<sup>1</sup>, A. K. Andreassen<sup>1</sup>, M. Yardley<sup>1</sup>, E. Gude<sup>1</sup>, E. Bjørkelund<sup>1</sup>, A. R. Authen<sup>1</sup>, I. Grov<sup>1</sup>, K. I. Pettersen<sup>1</sup>, C. Dall<sup>2</sup>, E. Prescott<sup>2</sup>, K. Karason<sup>3</sup>, L. Gullestad<sup>1</sup>, K. Nytrøen<sup>1</sup>. <sup>1</sup>Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, <sup>2</sup>Department of Cardiology, Bispebjerg University Hospital, Copenhagen, Denmark, <sup>3</sup>Department of Cardiology, Sahlgrenska University Hospital, Gothenborg, Sweden
- 6:05 PM** (466) *Effect of High Intensity Interval Training on Health Related Quality of Life in De Novo Heart Transplant Recipients-The HITT Study*; K. Rolid<sup>1</sup>, A. K. Andreassen<sup>1</sup>, M. Yardley<sup>1</sup>, E. Gude<sup>1</sup>, E. Bjørkelund<sup>1</sup>, A. R. Authen<sup>1</sup>, I. Grov<sup>1</sup>, K. I. Pettersen<sup>1</sup>, C. H. Dall<sup>2</sup>, E. Prescott<sup>2</sup>, K. Karason<sup>3</sup>, L. Gullestad<sup>1</sup>, K. Nytrøen<sup>1</sup>. <sup>1</sup>Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, <sup>2</sup>Department of Cardiology, Bispebjerg University Hospital, Copenhagen, Denmark, <sup>3</sup>Department of Cardiology, Sahlgrenska University Hospital, Gothenborg, Sweden
- 6:10 PM** (467) *Pre Transplant Quadriceps Strength is a Modifiable Predictor of Functional Outcomes Following Lung Transplantation*; J. R. Walsh<sup>1</sup>, D. C. Chambers<sup>2</sup>, S. T. Yerkovich<sup>2</sup>, N. R. Morris<sup>3</sup>, P. M. Hopkins<sup>2</sup>. <sup>1</sup>Physiotherapy, The Prince Charles Hospital, Brisbane, Australia, <sup>2</sup>Queensland Lung Transplant Unit, The Prince Charles Hospital, Brisbane, Australia, <sup>3</sup>School of Allied Health Sciences, Griffith University, Gold Coast, Australia
- 6:15 PM** (468) *What Happens to Frailty in the First Year after Lung Transplantation?*; L. M. Fuller<sup>1</sup>, H. Whitford<sup>2</sup>, Y. Cristiano<sup>2</sup>, R. Robinson<sup>1</sup>, R. Steward<sup>1</sup>, M. Poulsen<sup>1</sup>, W. Shi<sup>3</sup>, G. M. Snell<sup>4</sup>. <sup>1</sup>Physiotherapy, Alfred Hospital, Melbourne, Australia, <sup>2</sup>Respiratory Unit, Alfred Hospital, Melbourne, Australia, <sup>3</sup>Cardiothoracic Surgery, Alfred Hospital, Melbourne, Australia, <sup>4</sup>Lung Transplant Unit, Alfred Hospital, Melbourne, Australia
- 6:20 PM** (469) *QOLVAD Detects Changes in Emotional, Social, Cognitive and Physical Wellbeing after Continuous-Flow LVAD Implant*; J. A. Cowger<sup>1</sup>, C. S. Lee<sup>2</sup>, P. Eckman<sup>3</sup>, R. Garberich<sup>4</sup>, C. Weaver<sup>5</sup>, S. Joseph<sup>6</sup>, S. Hall<sup>6</sup>, S. Carrie<sup>7</sup>, S. Chaudhry<sup>8</sup>, S. E. Schroeder<sup>9</sup>, R. O. Hoffman, III<sup>10</sup>, D. Feldman<sup>11</sup>, G. Conway<sup>12</sup>, E. Y. Birati<sup>13</sup>, M. Soni<sup>14</sup>, J. Marble<sup>15</sup>, K. M. Faulkner<sup>2</sup>, K. E. Sandau<sup>16</sup>. <sup>1</sup>Cardiovascular Medicine, HF/Transplant/MCS, Henry Ford Hospital, Detroit, MI, <sup>2</sup>Boston College Connell School of Nursing, Boston, MA, <sup>3</sup>Cardiovascular Medicine, HF/Transplant/MCS, Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN, <sup>4</sup>Minneapolis Heart Institute Foundation, Minneapolis, MN, <sup>5</sup>Cardiovascular Medicine, HF/Transplant/MCS, Abbott Northwestern Hospital/Minneapolis Heart Institute, Minneapolis, MN, <sup>6</sup>Cardiovascular Medicine, HF/Transplant/MCS, Baylor University Medical Center, Dallas, TX, <sup>7</sup>Baylor University Medical Center, Dallas, TX, <sup>8</sup>Cardiovascular Medicine, HF/Transplant/MCS, Ascension Hospital/St Vincent, Indianapolis, IN, <sup>9</sup>Bryan Heart Center, Lincoln, NE, <sup>10</sup>University of Cincinnati Medical Center, Cincinnati, OH, <sup>11</sup>Cardiovascular Medicine, HF/Transplant/MCS, University of Cincinnati Medical Center, Cincinnati, OH, <sup>12</sup>Division of Cardiovascular Health and Disease, University of Cincinnati Medical Center, Cincinnati, OH, <sup>13</sup>Cardiovascular Medicine, HF/Transplant/MCS, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, <sup>14</sup>Department of Medicine, University of Pennsylvania, Philadelphia, PA, <sup>15</sup>Cardiovascular Medicine, HF/Transplant/MCS, University of Pennsylvania, Philadelphia, PA, <sup>16</sup>Cardiovascular Medicine, Bethel University; Allina Health, Minneapolis, MN
- 6:25 PM** (470) *Lack of Social Support is Not a Contraindication to VAD Therapy*; N. Robinson Smith<sup>1</sup>, E. Sowerby<sup>2</sup>, J. Meadows<sup>2</sup>, S. Tovey Brown<sup>3</sup>, A. Woods<sup>1</sup>, G. MacGowan<sup>1</sup>, S. Schueler<sup>1</sup>. <sup>1</sup>MCS Service Cardio Thoracic, Newcastle upon Tyne Hospital NHS Trust, Newcastle upon Tyne, United Kingdom, <sup>2</sup>Social Work, Newcastle upon Tyne Hospital NHS Trust, Newcastle upon Tyne, United Kingdom, <sup>3</sup>MCS Service Cardiothoracic, Newcastle upon Tyne Hospital NHS Trust, Newcastle upon Tyne, United Kingdom
- 6:30 PM** (471) *It Takes a Village: Pediatric Ventricular Assist Device Training and Education Practices among ACTION Centers*; K. Fields<sup>1</sup>, B. Hawkins<sup>2</sup>, J. Lantz<sup>3</sup>, M. Mehegan<sup>4</sup>, J. Murray<sup>5</sup>, L. Burkhart<sup>1</sup>, C. Villa<sup>1</sup>. <sup>1</sup>Cincinnati Children's Hospital Medical Center, Cincinnati, OH, <sup>2</sup>Boston Children's Hospital, Boston, MA,

<sup>3</sup>Children's Medical Center Dallas, Dallas, TX, <sup>4</sup>St. Louis Children's Hospital, Saint Louis, MO, <sup>5</sup>Lucille Packard Children's Hospital, Palo Alto, CA

6:35 PM

**(472) Lung Transplant Clinicians' Perceptions of Pocket PATH Synergy, an Interactive Health Technology (IHT) to Monitor Patients Remotely;** A. J. Devito Dabbs<sup>1</sup>, T. Irizarry<sup>1</sup>, M. Alrawashdeh<sup>1</sup>, J. M. Pilewski<sup>2</sup>, M. Morrell<sup>2</sup>, J. D'Cunha<sup>2</sup>, M. Dew<sup>2</sup>. <sup>1</sup>University of Pittsburgh School of Nursing, Pittsburgh, PA, <sup>2</sup>University of Pittsburgh School of Medicine, Pittsburgh, PA

6:40 PM

**(473) Pre-Lung Transplant Waitlist Mortality Rate Reduction Using Remote Video Monitoring Technology;** M. Zubrinic<sup>1</sup>, N. Marks<sup>2</sup>, L. Brzozowski<sup>3</sup>, J. Qiu<sup>3</sup>, D. Lin<sup>3</sup>, K. Wang<sup>3</sup>, J. De Romana<sup>1</sup>, L. Singer<sup>4</sup>, S. Keshavjee<sup>1</sup>. <sup>1</sup>Department of Surgery, University Health Network, Toronto, ON, Canada, <sup>2</sup>Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada, <sup>3</sup>Techna Institute & University Health Network, Toronto, ON, Canada, <sup>4</sup>Division of Respiriology, Department of Medicine, University Health Network, Toronto, ON, Canada

6:45 PM

**(474) A Pilot Randomized Placebo Controlled Trial of Inhaled Beclomethasone after Community-Acquired Respiratory Viral (CARV) Infection in Lung Transplant Recipients (LTR);** K. B. Bain<sup>1</sup>, K. A. Fester<sup>1</sup>, J. Iuppa<sup>2</sup>, K. Bakos<sup>1</sup>, B. Mittler<sup>3</sup>, K. Richardson<sup>3</sup>, P. Aguilar<sup>3</sup>, J. Alexander-Brett<sup>3</sup>, D. Byers<sup>3</sup>, H. Kulkarni<sup>3</sup>, E. Trulock<sup>3</sup>, C. Witt<sup>3</sup>, R. Yusen<sup>3</sup>, V. Puri<sup>4</sup>, D. Kreisel<sup>4</sup>, R. Hachem<sup>3</sup>. <sup>1</sup>Pharmacy, Barnes Jewish Hospital, Saint Louis, MO, <sup>2</sup>Pharmacy, University of Rochester Medical Center, Rochester, NY, <sup>3</sup>Pulmonary & Critical Care, Washington University, Saint Louis, MO, <sup>4</sup>Surgery, Washington University, Saint Louis, MO

6:50 PM

**(475) Effects of INR Variability and Time in the Therapeutic Range on the Rates of Gastrointestinal Bleeding in Patients Supported by Left Ventricular Assist Devices;** A. Mardis<sup>1</sup>, M. Freiter<sup>2</sup>, B. Mierzejewski<sup>2</sup>, M. Adams<sup>3</sup>. <sup>1</sup>Department of Pharmacy, Palmetto Health, Columbia, SC, <sup>2</sup>College of Pharmacy, University of South Carolina, Columbia, SC, <sup>3</sup>Department of Family and Preventive Medicine, University of South Carolina College of Medicine, Columbia, SC

6:55 PM

**(476) Appropriate Management of Drug Interactions Results in Safe Use of Hepatitis C Therapies in Heart Transplant Recipients;** K. Boyle, R. E. Fowler, A. Pollack, C. Edmonds, J. Gray, J. Lindenfeld, K. Schlendorf. Vanderbilt University Medical Center, Nashville, TN

THURSDAY, APRIL 4, 2019

6:00 PM - 7:00 PM

**MINI ORAL 11A & 11B: Pediatrics / Heart Failure (Adult)**

**Room: Pacifica 1-2**

**Target Audiences: PEDS, HF, LTX**

**Chairs:** Jennifer Conway, MD, and Tomasz Zielinski, MD

- 6:00 PM** (477) *Genetic Testing Outcomes in Pediatric Dilated Cardiomyopathy*; R. Khan<sup>1</sup>, E. Pahl<sup>1</sup>, L. Dellefave-Castillo<sup>2</sup>, K. Rychlik<sup>1</sup>, E. McNally<sup>2</sup>, G. Webster<sup>1</sup>. <sup>1</sup>Cardiology, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, <sup>2</sup>Cardiology, Northwestern Memorial Hospital, Chicago, IL
- 6:05 PM** (478) *Cardiac Resynchronization Therapy in Congenital Heart Disease and Pediatric Patients with Heart Failure is Associated with Improved Survival*; H. Chubb<sup>1</sup>, C. S. Almond<sup>2</sup>, D. N. Rosenthal<sup>2</sup>, A. V. Trela<sup>2</sup>, D. Hanisch<sup>2</sup>, K. S. Motonaga<sup>2</sup>, S. R. Ceresnak<sup>2</sup>, D. B. McElhinney<sup>2</sup>, A. M. Dubin<sup>2</sup>. <sup>1</sup>Stanford University, Palo Alto, CA, <sup>2</sup>Pediatric Cardiology, Stanford University, Palo Alto, CA
- 6:10 PM** (479) *A Simple Pediatric Heart Failure Symptom Score for Children Hospitalized with Acute Decompensated Heart Failure*; C. S. Almond, D. Rosenthal, J. Kwong, J. Dykes, V. Yarlagadda, S. Chen, C. Chen. Stanford University, Palo Alto, CA
- 6:15 PM** (480) *Distinction of Serum Biomarker Profiles between Adults and Children with Dilated Cardiomyopathy*; M. R. Gropler<sup>1</sup>, K. J. Lavine<sup>2</sup>, S. E. Lipshultz<sup>3</sup>, J. D. Wilkinson<sup>4</sup>, S. Colan<sup>5</sup>, J. Towbin<sup>6</sup>, L. Si<sup>7</sup>, C. E. Canter<sup>1</sup>, K. E. Simpson<sup>1</sup>. <sup>1</sup>Pediatrics, Washington University in Saint Louis School of Medicine, St Louis, MO, <sup>2</sup>Medicine, Washington University in Saint Louis School of Medicine, St Louis, MO, <sup>3</sup>Pediatrics, Wayne State University School of Medicine, Detroit, MI, <sup>4</sup>Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, <sup>5</sup>Pediatrics, Harvard Medical School, Boston, MA, <sup>6</sup>Pediatrics, University of Tennessee Health Science Center, Memphis, TN, <sup>7</sup>New England Research Institute, Watertown, MA
- 6:20 PM** (481) *Clinician Perspectives on the Potential Utility of a Patient Reported Outcomes Measure for Pediatric Heart Failure*; C. Chen, D. N. Rosenthal, S. Chen, J. C. Dykes, S. A. Hollander, C. S. Almond. Pediatric Cardiology, Stanford University, Palo Alto, CA
- 6:25 PM** (482) *Broadening ABO Incompatibility Pediatric Heart Transplantation, Even in Children 2 Years and Older*; R. Daulton, K. Riggs, F. Zafar, C. Villa, R. Bryant, D. L. Morales. Cardiothoracic Surgery, Children's Hospital Med Ctr, Cincinnati, OH
- 6:30 PM** (483) *Efficacy of Tafamidis in Patients with Hereditary or Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Results from the ATTR-ACT Trial*; M. Grogan<sup>1</sup>, R. Witteles<sup>2</sup>, S. J. Shah<sup>3</sup>, J. H. Schwartz<sup>4</sup>, B. Gundapaneni<sup>5</sup>, T. A. Patterson<sup>6</sup>, M. B. Sultan<sup>4</sup>, M. S. Maurer<sup>7</sup>. <sup>1</sup>Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, <sup>2</sup>Stanford University School of Medicine, Stanford, CA, <sup>3</sup>Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, <sup>4</sup>Pfizer Inc, New York, NY, <sup>5</sup>Department of Cardiovascular Diseases, Syneos Health, Raleigh, NC, <sup>6</sup>Pfizer Inc, Groton, CT, <sup>7</sup>Columbia University College of Physicians and Surgeons, New York, NY
- 6:35 PM** (484) *The Rising Epidemic of Resource Utilization for Adult Congenital Heart Disease-Related Heart Failure in the United States*; D. S. Burstein<sup>1</sup>, J. W. Rossano<sup>1</sup>, H. Griffis<sup>1</sup>, X. Zhang<sup>1</sup>, R. Fowler<sup>2</sup>, B. P. Frischhertz<sup>2</sup>, Y. Y. Kim<sup>1</sup>, J. Lindenfeld<sup>2</sup>, J. A. Mazurek<sup>3</sup>, J. N. Menachem<sup>2</sup>. <sup>1</sup>Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, <sup>2</sup>Cardiology, Vanderbilt University Medical Center, Nashville, TN, <sup>3</sup>Cardiology, Hospital of University of Pennsylvania, Philadelphia, PA
- 6:40 PM** (970) *Comparison of Long-Term Effects of Cell Therapy in Patients with Ischemic and Nonischemic Heart Failure*; G. Poglajen, G. Zemljic, S. Frljak, A. Cerar, M. Jaklič, B. Vrtovec. Advanced Heart Failure and Transplantation Center, University Medical Center Ljubljana, Ljubljana, Slovenia
- 6:45 PM** (486) *Myocardial Ischemia Correlates with Left Ventricular Systolic Dysfunction in Patients with Noncompaction Cardiomyopathy*; A. Cerar<sup>1</sup>, M. Jaklič<sup>1</sup>, M. Dolenc Novak<sup>2</sup>, B. Guzić Salobir<sup>2</sup>, R. Zbacnik<sup>3</sup>, M. Kozelj<sup>1</sup>, B. Vrtovec<sup>1</sup>. <sup>1</sup>Department of Cardiology, UMC Ljubljana, Ljubljana, Slovenia, <sup>2</sup>Department of Nuclear Medicine, UMC Ljubljana, Ljubljana, Slovenia, <sup>3</sup>Department of Radiology, UMC Ljubljana, Ljubljana, Slovenia

6:50 PM

**(487) Absence of Pre-Transplant Pulmonary Features of Sarcoidosis is of Low Negative Predictive Value in End-Stage Cardiac Sarcoidosis;** H. K. Rokadia<sup>1</sup>, A. K. Jamil<sup>2</sup>, R. El Tomi<sup>2</sup>, H. Zafar<sup>2</sup>, T. Nisar<sup>2</sup>, M. Petrozzi<sup>1</sup>, R. L. Gottlieb<sup>1</sup>. <sup>1</sup>Baylor University Medical Center, Dallas, TX, <sup>2</sup>Baylor Scott & White Research Institute, Dallas, TX

6:55 PM

**(488) Undiagnosed Cardiac Sarcoidosis Has a Significant First Presentation as Sudden Cardiac Death: An Autopsy Review;** D. Pedrotty<sup>1</sup>, A. Rosenbaum<sup>2</sup>, S. Kapa<sup>2</sup>, L. Blauwet<sup>2</sup>, J. Maleszewski<sup>3</sup>. <sup>1</sup>Heart Failure Cardiology, University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Cardiology, Mayo Clinic, Rochester, MN, <sup>3</sup>Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN



THURSDAY, APRIL 4, 2019

6:00 PM - 7:00 PM

**MINI ORAL 12A & 12B: Pulmonary Hypertension / Heart Transplantation (Adult)**

Room: Pacifica 7

Target Audiences: PH, HTX

Chairs: John Granton, MD and Joanna Pepke-Zaba, MD

- 6:00 PM** (489) *Demographic, Hemodynamic, and HRQL Differences between Methamphetamine-Associated and Idiopathic PAH: The Pulmonary Hypertension Association Registry*; N. A. Kolaitis<sup>1</sup>, R. T. Zamanian<sup>2</sup>, V. A. de Jesus Perez<sup>2</sup>, D. B. Badesch<sup>3</sup>, R. L. Benza<sup>4</sup>, C. D. Burger<sup>5</sup>, M. M. Chakinala<sup>6</sup>, J. Feldman<sup>7</sup>, M. R. Lammi<sup>8</sup>, S. C. Mathai<sup>9</sup>, K. W. Presberg<sup>10</sup>, J. C. Robinson<sup>11</sup>, J. S. Sager<sup>12</sup>, O. A. Shlobin<sup>13</sup>, M. A. Simon<sup>14</sup>, S. M. Kawut<sup>15</sup>, J. P. Singer<sup>1</sup>, T. De Marco<sup>1</sup>. <sup>1</sup>University of California, San Francisco, San Francisco, CA, <sup>2</sup>Stanford University, Palo Alto, CA, <sup>3</sup>University of Colorado Denver, Aurora, CO, <sup>4</sup>Allegheny General Hospital, Pittsburgh, PA, <sup>5</sup>Mayo Clinic Florida, Jacksonville, FL, <sup>6</sup>Washington University in St. Louis, St. Louis, MO, <sup>7</sup>Arizona Pulmonary Specialists, Phoenix, AZ, <sup>8</sup>Louisiana State University, New Orleans, LA, <sup>9</sup>Johns Hopkins University, Baltimore, MD, <sup>10</sup>Medical College of Wisconsin, Milwaukee, WI, <sup>11</sup>The Oregon Clinic, Portland, OR, <sup>12</sup>Cottage Pulmonary Hypertension Center, Santa Barbara, CA, <sup>13</sup>Inova Fairfax Medical Campus, Falls Church, VA, <sup>14</sup>University of Pittsburgh, Pittsburgh, PA, <sup>15</sup>University of Pennsylvania, Philadelphia, PA
- 6:05 PM** (490) *Comparison of Outcomes of Living-Donor Lobar and Cadaveric Lung Transplantation in Patients with Pulmonary Arterial Hypertension*; S. Ueda, T. Chen-Yoshikawa, Y. Yokoyama, H. Oda, M. Ikeda, J. Tokuno, H. Kayawake, H. Yamagishi, F. Gochi, R. Okabe, D. Nakajima, A. Ohsumi, H. Date. *Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan*
- 6:10 PM** (491) *Do Pulmonary Hypertensive Patients Have Worse Post Transplant Survival Than Non-Pulmonary Hypertensive Patients? An ISHLT Registry Analysis*; J. Lasky<sup>1</sup>, K. Tsui<sup>2</sup>, C. Alex<sup>2</sup>, M. Dia<sup>2</sup>, E. Jweied<sup>2</sup>, P. Pappas<sup>2</sup>, C. Wigfield<sup>2</sup>. <sup>1</sup>Rosalind Franklin University of Medicine and Science, Chicago, IL, <sup>2</sup>Lung Transplant, Advocate Christ Medical Center, Chicago, IL
- 6:15 PM** (492) *Exercise Pulmonary Hypertension and Progression to Resting Pulmonary Hypertension - Is TPR the Best Predictor?*; K. Kearney, N. Bart, V. Shah, P. Jain, E. Kotlyar, A. Keogh. *St Vincents Hospital, Darlinghurst, Australia*
- 6:20 PM** (1228) *Severe Pulmonary Arterial Hypertension Treated with ABI-009, nab-Sirolimus, an mTOR Inhibitor*; M. Simon<sup>1</sup>, M. Gomberg-Maitland<sup>2</sup>, R. J. Oudiz<sup>3</sup>, R. Machado<sup>4</sup>, F. Rischard<sup>5</sup>, J. M. Elinoff<sup>6</sup>, B. Grigorian<sup>7</sup>, A. N. Schmid<sup>7</sup>, S. Hou<sup>7</sup>, N. Desai<sup>7</sup>, M. Gladwin<sup>1</sup>. <sup>1</sup>Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>MSc. Inova Heart and Vascular Institute, VCU Medicine, Falls Church, VA, <sup>3</sup>LA Biomedical Research Institute, Harbor-UCLA Medical Center, Los Angeles, CA, <sup>4</sup>Indiana University, Indianapolis, IN, <sup>5</sup>Department of Medicine, University of Arizona, Tucson, AZ, <sup>6</sup>The NIH Clinical Center, Bethesda, MD, <sup>7</sup>Aadi Bioscience, Pacific Palisades, CA
- 6:25 PM** (495) *Two Polymorphic Gene Loci Associated with Treprostinil Dose in Pulmonary Arterial Hypertension*; M. A. Psotka<sup>1</sup>, V. Thomeas-McEwing<sup>2</sup>, E. R. Gamazon<sup>3</sup>, T. Hirota<sup>4</sup>, P. N. Friedman<sup>5</sup>, A. Konkashbaev<sup>3</sup>, M. Kubo<sup>4</sup>, Y. Nakamura<sup>6</sup>, M. J. Ratain<sup>7</sup>, R. L. Benza<sup>8</sup>, N. J. Cox<sup>3</sup>, M. I. Gomberg-Maitland<sup>1</sup>, M. L. Maitland<sup>2</sup>. <sup>1</sup>Inova Heart and Vascular Institute, Falls Church, VA, <sup>2</sup>Center for Personalized Health, Inova Schar Cancer Institute, Falls Church, VA, <sup>3</sup>Division of Genetic Medicine, Vanderbilt University School of Medicine, Nashville, TN, <sup>4</sup>Center for Integrative Medical Sciences, RIKEN, Tokyo, Japan, <sup>5</sup>Feinberg School of Medicine, Northwestern University, Chicago, IL, <sup>6</sup>Cancer Precision Medicine Research Center, Japanese Foundation for Cancer Research, Tokyo, Japan, <sup>7</sup>Department of Medicine, University of Chicago, Chicago, IL, <sup>8</sup>Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA
- 6:30 PM** (496) *Ralinepag Plasma Levels Correlate with Improvements in Functional and Hemodynamic Parameters in Patients with Pulmonary Arterial Hypertension*; H. W. Farber<sup>1</sup>, N. Sood<sup>2</sup>, I. R. Preston<sup>1</sup>, J. Adams<sup>3</sup>, J. Grundy<sup>3</sup>, C. King<sup>3</sup>, P. Klassen<sup>3</sup>, V. F. Tapson<sup>4</sup>, V. McLaughlin<sup>5</sup>, R. J. Oudiz<sup>6</sup>. <sup>1</sup>Professor of Medicine, Pulmonary, Critical Care and Sleep Division, Tufts Medical Center, Boston, MA, <sup>2</sup>University of Texas Health Science Center of Houston, Houston, TX, <sup>3</sup>Arena Pharmaceuticals, Inc, San Diego, CA, <sup>4</sup>Cedars-Sinai Medical Center, Los Angeles, CA, <sup>5</sup>Kim A. Eagle, MD, Endowed Professor of Cardiovascular Medicine, Director of Pulmonary Hypertension Program, University of Michigan, Ann Arbor, MI, <sup>6</sup>Department of Medicine, Division of Cardiology, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA

- 6:35 PM** (497) *The Effects of Inhaled Sodium Nitrite on Pulmonary Vascular Impedance in Patients with Pulmonary Hypertension Associated with HFpEF*; M. J. Bashline<sup>1</sup>, T. N. Bachman<sup>2</sup>, N. L. Helbling<sup>3</sup>, M. T. Gladwin<sup>4</sup>, M. A. Simon<sup>3</sup>. <sup>1</sup>Department of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>2</sup>Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, <sup>3</sup>Vascular Medicine Institute, UPMC Heart and Vascular Institute, Pittsburgh, PA, <sup>4</sup>Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA
- 6:40 PM** (498) *Association between Serial Measurements of Tricuspid Annular Plane Systolic Excursion and Mortality Post Heart Transplant*; J. K. Vishram-Nielsen<sup>1</sup>, F. Foroutan<sup>2</sup>, H. J. Ross<sup>2</sup>, F. Gustafsson<sup>3</sup>, T. A. Buchan<sup>2</sup>, A. Alba<sup>2</sup>. <sup>1</sup>The Heart Centre, Rigshospitalet, University of Copenhagen, Denmark, & Ted Rogers Center for Heart Research, UHN, Toronto, ON, Canada, <sup>2</sup>Ted Rogers Center for Heart Research, UHN, Toronto, ON, Canada, <sup>3</sup>The Heart Centre, Rigshospitalet, University of Copenhagen, Denmark, Copenhagen, Denmark
- 6:45 PM** (499) *Prognostic Value of Cardiac Magnetic Resonance Acquired at One Year after Heart Transplantation*; P. Pedrotti<sup>1</sup>, O. Rimoldi<sup>2</sup>, G. Masciocco<sup>1</sup>, L. D'Angelo<sup>1</sup>, G. Foti<sup>1</sup>, G. Quattrocchi<sup>1</sup>, A. Milazzo<sup>1</sup>, R. Facchetti<sup>3</sup>, C. Giannattasio<sup>1</sup>, M. Frigerio<sup>1</sup>. <sup>1</sup>Cardiothoracic and Vascular DPT, ASST Niguarda, Milan, Italy, <sup>2</sup>CNR, IBFM, Segrate (MI), Italy, <sup>3</sup>Health Science DPT, Bicocca University, Milan, Italy
- 6:50 PM** (500) *Can CT Measures of Thoracic Muscle Provide Prognostication among Heart Transplant Recipients?*; A. J. Kuchnia<sup>1</sup>, J. Lortie<sup>1</sup>, N. Stabo<sup>2</sup>, N. Tsuchiya<sup>2</sup>, T. Hess<sup>3</sup>, N. Binkley<sup>3</sup>, C. Francois<sup>2</sup>, M. L. Schiebler<sup>2</sup>, J. Hermsen<sup>4</sup>, R. Dhingra<sup>5</sup>. <sup>1</sup>Nutritional Sciences, University of Wisconsin-Madison, Madison, WI, <sup>2</sup>Department of Radiology, University of Wisconsin-Madison, Madison, WI, <sup>3</sup>Department of Medicine, University of Wisconsin-Madison, Madison, WI, <sup>4</sup>Department of Surgery, University of Wisconsin-Madison, Madison, WI, <sup>5</sup>Advanced Heart Failure and Transplantation section, Department of Medicine, University of Wisconsin-Madison, Madison, WI

**FRIDAY, APRIL 5, 2019**

**7:00 AM - 8:00 AM**

**SUNRISE SYMPOSIUM 07: Highways to Hell: Chronic Lung Allograft Dysfunction**

**Room: Pacifica 1-2**

**Target Audiences: BSTR, LF/LTX, PATH**

**Chairs:** Sangeeta M. Bhorade, MD, and Stijn E. Verleden, MD, PhD

**Session Summary:** The pathologies of Chronic Lung Allograft Dysfunction (CLAD) have been recognized since 1984, yet their mechanisms and definitive treatments remain enigmatic. Indeed, there are multiple rival hypotheses as to the cause of CLAD. Is CLAD a final common pathway, an integration of pathobiologies, or are some pathways overriding? This symposium will describe the scientific evidence for some of these pathways. A 15-min panel discussion with all speakers will conclude this session.

**7:00 AM**

***Immune Responses Cause CLAD***

Federica Meloni, MD, University of Pavia, Pavia, Italy

**7:15 AM**

***CLAD is a Disease of Accelerated Aging***

John R. Greenland, MD, PhD, UCSF Medical Center, San Francisco, CA, USA

**7:30 AM**

***Mesenchymal Stem Cells are the Cause of CLAD***

Vibha N. Lama, MD, MS, University of Michigan, Ann Arbor, MI, USA

**7:45 AM**

***15-min Panel Discussion***

**FRIDAY, APRIL 5, 2019**

**7:00 AM - 8:00 AM**

**SUNRISE SYMPOSIUM 08: Print, Replace or Innovate: Alternative Strategies to Cardiac Transplantation**

**Room: Pacifica 7**

**Target Audiences: HF/HTX, MCS**

**Chairs:** Mrinalini Krishnan, MD, and Ulrich Steinseifer, MD

**Session Summary:** This symposium will provide an overview of the potential alternatives to and fresh ideas for organ transplantation. Each speaker will provide an overview of the “state of the art” in their respective area of organ repair, regeneration or replacement, and will give insight into successes, challenges and potential of their respective areas, incorporating discussion of the clinical feasibility, ethics and potential of the respective therapies. A 15-min panel discussion with all speakers will conclude this session.

**7:00 AM**

***Copy and Paste vs. Renovate: Cardiac 3D Printing and Its Future Direction***

Doris A. Taylor, PhD, FAHA, FACC, Texas Heart Institute, Houston, TX, USA

**7:15 AM**

***‘When Pigs Fly’: Where Are We Now With Xenotransplantation?***

Richard Pierson, MD, Massachusetts General Hospital, Boston, MA, USA

**7:30 AM**

***Hitting Reset: Utility of Stem Cells to Regenerate the Heart***

Sonja Schrepfer, MD, PhD, UCSF Medical Center, San Francisco, CA, USA

**7:45 AM**

***15-min Panel Discussion***

**FRIDAY, APRIL 5, 2019**

**7:00 AM - 8:00 AM**

**SUNRISE SYMPOSIUM 09: MCS Infections: New Twists in an Old Saga**

**Room: Pacifica 3-5**

**Target Audiences: ID, MCS**

**Chairs:** Saima Aslam, MD, MS, and Jan D. Schmitto, MD, PhD, MBA

**Session Summary:** Infections are a leading cause of death in VAD recipients, and are associated with morbidity, readmissions and healthcare costs. This symposium will focus on state of the art updates on the prevalence of VAD infections and their consequences including neurologic complications. Infection control and quality practices can impact the rate of infections. The recent ISHLT consensus document discussing the prevention and management of MCS infections will be reviewed.

**7:00 AM**

***What are the Consequences of a VAD Infection?***

Palak Shah, MD, MS, Inova Fairfax Hospital, Falls Church, VA, USA

**7:15 AM**

***Q&A***

**7:20 AM**

***Infection Prevention for Patients with Mechanical Circulatory Support***

Margaret Hannan, MD, Mater Hospital, Dublin, Ireland

**7:35 AM**

***Q&A***

**7:40 AM**

***Molecular Pathogenesis and Diagnostic Strategies for MCS Infections***

Anton Peleg, MD, PhD, MPH, The Alfred Hospital and Monash University, Melbourne, Australia

**7:55 AM**

***Q&A***

**FRIDAY, APRIL 5, 2019**

**7:00 AM - 8:00 AM**

**SUNRISE SYMPOSIUM 10: Cardiac Reverse Remodeling in MCS: State of the Art**

**Room: Pacifica 6**

**Target Audiences: MCS, BSTR, PATH**

**Chairs:** Ivan Netuka, MD, PhD, and Joyce W. Wald, DO

**Session Summary:** Mechanical unloading of the left ventricle is a potent platform through which to study reverse remodeling. While we now understand that sufficient “recovery” to allow for device explantation is realistic in only a select population, the concept of reverse remodeling during LVAD still has much broader application. This symposium will highlight reverse remodeling during MCS starting with basic physiology and moving through clinical topics and commencing with a view to the future.

**7:00 AM**                    *Cardiac Recovery on Acute Mechanical Support - When to Wean and When to Transition*

Anna L. Meyer, MD, Leipzig Heart Center, Leipzig, Germany

**7:15 AM**                    *Q&A*

**7:20 AM**                    *LVAD Explantation for Cardiac Recovery – Who, When, and How*

Snehal R. Patel, MD, Montefiore Medical Center, Bronx, NY, USA

**7:35 AM**                    *Q&A*

**7:40 AM**                    *Present and Future of Cardiac Recovery and Durable MCS*

Stavros G. Drakos, MD, PhD, FACC, University of Utah School of Medicine, Salt Lake City, UT, USA

**7:55 AM**                    *Q&A*

**FRIDAY, APRIL 5, 2019**

**7:00 AM - 8:00 AM**

**SUNRISE SYMPOSIUM 11: The Mission IS Possible If You Choose to Accept it: The Processes of Performing Research**

**Room: Pacifica 10-12**

**Target Audience: NHSAH**

**Chairs:** Sarah Schettle, PA-C, and Mary Amanda Dew, PhD

**Session Summary:** Research has led to incredible advancements in organ failure/transplant outcomes. Despite its significance, not all transplant professionals have training or experience in the conduct of research. Launching (or continuing) a program of research can be intimidating for many. Experts in the field will provide guidance on the conduct of research from study development to dissemination findings. Tips for funding one's research will also be shared. A 15-min panel discussion with all speakers will conclude this session.

**7:00 AM**

***Don't Go Rogue: Planning and Launching a Research Study***

Pamela Combs, PhD, RN, University of Chicago, Chicago, IL, USA

**7:15 AM**

***The Fallout: Dissemination and Sharing your Results***

Desiree Robson, RN BSc (Hons), St Vincent's Hospital, Sydney, Australia

**7:30 AM**

***The Ghost Hunt: Funding Your Research***

Kathleen L. Grady, PhD, APN, FAAN, Northwestern Memorial Hospital, Chicago, IL, USA

**7:45 AM**

***15-min Panel Discussion***

**FRIDAY, APRIL 5, 2019**

**7:00 AM - 8:00 AM**

**SUNRISE SYMPOSIUM 12: A Bloody Mess: Management of Hematologic Complications in Transplantation and MCS**

**Room: Coral Sea**

**Target Audiences: PHARM, MCS**

**Chairs:** Bastian Schmack, MD, and Kyle L. Dawson, PharmD, MBA, BCPS

**Session Summary:** This symposium will aim to review pharmacotherapy management of hematologic complications in transplant and MCS including neutropenia, thrombocytopenia, anticoagulation with direct oral anticoagulants (DOACs), hemoglobin optimization, and bleeding reversal.

**7:00 AM**                    *I've Got Friends with Low Platelets (and Neutrophils): Management of Cytopenias After Transplant*  
Jennifer McDermott, PharmD, Spectrum Health, Grand Rapids, MI, USA

**7:15 AM**                    *Q&A*

**7:20 AM**                    *Thicker than Blood: Using DOACs in Transplantation and MCS*  
Sara Strout, PharmD, Johns Hopkins, MD, USA

**7:35 AM**                    *Q&A*

**7:40 AM**                    *Ain't No Hemoglobin High Enough: Approaches to Hemoglobin Optimization and Bleeding Reversal Pre- and Post-Surgery*  
Ian B. Hollis, PharmD, BCPS, University of North Carolina Medical Center, Chapel Hill, NC, USA

**7:55 AM**                    *Q&A*



**FRIDAY, APRIL 5, 2019**

**8:00 AM - 10:00 AM**

**PLENARY SESSION**

**Room: Grand Caribbean 1-7**

**Target Audience: ALL**

**Chairs:** David O. Taylor, MD, and Maryl R. Johnson, MD

**Session Summary:** Changing our Vantage Point: Incorporating New Ideas to Improve Care and Research in Transplantation

**8:00 AM**

***New Perspectives on Tolerance***

Sing Sing Way, MD, PhD, Cincinnati Children's Hospital, Cincinnati, OH, USA

**8:20 AM**

**(3) *Safety and Efficacy of Bacteriophage Therapy in Lung Transplant Candidates and Recipients***; A. Courtwright<sup>1</sup>, C. Koval<sup>2</sup>, S. Lehman<sup>3</sup>, S. Morales<sup>3</sup>, C. L. Furr<sup>3</sup>, F. Rosas<sup>3</sup>, M. Brownstein<sup>4</sup>, J. Fackler<sup>4</sup>, B. M. Sisson<sup>4</sup>, B. Biswas<sup>5</sup>, R. T. Schooley<sup>6</sup>, S. Aslam<sup>6</sup>. <sup>1</sup>*Pulmonary and Critical Care Medicine, University of Pennsylvania, Philadelphia, PA*, <sup>2</sup>*Department of Infectious Diseases, Cleveland Clinic Foundation, Cleveland, OH*, <sup>3</sup>*AmpliPhi Biosciences, San Diego, CA*, <sup>4</sup>*Adaptive Phage Therapeutics, Gaithersburg, MD*, <sup>5</sup>*Naval Medical Research Center, Fort Detrick, MD*, <sup>6</sup>*Department of Infectious Diseases, UC San Diego, San Diego, CA*

**8:35 AM**

***Q&A with Interactive Discussant***

Fernanda P Silveira, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

**8:40 AM**

**(4) *Increased Volume, Improved Quality, and Better Outcomes Using a Specialized Thoracic Adapted Recovery (STAR) Model for Thoracic Transplantation: Experience from 1000 Cases***; H. Tetteh<sup>1</sup>, P. Brandenhoff<sup>2</sup>, R. S. Higgins<sup>3</sup>. <sup>1</sup>*Department of Surgery, Uniformed Services University, Bethesda, MD*, <sup>2</sup>*Cardiothoracic Surgery, Thoracic Transplant Consultants, San Francisco, CA*, <sup>3</sup>*Department of Surgery, Johns Hopkins University, Baltimore, MD*

**8:55 AM**

***Q&A with Interactive Discussant***

Andreas Zuckermann, MD, Medical Univ of Vienna, Vienna, Austria

**9:00 AM**

***Transplant From Every Angle - An Interview***

**Interviewee:** Susan Hou, MD, Loyola University Medical Center, Maywood, IL, USA

**Interviewer:** Daniel F Dilling, MD, Loyola University Medical Center, Maywood, IL, USA

**9:20 AM**

***Countdown to Teamwork***

Colonel Mike Mullane, Astronaut, Albuquerque, NM, USA

FRIDAY, APRIL 5, 2019  
10:30 AM - 12:15 PM

SESSION 51 (ORAL): Cardiac Allograft Vasculopathy: A Never-ending Story  
Room: Pacifica 6  
Target Audiences: HTX, BSTR, PATH

Chairs: Yoshikatsu Saiki, MD, PhD, and Evan P Kransdorf, MD, PhD

- 10:30 AM** (217) *Identification of Latent Classes of Cardiac Allograft Vasculopathy Trajectories after Heart Transplantation and Their Determinants*; G. Coutance<sup>1</sup>, M. Racapé<sup>2</sup>, G. Bonnet<sup>3</sup>, M. Raynaud<sup>2</sup>, J. Van Keer<sup>2</sup>, M. Bories<sup>3</sup>, P. Bruneval<sup>3</sup>, J. Duong Van Huyen<sup>4</sup>, J. Taupin<sup>5</sup>, S. Varnous<sup>6</sup>, R. Guillemain<sup>7</sup>, X. Jouven<sup>3</sup>, A. Loupy<sup>4</sup>. <sup>1</sup>Paris Transplant Group, Pitié-Salpêtrière Hospital, Paris, France, <sup>2</sup>Paris Transplant Group, Paris, France, <sup>3</sup>Paris Transplant Group, Hôpital Européen Georges Pompidou, Paris, France, <sup>4</sup>Paris Transplant Group, Necker Hospital, Paris, France, <sup>5</sup>Saint Louis Hospital, Paris, France, <sup>6</sup>Pitié-Salpêtrière Hospital, Paris, France, <sup>7</sup>Hôpital Européen Georges Pompidou, Paris, France
- 10:45 AM** (218) *Leukotriene B4 Contributes to Development of Cardiac Allograft Vasculopathy*; K. K. Khush<sup>1</sup>, D. Wang<sup>2</sup>, G. Tediashvili<sup>2</sup>, H. Luikart<sup>1</sup>, N. D'Emilio<sup>1</sup>, Y. Moayed<sup>1</sup>, S. Schrepfer<sup>2</sup>. <sup>1</sup>Stanford University, Stanford, CA, <sup>2</sup>University of California San Francisco, San Francisco, CA
- 11:00 AM** (219) *Novel Descriptors of Coronary Wall Properties Measured by OCT at Baseline Are Associated with CAV-Related Intimal Thickening One Year after Heart Transplant*; Z. Chen<sup>1</sup>, M. Pazdernik<sup>2</sup>, A. Wahle<sup>1</sup>, H. Zhang<sup>1</sup>, V. Melenovsky<sup>2</sup>, J. Kautzner<sup>2</sup>, V. Karmazin<sup>2</sup>, H. Bedanova<sup>3</sup>, A. Tomasek<sup>3</sup>, E. Ozabalova<sup>3</sup>, M. Sonka<sup>1</sup>. <sup>1</sup>University of Iowa, Iowa City, IA, <sup>2</sup>Institute of Clinical and Experimental Medicine (IKEM), Prague, Czech Republic, <sup>3</sup>Cardiovascular and Transplantation Surgery Center, St. Annes University Hospital and Masaryk University Brno, Brno, Czech Republic
- 11:15 AM** (220) *Low Serum Magnesium is Associated with Increased Mortality and Cardiac Allograft Vasculopathy Following Heart Transplantation*; Y. Peled<sup>1</sup>, J. Lavee<sup>1</sup>, N. Shlomo<sup>2</sup>, T. Cohen<sup>2</sup>, A. Kogan<sup>1</sup>, E. Maor<sup>1</sup>, M. Shechter<sup>1</sup>, D. Freimark<sup>1</sup>, R. Klempfner<sup>1</sup>. <sup>1</sup>Sheba Medical Center Tel Hashomer and Tel-Aviv University, Ramat Gan, Israel, <sup>2</sup>Israeli Association for Cardiovascular Trials, Ramat Gan, Israel
- 11:30 AM** (221) *Increased Platelet Aggregation in Heart Transplant Recipients with Cardiac Allograft Vasculopathy*; K. P. Bjerre<sup>1</sup>, K. Berg<sup>1</sup>, T. S. Clemmensen<sup>2</sup>, S. H. Poulsen<sup>1</sup>, S. D. Kristensen<sup>1</sup>, A. Hvas<sup>1</sup>, E. L. Grove<sup>1</sup>, H. Eiskjær<sup>1</sup>. <sup>1</sup>Aarhus University Hospital, Aarhus N, Denmark, <sup>2</sup>Horsens Regional Hospital, Horsens, Denmark
- 11:45 AM** (222) *Mild Acute Cellular Rejection is Not Associated with Development of Cardiac Allograft Vasculopathy Assessed by Intravascular Ultrasound and Coronary Angiography in Heart Transplant Recipients - A Substudy of the SCHEDULE Trial*; L. M. Nelson<sup>1</sup>, A. K. Andreassen<sup>2</sup>, S. Arora<sup>2</sup>, B. Andersson<sup>3</sup>, E. Gude<sup>2</sup>, H. Eiskjær<sup>4</sup>, G. Rådegran<sup>5</sup>, G. Dellgren<sup>6</sup>, L. Gullestad<sup>7</sup>, F. Gustafsson<sup>1</sup>. <sup>1</sup>Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, <sup>2</sup>Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, <sup>3</sup>Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, <sup>4</sup>Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus, Denmark, <sup>5</sup>The Clinic for Heart Failure and Valvular Disease, Skåne University Hospital and Lund University, Lund, Sweden, <sup>6</sup>Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden, <sup>7</sup>Department of Cardiology, Oslo University Hospital, Rikshospitalet, and University of Oslo, Oslo, Norway
- 12:00 PM** (223) *Are Gene Expression Profile Testing Scores Associated with New Onset Cardiac Allograft Vasculopathy?*; A. Lala<sup>1</sup>, D. Hiller<sup>2</sup>, J. Yee<sup>2</sup>, K. Khush<sup>3</sup>, R. Alharethi<sup>4</sup>, S. Pinney<sup>5</sup>. <sup>1</sup>Medicine, Cardiology, Population Health Science, Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York, NY, <sup>2</sup>CareDx, Brisbane, CA, <sup>3</sup>Stanford University School of Medicine, Stanford, CA, <sup>4</sup>University of Utah School of Medicine, Salt Lake City, UT, <sup>5</sup>Medicine, Cardiology, Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York, NY

**FRIDAY, APRIL 5, 2019**  
**10:30 AM - 12:15 PM**

**SESSION 52: JOINT ISHLT/SCMR SYMPOSIUM: Cardiac MRI and the World of Heart Failure: When Two Disciplines Harmonize**

**Room: Pacifica 7**

**Target Audience: HF/HTX**

**Chairs:** Daniel Kim, MD, and Sonya Babu-Narayan, MBBS, BSc, PhD

**Session Summary:** In collaboration with the Society for Cardiovascular Magnetic Resonance (SCMR), this symposium will address how CMR advances in structural and functional imaging techniques have led to better cardiac tissue and anatomical characterization in complex patients. We will address its clinical role in the management of cardiomyopathies and heart transplant and explore pathological and imaging relationships while addressing standard and novel CMR based diagnostic approaches including contrast free imaging and imaging in patients with pacemakers. A 15-min panel discussion with all speakers will conclude this session.

- 10:30 AM**            ***MRI Sequences and Pathologic Correlates: The First Face of Janus***  
Annalisa Angelini, MD, University of Padua, Padua, Italy
- 10:45 AM**            ***MRI Sequences and Pathologic Correlates: The Second Face of Janus***  
Timothy C Wong, MD, MS, University of Pittsburg, Pittsburg, PA, USA
- 11:00 AM**            ***5 min Q&A***
- 11:05 AM**            ***CMR and Cardiomyopathies: A World Beyond Speckles***  
Victor A Ferrari, MD, Perelman School of Medicine, Philadelphia, PA, USA
- 11:20 AM**            ***CASE PRESENTATION: A Post-Transplant Patient with New Worsening of LV Function***  
Mandar Aras, MD, UCSF Medical Center, San Francisco, CA, USA
- 11:25 AM**            ***CMR and Heart Transplantation: One Stop Shop?***  
Sofia C Masri, MD, University of Washington, Seattle, WA, USA
- 11:40 AM**            ***CASE PRESENTATION: Patient with CHD and New Echocardiographic Findings: What Next?***  
Chesney Castleberry, MD, Washington University in St. Louis, St. Louis, MO, USA
- 11:45 AM**            ***CMR and Congenital Heart Disease: Not as Baffling as You Thought***  
Sonya Babu-Narayan, MBBS, BSc, PhD, Imperial College London, London, United Kingdom
- 12:00 PM**            ***15-min Panel Discussion***

FRIDAY, APRIL 5, 2019  
10:30 AM - 12:15 PM

SESSION 53 (ORAL): Chasing the Golden Snitch: Optimizing Outcomes of MCS Infections  
Room: Pacifica 1-2  
Target Audiences: ID, MCS

Chairs: Margaret M Hannan, MD, and Christine E Koval, MD

- 10:30 AM** (224) *Increased Risk of Stroke and Death in Ventricular Assist Device Patients Varies by ISHLT Infection Category: An INTERMACS Analysis*; P. Shah<sup>1</sup>, S. E. Birk<sup>2</sup>, L. B. Cooper<sup>1</sup>, M. A. Psoth<sup>1</sup>, J. K. Kirklin<sup>3</sup>, S. D. Barnett<sup>1</sup>, S. B. Katugaha<sup>4</sup>, S. Phillips<sup>1</sup>, M. M. Looby<sup>5</sup>, F. D. Pagani<sup>6</sup>, J. A. Cowger<sup>7</sup>. <sup>1</sup>Heart Failure and Transplantation, Inova Heart and Vascular Institute, Falls Church, VA, <sup>2</sup>School of Public Health, George Washington University, Washington, DC, <sup>3</sup>Cardiac Surgery, University of Alabama, Birmingham, AL, <sup>4</sup>Transplant Infectious Diseases, Inova Heart and Vascular Institute, Falls Church, VA, <sup>5</sup>Department of Pharmacy, Inova Heart and Vascular Institute, Falls Church, VA, <sup>6</sup>Cardiac Surgery, University of Michigan, Ann Arbor, MI, <sup>7</sup>Heart Failure and Transplantation, Henry Ford Hospital, Detroit, MI
- 10:45 AM** (225) *Epidemiology, Outcomes, and Effects of Device Flow Type on Ventricular Assist Devices (VAD) Infections: An IMACS Registry Analysis*; R. Xie<sup>1</sup>, J. Cowger<sup>2</sup>, J. K. Kirklin<sup>1</sup>, M. M. Hannan<sup>3</sup>, D. J. Goldstein<sup>4</sup>, S. Aslam<sup>5</sup>. <sup>1</sup>Department of Surgery, Division of Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, AL, <sup>2</sup>Henry Ford Hospitals, Farmington Hills, MI, <sup>3</sup>Mater Misericordiae University Hospital, Dublin, Ireland, <sup>4</sup>Department of Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY, <sup>5</sup>Division of Infectious Diseases and Global Public Health, University of California, San Diego, San Diego, CA
- 11:00 AM** (226) *A Comprehensive In Vitro Evaluation of Medihoney as an Anti-Biofilm Agent in Preventing Ventricular Assist Device Driveline Infections*; Y. Qu<sup>1</sup>, D. McGiffin<sup>2</sup>, C. Kure<sup>2</sup>, J. McLean<sup>2</sup>, C. Duncan<sup>2</sup>, A. Y. Peleg<sup>1</sup>. <sup>1</sup>Infectious Diseases, The Alfred Hospital and Monash University, Clayton, Australia, <sup>2</sup>Cardiothoracic Surgery, The Alfred Hospital and Monash University, Melbourne, Australia
- 11:15 AM** (227) *Efficacy of Pump Exchange with a Left Ventricular Assist Device Associated Infection*; L. Coyle, C. Gallagher, W. Cotts, P. Pappas, A. Tatoes. Heart and Vascular Institute, Advocate Christ Medical Center, Oak Lawn, IL
- 11:30 AM** (228) *Primary versus Delayed Sternal Closure in Left Ventricular Assist Device Implantation Patients: Impact on Infection*; M. H. Akay<sup>1</sup>, M. Cakici<sup>1</sup>, M. Alagoz<sup>1</sup>, M. K. Patel<sup>1</sup>, M. K. Jezovnik<sup>1</sup>, M. Ilic<sup>1</sup>, I. Salas De Armas<sup>2</sup>, K. Rajagopal<sup>1</sup>, R. Radovancevic<sup>1</sup>, S. Kumar<sup>1</sup>, M. Jumean<sup>1</sup>, B. Kar<sup>1</sup>, I. D. Gregoric<sup>1</sup>. <sup>1</sup>Department of Advanced Cardiopulmonary Therapies and Transplantation, The Univ. of Texas Health Science Center-Houston, Houston, TX, <sup>2</sup>Department of Advanced Cardiopulmonary Therapies and Transplantation, The University of Texas Health Science Center-Houston, Houston, TX
- 11:45 AM** (229) *Comparing the Incidence of Surgical Site Infections (SSI) Using Narrow versus Broad-Spectrum Perioperative Antibiotic Prophylaxis in Mechanical Circulatory Support (MCS) Patients*; L. D. Lam<sup>1</sup>, M. Payne-Cardona<sup>2</sup>, M. Fang<sup>2</sup>, R. Herra<sup>2</sup>, E. Coria Mondragon<sup>2</sup>, C. Runyan<sup>1</sup>, J. Moriguchi<sup>3</sup>, J. A. Kobashigawa<sup>3</sup>, L. S. Czer<sup>3</sup>, F. Arabia<sup>4</sup>, R. Zabner<sup>5</sup>. <sup>1</sup>Mechanical Circulatory Support, Cedars Sinai Comprehensive Transplant Center, Los Angeles, CA, <sup>2</sup>University of California, School of Pharmacy, San Francisco, CA, <sup>3</sup>Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, <sup>4</sup>Advanced Heart Program, Banner/University of Arizona, Phoenix, AZ, <sup>5</sup>Infectious Disease, Cedars Sinai Health System, Los Angeles, CA
- 12:00 PM** (230) *A Study of Infected Drivelines from Ventricular Assist Device Patients: The Presence of Microbial Biofilms and Micro-Gaps in the Driveline Tunnel*; Y. Qu<sup>1</sup>, D. McGiffin<sup>2</sup>, C. Hayward<sup>3</sup>, D. Robson<sup>3</sup>, C. Kure<sup>2</sup>, H. Thissen<sup>4</sup>, S. Marasco<sup>2</sup>, A. Zimet<sup>2</sup>, J. Negri<sup>2</sup>, P. Jansz<sup>5</sup>, K. Dhital<sup>5</sup>, A. Peleg<sup>1</sup>. <sup>1</sup>Infectious Diseases, The Alfred Hospital and Monash University, Melbourne, Australia, <sup>2</sup>Cardiothoracic Surgery, The Alfred Hospital and Monash University, Melbourne, Australia, <sup>3</sup>Department of Cardiology, St Vincent's Public Hospital, Sydney, Darlinghurst, Australia, <sup>4</sup>CSIRO, Melbourne, Australia, <sup>5</sup>Cardiothoracic Surgery, St Vincent's Public Hospital, Sydney, Darlinghurst, Australia

FRIDAY, APRIL 5, 2019  
10:30 AM - 12:15 PM

**SESSION 54 (ORAL): Swipe Right or Swipe Left? Matching Donors and Recipients in Lung Transplantation**  
**Room: Pacifica 10-12**  
**Target Audiences: LF/LTX, ID, PATH**

**Chairs:** Stephane Collaud, MD, and Walter Klepetko, MD

- 10:30 AM**      **(231) 5-Year Results from the ISHLT DCD Lung Transplant Registry Confirm Excellent Recipient Survival from Donation after Circulatory Death Donors;** D. E. Van Raemdonck<sup>1</sup>, S. Keshavjee<sup>2</sup>, B. Levvey<sup>3</sup>, W. S. Cherikh<sup>4</sup>, G. Snell<sup>3</sup>, M. E. Erasmus<sup>5</sup>, A. Simon<sup>6</sup>, A. Glanville<sup>7</sup>, S. Clark<sup>8</sup>, F. D'Ovidio<sup>9</sup>, P. Catarino<sup>10</sup>, K. McCurry<sup>11</sup>, M. Hertz<sup>12</sup>, R. Venkateswaran<sup>13</sup>, P. Hopkins<sup>14</sup>, I. Inci<sup>15</sup>, R. Walia<sup>16</sup>, D. Kreisel<sup>17</sup>, J. Mascaro<sup>18</sup>, D. F. Dilling<sup>19</sup>, P. Camp<sup>20</sup>, D. Mason<sup>21</sup>, M. Musk<sup>22</sup>, M. Burch<sup>23</sup>, A. Fisher<sup>8</sup>, R. Yusen<sup>17</sup>, J. Stehlik<sup>24</sup>, M. Cypel<sup>2</sup>.  
<sup>1</sup>University Hospitals Leuven, Leuven, Belgium, <sup>2</sup>University of Toronto, Toronto, ON, Canada, <sup>3</sup>Alfred Hospital, Melbourne, Australia, <sup>4</sup>UNOS, Richmond, VA, <sup>5</sup>University Medical Center Groningen, Groningen, Netherlands, <sup>6</sup>Harefield Hospital, London, United Kingdom, <sup>7</sup>St Vincent's Hospital, Sydney, Australia, <sup>8</sup>Freeman Hospital, Newcastle upon Tyne, United Kingdom, <sup>9</sup>Columbia University Presbyterian Hospital, New York, NY, <sup>10</sup>Royal Papworth Hospital, Cambridge, United Kingdom, <sup>11</sup>Cleveland Clinic, Cleveland, OH, <sup>12</sup>University of Minnesota, Minneapolis, MN, <sup>13</sup>Wythenshawe Hospital, Manchester, United Kingdom, <sup>14</sup>The Prince Charles Hospital, Brisbane, Australia, <sup>15</sup>University Hospital Zurich, Zurich, Switzerland, <sup>16</sup>St. Joseph's Hospital & Medical Center, Phoenix, AZ, <sup>17</sup>Washington University, St Louis, MO, <sup>18</sup>University Hospitals Birmingham, Birmingham, United Kingdom, <sup>19</sup>Loyola University Medical Center, Chicago, IL, <sup>20</sup>Brigham and Womens Hospital, Boston, MA, <sup>21</sup>Baylor University Medical Center, Dallas, TX, <sup>22</sup>Fiona Stanley Hospital, Perth, Australia, <sup>23</sup>Great Ormond Street for Children, London, United Kingdom, <sup>24</sup>University of Utah, Salt Lake City, UT
- 10:45 AM**      **(232) Estimated Impact of Hepatitis C Positive Lung Donor Utilization on US Donor Lung Supply;** J. Mooney, N. Purington, P. Mohabir, G. Dhillon. Department of Medicine, Stanford University School of Medicine, Stanford, CA
- 11:00 AM**      **(233) Center Variability in Organ Offer Acceptance and Waitlist Mortality in Lung Transplantation;** A. Y. Choi<sup>1</sup>, M. S. Mulvihill<sup>2</sup>, J. Weber<sup>3</sup>, H. Lee<sup>3</sup>, M. L. Cox<sup>2</sup>, B. A. Yerokun<sup>2</sup>, M. Kuchibhatla<sup>3</sup>, J. A. Klapper<sup>2</sup>, M. G. Hartwig<sup>2</sup>. <sup>1</sup>Duke University School of Medicine, Durham, NC, <sup>2</sup>Department of Surgery, Duke University Medical Center, Durham, NC, <sup>3</sup>Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC
- 11:15 AM**      **(234) Donation after Circulatory Death (DCD): A 10-Year Experience in Bilateral Lung Allograft Survival at a Single Australian Center;** D. R. Darley, M. Benzimra, R. Pearson, M. Malouf, A. Glanville, A. Havryk, M. Plit. Lung Transplantation, St Vincent's Hospital, Sydney, Australia
- 11:30 AM**      **(235) The Impact of the Calculated Panel Reactive Antibody Value on Wait List Outcomes for Lung Transplant Candidates;** M. Aversa<sup>1</sup>, L. Benvenuto<sup>1</sup>, H. Kim<sup>1</sup>, L. Shah<sup>1</sup>, H. Robbins<sup>1</sup>, B. P. Stanifer<sup>1</sup>, F. D'Ovidio<sup>1</sup>, E. Vasilescu<sup>2</sup>, J. Sonett<sup>1</sup>, S. Arcasoy<sup>1</sup>. <sup>1</sup>Lung Transplant Program, Columbia University Medical Center, New York, NY, <sup>2</sup>Pathology and Cell Biology, Columbia University Medical Center, New York, NY
- 11:45 AM**      **(236) Utilization of PHS Increased Risk Donors in Lung Transplant Reduces Median Waitlist Time without Reducing Survival;** T. Khuu<sup>1</sup>, R. Chand<sup>2</sup>, C. Lum<sup>2</sup>, A. Salimbangon<sup>3</sup>, A. Chang<sup>1</sup>, D. Ross<sup>4</sup>, A. Ardehali<sup>5</sup>, E. DePasquale<sup>1</sup>. <sup>1</sup>Transplant Services, UCLA, Los Angeles, CA, <sup>2</sup>Medicine, Cardiology, UCLA, Los Angeles, CA, <sup>3</sup>Transplant Service, UCLA, Los Angeles, CA, <sup>4</sup>Medicine, Pulmonology, UCLA, Los Angeles, CA, <sup>5</sup>Surgery, UCLA, Los Angeles, CA
- 12:00 PM**      **(237) Donor-Recipient Size Matching via Chest X-ray Measurements and Primary Graft Dysfunction Risk in Lung Transplantation;** D. Li, J. Weinkauff, D. Lien, A. Kapasi, A. Hirji, K. Halloran. Department of Medicine, University of Alberta, Edmonton, AB, Canada

FRIDAY, APRIL 5, 2019  
10:30 AM - 12:15 PM

SESSION 55 (ORAL): Score Now - Or Forever Hold Your Peace: Prediction and Risk in MCS  
Room: Grand Caribbean 1-7  
Target Audiences: MCS, NNSAH

Chairs: Stuart D. Russell, MD, and Finn Gustafsson, MD, PhD

- 10:30 AM** (238) *Sequential Chains of Adverse Events Post LVAD Implantation*; F. Movahedi<sup>1</sup>, R. L. Kormos<sup>2</sup>, L. Lohmueller<sup>3</sup>, L. Seese<sup>2</sup>, M. Kanwar<sup>4</sup>, S. Murali<sup>5</sup>, Y. Zhang<sup>6</sup>, R. Padman<sup>7</sup>, J. F. Antaki<sup>8</sup>. <sup>1</sup>Electrical Engineering, University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>Medicine, Heart and Vascular Institute, Pittsburgh, PA, <sup>3</sup>School of Computer Science, Carnegie Mellon University, Pittsburgh, PA, <sup>4</sup>Electrical Engineering, Cardiovascular Institute at Allegheny General Hospital, Pittsburgh, PA, <sup>5</sup>Cardiovascular Institute at Allegheny General Hospital, Pittsburgh, PA, <sup>6</sup>Weill Cornell Medicine, Pittsburgh, NY, <sup>7</sup>Heinz College of Information Systems and Public Policy, Pittsburgh, PA, <sup>8</sup>Meinig School of Biomedical Engineering, Cornell University, Pittsburgh, PA
- 10:45 AM** (239) *VE/VCO<sub>2</sub> Predicts RV Dysfunction and Mortality after Left Ventricular Assist Device: A Fresh Look at Cardiopulmonary Stress Testing for Prognostication*; J. Grinstein<sup>1</sup>, Y. Sawalha<sup>2</sup>, M. Hofmeyer<sup>1</sup>, F. Sheikh<sup>1</sup>, M. Rodrigo<sup>1</sup>, A. Kadakkal<sup>1</sup>, C. Barnett<sup>1</sup>, S. Kalantari<sup>3</sup>, I. Talati<sup>4</sup>, R. Zaghlool<sup>2</sup>, E. Molina<sup>1</sup>, S. Mohammed<sup>1</sup>, S. Najjar<sup>1</sup>. <sup>1</sup>MedStar Heart and Vascular Institute, Washington, DC, <sup>2</sup>MedStar Washington Hospital Center, Washington, DC, <sup>3</sup>University of Chicago, Chicago, IL, <sup>4</sup>Georgetown University School of Medicine, Washington, DC
- 11:00 AM** (240) *Features for Success: Factors Associated with Successful LVAD Outcomes at 1-Year Post Implant*; L. C. Lohmueller<sup>1</sup>, M. Kanwar<sup>2</sup>, S. Murali<sup>2</sup>, J. F. Antaki<sup>3</sup>. <sup>1</sup>Language Technologies Institute, Carnegie Mellon University, Pittsburgh, PA, <sup>2</sup>Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA, <sup>3</sup>Biomedical Engineering, Cornell University, Ithaca, NY
- 11:15 AM** (241) *Derivation and Validation of the EUROMACS Left Ventricular Assist Device Score for Long-Term Outcome - The EUROMACS-LVAD-Score*; B. Schrage<sup>1</sup>, N. Rübsamen<sup>2</sup>, C. Magnussen<sup>1</sup>, J. Gummert<sup>3</sup>, F. Schönrrath<sup>4</sup>, T. de By<sup>5</sup>, B. Meyns<sup>6</sup>, D. Westermann<sup>1</sup>, S. Blankenberg<sup>1</sup>, H. Reichenspurner<sup>1</sup>, A. Bernhardt<sup>1</sup>. <sup>1</sup>University Heart Center Hamburg, Hamburg, Germany, <sup>2</sup>University Heart Centre Hamburg, Hamburg, Germany, <sup>3</sup>Heart and Diabetes Center Bad Oeynhausen, Bad Oeynhausen, Germany, <sup>4</sup>German Heart Center Berlin, Berlin, Germany, <sup>5</sup>EUROMACS, Windsor, United Kingdom, <sup>6</sup>Cardiale Heelkunde, Leuven, Belgium
- 11:30 AM** (242) *A Novel Model Incorporating Pectoralis Muscle Measures to Predict Mortality after Ventricular Assist Device Implantation*; R. Cogswell<sup>1</sup>, T. Murray<sup>2</sup>, R. Araujo<sup>3</sup>, L. Teigen<sup>1</sup>, B. Trachtenberg<sup>3</sup>, J. Schultz<sup>1</sup>, R. John<sup>4</sup>, C. Martin<sup>1</sup>, J. Estep<sup>5</sup>. <sup>1</sup>Department of Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN, <sup>2</sup>School of Public Health, Department of Biostatistics, University of Minnesota, Minneapolis, MN, <sup>3</sup>Department of Medicine, Division of Cardiology, Houston Methodist, Houston, TX, <sup>4</sup>Department of Surgery, Division of Cardiovascular Surgery, University of Minnesota, Minneapolis, MN, <sup>5</sup>Department of Medicine, Division of Cardiology, Cleveland Clinic, Cleveland, OH
- 11:45 AM** (243) *Heart Failure Severity Stratification beyond INTERMACS Profiles: A Step towards Identification of Optimal LVAD Implantation Timing*; R. Cogswell<sup>1</sup>, J. Estep<sup>2</sup>, R. Araujo<sup>3</sup>, L. Teigen<sup>1</sup>, J. Schultz<sup>1</sup>, R. John<sup>4</sup>, C. Martin<sup>1</sup>, B. Trachtenberg<sup>3</sup>. <sup>1</sup>Department of Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN, <sup>2</sup>Department of Medicine, Division of Cardiology, Cleveland Clinic, Cleveland, OH, <sup>3</sup>Department of Medicine, Division of Cardiology, Houston Methodist, Houston, TX, <sup>4</sup>Department of Surgery, Division of Cardiovascular Surgery, University of Minnesota, Minneapolis, MN
- 12:00 PM** (244) *Geriatric Nutrition Risk Index is Associated with LVAD Recipient Survival with Cutoff Value of 92.68*; M. Kawabori<sup>1</sup>, S. Lofftus<sup>2</sup>, A. Vest<sup>1</sup>, V. Pramit<sup>2</sup>, Y. Zhan<sup>1</sup>, K. G. Warner<sup>1</sup>, H. Rastegar<sup>1</sup>, M. S. Kiernan<sup>1</sup>, F. Y. Chen<sup>1</sup>, G. S. Couper<sup>1</sup>. <sup>1</sup>Tufts Medical Center, Boston, MA, <sup>2</sup>Tufts University School of Medicine, Boston, MA

**FRIDAY, APRIL 5, 2019**  
**10:30 AM - 12:15 PM**

**SESSION 56: JOINT ISHLT/IPTA SYMPOSIUM: EBV and CMV are Not as Easy as 1-2-3 When Caring for Pediatric Thoracic Transplant Recipients**

**Room: Pacifica 3-5**

**Target Audiences: PEDS, HTX, ID, LTX, NHSAH, PHARM**

**Chairs:** Brian Feingold, MD, MS, and Klara Posfay-Barbe, MD, MS

**Session Summary:** In collaboration with the International Pediatric Transplant Association (IPTA), this symposium will focus on EBV and CMV in pediatric thoracic transplantation. We will cover monitoring, prevention, current and emerging therapies for these entities in pediatric thoracic transplant candidates and recipients. The session will appeal to the following groups: pediatric heart and lung transplant physicians, advance practice nurses, nursing, transplant coordinators, infectious disease clinicians, pharmacists, and translational virologists. A 15-min panel discussion with all speakers will conclude this session.

- 10:30 AM**            *The A-B-C's of EBV Monitoring in Pediatric Thoracic Transplant Recipients*  
Upton Allen, MBBS, MSc, FAAP, FRCPC, University of Toronto/Sick Kids, Toronto, ON, Canada
- 10:45 AM**            *EBV Prevention in Pediatrics: Fantasy or Reality?*  
Michael Green, MD, Children's Hospital of Pittsburgh, Pittsburgh, PA, USA
- 11:00 AM**            *First Line, Advanced, and Emerging Therapies for the Treatment of EBV Disease/PTLD in Pediatrics*  
Steven A Webber, MBChB, Vanderbilt University, Nashville, TN, USA
- 11:15 AM**            *Implications of EBV Disease on Long-Term Outcomes in Thoracic Transplant Recipients*  
Matthew J. Bock, MD, Loma Linda University, Loma Linda, CA, USA
- 11:30 AM**            *PCRs, Cellular Immunity and Immunogenetic Biomarkers: We've Got You Now CMV!*  
Klara Posfay-Barbe, MD, MS, Hopitaux Universitaires de Genève, Genève, Switzerland
- 11:45 AM**            *CMV Prevention and Treatment: Do It Yourself?... or Current Guidelines*  
Lara Danziger-Isakov, MD, Cincinnati Children's Hospital, Cincinnati, OH, USA
- 12:00 PM**            *15-min Panel Discussion*

**FRIDAY, APRIL 5, 2019**  
**10:30 AM - 12:15 PM**

**SESSION 57 (SYMPOSIUM): Take These Broken Lungs and Learn to Fly: Great Debates for Patients with PAH Awaiting Transplant**

**Room: Coral Sea**

**Target Audiences: PH, CTEPH, LF/LTX**

**Chairs:** Paul A. Corris, MB, FRCP, and Oksana A. Shlobin, MD

**Session Summary:** This symposium will explore the complex decision making in the care of patients with end stage pulmonary hypertension awaiting lung transplantation. Should patients with pulmonary hypertension ever be offered combined heart and lung transplantation? Should patients with Group 3 pulmonary hypertension be offered vasodilators as they become sicker before transplantation? Can urgency-based allocation systems be fair to patients with pulmonary hypertension?

- 10:30 AM**            ***CASE PRESENTATION: PAH Patient with Severe RV Dysfunction Prior to Transplant***  
Nicholas Kolaitis, MD, UCSF Medical Center, San Francisco, CA, USA
- 10:35 AM**            ***DEBATE: 'All You Need is Lungs': Lung Transplantation Alone is the Only Type of Organ Transplantation that Should Be Offered in Patients With End Stage PAH***  
Jerome Le Pavec, MD, Hôpital Marie Lannelongue, Le Plessis Robinson, France
- 10:50 AM**            ***DEBATE: 'All You Need is Lungs': Combined Heart/Lung Transplant Should Be Offered in Patients with End Stage PAH***  
Fernando Torres, MD, UT Southwestern Medical Center, Dallas, TX, USA
- 11:05 AM**            ***CASE PRESENTATION: Patient with Group 3 Disease and RV Dysfunction Awaiting Transplant***  
Caroline M Patterson, MD, Papworth Hospital, Cambridge, United Kingdom
- 11:10 AM**            ***DEBATE: Severe PH in Advanced Lung Disease (Group 3) Should Be Treated with Vasodilators (PRO)***  
Steven D. Nathan, MD, Inova Fairfax Hospital, Falls Church, VA, USA
- 11:25 AM**            ***DEBATE: Severe PH in Advanced Lung Disease (Group 3) Should Be Treated with Vasodilators (CON)***  
Adaani Frost, MD, Baylor College of Medicine, Houston, TX, USA
- 11:40 AM**            ***CASE PRESENTATION: Patient with PAH Listed for Lung Transplant Who is Getting Sicker***  
Errol L Bush, MD, Johns Hopkins, Baltimore, MD, USA
- 11:45 AM**            ***DEBATE: Let It Be, Let It Be, Speaking of Urgency Allocation, Let It Be: Urgency-Based Allocation Can Be Fair for Patients with PAH (PRO)***  
Thomas M. Egan, MD, MSC, University of North Carolina School of Medicine, Chapel Hill, NC, USA
- 12:00 PM**            ***DEBATE: Let It Be, Let It Be, Speaking of Urgency Allocation, Let It Be: Urgency-Based Allocation Can Be Fair for Patients with PAH (CON)***  
Helen M Whitford, MBBS, FRACP, Alfred Hospital, Melbourne, Australia



**FRIDAY, APRIL 5, 2019**  
**2:00 PM - 3:45 PM**

**SESSION 58 (SYMPOSIUM): Resilience in the Face of Calamity: The Art of Preventing PTE Disasters**  
**Room: Coral Sea**  
**Target Audiences: CTEPH, PH**

**Chairs:** Elie Fadel, MD, and John Cannon, MD

**Session Summary:** The success of Pulmonary Thromboendarterectomy (PTE) has improved over the years due to better understanding of the pathophysiological mechanisms leading to major complications. This knowledge has translated into better ability to prevent them, recognize them early on and manage them more appropriately. This symposium will review specific complications related to PTE and discuss how to manage them to achieve a successful outcome. A 15-min panel discussion with all speakers will conclude this session.

**2:00 PM**                    *Diagnosed with CTEPH and Decompensated Right Heart Failure: What are the Options?*

Marc de Perrot, MD, Toronto General Hospital, Toronto, ON, Canada

**2:15 PM**                    *ECMO as a Rescue: When, Why and How?*

David P Jenkins, FRCS, Papworth Hospital, Cambridge, United Kingdom

**2:30 PM**                    *Major Hemoptysis After PTE: How to Assess It and Treat It?*

David McGiffin, MD, Alfred Hospital and Monash University, Melbourne, Australia

**2:45 PM**                    *Severe Reperfusion Pulmonary Edema After PTE: Can We Prevent It?*

Kim M Kerr, MD, UCSD Medical Center, La Jolla, CA, USA

**3:00 PM**                    *Residual PH after PTE: When Should I Start to Worry and What Should I Do?*

Joanna Pepke-Zaba, MD, Papworth Hospital, Cambridge, United Kingdom

**3:15 PM**                    *Diagnosed with CTEPH and Heparin Induced Thrombocytopenia (HIT): How to Proceed?*

Olaf Mercier, MD, Centre Chirurgical Marie Lannelongue, Fontenay aux Roses, France

**3:30 PM**                    *15-min Panel Discussion*

FRIDAY, APRIL 5, 2019

2:00 PM - 3:45 PM

**SESSION 59 (ORAL): Heart Transplant Short-Term Outcomes: Getting it Right From the Start**

Room: Pacifica 7

Target Audiences: HTX, MCS

Chairs: Sung-Ho Jung, MD, and Marian Urban, MD

- 2:00 PM** (245) *LVAD Patients with RV Failure Pre-Heart Transplant Have Reduced Post-Transplant Survival*; Y. D. Barac, O. Jawitz, J. Schroder, M. Daneshmand, C. Patel, C. Milano. *Duke University Medical Center, Durham, NC*
- 2:15 PM** (246) *Predictors of Favorable Outcome in Patients Bridged to Transplant with Temporary Mechanical Circulatory Support Devices*; M. Yin<sup>1</sup>, O. Wever-Pinzon<sup>1</sup>, M. R. Mehra<sup>2</sup>, C. G. Selzman<sup>3</sup>, A. E. Toll<sup>4</sup>, W. S. Cherikh<sup>4</sup>, J. Nativi-Nicolau<sup>1</sup>, J. C. Fang<sup>1</sup>, A. G. Kfoury<sup>5</sup>, E. M. Gilbert<sup>1</sup>, L. Kemeyou<sup>1</sup>, S. H. McKellar<sup>3</sup>, A. Koliopoulou<sup>3</sup>, M. Vaduganathan<sup>2</sup>, S. Drakos<sup>1</sup>, J. Stehlik<sup>1</sup>. <sup>1</sup>*Cardiovascular Services, University of Utah, Salt Lake City, UT*, <sup>2</sup>*Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA*, <sup>3</sup>*Cardiothoracic Surgery, University of Utah, Salt Lake City, UT*, <sup>4</sup>*United Network for Organ Sharing, Richmond, VA*, <sup>5</sup>*Intermountain Healthcare, Salt Lake City, UT*
- 2:30 PM** (247) *In Hospital Outcomes in Adult Congenital Heart Disease Patients with Fontan Undergoing Heart Transplantation - A Decade Nationwide Analysis from 2004 until 2014*; G. A. Hernandez<sup>1</sup>, A. Lemor<sup>2</sup>, D. Clark<sup>3</sup>, V. Blumer<sup>1</sup>, R. Byrne<sup>3</sup>, R. Fowler<sup>3</sup>, E. Sandhaus<sup>3</sup>, A. Weingarten<sup>3</sup>, B. Frischhertz<sup>3</sup>, K. Schlendorf<sup>3</sup>, S. Zalawadiya<sup>3</sup>, J. Lindenfeld<sup>3</sup>, J. Menachem<sup>3</sup>. <sup>1</sup>*University of Miami, Miami, FL*, <sup>2</sup>*Henry Ford Hospital, Detroit, MI*, <sup>3</sup>*Vanderbilt University, Nashville, TN*
- 2:45 PM** (248) *Development and Validation of a Risk Model for Primary Graft Failure after Heart Transplantation and Comparison to the RADIAL Risk Score*; D. Reichart<sup>1</sup>, L. Castro<sup>2</sup>, N. Ruebsamen<sup>1</sup>, S. Blankenberg<sup>1</sup>, H. Reichenspurner<sup>2</sup>, A. Bernhardt<sup>2</sup>. <sup>1</sup>*Department of Cardiology, University Heart Center Hamburg, Hamburg, Germany*, <sup>2</sup>*Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany*
- 3:00 PM** (249) *Outcomes with Heartsizes Matching among Cardiac Transplant Recipients with Pulmonary Hypertension*; M. Shah<sup>1</sup>, O. Saeed<sup>1</sup>, J. Shin<sup>1</sup>, S. Murthy<sup>1</sup>, D. B. Sims<sup>1</sup>, S. Vukelic<sup>1</sup>, D. Goldstein<sup>2</sup>, S. J. Forest<sup>2</sup>, U. P. Jorde<sup>1</sup>, S. R. Patel<sup>1</sup>. <sup>1</sup>*Advanced HF/Transplant Cardiology, Montefiore Medical Center, Bronx, NY*, <sup>2</sup>*Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY*
- 3:15 PM** (250) *Insights from High-Performing Heart Transplant Centers across the Recipient Risk-Spectrum*; T. P. Singh<sup>1</sup>, M. R. Mehra<sup>2</sup>, K. Gauvreau<sup>3</sup>. <sup>1</sup>*Pediatrics, Harvard Medical School, Boston, MA*, <sup>2</sup>*Medicine, Harvard Medical School, Boston, MA*, <sup>3</sup>*Biostatistics, Harvard School of Public Health, Boston, MA*
- 3:30 PM** (251) *A Direct Heart-Transplantation Strategy in Selected Patients on Extra-Corporeal Membrane Oxygenation Achieved Favorable Post-Transplant Outcomes*; G. Coutance<sup>1</sup>, G. Lebreton<sup>1</sup>, N. Jacob<sup>1</sup>, N. Bréchet<sup>2</sup>, P. Demondion<sup>1</sup>, A. Bouglé<sup>3</sup>, L. Nguyen<sup>1</sup>, S. Varnous<sup>1</sup>, A. Combes<sup>2</sup>, P. Leprince<sup>1</sup>. <sup>1</sup>*Cardiac Surgery, Groupe Hospitalier Pitié-Salpêtrière, Paris, France*, <sup>2</sup>*Intensive Care Unit, Groupe Hospitalier Pitié-Salpêtrière, Paris, France*, <sup>3</sup>*Anaesthesiology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France*

**FRIDAY, APRIL 5, 2019**  
**2:00 PM - 3:45 PM**

**SESSION 60: JOINT ISHLT/ABTO SYMPOSIUM: Combining Experiences to Enhance Thoracic Organ Transplantation Worldwide**

**Room: Pacifica 3-5**

**Target Audiences: ID, HF/HTX, LF/LTX**

**Chairs:** Paulo M. Pego-Fernandes, MD, PhD, and Fernanda P Silveira, MD

**Session Summary:** This joint symposium with the Associação Brasileira de Transplante de Órgãos (ABTO: Brazilian Association of Organ Transplants) will provide the opportunity to exchange experiences between heart and lung transplant centers in Brazil and other centers around the world. Important topics regarding aspects of thoracic organ procurement in different countries and health systems as well as the regional variations in disease burden will be discussed. A 15-min panel discussion with all speakers will conclude this session.

- 2:00 PM**                    *The Largest Public Kidney Transplant Program in the World: What Lessons Should We Learn to Improve Thoracic Organ Transplantation?*  
Jose Osmar Medina Pestana, MD, Hospital do Rim e Hipertensão of Universidade Federal de São Paulo, São Paulo, Brazil
- 2:15 PM**                    *Few Potential Donors and One of the Largest (Lung) Transplant Systems of the World: How is it Possible?*  
Jonathan Yeung, MD, Toronto General Hospital, Toronto, ON, Canada
- 2:30 PM**                    *Tuberculosis and Thoracic Organ Transplantation: Pre- and Post-Transplant Management in Endemic Areas*  
Luis Fernando Aranha Camargo, MD, Universidade Federal de São Paulo/Escola Paulista de Medicina, São Paulo, Brazil
- 2:45 PM**                    *Tuberculosis and Thoracic Organ Transplantation: Pre- and Post-Transplant Management in Non-Endemic Areas*  
Amparo Sole, MD, Hospital Universitario La Fe, Valencia, Spain
- 3:00 PM**                    *Heart Transplant and Chagas Disease: Lessons Learned After 30 Years of Experience*  
Tania Mara Varejão Strabelli, MD, Heart Institute São Paulo Medical School, São Paulo, Brazil
- 3:15 PM**                    *Chagas Disease and Heart Failure Management in Non-Endemic Areas*  
Ricardo La Hoz, MD, UT Southwestern Medical Center, Dallas, TX, USA
- 3:30 PM**                    *15-min Panel Discussion*

**FRIDAY, APRIL 5, 2019**

**2:00 PM - 3:45 PM**

**SESSION 61 (SYMPOSIUM): Making Them Count: Enhancing Lung Donor Utilization**

**Room: Pacifica 10-12**

**Target Audiences: LF/LTX, ID**

**Chairs:** Aleem Siddique, MBBS, and Sakhee Kotecha, MBBS (Hons)

**Session Summary:** Patients with end stage heart and lung disease outnumber the annual thoracic transplants. Maximizing donor utilization is a key factor to addressing this imbalance, but donor management varies greatly across regions leading to significant heterogeneity in donor utilization. This symposium will describe proven and developing strategies for donor management to increase organ utilization as well as identify future directions and opportunities for improvement. A 15-min panel discussion with all speakers will conclude this session.

**2:00 PM**                    *Yin and Yang? Goal Directed Thoracic Organ Optimization Does Not Compromise Abdominal Organs*

Arne Neyrinck, MD, PhD, University Hospitals Leuven, Leuven, Belgium

**2:15 PM**                    *Practical Steps to Optimize the Heart and Lungs: The UK Experience*

Rajamiyer Venkateswaran, FRCS, Wythenshawe Hospital, Manchester, United Kingdom

**2:30 PM**                    *Carpe Diem - On the Cusp of an Explosion? Research in Donor Management*

George B. Mallory, MD, Texas Children's Hospital, Houston, TX, USA

**2:45 PM**                    *Impact of Using Infection Risk Donors Including NAT +HCV*

Marcelo Cypel, MD, Toronto General Hospital, Toronto, ON, Canada

**3:00 PM**                    *Making the Most in DCD Lung Transplant*

Dirk Van Raemdonck, MD, PhD, University Hospitals, Leuven, Belgium

**3:15 PM**                    *Use of Older Donors for Lung Transplantation: How Old is Too Old?*

Jonathan Singer, MD, MS, UCSF Medical Center, San Francisco, CA, USA

**3:30 PM**                    *15-min Panel Discussion*

FRIDAY, APRIL 5, 2019  
2:00 PM - 3:45 PM

**SESSION 62 (ORAL): Under New Management: Novel Strategies for MCS**  
**Room: Grand Caribbean 1-7**  
**Target Audiences: MCS, PHARM**

**Chairs:** Jan F Gummert, MD, PhD, and Gabriel Sayer, MD

- 2:00 PM** (252) *High Afterload Driving Poor Cardiac Output in LVAD Patients is Rectified with Nitrate Therapy*; A. Rosenbaum, A. Behfar. *Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN*
- 2:15 PM** (253) *Intravenous Iron Replacement in Patients with Left Ventricular Assist Devices. A Pilot Study*; A. Mardis<sup>1</sup>, C. Robinson<sup>2</sup>, B. Stafford<sup>2</sup>, J. Patel<sup>1</sup>, J. Barham<sup>2</sup>, A. Poole<sup>2</sup>, S. Branham<sup>2</sup>, J. Martin<sup>2</sup>, R. Napier<sup>3</sup>, P. McCann<sup>3</sup>. <sup>1</sup>*Department of Pharmacy, Palmetto Health, Columbia, SC*, <sup>2</sup>*Cardiothoracic Surgery, Palmetto Health, Columbia, SC*, <sup>3</sup>*Cardiology, Palmetto Health, Columbia, SC*
- 2:30 PM** (254) *A Trial of Complete Withdrawal of Anticoagulation Therapy in the Heartmate 3 Pump*; I. Netuka<sup>1</sup>, P. Ivak<sup>1</sup>, Z. Tucanova<sup>1</sup>, S. Gregor<sup>1</sup>, O. Szarszoi<sup>1</sup>, J. Rimsans<sup>2</sup>, J. Connors<sup>2</sup>, D. Crandall<sup>3</sup>, P. Sood<sup>3</sup>, M. Mehra<sup>2</sup>. <sup>1</sup>*Institute for Clinical & Experimental Medicine, Prague, Czech Republic*, <sup>2</sup>*Brigham and Women's Hospital, Boston, MA*, <sup>3</sup>*Abbott, Burlington, MA*
- 2:45 PM** (255) *A Long-Term Counterpulsation Heart Assist System Used as a Bridge to Decision in Advanced Congestive Heart Failure*; T. Symalla<sup>1</sup>, T. Song<sup>1</sup>, D. Onsager<sup>1</sup>, T. Ota<sup>1</sup>, C. LaBuhn<sup>1</sup>, P. Combs<sup>1</sup>, T. Lammy<sup>1</sup>, S. Patel-Raman<sup>2</sup>, G. Sayer<sup>3</sup>, G. Kim<sup>3</sup>, J. Raikhelkar<sup>3</sup>, N. Uriel<sup>3</sup>, V. Jeevanandam<sup>1</sup>. <sup>1</sup>*Cardiac Surgery, University of Chicago, Chicago, IL*, <sup>2</sup>*NuPulseCV, University of Chicago, Chicago, IL*, <sup>3</sup>*Cardiology, University of Chicago, Chicago, IL*
- 3:00 PM** (256) *Calculation of VAD Cardiac Cycle Volume Using HeartWare Waveform*; K. L. Kiehl<sup>1</sup>, B. N. Butzler<sup>1</sup>, M. T. Saltzberg<sup>2</sup>, D. Ishizawar<sup>2</sup>, A. A. Mohammed<sup>2</sup>, R. L. Kursel<sup>2</sup>, N. A. Gaglianello<sup>2</sup>. <sup>1</sup>*Advanced Heart Failure, Froedtert Hospital, Milwaukee, WI*, <sup>2</sup>*Advanced Heart Failure and Transplant Cardiology, The Medical College of Wisconsin, Milwaukee, WI*
- 3:15 PM** (553) *Right Heart Function Worsens in LVAD Patients with Decoupling between Pulmonary Artery and Wedge Pressures*; T. Imamura, B. Smith, J. Raikhelkar, D. Rodgers, G. Kim, S. Kalantari, A. Nguyen, N. Narang, B. Chung, I. Ebong, L. Holzhauser, D. Nitta, T. Fujino, C. Juricek, P. Combs, D. Onsager, T. Song, T. Ota, V. Jeevanandam, G. Sayer, N. Uriel. *University of Chicago, Chicago, IL*
- 3:30 PM** (258) *Outcomes of Obese Patients Bridged to Heart Transplantation with Continuous-Flow Left Ventricular Assist Devices*; A. K. Okoh<sup>1</sup>, S. Fugar<sup>2</sup>, M. Schulthies<sup>3</sup>, M. Russo<sup>1</sup>, K. Rivandra<sup>1</sup>, R. Yanagida<sup>1</sup>, M. Camacho<sup>1</sup>. <sup>1</sup>*RWJ Barnabas Health Newark Beth Israel Medical Center, RWJ Barnabas Health Newark Beth Israel Medical Center, Newark, NJ*, <sup>2</sup>*Division of Cardiology, Rush University Medical Center, Chicago, NJ*, <sup>3</sup>*RWJ Barnabas Health Newark Beth Israel Medical Center, Newark, NJ*

**FRIDAY, APRIL 5, 2019**

**2:00 PM - 3:45 PM**

**SESSION 63: JOINT ISHLT/ICCAC SYMPOSIUM: Faster, Higher, Stronger: Monitoring Exercise in Cyberspace**

**Room: Pacifica 6**

**Target Audiences: MCS, NNSAH**

**Chairs:** Peggy S. Blood, RN, MSN, and Simon Maltais, MD, PhD

**Session Summary:** Patient and healthcare provider partnerships can enhance patient outcomes. Remote care support and monitoring of MCS patients can improve patient independence and positively impact patient care. This joint symposium with the International Consortium of Circulatory Assist Clinicians (ICCAC) will discuss integration of self-care strategies, educational preparation, new technologies maximizing MCS patient management, strategies to reduce morbidity and mortality, the future of MCS support, and challenges and opportunities that advancing technology poses to current practice.

- 2:00 PM**            *Under Pressure: Continuous Pulmonary Artery Monitoring and LVAD*  
Finn Gustafsson, MD, PhD, Rigshospitalet, Copenhagen, Denmark
- 2:15 PM**            *Q&A*
- 2:20 PM**            *Care Anywhere: Remote Patient Monitoring*  
Michele C Kassemos, BSN, UCSF Medical Center, San Francisco, CA, USA
- 2:35 PM**            *Q&A*
- 2:40 PM**            *There's an App for That: Preparing the EMS*  
Thomas Schloeglhofer, MSc, Medical University of Vienna, Vienna, Austria
- 2:55 PM**            *Q&A*
- 3:00 PM**            *Frailty and Exercise Tolerance: How Are They Related?*  
Kavitha Muthiah, MBChB, PhD, St. Vincent's Hospital, Sydney, Australia
- 3:15 PM**            *Q&A*
- 3:20 PM**            *Let the Pacer Do the Work! Conduction Abnormalities in Heart Failure and Their Role in Exercise During VAD Support*  
Van-Khue Ton, MD PhD, University of Maryland School of Medicine, Baltimore, MD, USA
- 3:35 PM**            *Q&A*

FRIDAY, APRIL 5, 2019

2:00 PM - 3:45 PM

**SESSION 64 (ORAL): Highlights of Challenging Topics in Pediatric Heart Transplant and MCS**

Room: Pacifica 1-2

Target Audiences: PEDS, HF/HTX, MCS

Chairs: Estela Azeka, MD, and David L Sutcliffe, MD

- 2:00 PM** (259) *Simultaneous Pediatric Heart-Kidney Transplant Outcomes in the US: A 25 Year National Cohort Study*; S. Choudhry<sup>1</sup>, S. W. Denfield<sup>1</sup>, V. R. Dharnidharka<sup>2</sup>, Y. Wang<sup>1</sup>, J. F. Price<sup>1</sup>, A. G. Cabrera<sup>1</sup>, H. P. Tunuguntla<sup>1</sup>, W. J. Dreyer<sup>1</sup>. <sup>1</sup>Texas Children's Hospital, Baylor College of Medicine, Houston, TX, <sup>2</sup>Washington University School of Medicine, Saint Louis, MO
- 2:15 PM** (260) *Development and Validation of a Pediatric Heart Failure Risk-Prediction Model for Children Listed for Heart Transplantation in the Current Era*; C. Chen<sup>1</sup>, Y. Zhang<sup>2</sup>, E. Profita<sup>1</sup>, J. C. Dykes<sup>1</sup>, E. Liu<sup>1</sup>, K. Maeda<sup>3</sup>, C. S. Almond<sup>1</sup>. <sup>1</sup>Pediatric Cardiology, Stanford University, Palo Alto, CA, <sup>2</sup>Cardiothoracic Surgery, Clinical and Translational Research Program, Stanford University, Palo Alto, CA, <sup>3</sup>Cardiothoracic Surgery, Stanford University, Palo Alto, CA
- 2:30 PM** (261) *Cardiac Transplantation in Fontan Patients Has Equally Excellent Results as Biventricular Congenital Heart Disease Patients*; K. W. Riggs<sup>1</sup>, J. T. Broderick<sup>1</sup>, C. Chin<sup>2</sup>, R. Bryant III<sup>1</sup>, F. Zafar<sup>1</sup>, D. L. Morales<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, OH, <sup>2</sup>Pediatric Cardiology, Cincinnati Children's Hospital, Cincinnati, OH
- 2:45 PM** (262) *Speaking the Same Language? Assessing Blood Pressure Measurement and Effectiveness in Pediatric VAD Patients*; C. Villa<sup>1</sup>, D. Peng<sup>2</sup>, S. Auerbach<sup>3</sup>, S. Kindel<sup>4</sup>, S. Law<sup>5</sup>, A. Lorts<sup>1</sup>, M. Mehegan<sup>6</sup>, M. O'Connor<sup>7</sup>, M. Ploutz<sup>8</sup>, D. Rosenthal<sup>9</sup>, C. VanderPluym<sup>10</sup>, M. Zinn<sup>11</sup>, D. Sutcliffe<sup>12</sup>. <sup>1</sup>Cincinnati Children's Hospital Medical Center, Cincinnati, OH, <sup>2</sup>C.S. Mott Children's Hospital, Ann Arbor, MI, <sup>3</sup>Children's Hospital of Colorado, Aurora, CO, <sup>4</sup>Children's Hospital of Wisconsin, Milwaukee, WI, <sup>5</sup>New York Presbyterian/Morgan Stanley Children's Hospital, New York, NY, <sup>6</sup>St. Louis Children's Hospital, Saint Louis, MO, <sup>7</sup>Children's Hospital of Philadelphia, Philadelphia, PA, <sup>8</sup>Phoenix Children's Hospital, Phoenix, AZ, <sup>9</sup>Lucille Packard Children's Hospital, Palo Alto, CA, <sup>10</sup>Children's Hospital of Boston, Boston, MA, <sup>11</sup>Children's Hospital of Pittsburgh, Pittsburgh, PA, <sup>12</sup>Children's Medical Center Dallas, Dallas, TX
- 3:00 PM** (263) *Extracorporeal Membrane Oxygenation Use within 24 Hours of Heart Transplantation in Children: Incidence, Risk Factors, and Outcomes*; J. Godown<sup>1</sup>, D. W. Bearl<sup>1</sup>, C. Thurm<sup>2</sup>, M. Hall<sup>2</sup>, B. Feingold<sup>3</sup>, J. H. Soslow<sup>1</sup>, B. A. Mettler<sup>4</sup>, A. H. Smith<sup>5</sup>, E. Profita<sup>6</sup>, T. P. Singh<sup>7</sup>, D. A. Dodd<sup>1</sup>. <sup>1</sup>Pediatric Cardiology, Monroe Carell Jr. Children's Hospital, Nashville, TN, <sup>2</sup>Children's Hospital Association, Lenexa, KS, <sup>3</sup>Pediatric Cardiology, Children's Hospital of Pittsburgh, Pittsburgh, PA, <sup>4</sup>Pediatric Cardiothoracic Surgery, Monroe Carell Jr. Children's Hospital, Nashville, TN, <sup>5</sup>Pediatric Critical Care, Monroe Carell Jr. Children's Hospital, Nashville, TN, <sup>6</sup>Pediatric Cardiology, Lucille Packard Children's Hospital, Palo Alto, CA, <sup>7</sup>Pediatric Cardiology, Boston Children's Hospital, Boston, MA
- 3:15 PM** (264) *Risk Factors for Cardiac Causes of Death in Males with Duchenne Muscular Dystrophy*; C. A. Wittlieb-Weber<sup>1</sup>, K. K. Knecht<sup>2</sup>, C. R. Villa<sup>3</sup>, C. Cunningham<sup>4</sup>, M. J. Bock<sup>5</sup>, K. E. Gambetta<sup>6</sup>, A. K. Lal<sup>7</sup>, K. R. Schumacher<sup>8</sup>, S. P. Law<sup>9</sup>, S. R. Deshpande<sup>10</sup>, S. C. West<sup>11</sup>, J. M. Friedland-Little<sup>12</sup>, I. D. Lytrivi<sup>9</sup>, M. A. McCulloch<sup>13</sup>, R. J. Butts<sup>14</sup>, D. R. Weber<sup>1</sup>, J. N. Johnson<sup>15</sup>. <sup>1</sup>University of Rochester Medical Center, Rochester, NY, <sup>2</sup>University of Arkansas, Little Rock, AR, <sup>3</sup>Cincinnati Children's Hospital Medical Center, Cincinnati, OH, <sup>4</sup>Chentel.cunningham@albertahealthservices.ca, Edmonton, AB, Canada, <sup>5</sup>Loma Linda University Children's Hospital, Loma Linda, CA, <sup>6</sup>Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, <sup>7</sup>Primary Children's Hospital, Salt Lake City, UT, <sup>8</sup>C.S. Mott Children's Hospital, Ann Arbor, MI, <sup>9</sup>Morgan Stanley Children's Hospital of New York Presbyterian, New York, NY, <sup>10</sup>Children's National, Washington, DC, DC, <sup>11</sup>Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, <sup>12</sup>Seattle Children's Hospital, Seattle, WA, <sup>13</sup>University of Virginia Children's Hospital, Charlottesville, VA, <sup>14</sup>Children's Medical Center of Dallas, Dallas, TX, <sup>15</sup>Mayo Clinic Children's Center, Rochester, MN
- 3:30 PM** (265) *ABO Incompatible Listing in Early Childhood Results in Earlier Transplantation and Equal Post-Transplant Survival Despite Predominant Use in Sicker Patients*; S. Urschel<sup>1</sup>, M. McCoy<sup>1</sup>, Z. Reinhardt<sup>2</sup>, A. Dipchand<sup>3</sup>, R. S. Cantor<sup>4</sup>, D. A. Koehl<sup>4</sup>, J. K. Kirklin<sup>4</sup>, J. A. Ballweg<sup>5</sup>, K. R. Kanter<sup>6</sup>, W. Zuckerman<sup>7</sup>, J. Sparks<sup>8</sup>, W. F. Carlo<sup>9</sup>. <sup>1</sup>Pediatrics, University of Alberta, Edmonton, AB, Canada, <sup>2</sup>Pediatrics, Freeman Hospital, Newcastle upon Tyne, United Kingdom, <sup>3</sup>Pediatrics, Hospital for Sick Children, Toronto, ON,

Canada, <sup>4</sup>Kirklın Institute for Research in Surgical Outcomes (KIRSO), Birmingham, AL, <sup>5</sup>Pediatrics, Children's Hospital & Medical Center, Omaha, Omaha, NE, <sup>6</sup>Pediatrics, Emory University School of Medicine, Atlanta, GA, <sup>7</sup>Pediatrics, Columbia University Medical Center, New York, NY, <sup>8</sup>Pediatrics, University of Louisville, Louisville, KY, <sup>9</sup>Pediatrics, University of Alabama, Birmingham, AL



**FRIDAY, APRIL 5, 2019**

**4:15 PM - 6:00 PM**

**SESSION 65 (SYMPOSIUM): All Talk, No Action? New Strategies and Best Practices to Maximize Donor Heart Utilization**

**Room: Pacifica 7**

**Target Audiences: HF/HTX, LF/LTX**

**Chairs:** Kiran K Khush, MD, and James K. Kirklin, MD

**Session Summary:** The paucity of donors is still the primary limitation for heart transplantation across the world. Too many donor hearts are not accepted for concerns over particular risk factors. This symposium will explore novel ways to expand the donor pool. In a time when the waiting lists grow exponentially, our field must find ways to maximize donor utilization. A 15-min panel discussion with all speakers will conclude this session.

**4:15 PM**

***Perfect is the Enemy of Good: Using Marginal Donor Hearts***

David Rabkin, MD, Loma Linda University, Loma Linda, CA, USA

**4:30 PM**

***Riding the Epidemic: Hepatitis C + Donors Should Become Standard of Care***

Kelly Schlendorf, MD, Vanderbilt University, Nashville, TN, USA

**4:45 PM**

***Distance Makes the Heart Grow Fonder: Miles Should Not Limit Donor Acceptance***

Christopher S Hayward, MD, St. Vincent's Hospital, Sydney, Australia

**5:00 PM**

***Love It or Levophed It: High Dose Catecholamine Donor Support and Outcomes After Heart Transplantation***

Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria

**5:15 PM**

***DEBATE: All Nations Should Have an Opt Out System (PRO)***

Maria Dolores Cosio, MD, Hospital 12 Octubre, Madrid, Spain

**5:30 PM**

***DEBATE: All Nations Should Have an Opt Out System (CON)***

Peter J Bergin, MBBS, FRACP, Alfred Hospital, Melbourne, Australia

**5:45 PM**

***15-min Panel Discussion***

FRIDAY, APRIL 5, 2019

4:15 PM - 6:00 PM

SESSION 66 (ORAL): **Between the Devil and the Deep Blue Sea: Fungus or CMV?**

Room: Pacifica 1-2

Target Audiences: ID, HTX, LTX, PEDS, PHARM

Chairs: Shahid Husain, MD, MS, and Erik Verschuuren, MD, PhD

- 4:15 PM** (266) *Pentraxin-3 Polymorphisms are Associated with Invasive Pulmonary Aspergillosis after Lung Transplantation*; A. Van Herck<sup>1</sup>, A. Sacreas<sup>1</sup>, T. Heigl<sup>1</sup>, J. Kaes<sup>1</sup>, A. Vanstapel<sup>1</sup>, S. E. Verleden<sup>1</sup>, D. Lambrechts<sup>2</sup>, B. M. Vanaudenaerde<sup>1</sup>, G. M. Verleden<sup>1</sup>, R. Vos<sup>1</sup>. <sup>1</sup>Lung Transplant Unit, Department of Chronic Diseases, Metabolism & Ageing, University of Leuven, Leuven, Belgium, <sup>2</sup>Laboratory of Translational Genetics (VIB Center for Cancer Biology), Department of Human Genetics, University of Leuven, Leuven, Belgium
- 4:30 PM** (267) *Isavuconazonium Pharmacokinetic Interactions with Immunosuppression in Thoracic Transplant Recipients*; C. Burt<sup>1</sup>, J. Kozuch<sup>1</sup>, M. Mariski<sup>1</sup>, A. Feist<sup>1</sup>, K. Afshar<sup>2</sup>, G. Yung<sup>2</sup>, T. Floreth<sup>2</sup>, E. Golts<sup>3</sup>, S. Aslam<sup>4</sup>. <sup>1</sup>Pharmacy, University of California San Diego Health, San Diego, CA, <sup>2</sup>Pulmonology, University of California San Diego Health, San Diego, CA, <sup>3</sup>Cardiothoracic Surgery, University of California San Diego Health, San Diego, CA, <sup>4</sup>Infectious Diseases, University of California San Diego Health, San Diego, CA
- 4:45 PM** (268) *A Comparison of Aspergillus Prophylaxis with Voriconazole versus Isavuconazole in Lung Transplant Recipients*; D. D. Nanayakkara<sup>1</sup>, E. Blodget<sup>1</sup>, S. Ganesh<sup>2</sup>. <sup>1</sup>Infectious Diseases, University of Southern California, Los Angeles, CA, <sup>2</sup>Pulmonary and Critical Care Medicine, University of Southern California, Los Angeles, CA
- 5:00 PM** (269) *Quantiferon-CMV Guided Virostatic Prophylaxis after Heart Transplantation*; G. Poglajen, G. Zemljic, S. Frljak, R. Okrajšek, M. Šebeštjen, A. Cerar, V. Andro, M. Jakli, B. Vrtovec. *Advanced Heart Failure and Transplantation Center, University Medical Center Ljubljana, Ljubljana, Slovenia*
- 5:15 PM** (270) *Does the Use of Serum Ganciclovir Levels to Adjust Valganciclovir Dosing Prevent the Development of CMV Resistance in CMV Mismatched Heart Transplant Recipients? The Mid America Experience*; J. Linard<sup>1</sup>, C. Knutson<sup>1</sup>, R. Wells<sup>1</sup>, A. M. Borkon<sup>2</sup>, A. Kao<sup>3</sup>. <sup>1</sup>Cardiac Transplant, Saint Luke's Mid America Heart Institute, Kansas City, MO, <sup>2</sup>Cardiothoracic Surgery, Saint Luke's Mid America Heart Institute, Kansas City, MO, <sup>3</sup>Cardiology, Saint Luke's Mid America Heart Institute, Kansas City, MO
- 5:30 PM** (271) *Use of Letermovir for CMV Prophylaxis or Treatment in Thoracic Organ Transplant Recipients*; C. S. King, S. S. Aryal, A. Cochrane, A. Brown, O. Shlobin, K. Ahmad, L. Marinak, M. Fregoso, J. Chun, S. Nathan, P. Shah, S. Desai, S. Katugaha. *Inova Fairfax Hospital, Falls Church, VA*
- 5:45 PM** (272) *Impact of Prolonging CMV Prophylaxis in High-Risk (CMV D+/R-) Lung Transplant Recipients*; S. Herrera<sup>1</sup>, B. Khan<sup>2</sup>, S. Husain<sup>1</sup>, M. Binnie<sup>2</sup>, C. Chow<sup>2</sup>, T. Martinu<sup>2</sup>, C. Chaparro<sup>2</sup>, S. Keshavjee<sup>2</sup>, L. G. Singer<sup>2</sup>, J. Tikkanen<sup>2</sup>. <sup>1</sup>Multi Organ Transplant Unit, Division of Infectious Diseases, University Health Network, Toronto, ON, Canada, <sup>2</sup>Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada

FRIDAY, APRIL 5, 2019  
4:15 PM - 6:00 PM

**SESSION 67 (ORAL): Diagnostics and Immunosuppression in Lung Transplantation**

**Room: Pacifica 10-12**

**Target Audiences: LF/LTX, NHSAA, PHARM**

**Chairs:** Robert D Levy, MD, FRCPC, and Jonathan P Singer, MD, MS

- 4:15 PM**            **(273) ISHLT Consensus on Standardization of Bronchoalveolar Lavage in Lung Transplantation;** T. Martinu<sup>1</sup>, A. Koutsokera<sup>2</sup>, C. Benden<sup>2</sup>, E. Cantu<sup>3</sup>, D. Chambers<sup>4</sup>, M. Cypel<sup>1</sup>, J. Edelman<sup>5</sup>, A. Emtiazjoo<sup>6</sup>, A. J. Fisher<sup>7</sup>, J. R. Greenland<sup>8</sup>, D. Hayes<sup>9</sup>, D. M. Hwang<sup>10</sup>, B. C. Keller<sup>11</sup>, E. D. Lease<sup>12</sup>, M. Perch<sup>13</sup>, M. Sato<sup>14</sup>, J. L. Todd<sup>15</sup>, S. Verleden<sup>16</sup>, J. von der Thüsen<sup>17</sup>, S. S. Weigt<sup>18</sup>, S. Keshavjee<sup>1</sup>, \*. On Behalf of ISHLT BAL Standardization Workgroup<sup>1</sup>. <sup>1</sup>Toronto Lung Transplant Program, Toronto, ON, Canada, <sup>2</sup>University Hospital Zurich, Zurich, Switzerland, <sup>3</sup>University Hospital of Pennsylvania, Philadelphia, PA, <sup>4</sup>The Prince Charles Hospital, Brisbane, Australia, <sup>5</sup>Puget Sound VAMC, Seattle, WA, <sup>6</sup>University of Florida, Gainesville, FL, <sup>7</sup>Freeman Hospital, Newcastle, United Kingdom, <sup>8</sup>University of California San Francisco, San Francisco, CA, <sup>9</sup>Nationwide Children's Hospital, Columbus, OH, <sup>10</sup>Toronto General Hospital Research Institute, Toronto, ON, Canada, <sup>11</sup>The Ohio State University, Columbus, OH, <sup>12</sup>University of Washington, Seattle, WA, <sup>13</sup>Rigshospitalet, Copenhagen, Denmark, <sup>14</sup>University of Tokyo, Tokyo, Japan, <sup>15</sup>Duke University Medical Center, Durham, NC, <sup>16</sup>Katholieke Universiteit Leuven, Leuven, Belgium, <sup>17</sup>Erasmus Medical Center, Rotterdam, Netherlands, <sup>18</sup>University of California Los Angeles, Los Angeles, CA
- 4:30 PM**            **(274) Reduced Frailty after Lung Transplant is Associated with Survival;** A. Venado<sup>1</sup>, C. Huang<sup>2</sup>, D. V. Glidden<sup>2</sup>, A. Soong<sup>1</sup>, Y. Gao<sup>1</sup>, S. Hays<sup>1</sup>, J. Golden<sup>1</sup>, J. Kukreja<sup>3</sup>, L. E. Leard<sup>1</sup>, R. Shah<sup>1</sup>, M. Kleinhenz<sup>1</sup>, J. Greenland<sup>1</sup>, J. P. Singer<sup>1</sup>. <sup>1</sup>Pulmonary & Critical Care, University of California, San Francisco, San Francisco, CA, <sup>2</sup>Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, <sup>3</sup>Cardiothoracic Surgery, University of California, San Francisco, San Francisco, CA
- 4:45 PM**            **(275) A Combination of Delayed Gastric Emptying and Gastroesophageal Reflux Disease is Associated with Worse Outcomes in Lung Transplantation;** J. Fernandez-Castillo, E. Huszti, K. C. Zhang, R. Ghany, L. Levy, D. R. Darley, C. Chaparro, J. Tikkanen, S. Keshavjee, L. Singer, J. C. Yeung, T. Martinu. University of Toronto/UHN, Toronto, ON, Canada
- 5:00 PM**            **(276) Ten-Year-Experience with Alemtuzumab as Induction Therapy: A Single-Center Analysis of More Than 500 Patients;** A. Benazzo<sup>1</sup>, S. Schwarz<sup>1</sup>, D. Weber<sup>2</sup>, G. Murakozy<sup>1</sup>, C. Lambers<sup>2</sup>, B. Moser<sup>1</sup>, J. Matilla<sup>1</sup>, G. Lang<sup>2</sup>, S. Taghavi<sup>1</sup>, W. Klepetko<sup>1</sup>, K. Hoetzenecker<sup>1</sup>, P. Jaksch<sup>1</sup>. <sup>1</sup>Thoracic Surgery, Medical University of Vienna, Vienna, Austria, <sup>2</sup>Division of Thoracic Surgery, Medical University of Vienna, Vienna, Austria
- 5:15 PM**            **(277) Extracorporeal Photopheresis Improves Survival Probability and Lowers Hospital-Related Expenses In Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome;** C. Joukhadar<sup>1</sup>, R. Knobler<sup>2</sup>, A. Cho<sup>2</sup>, U. Just<sup>2</sup>, G. Muraközy<sup>3</sup>, P. Jaksch<sup>3</sup>. <sup>1</sup>J&P Medical Research Ltd, Vienna, Austria, <sup>2</sup>Department of Dermatology, Medical University of Vienna, Vienna, Austria, <sup>3</sup>Division of Thoracic Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria
- 5:30 PM**            **(278) Sirolimus + Tacrolimus Maintenance with No Induction Therapy May Maximize Survival in Lung Transplant Recipients;** M. Wijesinha, J. Hirshon, M. Terrin, L. Magder, C. Brown, K. Stafford, A. Iacono. University of Maryland School of Medicine, Baltimore, MD
- 5:45 PM**            **(279) End Stage Renal Disease after Lung Transplantation: An 11-Year National Cohort Study;** M. Kosztowski, X. Luo, J. Garonzik-Wang, R. Higgins, D. L. Segev, E. Bush. Department of Surgery, Johns Hopkins, Baltimore, MD

FRIDAY, APRIL 5, 2019  
4:15 PM - 6:00 PM

**SESSION 68 (ORAL): LV Recovery after MCS: From Promise to Reality?**

**Room: Pacifica 6**

**Target Audience: MCS**

**Chairs:** Ioannis Dimarakis, PhD, FRCS, and Amanda R Vest, MBBS MPH

- 4:15 PM** (280) *Hemodynamic and ECHO Measurements during VA ECMO Weaning Suggest Acceptable LV Unloading*; A. M. El Banayosy, C. Gordon, M. M. Koerner, M. D. Harper, D. Horstmannshof, D. Vanhooser, J. W. Long, A. El Banayosy. *INTEGRIS Baptist Medical Center, Oklahoma City, OK*
- 4:30 PM** (281) *Predicting Cardiac Recovery before Durable Left Ventricular Assist Device Implantation in Advanced Heart Failure Patients*; I. Taleb<sup>1</sup>, B. D. Horne<sup>2</sup>, M. Yin<sup>1</sup>, J. Nativi-Nicolau<sup>1</sup>, O. Wever-Pinzon<sup>1</sup>, S. McKellar<sup>1</sup>, W. T. Caine<sup>2</sup>, A. Koliopoulou<sup>1</sup>, R. Alharethi<sup>2</sup>, A. Kfoury<sup>2</sup>, E. M. Gilbert<sup>1</sup>, J. C. Fang<sup>1</sup>, J. Stehlik<sup>1</sup>, C. H. Selzman<sup>1</sup>, S. G. Drakos<sup>1</sup>. <sup>1</sup>University of Utah, Salt Lake City, UT, <sup>2</sup>Intermountain Medical Center, Salt Lake City, UT
- 4:45 PM** (282) *Does Indication for LVAD at Time of Implant Matter in Younger Patients?*; A. Lala<sup>1</sup>, J. Rowland<sup>1</sup>, A. Gelijns<sup>2</sup>, E. Bagiella<sup>2</sup>, A. Moskowitz<sup>2</sup>, B. Ferket<sup>1</sup>, S. Pinney<sup>3</sup>, M. Miller<sup>4</sup>, F. Pagani<sup>5</sup>, D. Mancini<sup>6</sup>. <sup>1</sup>Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York, NY, <sup>2</sup>Population Health Science, Icahn School of Medicine at Mount Sinai, New York, NY, <sup>3</sup>Medicine, Cardiology, Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York, NY, <sup>4</sup>NHLBI, Bethesda, MD, <sup>5</sup>Cardiothoracic Surgery, University of Michigan, Ann Arbor, NY, <sup>6</sup>Medicine, Cardiology, Population Health Science, Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York, NY
- 5:00 PM** (283) *Cardiac Reverse Remodeling and Recovery in Dilated Cardiomyopathy Medication-Naive Patients Requiring Durable Left Ventricular Assist Device Support*; I. Taleb<sup>1</sup>, M. Yin<sup>1</sup>, A. Koliopoulou<sup>1</sup>, M. Taleb<sup>1</sup>, E. Dranow<sup>1</sup>, L. Kemeyou<sup>1</sup>, W. T. Caine<sup>2</sup>, O. Wever-Pinzon<sup>1</sup>, R. Alharethi<sup>2</sup>, A. G. Kfoury<sup>2</sup>, J. Nativi-Nicolau<sup>1</sup>, J. C. Fang<sup>1</sup>, J. Stehlik<sup>1</sup>, C. H. Selzman<sup>1</sup>, S. G. Drakos<sup>1</sup>. <sup>1</sup>University of Utah, Salt Lake City, UT, <sup>2</sup>Intermountain Medical Center, Salt Lake City, UT
- 5:15 PM** (284) *Normalization of Metabolic Status after LVAD Implantation is Associated with Heart Failure Free Survival*; A. Nguyen, T. Imamura, B. Chung, L. Holzhauser, N. Narang, D. Rodgers, B. Smith, J. Raikhelkar, D. Onsager, T. Song, C. Juricek, T. Ota, V. Jeevanandam, G. Kim, G. Sayer, N. Uriel. *University of Chicago, Chicago, IL*
- 5:30 PM** (285) *Baseline ECHO a Suitable Screening Tool for LV Recovery during CF LVAD Support*; S. Rangasamy, O. Saeed, D. B. Sims, J. Shin, S. Murthy, S. Vukelic, D. Goldstein, U. Jorde, S. R. Patel. *Cardiology, Montefiore Medical Center, Bronx, NY*
- 5:45 PM** (286) *Long-Term Outcome of Patients after Successful LVAD Explant: A EUROMACS Study*; C. Antonides<sup>1</sup>, F. Schoenrath<sup>2</sup>, K. Veen<sup>1</sup>, R. Muslem<sup>1</sup>, I. Netuka<sup>3</sup>, J. Gummert<sup>4</sup>, B. Meyns<sup>5</sup>, M. Özbaran<sup>6</sup>, D. Schibilsky<sup>7</sup>, T. de By<sup>8</sup>, K. Caliskan<sup>9</sup>. <sup>1</sup>Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, Netherlands, <sup>2</sup>Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany, DZHK (German Center for Cardiovascular Research), partner site, Berlin, Germany, <sup>3</sup>Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, <sup>4</sup>Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center, NRW, Ruhr University Bochum, Bad Oeynhausen, Germany, <sup>5</sup>Department of Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium, <sup>6</sup>Department of Cardiovascular Surgery, Ege Üniversitesi Tıp Fakültesi, Izmir, Turkey, <sup>7</sup>Department of Cardiovascular Surgery, Universitäts-Herzzentrum Freiburg - Bad Krozingen, Freiburg, Germany, <sup>8</sup>EACTS, EUROMACS, Windsor, United Kingdom, <sup>9</sup>Department of Cardiology, Erasmus University Medical Center, Rotterdam, Netherlands

FRIDAY, APRIL 5, 2019

4:15 PM - 6:00 PM

**SESSION 69 (ORAL): Tricks of the Trade: Management Considerations with Continuous Flow LVADs**

**Room: Grand Caribbean 1-7**

**Target Audiences: MCS, EEP**

**Chairs:** Minoru Ono, MD, PhD, and Ivan Knezevic, MD

- 4:15 PM** (287) **Predictors and Impact of Vasoplegia after Continuous-Flow Left Ventricular Assist Device Implantation;** M. Kim, H. Lamba, R. Miller, J. George, S. Sattae, F. Cheema, A. Civitello, R. Delgado, A. Nair, A. Shafii, G. Loor, T. Rosengart, O. Frazier, J. Morgan, S. Chatterjee. *Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, TX*
- 4:30 PM** (288) **Longitudinal Trends in Gut Microbial Community Diversity among HF Patients Undergoing LVAD;** M. Yuzefpolskaya<sup>1</sup>, B. Bohn D.F.<sup>2</sup>, D. Onat<sup>1</sup>, A. Zuver<sup>1</sup>, D. L. Brunjes<sup>1</sup>, E. A. Royzman<sup>1</sup>, A. Pinsino<sup>3</sup>, K. L. Antler<sup>1</sup>, J. C. Hupf<sup>1</sup>, M. B. Dominguez<sup>1</sup>, A. R. Garan<sup>4</sup>, H. Takayama<sup>5</sup>, K. Takeda<sup>5</sup>, Y. Naka<sup>5</sup>, P. C. Colombo<sup>1</sup>, R. T. Demmer<sup>6</sup>. <sup>1</sup>Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY, <sup>2</sup>Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, <sup>3</sup>Medicine, Jacobi AECOM, Bronx, New York, NY, <sup>4</sup>Medicine, Division of Cardiology, Columbia University, New York, NY, <sup>5</sup>Surgery, Columbia University Medical Center, New York, NY, <sup>6</sup>Epidemiology and Community Health, University of Minnesota, Minneapolis, MN
- 4:45 PM** (289) **Novel Approach to Assess Intraventricular Pressure Difference in Patients with Left Ventricular Assist Device during Ramp Study;** K. Akiyama<sup>1</sup>, E. J. Stöhr<sup>2</sup>, R. Ji<sup>3</sup>, O. G. Jimenez<sup>4</sup>, I. Wu<sup>5</sup>, K. Itatani<sup>6</sup>, S. Miyazaki<sup>7</sup>, T. Furusawa<sup>7</sup>, T. Nishino<sup>7</sup>, B. J. McDonnell<sup>8</sup>, A. R. Garan<sup>3</sup>, M. Yuzefpolskaya<sup>3</sup>, P. C. Colombo<sup>3</sup>, Y. Naka<sup>1</sup>, H. Takayama<sup>1</sup>, K. Takeda<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, Columbia University Medical Center, New York, NY, <sup>2</sup>Cardiac Physiology and Health, Cardiff Metropolitan University, Cardiff, United Kingdom, <sup>3</sup>Cardiology, Columbia University Medical Center, New York, NY, <sup>4</sup>Surgery, Columbia University Medical Center, New York, NY, <sup>5</sup>Anesthesiology, Columbia University Medical Center, New York, NY, <sup>6</sup>Cardiovascular Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan, <sup>7</sup>Cardio Flow Design, Tokyo, Japan, <sup>8</sup>Cardiff Metropolitan University, Cardiff, United Kingdom
- 5:00 PM** (554) **Post-Implant Phosphodiesterase-5 Inhibitor Use is Associated with Increased Rates of Late Right Heart Failure after LVAD: An INTERMACS Analysis;** E. Grandin<sup>1</sup>, G. Gulati<sup>2</sup>, K. Kennedy<sup>3</sup>, F. Cabezas<sup>1</sup>, E. Y. Birati<sup>4</sup>, J. Rame<sup>4</sup>, P. Atluri<sup>5</sup>, F. D. Pagani<sup>6</sup>, J. K. Kirklin<sup>7</sup>, D. C. Naftel<sup>7</sup>, R. L. Kormos<sup>8</sup>, J. Teuteberg<sup>9</sup>, M. Kiernan<sup>2</sup>. <sup>1</sup>Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA, <sup>2</sup>Division of Cardiovascular Medicine, Tufts Medical Center, Boston, MA, <sup>3</sup>BIDMC Smith Center for Outcomes Research in Cardiology, St. Luke's Mid-America Heart Institute, Kansas City, MO, <sup>4</sup>Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, <sup>5</sup>Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, <sup>6</sup>Division of Cardiothoracic Surgery, University of Michigan, Ann Arbor, MI, <sup>7</sup>Division of Cardiothoracic Surgery, University of Alabama Birmingham, Birmingham, AL, <sup>8</sup>Division of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>9</sup>Division of Cardiovascular Medicine, Stanford University Medical Center, Stanford, CA
- 5:15 PM** (551) **Hemodynamic Evaluation of Right Ventricular Function before and after Impella 5.0 Placement for Cardiogenic Shock;** A. M. Wolfson, R. M. Cole, D. Emerson, J. Moriguchi, J. S. Chung, D. Ramzy. *Cedars-Sinai Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA*
- 5:30 PM** (292) **Does Low-Intensity Anticoagulation Using Vitamin K Antagonists Correlate with Factor X Activity Inpatients Implanted with the HeartMate 3 Pump? A Validation Analysis of the MAGENTUM 1 Study;** J. M. Connors<sup>1</sup>, I. Netuka<sup>2</sup>, P. Ivák<sup>3</sup>, Z. Tušková<sup>3</sup>, S. Gregor<sup>4</sup>, P. Sood<sup>5</sup>, D. Crandall<sup>6</sup>, M. R. Mehra<sup>7</sup>. <sup>1</sup>Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, <sup>2</sup>Institute for Clinical & Experimental Medicine, Prague, Czech Republic, <sup>3</sup>Department of Cardiovascular Surgery, Institute for Clinical & Experimental Medicine, Prague, Czech Republic, <sup>4</sup>Department of Pharmacy, Institute for Clinical & Experimental Medicine, Prague, Czech Republic, <sup>5</sup>Global Clinical Affairs, Heart Failure, Abbott, Burlington, MA, <sup>6</sup>Global Clinical, Heart Failure, Abbott, Burlington, MA, <sup>7</sup>Brigham and Women's Hospital, Harvard Medical School, Boston, MA
- 5:45 PM** (293) **Impact of Socioeconomic Status on Outcomes Post-Ventricular Assist Device Implantation;** J. J. Han<sup>1</sup>, A. Iyengar<sup>1</sup>, W. L. Patrick<sup>1</sup>, J. Goldenring<sup>2</sup>, M. Molina<sup>1</sup>, A. Ameer<sup>1</sup>, M. Helmers<sup>1</sup>, E. Y. Birati<sup>3</sup>, P. Atluri<sup>1</sup>.

*<sup>1</sup>Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Perelman School of Medicine, Philadelphia, PA, <sup>3</sup>Cardiology, Hospital of the University of Pennsylvania, Philadelphia, PA*

**FRIDAY, APRIL 5, 2019**

**4:15 PM - 6:00 PM**

**SESSION 70 (SYMPOSIUM): Matters of Life and Death: Palliative and End of Life Care in Transplant Medicine**

**Room: Pacifica 3-5**

**Target Audiences: NHSAH, PEDS, PH, PHARM**

**Chairs:** Melissa Cousino, PhD, and Rachel M Crackett, MSc

**Session Summary:** This symposium will include novel talks to advance the ways in which we care for organ failure/transplant patients at end of life (EOL). Covered topics will include: emotional support for patients at EOL, collaboration with ethics and palliative care teams, pharmacological management of patients at EOL, palliative care for the pediatric and adult congenital heart disease population, religious/cultural diversity in EOL, and addressing provider burn-out/self-care. A 15-min panel discussion with all speakers will conclude this session.

**4:15 PM**

***Beyond Life Support: Emotional Support for Patients at End of Life***

Bronwyn J. Levvey, RN, Grad Dip Clin Ep, Alfred Hospital, Melbourne, Australia

**4:30 PM**

***It's Complicated: Collaboration and Integration Between Palliative Care, Ethics and Transplant Teams***

Andrew Courtwright, MD, PhD, University of Pennsylvania, Philadelphia, PA, USA

**4:45 PM**

***Pharmacological Management of the MCS/Transplant Patient at End of Life***

Steven P Ivulich, BPharm, Alfred Hospital, Melbourne, Australia

**5:00 PM**

***Bringing PC to PEDS: Palliative Care for Pediatric Transplant and MCS Patients***

Elizabeth Blume, MD, Children's Hospital, Boston, MA, USA

**5:15 PM**

***Bridging the Gaps: Cultural and Regional Diversity and End of Life Care***

Rachel Hadler, MD, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

**5:30 PM**

***Self-Care for Us! Provider Heartbreak in Organ Failure/Transplant Care***

Julie Bidwell, PhD, UC Davis, Davis, CA, USA

**5:45 PM**

***15-min Panel Discussion***

**FRIDAY, APRIL 5, 2019**

**4:15 PM - 6:00 PM**

**SESSION 71 (SYMPOSIUM): Breaking Bad: The Right Ventricle and Exercise Hemodynamics Rediscovered**

**Room: Coral Sea**

**Target Audiences: PH, CTEPH, MCS**

**Chairs:** Arun Jose, MD, and Marc Simon, MD

**Session Summary:** In collaboration with the Pulmonary Vascular Research Institute (PVRI), this symposium will provide an overview into the mechanisms, clinical diagnosis and management of chronic right heart failure in left heart disease, scleroderma, and pulmonary hypertension. There will be a focus on the identification of maladaptive remodeling with discussion of the mechanisms contributing to maladaptive remodeling in right heart failure. We will explore the relationship of right ventricular function to functional capacity and highlight a debate on exercise challenge during right heart catheterization. A 15-min panel discussion with all speakers will conclude this session.

- 4:15 PM**                    *Back to the Future 1: Mechanisms of Chronic RV Failure*  
Ryan J Tedford, MD, Medical University of South Carolina, Charleston, NC, USA
- 4:30 PM**                    *Back to the Future 2: Metabolic Changes in the Failing Right Heart*  
Evangelos Michelakis, MD, University of Alberta, Alberta, AB, Canada
- 4:45 PM**                    *Don't Go Breaking My Heart: Scleroderma Related - a Specific Entity*  
Steven Hsu, MD, Johns Hopkins University, Baltimore, MD, USA
- 5:00 PM**                    *When the Going Gets Tough, the Tough Get Going: Management of Acute RV Failure*  
John Granton, MD, University of Toronto, Toronto, ON, Canada
- 5:15 PM**                    *DEBATE: We Should Exercise Our PH Patients During Right Heart Catheterization (PRO)*  
Susanna Mak, MD, PhD, Mount Sinai Hospital, Toronto, ON, Canada
- 5:30 PM**                    *DEBATE: We Should Exercise Our PH Patients During Right Heart Catheterization (CON)*  
Ivan Robbins, MD, Vanderbilt University, Nashville, TN, USA
- 5:45 PM**                    *15-min Panel Discussion*



FRIDAY, APRIL 5, 2019  
6:15 PM - 7:15 PM

**MINI ORAL 13: Cardiac Donors and Recipients: Valuable Insights**

Room: Pacifica 1-2

Target Audiences: HF/HTX, PHARM

Chairs: Rami Alharethi, MD, and Hye Won Lee, PhD

- 6:15 PM** (501) *Risk Stratification of Inotropic Therapy for Heart Transplant Candidates in the Era of Ventricular Assist Device Support*; L. K. Truby<sup>1</sup>, V. K. Topkara<sup>2</sup>, S. D. Russell<sup>1</sup>, C. B. Patel<sup>1</sup>, R. Agarwal<sup>1</sup>. <sup>1</sup>Duke University Medical Center, Durham, NC, <sup>2</sup>Columbia University Medical Center, New York, NY
- 6:20 PM** (502) *Mechanical Circulatory Support Patients Awaiting Heart Transplant with Positive ATIR Antibodies Have Acceptable Outcome Post-Heart Transplant*; D. H. Chang, J. Patel, M. Kittleson, D. Geft, S. Dimbil, R. Levine, C. Kawata, L. Czer, J. Moriguchi, D. Ramzy, J. A. Kobashigawa. Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
- 6:25 PM** (503) *Predictors and Clinical Outcomes of Vasoplegia in Patients Bridged to Heart Transplantation with Continuous Flow Left Ventricular Assist Devices*; R. Asleh, H. Alnsasra, S. D. Schettle, R. Taher, S. M. Dunlay, J. M. Stulak, R. C. Daly, A. Behfar, N. L. Pereira, A. L. Clavell, S. Multais, R. P. Frantz, S. S. Kushwaha. Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN
- 6:30 PM** (504) *Elevated Pre-Transplant Neutrophil to Lymphocyte Ratio is Associated with Increased Vasoplegia Syndrome in Cardiac Transplantation*; N. Ahmed, H. Gandhi, K. Rahgozar, S. Guo, E. Sun, O. Saeed, S. Patel, S. Murthy, J. J. Shin, S. Vukelic, S. Forest, D. J. Goldstein, U. P. Jorde, D. B. Sims. Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY
- 6:35 PM** (505) *Utility of Routine versus Triggered Evaluations of Rejection Greater Than Two Years Following Heart Transplant*; J. R. Golbus, M. C. Konerman, K. D. Aaronson. Internal Medicine, University of Michigan, Ann Arbor, MI
- 6:40 PM** (506) *Protocol Endomyocardial Biopsy beyond Six Months - It's Time to Move On*; K. Oh<sup>1</sup>, M. H. Mustehsan<sup>1</sup>, D. B. Sims<sup>1</sup>, O. Saeed<sup>1</sup>, S. Vukelic<sup>1</sup>, J. J. Shin<sup>1</sup>, S. Murthy<sup>1</sup>, A. Luke<sup>1</sup>, S. J. Forest<sup>2</sup>, D. Goldstein<sup>2</sup>, U. Jorde<sup>1</sup>, S. R. Patel<sup>1</sup>. <sup>1</sup>Medicine, Division of Cardiology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, <sup>2</sup>Cardiovascular and Thoracic Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY
- 6:45 PM** (507) *Clinical Utility of the IMPACT Score for Mortality Prediction after Heart Transplantation: External Validation Study*; C. D. Ortiz Bautista<sup>1</sup>, J. Muniz Garcia<sup>2</sup>, F. Gonzalez-Vilchez<sup>3</sup>, J. Segovia Cubero<sup>4</sup>, M. G. Crespo Leiro<sup>5</sup>, R. Lopez Vilella<sup>6</sup>, J. Gonzalez Costelo<sup>7</sup>, E. Roig Minguel<sup>8</sup>, J. M. Arizon Del Prado<sup>9</sup>, J. M. Sobrino Marquez<sup>10</sup>, I. P. Garrido Bravo<sup>11</sup>, J. F. Delgado Jimenez<sup>12</sup>. <sup>1</sup>Cardiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, <sup>2</sup>Instituto de Investigación Biomédica (INIBIC), Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, <sup>3</sup>Cardiology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, <sup>4</sup>Cardiology, Hospital Universitario Puerta de Hierro, Madrid, Spain, <sup>5</sup>Cardiology, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, <sup>6</sup>Cardiology, Hospital Universitario La Fe, Valencia, Spain, <sup>7</sup>Cardiology, Hospital Universitario de Bellvitge, Barcelona, Spain, <sup>8</sup>Cardiology, Hospital Santa Creu i Sant Pau, Barcelona, Spain, <sup>9</sup>Cardiology, Hospital Universitario Reina Sofía, Córdoba, Spain, <sup>10</sup>Cardiology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, <sup>11</sup>Cardiology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, <sup>12</sup>Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain
- 6:50 PM** (508) *One but Not the Same: Risk Factors for Early Post-Transplant Mortality Differ between Medically Managed Patients and Those Bridged to Transplant with Left Ventricular Assist Devices*; L. K. Truby<sup>1</sup>, M. Farr<sup>2</sup>, V. K. Topkara<sup>2</sup>. <sup>1</sup>Duke University Medical Center, Durham, NC, <sup>2</sup>Columbia University Medical Center, New York, NY
- 6:55 PM** (509) *Cardiac Transplantation across Preformed HLA-Antibody Barriers: Results of a Peritransplant Desensitization Protocol*; F. Ius<sup>1</sup>, S. V. Rojas<sup>1</sup>, T. Kaufeld<sup>1</sup>, W. Sommer<sup>1</sup>, C. Bara<sup>1</sup>, J. Salman<sup>1</sup>, T. Siemeni<sup>1</sup>, R. Poyanmehr<sup>1</sup>, D. Bobylev<sup>1</sup>, M. Avsar<sup>1</sup>, I. Tudorache<sup>1</sup>, C. S. Falk<sup>2</sup>, A. Haverich<sup>1</sup>, G. Warnecke<sup>1</sup>. <sup>1</sup>Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, <sup>2</sup>Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany

7:00 PM

**(510) Treatment of Therapy-Resistant Hyperlipidaemia after Heart Transplant with PCSK9-Inhibitors;** K. Uyanik-Uenal<sup>1</sup>, M. Stoegerer-Lanzenberger<sup>2</sup>, K. Auersperg<sup>1</sup>, A. Aliabadi-Zuckermann<sup>1</sup>, G. Laufer<sup>1</sup>, A. Zuckermann<sup>1</sup>. <sup>1</sup>Department of Cardiac Surgery, Medical University of Vienna (AKH), Vienna, Austria, <sup>2</sup>3rd Medical Department for Metabolic Disorders and Nephrology, Hospital Hietzing, Vienna, Austria

7:05 PM

**(511) Change in Health-Related Quality of Life from Before to Early after Surgery: Findings from the Sustaining Quality of Life of the Aged: Transplant or Mechanical Support (SUSTAIN-IT) Study;** K. L. Grady<sup>1</sup>, A. Kao<sup>2</sup>, M. Dew<sup>3</sup>, R. Kormos<sup>4</sup>, A. Andrei<sup>1</sup>, H. Adam<sup>1</sup>, Y. Xu<sup>1</sup>, D. Pham<sup>1</sup>, L. Pollan<sup>1</sup>, C. Yancy<sup>5</sup>, E. Hsich<sup>6</sup>, W. Cotts<sup>7</sup>, S. LaRue<sup>8</sup>, M. Petty<sup>9</sup>, S. V. Pamboukian<sup>10</sup>, F. Pagani<sup>11</sup>, B. Lampert<sup>12</sup>, M. Johnson<sup>13</sup>, M. Murray<sup>1</sup>, K. Tekeda<sup>14</sup>, M. Yuzefpolskaya<sup>15</sup>, S. Silvestry<sup>16</sup>, J. Kirklin<sup>17</sup>, S. Collum<sup>1</sup>, J. Spertus<sup>2</sup>. <sup>1</sup>Surgery / Cardiac Surgery, Northwestern University, Chicago, IL, <sup>2</sup>Medicine, University of Missouri - Kansas City, Kansas City, MO, <sup>3</sup>Psychiatry, University of Pittsburgh, Pittsburgh, PA, <sup>4</sup>Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA, <sup>5</sup>Medicine, Northwestern University, Chicago, IL, <sup>6</sup>Medicine, Cleveland Clinic, Cleveland, OH, <sup>7</sup>Medicine, Advocate Christ Medical Center, Oak Lawn, IL, <sup>8</sup>Medicine, Washington University, St. Louis, MO, <sup>9</sup>Surgery, University of Minnesota Medical Center, Minneapolis, MN, <sup>10</sup>Medicine, University of Alabama, Birmingham, AL, <sup>11</sup>Surgery, University of Michigan, Ann Arbor, MI, <sup>12</sup>Medicine, Ohio State University, Columbus, OH, <sup>13</sup>Medicine, University of Wisconsin, Madison, WI, <sup>14</sup>Surgery, Columbia University, New York, NY, <sup>15</sup>Medicine, Columbia University, New York, NY, <sup>16</sup>Surgery, Florida Hospital, Maitland, FL, <sup>17</sup>Surgery, University of Alabama - Birmingham, Birmingham, AL

7:10 PM

**(512) Intraoperative Perfusion Strategies during Heart Transplantation: Are We Optimizing Renal Protection?;** N. M. Foley, M. Kuzemchak, Y. Tipograf, C. White-Dzuro, K. Balsara, K. Schlendorf, M. Danter, A. Shah. Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN

FRIDAY, APRIL 5, 2019

6:15 PM - 7:15 PM

**MINI ORAL 14: Unique Considerations for Special Heart Transplant Populations**

Room: Pacifica 7

Target Audiences: HF/HTX, NHSAH

Chairs: Alejandro M Bertolotti, MD, and Van N Selby, MD

- 6:15 PM** (513) *Heart Transplantation for Cardiac Amyloidosis - Worthwhile?*; J. Patel, M. Kittleson, R. Levine, S. Sana, A. Shen, D. Geft, B. Azarbal, E. Kransdorf, J. Kobashigawa. *Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA*
- 6:20 PM** (514) *Contemporary Outcomes in Patients with Cardiac Amyloidosis Undergoing Heart Transplantation*; K. Alexander<sup>1</sup>, C. Barrett<sup>2</sup>, K. Dobos<sup>1</sup>, P. Cheng<sup>1</sup>, R. Liao<sup>1</sup>, M. Wheeler<sup>1</sup>, M. Liedtke<sup>1</sup>, D. Weisshaar<sup>3</sup>, R. Wittles<sup>1</sup>. <sup>1</sup>Stanford University Medical Center, Stanford, CA, <sup>2</sup>University of Colorado, Aurora, CO, <sup>3</sup>Kaiser Permanente Santa Clara Medical Center, Santa Clara, CA
- 6:25 PM** (515) *The Evolving Long-Term Outcome of Heart Transplantation in Amyloid Patients*; J. Patel, M. Kittleson, D. H. Chang, R. Cole, R. Levine, S. Dimbil, A. Jain, B. Kearney, L. Czer, A. Hage, F. Esmailian, J. A. Kobashigawa. *Cedars-Sinai Smidt Heart Institute, Los Angeles, CA*
- 6:30 PM** (979) *Heart Transplantation in Cardiac Amyloidosis: A Ten Year Experience*; J. P. Donnelly<sup>1</sup>, E. G. Soltész<sup>2</sup>, M. Z. Tong<sup>2</sup>, S. A. Hall<sup>3</sup>, P. Kale<sup>3</sup>, J. D. Estep<sup>1</sup>, M. Hanna<sup>1</sup>. <sup>1</sup>Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, <sup>2</sup>Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH, <sup>3</sup>Annette C. and Harold C. Simmons Transplant Institute, Baylor Scott & White Research Institute, Dallas, TX
- 6:35 PM** (516) *Differential Gene Expression by Race and Impact on Risk after Heart Transplantation*; Y. Moayed<sup>1</sup>, C. S. Fan<sup>2</sup>, R. J. Miller<sup>3</sup>, D. Hillier<sup>4</sup>, M. Tremblay-Gravel<sup>1</sup>, M. A. Shullo<sup>5</sup>, R. Woodward<sup>4</sup>, J. Yee<sup>4</sup>, C. Manlhiot<sup>6</sup>, S. Pinney<sup>7</sup>, S. A. Hall<sup>8</sup>, K. K. Khush<sup>9</sup>, H. J. Ross<sup>10</sup>, J. J. Teuteberg<sup>9</sup>. <sup>1</sup>Medicine, Stanford University, Stanford, CA, <sup>2</sup>Biostatistics and Epidemiology, University Health Network, University of Toronto, University of Toronto, ON, Canada, <sup>3</sup>Medicine, Division of Cardiology, Stanford University, Palo Alto, CA, <sup>4</sup>CareDx, CareDx, Brisbane, CA, <sup>5</sup>Pharmacy, West Virginia University, Morgantown, WV, <sup>6</sup>Biostatistics, University Health Network, University of Toronto, Toronto, ON, Canada, <sup>7</sup>Medicine, Division of Cardiology, Mount Sinai New York, NYC, NY, <sup>8</sup>Medicine, Division of Cardiology, Baylor Health Care, Dallas, TX, <sup>9</sup>Medicine, Division of Cardiology, Stanford University, Stanford, CA, <sup>10</sup>Medicine, Division of Cardiology, University Health Network, University of Toronto, Toronto, ON, Canada
- 6:40 PM** (517) *Comparison of Patients Undergoing Multiorgan Transplantation with or without Prior Ventricular Assist Device*; M. E. Currie<sup>1</sup>, D. Banerjee<sup>2</sup>, Y. Shudo<sup>1</sup>, B. Lingala<sup>1</sup>, Y. Zhu<sup>1</sup>, F. Haddad<sup>2</sup>, J. Woo<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, Stanford University, Stanford, CA, <sup>2</sup>Medicine, Stanford University, Stanford, CA
- 6:45 PM** (518) *10-Year Outcomes in Heart-Kidney Transplant Patients: Is There a Protective Effect for the Donor Heart?*; L. Czer, M. Kittleson, J. Patel, E. Kransdorf, R. Levine, S. Dimbil, R. Sharoff, B. Kearney, D. H. Chang, M. Hamilton, F. Esmailian, J. A. Kobashigawa. *Cedars-Sinai Smidt Heart Institute, Los Angeles, CA*
- 6:50 PM** (520) *Improving Nutrition Practices for Critically Ill Postoperative Heart Transplant and Ventricular Assist Device Implant Patients*; R. Modir<sup>1</sup>, V. Rao<sup>2</sup>, J. Teuteberg<sup>3</sup>, D. Banerjee<sup>3</sup>, P. Oyer<sup>4</sup>, Z. Tulu<sup>5</sup>, E. Hadhazy<sup>6</sup>, W. Hiesinger<sup>4</sup>, S. Jimenez<sup>3</sup>, L. Tu<sup>1</sup>, C. Hill<sup>2</sup>. <sup>1</sup>Heart Transplant/Clinical Nutrition, Stanford University Hospital, Stanford, CA, <sup>2</sup>Anesthesia - Cardiac, Stanford University Hospital, Stanford, CA, <sup>3</sup>Cardiovascular Medicine, Stanford University Hospital, Stanford, CA, <sup>4</sup>Cardiothoracic Surgery - Adult Cardiac Surgery, Stanford University Hospital, Stanford, CA, <sup>5</sup>Solid Organ Transplant, Stanford Health Care, Stanford, CA, <sup>6</sup>Stanford Health Care, Stanford, CA
- 6:55 PM** (521) *The BRIGHT Study Shows Geographical Disparities in Body Mass Index among Heart Transplant Recipients*; M. Alrawashdeh<sup>1</sup>, M. R. Molina<sup>2</sup>, S. Beckmann<sup>3</sup>, K. Denhaerynck<sup>3</sup>, F. Dobbels<sup>4</sup>, S. De Geest<sup>3</sup>. <sup>1</sup>Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, <sup>2</sup>Hospital of the University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Institute of Nursing Science, University of Basel, Basel, Switzerland, <sup>4</sup>Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium

7:00 PM

**(522) Weight Gain Post Heart Transplantation is Associated with an Increased Risk for Allograft Vasculopathy and Rejection;** Y. Peled, D. Freimark, E. Nachum, M. Arad, D. Elian, Y. Kassif, N. Shlomo, R. Klempfner, J. Lavee. *Sheba Medical Center Tel Hashomer and Tel-Aviv University, Ramat Gan, Israel*

7:05 PM

**(523) The Gift That Keeps on Giving? The Impact of Donor Coronary Atherosclerosis on the Development of Coronary Allograft Vasculopathy by IVUS;** Y. Moayed<sup>1</sup>, C. S. Fan<sup>2</sup>, R. J. Miller<sup>3</sup>, M. Tremblay-Gravel<sup>3</sup>, M. Kawana<sup>3</sup>, H. I. Luikart<sup>1</sup>, N. D'Emilio<sup>3</sup>, J. Gordon<sup>3</sup>, J. T. Parizo<sup>3</sup>, G. Oro<sup>3</sup>, R. Wainwright<sup>3</sup>, W. Hiesinger<sup>4</sup>, C. Manlhiot<sup>2</sup>, H. J. Ross<sup>5</sup>, K. K. Khush<sup>3</sup>, J. J. Teuteberg<sup>3</sup>. <sup>1</sup>*Medicine, Stanford University, Stanford, CA*, <sup>2</sup>*Biostatistics, University Health Network, University of Toronto, Toronto, ON, Canada*, <sup>3</sup>*Medicine, Division of Cardiology, Stanford University, Stanford, CA*, <sup>4</sup>*Cardiovascular Surgery, Stanford University, Stanford, CA*, <sup>5</sup>*Medicine, Division of Cardiology, University Health Network, University of Toronto, Toronto, ON, Canada*

7:10 PM

**(524) Induction with Rabbit-Thymoglobulin (r-ATG) is Associated with Lower Cardiac Allograft Vasculopathy (CAV);** S. Madan, S. R. Patel, O. Saeed, S. Forest, W. A. Jakobleff, J. J. Shin, D. B. Sims, D. J. Goldstein, U. P. Jorde. *Montefiore Medical Center, Bronx, NY*

FRIDAY, APRIL 5, 2019

6:15 PM - 7:15 PM

**MINI ORAL 15A & 15B: Infectious Diseases / Basic Science and Translational Research**

Room: Pacifica 3-5

Target Audiences: BSTR, ID, HTX, LTX, MCS, PATH, PEDS

Chairs: Tobias Deuse, MD, PhD, and Ignacio Echenique, MD

- 6:15 PM** (525) *Cytomegalovirus Infection among Pediatric Heart Transplant Recipients in the Current Era of Valganciclovir Prophylaxis: Impact on Post-Transplant Outcomes*; B. B. Das<sup>1</sup>, J. Niu<sup>2</sup>, P. K. Sue<sup>3</sup>, B. K. Prusty<sup>4</sup>. <sup>1</sup>Joe DiMaggio Children's Heart Institute, Hollywood, FL, <sup>2</sup>Memorial Healthcare System, Hollywood, FL, <sup>3</sup>UT Southwestern Medical Center, Dallas, TX, <sup>4</sup>University of Wuerzburg, Wuerzburg, Germany
- 6:20 PM** (526) *KPC Klebsiella Identification Significantly Increases Risk of Bronchial Dehiscence in Lung Transplant Recipients*; J. Suh<sup>1</sup>, W. Yu<sup>1</sup>, S. Song<sup>1</sup>, J. Lee<sup>1</sup>, M. Park<sup>2</sup>, S. Kim<sup>2</sup>, J. Song<sup>2</sup>, S. Jeong<sup>2</sup>, H. Paik<sup>1</sup>. <sup>1</sup>Thoracic Surgery, Yonsei University College of Medicine, Seoul, Korea, Republic of, <sup>2</sup>Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of
- 6:25 PM** (527) *Late Onset Invasive Pulmonary Aspergillosis in Lung Transplant Recipients Treated with a Preemptive/ Targeted Antifungal Therapy Strategy: 4 Year Follow Up*; S. Herrera<sup>1</sup>, A. Farooq<sup>1</sup>, S. Davoudi<sup>1</sup>, T. Martinu<sup>2</sup>, D. Kumar<sup>1</sup>, A. Humar<sup>1</sup>, C. Rotstein<sup>1</sup>, L. G. Singer<sup>2</sup>, S. Keshavjee<sup>2</sup>, S. Husain<sup>1</sup>. <sup>1</sup>Multi Organ Transplant Unit, Division of Infectious Diseases, University Health Network, Toronto, ON, Canada, <sup>2</sup>Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada
- 6:30 PM** (528) *Pre Transplant Interleukin 10 Levels are Higher in Lung Recipients with Post Transplant Infections*; L. Calahorra<sup>1</sup>, E. Sarmiento<sup>1</sup>, J. Cifrian<sup>2</sup>, C. Bravo<sup>3</sup>, R. Laporta<sup>4</sup>, M. Ussetti<sup>4</sup>, A. De Pablos<sup>5</sup>, A. Soler<sup>6</sup>, J. Carbone<sup>1</sup>. <sup>1</sup>Clinical Immunology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, <sup>2</sup>Pneumology, Hospital Universitario Marques de Valdecilla, Santander, Spain, <sup>3</sup>Pneumology, Hospital Universitario Valle de Hebron, Barcelona, Spain, <sup>4</sup>Pneumology, Hospital Universitario Puerta de Hierro, Madrid, Spain, <sup>5</sup>Pneumology, Hospital Universitario Doce de Octubre, Madrid, Spain, <sup>6</sup>Pneumology, Hospital Universitario La Fe, Valencia, Spain
- 6:35 PM** (529) *Correlation of ImmuKnow Assay Levels with Rejection and Infection after Heart Transplantation*; D. Nitta, T. Imamura, B. Chung, A. Nguyen, J. Raikhelkar, N. Sarswat, L. Lourenco, B. Smith, L. Holzhauser, G. Kim, I. Ebong, T. Fujino, N. Narang, C. Murks, T. Riley, J. Powers, V. Jeevanandam, G. Sayer, N. Uriel. University of Chicago, Chicago, IL
- 6:40 PM** (530) *IgG2 Insufficiency before Heart Transplantation as a Risk Factor of Early Deadly Infections*; J. Carbone<sup>1</sup>, J. Navarro<sup>1</sup>, I. Sousa<sup>2</sup>, E. Zatarain<sup>2</sup>, J. Fernandez-Yañez<sup>2</sup>, P. Muñoz<sup>3</sup>, M. Valerio<sup>3</sup>, E. Sarmiento<sup>1</sup>. <sup>1</sup>Clinical Immunology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, <sup>2</sup>Cardiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, <sup>3</sup>Microbiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- 6:45 PM** (531) *Effective Reduction of Postoperative Infections through Routine Preoperative Decolonization with Chlorhexidine and Mupirocin Prior to Left Ventricular Assist Device Implantation*; S. George<sup>1</sup>, R. Leasure<sup>2</sup>, A. McGovern<sup>1</sup>, H. Setidadi<sup>1</sup>, D. A. Horstmanshof<sup>1</sup>. <sup>1</sup>INTEGRIS Baptist Medical Center, Oklahoma City, OK, <sup>2</sup>College of Nursing, University of Oklahoma, Oklahoma City, OK
- 6:50 PM** (532) *Novel Bacteriophage Therapy for Treatment of Ventricular Assist Device Infections*; S. Aslam<sup>1</sup>, V. Pretorius<sup>1</sup>, E. Adler<sup>1</sup>, S. Lehman<sup>2</sup>, S. Morales<sup>2</sup>, A. Gaidamaka<sup>2</sup>, C. Furr<sup>2</sup>, F. Rosas<sup>2</sup>, K. Bishop-Lilly<sup>3</sup>, B. Biswas<sup>3</sup>, B. Sisson<sup>4</sup>, J. Fackler<sup>4</sup>, M. Trigg<sup>4</sup>, R. Schooley<sup>1</sup>. <sup>1</sup>University of California, San Diego, San Diego, CA, <sup>2</sup>AmpliPhi Biosciences, San Diego, CA, <sup>3</sup>Naval Medical Research Center, Fort Detrick, MD, <sup>4</sup>Adaptive Phage Therapeutics, Gaithersburg, MD
- 6:55 PM** (790) *Role of Gallium-SPECT-CT in Predicting Outcomes of Patients with Ventricular Assist Device-Specific Percutaneous Driveline Infection*; Y. Kimura<sup>1</sup>, O. Seguchi<sup>1</sup>, H. Mochizuki<sup>1</sup>, K. Iwasaki<sup>1</sup>, K. Toda<sup>1</sup>, Y. Kumai<sup>1</sup>, K. Kuroda<sup>1</sup>, S. Nakajima<sup>1</sup>, T. Watanabe<sup>1</sup>, Y. Matsumoto<sup>2</sup>, S. Fukushima<sup>2</sup>, M. Yanase<sup>1</sup>, T. Fujita<sup>2</sup>, J. Kobayashi<sup>2</sup>, N. Fukushima<sup>1</sup>. <sup>1</sup>Department of Transplant Medicine, National Cerebral and Cardiovascular Centre, Osaka, Japan, <sup>2</sup>Department of Cardiac Surgery, National Cerebral and Cardiovascular Centre, Osaka, Japan

7:00 PM

**(534) *The Impact of Biomarkers in Predicting the Response to CD34+ Cell Therapy in Non-Ischemic Dilated Cardiomyopathy Patients***; G. Zemljic, M. Jaklic, A. Cerar, S. Frljak, G. Poglajen, B. Vrtovec. *Advanced Heart Failure and Transplantation Centre, University Medical Centre Ljubljana, Ljubljana, Slovenia*

7:05 PM

**(535) *LVAD Therapy Induces Changes in Myocardial Glucose Metabolism and Clock Genes***; K. Dhar<sup>1</sup>, A. KC<sup>1</sup>, F. Qiu<sup>2</sup>, H. Basma<sup>1</sup>, J. Um<sup>3</sup>, D. Anderson<sup>1</sup>, B. Lowes<sup>1</sup>. <sup>1</sup>*Internal Medicine, University of Nebraska Medical Center, Omaha, NE*, <sup>2</sup>*Bio Statistics, University of Nebraska Medical Center, Omaha, NE*, <sup>3</sup>*Surgery, University of Nebraska Medical Center, Omaha, NE*

7:10 PM

**(536) *Sphingosine-1-Phosphate Receptor Agonist Fingolimod Reduces Myocardial Ischemia-Reperfusion Injury and Apoptosis Increasing Long-Term Left Ventricular Function after Heart Transplantation***; A. Rungatscher, D. Linardi, A. Naseer, R. Mani, S. Hoxha, G. B. Luciani, G. Faggian. *Division of Cardiac Surgery, Department of Surgery, University of Verona, Verona, Italy*

FRIDAY, APRIL 5, 2019

6:15 PM - 7:15 PM

**MINI ORAL 16: Lung Transplant Outcomes**

Room: Pacifica 10-12

Target Audiences: LTX, NNSAH, PHARM

Chairs: Jussi Tikkanen, MD, PhD, and Ramsey Hachem, MD

- 6:15 PM** (537) *Reconsidering Indication of Lung Transplantation for Late-Onset Noninfectious Pulmonary Complications after Hematopoietic Stem Cell Transplantation*; M. Noguchi, T. F. Chen-Yoshikawa, H. Kayawake, Y. Yamada, Y. Yutaka, D. Nakajima, M. Hamaji, A. Ohsumi, H. Date. *Thoracic Surgery, Kyoto University Hospital, Kyoto City, Japan*
- 6:20 PM** (538) *Inhaled Cyclosporine-Based Immunosuppression Regimen for Lung Transplant Associated Malignancy*; I. Timofte<sup>1</sup>, M. Terrin<sup>2</sup>, A. Gandhi<sup>2</sup>, R. Yang<sup>2</sup>, M. Wijesinha<sup>2</sup>, R. Vesselinov<sup>2</sup>, P. McLaughlin<sup>2</sup>, N. Costa<sup>2</sup>, D. Kaczorowski<sup>2</sup>, R. Madathil<sup>2</sup>, B. Griffith<sup>2</sup>, A. Iacono<sup>2</sup>. <sup>1</sup>*Pulmonary and Critical Care, UMMC, Baltimore, MD*, <sup>2</sup>*UMMC, Baltimore, MD*
- 6:25 PM** (539) *CLAD Phenotypes Determined by Change in Spirometric Index Associate with Quantitative Image Analyses*; S. S. Weigt<sup>1</sup>, G. Kim<sup>1</sup>, F. Abtin<sup>1</sup>, H. Jones<sup>2</sup>, Y. Shino<sup>1</sup>, A. DerHovanessian<sup>1</sup>, D. Sayah<sup>1</sup>, R. Sagar<sup>1</sup>, J. P. Lynch III<sup>1</sup>, J. A. Belperio<sup>1</sup>, D. J. Ross<sup>1</sup>, J. Goldin<sup>1</sup>. <sup>1</sup>*UCLA, Los Angeles, CA*, <sup>2</sup>*Cedars Sinai, Los Angeles, CA*
- 6:30 PM** (540) *Single versus Double Lung Transplantation for Chronic Obstructive Lung Disease(COPD)*; I. Timofte<sup>1</sup>, R. Vesselinov<sup>2</sup>, M. Terrin<sup>2</sup>, M. Wijesinha<sup>2</sup>, D. Kaczorowski<sup>2</sup>, R. Mandathil<sup>2</sup>, R. Wise<sup>3</sup>, A. Sternberg<sup>3</sup>, B. Griffith<sup>1</sup>, A. Iacono<sup>2</sup>. <sup>1</sup>*Pulmonary and Critical Care, UMMC, Baltimore, MD*, <sup>2</sup>*UMMC, Baltimore, MD*, <sup>3</sup>*Pulmonary and Critical Care, Johns Hopkins University School of Medicine, Baltimore, MD*
- 6:35 PM** (541) *Risk Factors Associated with Airway Complications after Lung Transplantation*; A. Bery<sup>1</sup>, P. Aguilar<sup>1</sup>, D. Byers<sup>1</sup>, D. Kreisel<sup>2</sup>, H. Kulkarni<sup>1</sup>, R. Nava<sup>2</sup>, V. Puri<sup>2</sup>, E. Trulock<sup>1</sup>, C. Witt<sup>1</sup>, R. Yusen<sup>1</sup>, R. Hachem<sup>1</sup>. <sup>1</sup>*Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, MO*, <sup>2</sup>*Division of Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO*
- 6:40 PM** (542) *Pushing the Envelope in Single Lung Transplantation for Secondary Pulmonary Hypertension: Identifying an Upper Limit of Pressures*; G. Sunagawa<sup>1</sup>, M. Kashem<sup>1</sup>, E. Leotta<sup>1</sup>, F. Kromah<sup>1</sup>, S. Brann<sup>1</sup>, J. Gomez-Abraham<sup>1</sup>, S. Keshavamurthy<sup>1</sup>, K. Minakata<sup>1</sup>, F. Cordova<sup>2</sup>, Y. Toyoda<sup>1</sup>, N. Shigemura<sup>1</sup>. <sup>1</sup>*Cardiovascular Surgery, Temple University Hospital, Philadelphia, PA*, <sup>2</sup>*Thoracic Medicine and Surgery, Temple University Hospital, Philadelphia, PA*
- 6:45 PM** (543) *Predicting Survival for Lung Retransplantation Patients at One and Five Years*; E. S. Clausen<sup>1</sup>, J. M. Weber<sup>2</sup>, M. L. Neely<sup>2</sup>, S. M. Palmer<sup>1</sup>. <sup>1</sup>*Pulmonary and Critical Care Medicine, Duke University, Durham, NC*, <sup>2</sup>*Biostatistics and Bioinformatics, Duke University, Durham, NC*
- 6:50 PM** (544) *Do the Pretransplant Use of Statins in a Recipient Reduce the Incidence of Primary Graft Dysfunction after Lung Transplant?*; I. Bello<sup>1</sup>, E. Coll<sup>2</sup>, A. Sandiumenge<sup>3</sup>, L. Romero<sup>1</sup>, A. Jauregui<sup>1</sup>, J. Pérez<sup>1</sup>, J. Ochoa<sup>1</sup>, S. Peñafiel<sup>1</sup>, L. Sánchez<sup>1</sup>, F. Ascanio<sup>1</sup>, M. Montoya<sup>1</sup>, E. San Ginés<sup>1</sup>, J. Sacanell<sup>4</sup>, C. Berastegui<sup>5</sup>, C. Vázquez<sup>6</sup>, I. Los Arcos<sup>7</sup>, M. Deu<sup>1</sup>. <sup>1</sup>*Thoracic Surgery, Vall d'Hebron University Hospital, Barcelona, Spain*, <sup>2</sup>*Organización Nacional de Trasplantes (ONT), Madrid, Spain*, <sup>3</sup>*Transplant Coordination, Vall d'Hebron University Hospital, Barcelona, Spain*, <sup>4</sup>*Intensive Unit Care, Vall d'Hebron University Hospital, Barcelona, Spain*, <sup>5</sup>*Pulmonologist, Vall d'Hebron University Hospital, Barcelona, Spain*, <sup>6</sup>*Anesthesiologist, Vall d'Hebron University Hospital, Barcelona, Spain*, <sup>7</sup>*Vall d'Hebron University Hospital, Barcelona, Spain*
- 6:55 PM** (545) *Single and Double Lung Transplantation Have Equivalent Functional Status Outcomes at One Year*; N. K. Ranganath<sup>1</sup>, T. C. Geraci<sup>1</sup>, J. Malas<sup>1</sup>, K. G. Phillips<sup>1</sup>, D. E. Smith<sup>1</sup>, B. E. Lonze<sup>2</sup>, M. B. Lesko<sup>3</sup>, L. F. Angel<sup>3</sup>, Z. N. Kon<sup>1</sup>. <sup>1</sup>*Cardiothoracic Surgery, NYU Langone Health, New York, NY*, <sup>2</sup>*Surgery, NYU Langone Health, New York, NY*, <sup>3</sup>*Medicine, NYU Langone Health, New York, NY*
- 7:00 PM** (546) *Frailty is Associated with Greater Impairments in Health-Related Quality of Life after Lung Transplantation Than Before*; N. A. Kolaitis<sup>1</sup>, A. Soong<sup>1</sup>, Y. Gao<sup>1</sup>, R. J. Shah<sup>1</sup>, A. Venado<sup>1</sup>, S. R. Hays<sup>1</sup>, J. Kukreja<sup>2</sup>, J. Golden<sup>1</sup>, L. E. Leard<sup>1</sup>, J. R. Greenland<sup>1</sup>, M. Kleinhenz<sup>1</sup>, P. P. Katz<sup>1</sup>, P. D. Blanc<sup>1</sup>, J. P. Singer<sup>1</sup>. <sup>1</sup>*Medicine, University of California, San Francisco, San Francisco, CA*, <sup>2</sup>*Surgery, University of California, San Francisco, San Francisco, CA*

7:05 PM

**(547) High Lung Allocation Scores Do Not Preclude Improvement in Health-Related Quality of Life after Lung Transplantation;** A. A. Perez, S. R. Hays, Y. Gao, A. Soong, M. Kleinhenz, L. E. Leard, J. Kukreja, A. Venado, J. A. Golden, R. J. Shah, P. Blanc, J. Greenland, J. P. Singer. *UCSF, San Francisco, CA*

7:10 PM

**(548) Less Delayed Chest Closure, Systemic Edema, and Postoperative Bleeding in Lung Transplantation Using ECMO, Compared with CPB;** M. Ikeda<sup>1</sup>, A. Aoyama<sup>1</sup>, H. Oda<sup>1</sup>, Y. Yokoyama<sup>1</sup>, H. Kayawake<sup>1</sup>, J. Tokuno<sup>1</sup>, S. Ueda<sup>1</sup>, F. Gochi<sup>1</sup>, R. Okabe<sup>1</sup>, M. Saito<sup>1</sup>, J. Fukuyama<sup>2</sup>, M. Okuda<sup>2</sup>, K. Yamazaki<sup>3</sup>, K. Minatoya<sup>3</sup>, Y. Yamada<sup>1</sup>, Y. Yutaka<sup>1</sup>, D. Nakajima<sup>1</sup>, M. Hamaji<sup>1</sup>, A. Ohsumi<sup>1</sup>, T. Menju<sup>1</sup>, T. Sato<sup>1</sup>, M. Sonobe<sup>1</sup>, T. F. ChenYoshikawa<sup>1</sup>, H. Date<sup>1</sup>. <sup>1</sup>*Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan*, <sup>2</sup>*Medical Equipment, Kyoto University Hospital, Kyoto, Japan*, <sup>3</sup>*Cardiovascular Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan*



FRIDAY, APRIL 5, 2019  
6:15 PM - 7:15 PM

**MINI ORAL 17: LVAD Physiology: Effects on End Organs**

**Room: Pacifica 6**

**Target Audience: MCS**

**Chairs:** Snehal R. Patel, MD, and Josef Stehlik, MD, MPH

- 6:15 PM** (561) *Unexpected Contribution of Pulsatility to Pump Thrombosis*; J. Engelman, K. Muthiah, P. Jain, D. Robson, P. Jansz, C. Hayward. *Heart Failure and Transplant Unit, St Vincent's Hospital, Sydney, Australia*
- 6:20 PM** (562) *CCR5 Expression is Lower in Women, and Mediates Sex-Based Differences in Post-LVAD Right Ventricular Failure*; A. Nayak<sup>1</sup>, A. A. Morris<sup>1</sup>, C. M. Sciortino<sup>2</sup>, C. Neill<sup>3</sup>, R. L. Kormos<sup>2</sup>, C. McTiernan<sup>4</sup>, J. Larsen<sup>3</sup>, T. N. Bachman<sup>4</sup>, K. Hanley-Yanez<sup>4</sup>, D. M. McNamara<sup>2</sup>, M. A. Simon<sup>2</sup>. <sup>1</sup>Emory University, Atlanta, GA, <sup>2</sup>University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>3</sup>University of Pittsburgh School of Medicine, Pittsburgh, PA, <sup>4</sup>University of Pittsburgh Vascular Medicine Institute, Pittsburgh, PA
- 6:25 PM** (563) *Impact of Left Ventricular Assist Device Placement on Chronic Kidney Diseases: A Multicenter Longitudinal Study*; Y. C. Yalcin<sup>1</sup>, R. Muslem<sup>1</sup>, K. Veen<sup>1</sup>, R. J. Tedford<sup>2</sup>, B. Tomashitis<sup>2</sup>, Y. Al Najam<sup>1</sup>, A. Kilic<sup>3</sup>, B. Houston<sup>2</sup>, J. J. Brugts<sup>1</sup>, A. C. Constantinescu<sup>1</sup>, O. C. Manintveld<sup>1</sup>, S. Hsu<sup>4</sup>, A. J. Bogers<sup>1</sup>, K. Caliskan<sup>1</sup>. <sup>1</sup>Thoraxcenter, Erasmus University, Rotterdam, Netherlands, <sup>2</sup>Cardiology, University of South Carolina, Charleston, SC, <sup>3</sup>Cardiothoracic Surgery, Johns Hopkins School of Medicine, Baltimore, MD, <sup>4</sup>Cardiology, Johns Hopkins School of Medicine, Baltimore, MD
- 6:30 PM** (564) *Elevated Shear Associated with MCS Devices Yields Unique Platelet Membrane Lipid Species: Pro-Thrombotic Agonists?*; A. Sweedo<sup>1</sup>, L. M. Wise<sup>2</sup>, Y. Roka-Moia<sup>3</sup>, J. Sheriff<sup>4</sup>, D. Bluestein<sup>4</sup>, J. G. Purdy<sup>2</sup>, M. J. Slepian<sup>3</sup>. <sup>1</sup>Biomedical Engineering, University of Arizona, Tucson, AZ, <sup>2</sup>Immunobiology, University of Arizona, Tucson, AZ, <sup>3</sup>Medicine, University of Arizona, Tucson, AZ, <sup>4</sup>Biomedical Engineering, Stony Brook University, Stony Brook, NY
- 6:35 PM** (565) *Time-Dependent Association of Renal Function with Long-Term Survival Following LVAD Implantation*; H. Vidula, S. McNitt, M. Wang, S. Polonsky, S. Sherazi, I. Gosev, B. Ayers, K. Wood, B. Barrus, J. Alexis, L. Chen, V. Kutuyifa, I. Goldenberg. *Univ of Rochester, Rochester, NY*
- 6:40 PM** (566) *Metabolic Vasoreactivity in the Middle Cerebral Artery of Heart Failure Patients with and without Continuous-Flow Left Ventricular Support*; R. Ji<sup>1</sup>, K. Akiyama<sup>2</sup>, F. Castagna<sup>1</sup>, A. Pinsino<sup>1</sup>, J. R. Cockcroft<sup>3</sup>, M. Yuzefpolskaya<sup>1</sup>, A. Garan<sup>1</sup>, V. K. Topkara<sup>1</sup>, M. T. Pineda<sup>4</sup>, H. Takayama<sup>4</sup>, K. Takeda<sup>4</sup>, Y. Naka<sup>4</sup>, P. C. Colombo<sup>1</sup>, B. McDonnell<sup>3</sup>, E. J. Stöhr<sup>3</sup>, J. Z. Willey<sup>5</sup>. <sup>1</sup>Medicine, Columbia University Medical Center, New York, NY, <sup>2</sup>Surgery, Columbia University Medical Center, New York, NY, <sup>3</sup>Physiology & Health, Cardiff Metropolitan University, Cardiff, CF5 2YB, United Kingdom, <sup>4</sup>Cardiothoracic Surgery, Columbia University Medical Center, New York, NY, <sup>5</sup>Neurology Stroke, Columbia University Medical Center, New York, NY
- 6:45 PM** (567) *Incidence and Predictors of Long-Term Renal Function Deterioration after Implantation of a Centrifugal, Continuous-Flow Device for Bridge to Transplant*; N. Kikuchi, A. Yoshimura, H. Hattori, A. Suzuki, T. Shiga, H. Niinami, N. Hagiwara, S. Nunoda. *Tokyo Women's Medical University, Tokyo, Japan*
- 6:50 PM** (568) *Baseline LVAD Flow is an Important Risk for Hemoresponse to Blood Stream Infection in LVAD Patients with Fixed Cardiac Output*; N. Bart<sup>1</sup>, S. Emmanuel<sup>2</sup>, D. Andresen<sup>3</sup>, K. Muthiah<sup>1</sup>, C. S. Hayward<sup>1</sup>. <sup>1</sup>Heart Transplant and Failure, St Vincents Hospital, Sydney, Australia, <sup>2</sup>Cardiothoracic Surgery, St Vincents Hospital, Sydney, Australia, <sup>3</sup>Infectious Disease, St Vincents Hospital, Sydney, Australia
- 6:55 PM** (569) *What Happens to Right Ventricular Strain and Function Following Tricuspid Valve Repair in Patients Undergoing Implantation of a Left Ventricular Assist Device?*; O. N. Kislitsina<sup>1</sup>, A. S. Anderson<sup>1</sup>, J. D. Thomas<sup>1</sup>, J. D. Rich<sup>1</sup>, J. E. Wilcox<sup>1</sup>, E. E. Vorovich<sup>1</sup>, A. Zhou<sup>2</sup>, A. C. Andrei<sup>3</sup>, R. Harap<sup>1</sup>, P. M. McCarthy<sup>4</sup>, C. W. Yancy<sup>1</sup>, D. T. Pham<sup>4</sup>. <sup>1</sup>Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL, <sup>2</sup>CTU, Northwestern University Feinberg School of Medicine, Chicago, IL, <sup>3</sup>Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, <sup>4</sup>Cardiac Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL
- 7:00 PM** (570) *Cystatin C is Superior to Creatinine for Prediction of Adverse Events in Heart Failure Patients Undergoing LVAD Implant*; A. Pinsino<sup>1</sup>, A. Gaudig<sup>2</sup>, E. A. Royzman<sup>2</sup>, M. B. Dominguez<sup>2</sup>, J. Radhakrishnan<sup>2</sup>,

K. Toma<sup>2</sup>, A. M. Zuver<sup>2</sup>, M. Tiburcio<sup>3</sup>, V. Topkara<sup>2</sup>, A. Masoumi<sup>2</sup>, A. R. Garan<sup>2</sup>, H. Takayama<sup>3</sup>, K. Takeda<sup>3</sup>, Y. Naka<sup>3</sup>, R. T. Faillace<sup>1</sup>, R. T. Demmer<sup>4</sup>, P. C. Colombo<sup>2</sup>, M. Yuzefpolskaya<sup>2</sup>. <sup>1</sup>*Medicine, Jacobi AECOM, Bronx, NY*, <sup>2</sup>*Department of Medicine, Columbia University Medical Center, New York, NY*, <sup>3</sup>*Department of Surgery, Columbia University Medical Center, New York, NY*, <sup>4</sup>*Epidemiology and Community Health, University of Minnesota, Minneapolis, MN*

**7:05 PM**

**(571) Trends and Predictors of Acute Kidney Injury in Patients with and without Chronic Kidney Disease Undergoing Left Ventricular Assist Device Implantation: A Nationwide Inpatient Sample Analysis;** S. Ranka<sup>1</sup>, M. Pahuja<sup>2</sup>, S. Mony<sup>3</sup>, T. Akhtar<sup>1</sup>, O. Chahab<sup>2</sup>, H. Abubakar<sup>4</sup>, A. Yassen<sup>2</sup>, T. Ando<sup>2</sup>, P. Alvarez<sup>5</sup>, L. Afonso<sup>2</sup>, A. Brisoulis<sup>5</sup>. <sup>1</sup>*John H Stroger Hospital of Cook County, Chicago, IL*, <sup>2</sup>*Detroit Medical Center Wayne State University, Detroit, MI*, <sup>3</sup>*University of South Florida, Tampa, FL*, <sup>4</sup>*Detroit Medical Center Wayne State University, Chicago, IL*, <sup>5</sup>*University of Iowa, Iowa City, IA*

**7:10 PM**

**(572) Advanced Kidney Disease in the Left Ventricular Assist Device Population: Impact on Disease Progression, Morbidity and Mortality;** J. Grinstein, A. Kadakkal, M. Rodrigo, M. Hofmeyer, S. Mohammed, P. E. Craig, R. Torguson, E. Molina, S. Najjar, F. Sheikh. *MedStar Heart and Vascular Institute, Washington, DC*

FRIDAY, APRIL 5, 2019  
6:15 PM - 7:15 PM

**MINI ORAL 18: MCS: Right Heart Failure**

**Room: Coral Sea**

**Target Audience: MCS**

**Chairs:** Cristiano Amarelli, MD, and Pavan Atluri, MD

- 6:15 PM** (549) *Home Inotropic Therapy Post Left Ventricular Assist Device Placement*; S. Pauwaa, K. Meehan, L. Kukla, N. Krause, T. Aicher, G. Macaluso, A. Andrade, A. Joshi, C. Sciamanna, M. Dia, P. Pappas, A. Tatooles, W. Cotts. *Advocate Christ Medical Center, Oak Lawn, IL*
- 6:20 PM** (550) *The Effect of Right Ventricular Arterial Uncoupling on Mortality in Cardiogenic Shock*; V. Nguyen<sup>1</sup>, J. McCabe<sup>1</sup>, C. Mahr<sup>1</sup>, T. Jones<sup>2</sup>, M. Tan<sup>3</sup>, R. Cheng<sup>1</sup>, T. Dardas<sup>1</sup>, S. Masri<sup>1</sup>. <sup>1</sup>Department of Medicine, Division of Cardiology, University of Washington, Seattle, WA, <sup>2</sup>Department of Medicine, Division of Cardiovascular Medicine, University of Utah, Salt Lake City, UT, <sup>3</sup>Department of Medicine, University of Washington, Seattle, WA
- 6:25 PM** (1119) *The Model for End-Stage Liver Disease Score and Survival after the Total Artificial Heart*; A. Jahangiri<sup>1</sup>, M. Smallfield<sup>1</sup>, A. Andreae<sup>2</sup>, K. Desai<sup>2</sup>, T. Johnson<sup>3</sup>, J. Hillary<sup>3</sup>, E. Sawey<sup>1</sup>, J. Cook<sup>4</sup>, D. Tang<sup>1</sup>, V. Kasirajan<sup>1</sup>, K. B. Shah<sup>1</sup>. <sup>1</sup>Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, <sup>2</sup>Virginia Commonwealth University School of Medicine, Richmond, VA, <sup>3</sup>Internal Medicine, Virginia Commonwealth University, Richmond, VA, <sup>4</sup>Vanderbilt Heart and Vascular Institute, Vanderbilt University Medical Center, Nashville, TN
- 6:30 PM** (552) *Timing of Right Heart Failure after Left Ventricular Assist Device is Associated with Survival after Heart Transplantation*; E. M. Senser<sup>1</sup>, F. Cabezas<sup>2</sup>, E. W. Grandin<sup>2</sup>. <sup>1</sup>Internal Medicine, Beth Israel Deaconess Medical Center, Boston, MA, <sup>2</sup>Cardiology, Beth Israel Deaconess Medical Center, Boston, MA
- 6:35 PM** (1117) *Relationship between Length of Hospital Stay Post LVAD Implant and Survival: The Potential for Understanding a Less Sick Population*; S. Silvestry<sup>1</sup>, J. Rogers<sup>2</sup>, W. Cotts<sup>3</sup>, M. Slaughter<sup>4</sup>, S. Prasad<sup>5</sup>, M. Jacoski<sup>6</sup>, F. Pagani<sup>7</sup>, L. Stein<sup>8</sup>. <sup>1</sup>Cardiac Surgery, Florida Hospital Transplant Hospital, Orlando, FL, <sup>2</sup>Cardiology, Duke University, Durham, NC, <sup>3</sup>Cardiology, Advocate Christ Medical Center, Oak Lawn, IL, <sup>4</sup>Cardiac Surgery, University of Louisville, Louisville, KY, <sup>5</sup>Cardiac Surgery, University of Rochester, Rochester, NY, <sup>6</sup>Medtronic, Framingham, MA, <sup>7</sup>Cardiac Surgery, University of Michigan, Ann Arbor, MI, <sup>8</sup>Cardiac Surgery, SUNY Downstate, Brooklyn, NY
- 6:40 PM** (1118) *Safety of Mechanical Circulatory Support for Left Ventricular Non-Compaction: Single Center Experience*; A. Bansal<sup>1</sup>, F. Akhtar<sup>1</sup>, M. Bansal<sup>2</sup>, S. Desai<sup>3</sup>, D. Jacks<sup>1</sup>, Y. Gilliland<sup>3</sup>. <sup>1</sup>Cardiothoracic Surgery, Ochsner Clinic Foundation, New Orleans, LA, <sup>2</sup>Pathology, Ochsner Clinic Foundation, New Orleans, LA, <sup>3</sup>Heart Transplant Med, Ochsner Clinic Foundation, New Orleans, LA
- 6:45 PM** (895) *Tricuspid Regurgitation Predicts Late Onset Right Heart Failure after Left Ventricular Assist Device Implantation*; O. Gonzalez Fernandez, N. Bouzas Cruz, C. Ferrera Duran, A. Woods, N. Robinson-Smith, S. Tovey, G. Parry, K. Booth, G. MacGowan, S. Schueler. *Freeman Hospital, Newcastle upon Tyne, United Kingdom*
- 6:50 PM** (556) *Utilization of Combined Mechanical Circulatory Support Devices in Cardiogenic Shock: Insights from the National Inpatient Sample*; M. Pahuja<sup>1</sup>, S. Ranka<sup>2</sup>, S. Mony<sup>3</sup>, O. Chahab<sup>4</sup>, T. Ando<sup>4</sup>, H. Abubakar<sup>4</sup>, A. Yassen<sup>4</sup>, P. Alvarez<sup>5</sup>, L. Afonso<sup>6</sup>, A. Brisoulis<sup>5</sup>. <sup>1</sup>Detroit Medical Center/Wayne State University, Detroit, ME, <sup>2</sup>John H Stroger Hospital of Cook County, Chicago, IL, <sup>3</sup>University of South Florida, Tampa, FL, <sup>4</sup>Detroit Medical Center Wayne State University, Detroit, MI, <sup>5</sup>University of Iowa, Iowa City, IA, <sup>6</sup>Detroit Medical Center/Wayne State University, Detroit, MI
- 6:55 PM** (557) *Temporary Mechanical Circulatory Support, a New Paradigm in Bridging Patients to Heart Transplantation: Comparing Outcomes versus Durable Left Ventricular Assist Devices*; J. S. Chung, D. Emerson, D. Ramzy, A. Akhmerov, R. M. Cole, D. Megna, F. Esmailian, J. Moriguchi, J. A. Kobashigawa, A. Trento. *Cedars-Sinai Medical Center, Los Angeles, CA*
- 7:00 PM** (558) *Temporary Mechanical Circulatory Support as a Bridge to Heart Transplantation: Insights from the UNOS Database*; A. K. Okoh<sup>1</sup>, S. Fugar<sup>2</sup>, M. Schulthies<sup>3</sup>, M. Russo<sup>1</sup>, R. Karanam<sup>1</sup>, M. Zucker<sup>1</sup>, R. Yanagida<sup>1</sup>,

M. Camacho<sup>1</sup>. <sup>1</sup>*RWJ Barnabas Health Newark Beth Israel Medical Center, RWJ Barnabas Health Newark Beth Israel Medical Center, Newark, NJ*, <sup>2</sup>*Division of Cardiology, Rush University Medical Center, Chicago, IL*, <sup>3</sup>*RWJ Barnabas Health Newark Beth Israel Medical Center, Newark, NJ*

**7:05 PM**

**(559) *Novel Percutaneous Dual Lumen Cannula Right Ventricular Assist Device Provides Effective Support for Patients after Left Ventricular Assist Device Implantation***; M. Salna, A. R. Garan, A. Kirtane, D. Karpaliotis, P. Green, T. Vahl, H. Takayama, J. Sanchez, P. Kurlansky, M. Yuzefpolskaya, P. C. Colombo, Y. Naka, K. Takeda. *Columbia University Medical Center, New York, NY*

**7:10 PM**

**(560) *Direct Cavo-Pulmonary Stent Mounted Right Ventricular Assist Device***; J. Park, P. Bonde. *Yale School of Medicine, New Haven, CT*

**SATURDAY, APRIL 6, 2019**

**7:00 AM - 8:00 AM**

**SUNRISE SYMPOSIUM 13: A Fork in the Road: How Can We Compare Interventional Therapies in CTEPH?**

**Room: Coral Sea**

**Target Audiences: CTEPH, PH**

**Chairs:** Isabelle Opitz, MD, and Gustavo A. Heresi, MD

**Session Summary:** Interventional options for the treatment of CTEPH are expanding with BPA recently emerging as an option, in addition to PTE surgery. Yet, how can we compare the two therapies when there are differences in patient populations, procedures performed, and variability in reporting of risks and outcomes? This symposium will address these issues and facilitate discussion on how we can move toward more uniform reporting of outcomes.

**7:00 AM**

***Challenges in Risk Stratification of CTEPH Patients***

Raymond L. Benza, MD, Allegheny General Hospital, Pittsburgh, PA, USA

**7:15 AM**

***Therapeutic Outcomes: Beyond Mortality, What Are The Other Important Endpoints?***

Marion Delcroix, MD, University Hospital Leuven, Leuven, Belgium

**7:30 AM**

***Balloon Pulmonary Angioplasty: Defining Essential Differences in Procedure Technique and Uniform Definitions of Complications***

Aiko Ogawa, MD, Okayama Medical Center, Okayama, Japan

**7:45 AM**

***Can We Compare Apples to Oranges? How Can We Design a Meaningful Trial to Compare PTE and BPA?***

William Auger, MD, UCSD Medical Center, La Jolla, CA, USA

**SATURDAY, APRIL 6, 2019**

**7:00 AM - 8:00 AM**

**SUNRISE SYMPOSIUM 14: One Size Does Not Fit All: Personalized Medicine in Heart Transplantation**

**Room: Pacifica 7**

**Target Audiences: HF/HTX, PHARM**

**Chairs:** Douglas Greig, MD, and Christina Aquilante, PharmD

**Session Summary:** Immunosuppression management balances the risks of under-immunosuppression and allograft rejection with the risks of over-immunosuppression and infection. Recent studies have demonstrated the efficacy of tacrolimus monotherapy, the utility of gene-expression profiling and the T-cell immune monitoring assay for minimization of immunosuppression. This symposium will serve to review approaches to minimization of immunosuppression as well as the pros and cons. A 15-min panel discussion with all speakers will conclude this session.

**7:00 AM**

***The ABCs of Immunosuppression: Patient Profiles and Personalized Therapy***

Eugene DePasquale, MD, UCLA Medical Center, Los Angeles, CA, USA

**7:15 AM**

***The Nuts and Bolts of Tailoring Immunosuppression: Impact on Long-Term Issues in Heart Transplantation***

Marisa G. Crespo-Leiro, MD, Hospital University A Coruña, La Coruña, Spain

**7:30 AM**

***Minimizing Immunosuppression: Do All Roads Lead Home?***

Satish Arora, MD, Oslo University Hospital, Oslo, Norway

**7:45 AM**

***15-min Panel Discussion***

**SATURDAY, APRIL 6, 2019**

**7:00 AM - 8:00 AM**

**SUNRISE SYMPOSIUM 15: Lung Transplant Candidate Selection: Challenging Cases**

**Room: Pacifica 10-12**

**Target Audiences: LF/LTX, ID, NNSAH, PEDS**

**Chairs:** Edward Cantu, III, MD, and Mark Benzmira, MD

**Session Summary:** Guidelines for lung transplant candidacy were last updated in 2014 and include significant numbers of absolute and strong relative contraindications. In the last 5 years there has been a dramatic increase in the willingness of transplant programs to push the boundaries of transplant candidacy and a concomitant increase in the published literature regarding extended criteria recipients. This symposium focuses on several potential avenues for increased lung transplant candidate access. A 15-min panel discussion with all speakers will conclude this session.

**7:00 AM**

***Is HIV a Contra-Indication for Lung Transplant?***

Paolo Grossi, MD, PhD, University of Insubria, Varese, Italy

**7:15 AM**

***Scleroderma: The Ability to Swallow is Optional***

Maria M. Crespo, MD, University of Pennsylvania, Philadelphia, PA, USA

**7:30 AM**

***So Many Antibodies...***

Adriana Zeevi, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

**7:45 AM**

***15-min Panel Discussion***

**SATURDAY, APRIL 6, 2019**

**7:00 AM - 8:00 AM**

**SUNRISE SYMPOSIUM 16: Fragility: Not Necessarily Failure**

**Room: Pacifica 6**

**Target Audiences: NHSAH, HF/HTX, LF/LTX, MCS**

**Chairs:** Louise M. Fuller, PT, and Rose DeRosa, PA-C

**Session Summary:** A multi-disciplinary approach to the assessment and treatment of a complex frail patient will be highlighted. A case study describing a patient with end stage disease will be presented who is experiencing nutritional, cognitive, and mental health concerns. Individual talks addressing these issues will be from a physician, psychologist, and dietitian. The symposium will conclude by involving the audience in an open discussion on issues raised in one's clinical experience with frail patients.

**7:00 AM**

***Dying, Not Necessarily Doomed***

Oscar Gonzalez Fernandez, MD, Hospital Universitario La Paz, Madrid, Spain

**7:15 AM**

***Cognitive Deficits, Not Necessarily Crazy***

Patrick J. Smith, PhD, MPH, Duke University Medical Center, Durham, NC, USA

**7:30 AM**

***Withered, Not Necessarily Wasted***

Kirsten Diegel, RD, LDN, Temple University Hospital, Philadelphia, PA, USA

**7:45 AM**

***15-min Panel Discussion***



**SATURDAY, APRIL 6, 2019**

**7:00 AM - 8:00 AM**

**SUNRISE SYMPOSIUM 17: A Brand-New Day: The New Normal in Pediatric Thoracic Transplantation**

**Room: Pacifica 1-2**

**Target Audiences: PEDS, LF/LTX, PATH**

**Chairs:** Melinda P. Solomon, MD, FRCPC, and Marc G. Schechter, MD

**Session Summary:** With improvements in the care of children with cystic fibrosis and pulmonary hypertension, the demographics of pediatric lung and heart lung transplantation are changing. This symposium will focus on the new demographics of pediatric lung and heart lung transplant recipients, the new challenges, and the impacts of these changes on pediatric transplant programs.

- 7:00 AM**                    *The Changing Pediatric Lung Transplant Recipient*  
Samuel B. Goldfarb, MD, Children's Hospital of Philadelphia, Philadelphia, PA, USA
- 7:15 AM**                    *Q&A*
- 7:20 AM**                    *Childhood Interstitial Lung Disease (ChiLD) and Transplant*  
Nicolaus Schwerk, MD, Hannover Medical School, Hannover, Germany
- 7:35 AM**                    *Q&A*
- 7:40 AM**                    *When One is Not Enough - Indications for Heart Lung Transplant*  
Maria C. Gazzaneo, MD, Texas Children's Hospital, Houston, TX, USA
- 7:55 AM**                    *Q&A*

**SATURDAY, APRIL 6, 2019**

**7:00 AM - 8:00 AM**

**SUNRISE SYMPOSIUM 18: So Your Patient is on ECMO ... Now What? Considerations for Drug Dosing and Anticoagulation in ECMO**

**Room: Pacifica 3-5**

**Target Audiences: PHARM, MCS**

**Chairs:** Patricia Uber, PharmD, and Charles Hoopes, MD

**Session Summary:** ECMO presents unique drug dosing and medication management challenges. This symposium will discuss the approach to optimal pharmacotherapy management for ECMO patients with a focus on anti-infectives and anticoagulation. Anecdotes and clinical pearls for ECMO in special populations will also be discussed.

**7:00 AM**

***Keeping Things Moving: Anticoagulation on ECMO***

Christopher Michaud, PharmD, BCPS, Spectrum Health, Grand Rapids, MI, USA

**7:15 AM**

***Q&A***

**7:20 AM**

***What's My Vd Again? Drug Dosing on ECMO with a Focus on Anti-Infectives***

Haifa Lyster, MSc, Royal Brompton, Middlesex, United Kingdom

**7:35 AM**

***Q&A***

**7:40 AM**

***ECMO and What Else? Approach to Management of ECMO in Special Populations***

Konrad Hoetzenecker, MD, PhD, Medical University of Vienna, Vienna, Austria

**7:55 AM**

***Q&A***

**SATURDAY, APRIL 6, 2019**

**8:00 AM - 10:00 AM**

**PLENARY SESSION**

**Room: Pacifica 6**

**Target Audience: ALL**

**Chairs:** Stuart C Sweet, MD, PhD, and Stephan M. Ensminger, MD, DPhil

- 8:00 AM**                    *Awards Presentations*  
Kathleen L Grady, PhD, APN, FAAN, Northwestern Memorial Hospital, Chicago, IL, USA
- 8:30 AM**                    *What's Hot, What's New: Basic Science Overview*  
Stijn E Verleden, PhD, KU Leuven, Leuven, Belgium
- 8:50 AM**                    *What's Hot, What's New: Clinical Science Overview*  
Maria Rosa Costanzo, MD, Midwest Heart Specialists-Advocate Medical, Naperville, IL, USA
- 9:10 AM**                    *PRESIDENT'S DEBATE: Resource Limits: It's Time to Abandon Retransplantation (PRO)*  
Josef Stehlik, MD, MPH, University of Utah School of Medicine, Salt Lake City, UT, USA
- 9:30 AM**                    *PRESIDENT'S DEBATE: Resource Limits: It's Time to Abandon Retransplantation (CON)*  
Andrew J Fisher, FRCP, PhD, Newcastle University, Newcastle Upon Tyne, United Kingdom
- 9:50 AM**                    *Debate Rebuttal (PRO)*  
Josef Stehlik, MD, MPH, University of Utah School of Medicine, Salt Lake City, UT, USA
- 9:55 AM**                    *Debate Rebuttal (CON)*  
Andrew J Fisher, FRCP, PhD, Newcastle University, Newcastle Upon Tyne, United Kingdom

**SATURDAY, APRIL 6, 2019**

**10:15 AM - 12:00 PM**

**SESSION 72 (SYMPOSIUM): Seeing the Light: Antibodies in Thoracic Transplantation**

**Room: Pacifica 3-5**

**Target Audiences: BSTR, HF/HTX, LF/LTX, PHARM**

**Chairs:** Jon A. Kobashigawa, MD, and Edward Horn, PharmD, BCPS

**Session Summary:** The goal of this symposium is to provide the audience with a deeper understanding of antibody-mediated mechanisms and potential downstream consequences of antibodies in transplantation. Presentations will discuss the basic science of immunology, the role of donor specific antibodies and emerging management strategies. A 15-min panel discussion with all speakers will conclude this session.

- 10:15 AM**            *The Pre-Transplant Alphabet Soup – MFI, CIQ, HLA*  
Christine Falk, MD, Hannover Medical School, Hannover, Germany
- 10:30 AM**            *Seeing Ghosts? The Role of Non-DSA and Non-HLA in the Transplant Recipient*  
Antoine Roux, MD, Hôpital Foch, Paris, France
- 10:45 AM**            *The Needles in the Haystack: Diagnostic Challenges in Antibody-Mediated Rejection*  
Agnieszka Ciarka, MD, PhD, Catholic University of Leuven, Leuven, Belgium
- 11:00 AM**            *The Transplant Toolbox: Dealing with DSA Now and in the Future*  
Miae Kim, PharmD, Brigham & Women's Hospital, Boston, MA, USA
- 11:15 AM**            *DEBATE: Photopheresis is Useful for Rejection Management (PRO)*  
Peter Jaksch, MD, Medical University of Vienna, Vienna, Austria
- 11:30 AM**            *DEBATE: Photopheresis is Useful for Rejection Management (CON)*  
Michael Shullo, PharmD, University of West Virginia, Morgantown, WV, USA
- 11:45 AM**            *15-min Panel Discussion*

SATURDAY, APRIL 6, 2019  
10:15 AM - 12:00 PM

SESSION 73 (ORAL): Life on the Cutting Edge: CTEPH and Surgical Management of Pulmonary Hypertension  
Room: Pacifica 1-2  
Target Audiences: CTEPH, PH

Chairs: Andrea M D'Armini, and Michael M. Madani, MD

- 10:15 AM**      **(294) Preoperative C-Reactive Protein Predicts Early Postoperative Outcomes after Pulmonary Endarterectomy in Patients with Chronic Thromboembolic Pulmonary Hypertension;** J. Arthur<sup>1</sup>, M. Amsallem<sup>1</sup>, J. Guihaire<sup>2</sup>, F. Haddad<sup>3</sup>, L. Lamrani<sup>1</sup>, S. Feuillet<sup>4</sup>, F. Stephan<sup>5</sup>, X. Jais<sup>6</sup>, M. Humbert<sup>7</sup>, G. Simonneau<sup>7</sup>, O. Mercier<sup>4</sup>, E. Fadel<sup>4</sup>. <sup>1</sup>Research and Innovation Unit, Marie Lannelongue Hospital, Paris Sud University, Le Plessis Robinson, France, <sup>2</sup>Adult Cardiac Surgery, Marie Lannelongue Hospital, Paris Sud University, Le Plessis Robinson, France, <sup>3</sup>Division of Cardiovascular Medicine, Stanford University School of Medicine, Palo Alto, CA, <sup>4</sup>Thoracic and Vascular Surgery and Heart-Lung Transplantation, Marie Lannelongue Hospital, Paris Sud University, Le Plessis Robinson, France, <sup>5</sup>Adult Intensive Care Unit, Marie Lannelongue Hospital, Paris Sud University, Le Plessis Robinson, France, <sup>6</sup>Respiratory Medicine, Kremlin Bicetre Hospital, Paris Sud University, Kremlin Bicêtre, France, <sup>7</sup>Respiratory Medicine, Kremlin Bicetre Hospital, Paris Sud University, Kremlin Bicetre, France
- 10:30 AM**      **(295) Right Ventricular Reverse Remodeling after Pulmonary Endarterectomy in Patients with Chronic Thrombo Embolic Pulmonary Hypertension;** S. Guimaron<sup>1</sup>, J. Guihaire<sup>1</sup>, M. Amsallem<sup>1</sup>, A. Potier<sup>2</sup>, A. Amatogauberville<sup>3</sup>, L. Mabile<sup>4</sup>, M. Isorni<sup>3</sup>, L. Lamrani<sup>1</sup>, E. Fadel<sup>5</sup>, O. Mercier<sup>5</sup>. <sup>1</sup>Research and Innovation Unit Research Lab, Marie Lannelongue Hospital, Le Plessis Robinson, France, <sup>2</sup>Marie Lannelongue Hospital, Le Plessis Robinson, France, <sup>3</sup>Department of Radiology, Marie Lannelongue Hospital, Le Plessis Robinson, France, <sup>4</sup>Department of Nuclear Medicine and Radiology, Marie Lannelongue Hospital, Le Plessis Robinson, France, <sup>5</sup>Thoracic and Vascular Surgery and Heart-Lung Transplantation, Marie Lannelongue Hospital, Le Plessis Robinson, France
- 10:45 AM**      **(296) Outcome after Pulmonary Endarterectomy for Segmental Chronic Thromboembolic Pulmonary Hypertension;** M. de Perrot<sup>1</sup>, K. McRae<sup>1</sup>, L. Donahoe<sup>1</sup>, M. McInnis<sup>1</sup>, J. Thenganatt<sup>1</sup>, A. Bykova<sup>1</sup>, K. Tan<sup>1</sup>, J. Moric<sup>1</sup>, S. Mak<sup>2</sup>, J. Granton<sup>1</sup>. <sup>1</sup>Toronto General Hospital, Toronto, ON, Canada, <sup>2</sup>Mount Sinai Hospital, Toronto, ON, Canada
- 11:00 AM**      **(297) Pulmonary Endarterectomy in CTED: The Pavia Experience;** M. Pin, A. Sciortino, A. Celentano, L. J. Masiglat, E. Borrelli, V. N. Merli, B. Vanini, C. Klersy, G. Silvaggio, C. Monterosso, A. M. D'Armini. Policlinico San Matteo, Policlinico San Matteo, Pavia, Italy
- 11:15 AM**      **(298) Characteristics and Management of Patients Following Pulmonary Embolism: A Focus on Screening for Chronic Thromboembolic Pulmonary Hypertension;** M. Kanwar<sup>1</sup>, M. Cole<sup>2</sup>, M. Gauthier-Loiselle<sup>3</sup>, A. M. Manceur<sup>3</sup>, C. Lickert<sup>2</sup>, M. Greenberg<sup>3</sup>, P. Lefebvre<sup>3</sup>, W. Drake<sup>2</sup>, R. Benza<sup>1</sup>. <sup>1</sup>Allegheny General Hospital, Pittsburgh, PA, <sup>2</sup>Actelion Pharmaceuticals Inc., San Francisco, CA, <sup>3</sup>Analysis Group Inc., San Francisco, CA
- 11:30 AM**      **(299) Correlation of Surgical and Computed Tomography Pulmonary Angiographic Level of Disease in Chronic Thromboembolic Pulmonary Hypertension;** M. C. McInnis<sup>1</sup>, M. de Perrot<sup>2</sup>, D. C. Wang<sup>1</sup>, L. Donahoe<sup>2</sup>, K. T. Tan<sup>1</sup>, J. Kavanagh<sup>1</sup>. <sup>1</sup>Department of Medical Imaging, University of Toronto, Toronto, ON, Canada, <sup>2</sup>Department of Surgery, University of Toronto, Toronto, ON, Canada
- 11:45 AM**      **(300) Medical and Surgical Management of ECLS as Bridge to Recovery and Transplantation for Pulmonary Hypertension: A Large Single Center Experience;** E. B. Rosenzweig<sup>1</sup>, W. D. Gannon<sup>2</sup>, C. L. Agerstrand<sup>3</sup>, D. Abrams<sup>3</sup>, D. Brodie<sup>3</sup>, M. D. Bacchetta<sup>2</sup>. <sup>1</sup>Pediatrics and Medicine, Columbia University Medical Center - NYP, New York, NY, <sup>2</sup>Surgery, Vanderbilt University Medical Center, Nashville, TN, <sup>3</sup>Medicine, Columbia University Medical Center - NYP, New York, NY

**SATURDAY, APRIL 6, 2019**  
**10:15 AM - 12:00 PM**

**SESSION 74 (ORAL): Frontiers of Cost-Efficacy and Policy in Transplant and MCS**

**Room: Coral Sea**

**Target Audiences: EEP, HF/HTX, MCS**

**Chairs:** Richard Dorent, MD, and Van Khue Ton, MD, PhD

- 10:15 AM**            **(301) *Costs Associated with the First Clinical Trial Evaluating the Safety and Efficacy of the Thoracotomy Approach for Implantation of a Small Intrapericardial Centrifugal LVAD***; N. A. Mokadam<sup>1</sup>, E. McGee<sup>2</sup>, G. Wieselthaler<sup>3</sup>, D. T. Pham<sup>4</sup>, S. Bailey<sup>5</sup>, G. Pretorius<sup>6</sup>, T. Boeve<sup>7</sup>, E. Ismyrloglou<sup>8</sup>, M. Strueber<sup>9</sup>. <sup>1</sup>*The Ohio State University Wexner Medical Center, Columbus, OH*, <sup>2</sup>*Loyola University Medical Center, Maywood, IL*, <sup>3</sup>*University of California San Francisco, San Francisco, CA*, <sup>4</sup>*Northwestern University Feinberg School of Medicine, Chicago, IL*, <sup>5</sup>*Allegheny Health Network, Pittsburgh, PA*, <sup>6</sup>*University of California San Diego, La Jolla, CA*, <sup>7</sup>*Spectrum Health, Grand Rapids, MI*, <sup>8</sup>*Medtronic, Maastricht, Netherlands*, <sup>9</sup>*Newark Beth Israel Medical Center, Newark, NJ*
- 10:30 AM**            **(302) *Cost-Effectiveness of a Small Intrapericardial Centrifugal LVAD versus Medical Management and Heart Transplantation***; S. Silvestry<sup>1</sup>, C. Mahr<sup>2</sup>, M. S. Slaughter<sup>3</sup>, W. C. Levy<sup>2</sup>, R. K. Cheng<sup>2</sup>, D. M. May<sup>4</sup>, E. Ismyrloglou<sup>5</sup>, S. I. Tsintzos<sup>6</sup>, E. Tuttle<sup>7</sup>, K. Cook<sup>7</sup>, E. Birk<sup>7</sup>, W. G. Cotts<sup>8</sup>. <sup>1</sup>*Florida Hospital Transplant Institute, Orlando, FL*, <sup>2</sup>*University of Washington, Seattle, WA*, <sup>3</sup>*University of Louisville, Louisville, KY*, <sup>4</sup>*Medtronic, Mounds View, MN*, <sup>5</sup>*Medtronic, Maastricht, Netherlands*, <sup>6</sup>*Medtronic, Tolochenaz, Switzerland*, <sup>7</sup>*Analysis Group, Menlo Park, CA*, <sup>8</sup>*Advocate Christ Medical Center, Oak Lawn, IL*
- 10:45 AM**            **(303) *Cost Effectiveness of Using Hepatitis C Virus (HCV)-Viremic Hearts for Transplantation into HCV-Negative Recipients***; C. Logan<sup>1</sup>, I. Yumul<sup>2</sup>, S. Aslam<sup>1</sup>, N. Martin<sup>1</sup>. <sup>1</sup>*University of California, San Diego, San Diego, CA*, <sup>2</sup>*University of Iowa, Iowa City, IA*
- 11:00 AM**            **(304) *Disparities in Utilization of Hepatitis C Virus Positive Hearts for Transplantation***; C. Wainaina<sup>1</sup>, J. Trageser<sup>1</sup>, A. Hahn<sup>1</sup>, C. Lay<sup>2</sup>, V. Pretorius<sup>2</sup>, S. Aslam<sup>2</sup>. <sup>1</sup>*Lifesharing, San Diego, CA*, <sup>2</sup>*University of California, San Diego, San Diego, CA*
- 11:15 AM**            **(305) *Validating Patient Prioritization in the 2018 Revised UNOS Heart Allocation System: A Single Center Experience***; A. Nayak, Y. Ko, N. Chesnut, A. Pekarek, R. T. Cole, K. Bhatt, D. Gupta, M. Burke, S. R. Laskar, T. S. Attia, A. Smith, J. Vega, A. A. Morris. *Emory University, Atlanta, GA*
- 11:30 AM**            **(306) *Consequences of a Revised Heart Allocation System on the Cost Effectiveness of Cardiac Transplantation in the United States: Game Theory Based Insights***; M. Saltzberg. *Comprehensive Heart Failure and Transplant Program, Medical College of Wisconsin, Milwaukee, WI*
- 11:45 AM**            **(307) *Commercial Airlines as a Viable, Safe and Cost Effective Way for Transporting the Donor Hearts across the Country: Single Center Experience***; K. Bala Krishnan<sup>1</sup>, K. Suresh Rao<sup>2</sup>, M. K. Tanguturu<sup>2</sup>, M. Rajam<sup>1</sup>, A. Aravind<sup>2</sup>, J. Dushyanthan<sup>2</sup>, R. Subramanian<sup>2</sup>, V. Ramanan<sup>2</sup>. <sup>1</sup>*Cardiac Surgery, Fortis Malar Hospital, Chennai, India*, <sup>2</sup>*Cardiac Anesthesia & Critical Care, Fortis Malar Hospital, Chennai, India*

**SATURDAY, APRIL 6, 2019**  
**10:15 AM - 12:00 PM**

**SESSION 75 (SYMPOSIUM): Cardiac Allograft Vasculopathy: Have Hope, Ye Who Enter**  
**Room: Pacifica 7**  
**Target Audience: HF/HTX**

**Chairs:** Kyung-Hee Kim, MD, PhD, and Stephan Ensminger, MD, DPhil

**Session Summary:** This symposium will focus on changing disease epidemiology and outcomes; role of noninvasive surveillance, particularly novel approaches such as PET; advanced coronary imaging for early CAV including intracoronary imaging, plaque characterization and intracoronary haemodynamics; pharmacologic therapy including mTORi and non-immune based strategies such as antiplatelet and lipid lowering therapies, and end with a captivating debate on the role of revascularization and defibrillators for CAV treatment. A 10-min panel discussion with all speakers will conclude this session.

- 10:15 AM**            *Shifting CAV Landscape: Definitions, Epidemiology, and Pathophysiology*  
Michael Pham, MD, California Pacific Medical Center, San Francisco, CA, USA
- 10:30 AM**            *Resisting Invasion: Traditional and Novel Non-Invasive Imaging Surveillance for CAV*  
Sharon Chih, MBBS, PhD, University of Ottawa Heart Institute, Ottawa, ON, Canada
- 10:45 AM**            *New Tricks for an Old Dog: Intracoronary Imaging and Hemodynamics - A New Classification for CAV?*  
Tor S Clemmensen, MD, Aarhus University Hospital, Skejby, Denmark
- 11:00 AM**            *If I Knew Then What I Know Now: Old and New Drugs for CAV Prevention and Regression*  
Yael Peled, MD, Sheba Medical Center, Tel Hashomer, Israel
- 11:15 AM**            *CASE PRESENTATION: Young Man s/p AMR Treatment Who Later Died Suddenly - What Should Have Been Done?*  
Livia Goldraich, MD, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil
- 11:20 AM**            *DEBATE: Preventing the Invasion of the Body Snatchers: All Patients with CAV Should Have Revascularization and Defibrillators (PRO)*  
Howard Eisen, MD, Pennsylvania College of Medicine, Hershey, PA, USA
- 11:35 AM**            *DEBATE: Preventing the Invasion of the Body Snatchers: All Patients with CAV Should Have Revascularization and ICDs (CON)*  
Mandeep Mehra, MD, FRCP, FACC, FESC, Brigham and Women's Hospital, Boston, MA, USA
- 11:50 AM**            *10-min Panel Discussion*

**SATURDAY, APRIL 6, 2019**  
**10:15 AM - 12:00 PM**

**SESSION 76 (SYMPOSIUM): Location, Location, and Allocation: Worldwide Application of Broader Sharing in Lung Transplant**

**Room: Pacifica 10-12**

**Target Audiences: LF/LTX, PH**

**Chairs:** Duane M Davis, MD, and James L. Lordan, MB, FRCP

**Session Summary:** Lung allocation in the United States recently moved to broader geographic sharing. This symposium will review lung allocation throughout the world as it relates to this concept. Topics will include an overview of international lung allocation, the US lung allocation system, review of modeled data on this principle, updated US data available since policy implementation, and a review of this concept as it affects allocation over greater distances in Canada and Australia.

**10:15 AM**            *Lung Allocation Systems: Similarities and Differences*  
Jens Gottlieb, MD, Hannover Medical School, Hannover, Germany

**10:30 AM**            *Q&A*

**10:35 AM**            *Changes in US Lung Allocation: Support for Broader Sharing*  
Marie Budev, DO, MPH, Cleveland Clinic, Cleveland, OH, USA

**10:50 AM**            *Q&A*

**10:55 AM**            *Implementation of 250 Nautical Miles as the First Region of Lung Allocation in the US: Early Results*  
Kevin Chan, MD, University of Michigan, Ann Arbor, MI, USA

**11:10 AM**            *Q&A*

**11:15 AM**            *Effects of Distance on Lung Allocation in Australia/New Zealand*  
Dan Chambers, MBBS, FRACP, The Prince Charles Hospital, Brisbane, Australia

**11:30 AM**            *Q&A*

**11:35 AM**            *Effects of Distance on Lung Allocation in Canada*  
Alim Hirji, MD, University of Alberta, Edmonton, AB, Canada

**11:50 AM**            *Q&A*



SATURDAY, APRIL 6, 2019

10:15 AM - 12:00 PM

**SESSION 77 (ORAL): Thicker than Water? Bleeding and LVADs**

**Room: Pacifica 6**

**Target Audience: MCS**

**Chairs:** Emil Najjar, MD, and Ulrich Jorde, MD

- 10:15 AM** (308) *Prospective Validation of the First Endoscopic Management Algorithm for Gastrointestinal Bleeding in Patients with Left Ventricular Assist Devices*; J. Axelrad<sup>1</sup>, A. S. Faye<sup>2</sup>, A. Pinsino<sup>3</sup>, B. Cagliostro<sup>3</sup>, A. Thanataveerat<sup>4</sup>, L. Effner<sup>3</sup>, F. M. Pineda<sup>3</sup>, A. R. Garan<sup>3</sup>, H. Takayama<sup>5</sup>, K. Takeda<sup>5</sup>, Y. Naka<sup>5</sup>, P. C. Colombo<sup>3</sup>, T. Gonda<sup>2</sup>, M. Yuzefpolskaya<sup>3</sup>. <sup>1</sup>Gastroenterology, NYU Langone, NYC, NY, <sup>2</sup>Gastroenterology, Columbia University Medical Center, NYC, NY, <sup>3</sup>Cardiology, Columbia University Medical Center, NYC, NY, <sup>4</sup>Biostatistics, Columbia University Medical Center, NYC, NY, <sup>5</sup>CT Surgery, Columbia University Medical Center, NYC, NY
- 10:30 AM** (309) *Hemocompatibility Related Outcomes of Centrifugal and Axial Flow LVADs: An IMACS Registry Analysis*; S. J. Forest, Y. Xia, O. Saeed, S. Patel, U. Jorde, D. J. Goldstein. Montefiore Medical Center, Bronx, NY
- 10:45 AM** (310) *Promising Novel Treatment with Intravenous Bevacizumab for Refractory Gastrointestinal Bleeding from Angiodysplastic Lesions in Patients Supported with a Continuous-Flow Left Ventricular Assist Device: A Pilot Study*; R. Asleh, S. D. Schettle, S. Maltais, R. C. Daly, V. Iyer, J. M. Stulak, R. Rodeheffer. Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN
- 11:00 AM** (311) *Prediction of GIB Using R<sub>2</sub> CHA<sub>2</sub>DS<sub>2</sub> VASc Risk Score*; A. Critsinelis<sup>1</sup>, H. Lamba<sup>1</sup>, S. Chatterjee<sup>1</sup>, F. Cheema<sup>1</sup>, A. Civitello<sup>1</sup>, R. Delgado<sup>1</sup>, A. Nair<sup>1</sup>, A. Shafii<sup>2</sup>, G. Loor<sup>1</sup>, T. Rosengart<sup>1</sup>, O. Frazier<sup>1</sup>, J. Morgan<sup>1</sup>. <sup>1</sup>Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, TX, <sup>2</sup>Baylor College of Medicine, Houston, TX
- 11:15 AM** (312) *Experimental Venous Congestion Causes Peripheral Release of Angiopoietin-2 and Tissue Necrosis Factor- $\alpha$  - A New Insight into the Pathophysiology of Gastrointestinal Bleeding in CF-LVAD Patients*; P. C. Colombo<sup>1</sup>, F. Castagna<sup>1</sup>, D. Onat<sup>1</sup>, S. M. Lagana<sup>2</sup>, W. Y. Ka<sup>1</sup>, E. A. Royzman<sup>1</sup>, A. S. Faye<sup>3</sup>, J. E. Axelrad<sup>4</sup>, T. A. Gonda<sup>3</sup>, A. R. Garan<sup>5</sup>, H. Takayama<sup>6</sup>, K. Takeda<sup>6</sup>, Y. Naka<sup>6</sup>, G. Parkis<sup>7</sup>, M. Yuzefpolskaya<sup>1</sup>, R. Demmer<sup>8</sup>. <sup>1</sup>Cardiology, Columbia University Medical Center, New York, NY, <sup>2</sup>Pathology & Cell Biology, Columbia University Medical Center, New York, NY, <sup>3</sup>Digestive & Liver Diseases, Columbia University Medical Center, New York, NY, <sup>4</sup>Gastroenterology, New York University, New York, NY, <sup>5</sup>Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY, <sup>6</sup>Surgery, Columbia University Medical Center, New York, NY, <sup>7</sup>Columbia University Medical Center, New York, NY, <sup>8</sup>Epidemiology and Community Health, University of Minnesota, Minneapolis, MN
- 11:30 AM** (313) *Digoxin Restores Angiogenic Equilibrium in CF- LVAD Patients*; S. Vukelic<sup>1</sup>, S. Patel<sup>1</sup>, P. Vlismas<sup>1</sup>, T. Chinnadurai<sup>1</sup>, D. Sims<sup>1</sup>, S. Murthy<sup>1</sup>, J. Shin<sup>1</sup>, O. Saeed<sup>1</sup>, N. Sibinga<sup>2</sup>, S. Forest<sup>3</sup>, D. Goldstein<sup>3</sup>, U. Jorde<sup>1</sup>. <sup>1</sup>Cardiology, Montefiore MC AECOM, New York, NY, <sup>2</sup>Cardiology, AECOM, New York, NY, <sup>3</sup>Cardiothoracic & Vascular Surgery, Montefiore MC AECOM, New York, NY
- 11:45 AM** (314) *Gastrointestinal Angiodysplasia is Part of the Vascular Pathophysiology of Advanced Heart Failure*; S. R. Patel, S. Vukelic, J. Kwah, T. Chinnadurai, O. Saeed, D. Goldstein, U. P. Jorde. Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY

SATURDAY, APRIL 6, 2019  
12:15 PM - 2:00 PM

SESSION 78 (ORAL): The Beginning of the End in Lung Transplantation: PGD, AMR and CLAD  
Room: Pacifica 3-5  
Target Audiences: BSTR, LTX, PEDS, PATH

Chairs: Bart M. Vanaudenaerde, MSc, PhD, and Stephen C Juvet, MD, PhD, FRCPC

- 12:15 PM**      **(320) Development of a New Local Therapeutic Approach for BOS: Efficacy of Imatinib Loaded -antiCD44 Coated Gold Nanoparticles In Vitro and In Vivo;** F. Meloni<sup>1</sup>, R. Di Paola<sup>2</sup>, P. Morbini<sup>3</sup>, L. Pandolfi<sup>4</sup>, V. Frangipane<sup>4</sup>, E. Gugliandolo<sup>2</sup>, E. Cova<sup>5</sup>, M. Colombo<sup>6</sup>, D. Prosperi<sup>6</sup>, P. Vitulo<sup>7</sup>, G. Ferrario<sup>8</sup>, R. Fusco<sup>2</sup>, C. Pacini<sup>6</sup>, R. Siracusa<sup>2</sup>, S. Cuzzocrea<sup>2</sup>. <sup>1</sup>Internal Medicine, University of Pavia, Pavia, Italy, <sup>2</sup>Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy, <sup>3</sup>Molecular Medicine, University of Pavia, Pavia, Italy, <sup>4</sup>Respiratory Diseases, IRCCS San Matteo, Pavia, Italy, <sup>5</sup>Pathology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, <sup>6</sup>Department of Biotechnology and Bioscience, University of Milano Bicocca, Milan, Italy, <sup>7</sup>Respiratory Disease Unit, IRCCS ISMETT, Palermo, Italy, <sup>8</sup>Pathologysection Department of Molecular Medicine, University of Pavia, Pavia, Italy
- 12:30 PM**      **(316) B Cells Drive iBALT Formation in a Mouse Model of Chronic Lung Allograft Dysfunction;** N. F. Smirnova<sup>1</sup>, T. M. Conlon<sup>2</sup>, C. Morrone<sup>2</sup>, A. O. Yildirim<sup>2</sup>, O. Eickelberg<sup>1</sup>. <sup>1</sup>PSCCM, University of Colorado - Anschutz Medical Campus, Aurora, CO, <sup>2</sup>Comprehensive Pneumology Center, Munich, Germany
- 12:45 PM**      **(317) Linking CLAD in Lung Transplant Recipients after 3 Years Follow Up with Transplant Arteriosclerosis in Humanized Mice;** T. Siemeni<sup>1</sup>, A. Knöfel<sup>1</sup>, F. Ius<sup>1</sup>, J. Salman<sup>1</sup>, W. Sommer<sup>1</sup>, M. Avsar<sup>1</sup>, R. Poyanmehr<sup>1</sup>, C. Kühn<sup>1</sup>, C. Falk<sup>2</sup>, I. Tudorache<sup>1</sup>, A. Haverich<sup>1</sup>, G. Warnecke<sup>1</sup>. <sup>1</sup>Hannover HTTG, Hannover, Germany, <sup>2</sup>Hannover Transplant Immunology, Hannover, Germany
- 1:00 PM**      **(318) Pulmonary Antibody-Mediated Rejection (AMR) Accelerates Aging-Evidence from Whole Genome DNA Methylation Sequencing;** S. Agbor-Enoh<sup>1</sup>, F. Seifuddin<sup>1</sup>, M. Pirooznia<sup>2</sup>, M. Jang<sup>1</sup>, H. Valantine<sup>1</sup>. <sup>1</sup>Genomic Research Alliance for Transplantation (GRAfT), Division of Intramural Research, National Heart, Lung, and Blood Institute, Bethesda, MD, <sup>2</sup>Genomic Research Alliance for Transplantation (GRAfT), Division of Intramural Research, National Heart, Lung and Blood Institute, Bethesda, MD
- 1:15 PM**      **(319) Increased NKG2C+ Natural Killer Cells in Bronchoalveolar Lavage Precede CMV Viremia and Are Associated with CLAD or Death in Lung Transplant Recipients;** D. R. Calabrese<sup>1</sup>, T. Chong<sup>1</sup>, A. S. Wang<sup>1</sup>, J. P. Singer<sup>1</sup>, M. Gottschall<sup>2</sup>, S. R. Hays<sup>1</sup>, J. A. Golden<sup>1</sup>, J. Kukreja<sup>3</sup>, Q. Tang<sup>3</sup>, J. R. Greenland<sup>4</sup>. <sup>1</sup>Department of Medicine, University of California San Francisco, San Francisco, CA, <sup>2</sup>Department of Clinical Lab Medicine, University of California San Francisco, San Francisco, CA, <sup>3</sup>Department of Surgery, University of California San Francisco, San Francisco, CA, <sup>4</sup>Medical Service, VA Health Care System, San Francisco, CA
- 1:30 PM**      **(7) A Novel Injury Site-Targeted Complement Inhibitor Which Protects against Lung Transplant Ischemia Reperfusion Injury;** C. Li<sup>1</sup>, K. Patel<sup>2</sup>, P. Allen<sup>2</sup>, Z. TU<sup>1</sup>, J. Kilkenny<sup>1</sup>, C. Wallace<sup>1</sup>, S. Nadig<sup>1</sup>, S. Tomlinson<sup>1</sup>, C. Atkinson<sup>1</sup>. <sup>1</sup>Departments of Microbiology and Immunology, and Surgery, Medical University of South Carolina, Charleston, SC, <sup>2</sup>Department of Surgery, Medical University of South Carolina, Charleston, SC
- 1:45 PM**      **(321) Receptor Tyrosine Kinase Inhibitor Nintedanib as Treatment Option in Bronchiolitis Obliterans after Airway Transplantation;** C. Heim<sup>1</sup>, J. Mauer<sup>1</sup>, A. Kuckhahn<sup>1</sup>, J. Distler<sup>1</sup>, B. Spriewald<sup>1</sup>, M. Ramsperger-Gleixner<sup>1</sup>, M. Weyand<sup>1</sup>, S. M. Ensminger<sup>2</sup>. <sup>1</sup>University of Erlangen, Erlangen, Germany, <sup>2</sup>University of Luebeck, Lubeck, Germany

SATURDAY, APRIL 6, 2019  
12:15 PM - 2:00 PM

SESSION 79 (ORAL): Go with the Flow: Hemodynamic Guiding Therapies in Heart Failure  
Room: Pacifica 1-2  
Target Audiences: HF, HTX

Chairs: Jorge Silva Enciso, MD, and Maria A Castel, MD, PhD

- 12:15 PM** (322) *PH in Heart Transplant (HT) Candidates: Don't Look at Ghosts, Search the Evil in the Details*; M. Masetti, A. Moretta, A. Russo, F. Dardi, M. Palazzini, S. Martin Suarez, A. Loforte, F. Grigioni, N. Galiè, L. Potena. *Cardiovascular Department, Bologna University Hospital, Bologna, Italy*
- 12:30 PM** (323) *Ratio of Systolic Blood Pressure to Pulmonary Capillary Wedge Pressure Ratio: A Novel Prognostic Marker in Chronic Heart Failure*; N. Narang, T. Imamura, J. E. Blair, L. Holzhauser, I. Ebong, M. N. Belkin, A. Kanelidis, A. Oehler, D. Yu, T. Fujino, D. Nitta, B. Chung, A. Nguyen, B. A. Smith, J. Raikhelkar, N. Sarswat, G. H. Kim, V. Jeevanandam, G. Sayer, N. Uriel. *University of Chicago Medical Center, Chicago, IL*
- 12:45 PM** (324) *Association between Central Hemodynamics and Glomerular Filtration Rate in Patients with Advanced Heart Failure*; E. Bobbio<sup>1</sup>, S. Esmaily<sup>2</sup>, E. Bollano<sup>3</sup>, S. Bartfay<sup>3</sup>, P. Dahlberg<sup>3</sup>, G. Dellgren<sup>4</sup>, K. Karason<sup>3</sup>. <sup>1</sup>*Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden*, <sup>2</sup>*Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden*, <sup>3</sup>*Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden*, <sup>4</sup>*Transplantation, Sahlgrenska University Hospital, Gothenburg, Sweden*
- 1:00 PM** (325) *Use of Remote Dielectric Sensing (ReDS) as Point-of-Care Testing Following Heart Failure Hospitalization and Risk of 30-Day Readmission*; M. H. Barghash<sup>1</sup>, A. Lala<sup>1</sup>, G. Giustino<sup>1</sup>, A. Parikh<sup>1</sup>, J. Ullman<sup>1</sup>, S. S. Mitter<sup>1</sup>, S. Konje<sup>2</sup>, B. Keith<sup>1</sup>, N. Moss<sup>1</sup>, D. Mancini<sup>1</sup>, M. G. Trivieri<sup>1</sup>, J. Contreras<sup>1</sup>, D. Burkhoff<sup>3</sup>, S. P. Pinney<sup>1</sup>. <sup>1</sup>*The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Hospital, New York, NY*, <sup>2</sup>*Department of Medicine, Mount Sinai Hospital, New York, NY*, <sup>3</sup>*Department of Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY*
- 1:15 PM** (326) *Lung Ultrasound May Reduce Heart Failure Hospitalizations: Preliminary Results from the LUS-HF Trial*; M. Rivas-Lasarte<sup>1</sup>, A. Maestro-Benedicto<sup>1</sup>, J. Fernandez-Martinez<sup>1</sup>, J. Álvarez-García<sup>1</sup>, E. Solé-González<sup>1</sup>, L. López-López<sup>2</sup>, S. Mirabet-Perez<sup>2</sup>, V. Brossa-Loidi<sup>2</sup>, A. Sionis<sup>1</sup>, J. Cinca<sup>1</sup>, E. Roig<sup>2</sup>. <sup>1</sup>*Cardiology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain*, <sup>2</sup>*Cardiology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain*
- 1:30 PM** (327) *Cardiac Autonomic Nerves Stimulation Improves Hemodynamics: A Pilot Study in Advanced Heart Failure Patients*; T. Diaz<sup>1</sup>, C. Marin y Kall<sup>2</sup>, J. Boehmer<sup>3</sup>, M. Cowie<sup>4</sup>, A. Mebazaa<sup>5</sup>, M. Cuchiara<sup>6</sup>. <sup>1</sup>*Pacifica Salud Hospital Punta Pacífica, Panama City, Panama*, <sup>2</sup>*International Medicine Institute, University of Miami, Miami, FL*, <sup>3</sup>*Penn State Hershey Heart and Vascular Institute, Hershey, PA*, <sup>4</sup>*National Heart and Lung Institute, Imperial College London, London, United Kingdom*, <sup>5</sup>*University Paris Diderot, Paris, France*, <sup>6</sup>*NeuroTronik Inc, Durham, NC*
- 1:45 PM** (328) *Cell Therapy is Associated with Reduction of Functional Mitral Regurgitation in Cardiomyopathy Patients with High End-Diastolic Volumes*; S. Frljak<sup>1</sup>, G. Zemljic<sup>1</sup>, G. Poglajen<sup>1</sup>, A. Cerar<sup>1</sup>, M. Jaklic<sup>1</sup>, F. Haddad<sup>2</sup>, B. Vrtovec<sup>1</sup>. <sup>1</sup>*Advanced Heart Failure and Transplantation Center, UMC Ljubljana, Ljubljana, Slovenia*, <sup>2</sup>*Stanford Cardiovascular Institute, Stanford, CA*

SATURDAY, APRIL 6, 2019

12:15 PM - 2:00 PM

**SESSION 80 (ORAL): Heart Transplant Long-Term Outcomes: In It for the Long Haul**

**Room: Pacifica 7**

**Target Audiences: HTX, PATH**

**Chairs:** Eugene C DePasquale, MD, and Marta Farrero Torres, MD, PhD

- 12:15 PM** (329) *End Stage Renal Disease after Cardiac Transplantation: An 11-Year National Cohort Study*; M. Kosztowski, J. M. Garonzik-Wang, A. Massie, R. S. Higgins, D. L. Segev, A. Kilic. *Department of Surgery, Johns Hopkins, Baltimore, MD*
- 12:30 PM** (330) *HLA-G 14BP Polymorphism Matching Protects against Development of Post-Transplant Malignancy Following Heart Transplantation*; M. B. Adamson<sup>1</sup>, R. V. Ribeiro<sup>1</sup>, F. Yu<sup>1</sup>, J. Lazarte<sup>1</sup>, K. Runeckles<sup>2</sup>, C. Manlhiot<sup>2</sup>, V. Rao<sup>1</sup>, D. Delgado<sup>1</sup>. <sup>1</sup>*Peter Munk Cardiac Centre, Toronto, ON, Canada*, <sup>2</sup>*The Hospital for Sick Children, Toronto, ON, Canada*
- 12:45 PM** (331) *The Impact of New Onset Post-Transplant Diabetes on Outcomes after Heart Transplantation*; A. R. Vest<sup>1</sup>, W. S. Cherikh<sup>2</sup>, S. M. Noreen<sup>2</sup>, J. Stehlik<sup>3</sup>, K. K. Khush<sup>4</sup>. <sup>1</sup>*Tufts Medical Center, Boston, MA*, <sup>2</sup>*United Network for Organ Sharing (UNOS), Richmond, VA*, <sup>3</sup>*University of Utah, Salt Lake City, UT*, <sup>4</sup>*Stanford University, Stanford, CA*
- 1:00 PM** (332) *Severe Acute Kidney Injury after Cardiac Transplantation is a Marker of Poor Early Outcome and Impacts on Late Renal Function - A UK Cohort Study*; L. Wang<sup>1</sup>, T. Wang<sup>2</sup>, S. N. Rushton<sup>3</sup>, A. J. Fisher<sup>1</sup>, N. S. Sheerin<sup>4</sup>, J. H. Dark<sup>1</sup>. <sup>1</sup>*Cardiothoracic Services, Freeman Hospital, Newcastle upon Tyne, United Kingdom*, <sup>2</sup>*Univeristy College London, London, United Kingdom*, <sup>3</sup>*Statistics and Clinical Studies, National Health Service Blood and Transplant, Bristol, United Kingdom*, <sup>4</sup>*Renal Services, Freeman Hospital, Newcastle upon Tyne, United Kingdom*
- 1:15 PM** (333) *The Impact of Complement-Binding Donor-Specific Antibodies on Adverse Events Long-Term after Heart Transplantation*; J. A. Kobashigawa, M. Kittleson, D. H. Chang, E. Kransdorf, R. Levine, S. Dimbil, C. Kawata, M. Olymbios, A. Velleca, L. Czer, X. Zhang, J. Chung, J. Patel. *Cedars-Sinai Smidt Heart Institute, Los Angeles, CA*
- 1:30 PM** (439) *Heart Transplantation Survival and the Use of Traumatically Brain-Injured Donors*; Y. D. Barac, O. Jawitz, J. Klapper, J. Schroder, M. Daneshmand, C. Patel, C. Milano, M. Hartwig. *Duke University Medical Center, Durham, NC*
- 1:45 PM** (335) *Association between AT1R Autoantibody with Adverse Outcomes in Patients Bridged to Heart Transplant Using Continuous Flow Ventricular Assist Device*; V. Q. Chau<sup>1</sup>, K. Nicholson<sup>1</sup>, M. Flattery<sup>1</sup>, F. McDougan<sup>2</sup>, K. Desai<sup>1</sup>, P. Uber<sup>1</sup>, G. Gupta<sup>3</sup>, P. Kimball<sup>2</sup>, K. B. Shah<sup>1</sup>. <sup>1</sup>*Division of Cardiology and Pauley Heart Center, Virginia Commonwealth University, Richmond, VA*, <sup>2</sup>*Division of Transplant Surgery, Virginia Commonwealth University, Richmond, VA*, <sup>3</sup>*Division of Transplant Nephrology, Virginia Commonwealth University, Richmond, VA*

SATURDAY, APRIL 6, 2019

12:15 PM - 2:00 PM

**SESSION 81 (ORAL): Primary Graft Dysfunction and Acute Lung Rejection**

Room: Coral Sea

Target Audiences: LF/LTX, BSTR, PATH

Chairs: Alejandro M Bertolotti, MD, and Clemens Aigner, MD

- 12:15 PM** (336) *The New View of Pre-Lung Transplant Determinants for Predicting De Novo Donor Specific Antibody and Transplant Rejection*; A. Zhang<sup>1</sup>, D. Thomas<sup>1</sup>, J. Allen<sup>1</sup>, K. McCurry<sup>2</sup>, M. Budev<sup>2</sup>. <sup>1</sup>Allogen Laboratories, Cleveland Clinic, Cleveland, OH, <sup>2</sup>Cleveland Clinic, Cleveland, OH
- 12:30 PM** (337) *Inflammatory Events Precede Development of De Novo DSA after Lung Transplantation*; I. L. Ponor<sup>1</sup>, A. Jackson<sup>2</sup>, A. Cochrane<sup>3</sup>, I. Tunc<sup>4</sup>, M. Jang<sup>4</sup>, J. Mathew<sup>5</sup>, N. D'Emilio<sup>6</sup>, H. I. Luikart<sup>6</sup>, I. Timofte<sup>7</sup>, A. Brown<sup>8</sup>, P. Shah<sup>9</sup>, S. Nathan<sup>8</sup>, A. Iacono<sup>7</sup>, J. B. Orens<sup>9</sup>, C. Marboe<sup>10</sup>, G. J. Berry<sup>11</sup>, K. Khush<sup>12</sup>, H. Valentine<sup>13</sup>, S. Agbor-Enoh<sup>14</sup>. <sup>1</sup>Medicine, Johns Hopkins SoM, Baltimore, MD, <sup>2</sup>Medicine-Immunogenetics and Transplantation Immunology, Johns Hopkins Univ, Baltimore, MD, <sup>3</sup>Medicine, Inova Fairfax Hospital, Fairfax, VA, <sup>4</sup>Div of Intramural Research, National Heart, Lung, and Blood Institute-NIH, Bethesda, MD, <sup>5</sup>Pulm and Critical Care, Johns Hopkins SoM, Baltimore, MD, <sup>6</sup>Div of Cardiology, Stanford Univ SoM, Stanford, CA, <sup>7</sup>Pulm and Critical Care Medicine, Univ of Maryland Medical Center, Baltimore, MD, <sup>8</sup>Inova Heart and Vascular Institute, Inova Fairfax Hospital, Fairfax, VA, <sup>9</sup>Pulm and Critical Care Medicine, Johns Hopkins SoM, Baltimore, MD, <sup>10</sup>Pathology, New York Presbyterian Univ Hospital of Cornell and Columbia, New York, NY, <sup>11</sup>Pathology, Stanford Univ SoM, Palo Alto, CA, <sup>12</sup>Cardiology, Stanford Univ SoM, Palo Alto, CA, <sup>13</sup>Div of Intramural Research, National Heart, Lung, and Blood Institute-NIH, Bethesda, MD, <sup>14</sup>Div of Intramural Research, National Heart, Lung, and Blood Institute-NIH, Bethesda, MD
- 12:45 PM** (338) *Transcriptome Profiles of the Circulating Extracellular Vesicles in Acute Lung Allograft Rejection*; S. Joo<sup>1</sup>, M. Puhka<sup>2</sup>, R. Krebs<sup>1</sup>, P. Mattila<sup>3</sup>, M. Kankainen<sup>3</sup>, K. Dhaygude<sup>1</sup>, E. Rouvinen<sup>1</sup>, P. Ravio<sup>4</sup>, K. Lemström<sup>1</sup>. <sup>1</sup>Transplantation Laboratory, University of Helsinki, Helsinki, Finland, <sup>2</sup>EV core, Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland, <sup>3</sup>Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland, <sup>4</sup>Heart and Lung Center, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
- 1:00 PM** (339) *Profiling Pre-Existing Autoantibodies for Prediction of Primary Graft Dysfunction*; V. Kaza<sup>1</sup>, C. Zhu<sup>1</sup>, L. Feng<sup>1</sup>, A. Reddy<sup>2</sup>, L. Terada<sup>1</sup>, M. Mohanka<sup>1</sup>, C. Lacelle<sup>3</sup>, S. Bollineni<sup>1</sup>, A. Banga<sup>1</sup>, J. Mullins<sup>1</sup>, F. Torres<sup>1</sup>, Q. Li<sup>1</sup>. <sup>1</sup>Internal Medicine, UT Southwestern Medical Center, Dallas, TX, <sup>2</sup>Internal Medicine, Southwest Pulmonary Associates, Dallas, TX, <sup>3</sup>UT Southwestern Medical Center, Dallas, TX
- 1:15 PM** (340) *Correlation between Early B and NK Cell Frequencies and in Relation to CLAD Development and PGD 24h after Lung Transplantation*; A. Knoefel<sup>1</sup>, F. Ius<sup>1</sup>, T. Nakagiri<sup>1</sup>, J. Salman<sup>1</sup>, T. Siemeni<sup>1</sup>, W. Sommer<sup>1</sup>, C. Kuehn<sup>1</sup>, M. Avsar<sup>1</sup>, T. Welte<sup>2</sup>, I. Tudorache<sup>1</sup>, C. S. Falk<sup>3</sup>, A. Haverich<sup>1</sup>, G. Warnecke<sup>1</sup>. <sup>1</sup>HTTG, MHH, Hannover, Germany, <sup>2</sup>Pneumology, MHH, Hannover, Germany, <sup>3</sup>Transplant Immunology, MHH, Hannover, Germany
- 1:30 PM** (341) *miRNAs in Lung Transplantation: Small Things That Make Big Differences*; V. Vaira<sup>1</sup>, V. S. Musso<sup>2</sup>, A. Terrasi<sup>1</sup>, G. Gaudio<sup>3</sup>, S. Ferreo<sup>3</sup>, V. Rossetti<sup>3</sup>, L. C. Morlacchi<sup>3</sup>, D. Tosi<sup>2</sup>, A. Palleschi<sup>2</sup>. <sup>1</sup>Università degli Studi of Milan, Milan, Italy, <sup>2</sup>Thoracic Surgery and Lung Transplant Unit, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy, <sup>3</sup>Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy
- 1:45 PM** (342) *Risk Factors for Primary Graft Dysfunction in Patients with Cystic Fibrosis Receiving Lung Transplants*; J. A. Martin<sup>1</sup>, M. K. Porteous<sup>1</sup>, E. Cantu<sup>2</sup>, D. J. Lederer<sup>3</sup>, L. Snyder<sup>4</sup>, A. Weinacker<sup>5</sup>, J. B. Orens<sup>6</sup>, P. D. Shah<sup>6</sup>, V. N. Lama<sup>7</sup>, J. McDyer<sup>8</sup>, K. M. Wille<sup>9</sup>, C. A. Hage<sup>10</sup>, J. Singer<sup>11</sup>, L. B. Ware<sup>12</sup>, M. Oyster<sup>1</sup>, M. Brown<sup>1</sup>, J. D. Christie<sup>1</sup>, J. M. Diamond<sup>1</sup>. <sup>1</sup>Medicine, University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Surgery, University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Medicine, Columbia University, New York, NY, <sup>4</sup>Medicine, Duke University, Durham, NC, <sup>5</sup>Medicine, Stanford University, Palo Alto, CA, <sup>6</sup>Medicine, Johns Hopkins University, Baltimore, MD, <sup>7</sup>Medicine, University of Michigan, Ann Arbor, MI, <sup>8</sup>Medicine, University of Pittsburgh, Pittsburgh, PA, <sup>9</sup>Medicine, University of Alabama at Birmingham, Birmingham, AL, <sup>10</sup>Medicine, Indiana University, Indianapolis, IN, <sup>11</sup>Medicine, University of California San Francisco, San Francisco, CA, <sup>12</sup>Medicine, Vanderbilt University, Nashville, TN

SATURDAY, APRIL 6, 2019

12:15 PM - 2:00 PM

**SESSION 82 (ORAL): Donor Lung Management: Can We Do Better?**

Room: Pacifica 10-12

Target Audiences: LF/LTX, EEP, PATH

Chairs: Sara J. Shumway, MD, and Ahmed Menaouar, PhD

- 12:15 PM** (343) *High Calculated Panel Reactive Antigen (cPRA) is Associated with Decreased Rates of Transplantation and Increased Waitlist Mortality in Lung Transplantation: A UNOS/OPTN Registry Analysis*; Y. D. Barac, M. Mulvihill, O. Jawitz, J. Haney, J. Klapper, M. Daneshmand, M. Hartwig. *Duke University Medical Center, Durham, NC*
- 12:30 PM** (344) *Effect of Lung Protective Ventilation in Organ Donors on Lung Procurement and Recipient Survival: Results from a Nationwide Cohort Study*; H. Mal<sup>1</sup>, G. Santin<sup>2</sup>, C. Legeai<sup>2</sup>, C. Cantrelle<sup>2</sup>, L. Durand<sup>2</sup>, G. Cheisson<sup>3</sup>, L. Saint-Marcel<sup>4</sup>, I. Pipien<sup>2</sup>, L. Durin<sup>2</sup>, O. Bastien<sup>2</sup>, R. Dorent<sup>2</sup>. <sup>1</sup>Hôpital Bichat - APHP, Paris, France, <sup>2</sup>Direction Prélèvement Greffe Organes Tissus, Agence de la Biomédecine, Saint-Denis, France, <sup>3</sup>Hôpital Kremlin-Bicêtre, AP-HP, Kremlin Bicêtre, France, <sup>4</sup>Hôpital Genevois, Annecy, France
- 12:45 PM** (345) *Despite Growing Utilization, the Use of Public Health Service Increased Risk Donors for Lung Transplantation is Not Associated with Increased Mortality*; D. J. Hall<sup>1</sup>, E. I. Jeng<sup>1</sup>, J. A. Gregg<sup>2</sup>, A. Pelaez<sup>3</sup>, A. Emtiajoo<sup>3</sup>, S. Chandrashekar<sup>3</sup>, M. Pipkin<sup>1</sup>, T. Beaver<sup>1</sup>, T. N. Machuca<sup>1</sup>. <sup>1</sup>Thoracic and Cardiovascular Surgery, University of Florida, Gainesville, FL, <sup>2</sup>Nephrology, Hypertension, and Renal Transplantation, University of Florida, Gainesville, FL, <sup>3</sup>Pulmonary, Critical Care and Sleep Medicine, University of Florida, Gainesville, FL
- 1:00 PM** (346) *Donor-Bound Predictors for Primary Graft Function in Lung Transplantation - Results from a Prospective Multicenter Study*; A. Benazzo<sup>1</sup>, S. Schwarz<sup>1</sup>, M. Muckenhuber<sup>1</sup>, T. Schweiger<sup>1</sup>, R. Vamos Ferenc<sup>2</sup>, S. Taghavi<sup>1</sup>, G. Lang<sup>3</sup>, S. Azad<sup>4</sup>, P. Jaksch<sup>1</sup>, M. Cypel<sup>5</sup>, W. Klepetko<sup>1</sup>, S. Keshavjee<sup>6</sup>, K. Hoetzenecker<sup>1</sup>. <sup>1</sup>Thoracic Surgery, Medical University of Vienna, Vienna, Austria, <sup>2</sup>Thoracic Surgery, Medical University of Budapest, Budapest, Hungary, <sup>3</sup>Division of Thoracic Surgery, University of Vienna, Vienna, Austria, <sup>4</sup>Toronto Lung Transplant Program Toronto General Hospital, University Health Network University of Toronto, Toronto, ON, Canada, <sup>5</sup>Toronto Lung Transplant Program Toronto General Hospital, University Health Network, University of Toronto, Ontario, ON, Canada, <sup>6</sup>Toronto Lung Transplant Program Toronto General Hospital, Toronto General Hospital University Health Network University of Toronto, Toronto, ON, Canada
- 1:15 PM** (347) *Unfavorable Donor after Cardiac Death Characteristics in Lung Transplantation: An Analysis of the UNOS Registry*; A. Y. Choi<sup>1</sup>, O. K. Jawitz<sup>2</sup>, V. Raman<sup>2</sup>, Y. Barac<sup>2</sup>, M. S. Mulvihill<sup>2</sup>, C. Moore<sup>2</sup>, M. G. Hartwig<sup>2</sup>. <sup>1</sup>Duke University School of Medicine, Durham, NC, <sup>2</sup>Department of Surgery, Duke University Medical Center, Durham, NC
- 1:30 PM** (348) *The Impact of Removing the Donor Service Area (DSA) as the First Unit of Allocation for Lungs in the United States*; R. R. Lehman<sup>1</sup>, K. Uccellini<sup>1</sup>, E. Lease<sup>2</sup>, R. Daly<sup>3</sup>, K. M. Chan<sup>4</sup>. <sup>1</sup>United Network for Organ Sharing, Richmond, VA, <sup>2</sup>University of Washington, Seattle, WA, <sup>3</sup>Mayo Clinic, Rochester, MN, <sup>4</sup>University of Michigan, Ann Arbor, MI
- 1:45 PM** (349) *Donor-Recipient Weight Mismatch and Primary Graft Dysfunction Risk Post-Lung Transplantation*; A. Hirji, D. Li, A. Kapasi, J. Weinkauff, D. Lien, K. Halloran. *Lung Transplant Program, University of Alberta, Edmonton, AB, Canada*

SATURDAY, APRIL 6, 2019  
12:15 PM - 2:00 PM

SESSION 83 (ORAL): What's Holding Me Back? Exercise in LVAD Patients  
Room: Pacifica 6  
Target Audiences: MCS, NNSAH

Chairs: Ivan Knezevic, MD, and Jose Gonzalez-Costello, MD

- 12:15 PM** (350) *Routine Right Heart Catheterization in LVAD Patients Awaiting Heart Transplant: What is the Appropriate Surveillance Interval?*; D. Ruan<sup>1</sup>, M. Farr<sup>2</sup>, V. Topkara<sup>2</sup>, A. R. Garan<sup>2</sup>, J. Sanchez<sup>1</sup>, P. Kurlansky<sup>3</sup>, M. Yuzefpolskaya<sup>2</sup>, P. Colombo<sup>2</sup>, H. Takayama<sup>4</sup>, Y. Naka<sup>4</sup>, K. Takeda<sup>4</sup>. <sup>1</sup>Columbia University Vagelos College of Physicians & Surgeons, New York, NY, <sup>2</sup>Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, <sup>3</sup>Department of Surgery, Columbia University Irving Medical Center, New York, NY, <sup>4</sup>Division of Cardiothoracic Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, NY
- 12:30 PM** (351) *Cardiac and Cerebrovascular Response to Exercise in the Setting of Mechanical Circulatory Support among Individuals with Advanced Heart Failure*; T. Tran<sup>1</sup>, G. Coe<sup>1</sup>, M. Bradley<sup>1</sup>, K. O'Gea<sup>1</sup>, M. Spotts<sup>1</sup>, M. Ostertag<sup>1</sup>, S. Laing<sup>1</sup>, L. C. Prado<sup>1</sup>, C. Cornwell<sup>2</sup>, J. Paul<sup>1</sup>, W. Cornwell<sup>1</sup>. <sup>1</sup>University of Colorado, Aurora, CO, <sup>2</sup>Ohio State University, Columbus, OH
- 12:45 PM** (352) *Echocardiographic Predictors of Left Ventricle Unloading after LVAD Implantation*; A. Duran, A. Guha, A. Bhimaraj, J. Estep, B. Trachtenberg, M. H. Park, N. Salam, F. Hussain, I. Hussain. *Houston Methodist Hospital, Houston, TX*
- 1:00 PM** (353) *Comparison of Exercise Hemodynamics in Patients Supported with Centrifugal and Axial Flow Left Ventricular Assist Devices*; N. Moss<sup>1</sup>, A. Parikh<sup>1</sup>, V. Rakita<sup>2</sup>, A. Lala<sup>1</sup>, S. Mitter<sup>1</sup>, J. Roldan<sup>1</sup>, A. Cuca<sup>1</sup>, M. Barghash<sup>1</sup>, J. Contreras<sup>1</sup>, S. Pinney<sup>1</sup>, A. Anyanwu<sup>1</sup>, D. M. Mancini<sup>1</sup>. <sup>1</sup>Mount Sinai Hospital, New York, NY, <sup>2</sup>Temple University Hospital, Philadelphia, PA
- 1:15 PM** (354) *High Right Ventricular Afterload is Associated with Impaired Exercise Tolerance in LVAD Patients*; V. Ton<sup>1</sup>, L. Dees<sup>1</sup>, E. Sorensen<sup>1</sup>, E. Feller<sup>1</sup>, R. Madathil<sup>1</sup>, D. Kaczorowski<sup>1</sup>, B. Griffith<sup>1</sup>, R. J. Tedford<sup>2</sup>, G. Ramani<sup>1</sup>. <sup>1</sup>University of Maryland School of Medicine, Baltimore, MD, <sup>2</sup>Medical University of South Carolina, Charleston, SC
- 1:30 PM** (355) *Exercise-Induced Hypoxemia Predicts Heart Failure Hospitalization and Death in Patients Supported with Left Ventricular Assist Devices*; D. M. Koerber<sup>1</sup>, A. N. Rosenbaum<sup>2</sup>, T. P. Olson<sup>2</sup>, S. Kushwaha<sup>2</sup>, J. Stulak<sup>3</sup>, S. Maltais<sup>3</sup>, A. Behfar<sup>1</sup>. <sup>1</sup>Center for Regenerative Medicine, Mayo Clinic, Rochester, MN, <sup>2</sup>Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, <sup>3</sup>Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN
- 1:45 PM** (356) *Prospective Evaluation of LVAD Risk Scores' Capacity to Predict Cardiopulmonary Exercise Parameters*; A. Dorken<sup>1</sup>, P. Öztürk<sup>2</sup>, E. Demir<sup>3</sup>, Ç. Engin<sup>2</sup>, S. Nalbantgil<sup>3</sup>, T. Yagdi<sup>2</sup>, M. Özbaran<sup>2</sup>. <sup>1</sup>Ege University Faculty of Medicine, Izmir, Turkey, <sup>2</sup>Cardiovascular Surgery, Ege University Faculty of Medicine, Izmir, Turkey, <sup>3</sup>Cardiology, Ege University Faculty of Medicine, Izmir, Turkey

Wednesday, April 3, 2019

6:00 PM - 7:15 PM

**POSTER SESSION 1: BASIC SCIENCE & TRANSLATIONAL RESEARCH**

**Room: Hibiscus 1**

**Poster Discussants:**

Christian Heim, MD, University of Erlangen, Erlangen, Germany

Daniel Pauly, MD, PhD, University of Missouri, Kansas City, MO, USA

Ciara Shaver, MD, PhD, Vanderbilt University Medical Center, Nashville, TN, USA

Akira Shimamoto, MD, PhD, Mie Univ Graduate School of Medicine, Tsu, Japan

Nikolaos Skartsis, MD, PhD, UCSF Medical Center, San Francisco, CA, USA

**(573) Sub-Normothermic Ex-Vivo Lung Perfusion Attenuates Ischemia Reperfusion Injury from Donation after Circulatory Death Donors;** T. Maeyashiki, S. Arni, I. Iskender, W. Weder, I. Inci. *Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland*

**(574) Metabolic Alterations in Myocardial Metabolism during Ex Situ Heart Perfusion;** S. Hatami, C. W. White, X. Qi, M. Buchko, S. Himmat, N. Aboelnazar, J. Nagendran, D. Freed. *Department of Surgery, University of Alberta, Edmonton, AB, Canada*

**(575) Continuous Hemodialysis during Ex Vivo Lung Perfusion Allows for Improved Maintenance of Perfusate Composition, without Compromising Functional Performance;** M. T. Buchko<sup>1</sup>, S. Himmat<sup>1</sup>, C. J. Stewart<sup>1</sup>, S. Hatami<sup>1</sup>, P. Dromparis<sup>2</sup>, B. Adam<sup>2</sup>, D. H. Freed<sup>1</sup>, J. Nagendran<sup>1</sup>. <sup>1</sup>*Department of Surgery, Division of Cardiac Surgery, University of Alberta, Edmonton, AB, Canada*, <sup>2</sup>*Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada*

**(576) Recombinant Thrombomodulin Reduce Histone-Induced Rat Lung Transplant Model of Primary Graft Dysfunction;** K. Nakao, M. Anraku, T. Murayama, A. Hosoi, K. Kakimi, J. Nakajima. *University of Tokyo, Tokyo, Japan*

**(577) Recipient Treatment with n-octanoyl Dopamine Improves Post Transplant Graft Function from Brain-Dead Heart Donor in Rats;** S. Loganathan<sup>1</sup>, Y. Guo<sup>1</sup>, S. Korkmaz-Icöz<sup>1</sup>, P. Zhou<sup>1</sup>, P. Brlecic<sup>1</sup>, T. Radovits<sup>2</sup>, M. Ruppert<sup>1</sup>, A. A. Sayour<sup>1</sup>, B. Yard<sup>3</sup>, M. Karck<sup>1</sup>, G. Szabó<sup>1</sup>. <sup>1</sup>*Cardiac Surgery, Heidelberg University Hospital, Heidelberg, Germany*, <sup>2</sup>*Heart and Vascular Center, Semmelweis University, Budapest, Hungary*, <sup>3</sup>*Medicine V (Nephrology/Endocrinology/Rheumatology), University Medical Centre Mannheim, Mannheim, Germany*

**(578) Endothelial Stabilization Reduces the Effects of Brain Death Induced Acute Lung Injury Post-Transplant;** Z. Tu<sup>1</sup>, P. Allen<sup>2</sup>, C. Wallace<sup>1</sup>, C. Li<sup>1</sup>, J. Kilkenny<sup>1</sup>, K. Patel<sup>1</sup>, S. Nadig<sup>1</sup>, C. Atkinson<sup>1</sup>. <sup>1</sup>*Departments of Microbiology and Immunology, and Surgery, Medical University of South Carolina, Charleston, SC*, <sup>2</sup>*Medical University of South Carolina, Charleston, SC*

**(579) Ex Situ Heart Perfusion Improves Preservation of Endothelial Function in Both DBD and DCD Hearts;** R. Ribeiro<sup>1</sup>, F. Yu<sup>1</sup>, J. S. Alvarez<sup>1</sup>, M. B. Adamson<sup>1</sup>, E. Paradiso<sup>1</sup>, L. Xin<sup>1</sup>, B. Gellner<sup>2</sup>, V. Bissoondath<sup>1</sup>, M. Meineri<sup>3</sup>, V. Rao<sup>1</sup>, M. V. Badiwala<sup>1</sup>. <sup>1</sup>*Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada*, <sup>2</sup>*Mechanical Engineering, University of Toronto, Toronto, ON, Canada*, <sup>3</sup>*Cardiovascular Anesthesia, Toronto General Hospital, Toronto, ON, Canada*

**(580) Assessment of Predictive Biomarkers Associated with Ischemia/Reperfusion Injury and Primary Graft Dysfunction in Lung Transplants;** C. Landry<sup>1</sup>, A. Privé<sup>2</sup>, A. Menaouar<sup>2</sup>, D. Adam<sup>3</sup>, A. Dagenais<sup>4</sup>, M. Merjaneh<sup>2</sup>, J. F. Germain<sup>5</sup>, N. Noiseux<sup>6</sup>, J. F. Cailhier<sup>1</sup>, Y. Berthiaume<sup>7</sup>, C. Poirier<sup>1</sup>, P. Ferraro<sup>6</sup>, E. Brochiero<sup>3</sup>. <sup>1</sup>*CRCHUM/CHUM/Faculty of Medicine, University of Montréal, Montréal, QC, Canada*, <sup>2</sup>*CRCHUM, Montréal, QC, Canada*, <sup>3</sup>*CRCHUM/Faculty of Medicine, University of Montréal, Montréal, QC, Canada*, <sup>4</sup>*IRCM, Montréal, QC, Canada*, <sup>5</sup>*CRCHUM/CHUM, Montréal, QC, Canada*, <sup>6</sup>*CRCHUM/CHUM/Department of Surgery, University of Montréal, Montréal, QC, Canada*, <sup>7</sup>*CHUM, IRCM, Faculty of Medicine, University of Montréal, Montréal, QC, Canada*

**(581) Effects of Ex Vivo Perfusion and Il-6 Receptor Blockade on Ischemia Reperfusion Injury in Cardiac Transplantation;** C. Falk<sup>1</sup>, F. Ius<sup>2</sup>, S. V. Rojas-Hernandez<sup>2</sup>, B. Wiegmann<sup>2</sup>, F. Wandrer<sup>1</sup>, T. Kaufeld<sup>2</sup>, W. Sommer<sup>2</sup>, C. Bara<sup>2</sup>, J. Salman<sup>2</sup>, T. Siemeni<sup>2</sup>, R. Poyanmehr<sup>2</sup>, D. Bobylev<sup>2</sup>, I. Tudorache<sup>2</sup>, I. Tudorache<sup>2</sup>, M. Avsar<sup>2</sup>, A. Haverich<sup>2</sup>, G. Warnecke<sup>2</sup>. <sup>1</sup>*Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany*, <sup>2</sup>*Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany*

**(582) Contractility versus Metabolic Cardiac Assessment during Ex Situ Heart Perfusion: A Pre-Clinical Transplant Study;** R. Ribeiro<sup>1</sup>, J. Alvarez<sup>1</sup>, B. Gellner<sup>2</sup>, L. Xin<sup>1</sup>, E. Paradiso<sup>1</sup>, F. Yu<sup>3</sup>, M. B. Adamson<sup>1</sup>, F. Foroutan<sup>1</sup>, V. Bissoondath<sup>1</sup>, M. Meineri<sup>1</sup>, V. Rao<sup>1</sup>, M. V. Badiwala<sup>1</sup>. <sup>1</sup>*Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada*, <sup>2</sup>*Mechanical Engineering, University of Toronto, Toronto, ON, Canada*, <sup>3</sup>*Cardiovascular Surgery, University of Toronto, Toronto, ON, Canada*



- (583) Influence of Various Perfusion Temperatures on Lung Graft Preservation during Ex Vivo Lung Perfusion;** S. Burki, K. Noda, A. Kumar, B. Philips, P. G. Sanchez, J. D'Cunha. *Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA*
- (584) Reperfusion Inflammatory State of Human Lungs during Cellular Ex-Vivo Perfusion;** K. S. Ayyat, T. Okamoto, H. Niikawa, H. Elgharably, Y. Itoda, R. Fairchild, K. R. McCurry. *Cleveland Clinic, Cleveland, OH*
- (585) The Effect of Prostaglandin E1 on Pulmonoplegia before and after Ex Vivo Lung Perfusion;** K. Noda, A. Kumar, S. Burki, B. Philips, P. G. Sanchez, J. D'Cunha. *Department of Cardiothoracic Surgery, Univ of Pittsburgh Medical Center, Pittsburgh, PA*
- (586) Brain Death-Induced Donor Heart Injury Diminished by Melatonin Treatment via Suppressing DAMP Signaling;** F. Lee<sup>1</sup>, P. Sung<sup>2</sup>, K. Chen<sup>3</sup>, Y. Li<sup>2</sup>, Y. Chen<sup>2</sup>, M. Lee<sup>4</sup>, H. Yip<sup>5</sup>. <sup>1</sup>Cardiovascular Surgery; Institute for Translational Research in Biomedicine, Kaohsiung Chang Gung Mem Hosp, Chang Gung University, Kaohsiung, Taiwan, <sup>2</sup>Cardiology, Kaohsiung Chang Gung Mem Hosp, Kaohsiung, Taiwan, <sup>3</sup>Anesthesiology, Kaohsiung Chang Gung Mem Hosp, Nangang Dist. Taipei, Taiwan, <sup>4</sup>Othopedic Surgery, Kaohsiung Chang Gung Mem Hosp, Kaohsiung, Taiwan, <sup>5</sup>Cardiology; Institute for Translational Research in Biomedicine, Kaohsiung Chang Gung Mem Hosp; Chang Gung University, Kaohsiung, Taiwan
- (587) Ees Estimation Using Machine Learning Approach during Ex Vivo Heart Perfusion to Predict Early Graft Survival: A Preliminary Study in Porcine Model;** L. Xin<sup>1</sup>, W. Xiao<sup>2</sup>, W. Yao<sup>1</sup>, Y. Liu<sup>2</sup>, R. V. Ribeiro<sup>1</sup>, B. Gellner<sup>1</sup>, J. Alvarez<sup>3</sup>, F. Yu<sup>1</sup>, E. Paradiso<sup>3</sup>, M. Adamson<sup>1</sup>, V. Bissoondath<sup>3</sup>, J. Hiansen<sup>3</sup>, M. Meineri<sup>1</sup>, Y. Sun<sup>1</sup>, M. Badiwala<sup>1</sup>. <sup>1</sup>University of Toronto, Toronto, ON, Canada, <sup>2</sup>Shanghai University, Shanghai, China, <sup>3</sup>UHN, Toronto, ON, Canada
- (588) Human Hearts Declined for Transplant Were Resuscitated on the Visible Heart® Apparatus;** A. Shaffer<sup>1</sup>, E. Schinstock<sup>2</sup>, M. Bateman<sup>2</sup>, T. Iles<sup>2</sup>, P. Iazzo<sup>2</sup>. <sup>1</sup>Department of Surgery, Division of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN, <sup>2</sup>Department of Surgery, University of Minnesota, Minneapolis, MN
- (589) Prolonged Cold-Ischemia Increases Reactive Oxygen Species and Activates Autophagy by Enhancing Glycolysis in the Graft through the mTOR Signaling Pathway in Orthotopic Lung Transplantation of Rats;** H. Lin<sup>1</sup>, S. Dai<sup>2</sup>, W. Liu<sup>2</sup>, X. Liu<sup>2</sup>, B. Yu<sup>2</sup>, J. Tang<sup>2</sup>. <sup>1</sup>Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, China, <sup>2</sup>Department of Thoracic Surgery, The First Affiliated Hospital of Nanchang Univeristy, Nanchang, China
- (590) Prolongation of the Agonal Phase in the DCD Donor Results in Impairment of Myocardial Contractility Following DCD Heart Resuscitation;** A. A. Ali<sup>1</sup>, P. Downey<sup>2</sup>, M. Anwer<sup>1</sup>, P. Bonde<sup>1</sup>, Z. Ali<sup>2</sup>. <sup>1</sup>Cardiothoracic Surgery, Yale University, New Haven, CT, <sup>2</sup>Cardiology, Columbia University, New York, NY
- (591) A Porcine Model Comparing NRP and Cold Storage versus NRP and Ex-Situ Perfusion in the Distant Procurement of DCD Hearts;** A. Page<sup>1</sup>, S. Messer<sup>1</sup>, P. White<sup>2</sup>, S. Colah<sup>1</sup>, N. Razzaq<sup>1</sup>, T. Stathopoulou<sup>3</sup>, J. Viscasillas<sup>3</sup>, H. Alibhai<sup>3</sup>, S. Large<sup>1</sup>. <sup>1</sup>Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom, <sup>2</sup>Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom, <sup>3</sup>Royal Veterinary College, London, United Kingdom
- (592) Hypoxia-Reperfusion in a Rodent Model of DCD Cardiac Resuscitation Leads to Improved Myocyte Function Compared to Conventional Ischemia Reperfusion Injury;** A. A. Ali<sup>1</sup>, P. Downey<sup>2</sup>, M. Anwer<sup>1</sup>, P. Bonde<sup>1</sup>, Z. A. Ali<sup>2</sup>. <sup>1</sup>Cardiothoracic Surgery, Yale University, New Haven, CT, <sup>2</sup>Cardiology, Columbia University, New York, NY
- (593) Comprehensive Analysis of Differential Expressed Genes Related with Myocardial Reverse Remodeling Following HeartWare Ventricular Assist Device Implantation;** Y. Shudo<sup>1</sup>, K. J. Jaatinen<sup>1</sup>, M. Nishiga<sup>2</sup>, I. Y. Chen<sup>2</sup>, C. L. Greene<sup>1</sup>, T. K. Koyano<sup>1</sup>, R. W. Fong<sup>1</sup>, J. H. Boyd<sup>1</sup>, A. M. Lee<sup>1</sup>, W. Hiesinger<sup>1</sup>, J. Woo<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA, <sup>2</sup>Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA
- (594) Clinical Parameters of Right Ventricular Dysfunction Predict Depressed RV Myofilament Function;** M. I. Aslam, B. Lin, D. Kass, S. Hsu. *Department of Medicine, Division of Cardiology, Johns Hopkins Hospital, Baltimore, MD*
- (595) Acute Metabolomic Changes after Implantation of a Left Ventricular Assist Device;** N. Clendenen<sup>1</sup>, W. Cornwell<sup>2</sup>, J. Pal<sup>3</sup>, N. Weitzel<sup>1</sup>. <sup>1</sup>Anesthesiology, University of Colorado, Aurora, CO, <sup>2</sup>Cardiology, University of Colorado, Aurora, CO, <sup>3</sup>Cardiothoracic Surgery, University of Colorado, Aurora, CO
- (596) Characteristics of Urine Cell-Free DNA in Heart and Lung Transplant;** K. Bhatti<sup>1</sup>, S. Agbor-Enoh<sup>1</sup>, I. Tunc<sup>2</sup>, A. Marishta<sup>1</sup>, Y. Yang<sup>1</sup>, U. Fideli<sup>1</sup>, J. Mathew<sup>3</sup>, A. Iacono<sup>4</sup>, J. Zhu<sup>5</sup>, M. Pirooznia<sup>2</sup>, M. Jang<sup>1</sup>, H. Valentine<sup>1</sup>. <sup>1</sup>Laboratory of Transplant Genomics, National Heart, Lung, and Blood Institute, Bethesda, MD, <sup>2</sup>Bioinformatics and Computational Biology Core, National Heart, Lung, and Blood Institute, Bethesda, MD, <sup>3</sup>Pulmonary and Critical Care, Johns Hopkins School of Medicine, Baltimore, MD, <sup>4</sup>University of Maryland Medical Center, Baltimore, MD, <sup>5</sup>Div of Intramural Research, National Heart, Lung, and Blood Institute, Bethesda, MD

**(597) Stimulation of Cardiac Angiogenesis through Growth Factors with a Fibrin Gel Delivery Platform;** L. Melly<sup>1</sup>, A. Grosso<sup>2</sup>, C. Stanciu Pop<sup>1</sup>, M. Nollevaux<sup>1</sup>, N. Di Maggio<sup>2</sup>, A. Banfi<sup>2</sup>, B. Rondelet<sup>1</sup>. <sup>1</sup>CHU UCL Namur, Yvoir, Belgium, <sup>2</sup>Cell and Gene Therapy, Department of Biomedicine, Basel, Switzerland

**(598) Hyaluronic Acid Decorated-Liposome are Good Biocompatible Nano-Carrier for Drug Delivery to Mesenchymal Cells Derived from BAL of Bronchiolitis Obliterans Patients;** F. Meloni<sup>1</sup>, L. Pandolfi<sup>1</sup>, V. Frangipane<sup>1</sup>, E. Cova<sup>2</sup>, S. Arpicco<sup>3</sup>, A. Marengo<sup>3</sup>, C. Bocca<sup>4</sup>, M. Monti<sup>5</sup>. <sup>1</sup>Respiratory Diseases, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, <sup>2</sup>Pathology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, <sup>3</sup>Department of Department of Drug Science and Technology, University of Turin, Turin, Italy, <sup>4</sup>Department Clinical and Biological Sciences, University of Turin, Turin, Italy, <sup>5</sup>Laboratori di Biotecnologie, Centro Ricerche di Medicina Rigenerativa, IRCCS Policlinico San Matteo Foundation, Pavia, Italy

**(599) Influence of CYP2C9 and VKORC1 on Warfarin Dose and Complications in Kazakhstani Patients with Left Ventricular Assist Device;** A. R. Akilzhanova<sup>1</sup>, M. R. Zhalbinova<sup>1</sup>, S. E. Rakhimova<sup>1</sup>, S. A. Andosova<sup>2</sup>, Z. S. Zhumadilov<sup>3</sup>, M. S. Bekbossynova<sup>2</sup>. <sup>1</sup>Laboratory of Genomic and Personalised Medicine, Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan, <sup>2</sup>National Research Cardiac Surgery Center, Astana, Kazakhstan, <sup>3</sup>University Medical Center, Nazarbayev University, Astana, Kazakhstan

**(600) Modeling Right Ventricular Heart Failure in Congenital Heart Disease;** A. Azakie<sup>1</sup>, M. J. Doyle<sup>2</sup>, C. M. Martin<sup>2</sup>. <sup>1</sup>Cardiac Surgery, Children's Heart Center at St. Vincent, Indianapolis, IN, <sup>2</sup>Medicine, University of Minnesota, Minneapolis, MN

**(601) Comparison of Endothelin-1 Level in Group I Pulmonary Hypertension vs. Group II Pulmonary Hypertension Both at Rest and at Peak Exercise;** A. Albulushi, A. Patel, D. Stoller, M. Hyden, A. Burdorf, L. Brian, R. Zolty. University of Nebraska Medical Center, Omaha, NE

**(602) Galectin-3 Expression in the Left Ventricular Interstitium of Dogs with Chronic Heart Failure: Association with Interstitial Fibrosis;** H. N. Sabbah, V. Singh-Gupta, R. C. Gupta. Medicine, Henry Ford Health System, Detroit, MI

**(603) Characterization of Donor-Specific Alloreactive CD4<sup>+</sup> and CD8<sup>+</sup> Cellular Immune T Cell Responses in the Lung Allograft and Blood in Lung Transplant Recipients;** I. Popescu, C. Iasella, E. Lendermon, S. Winters, J. Sembrat, M. Saul, X. Chen, N. Seyed, B. Hewitt, R. Koshy, Y. Zhang, W. Xu, V. Touchmanov, M. Brown, B. Johnson, S. Kilaru, M. R. Morrell, J. Pilewski, J. F. McDyer. University of Pittsburgh, Pittsburgh, PA

Wednesday, April 3, 2019

6:00 PM - 7:15 PM

**POSTER SESSION 1: BASIC SCIENCE AND TRANSLATIONAL RESEARCH**

**Room: Hibiscus 2**

**Poster Discussants:**

Laurens J. Ceulemans, MD, PhD, University Hospitals Leuven, Leuven, Belgium

Wayne W. Hancock, MD, PhD, Children's Hospital of Philadelphia, Philadelphia, PA, USA

James L. Lordan, MB, FRCP, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

Pradeep P. A. Mammen, MD, FACC, FAHA, UT Southwestern Medical Center, Dallas, TX, USA

Natalia Smirnova, PhD, University of Colorado, Denver, CO, USA

Nicole M. Valenzuela, PhD, D(ABHI), UCLA Immunogenetics Center, Los Angeles, CA, USA

**(604) Reproducible Model for Chronic Stable Heart Failure in Ovine Species;** N. Sadat<sup>1</sup>, C. Torregroza<sup>1</sup>, D. Scheiber<sup>1</sup>, C. Gomez<sup>1</sup>, R. Westenfeld<sup>1</sup>, J. von der Beek<sup>2</sup>, I. J. Knorr<sup>2</sup>, P. Akhyari<sup>1</sup>, M. Sager<sup>2</sup>, A. Lichtenberg<sup>1</sup>, D. Saeed<sup>1</sup>. <sup>1</sup>Cardiovascular Surgery, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany, <sup>2</sup>Department of Animal Research and Animal Protection, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany

**(606) Natural Antibodies and Left Ventricular Assist Device Complications;** S. B. See<sup>1</sup>, A. Pinsino<sup>2</sup>, N. Kunimune<sup>1</sup>, D. Onat<sup>2</sup>, E. Hittesdorf<sup>3</sup>, A. R. Garan<sup>2</sup>, V. K. Topkara<sup>2</sup>, N. Yoshifumi<sup>4</sup>, H. Takayama<sup>4</sup>, K. Takeda<sup>4</sup>, P. C. Colombo<sup>2</sup>, G. Wagener<sup>3</sup>, M. Yuzefpolskaya<sup>2</sup>, E. Zorn<sup>1</sup>. <sup>1</sup>Columbia Center for Translational Immunology, Columbia University, New York, NY, <sup>2</sup>Medicine, Columbia University, New York, NY, <sup>3</sup>Anesthesiology, Columbia University, New York, NY, <sup>4</sup>Surgery, Columbia University, New York, NY

**(607) Dynamic BCMA Expression by Alloreactive B Cells Coupled with Donor Specific Antibody Production during De Novo Alloantibody Responses;** I. Kim, G. D. Wu, N. Chai, S. Jordan, A. Klein. Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA

**(608) ZFYVE21 is a Novel Complement-Induced Rab5 Effector Protein Mediating Cardiac Allograft Vasculopathy;** D. Jane-Wit, C. Fang, L. Liu, L. Qin, G. Li, G. Tellides, J. S. Pober. Dept of Cardiology, Yale School of Medicine, New Haven, CT

**(609) miR-155 Plays an Essential Role in Anti-MHC-Induced Obliterative Airway Disease;** R. Ravichandran, Y. Itabashi, W. Liu, T. Mohanakumar. Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ

**(610) Elevead Cysteine-Protease Activity in Bronchiolitis Obliterans Syndrome;** C. Morrone<sup>1</sup>, N. Smirnova<sup>2</sup>, N. Kneidinger<sup>3</sup>, H. Schiller<sup>1</sup>, O. Eickelberg<sup>2</sup>, A. Yildirim<sup>1</sup>. <sup>1</sup>Comprehensive Pulmonary Center, CPC/ILBD and Helmholtz Zentrum Munich, Munich, Germany, <sup>2</sup>University of Colorado Denver, Denver, Colorado, CO, <sup>3</sup>Department of Internal Medicine V, Comprehensive Pneumology Munich, Munich, Germany

**(611) CTLA4-Ig Therapy Attenuates Bronchiolitis Obliterans after Mouse Intrapulmonary Tracheal Transplantation Model through Possibility of Effect of LAG3<sup>+</sup>Tregs;** Y. Suzuki, H. Oishi, M. Kanehira, Y. Matsuda, T. Sado, M. Noda, J. Funahashi, A. Sakurada, Y. Okada. Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku Univ, Sendai, Japan

**(612) Circulating Exosomes from Lung Transplant Recipients Diagnosed with Bronchiolitis Obliterans Syndrome Induces Immune Responses in C57BL/6 Mice Leading to Obliterative Airway Disease and miRNA 155 Plays an Essential Role in Immune Activation;** S. Bansal, M. Sharma, M. A. Smith, R. M. Bremner, T. Mohanakumar. Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ

**(613) Pioglitazone Induces Infiltrations of Regulatory T Cells in the Tracheal Graft and Attenuates Allograft Rejection;** T. Shigenobu, T. Ohtsuka<sup>2</sup>, M. Shimoda<sup>3</sup>. <sup>1</sup>Thoracic Surgery, Saiseikai Utsunomiya Hospital, Utsunomiya, Japan, <sup>2</sup>Thoracic Surgery, Jikei University School of Medicine, Tokyo, Japan, <sup>3</sup>Pathology, Keio University School of Medicine, Tokyo, Japan

**(614) Donor Brain Death Affects Tolerance Induction in Non-Human Primates;** W. Sommer<sup>1</sup>, J. M. O<sup>2</sup>, K. B. Pruner<sup>2</sup>, J. T. Paster<sup>2</sup>, A. Bean<sup>2</sup>, A. Dehnadi<sup>2</sup>, I. M. Hanekamp<sup>2</sup>, I. Rosales<sup>3</sup>, R. N. Smith<sup>3</sup>, R. B. Colvin<sup>3</sup>, G. Benichou<sup>2</sup>, J. S. Allan<sup>2</sup>, T. Kawai<sup>2</sup>, J. C. Madsen<sup>2</sup>. <sup>1</sup>Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany, <sup>2</sup>Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, <sup>3</sup>Department of Pathology, Massachusetts General Hospital, Boston, MA

**(615) BIUx2x2;** N. Diakos<sup>1</sup>, I. Taleb<sup>1</sup>, O. Wever Pinzon<sup>1</sup>, H. Javan<sup>1</sup>, A. Kfoury<sup>2</sup>, J. Stehlik<sup>1</sup>, W. Caine<sup>2</sup>, J. Nativi<sup>1</sup>, A. Koliopoulou<sup>1</sup>, M. Yin<sup>1</sup>, L. McCreath<sup>1</sup>, A. Thodou<sup>1</sup>, T. Sankar<sup>1</sup>, E. Gilbert<sup>1</sup>, C. Selzman<sup>1</sup>, S. Drakos<sup>1</sup>. <sup>1</sup>Cardiology, University of Utah, Salt Lake City, UT, <sup>2</sup>Cardiology, Intermountain Medical Center, Salt Lake City, UT

**(616) Complement (C3a) Levels are Increased in the Bronchoalveolar Lavage Fluid of Patient with All Chronic Lung Allograft Dysfunction Phenotypes;** M. P. Combs, R. Vittal, D. S. Wheeler, N. M. Walker, V. N. Lama. *Department of Medicine, University of Michigan, Ann Arbor, MI*

**(617) Changes of Immune Cells during the First Post-Transplant Year Guide the Way for Future Tolerance Induction Therapies;** M. Dieterlen, K. Klaeske, J. Fischer, K. Jawad, J. Garbade, S. Klein, S. Eifert, M. A. Borger, S. Lehmann. *Clinic for Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany*

**(618) Cytokine Expression and Alloreactivity in a Humanized Mouse Transplant Arteriosclerosis Model Reflects Primary Graft Dysfunction in Lung Transplant Recipients;** A. Knoefel<sup>1</sup>, T. Siemeni<sup>1</sup>, N. Madrahimov<sup>1</sup>, W. Sommer<sup>1</sup>, M. Avsar<sup>1</sup>, F. Ius<sup>1</sup>, I. Tudorache<sup>1</sup>, C. Kuehn<sup>2</sup>, K. Daemen<sup>3</sup>, A. Haverich<sup>1</sup>, C. S. Falk<sup>3</sup>, G. Warnecke<sup>1</sup>. <sup>1</sup>HTTG, MHH, Hannover, Germany, <sup>2</sup>MHH, HTTG, Germany, <sup>3</sup>Transplantation immunology, MHH, Hannover, Germany

**(619) A Longitudinal Study of  $\gamma\delta$  T Cell Subsets Post Lung Transplant: Potential Players in CMV Immunity;** L. Sullivan<sup>1</sup>, E. Shaw<sup>2</sup>, G. Snell<sup>1</sup>, A. Brooks<sup>2</sup>, G. Westall<sup>1</sup>. <sup>1</sup>Lung Transplant Service, The Alfred, Melbourne, Australia, <sup>2</sup>Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia

**(620) Mechanisms of Antibody Mediated Rejection in the Absence of Donor Specific Antibodies;** S. B. See<sup>1</sup>, B. S. Mantell<sup>2</sup>, K. J. Clerkin<sup>1</sup>, B. Ray<sup>3</sup>, R. E. Vasilescu<sup>4</sup>, C. C. Marboe<sup>5</sup>, Y. Naka<sup>6</sup>, S. Restaino<sup>7</sup>, P. C. Colombo<sup>7</sup>, L. J. Addonizio<sup>2</sup>, M. A. Farr<sup>7</sup>, E. Zorn<sup>1</sup>. <sup>1</sup>Columbia Center for Translational Immunology, Columbia Univ Medical Center, New York, NY, <sup>2</sup>Pediatric Cardiology, Columbia Univ Medical Center, New York, NY, <sup>3</sup>Immucor, Inc., Norcross, GA, <sup>4</sup>Pathology and Cell Biology, Columbia University Medical Center, New York, NY, <sup>5</sup>Department of Pathology and Cell Biology, Columbia Univ Medical Center, New York, NY, <sup>6</sup>Cardiothoracic Surgery, Columbia Univ Medical Center, New York, NY, <sup>7</sup>Cardiology, Columbia University Medical Center, New York, NY

**(621) Standard Drug Immunosuppression Eliminates Peripheral Transitional B Cells but Does Not Create a Distinct Genetic Signature in Non-Human Primates;** A. Bean<sup>1</sup>, J. T. Paster<sup>1</sup>, K. B. Pruner<sup>1</sup>, J. O<sup>1</sup>, W. Sommer<sup>2</sup>, K. Robinson<sup>3</sup>, I. M. Hanekamp<sup>1</sup>, G. Benichou<sup>1</sup>, J. C. Madsen<sup>1</sup>. <sup>1</sup>Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, <sup>2</sup>Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany, <sup>3</sup>Beth Israel Deaconess Medical Center, Boston, MA

**(622) Comparative Behaviour of Allogeneic Spleen versus Bone Marrow Cells in Non-Conditioned Neonatal Mice: Insights into Robust Heart Transplant Tolerance;** R. A. Bascom, K. Tao, L. J. West. *University of Alberta, Edmonton, AB, Canada*

**(623) Decreased Club Cell Secretory Protein in Bronchoalveolar Lavage is Associated with Chronic Lung Allograft Dysfunction (CLAD) but Not with CLAD Phenotypes;** L. Levy, E. Huszti, A. Tigert, S. Moshkelgosha, B. Joe, T. Saito, J. Tikkanen, S. Keshavjee, S. Juvet, T. Martinu. *Toronto Lung Transplant Program, Toronto, ON, Canada*

**(624) CRISPR-Mediated IL-10 Gene Activation as a Novel Gene Therapeutic Strategy in Lung Transplantation;** K. Mesaki, O. Silverberg, Z. Guan, S. Juvet, T. Martinu, M. Cypel, T. Waddell, M. Liu, S. Keshavjee. *Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada*

**(625) Lung Bile Acid as Biomarker of Microaspiration and Its Relationship to Lung Inflammation;** M. Ahmed<sup>1</sup>, L. Levy<sup>1</sup>, S. E. Hunter<sup>1</sup>, K. C. Zhang<sup>1</sup>, E. Huszti<sup>2</sup>, K. M. Boonstra<sup>1</sup>, A. T. Sage<sup>1</sup>, S. Azad<sup>1</sup>, R. Zamel<sup>1</sup>, R. Ghany<sup>1</sup>, J. C. Yeung<sup>1</sup>, O. M. Crespin<sup>3</sup>, C. Frankel<sup>4</sup>, M. Budev<sup>5</sup>, P. Shah<sup>6</sup>, L. D. Snyder<sup>4</sup>, J. Belperio<sup>7</sup>, L. G. Singer<sup>1</sup>, S. S. Weigt<sup>7</sup>, J. L. Todd<sup>4</sup>, S. M. Palmer<sup>4</sup>, S. Keshavjee<sup>1</sup>, T. Martinu<sup>1</sup>, \*. For CTOT-20 Investigators<sup>1</sup>. <sup>1</sup>Toronto Lung Transplant Program, Toronto, ON, Canada, <sup>2</sup>BioStatistics Research Unit, University Health Network, Toronto, ON, Canada, <sup>3</sup>University Health Network, Toronto, ON, Canada, <sup>4</sup>Duke University Medical Center, Durham, NC, <sup>5</sup>Cleveland Clinic, Cleveland, OH, <sup>6</sup>Johns Hopkins University Hospital, Baltimore, MD, <sup>7</sup>University of California Los Angeles, Los Angeles, CA

**(626) Myeloid-Derived Suppressor Cells in Lung Transplant Recipients;** T. Heigl<sup>1</sup>, A. Singh<sup>2</sup>, B. Saez<sup>1</sup>, J. Kaes<sup>1</sup>, A. Van Herck<sup>1</sup>, A. Sacreas<sup>1</sup>, H. Beeckmans<sup>1</sup>, S. Verleden<sup>1</sup>, D. Van Raemdonck<sup>1</sup>, G. Verleden<sup>1</sup>, B. Vanaudenaerde<sup>1</sup>, D. Hartl<sup>2</sup>, R. Vos<sup>1</sup>. <sup>1</sup>Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium, <sup>2</sup>Universitätsklinik für Kinder-und Jugendmedizin, Tuebingen, Tuebingen, Germany

**(627) Heart-Associated Cytokine and Endothelial Patterns Dominate the Ischemia Reperfusion Response in Recipients of Combined Heart/Lung Transplantation in Comparison to Lung Transplantation;** B. Wiegmann<sup>1</sup>, N. Ledwoch<sup>2</sup>, R. Bellmas-Sanz<sup>2</sup>, F. Ius<sup>1</sup>, W. Sommer<sup>1</sup>, S. Rojas-Hernandez<sup>1</sup>, I. Tudorache<sup>1</sup>, C. Kühn<sup>1</sup>, M. Avsar<sup>1</sup>, A. Haverich<sup>1</sup>, G. Warnecke<sup>1</sup>, C. Falk<sup>2</sup>. <sup>1</sup>Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany, <sup>2</sup>Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany

**(628) Lung T Cell Activation in an Outbred Pig Transplant and Ischemia-Reperfusion Injury Model;** A. Duong, L. Caldarone, A. Mariscal, L. Huang, C. Xu, S. Keshavjee, M. Liu, S. Juvet, T. Martinu. *Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada*

**(629) Orthotopic Implantation with Immature Mouse Fetal Lung Did Not Self-Organize Airways Structures, but Improved Prognosis of Mice with Paraquat-Induced Severe Lung Injury;** R. Okabe<sup>1</sup>, T. Chen-Yoshikawa<sup>2</sup>, A. Yoshizawa<sup>3</sup>, T. Hirashima<sup>4</sup>, F. Gochi<sup>1</sup>, H. Yamagishi<sup>1</sup>, A. Takahagi<sup>1</sup>, M. Saito<sup>1</sup>, A. Ohsumi<sup>1</sup>, D. Nakajima<sup>1</sup>, M. Hamaji<sup>1</sup>, H. Date<sup>1</sup>, T. Takebe<sup>5</sup>. <sup>1</sup>Thoracic Surgery, Kyoto University, Kyoto City, Japan, <sup>2</sup>Thoracic Surgery, Kyoto University, Kyoto City, Japan, <sup>3</sup>Pathology, Kyoto University, Kyoto City, Japan, <sup>4</sup>Pathology and Biology of Diseases, Kyoto University, Kyoto City, Japan, <sup>5</sup>Pediatrics, Cincinnati College of Medicine, Cincinnati, OH

**(630) Development and Ex Vivo Functional Evaluation of Bioengineered Lungs;** C. Givens, I. Abdel Fattah, B. Fioret, G. Winchester, M. N. James, E. Stoyan, E. Wright, J. Lee, T. Zimmerman, M. Vadhavkar, K. Guthrie, T. H. Petersen, B. A. Nsiah. United Therapeutics, Durham, NC

**(631) Impact of Severe Tricuspid Valve Insufficiency on the Performance of the Left Ventricular Assist Devices. Acute and Chronic Animal Studies;** C. Gomez<sup>1</sup>, C. Torregroza<sup>1</sup>, N. Sadat<sup>1</sup>, D. Scheiber<sup>1</sup>, J. von der Beek<sup>2</sup>, R. Westenfeld<sup>1</sup>, I. J. Knorr<sup>2</sup>, P. Akhyari<sup>1</sup>, M. Sager<sup>2</sup>, A. Lichtenberg<sup>1</sup>, D. Saeed<sup>1</sup>. <sup>1</sup>Cardiovascular Surgery, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany, <sup>2</sup>Department of Animal Research and Animal Protection, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany

**(632) Stem Cells Transplantation Improves Kidney Function in Cardio-Renal Syndrome Type II: Insight into Pathophysiological Mechanisms;** G. Vescovo<sup>1</sup>, C. Castellani<sup>2</sup>, M. Fedrigo<sup>2</sup>, A. Di Francesco<sup>2</sup>, G. M. Virzi<sup>3</sup>, G. M. Vescovo<sup>2</sup>, R. Tavano<sup>4</sup>, M. Pozzobon<sup>5</sup>, A. Angelini<sup>2</sup>. <sup>1</sup>Internal Medicine, S. Antonio Hospital, Padova, Italy, <sup>2</sup>Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy, <sup>3</sup>Department of Nephrology, Dialysis and Transplant, San Bortolo Hospital, Vicenza, Italy, <sup>4</sup>Dept. Biomedical Sciences, University of Padova, Padova, Italy, <sup>5</sup>Dept. Women and Children Health Institute of Pediatric Research Città della Speranza, University of Padova, Padova, Italy

**(633) The Case for Pig Heart Xenotransplantation in Infants with Complex Congenital Heart Disease;** H. Hara<sup>1</sup>, Q. Li<sup>1</sup>, C. A. Banks<sup>1</sup>, T. Yamamoto<sup>1</sup>, D. Ayares<sup>2</sup>, D. C. Cleveland<sup>3</sup>, D. K. Cooper<sup>1</sup>. <sup>1</sup>Surgery, University of Alabama at Birmingham, Birmingham, AL, <sup>2</sup>Revivacor, Blacksburg, VA, <sup>3</sup>Cardio Thoracic Surgery, University of Alabama at Birmingham, Birmingham, AL

**(634) Improvement of Left Ventricular Ejection Fraction by a Novel Electrical Microcurrent Therapy in a Sheep Model of Chronic Heart Failure;** L. Napp<sup>1</sup>, C. Baum<sup>2</sup>, G. Dogan<sup>3</sup>, J. S. Hanke<sup>3</sup>, T. Meyer<sup>4</sup>, P. Goettel<sup>5</sup>, K. Brandes<sup>5</sup>, S. Sarikouch<sup>3</sup>, C. Bara<sup>3</sup>, J. Bauersachs<sup>1</sup>, A. Haverich<sup>3</sup>, J. Mueller<sup>5</sup>, J. D. Schmitto<sup>3</sup>. <sup>1</sup>Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany, <sup>2</sup>University of Veterinary Medicine, Hannover, Germany, <sup>3</sup>Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany, <sup>4</sup>MedImplant, Hannover, Germany, <sup>5</sup>BerlinHeals, Zug, Switzerland

**Wednesday, April 3, 2019**

**6:00 PM - 7:15 PM**

**POSTER SESSION 1: PATHOLOGY**

**Room: Hibiscus 2**

**Poster Discussants:**

Marny Fedrigo, MD, University of Padua, Padua, Italy

Brandon T. Larsen, MD, PhD, University of Arizona Medical Center, Tucson, AZ, USA

**(605) *Mast Cell Expression in Heart Transplant Acute Cellular Rejection (ACR): A Retrospective Single Institution Analysis*; S. Boyes<sup>1</sup>, R. Nigdelioglu<sup>1</sup>, S. Mehrotra<sup>1</sup>, S. Pambuccian<sup>1</sup>, M. Walsh<sup>2</sup>, V. Ananthanarayanan<sup>1</sup>. <sup>1</sup>Loyola University Medical Center, Maywood, IL, <sup>2</sup>University of Illinois at Chicago, Chicago, IL**

Wednesday, April 3, 2019

6:00 PM - 7:15 PM

**POSTER SESSION 1: ECONOMICS, ETHICS, PUBLIC POLICY**

**Room: Gardenia 2**

**Poster Discussants:**

Nancy P. Blumenthal, CRNP, Hospital of University of Pennsylvania, Philadelphia, PA, USA

Jay D. Pal, MD, PhD, University of Colorado, Aurora, CO, USA

**(635) Heart Allocation in France Since the Introduction of the New Allocation System;** B. Audry<sup>1</sup>, C. Jasseron<sup>1</sup>, C. Legeai<sup>1</sup>, L. Sebbag<sup>2</sup>, C. Goeminne<sup>3</sup>, O. Bastien<sup>1</sup>, C. Jacquelinet<sup>1</sup>, R. Dorent<sup>1</sup>. <sup>1</sup>Agence de la Biomedecine, Saint-Denis la Plaine, France, <sup>2</sup>CHU Lyon, Lyon, France, <sup>3</sup>CHRU Lille, Lille, France

**(636) Behavioural Economic Nudge Policy, Organ-Donation and Heart Transplant Conversion Rates in Alberta, Canada. A Ten-Year Retrospective Analysis;** P. F. Kantor<sup>1</sup>, A. Yong<sup>2</sup>, D. J. Kutsogiannis<sup>3</sup>. <sup>1</sup>Paediatrics, Stollery Children's Hosp, Edmonton, AB, Canada, <sup>2</sup>Transplant Services, Alberta Health Services, Edmonton, AB, Canada, <sup>3</sup>Critical Care Medicine, University of Alberta, Edmonton, AB, Canada

**(637) Regional and Socioeconomic Distribution, Healthcare Utilization, and In-Hospital Mortality of Heart Transplantation;** J. Newman<sup>1</sup>, C. Mullan<sup>2</sup>, M. Geib<sup>3</sup>, G. Stevens<sup>4</sup>, D. Majure<sup>4</sup>, S. Hussain<sup>1</sup>, H. Fernandez<sup>1</sup>, A. Hartman<sup>1</sup>, B. Lima<sup>1</sup>. <sup>1</sup>Cardiovascular and Thoracic Surgery, Northwell Health, Manhasset, NY, <sup>2</sup>Cardiac and Thoracic Surgery, Yale School of Medicine, New Haven, CT, <sup>3</sup>University of Texas Health Science Center, San Antonio, San Antonio, TX, <sup>4</sup>Cardiology, Northwell Health, Manhasset, NY

**(638) Quantifying the Effects of Training in Lung Transplantation: Lessons from NASA;** N. Chilvers, A. W. Clark, M. I. Mydin, S. Clark. Cardiothoracic Surgery, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

**(639) Validity and Reliability of the Quality of Life with a Left Ventricular Assist Device (QOLVAD) Questionnaire;** K. E. Sandau<sup>1</sup>, C. S. Lee<sup>2</sup>, K. M. Faulkner<sup>2</sup>, P. Eckman<sup>3</sup>, R. Garberich<sup>4</sup>, B. Pozehl<sup>5</sup>, C. Y. Jurgens<sup>6</sup>, C. E. Weaver<sup>7</sup>, S. Joseph<sup>8</sup>, S. A. Hall<sup>8</sup>, S. Carey<sup>8</sup>, J. A. Cowger<sup>9</sup>, S. P. Chaudhry<sup>10</sup>, S. E. Schroeder<sup>11</sup>, R. O. Hoffman III<sup>12</sup>, D. Feldman<sup>12</sup>, G. Conway<sup>12</sup>, E. Birati<sup>13</sup>, M. Soni<sup>14</sup>, J. Marble<sup>15</sup>, M. S. Kunz<sup>16</sup>, K. M. Storey<sup>16</sup>, B. A. Hoglund<sup>17</sup>. <sup>1</sup>Bethel University, St. Paul, MN, <sup>2</sup>Boston College Connell School of Nursing, Chestnut Hill, MA, <sup>3</sup>Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN, <sup>4</sup>Minneapolis Heart Institute Foundation, Minneapolis, MN, <sup>5</sup>University of Nebraska Medical Center College of Nursing, Omaha, NE, <sup>6</sup>Stony Brook University, School of Nursing, Stony Brook, NY, <sup>7</sup>Abbott Northwestern Hospital/Minneapolis Heart Institute, Minneapolis, MN, <sup>8</sup>Baylor University Medical Center, Dallas, TX, <sup>9</sup>Henry Ford Hospitals, Detroit, MI, <sup>10</sup>St. Vincent Heart Center/St. Vincent, Indianapolis, IN, <sup>11</sup>Bryan Heart Center, Lincoln, NE, <sup>12</sup>University of Cincinnati Medical Center, Cincinnati, OH, <sup>13</sup>Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, <sup>14</sup>Department of Medicine, University of Pennsylvania, Philadelphia, PA, <sup>15</sup>University of Pennsylvania, Philadelphia, PA, <sup>16</sup>Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, MN, <sup>17</sup>Metropolitan State University, St. Paul, MN

**(640) The CMS Changes to a US ECMO Reimbursement: The Financial Impact upon ECMO Programs;** R. A. Rose, P. Combs, R. Piech, C. LaBuhn, V. Jeevanandam, T. Song. University of Chicago, Chicago, IL

**(641) Hospitalization Rate among LVAD Patients during the Last Decade in the United States;** S. Shore<sup>1</sup>, Z. Geng<sup>2</sup>, S. Adusumalli<sup>3</sup>, M. Seigerman<sup>2</sup>, J. Mazurek<sup>2</sup>, J. Wald<sup>2</sup>, M. Tanna<sup>2</sup>, P. Atluri<sup>4</sup>, P. Groeneveld<sup>2</sup>, E. Y. Birati<sup>2</sup>. <sup>1</sup>Cardiology, University of Michigan, Ann Arbor, PA, <sup>2</sup>Cardiology, University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Cardiology, Hospital of the University of Pennsylvania, Philadelphia, PA, <sup>4</sup>Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA

**(642) Cost Comparison between Subclavian-Artery Intra-Aortic Balloon Pump and Intravascular Ventricular Assist System as a Bridge to Transplant Therapy;** T. Lamm, C. LaBuhn, P. Combs, E. Gonzales, T. Ota, T. Song, D. Onsager, V. Jeevanandam. Cardiac Surgery, University of Chicago, Chicago, IL

Wednesday, April 3, 2019

6:00 PM - 7:15 PM

**POSTER SESSION 1: HEART TRANSPLANTATION (ADULT)**

**Room: Timor Sea 2**

**Poster Discussants:**

Natasha Altman, MD, University of Colorado, Denver, CO, USA  
Richard Cheng, MD, University of Washington, Seattle, WA, USA  
Sharon Chih, MD, University of Ottawa Heart Institute, Ottawa, Canada  
Amy Hackmann, MD, University of Southern California, Los Angeles, CA, USA  
Tomoko Kato, MD, PhD, National Cardiovascular Center, Tokyo, Japan  
Anthony Lemaire, MD, Robert Wood Johnson Med Ctr, Princeton, NJ, USA  
Luciano Potena, MD, PhD, University of Bologna, Bologna, Italy  
Andreas Zuckermann, MD, Medical Univ of Vienna, Vienna, Austria

**(643) Frequent Use of Organs after Rescue Allocation for Heart Transplantation: Can We Still Achieve Adequate Results?; U. Boeken<sup>1</sup>, A. Mehdiani<sup>1</sup>, C. Boettger<sup>1</sup>, D. Saeed<sup>1</sup>, R. Westenfeld<sup>2</sup>, B. Sowinski<sup>1</sup>, H. Aubin<sup>1</sup>, H. Dalyanoglu<sup>1</sup>, P. Akhyari<sup>1</sup>, A. Lichtenberg<sup>1</sup>. <sup>1</sup>Cardiovascular Surgery, University Hospital, Duesseldorf, Germany, <sup>2</sup>Cardiology, University Hospital, Duesseldorf, Germany**

**(644) Echocardiographic Characteristics Associated with Left Ventricular Recovery in Donor Hearts; A. Bhatia<sup>1</sup>, J. Ji<sup>2</sup>, J. Peacock<sup>2</sup>, J. Hartupee<sup>1</sup>, G. Ewald<sup>1</sup>. <sup>1</sup>Division of Cardiology, Washington University School of Medicine, St. Louis, MO, <sup>2</sup>Washington University School of Medicine, St. Louis, MO**

**(645) Application of Predicted Heart Mass Difference in a Canadian Cohort of Heart Transplant Recipients; V. M. Molinero<sup>1</sup>, F. Foroutan<sup>1</sup>, J. G. Duero Posada<sup>1</sup>, S. Chih<sup>2</sup>, M. Badiwala<sup>1</sup>, H. J. Ross<sup>1</sup>, A. C. Alba<sup>1</sup>. <sup>1</sup>Cardiology, UHN, Toronto, ON, Canada, <sup>2</sup>Cardiology, Ottawa Heart Institute, Ottawa, ON, Canada**

**(646) What Antigens to Avoid in Heart Transplant to Optimize Outcome via the Virtual Crossmatch; E. Kransdorf, J. Patel, M. Kittleson, D. Chang, S. Dimbil, R. Levine, A. Shen, A. Jain, M. Olymbios, L. Czer, X. Zhang, J. Kobashigawa. Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA**

**(647) Thyroid Hormone Improved Heart Transplant Recipient Survival; K. Carter<sup>1</sup>, S. Lirette<sup>1</sup>, R. P. Cochran<sup>1</sup>, L. Creswell<sup>1</sup>, A. Panos<sup>1</sup>, D. A. Baran<sup>2</sup>, H. Copeland<sup>1</sup>. <sup>1</sup>University of MS Medical Center, Jackson, MS, <sup>2</sup>Sentara Healthcare, Norfolk, VA**

**(648) Impaired Outcome after Heart Transplantation: Impact of Donor Age and Ischemic Time; C. Boettger, A. Mehdiani, P. Akhyari, A. Albert, H. Dalyanoglu, R. Westenfeld, D. Saeed, H. Aubin, A. Lichtenberg, U. Boeken. Cardiovascular Surgery, University Hospital, Duesseldorf, Germany**

**(649) Specialized Thoracic Adapted Recovery (STAR) Team Model for Heart Transplantation: 1000 Recoveries; H. Tetteh<sup>1</sup>, P. Brandenhoff<sup>2</sup>, R. S. Higgins<sup>3</sup>. <sup>1</sup>Department of Surgery, Uniformed Services University, Bethesda, MD, <sup>2</sup>Cardiothoracic Surgery, Thoracic Transplant Consultants, San Francisco, CA, <sup>3</sup>Department of Surgery, Johns Hopkins University, Baltimore, MD**

**(650) Single Center Experience of Hepatitis C Donor Viremic Cardiac Transplantation; K. L. Morris<sup>1</sup>, J. P. Adlam<sup>2</sup>, M. Bochan<sup>3</sup>, M. Padanilam<sup>1</sup>, A. Patel<sup>1</sup>, R. Garcia-Cortes<sup>1</sup>, S. Chaudhry<sup>1</sup>, S. Tompkins<sup>1</sup>, C. Salerno<sup>4</sup>, A. Ravichandran<sup>1</sup>. <sup>1</sup>Cardiology, St. Vincent Hospital, Indianapolis, IN, <sup>2</sup>Internal Medicine, St. Vincent Hospital, Indianapolis, IN, <sup>3</sup>Infectious Disease, St. Vincent Hospital, Indianapolis, IN, <sup>4</sup>Cardiovascular Surgery, St. Vincent Hospital, Indianapolis, IN**

**(651) Heart Transplant Under Sizing is Associated with Adverse Early Hemodynamics but Does Not Affect Survival; L. Holzhauser, A. J. Kanelidis, T. Imamura, N. Bassi, T. Fujino, N. Daisuke, C. Murks, J. Powers, T. Riley, A. Nguyen, B. Chung, J. Raikhelkar, B. Smith, G. Kim, G. Sayer, N. Uriel. University of Chicago, Chicago, IL**

**(652) Analysis of Discrepancy between Expected and Actual Donor-Recipient Matching in Heart Transplantation; C. R. Chen<sup>1</sup>, M. Connellan<sup>2</sup>, E. Granger<sup>2</sup>, Y. Kawanishi<sup>2</sup>, A. Jabbour<sup>2</sup>, P. Macdonald<sup>2</sup>, K. Muthiah<sup>2</sup>, C. Hayward<sup>2</sup>, K. Dhital<sup>2</sup>. <sup>1</sup>Faculty of Medicine, The University of New South Wales, Sydney, Australia, <sup>2</sup>Heart and Lung Transplant Unit, St Vincent's Hospital, Sydney, Australia**

**(653) Donor and Recipient Racial Mismatch Impacts Thoracic Organ Transplant Survival; K. Cox<sup>1</sup>, K. Carter<sup>1</sup>, S. Lirette<sup>1</sup>, R. Cochran<sup>1</sup>, L. Creswell<sup>1</sup>, A. Panos<sup>1</sup>, D. Baran<sup>2</sup>, H. Copeland<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, University of Mississippi Medical Center, Jackson, MS, <sup>2</sup>Sentara Healthcare, Norfolk, VA**



- (654) Does Donor-Recipient Age Difference Matter in the Outcome of Heart Transplantation?**; E. Ram, J. Lavee, Y. Kassif, D. Elian, M. Katz, R. Klempfner, D. Freimark, Y. Peled. *Sheba Medical Center Tel Hashomer and Tel-Aviv University, Ramat Gan, Israel*
- (655) Donor Age Significantly Impacts Long Term Survival of Patients Undergoing Heart Transplantation**; E. Lushaj, R. Dhingra, S. Osaki, M. Johnson, T. Kohmoto. *University of Wisconsin, Madison, WI*
- (656) Characteristics of Hepatitis C+ vs Hepatitis C- Donors**; E. Sandhaus, S. Zalawadiya, C. Schwartz, S. Ruzevich-Scholl, A. Dutton, M. Wigger, M. Brinkley, J. Menachem, A. Shah, M. Danter, K. Balsara, L. Punnoose, S. Sacks, H. Ooi, J. Lindenfeld, K. Schlendorf. *Vanderbilt University, Nashville, TN*
- (657) Effect of Recipient Race on Quality of Donors Allocated to Heart Transplant Recipients**; B. Smith<sup>1</sup>, W. Parker<sup>1</sup>, S. Kalantari<sup>1</sup>, J. Raikhelkar<sup>1</sup>, G. Kim<sup>1</sup>, N. Sarswat<sup>1</sup>, G. Sayer<sup>1</sup>, A. Nguyen<sup>1</sup>, B. Chung<sup>1</sup>, L. Holzhauser<sup>1</sup>, N. Narang<sup>1</sup>, I. Ebong<sup>1</sup>, J. Rich<sup>2</sup>, A. Anderson<sup>2</sup>, N. Uriel<sup>1</sup>, E. Vorovich<sup>2</sup>. <sup>1</sup>*University of Chicago, Chicago, IL*, <sup>2</sup>*Northwestern Memorial Hospital, Chicago, IL*
- (658) Achievement of Donor Management Goals and Primary Graft Dysfunction after Heart Transplant**; L. Benck<sup>1</sup>, E. Kransdorf<sup>1</sup>, J. Patel<sup>1</sup>, D. Malinoski<sup>2</sup>, R. Levine<sup>1</sup>, C. Neimann<sup>3</sup>, J. A. Kobashigawa<sup>1</sup>. <sup>1</sup>*Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA*, <sup>2</sup>*Division of Surgery, Oregon Health & Science University, Portland, OR*, <sup>3</sup>*Department of Anesthesia, University of California San Francisco, San Francisco, CA*
- (659) Efficacy of HTK Solution in the Preservation of Donor Hearts**; P. C. Tang, M. Mokbel, M. Romano, J. Haft, K. Aaronson, F. Pagani. *Cardiac Surgery, University of Michigan-Ann Arbor, Ann Arbor, MI*
- (660) Donor Left Ventricular Hypertrophy: Over-Rated or Does Donor History of Hypertension Make a Difference for Post-Heart Transplant Outcome?**; M. Kittleson, J. Patel, D. H. Chang, E. Kransdorf, R. Levine, S. Dimbil, K. Nishihara, T. Kao, L. Czer, A. Hage, J. Chung, J. A. Kobashigawa. *Cedars-Sinai Smidt Heart Institute, Los Angeles, CA*
- (661) Heart Transplantation with Older Donors Age: Single Centre Experience**; C. Di Nora<sup>1</sup>, S. Sponga<sup>1</sup>, A. Lechiancole<sup>1</sup>, C. Nalli<sup>1</sup>, G. Guzzi<sup>1</sup>, V. Tursi<sup>2</sup>, U. Livi<sup>1</sup>. <sup>1</sup>*Cardiothoracic Department, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy*, <sup>2</sup>*Cardiothoracic Department, Azienda Sanitaria Universitaria Integrata, Udine, Italy*
- (662) Short and Stout Female Donors in Heart Transplantation: Do They Make a Difference?**; D. H. Chang, M. Kittleson, J. Patel, D. Geft, R. Levine, S. Dimbil, K. Nishihara, T. Kao, L. Czer, A. Trento, J. A. Kobashigawa. *Cedars-Sinai Smidt Heart Institute, Los Angeles, CA*
- (663) Heart Transplant Candidates Perceptions of the Newly Implemented United Network for Organ Sharing Heart Allocation System: An Eye Opener**; N. T. Rivera, B. Bednar, O. Wu, M. Loebe, A. Badiye. *Miami Transplant Institute, Jackson Health System in affiliation with University of Miami Health System, Miami, FL*
- (664) Coronary Angiography and Intravascular Ultrasound in an Ex-Vivo Perfused Heart Using the Organ Care System (OCS)**; D. Schibilsky<sup>1</sup>, Q. Zhou<sup>2</sup>, T. Wengenmayer<sup>2</sup>, S. Maier<sup>1</sup>, C. Benk<sup>1</sup>, M. Berchtold-Herz<sup>3</sup>, F. Beyersdorf<sup>1</sup>, M. Siepe<sup>1</sup>. <sup>1</sup>*Department Cardiovascular Surgery, University Heart Center Freiburg • Bad Krozingen, Faculty of Medicine, Albert-Ludwigs-University Freiburg, Germany, Freiburg, Germany*, <sup>2</sup>*Department of Cardiology, University Heart Center Freiburg • Bad Krozingen, Faculty of Medicine, Albert-Ludwigs-University Freiburg, Germany, Freiburg, Germany*, <sup>3</sup>*Department Cardiovascular Surgery, University Heart Center Freiburg • Bad Krozingen, Freiburg, Germany Faculty of Medicine, Albert-Ludwigs-University Freiburg, Germany, Freiburg, Germany*
- (665) Successful Use of Female Donors in Heart Transplantation: A Single Center Experience**; N. Rajagopalan, D. R. Dennis, J. Akhtarekhavari, M. E. Sekela. *University of Kentucky, Lexington, KY*
- (666) Short-Term Outcome after Heart Transplantation is Comparable When Using Extended-Criteria Donors**; G. Poglajen, G. Zemljic, S. Frljak, R. Okrajšek, M. Šešelj, A. Cerar, V. Andročec, M. Jaklič, B. Vrtovec. *Advanced Heart Failure and Transplantation Center, University Medical Center Ljubljana, Ljubljana, Slovenia*
- (667) Can Donor Step Up Pressure Predict Primary Graft Dysfunction in Recipients Post Heart Transplantation?**; S. Das De<sup>1</sup>, S. Avtaar Singh<sup>1</sup>, K. Morcos<sup>1</sup>, Y. Hegazy<sup>1</sup>, A. Barton<sup>2</sup>, M. McGowan<sup>2</sup>, A. Smyth<sup>2</sup>, J. Dalzell<sup>2</sup>, P. Curry<sup>1</sup>, N. Al-Attar<sup>1</sup>. <sup>1</sup>*Cardiothoracic Surgery, Golden Jubilee National Hospital, Glasgow, United Kingdom*, <sup>2</sup>*Scottish National Advanced Heart Failure Service, Golden Jubilee National Hospital, Glasgow, United Kingdom*
- (668) Impact of the New Heart Allocation System in France on Candidates' Profile and Waitlist Outcomes**; C. Jasseron<sup>1</sup>, C. Legeai<sup>1</sup>, G. Lebreton<sup>2</sup>, M. Kindo<sup>3</sup>, B. Audry<sup>1</sup>, C. Jacquelinet<sup>1</sup>, O. Bastien<sup>1</sup>, R. Dorent<sup>1</sup>. <sup>1</sup>*Agence de la Biomedecine, Saint-Denis la Plaine, France*, <sup>2</sup>*Hôpital La Salpêtrière, Paris, France*, <sup>3</sup>*Hôpital de Strasbourg, Strasbourg, France*

- (669) Effect of Donor Simvastatin Treatment on Cardiac Allograft Ischemia-Reperfusion Injury (IRI) - 1-Year Follow-Up Analysis of a Randomized Prospective Single-Center Clinical Trial;** E. Holmström<sup>1</sup>, A. Nykänen<sup>2</sup>, S. Syrjälä<sup>1</sup>, R. Tuuminen<sup>1</sup>, J. Jokinen<sup>2</sup>, R. Krebs<sup>1</sup>, K. Lemström<sup>2</sup>. <sup>1</sup>Transplantation Laboratory, University of Helsinki, Helsinki, Finland, <sup>2</sup>Cardiac Surgery, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland
- (670) Clinical Outcomes of Perioperative Desensitization in Orthotopic Heart Transplant Recipients;** M. E. Plazak<sup>1</sup>, B. N. Reed<sup>1</sup>, S. E. Gale<sup>1</sup>, S. Hammad<sup>2</sup>, V. Ton<sup>3</sup>, D. J. Kaczorowski<sup>3</sup>, T. J. Trobiano<sup>2</sup>, B. R. Ravichandran<sup>2</sup>. <sup>1</sup>University of Maryland School of Pharmacy, Baltimore, MD, <sup>2</sup>University of Maryland Medical Center, Baltimore, MD, <sup>3</sup>University of Maryland School of Medicine, Baltimore, MD
- (671) Impact of Mobile Health in Heart Transplant Management: The mHeart Study;** M. Gomis<sup>1</sup>, S. Mirabet<sup>2</sup>, M. Manges<sup>1</sup>, E. Rodríguez-Murphy<sup>1</sup>, J. De Pourcq<sup>1</sup>, A. Feliu<sup>1</sup>, A. Aretio<sup>1</sup>, A. Ferrero<sup>2</sup>, V. Brossa<sup>2</sup>, L. Lopez<sup>2</sup>, E. Roig<sup>2</sup>. <sup>1</sup>Pharmacy Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, <sup>2</sup>Cardiology Dept, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- (672) Long-Term Sirolimus for Primary Immunosuppression and Incidence of De Novo Malignancy Following Heart Transplantation;** R. Asleh<sup>1</sup>, X. Li<sup>1</sup>, H. Alnsasra<sup>2</sup>, A. Briasoulis<sup>1</sup>, B. Smith<sup>1</sup>, W. Kremers<sup>1</sup>, N. L. Pereira<sup>1</sup>, B. S. Edwards<sup>1</sup>, R. C. Daly<sup>1</sup>, J. M. Stulak<sup>1</sup>, A. Clavell<sup>1</sup>, S. S. Kushwaha<sup>1</sup>. <sup>1</sup>Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, <sup>2</sup>Cardiovascular Diseases, Mayo Clinic, Rochester, MN
- (673) Safety and Efficacy of Extended-Release Tacrolimus in De Novo Heart Transplant Recipients: Preliminary Results from a Phase-II Trial;** K. Martits-Chalangan<sup>1</sup>, T. Sam<sup>1</sup>, C. Y. Guerrero-Miranda<sup>2</sup>, P. Kale<sup>2</sup>, D. M. Clark<sup>1</sup>, A. Doss<sup>1</sup>, V. L. Flores<sup>1</sup>, H. Zafar<sup>1</sup>, J. Felius<sup>1</sup>, R. L. Gottlieb<sup>2</sup>, S. A. Hall<sup>2</sup>. <sup>1</sup>Baylor Scott & White Research Institute, Dallas, TX, <sup>2</sup>Baylor Univ Medical Center, Dallas, TX
- (674) Application of Precision Medicine in Heart Transplant Induction Delivers on Outcomes;** T. Sam, S. McKean, T. Nisar, A. Jamil, E. Yoon, S. Hall. Baylor University Medical Center, Dallas, TX
- (675) Use of PCSK9 Inhibitor Therapy in a Small Cohort of Heart Transplant Recipients with Statin Intolerance or Refractory Hyperlipidemia;** R. Jackson, D. Jennings, M. Gaine, T. Fanek, A. Mabasa, J. Lee, A. Kleet, F. Latif, S. Restaino, M. Farr. Medicine, Columbia University Medical Center, New York, NY
- (676) Desensitization in Patients Bridged to Urgent Heart Transplantation under Extracorporeal Membrane Oxygenation Support: A Preliminary Experience;** J. Guihaire, S. Davino, M. Kloeckner, R. Ramadan, A. Azmoun, F. Stephan, P. Deleuze. Adult Cardiac Surgery, Marie Lannelongue Hospital, Paris Sud University, Le Plessis Robinson, France
- (677) Evaluation of Early Allograft Function in Donor HCV-Positive to Recipient HCV-Negative Cardiac Transplantation Managed with Preemptive Direct Acting Antiviral Therapy;** T. A. Lebeis<sup>1</sup>, M. E. Afari<sup>1</sup>, E. D. Bethea<sup>2</sup>, K. Gaj<sup>1</sup>, J. L. Gustafson<sup>2</sup>, K. Turvey<sup>1</sup>, E. Coglianese<sup>1</sup>, S. S. Thomas<sup>1</sup>, C. Newton-Cheh<sup>1</sup>, N. Ibrahim<sup>1</sup>, W. D. Carlson<sup>1</sup>, J. E. Ho<sup>1</sup>, M. Naylor<sup>1</sup>, J. K. Steiner<sup>1</sup>, A. Spahillari<sup>1</sup>, M. A. Villavicencio-Theoduloz<sup>3</sup>, D. A. D'Alessandro<sup>3</sup>, C. Soydar<sup>1</sup>, N. Lever<sup>1</sup>, R. T. Chung<sup>2</sup>, G. D. Lewis<sup>1</sup>. <sup>1</sup>Cardiology Division, Massachusetts General Hospital, Boston, MA, <sup>2</sup>Liver Center and Gastrointestinal Division, Massachusetts General Hospital, Boston, MA, <sup>3</sup>Cardiothoracic Surgery Division, Massachusetts General Hospital, Boston, MA
- (678) Is There a Benefit of Metformin after Heart Transplantation?;** D. H. Chang, J. Patel, M. Kittleson, E. Kransdorf, S. Dimbil, R. Levine, T. Kao, T. Hage, L. Czer, A. Hage, A. Trento, J. A. Kobashigawa. Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
- (679) 5-Year Outcome of Photopheresis in Heart-Transplantation with Refractory/Persistent Rejection;** J. Patel, M. Kittleson, D. Chang, E. Kransdorf, R. Levine, S. Dimbil, T. Kao, L. Czer, R. Cole, F. Esmailian, J. Kobashigawa. Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA
- (680) Incidence of Vasoplegic Syndrome after Cardiac Transplant in Patients Treated with Sacubitril/Valsartan;** J. M. Dominguez<sup>1</sup>, J. Pàmies<sup>2</sup>, S. Mirabet<sup>2</sup>, E. García-Romero<sup>3</sup>, J. Gonzalez-Costello<sup>4</sup>, M. Farrero<sup>1</sup>, F. Perez-Villa<sup>5</sup>. <sup>1</sup>Heart Failure and Heart Transplant Unit, Hospital Clinic, Barcelona, Spain, <sup>2</sup>Heart Failure and Heart Transplant Unit, Hospital de la Santa Creu y Sant Pau, Barcelona, Spain, <sup>3</sup>Heart Failure and Heart Transplant Unit, Hospital Universitari Bellvitge, Barcelona, Spain, <sup>4</sup>Hospital Universitari de Bellvitge, Barcelona, Spain, <sup>5</sup>Heart Failure and Hear Transplant Unit, Hospital Clinic, Barcelona, Spain
- (681) Hypomagnesemia is Associated with New-Onset Diabetes Mellitus Following Heart Transplantation;** Y. Peled<sup>1</sup>, J. Lavee<sup>1</sup>, E. Ram<sup>1</sup>, N. Shlomo<sup>2</sup>, T. Ovdad<sup>2</sup>, A. Peled<sup>3</sup>, D. Freimark<sup>1</sup>, R. Klempfner<sup>1</sup>, M. Shechter<sup>1</sup>. <sup>1</sup>Sheba Medical Center Tel Hashomer and Tel-Aviv Univ, Ramat Gan, Israel, <sup>2</sup>Israeli Association for Cardiovascular Trials, Ramat Gan, Israel, <sup>3</sup>Clalit Health Services, Lod, Israel
- (682) Heart Transplant Induction Therapy in Canada: A National Survey;** S. Jia<sup>1</sup>, D. Nagpal<sup>2</sup>, R. A. Davey<sup>3</sup>, S. De<sup>3</sup>, R. McKelvie<sup>3</sup>, L. A. Goldraich<sup>3</sup>, S. J. Smith<sup>3</sup>. <sup>1</sup>Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, <sup>2</sup>Cardiac Surgery, London Health Sciences Centre, London, ON, Canada, <sup>3</sup>Cardiology, London Health Sciences Centre, London, ON, Canada

**(683) De-Novo Malignancy in Cardiac Transplant Recipients-Single Centre Experience;** L. Saiva<sup>1</sup>, B. Parlon<sup>1</sup>, T. Baby<sup>1</sup>, C. Halley<sup>2</sup>, L. Nolke<sup>1</sup>, N. Mahon<sup>2</sup>, J. O'Neill<sup>3</sup>. <sup>1</sup>Heart and Lung Transplant, Mater Misericordiae University Hospital, Dublin 7, Ireland, <sup>2</sup>Cardiology, Mater Misericordiae University Hospital, Dublin 7, Ireland, <sup>3</sup>Consultant Transplant Cardiologist, Mater Misericordiae University Hospital, Dublin 7, Ireland

**(684) Effect of Bortezomib Desensitization Therapy on Levels of AT1R Antibody;** X. Zhang<sup>1</sup>, J. Patel<sup>2</sup>, J. Kobashigawa<sup>2</sup>. <sup>1</sup>HLA and Immunogenetics Laboratory, Cedars-Sinai Health System, Los Angeles, CA, <sup>2</sup>Cardiology, Cedars-Sinai Health System, Los Angeles, CA

**(685) Outcomes after Early Initiation of mTOR-Inhibitors in Adult Cardiac Transplant Recipients;** J. Batra<sup>1</sup>, D. Jennings<sup>1</sup>, A. R. Garan<sup>1</sup>, L. K. Truby<sup>1</sup>, F. Latif<sup>1</sup>, S. Restaino<sup>1</sup>, J. Haythe<sup>1</sup>, M. Yuzefpolskaya<sup>1</sup>, K. Takeda<sup>2</sup>, H. Takayama<sup>2</sup>, Y. Naka<sup>2</sup>, P. Colombo<sup>1</sup>, M. Farr<sup>1</sup>, V. K. Topkara<sup>1</sup>. <sup>1</sup>Medicine, Columbia University, New York, NY, <sup>2</sup>Surgery, Columbia University, New York, NY

**(686) Characteristics of Cardiopulmonary Exercise Tests in Heart Transplantation Patients: The Importance of Chronotropic Incompetence in Predicting Exercise Capacity;** Y. Peled, E. Ram, H. Patal, J. Lavee, J. Buber, R. Klempfner. Sheba Medical Center Tel Hashomer and Tel-Aviv University, Ramat Gan, Israel

**(687) EVOLVD: Cholesterol Lowering with EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-Novo Heart Transplant Recipients: Rationale and Design of a Randomized, Controlled Trial;** K. Broch<sup>1</sup>, F. Gustafsson<sup>2</sup>, G. Rådegran<sup>3</sup>, L. B. Karl<sup>4</sup>, H. Eiskjær<sup>5</sup>, K. Karason<sup>6</sup>, G. Dellgren<sup>6</sup>, J. Lommi<sup>4</sup>, M. Pentikäinen<sup>4</sup>, S. Arora<sup>1</sup>, E. Gude<sup>1</sup>, A. K. Andreassen<sup>1</sup>, L. Gullestad<sup>1</sup>. <sup>1</sup>Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway, <sup>2</sup>Cardiology, Rigshospitalet, Copenhagen, Denmark, <sup>3</sup>The Section for Heart Failure and Valvular Disease, VO. Heart and Lung Medicine, Skåne University Hospital, Oslo, Sweden, <sup>4</sup>Cardiology, Helsinki University Hospital Heart and Lung Center, Helsinki, Finland, <sup>5</sup>Cardiology, Aarhus University Hospital, Skejby, Aarhus, Denmark, <sup>6</sup>Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden

**(688) Metformin Therapy is Associated with Reduced Risk of Vasculopathy and Cardiovascular Mortality after Heart Transplantation;** Y. Peled<sup>1</sup>, E. Ram<sup>1</sup>, Y. Har-Zahav<sup>1</sup>, N. Shlomo<sup>2</sup>, Y. Kassif<sup>1</sup>, A. Kogan<sup>1</sup>, E. Maor<sup>1</sup>, D. Freimark<sup>1</sup>, R. Klempfner<sup>1</sup>, J. Lavee<sup>1</sup>. <sup>1</sup>Sheba Medical Center Tel Hashomer and Tel-Aviv University, Ramat Gan, Israel, <sup>2</sup>Israeli Association for Cardiovascular Trials, Ramat Gan, Israel

Wednesday, April 3, 2019

6:00 PM - 7:15 PM

**POSTER SESSION 1: HEART TRANSPLANTATION (ADULT)**

**Room: Timor Sea 1**

**Poster Discussants:**

Markus Barten, MD, PhD, University Heart Center Hamburg, Hamburg, Germany  
Brian Clarke, MD, Libin Cardiovascular Institute/University of Calgary, Calgary, Canada  
Robert Cole, MD, Emory University School of Medicine, Atlanta, GA, USA  
Mahazarin Ginwalla, MD, University Hospital Cleveland Medical Center, Cleveland, OH, USA  
Eileen Hsich, MD, Cleveland Clinic Foundation, Cleveland, OH, USA  
George Javorsky, MBBS, FRACP, Prince Charles Hospital, Brisbane, Australia  
Karl Lemstrom, MD, PhD, Helsinki University, Helsinki, Finland  
Donna Mancini, MD, Mount Sinai Medical Center, New York, NY, USA  
Ravikumar Ratnagiri, MD, Gleneagles Global Hospital, Chennai, India

**(689) Everolimus Immunosuppression in De Novo Heart Transplant Recipients: Clinical and Intravascular Ultrasound Study;** H. Choi, J. Hong, M. Kim, S. Lee, J. Kim. *Cardiology, Asan Medical Center, Seoul, Korea, Republic of*

**(690) Effect of High-Intensity Interval Training on Progression of Coronary Artery Vasculopathy in De Novo Heart Transplant Recipients;** K. Nytrøen<sup>1</sup>, K. Rolid<sup>1</sup>, E. Bjørkelund<sup>2</sup>, K. Karason<sup>3</sup>, F. Gustafsson<sup>4</sup>, O. Solberg<sup>1</sup>, L. Gullestad<sup>1</sup>, S. Arora<sup>5</sup>. <sup>1</sup>*Department of Cardiology, Oslo Univ Hosp Rikshospitalet, Oslo, Norway*, <sup>2</sup>*Oslo University Hospital, Oslo, Norway*, <sup>3</sup>*Sahlgrenska University Hospital, Gothenburg, Sweden*, <sup>4</sup>*Rigshospitalet University Hospital, Copenhagen, Denmark*, <sup>5</sup>*Oslo University Hospital Rikshospital, Oslo, Norway*

**(691) Intensity of Statin Therapy Affects Progression of Coronary Artery Vasculopathy;** J. Power<sup>1</sup>, M. Patarroyo<sup>2</sup>. <sup>1</sup>*Allegheny Health Network, Pittsburgh, PA*, <sup>2</sup>*University of Texas Houston Memorial Hermann Hospital, Houston, TX*

**(692) Deep Learning Facilitates Automation of Wall Layer Quantification in Heart Transplant Coronary OCT;** S. Mullan<sup>1</sup>, Z. Chen<sup>1</sup>, M. Pazdernik<sup>2</sup>, H. Zhang<sup>1</sup>, A. Wahle<sup>1</sup>, V. Melenovsky<sup>2</sup>, J. Kautzner<sup>2</sup>, V. Karmazin<sup>2</sup>, H. Bedanova<sup>3</sup>, A. Tomasek<sup>3</sup>, E. Ozabalova<sup>3</sup>, M. Sonka<sup>1</sup>. <sup>1</sup>*Iowa Institute for Biomedical Imaging, University of Iowa, Iowa City, IA*, <sup>2</sup>*Institute of Clinical and Experimental Medicine, Prague, Czech Republic*, <sup>3</sup>*Department of Cardiovascular Diseases, St. Annes University Hospital and Masaryk University, Brno, Czech Republic*

**(693) Intracoronary Intimal Thickness in Transplant Recipients of Hepatitis C-Positive Donor Hearts;** S. Zalawadiya<sup>1</sup>, J. Lindenfeld<sup>1</sup>, E. Haddad<sup>2</sup>, A. Shah<sup>3</sup>, M. Wigger<sup>1</sup>, S. Negrotto<sup>2</sup>, M. Danter<sup>3</sup>, D. Brinkley<sup>1</sup>, J. Menachem<sup>1</sup>, L. Punnoose<sup>1</sup>, S. Brown Sacks<sup>1</sup>, H. Ooi<sup>1</sup>, K. Balsara<sup>3</sup>, R. Perri<sup>4</sup>, J. Awad<sup>4</sup>, S. Smith<sup>1</sup>, R. Fowler<sup>1</sup>, H. O'Dell<sup>4</sup>, C. Darragh<sup>4</sup>, S. Ruzevich-Scholl<sup>1</sup>, K. Schlendorf<sup>1</sup>. <sup>1</sup>*Heart Failure and Transplantation, Vanderbilt University Medical Center, Nashville, TN*, <sup>2</sup>*Cardiology, Vanderbilt University Medical Center, Nashville, TN*, <sup>3</sup>*Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN*, <sup>4</sup>*Gastroenterology and Hepatology, Vanderbilt University Medical Center, Nashville, TN*

**(694) Myocardial Flow Reserve Using <sup>13</sup>N Ammonia PET for Detection of Cardiac Allograft Vasculopathy;** N. Kikuchi, E. Yamamoto, H. Hattori, M. Nagao, M. Momose, T. Shiga, N. Hagiwara, H. Niinami, S. Nunoda. *Tokyo Women's Medical University, Tokyo, Japan*

**(695) Silent Ischemia and Arrhythmia after Heart Transplantation: Relation to Cardiac Allograft Vasculopathy;** K. Berg, K. Bjerre, T. Clemmensen, S. Poulsen, H. Eiskjær. *Cardiology, AUH, Aarhus University Hospital, Århus, Denmark*

**(696) Does Aspirin Reduce the Rate of Early Cardiac Allograft Vasculopathy (CAV) Following Heart Transplant?;** J. E. Bloom<sup>1</sup>, C. Pereira Kessler Iglesias<sup>2</sup>, J. Moskovitch<sup>1</sup>, D. Letchford<sup>3</sup>, E. Kotlyar<sup>4</sup>, S. Offen<sup>4</sup>, A. Keogh<sup>4</sup>, A. Jabbour<sup>4</sup>, C. Hayward<sup>4</sup>, D. M. Kaye<sup>5</sup>, K. Muthiah<sup>4</sup>, P. Macdonald<sup>4</sup>. <sup>1</sup>*Department of Cardiology, Alfred Health, Melbourne, Australia*, <sup>2</sup>*Cardiology, St Vincent's Hospital, Sydney, Australia*, <sup>3</sup>*Department of Cardiology, St Vincent's Hospital, Saturday, Australia*, <sup>4</sup>*Department of Cardiology, St Vincent's Hospital, Sydney, Australia*, <sup>5</sup>*Department of Cardiology, Alfred Health, Baker Institute, Melbourne, Australia*

**(697) What is the Role of Angiogenesis Markers in Cardiac Allograft Vasculopathy Following Heart Transplantation?;** L. Holzhauser, T. Imamura, T. Riley, J. Powers, C. Murks, B. Chung, V. Jeevanandam, A. Nguyen, N. Narang, I. Ebong, N. Sandeep, J. Raikhelkar, B. Smith, G. Sayer, G. Kim, F. Alenghat, N. Uriel. *University of Chicago, Chicago, IL*

**(698) Effect of Heart Rate on Early Progression of Cardiac Allograft Vasculopathy: A Prospective Study Using Highly Automated 3-D Optical Coherence Tomography Analysis;** M. Pazdernik<sup>1</sup>, D. Wichterle<sup>1</sup>, Z. Chen<sup>2</sup>, H. Zhang<sup>2</sup>, A. Wahle<sup>2</sup>, J. Kautzner<sup>1</sup>, V. Melenovsky<sup>1</sup>, I. Malek<sup>1</sup>, V. Karmazin<sup>1</sup>, H. Bedanova<sup>3</sup>, E. Ozabalova<sup>3</sup>, A. Tomasek<sup>3</sup>, T. Kovarnik<sup>4</sup>, M. Sonka<sup>2</sup>. <sup>1</sup>*IKEM, Prague, Czech Republic*, <sup>2</sup>*Iowa Institute for Biomedical Imaging, University of Iowa, Iowa City, IA*, <sup>3</sup>*Cardiovascular and Transplantation Surgery, Brno, Czech Republic*, <sup>4</sup>*General University Hospital in Prague, Prague, Czech Republic*

**(699) A Single Center Analysis of Graft Vasculopathy Post Pregnancy in the Heart Transplant Recipient;** S. Adams, M. Wigger. *Heart Transplant, Vanderbilt, Nashville, TN*

**(700) Does Cytomegalovirus Truly Increase Cardiac Allograft Vasculopathy via First-Year Intravascular Ultrasound after Heart Transplant in the Tacrolimus Era?;** S. Dimbil, M. Kittleson, J. Patel, D. Geft, R. Cheng, R. Levine, T. Sato, L. Czer, B. Azarbal, R. Zabner, P. Zakowski, J. A. Kobashigawa. *Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA*

**(701) 1-Year Coronary IVUS in Heart Transplant Recipient Fails to Predict 10-Year Cardiovascular Mortality;** A. Verde<sup>1</sup>, I. Bossi<sup>1</sup>, A. Iconelli<sup>2</sup>, G. Masciocco<sup>1</sup>, L. D'Angelo<sup>1</sup>, M. Varrenti<sup>1</sup>, C. Santolamazza<sup>1</sup>, A. Giglio<sup>1</sup>, E. Perna<sup>1</sup>, G. Foti<sup>1</sup>, A. Garascia<sup>1</sup>, M. Cipriani<sup>1</sup>, E. Ammirati<sup>1</sup>, M. Frigerio<sup>1</sup>. <sup>1</sup>*De Gasperis Cardio Center, ASST Big Metropolitan Hospital Niguarda, Milano, Italy*, <sup>2</sup>*Department of Cardiovascular and Thoracic Sciences, Catholic University of the Sacred Heart, Roma, Italy*

**(702) Novel Intravascular Ultrasound Measurements to Assess for Coronary Allograft Vasculopathy in Patients after Orthotopic Heart Transplant;** T. J. Fendler<sup>1</sup>, D. M. Safley<sup>1</sup>, A. Kao<sup>2</sup>, B. A. Austin<sup>1</sup>, A. Borkon<sup>3</sup>, H. Brandt<sup>4</sup>, K. F. Kennedy<sup>4</sup>, B. W. Sperry<sup>1</sup>. <sup>1</sup>*Cardiovascular Diseases, St. Luke's Mid America Heart Institute / UMKC, Kansas City, MO*, <sup>2</sup>*Cardiovascular Diseases, St. Luke's Mid America Heart Institute / UMKC, Kansas City, MO*, <sup>3</sup>*Cardiothoracic Surgery, St. Luke's Mid America Heart Institute, Kansas City, MO*, <sup>4</sup>*Cardiovascular Diseases, St. Luke's Mid America Heart Institute, Kansas City, MO*

**(705) The Role of Transpulmonary Gradient and Mean Pulmonary Artery Pressure in Risk Stratification of Heart Transplant Candidates with Pulmonary Hypertension;** L. K. Truby, R. Agarwal, S. D. Russell, C. B. Patel, J. G. Rogers. *Duke University Medical Center, Durham, NC*

**(706) High Intra-Patient Variability of Echocardiographic Parameters is Associated with Heart Transplantation Outcomes: Report of a Real-World Experience;** Y. Peled<sup>1</sup>, M. Feinberg<sup>1</sup>, J. Lavee<sup>1</sup>, O. Vatury<sup>1</sup>, I. Hay<sup>1</sup>, S. Ben Zekry<sup>1</sup>, N. Shlomo<sup>2</sup>, R. Koperstein<sup>1</sup>, E. Schwammenthal<sup>1</sup>. <sup>1</sup>*Sheba Medical Center Tel Hashomer and Tel-Aviv University, Ramat Gan, Israel*, <sup>2</sup>*Israeli Association for Cardiovascular Trials, Ramat Gan, Israel*

**(707) Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients (IronIC): Rationale and Design of a Randomized, Controlled Trial;** K. V. Brautaset, C. M. Østby, T. Vartdal, K. Rolid, E. Gude, A. K. Andreassen, L. Gullestad, K. Broch. *Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway*

**(708) Implantable Cardioverter-Defibrillators in Heart Transplant Recipients with Allograft Failure;** E. M. DeFilippis<sup>1</sup>, A. R. Garan<sup>1</sup>, R. C. Givens<sup>1</sup>, L. K. Truby<sup>2</sup>, F. Latif<sup>1</sup>, S. W. Restaino<sup>1</sup>, K. Takeda<sup>1</sup>, H. Takayama<sup>1</sup>, Y. Naka<sup>1</sup>, P. C. Colombo<sup>1</sup>, M. A. Farr<sup>1</sup>, V. K. Topkara<sup>1</sup>. <sup>1</sup>*Columbia University Medical Center, New York, NY*, <sup>2</sup>*Duke University Medical Center, Durham, NC*

**(709) Outcome after Heart Transplantation in High-Urgent Listed Patients on LVAD: Impact of Type of Complication;** U. Boeken, C. Boettger, A. Mehdiani, A. Albert, B. Sowinski, D. Saeed, H. Aubin, R. Westenfeld, P. Akhyari, A. Lichtenberg. *Cardiovascular Surgery, University Hospital, Duesseldorf, Germany*

**(710) Impact of High-Urgent Status on Outcome after Use of Undersized Donors for Orthotopic Heart Transplantation;** U. Boeken, P. Akhyari, A. Albert, B. Sowinski, H. Dalyanoglu, R. Westenfeld, D. Saeed, H. Aubin, A. Mehdiani, A. Lichtenberg. *Cardiovascular Surgery, University Hospital, Duesseldorf, Germany*

**(711) Biopsy-Negative Rejection Late after Heart Transplantation: Impact on Long-Term Outcome;** A. Wolfson, M. Kittleson, J. Patel, E. Kransdorf, R. Cole, R. Levine, S. Dimbil, A. Lam, L. Czer, A. Hage, J. Chung, J. Moriguchi, J. A. Kobashigawa. *Cedars-Sinai Smidt Heart Institute, Los Angeles, CA*

**(712) Prevalence of Iron Deficiency in Heart Transplant Recipients;** K. Brautaset, C. M. Østby, G. Tjønnås, E. Gude, A. K. Andreassen, L. Gullestad, K. Broch. *Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway*

**(713) Does Cell-Free DNA Detect the Development of De Novo Donor Specific Antibodies;** J. A. Kobashigawa<sup>1</sup>, J. Patel<sup>1</sup>, E. Kransdorf<sup>1</sup>, D. Chang<sup>1</sup>, M. Kittleson<sup>1</sup>, S. Dimbil<sup>1</sup>, R. Levine<sup>1</sup>, S. Sana<sup>1</sup>, A. Wolfson<sup>1</sup>, L. Czer<sup>1</sup>, M. Hamilton<sup>1</sup>, R. Woodward<sup>2</sup>, F. Esmailian<sup>1</sup>. <sup>1</sup>*Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA*, <sup>2</sup>*CareDx, Inc., Brisbane, CA*

- (714) Efficacy and Safety of Idarucizumab for Rapid Reversal from Dabigatran in Patients Undergoing Orthotopic Heart Transplantation;** I. Kim<sup>1</sup>, H. Kim<sup>1</sup>, W. Chang<sup>1</sup>, J. Kim<sup>1</sup>, N. Park<sup>1</sup>, J. Youn<sup>2</sup>, S. Choi<sup>1</sup>, S. Jun<sup>1</sup>, Y. Cho<sup>1</sup>, H. Yoon<sup>1</sup>, C. Nam<sup>1</sup>, S. Han<sup>1</sup>, S. Hur<sup>1</sup>, H. Park<sup>1</sup>. <sup>1</sup>Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of, <sup>2</sup>Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Daegu, Korea, Republic of
- (715) Use of dd-cfDNA in Real World Practice: Single Center Experience;** J. Smith<sup>1</sup>, J. Fuentes<sup>1</sup>, T. Khuu<sup>1</sup>, W. Carpenter<sup>1</sup>, D. Cruz<sup>1</sup>, M. Cadeiras<sup>2</sup>, M. C. Deng<sup>1</sup>, E. C. DePasquale<sup>1</sup>. <sup>1</sup>UCLA, Los Angeles, CA, <sup>2</sup>UC Davis, Sacramento, CA
- (716) Heart Transplantation Outcomes in Liver Cirrhosis: Influence of Ascites on Post-Transplantation Survival;** H. Kim, J. Kim, S. Lee, H. Joo, K. Yoo, Y. Youn. Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
- (717) Trends in Post-Heart Transplant Biopsies for Graft Rejection versus Non-Rejection;** A. K. Jamil<sup>1</sup>, T. Nisar<sup>1</sup>, A. Afzal<sup>2</sup>, A. Y. Kluger<sup>3</sup>, J. Felius<sup>1</sup>, D. Wencker<sup>2</sup>, P. Kale<sup>2</sup>, S. A. Hall<sup>2</sup>. <sup>1</sup>Baylor Scott & White Research Institute, Dallas, TX, <sup>2</sup>Baylor University Medical Center, Dallas, TX, <sup>3</sup>Baylor Heart and Vascular Institute, Dallas, TX
- (718) Back to ECG in Predicting Graft Dysfunction in the Era of Molecular Assays: Einthoven's Revenge?;** M. Masetti, E. Presta, F. Corazza, N. Laganà, S. Boschi, L. Giovannini, A. Russo, F. Grigioni, L. Potena. Cardiovascular Department, Bologna University Hospital, Bologna, Italy
- (719) Early Detection of Imminent Morbidity after Heart Transplantation (htx) by Means of Procalcitonin (PCT) combined with Highly Sensitive Cardiac Troponin T (hs-cTNT);** U. Boeken, A. Mehdiani, A. Albert, H. Aubin, H. Dalyanoglu, R. Westenfeld, B. Sowinski, D. Saeed, P. Akhyari, A. Lichtenberg. Cardiovascular Surgery, University Hospital, Duesseldorf, Germany
- (720) Non-Invasive Venous Waveform Analysis (NIVA) for Monitoring Pulmonary Capillary Wedge Pressure Post-Orthotopic Heart Transplantation: A Proof of Concept Study;** B. D. Alvis<sup>1</sup>, T. S. Hopper<sup>2</sup>, M. Polcz<sup>3</sup>, K. M. Hocking<sup>3</sup>, J. Whitfield<sup>4</sup>, C. Brophy<sup>3</sup>, S. Eagle<sup>1</sup>, J. Lindenfeld<sup>5</sup>. <sup>1</sup>Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, <sup>2</sup>Medical School, Vanderbilt University College of Medicine, Nashville, TN, <sup>3</sup>Surgery, Vanderbilt University Medical Center, Nashville, TN, <sup>4</sup>Volumetrix, LLC, Nashville, TN, <sup>5</sup>Cardiology, Vanderbilt University Medical Center, Nashville, TN
- (721) Does Antibody-Mediated Rejection in the First-Month after Heart Transplant Lead to Poor Longer-Term Outcome?;** E. Kransdorf, J. Patel, M. Kittleson, D. H. Chang, R. Levine, S. Dimbil, A. Bitterman, A. Velleca, L. Czer, J. Moriguchi, F. Esmailian, J. A. Kobashigawa. Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
- (722) Efficacy and Safety of Ivabradine Application in the Early Period after Heart Transplantation;** U. Boeken, A. Albert, A. Mehdiani, B. Sowinski, R. Westenfeld, H. Aubin, D. Saeed, P. Akhyari, A. Lichtenberg. Cardiovascular Surgery, University Hospital, Duesseldorf, Germany
- (723) Inflammatory Cardiomyopathy (ICM): Long-Term Survival after Heart Transplantation or Implantation of Mechanical Circulatory Support;** S. Esmaily<sup>1</sup>, E. Bobbio<sup>1</sup>, E. Bollano<sup>2</sup>, P. Dahlberg<sup>2</sup>, S. Bartfay<sup>2</sup>, G. Dellgren<sup>3</sup>, K. Karason<sup>3</sup>. <sup>1</sup>Sahlgrenska Academy, Institute of Medicine, Gothenburg, Sweden, <sup>2</sup>Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, <sup>3</sup>Department of Transplantation, Sahlgrenska University Hospital, Gothenburg, Sweden
- (724) Use of dd-cfDNA in Multiorgan Transplantation;** E. C. DePasquale, J. Smith, J. Fuentes, T. Khuu, M. C. Deng. UCLA, Los Angeles, CA
- (725) Idarucizumab for the Reversal of Dabigatran in Patients Undergoing Heart Transplantation;** J. M. Van Keer, T. Vanassche, W. Droogne, S. Rex, F. Rega, J. Van Cleemput, P. Verhamme. Cardiology, University Hospitals Leuven, Leuven, Belgium
- (726) Incidence and Effect of VA-ECMO Use in Primary Graft Failure Patients after Heart Transplantation;** M. Kawabori<sup>1</sup>, M. A. Mastroianni<sup>2</sup>, J. A. Reich<sup>1</sup>, Y. Zhan<sup>1</sup>, K. G. Warner<sup>1</sup>, H. Rastegar<sup>1</sup>, A. Vest<sup>1</sup>, D. Denofrio<sup>1</sup>, F. Y. Chen<sup>1</sup>, G. S. Couper<sup>1</sup>. <sup>1</sup>Tufts Medical Center, Boston, MA, <sup>2</sup>Tufts University School of Medicine, Boston, MA
- (727) Heightened Immune Response in Heart Transplant Patients Surviving Severe Primary Graft Dysfunction;** J. Patel, M. Kittleson, D. Chang, E. Kransdorf, R. Levine, S. Dimbil, R. Sharoff, L. Czer, A. Hage, F. Esmailian, J. A. Kobashigawa. Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA
- (728) International Society for Heart and Lung Transplantation Defined Primary Graft Dysfunction in Heart Transplant Recipients Predicts 30-Day Mortality;** N. F. Smith<sup>1</sup>, S. Salehi Omran<sup>2</sup>, M. V. Genuardi<sup>2</sup>, E. Horn<sup>3</sup>, M. Keebler<sup>2</sup>, G. Hickey<sup>4</sup>, R. Kormos<sup>4</sup>. <sup>1</sup>University of Pittsburgh School of Medicine, Pittsburgh, PA, <sup>2</sup>University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>3</sup>University of Pittsburgh School of Pharmacy, Pittsburgh, PA, <sup>4</sup>University of Pittsburgh School of Medicine; University of Pittsburgh Medical Center, Pittsburgh, PA

**(729) Cardiac Transplantation Primary Graft Dysfunction Incidence and Predictors;** L. Xie, S. S. Nathan, R. Radovancevic, M. Jumean, B. Kar, I. D. Gregoric. *Department of Advanced Cardiopulmonary Therapies and Transplantation, The Univ. of Texas Health Science Center-Houston, Houston, TX*

**(730) The Interaction of Amiodarone and LVAD in Severe Primary Graft Dysfunction;** T. Chinnadurai<sup>1</sup>, W. Hanif<sup>1</sup>, S. R. Patel<sup>1</sup>, D. Sims<sup>1</sup>, O. Saeed<sup>1</sup>, S. Murthy<sup>1</sup>, J. Shin<sup>1</sup>, S. Vukelic<sup>1</sup>, S. Forest<sup>2</sup>, W. Jakobleff<sup>2</sup>, D. Goldstein<sup>2</sup>, U. P. Jorde<sup>1</sup>. <sup>1</sup>*Cardiology, Montefiore Medical Center, Bronx, NY*, <sup>2</sup>*Cardiothoracic, Montefiore Medical Center, Bronx, NY*

**(731) Treatment with a Statin or Spironolactone is Associated with a Reduced Risk for Primary Graft Dysfunction and Mortality;** Y. Peled, E. Ram, D. Freimark, Y. Kassif, N. Shlomo, A. Kogan, E. Maor, R. Klempfner, J. Lavee. *Sheba Medical Center Tel Hashomer and Tel-Aviv University, Ramat Gan, Israel*

**(732) Cardiac Biomarkers for Early Identification of Primary Graft Dysfunction;** V. Jernryd<sup>1</sup>, C. Metzch<sup>2</sup>, G. J. Smith<sup>3</sup>, B. Andersson<sup>4</sup>, J. Nilsson<sup>5</sup>. <sup>1</sup>*Clinical Sciences Lund, Cardiothoracic Surgery, Lund University and Skane University Hospital, Lund, Sweden*, <sup>2</sup>*Clinical Sciences Lund, Anesthesiology, Lund University and Skane University Hospital, Lund, Sweden*, <sup>3</sup>*Clinical Sciences Lund, Cardiology, Lund University and Skane University Hospital, Lund, Sweden*, <sup>4</sup>*Clinical Sciences Lund, Surgery, Lund University and Skane University Hospital, Lund, Sweden*, <sup>5</sup>*Skanes University Hospital Cardiothoracic Surgery, Lund, Sweden*

**(733) Preoperative Amiodarone and Primary Graft Dysfunction in Heart Transplantation;** A. Servais<sup>1</sup>, S. Bowman<sup>1</sup>, S. Lundgren<sup>2</sup>, D. Klepser<sup>2</sup>, H. Brink<sup>1</sup>. <sup>1</sup>*Nebraska Medicine, Omaha, NE*, <sup>2</sup>*University of Nebraska Medical Center, Omaha, NE*

**(734) Graft Recovery Estimation at Transplantation (GREAT) Algorithm Identifies the Most Important Risk Factors for Primary Graft Dysfunction for Heart Transplantation;** M. Leacche<sup>1</sup>, P. Wilton<sup>2</sup>, G. Marco<sup>1</sup>, S. Fitch<sup>1</sup>, N. Manandhar Shrestha<sup>1</sup>, M. Dickinson<sup>1</sup>, T. Boeve<sup>1</sup>, S. Jovinge<sup>2</sup>. <sup>1</sup>*Fredrik Meijer Heart and Vascular Institute, Fredrik Meijer Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI*, <sup>2</sup>*Fredrik Meijer Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI*

**(735) Does the Model for End-Stage Liver Disease Predict Primary Graft Dysfunction?;** R. Levine, J. Patel, M. Kittleson, D. Geft, E. Kransdorf, S. Dimbil, E. Passano, S. Sana, L. Czer, A. Hage, D. Ramzy, J. A. Kobashigawa. *Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA*

**(736) 1-Year Graft Function and Hemodynamics in Heart Transplant Patients Who Experienced Severe Primary Graft Dysfunction;** K. Takeda<sup>1</sup>, M. A. Farr<sup>1</sup>, A. R. Garan<sup>1</sup>, V. Topkara<sup>1</sup>, C. Marisa<sup>2</sup>, L. Witer<sup>1</sup>, S. Restaino<sup>1</sup>, M. Yuzefpolskaya<sup>1</sup>, P. C. Colombo<sup>1</sup>, H. Takayama<sup>1</sup>, Y. Naka<sup>1</sup>. <sup>1</sup>*Columbia University, NY, NY*, <sup>2</sup>*Columbia, New York, NY*

**(737) Correlation between Ischemia Time and Primary Graft Dysfunction in Cardiac Transplant at a Brazilian Center;** F. R. Walter, C. B. Cunha, D. L. Ferraz, F. A. Figueira, I. T. Silva, R. M. Tchaick, A. D. Júnior, J. D. Júnior, J. P. Oliveira, A. P. Melo, R. M. Carneiro, P. J. Silva, K. S. Nascimento, T. M. Caldas, S. S. D'Azevedo, T. L. Silva, V. S. Monteiro. *Departamento de Cirurgia Cardiovascular, Transplante Cardíaco e Assistência Circulatória Mecânica, Instituto de Medicina Integral Professor Fernando Figueira - IMIP, Recife, Brazil*

Wednesday, April 3, 2019

6:00 PM - 7:15 PM

**POSTER SESSION 1: NURSING, HEALTH SCIENCES, ALLIED HEALTH**

**Room: Gardenia 2**

**Poster Discussants:**

Flavio Epstein, PhD, Kaiser Permanente, San Francisco, CA, USA

Margaret Fregoso, NP, Inova Fairfax Hospital, Falls Church, VA, USA

Donna Hickling, Queensland Health, Brisbane, Australia

Angela Velleca, RN, BSN, CCTC, Cedars Sinai Heart Institute, Los Angeles, CA, USA

**(738) *Review of Lung Transplantation for Patients 65 Years and Older with Idiopathic Pulmonary Fibrosis in Ireland*; I. Byrne, P. Grehan. *Physiotherapy, Mater Misericordiae University Hospital, Dublin, Ireland***

**(739) *The Importance of Physiotherapy in Promoting Bone Health for Children Supported by VAD: Early Mobilisation and Weight Bearing Guidelines*; K. Caulfield. *Paediatric Physiotherapy, Freeman Hospital, Newcastle upon Tyne, United Kingdom***

**(740) *Distal Intestinal Obstruction Syndrome and Constipation Following Lung Transplantation, Incidence and Nutritional Consequences*; S. Murphy<sup>1</sup>, J. O'Mahony<sup>1</sup>, M. McKiernan<sup>1</sup>, S. Doyle<sup>2</sup>, J. J. Egan<sup>3</sup>. <sup>1</sup>*Nutrition and Dietetics, Mater University Hospital, Dublin, Ireland*, <sup>2</sup>*Dublin Institute of Technology, Dublin, Ireland*, <sup>3</sup>*Mater University Hospital, Dublin, Ireland***

**(741) *Anticholinergic Burden and Cognitive Impairment in Patients with Heart Failure*; J. Salyer<sup>1</sup>, L. Sargent<sup>1</sup>, C. Tirado<sup>2</sup>, M. P. Flattery<sup>3</sup>, K. B. Shah<sup>3</sup>. <sup>1</sup>*Adult Health, Virginia Commonwealth University, Richmond, VA*, <sup>2</sup>*Psychology, Virginia Commonwealth University, Richmond, VA*, <sup>3</sup>*Pauley Heart Center, VCUHealth, Richmond, VA***

**(742) *Showering with the Driveline Exit Site Exposed to Well Water Does Not Increase Rates of Driveline Exit Site Infection*; C. Ballew<sup>1</sup>, M. Young<sup>2</sup>, E. Burns<sup>2</sup>, S. Mazimba<sup>2</sup>. <sup>1</sup>*University of Virginia Health System, Ivy, VA*, <sup>2</sup>*University of Virginia Health System, Charlottesville, VA***

**(743) *International Practices for Driveline Exit Site Care and Infection Prevention in Ventricular Assist Devices*; S. E. Schroeder<sup>1</sup>, B. Shay<sup>2</sup>, T. Schlöglhofer<sup>3</sup>, J. Casida<sup>4</sup>. <sup>1</sup>*MCS Team, Cardiothoracic Surgery, Bryan Heart, Lincoln, NE*, <sup>2</sup>*Advanced Heart Failure/MCS, Christiana Care Health System, Newark, DE*, <sup>3</sup>*Division of Cardiac Surgery, Center of Medical Physics and Biomedical Engineering, Medical Univ of Vienna, Vienna, Austria*, <sup>4</sup>*School of Nursing, Faculty Associate, John Hopkins Univ, Baltimore, MD***

**(744) *The Organ Care System Training Manual for Hearts Donated after Circulatory Death: The Experience of One UK Centre after 50 Successful DCD Heart Transplants*; C. Ellis, J. Baxter, R. Quigley, S. Messer, A. Page, E. Pavlushkov, S. Large, S. Tsui, P. Catarino, M. Berman, K. Morley. *Transplant Unit, Royal Papworth Hospital, Cambridge, United Kingdom***

**(745) *Ventricular Assist Device Therapy Evaluation and Implantation Timing: A Destination Therapy Center's Perspective*; S. E. Schroeder<sup>1</sup>, J. A. Steuter<sup>2</sup>. <sup>1</sup>*MCS Team, Cardiothoracic Surgery, Bryan Heart, Lincoln, NE*, <sup>2</sup>*Division of Cardiology, Bryan Heart, Lincoln, NE***

**(746) *A Qualitative Analysis of Adolescent and Young Adult Decision Making about Heart Transplant*; C. Smith<sup>1</sup>, V. Miller<sup>2</sup>, K. Uzark<sup>1</sup>, R. Lowery<sup>1</sup>, K. R. Schumacher<sup>1</sup>, M. K. Cousino<sup>1</sup>. <sup>1</sup>*Pediatrics, C.S. Mott Children's Hospital, Ann Arbor, MI*, <sup>2</sup>*Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA***

**(747) *Establishing a Nursing-Led Ex-Vivo Lung Perfusion Program: A Primer*; D. Miller, N. Wrenn, M. Tran, J. Murala, K. Gaskie, A. Banga, F. Torres, M. Wait. *UT Southwestern Medical Center, Dallas, TX***

**(748) *Professional Employment Following Thoracic Transplantation*; C. Kugler<sup>1</sup>, S. Jobst<sup>1</sup>, J. Schaefer<sup>1</sup>, H. Spaderna<sup>2</sup>, C. Kleiser<sup>1</sup>. <sup>1</sup>*Faculty for Medicine, Albert-Ludwigs-Univ Freiburg, Freiburg, Germany*, <sup>2</sup>*Health Psychology, Univ Trier, Freiburg, Germany***



**(749) Relationship of Spiritual Wellbeing and Depressive Symptoms for Patients with a Left-Ventricular Assist Device (LVAD);** K. E. Sandau<sup>1</sup>, C. S. Lee<sup>2</sup>, R. Garberich<sup>3</sup>, C. E. Weaver<sup>4</sup>, S. Joseph<sup>5</sup>, S. A. Hall<sup>5</sup>, S. Carey<sup>5</sup>, J. A. Cowger<sup>6</sup>, S. P. Chaudhry<sup>7</sup>, S. E. Schroeder<sup>8</sup>, R. O. Hoffman, III<sup>9</sup>, D. Feldman<sup>9</sup>, G. Conway<sup>9</sup>, E. Y. Birati<sup>10</sup>, M. Soni<sup>11</sup>, J. Marble<sup>12</sup>, M. S. Kunz<sup>13</sup>, K. M. Storey<sup>13</sup>, K. M. Faulkner<sup>14</sup>, P. Eckman<sup>3</sup>. <sup>1</sup>Bethel University, St. Paul, MN, <sup>2</sup>Boston College Connell School of Nursing, Boston, MA, <sup>3</sup>Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN, <sup>4</sup>Abbott Northwestern Hospital/Minneapolis Heart Institute, Minneapolis, MN, <sup>5</sup>Baylor University Medical Center, Dallas, TX, <sup>6</sup>Henry Ford Hospitals, Detroit, MI, <sup>7</sup>St. Vincent Heart Center/St. Vincent Indianapolis, Indianapolis, IN, <sup>8</sup>Bryan Heart Center, Lincoln, NE, <sup>9</sup>University of Cincinnati Medical Center, Cincinnati, OH, <sup>10</sup>Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, <sup>11</sup>Department of Medicine, University of Pennsylvania, University of Pennsylvania, PA, <sup>12</sup>University of Pennsylvania, Philadelphia, PA, <sup>13</sup>Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, MN, <sup>14</sup>Boston College Connell School of Nursing, Chestnut Hill, MA

**(750) Describing the End of Life Experience of Patients Supported with a Life-Sustaining Left Ventricular Assist Device (LVAD) as Bridge to Transplantation in a UK Centre;** D. Weiland, M. McKenna. Specialist Palliative Care Team, Freeman Hospital, Newcastle upon Tyne, United Kingdom

**(751) Vanishing MCS Caregiver: Insights into the Impact of Machines on the Caring Relationship;** B. Coleman<sup>1</sup>, B. Martinez<sup>1</sup>, H. Barone<sup>2</sup>, M. Williams<sup>1</sup>, H. Aronow<sup>1</sup>, K. Sandau<sup>1</sup>, L. Ansryan<sup>1</sup>, J. Felice<sup>1</sup>, J. Hajj<sup>1</sup>, L. Olanisa<sup>1</sup>, N. Huie<sup>1</sup>, A. Fishman<sup>1</sup>, M. Olman<sup>1</sup>, M. White<sup>2</sup>, J. Pamu<sup>1</sup>, D. H. Chang<sup>2</sup>. <sup>1</sup>Cedars-Sinai Medical Center, Los Angeles, CA, <sup>2</sup>Cedars-Sinai Smidt Heart Institute, Los Angeles, CA

**(752) Assessment of Pre-Transplant Perceptions during Transition to Lung Transplant;** L. N. Fessler<sup>1</sup>, K. W. Wright<sup>1</sup>, G. Pace<sup>1</sup>, S. Andrews<sup>2</sup>, M. Davis<sup>3</sup>, K. Raffensperger<sup>4</sup>, J. Seymour<sup>4</sup>, M. Lagergren<sup>5</sup>, N. West<sup>6</sup>, C. Merlo<sup>6</sup>, P. Shah<sup>6</sup>. <sup>1</sup>Surgery, Johns Hopkins Hospital, Baltimore, MD, <sup>2</sup>Psychiatry, Johns Hopkins Hospital, Baltimore, MD, <sup>3</sup>Nutrition, Johns Hopkins Hospital, Baltimore, MD, <sup>4</sup>Johns Hopkins Hospital, Baltimore, MD, <sup>5</sup>Social Work, Johns Hopkins Hospital, Baltimore, MD, <sup>6</sup>Pulmonary, Johns Hopkins Hospital, Baltimore, MD

**(753) Self-Care Management after Ventricular Assist Device Implantation: Recipient Needs and Experiences after Hospital Discharge;** W. Alonso<sup>1</sup>, E. Mollard<sup>1</sup>, L. Zimmerman<sup>1</sup>, S. Lundgren<sup>2</sup>, A. Clark<sup>3</sup>, B. Pozehl<sup>1</sup>. <sup>1</sup>College of Nursing, University of Nebraska Medical Center, Omaha, NE, <sup>2</sup>College of Medicine, University of Nebraska Medical Center, Omaha, NE, <sup>3</sup>Cardiothoracic Surgery, Nebraska Medicine, Omaha, NE

**(754) Using Patient Feedback to Drive Psychological Care in Awake Extracorporeal Life Support;** M. Sanchez<sup>1</sup>, A. Simon<sup>2</sup>, M. Carby<sup>3</sup>, A. Reed<sup>3</sup>. <sup>1</sup>Psychological Medicine, Royal Brompton & Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom, <sup>2</sup>Director, MCS and Cardiothoracic Transplantation, Royal Brompton & Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom, <sup>3</sup>Lung Transplantation, Royal Brompton & Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom

Wednesday, April 3, 2019

6:00 PM - 7:15 PM

## **POSTER SESSION 1: PHARMACY AND PHARMACOLOGY**

Room: Gardenia 1

### **Poster Discussants:**

Edward Horn, PharmD, University of Pittsburgh, Pittsburgh, PA, USA

Amanda Ingemi, PharmD, Sentara Norfolk General Hospital, Norfolk, VA, USA

**(755) Direct Oral Anticoagulants: An Evaluation of the Safety and Efficacy in Cardiothoracic Transplant Recipients;** T. Pasley, A. Logan, A. Brueckner, L. Bowman-Anger, A. Silverman, A. Rumore. *Tampa General Hospital, Tampa, FL*

**(756) Outcomes Associated with Opioid Use in Cardiothoracic Transplant Recipients;** A. J. Brueckner, A. T. Logan, A. L. Rumore, L. J. Bowman. *Pharmacy, Tampa General Hospital, Tampa, FL*

**(757) Effect of Glecaprevir-Pibrentasvir on Tacrolimus Dosage Requirements in Cardiac Transplant Recipients;** T. C. Lewis, C. Gidea, A. Reventovich, N. Moazami. *Transplant Institute, NYU Langone Health, New York, NY*

**(758) The Efficacy of Intensive Monitoring of Serum Tacrolimus Level Post Itraconazole Cessation in Preventing Rejection after Heart Transplant;** N. Song<sup>1</sup>, K. Muthiah<sup>1</sup>, J. Phan<sup>1</sup>, K. Kearney<sup>1</sup>, C. Pereira Kessler Iglesias<sup>1</sup>, F. Burrows<sup>2</sup>, L. Carlos<sup>2</sup>, C. Hayward<sup>1</sup>, A. Keogh<sup>1</sup>, A. Jabbour<sup>1</sup>, E. Kotlyar<sup>1</sup>, P. Macdonald<sup>1</sup>. <sup>1</sup>Heart Transplant Unit, St Vincent's Hospital, Sydney, Darlinghurst, Australia, <sup>2</sup>Pharmacy, St Vincent's Hospital, Sydney, Darlinghurst, Australia

**(759) Association of Time to Therapeutic Calcineurin Inhibitor (CNI) Levels to Biopsy-Proven Acute Rejection (BPAR) after Heart Transplantation;** A. Patel<sup>1</sup>, S. K. Ahmed<sup>2</sup>, M. W. Soto-Arenall<sup>1</sup>, P. C. Patel<sup>1</sup>, D. S. Yip<sup>1</sup>. <sup>1</sup>Mayo Clinic in Florida, Jacksonville, FL, <sup>2</sup>Montefiore Medical Center, New York City, NY

**(760) Kidney Function in Lung Transplant Patients Receiving IV Tacrolimus;** G. Waldman<sup>1</sup>, A. Feist<sup>2</sup>, L. Awdishu<sup>2</sup>, G. Yung<sup>2</sup>, K. Afshar<sup>2</sup>. <sup>1</sup>Massachusetts General Hospital, Boston, MA, <sup>2</sup>UC San Diego Health, San Diego, CA

**(761) Evaluation of Outpatient Anticoagulation Bridging after Left Ventricular Assist Device (LVAD) Implantation;** R. Rainess<sup>1</sup>, L. Alderman<sup>1</sup>, A. Butler<sup>2</sup>, T. Cicci<sup>3</sup>, M. Yoder<sup>3</sup>, B. Pisani<sup>4</sup>. <sup>1</sup>Wingate University School of Pharmacy, Wingate, NC, <sup>2</sup>Campbell University College of Pharmacy & Health Science, Buies Creek, NC, <sup>3</sup>Acute Care Services Pharmacy, Wake Forest Baptist Medical Center, Winston-Salem, NC, <sup>4</sup>Professor of Medicine, Cardiology, Wake Forest Baptist Medical Center, Winston-Salem, NC

**(762) Use of Cangrelor during Venoarterial Extracorporeal Membrane Oxygenation Following Percutaneous Coronary Intervention;** A. M. Ciolek<sup>1</sup>, K. Ma<sup>1</sup>, D. L. Jennings<sup>1</sup>, A. R. Garan<sup>2</sup>, A. Eisenberger<sup>3</sup>. <sup>1</sup>Pharmacy, NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, NY, <sup>2</sup>Medical Cardiology, Columbia University, New York, NY, <sup>3</sup>Hematology, Columbia University, New York, NY

**(763) An Evaluation of Warfarin Dose Changes after Discharge from Mechanical Circulatory Support Device Implantation;** R. H. Cosgrove<sup>1</sup>, R. L. Basken<sup>1</sup>, J. R. Finger<sup>1</sup>, J. L. Deangelo<sup>1</sup>, R. G. Smith<sup>2</sup>, T. Kazui<sup>3</sup>, Z. Khalpey<sup>3</sup>. <sup>1</sup>Department of Pharmacy Services, Banner University Medical Center - Tucson, Tucson, AZ, <sup>2</sup>Artificial Heart Department, Banner University Medical Center - Tucson, Tucson, AZ, <sup>3</sup>Division of Cardiothoracic Surgery, University of Arizona, Tucson, AZ

Wednesday, April 3, 2019

6:00 PM - 7:15 PM

**POSTER SESSION 1: JUNIOR FACULTY CASE REPORTS: INFECTIOUS DISEASES**

**Room: Banda Sea 2**

**Poster Discussants:**

Shalika Katugaha, MD, INOVA Fairfax Hospital, Falls Church, VA, USA

Me-Linh Luong, MD, St. Luc Hospital, Montreal, Canada

Erik Verschuuren, MD, PhD, University Medical Centre Groningen, Groningen, Netherlands

**(1245) *Letemovir for Prevention of CMV Infection after Lung Transplantation***; B. C. Keller<sup>1</sup>, P. Burcham<sup>2</sup>, S. Kirkby<sup>1</sup>, D. R. Nunley<sup>1</sup>, I. Poojary<sup>1</sup>, M. Howsare<sup>1</sup>, B. A. Whitson<sup>3</sup>, M. Lustberg<sup>1</sup>. <sup>1</sup>*Internal Medicine, The Ohio State University, Columbus, OH*, <sup>2</sup>*Pharmacology, The Ohio State University, Columbus, OH*, <sup>3</sup>*Cardiac Surgery, The Ohio State University, Columbus, OH*

**(1246) *Previous Contaminant, Now Emerging Pathogen***; A. Arjuna, S. Chandrashekar, E. Rodriguez, A. Pelaez. *Pulmonary and Critical Care Medicine, University of Florida, Gainesville, FL*

**(1247) *Cardiac Transplantation as Salvage Therapy Following Bartonella henselae Infective Endocarditis***; W. Kuan<sup>1</sup>, K. Dulnuan<sup>2</sup>, M. Guglin<sup>1</sup>, A. Kolodziej<sup>1</sup>, H. El Haddad<sup>1</sup>, N. Rajagopalan<sup>1</sup>. <sup>1</sup>*University of Kentucky Healthcare, Lexington, KY*, <sup>2</sup>*University of Louisville, Louisville, KY*

**(1248) *An Unusual Case of Diffuse Lymphadenopathy in a Heart Transplant Recipient***; I. Selevany, P. Kim, H. Wang, E. Adler, B. Greenberg, S. Aslam. *University of California, San Diego, San Diego, CA*

**(1249) *Conundrum of Azole Resistance***; C. Rutherford, J. Kleinerova, P. Ging, D. G. Healy, O. MacEaney, M. M. Hannan, B. Lynch, J. J. Egan. *National Heart and Lung Transplant Centre, Mater Misericordiae University Hospital, Dublin, Ireland*

**(1250) *Strategy and Challenges for Performing Heart Transplants in Patients with Active Tuberculosis: A Case Report***; A. C. Mendes, L. C. Hastenteufel, M. B. Gazzana, M. D. Alves, G. Torres, R. Nazario, F. Scolari, N. Clausell, L. Goldraich. *Hospital de Clínicas Porto Alegre, Porto Alegre, Brazil*

**(1251) *Long Term Mechanical Circulatory Support Device and Disseminated Histoplasmosis - A Case Series***; V. Moorthy, M. Veerasamy, S. Lee, R. Grayburn, C. Fahlsing, J. de Sanctis. *Spectrum Health, Grand Rapids, MI*

**(1252) *Is PJP Prophylaxis Sufficient to Prevent Acute Toxoplasmosis in Solid Organ Transplant World?***; S. Nandavaram<sup>1</sup>, L. Benninger<sup>2</sup>, S. Chandrashekar<sup>2</sup>, A. Emtiazoo<sup>2</sup>, H. Alnuaimat<sup>2</sup>, T. Machuca<sup>3</sup>, M. Pipkin<sup>4</sup>, A. Shahmohammadi<sup>2</sup>, C. Lin<sup>2</sup>, V. Scheuble<sup>2</sup>, A. Pelaez<sup>2</sup>. <sup>1</sup>*Surgery, University of Kentucky, Lexington, KY*, <sup>2</sup>*Medicine, University of Florida, Gainesville, FL*, <sup>3</sup>*Surgery, University of Florida, Gainesville, FL*, <sup>4</sup>*Surgery, University of Florida, Gainesville, FL*

**(1253) *Donor-Derived Strongyloides Hyperinfection Syndrome in a Lung Transplant Recipient***; K. Ahmad<sup>1</sup>, O. Shlobin<sup>1</sup>, S. Aryal<sup>1</sup>, S. Nathan<sup>1</sup>, C. King<sup>1</sup>, A. Brown<sup>1</sup>, S. Katugaha<sup>2</sup>. <sup>1</sup>*Transplant, Inova Fairfax Medical Center, Falls Church, VA*, <sup>2</sup>*Infectious Disease, Inova Fairfax Medical Center, Falls Church, VA*

**(1254) *Fatal Scedosporium apiospermum Complex Left Ventricular Assist Device (LVAD) Infection Precipitating Pump Thrombosis***; S. J. Chung<sup>1</sup>, F. Y. Chan<sup>1</sup>, T. Tan<sup>2</sup>, J. Soon<sup>2</sup>, L. L. Teo<sup>3</sup>, D. K. Sim<sup>3</sup>, Y. Tan<sup>4</sup>, T. Tan<sup>1</sup>, B. Tan<sup>1</sup>, C. Sivathanan<sup>2</sup>. <sup>1</sup>*Department of Infectious Diseases, Singapore General Hospital, Singapore, Singapore*, <sup>2</sup>*Department of Cardiothoracic Surgery, National Heart Centre, Singapore, Singapore*, <sup>3</sup>*Department of Cardiology, National Heart Centre, Singapore, Singapore*, <sup>4</sup>*Department of Microbiology, Singapore General Hospital, Singapore, Singapore*

**(1255) *Cryptococcus Laurentii Hip Infection after Lung Transplant***; M. K. Kim<sup>1</sup>, W. Brown<sup>2</sup>, O. Shlobin<sup>2</sup>, C. King<sup>2</sup>, S. Aryal<sup>2</sup>, K. Ahmad<sup>2</sup>, A. Cochrane<sup>2</sup>, L. Marinak<sup>2</sup>, S. B. Katugaha<sup>3</sup>. <sup>1</sup>*Department of Medicine, Inova Fairfax Hospital, Falls Church, VA*, <sup>2</sup>*Inova Advanced Lung Disease and Transplant, Inova Fairfax Hospital, Falls Church, VA*, <sup>3</sup>*Infectious Diseases Physicians, Inc., Inova Fairfax Hospital, Falls Church, VA*

**(1256) *A Stealth Invader under CMV Cover***; N. Pempalung<sup>1</sup>, R. A. Miller<sup>2</sup>, B. D. Alexander<sup>2</sup>. <sup>1</sup>*Johns Hopkins University School of Medicine, Baltimore, MD*, <sup>2</sup>*Duke University Medical Center, Durham, NC*

**(1257) *Blastomycosis Necrotizing Pneumonia: Timing of Transplant Listing***; K. Pennington, M. Wylam, S. Peters, J. Scott, J. Stulak, R. Razonable, M. Brutinel, H. Sekiguchi, C. Kennedy. *Mayo Clinic, Rochester, MN*

**(1258) Feline Fevers!;** A. Arjuna, S. Chandrashekar, H. Alnuaimat, A. Pelaez, D. Schain. *Pulmonary and Critical Care Medicine, University of Florida, Gainesville, FL*

**(1259) Cardiac Aspergillosis in a Lung Transplant Recipient;** T. K. Rajab, S. Singh, H. Mallidi, H. Goldberg, A. E. Woolley. *Brigham and Women's Hospital, Boston, MA*

**(1260) Acute Myocarditis after Lung Transplantation;** J. E. Afonso<sup>1</sup>, I. Wozniak<sup>2</sup>, R. Carraro<sup>1</sup>, R. H. Teixeira<sup>2</sup>, L. T. Pires<sup>2</sup>, P. L. Camargo<sup>1</sup>, S. Mangini<sup>2</sup>. <sup>1</sup>*Lung Transplant, Albert Einstein Jewish Hospital, Sao Paulo, Brazil*, <sup>2</sup>*Heart Transplant, Albert Einstein Jewish Hospital, Sao Paulo, Brazil*

**(1261) A Case of Aspergillus Mural Endocarditis after Liver-Kidney Transplantation;** H. Choi<sup>1</sup>, G. Kim<sup>2</sup>, J. Youn<sup>3</sup>, Y. Yoon<sup>2</sup>, Y. Cho<sup>2</sup>, G. Cho<sup>2</sup>. <sup>1</sup>*Hallym Sacred Heart Hospital, Anyang, Korea, Republic of*, <sup>2</sup>*Seoul National University Bundang Hospital, Seongnam, Korea, Republic of*, <sup>3</sup>*Dongtan Sacred Heart Hospital, Hwaseong, Korea, Republic of*

**(1262) Carbapenem-Resistant Enterobacteriaceae Pneumonia Early after Single Lung Transplant;** S. El Hajj<sup>1</sup>, R. El-Lababidi<sup>1</sup>, M. Mooty<sup>2</sup>, M. Balkis<sup>2</sup>, F. Hamed<sup>3</sup>. <sup>1</sup>*Pharmacy, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates*, <sup>2</sup>*Infectious Diseases, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates*, <sup>3</sup>*Transplant Pulmonology, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates*

**(1263) Acute Severe Purulent Pericardial Effusion in Heart Transplantation;** P. Avellana, A. Ini, K. Waisten, D. Radlovachki, M. Ajzenszlos, W. Esteban, S. Belforte, L. Ahualli. *Hospital Cosme Argerich, Buenos Aires, Argentina*

**(1264) Cardiac Aspergillosis - 1 Year after Cardiac Transplant;** A. E. Woolley<sup>1</sup>, T. K. Rajab<sup>2</sup>, M. R. Mehra<sup>3</sup>, A. Coppolino<sup>4</sup>, E. L. Woodcome<sup>3</sup>, D. S. Page<sup>3</sup>, L. R. Baden<sup>1</sup>, S. K. Singh<sup>2</sup>. <sup>1</sup>*Infectious Diseases, Brigham and Womens Hospital, Boston, MA*, <sup>2</sup>*Cardiac Surgery, Brigham and Womens Hospital, Boston, MA*, <sup>3</sup>*Cardiology, Brigham and Womens Hospital, Boston, MA*, <sup>4</sup>*Thoracic Surgery, Brigham and Womens Hospital, Boston, MA*

Wednesday, April 3, 2019

6:00 PM - 7:15 PM

**POSTER SESSION 1: JUNIOR FACULTY CASE REPORTS: MECHANICAL CIRCULATORY SUPPORT**

Room: Banda Sea 2

**Poster Discussants:**

Stephane Collaud, MD, Essen, Germany

Adam Putschogel, DO, Mayo Clinic, Rochester, MN, USA

**(1265) A Cautionary Tale: Importance of Considering Left Ventricular Outflow Tract Geometry and Aortic Root Size When Treating Severe AR in a Frail LVAD Patient;** K. Kearney, N. Bart, J. Phan, N. Song, A. Jabbour, E. Kotlyar, P. Macdonald, K. Muthiah, D. Roy, D. Baron, C. Hayward. *St Vincents Hospital, Darlinghurst, Australia*

**(1266) Percutaneous Bi-Ventricular Support for Cardiogenic Shock after High Risk Coronary Artery Bypass: A Case Review;** A. B. Cole<sup>1</sup>, D. Joyce<sup>1</sup>, L. Durham<sup>1</sup>, N. Gaglianella<sup>2</sup>, D. Ishizawa<sup>2</sup>, L. Joyce<sup>1</sup>, R. Kursel<sup>2</sup>, M. Saltzberg<sup>2</sup>, A. Mohammed<sup>2</sup>.

<sup>1</sup>Cardiothoracic Surgery, Medical College of Wisconsin, Milwaukee, WI, <sup>2</sup>Advanced Heart Failure, Medical College of Wisconsin, Milwaukee, WI

**(1267) Hypoxia on Venous-Venous Extracorporeal Membrane Oxygenation after Uncomplicated Single Lung Transplant;** D. P. Logsdon<sup>1</sup>, A. Kiankhooy<sup>2</sup>, P. McFadden<sup>2</sup>, A. Hackmann<sup>2</sup>. <sup>1</sup>University of Southern California, Los Angeles, CA, <sup>2</sup>Cardiothoracic Surgery, University of Southern California, Los Angeles, CA

**(1269) Prophylactic Percutaneous Circulatory Support in High Risk Transcatheter Aortic Valve Replacement (TAVR);** J. Castrodeza, A. Serrador Frutos, I. Amat-Santos, I. Sayago Silva, J. San Román. *Hospital Clinico Universitario Valladolid, Valladolid, Spain*

**(1270) Fulminant GCM Bridged to Transplant with Heartware HVADs in Biventricular Configuration;** P. Pirlamarla<sup>1</sup>, A. Anyanwu<sup>2</sup>, A. Pawale<sup>2</sup>, G. Larocca<sup>2</sup>, D. M. Mancini<sup>2</sup>, N. Moss<sup>2</sup>. <sup>1</sup>Thomas Jefferson University Hospital, Philadelphia, PA, <sup>2</sup>Mount Sinai Hospital, New York, NY

**(1271) Percutaneous Temporary RVAD Support via Protek-Duo TandemLung to Treat Right Heart Failure Secondary to Scleroderma Severe Pulmonary Artery Hypertension;** J. A. Gomez-Abraham<sup>1</sup>, S. Brann<sup>1</sup>, K. Minakata<sup>1</sup>, S. Keshavamurthy<sup>1</sup>, G. Sunagawa<sup>1</sup>, M. Kashem<sup>1</sup>, B. O'Neill<sup>2</sup>, Y. Toyoda<sup>1</sup>. <sup>1</sup>Surgery, Temple University School of Medicine. Division of Cardiovascular Surgery, Philadelphia, PA, <sup>2</sup>Medicine, Temple University School of Medicine. Division of Interventional Cardiology, Philadelphia, PA

**(1272) Cardiogenic Shock in a Heart Transplant Patient Necessitating Mechanical Circulatory Support;** S. P. Jaganathan, E. K. Powell, D. S. Feldman. *University of Cincinnati Medical Center, Cincinnati, OH*

**(1273) Implantation of a Left Ventricular Assist Device (HeartMate 3) as Destination Therapy in a Patient with Antiphospholipid Syndrome;** A. Z. Pinatto<sup>1</sup>, S. R. Siqueira<sup>2</sup>, F. Scussel<sup>1</sup>, M. S. Lira<sup>1</sup>, L. C. Sampaio<sup>1</sup>, P. P. Fernandes<sup>2</sup>, M. S. Avila<sup>2</sup>, L. A. Hajjar<sup>1</sup>, E. A. Bocchi<sup>2</sup>, S. M. Ayub-Ferreira<sup>1</sup>. <sup>1</sup>Insuficiência Cardíaca e Transplante, Instituto do Coração, Faculdade de Medicina de São Paulo, São Paulo, Brazil, <sup>2</sup>Instituto do Coração, Faculdade de Medicina de São Paulo, São Paulo, Brazil

**(1274) Rescue Therapy for Acute Pulmonary Hypertension Related to Sickle Cell Disease;** P. Mudigonda<sup>1</sup>, V. Cotarlan<sup>2</sup>, J. M. Elwing<sup>3</sup>. <sup>1</sup>Division of Cardiovascular Health and Disease, University of Cincinnati, Cincinnati, OH, <sup>2</sup>Advanced Heart Failure and Transplant, University of Cincinnati, Cincinnati, OH, <sup>3</sup>Pulmonary Hypertension Program, Division of Pulmonary, Critical Care and Sleep Medicine, University of Cincinnati, Cincinnati, OH

**(1275) Cholecystitis after Left Ventricular Assist Device Implantation; a Case Series;** K. Ahmad<sup>1</sup>, D. Mehta<sup>2</sup>, K. Meehan<sup>2</sup>, N. Krause<sup>2</sup>, S. Pauwaa<sup>2</sup>, A. Tatoes<sup>2</sup>, P. Pappas<sup>2</sup>, G. Macaluso<sup>2</sup>, W. Cotts<sup>2</sup>, C. Sciamanna<sup>2</sup>, A. Joshi<sup>2</sup>, A. Andrade<sup>2</sup>. <sup>1</sup>Brown University, Providence, RI, <sup>2</sup>Advocate Christ Medical Center, Oak Lawn, IL

**(1276) VA-ECMO Use in Staged Combined Heart-Kidney Transplant;** T. Al Saadi, A. Joshi, A. Andrade, W. Cotts, G. Macaluso, S. Pauwaa, M. Dia, A. Tatoes, P. Pappas, C. Sciamanna. *Advocate Christ Medical Center, Oak Lawn, IL*

**(1277) Implantation of Implantable Left Ventricular Assist Device for Bridging to Transplantation in Patients with Female Dystrophinopathy: Two Case Reports;** H. Mochizuki<sup>1</sup>, K. Iwasaki<sup>1</sup>, Y. Kimura<sup>1</sup>, K. Toda<sup>1</sup>, Y. Kumai<sup>1</sup>, K. Kuroda<sup>1</sup>, S. Nakajima<sup>1</sup>, T. Watanabe<sup>1</sup>, O. Seguchi<sup>1</sup>, M. Yanase<sup>1</sup>, T. Fujita<sup>2</sup>, J. Kobayashi<sup>2</sup>, N. Fukushima<sup>1</sup>. <sup>1</sup>Transplant Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan, <sup>2</sup>Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan

**(1278) *It Takes a Village to Take Care of a Left Ventricular Assist Device***; D. Tang<sup>1</sup>, A. Ghaly<sup>2</sup>, M. Huang<sup>3</sup>, K. Mody<sup>1</sup>, D. Iyer<sup>1</sup>.  
<sup>1</sup>Rutgers - Robert Wood Johnson University Hospital, New Brunswick, NJ, <sup>2</sup>Cardiothoracic Surgey, Rutgers - Robert Wood Johnson University Hospital, New Brunswick, NJ, <sup>3</sup>Cardiology, Rutgers - Robert Wood Johnson University Hospital, New Brunswick, NJ

**(1279) *Veno-Arterial Extracorporeal Membrane Oxygenation with Chemotherapy in B-Cell Lymphoma Which Induced Tracheal Collapse***; X. Xu, M. Huang. General ICU, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China

**(1280) *Left Axillary Artery Side Graft ECMO Cannulation and Direct Pre-Oxygenator Heparin Infusion***; O. Altas, O. Yerlikhan, T. Özer, S. Sarikaya, K. Kirali. Cardiovascular Surgery, Kosuyolu Heart Training and Research Hospital, Istanbul, Turkey

Wednesday, April 3, 2019

6:00 PM - 7:15 PM

**POSTER SESSION 1: JUNIOR FACULTY CASE REPORTS: PEDIATRICS**

**Room: Banda Sea 2**

**Poster Discussants:**

Chesney Castleberry, MD, St. Louis Children's Hospital, St. Louis, MO, USA

Michelle Ploutz, MD, MPH, Phoenix Children's Hospital, Phoenix, AZ, USA

Ann Punnoose, MD, Children's Hospital of Wisconsin, Milwaukee, WI, USA

**(1281) Successful Treatment of Adenoviremia with Bricidofovir in a Pediatric Heart Transplant Recipient;** S. M. Lyon, J. J. Parent. *Pediatric Cardiology, Indiana University, Indianapolis, IN*

**(1282) Increased VAD Flow is Required in Fontans with Significant AP Collaterals;** E. K. Bedzra<sup>1</sup>, A. C. Nutting<sup>2</sup>, M. N. Kavarana<sup>1</sup>. <sup>1</sup>*Surgery, Medical University of South Carolina, Charleston, SC*, <sup>2</sup>*Pediatrics, Medical University of South Carolina, Charleston, SC*

**(1283) Anamnestic Response Treated with Total Lymphoid Irradiation after Pediatric Heart Transplantation;** A. M. Ybarra<sup>1</sup>, J. Scheel<sup>1</sup>, D. Phelan<sup>2</sup>, K. E. Simpson<sup>1</sup>, A. Abarbanell<sup>2</sup>, C. E. Canter<sup>1</sup>, P. Eghtesady<sup>2</sup>, C. D. Castleberry<sup>1</sup>. <sup>1</sup>*Pediatric Cardiology, Washington University in St. Louis, St. Louis, MO*, <sup>2</sup>*Washington University in St. Louis, St. Louis, MO*

**(1284) "Acquired" Brugada Syndrome in a Cardiac Allograft;** A. Power<sup>1</sup>, S. Lévesque<sup>2</sup>, A. I. Dipchand<sup>1</sup>, E. Jean-St-Michel<sup>1</sup>, E. A. Stephenson<sup>1</sup>, S. Mital<sup>1</sup>, A. Jeewa<sup>1</sup>. <sup>1</sup>*Hospital for Sick Children, Toronto, ON, Canada*, <sup>2</sup>*Sherbrooke Genomic Medicine, Sherbrooke, QC, Canada*

**(1285) Relieving Bronchial Compression Due to Cardiomegaly; the Role of Aortopexy When LVAD Support Just Isn't Enough;** J. A. Laks<sup>1</sup>, M. Haranal<sup>2</sup>, P. Purcell<sup>3</sup>, S. L. Cushing<sup>3</sup>, M. Mazwi<sup>4</sup>, O. Honjo<sup>2</sup>, A. Jeewa<sup>1</sup>. <sup>1</sup>*Division of Cardiology, Labatt Family Heart Centre, The Hospital for Sick Children, Toronto, ON, Canada*, <sup>2</sup>*Division of Cardiovascular Surgery, The Hospital for Sick Children, Toronto, ON, Canada*, <sup>3</sup>*Division of Otolaryngology, The Hospital for Sick Children, Toronto, ON, Canada*, <sup>4</sup>*Division of Critical Care Medicine, The Hospital for Sick Children, Toronto, ON, Canada*

**(1286) Left Ventricular Assist Device as a Bride-to-Decision in a Williams Syndrome Child with Dilated Cardiomyopathy;** Y. Shin<sup>1</sup>, Y. Shin<sup>1</sup>, J. Jung<sup>2</sup>, H. Park<sup>1</sup>. <sup>1</sup>*Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Seoul, Korea, Republic of*, <sup>2</sup>*Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea, Republic of*

**(1287) BK Virus as a Rare Cause of Native Kidney Failure after Pediatric Heart Transplantation;** D. W. Bearl<sup>1</sup>, J. Godown<sup>1</sup>, K. Jabs<sup>2</sup>, D. E. Dulek<sup>3</sup>, D. A. Dodd<sup>1</sup>. <sup>1</sup>*Pediatric Cardiology, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN*, <sup>2</sup>*Pediatric Nephrology, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN*, <sup>3</sup>*Pediatric Infectious Diseases, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN*

**(1288) First Pediatric HeartMate3 Implantation: US Experience;** N. Zwintscher<sup>1</sup>, S. Desai<sup>2</sup>, A. Bansal<sup>1</sup>. <sup>1</sup>*Cardiothoracic Surgery, Ochsner Medical Center, New Orleans, LA*, <sup>2</sup>*Heart Transplant, Ochsner Medical Center, New Orleans, LA*

**(1289) Successful Heart Transplant in an Infant with Noonan Syndrome;** R. L. Shih<sup>1</sup>, D. Gupta<sup>1</sup>, A. Kimbro<sup>1</sup>, B. A. Pietra<sup>1</sup>, J. Phillip<sup>2</sup>, F. J. Fricker<sup>1</sup>. <sup>1</sup>*Pediatric Cardiology, University of Florida College of Medicine, Gainesville, FL*, <sup>2</sup>*University of Florida, Gainesville, FL*

Wednesday, April 3, 2019

6:00 PM - 7:15 PM

**POSTER SESSION 1: JUNIOR FACULTY CASE REPORTS: MECHANICAL CIRCULATORY SUPPORT**

**Room: Banda Sea 1**

**Poster Discussants:**

Mustafa Ahmed, MD, University of Florida, Gainesville, FL, USA  
Sai Bhagra, MRCP (UK), Toronto General Hospital, Toronto, Canada  
Robert Hooker, MD, South Florida Hospital, Tampa, FL, USA  
Isabelle Opitz, MD, University Hospital Zurich, Zurich, Switzerland  
Maryse Palardy, MD, University of Michigan, Ann Arbor, MI, USA  
Martin Strueber, MD, Beth Israel Medical Center, Newark, NJ, USA

**(1290) Double Sequential Defibrillation for LVAD Patient in Refractory Ventricular Fibrillation;** M. DiVita, M. Montgomery, M. Zucker, L. Letarte. *Newark Beth Israel Med Ctr, Newark, NJ*

**(1291) LVAD Inflow Cannula Obstruction from Myocardial Edema Post Intraoperative VT Ablation;** S. D. Rao, L. Ziegler, S. E. Olin, V. Kulkarni, J. Arkles, P. Mather, P. Atluri. *Heart Transplant, University of Pennsylvania, Philadelphia, PA*

**(1292) Use of an Implantable Pulmonary Artery Pressure Monitor to Guide Hemodynamic Echocardiogram-Based LVAD Ramp Testing for Presumed Pump Thrombosis;** S. Sharma<sup>1</sup>, A. Oseran<sup>1</sup>, M. E. Afari<sup>2</sup>, T. Lebeis<sup>2</sup>, L. Arrighi<sup>2</sup>, J. Camuso<sup>3</sup>, K. Milley<sup>3</sup>, J. Ruckel<sup>2</sup>, M. Swan<sup>2</sup>, D. Sullivan<sup>2</sup>, G. D. Lewis<sup>2</sup>, S. Thomas<sup>2</sup>. <sup>1</sup>Medicine, Massachusetts General Hospital, Boston, MA, <sup>2</sup>Cardiology, Massachusetts General Hospital, Boston, MA, <sup>3</sup>Cardiac Surgery, Massachusetts General Hospital, Boston, MA

**(1293) Colonic Mass and Gastrointestinal Bleeding after Left Ventricular Assist Device Implant: A Rare Case of Cytomegalovirus Colitis;** M. F. Sullivan<sup>1</sup>, M. A. Psocka<sup>1</sup>, L. B. Cooper<sup>1</sup>, C. W. May<sup>1</sup>, S. S. Desai<sup>1</sup>, R. Singh<sup>2</sup>, M. Abedi<sup>3</sup>, S. B. Katugaha<sup>4</sup>, H. Mani<sup>5</sup>, P. Shah<sup>1</sup>. <sup>1</sup>Cardiovascular Disease, Inova Heart and Vascular Institute, Falls Church, VA, <sup>2</sup>Thoracic and Cardiac Surgery, Inova Heart and Vascular Institute, Falls Church, VA, <sup>3</sup>Gastroenterology, Inova Fairfax Medical Campus, Falls Church, VA, <sup>4</sup>Infectious Disease Physicians, Inc., Annandale, VA, <sup>5</sup>Pathology, Inova Fairfax Medical Campus, Falls Church, VA

**(1294) The Wythenshawe Hybrid Circuit in Complicated Lung Transplantation;** A. J. Brazier, E. Seville, W. Hesford, P. Exton, B. Pate, N. Sinstadt, M. Sanders, E. Dosouto, J. B. Barnard. *Cardiothoracic Surgery, Wythenshawe Hospital, Manchester, UK*

**(1295) Applying Heart String Anastomotic Device for Left Ventricular Assist Device Outflow Graft Anastomosis;** A. Mehdiani<sup>1</sup>, N. Kalampokas<sup>1</sup>, A. Albert<sup>1</sup>, U. Boeken<sup>1</sup>, P. Akhyari<sup>1</sup>, R. Westenfeld<sup>2</sup>, H. Aubin<sup>1</sup>, A. Lichtenberg<sup>1</sup>, D. Saeed<sup>1</sup>. <sup>1</sup>Cardiovascular Surgery, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany, <sup>2</sup>Heinrich-Heine University Dusseldorf, Dusseldorf, Germany

**(1296) A Novel Approach to Aortic Root Thrombus and Left Main Coronary Artery Occlusion in a Patient with a Left Ventricular Assist Device;** B. DeMoss, D. Markham, G. Chang, A. Thobani, R. Cole, J. Miller. *Emory University School of Medicine, Atlanta, GA*

**(1297) First Percutaneous Right Ventricular Assist Device Placement through Persistent Left Superior Vena Cava;** G. Sunagawa<sup>1</sup>, S. Brann<sup>1</sup>, B. O'Murchu<sup>2</sup>, J. Pelberg<sup>2</sup>, A. Singh<sup>2</sup>, A. Vaidya<sup>2</sup>, E. Hamad<sup>2</sup>, Y. Toyoda<sup>1</sup>. <sup>1</sup>Cardiovascular Surgery, Temple University Hospital, Philadelphia, PA, <sup>2</sup>Cardiology, Temple University Hospital, Philadelphia, PA

**(1298) HeartWare LVAD in Adult Patients with Complex Single Ventricle Physiology and Failed Systemic Ventricle;** J. M. Griffin<sup>1</sup>, M. J. Lewis<sup>1</sup>, M. Yuzefpolskaya<sup>1</sup>, M. Cevasco<sup>1</sup>, R. Te-Frey<sup>1</sup>, M. Tiburcio<sup>1</sup>, J. Ginns<sup>2</sup>, R. W. Elder<sup>3</sup>, M. Rosenbaum<sup>1</sup>, M. A. Farr<sup>1</sup>, P. C. Colombo<sup>1</sup>, H. Takayama<sup>1</sup>, K. Takeda<sup>1</sup>, K. M. Axsom<sup>1</sup>, Y. Naka<sup>1</sup>. <sup>1</sup>Columbia University Medical Center, New York, NY, <sup>2</sup>Weill Cornell Medical Center, New York, NY, <sup>3</sup>Yale - New Haven Hospital, New Haven, CT

**(1299) Impact of A-V Synchrony on LVAD Flow and Pulsatility;** R. I. Goldberg<sup>1</sup>, A. Sridharan<sup>1</sup>, A. Vest<sup>1</sup>, D. DeNofrio<sup>1</sup>, G. Couper<sup>2</sup>, M. Kawabori<sup>2</sup>, M. S. Kiernan<sup>1</sup>. <sup>1</sup>Cardiology, Tufts Medical Center, Boston, MA, <sup>2</sup>Cardiac Surgery, Tufts Medical Center, Boston, MA

**(1300) An Unusual Case of Acquired Hypoxemia Following LVAD;** S. N. Purohit<sup>1</sup>, A. L. Strobel<sup>1</sup>, A. A. Desai<sup>1</sup>, M. T. Marsala<sup>1</sup>, T. M. Bull<sup>2</sup>, D. Vargas<sup>3</sup>, J. D. Kay<sup>1</sup>, N. L. Altman<sup>1</sup>. <sup>1</sup>Cardiology, University of Colorado, Denver, CO, <sup>2</sup>Pulmonology, University of Colorado, Denver, CO, <sup>3</sup>Radiology, University of Colorado, Denver, CO

**(1301) HeartMate III Outflow Graft Thrombosis;** J. Eulert-Grehn<sup>1</sup>, C. Klein<sup>2</sup>, V. Falk<sup>1</sup>, E. Potapov<sup>1</sup>, C. T. Starck<sup>1</sup>. <sup>1</sup>Cardiac, Thoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany, <sup>2</sup>Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany



**(1302) Innumerable Systemic-Pulmonary Shunt Formation during ECMO Support;** D. Yoshioka, K. Toda, A. Satoh, S. Miyagawa, Y. Yoshikawa, H. Hata, Y. Sawa. *Osaka University Graduate School of Medicine, Osaka, Japan*

**(1303) Trimming the Waistline as a Bridge to Transplant in LVAD Patients;** O. Ali, R. Donovan, H. Eisen. *Penn State Hershey Medical Center, Hershey, PA*

**(1304) A Twist of Fate: Diagnosing LVAD Flow Obstruction from Late Twisting of the Outflow Graft;** I. Tea<sup>1</sup>, D. Miranda<sup>1</sup>, I. Hussain<sup>1</sup>, S. Chang<sup>1</sup>, C. Lin<sup>1</sup>, F. Beg<sup>1</sup>, J. Bhatt<sup>1</sup>, A. Guha<sup>1</sup>, E. Suarez<sup>2</sup>. <sup>1</sup>*Cardiology, Houston Methodist Hospital, Houston, TX*, <sup>2</sup>*Cardiothoracic Surgery, Houston Methodist Hospital, Houston, TX*

**(1305) Utilization of Cardiac MRI for Risk Stratification of Right Ventricular Failure Post Left Ventricular Assist Device Implantation. A Case Series;** A. Mahmoud<sup>1</sup>, M. A. Al-Ani<sup>2</sup>, D. Mahtta<sup>1</sup>, J. Vilaro<sup>2</sup>, M. Ahmed<sup>2</sup>. <sup>1</sup>*Internal Medicine, University of Florida, Gainesville, FL*, <sup>2</sup>*Internal Medicine - Cardiology, University of Florida, Gainesville, FL*

**(1306) Successful HVAD Left Ventricular Assist Device Implantation after ACORN Corcap Placement;** M. Kawabori<sup>1</sup>, E. Wang<sup>2</sup>, M. Rambukwella<sup>2</sup>, B. Deng<sup>2</sup>, N. J. Toomey<sup>2</sup>, C. Cassidy<sup>2</sup>, Y. Zhan<sup>1</sup>, F. Y. Chen<sup>1</sup>, G. S. Couper<sup>1</sup>. <sup>1</sup>*Tufts Medical Center, Boston, MA*, <sup>2</sup>*Tufts University School of Medicine, Boston, MA*

**(1307) Simple, Effective and Inexpensive Distal Embolic Protection in Removing Impella 5.0 "Vessel Loop" Technique;** M. Kawabori<sup>1</sup>, V. Pramil<sup>2</sup>, N. K. Kapur<sup>1</sup>, Y. Zhan<sup>1</sup>, K. Ohlrich<sup>2</sup>, E. Wang<sup>2</sup>, M. Rambukwella<sup>2</sup>, P. Shindgikar<sup>1</sup>, F. Y. Chen<sup>1</sup>, G. S. Couper<sup>1</sup>. <sup>1</sup>*Tufts Medical Center, Boston, MA*, <sup>2</sup>*Tufts University School of Medicine, Boston, MA*

**(1308) Minimally-Invasive Single Incision Temporary Biventricular Assist Device Insertion;** E. Sandoval, A. Fernandez-Cisneros, R. Pruna, D. Pereda. *Cardiovascular Surgery, Hospital Clínic, Barcelona, Spain*

**(1309) Heart Mate 3 LVAD Implant with Left Subcostal Approach as a BTT Replacing HMII LVAD (DT) Complicated with Recurrent Pump Thrombosis in a Patient with Non Ischemic Cardiomyopathy Ultimately on Heart Transplant List;** J. A. Gomez-Abraham<sup>1</sup>, K. Minakata<sup>1</sup>, S. Keshavamurthy<sup>1</sup>, S. Brann<sup>1</sup>, F. Kromah<sup>1</sup>, M. Kashem<sup>1</sup>, E. Hamad<sup>2</sup>, R. Alvarez<sup>3</sup>, Y. Toyoda<sup>1</sup>. <sup>1</sup>*Surgery, Temple Univ School of Medicine. Division of Cardiothoracic Surgery, Philadelphia, PA*, <sup>2</sup>*Medicine, Temple Univ School of Medicine. Division of Cardiology, Philadelphia, PA*, <sup>3</sup>*Medicine, Temple Univ School of Medicine. Division of Cardiology, Philadelphia, PA*

**(1310) Cardiogenic Shock Due to Acute Aortic Insufficiency Six Weeks Post Device Implantation;** N. Narang, L. Holzhauser, I. Ebong, A. Nguyen, B. Chung, C. Juricek, T. Song, D. Onsager, T. Ota, V. Jeevanandam, B. Smith, S. Kalantari, N. Sarswat, J. Raikhelkar, G. Kim, G. Sayer, N. Uriel. *University of Chicago Medical Center, Chicago, IL*

**(1311) Permanent Dialysis Access in a Total Artificial Heart Patient;** B. B. Hair<sup>1</sup>, L. Kirksey<sup>2</sup>, M. Z. Tong<sup>3</sup>, N. Smedira<sup>3</sup>, M. Hanna<sup>4</sup>. <sup>1</sup>*Cleveland Clinic Lerner College of Medicine, Cleveland Clinic Foundation, Cleveland, OH*, <sup>2</sup>*Department of Vascular Surgery, Cleveland Clinic Foundation, Cleveland, OH*, <sup>3</sup>*Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH*, <sup>4</sup>*Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH*

**(1312) LVAD Decommission with Percutaneous Outflow Graft Occlusion: A Word of Caution;** K. Oh<sup>1</sup>, O. Saeed<sup>1</sup>, J. Wiley<sup>1</sup>, R. H. Pass<sup>2</sup>, N. J. Sutton<sup>2</sup>, S. Madan<sup>1</sup>, M. Shah<sup>1</sup>, K. Rahgozar<sup>3</sup>, S. R. Patel<sup>1</sup>, S. Vukelic<sup>1</sup>, D. B. Sims<sup>1</sup>, D. Goldstein<sup>4</sup>, U. P. Jorde<sup>1</sup>. <sup>1</sup>*Medicine, Div of Cardiology, Montefiore Med Center/Albert Einstein College of Medicine, Bronx, NY*, <sup>2</sup>*Pediatric Cardiology, Montefiore Med Center/Albert Einstein College of Medicine, Bronx, NY*, <sup>3</sup>*Medicine, Montefiore Med Center/Albert Einstein College of Medicine, Bronx, NY*, <sup>4</sup>*Cardiovascular and Thoracic Surgery, Montefiore Med Center/Albert Einstein College of Medicine, Bronx, NY*

**(1313) Enoxaparin in a Dialysis-Dependent LVAD Patient with Presumed Pump Thrombosis;** A. Mardis<sup>1</sup>, S. Blandy<sup>1</sup>, S. Branham<sup>2</sup>, J. Barham<sup>2</sup>, A. Poole<sup>2</sup>, P. McCann<sup>3</sup>, J. Martin<sup>2</sup>, R. Napier<sup>3</sup>. <sup>1</sup>*Department of Pharmacy, Palmetto Health, Columbia, SC*, <sup>2</sup>*Cardiothoracic Surgery, Palmetto Health, Columbia, SC*, <sup>3</sup>*Cardiology, Palmetto Health, Columbia, SC*

**(1314) Case Report on Interventional Treatment of HeartMate 3 LVAD Outflow Graft Twisting with a Bare Metal Stent Insertion;** A. Juraszek<sup>1</sup>, J. Szymański<sup>1</sup>, M. Demkow<sup>2</sup>, M. Sobieszkańska-Małek<sup>3</sup>, M. Kuśmierczyk<sup>1</sup>. <sup>1</sup>*Dept of Cardiac Surgery and Transplantation, Warsaw Institute of Cardiology, Warsaw, Poland*, <sup>2</sup>*Dept of Coronary and Structural Heart Disease, Warsaw Institute of Cardiology, Warsaw, Poland*, <sup>3</sup>*Dept of Heart Failure and Transplantation, Warsaw Institute of Cardiology, Warsaw, Poland*

**(1315) Computed Tomography in Diagnosing Thrombosis of the LVAD's Outflow-Graft: Still a Challenge;** A. Addas, J. Fischer, S. Lehmann, J. Garbade, M. Borger, A. Meyer. *Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany*

**(1316) Intracardiac Echocardiography a Novel Approach in the Evaluation Total Artificial Heart Function;** C. Buto-Colletti, J. N. Koneru. *Virginia Commonwealth University, Virginia Commonwealth University, Richmond, VA*

**(1317) Left Ventricular Assist Device Support in a Patient with Ischemic Cardiomyopathy from Untreated Homocystinuria;** A. M. Shah<sup>1</sup>, N. Bansal<sup>2</sup>, D. Hsu<sup>2</sup>, J. Lamour<sup>2</sup>, D. Sims<sup>1</sup>, J. Shin<sup>1</sup>, U. Jorde<sup>1</sup>, D. Goldstein<sup>3</sup>, W. Jakobleff<sup>3</sup>, G. Peek<sup>3</sup>. <sup>1</sup>Division of Cardiology, Montefiore Medical Center, Bronx, NY, <sup>2</sup>Pediatric Cardiology, Montefiore Medical Center, Bronx, NY, <sup>3</sup>Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY

**(1318) Caught in the Act: Left Ventricular Assist Device Suction Event Diagnosed with Electrocardiogram Gated Computed Tomography Angiography;** M. Kawabori<sup>1</sup>, M. Rambukwella<sup>2</sup>, E. Wang<sup>2</sup>, C. Cassidy<sup>2</sup>, K. Barry<sup>2</sup>, A. Soin<sup>2</sup>, S. Lofftus<sup>2</sup>, V. Pramil<sup>2</sup>, F. Y. Chen<sup>1</sup>, G. S. Couper<sup>1</sup>. <sup>1</sup>Tufts Medical Center, Boston, MA, <sup>2</sup>Tufts University School of Medicine, Boston, MA

**(1319) An Unusual Cause of Outflow Graft Thrombosis;** M. Veerasamy, T. Boeve, D. Fermin. Spectrum Health, Grand Rapids, MI

**(1320) Changes in Pulmonary Vascular Resistance and the Incidence of Right Heart Failure in Post Cardiac Transplant Patients Bridged with Biventricular Assist Devices;** S. Adhikari<sup>1</sup>, G. Rubin<sup>2</sup>, K. Meehan<sup>3</sup>, A. Andrade<sup>3</sup>, W. Cotts<sup>3</sup>, S. Pauwaa<sup>3</sup>, A. Joshi<sup>3</sup>, C. Sciamanna<sup>3</sup>, P. Pappas<sup>3</sup>, A. Tatoes<sup>3</sup>, G. Macaluso<sup>3</sup>. <sup>1</sup>University of Illinois-Christ, Oak Lawn, IL, <sup>2</sup>Advocate Lutheran General Hospital, Park Ridge, IL, <sup>3</sup>Advocate Christ Medical Center, Oak Lawn, IL

**(1321) A Case of Beta Blocker Therapy for Harlequin Syndrome in Venoarterial ECMO;** S. Kaur<sup>1</sup>, R. Hussain<sup>1</sup>, B. Maffre<sup>1</sup>, I. Gregoric<sup>1</sup>, B. Kar<sup>1</sup>, B. Akkanti<sup>1</sup>, K. Dinh<sup>1</sup>, S. Nathan<sup>2</sup>, M. Jumean<sup>2</sup>, S. Kumar<sup>2</sup>, I. Salas de Armas<sup>2</sup>, J. Patel<sup>2</sup>, M. Patel<sup>2</sup>. <sup>1</sup>Pulmonary, Critical Care and Sleep Medicine, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, <sup>2</sup>University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX

**(1322) Beating the Odds: ECMO CPR to Rescue Patient with Cardiogenic Shock Due to Non-Hodgkin Lymphoma;** I. Saba, M. Loebe, R. Cifuentes, N. Thakkar, A. Badiye, A. Ghodsizad, S. Chaparro, N. Brozzi. University of Miami, Miami, FL

**(1323) Evolving Indications of Left Ventricular Assist Device Therapies: Long-Term LVAD Support for Chagas Cardiomyopathy;** N. A. Brozzi<sup>1</sup>, I. C. Saba<sup>1</sup>, S. Chaparro<sup>2</sup>, C. Franco Mesa<sup>3</sup>, T. Patricelli<sup>1</sup>, A. Ghodsizad<sup>1</sup>, N. Rivera Takkar<sup>2</sup>, A. Badiye<sup>2</sup>, M. Loebe<sup>1</sup>. <sup>1</sup>Surgery, University of Miami, Miami, FL, <sup>2</sup>Medicine, University of Miami, Miami, FL, <sup>3</sup>Universidad CES, Medellin, Colombia

**(1324) Minimally Invasive Approach of Left Ventricular Assist Device Implantation: Friend or Foe?;** N. T. Rivera, N. Brozzi, M. Loebe, S. Chaparro, A. Badiye. Miami Transplant Institute, Jackson Health System in affiliation with University of Miami Health System, Miami, FL

**(1325) Mechanical Circulatory Support for Right Ventricular Failure in Idiopathic Pulmonary Fibrosis Patient Who is Waiting for Lung Transplantation with VV ECMO: VVA ECMO or RVAD?;** S. Lee<sup>1</sup>, D. Kim<sup>2</sup>. <sup>1</sup>Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of, <sup>2</sup>

**(1326) A Bailout Approach with Heart Mate-III in Deteriorating Heart Transplant Patient with Graft Dysfunction;** F. Khaliel, F. Alshamdin, U. Kjellman. Cardiac Surgery, King Faisal Specialist Hospital & RC, Riyadh, Saudi Arabia

**(1327) North-North Syndrome: Regional Differential Hypoxia in Patients with Centrally Cannulated Veno-Arterial Extracorporeal Membrane Oxygenation;** M. Tsai. ECMO, AdventHealth, Orlando, FL

**(1328) The Opportunistic Use of the Continuous Renal Replacement Therapy Circuit as a Physiologically Friendly Rapid Infuser during Catastrophic Bleeding;** M. Tsai. ECMO, AdventHealth, Orlando, FL

**(1329) Extended Infusion Alteplase for Refractory Left Ventricular Assist Device Pump Thrombosis;** A. Mardis<sup>1</sup>, S. Frye<sup>1</sup>, A. Poole<sup>2</sup>, S. Branham<sup>2</sup>, J. Barham<sup>2</sup>, R. Napier<sup>3</sup>, P. McCann<sup>3</sup>, J. Martin<sup>2</sup>. <sup>1</sup>Department of Pharmacy, Palmetto Health, Columbia, SC, <sup>2</sup>Cardiothoracic Surgery, Palmetto Health, Columbia, SC, <sup>3</sup>Cardiology, Palmetto Health, Columbia, SC

**(1330) Application of VA ECMO in Patients with a High MELD-XI Score as a Bridge to VAD Implantation: Fact or Motion Sickness;** A. Badiye<sup>1</sup>, R. R. Gonzalez<sup>2</sup>, J. Bauerlein<sup>3</sup>, A. Grant<sup>2</sup>, M. Loebe<sup>2</sup>, P. Rusconi<sup>3</sup>, A. Ghodsizad<sup>2</sup>. <sup>1</sup>Cardiology, Miami Transplant Institute University of Miami, Miami, FL, <sup>2</sup>Surgery, Miami Transplant Institute University of Miami, Miami, FL, <sup>3</sup>Miami Transplant Institute University of Miami, Miami, FL

**(1331) Plasma Leakage-Induced Outflow Graft Obstruction in a Jarvik 2000 Patient;** T. Ushijima<sup>1</sup>, K. Hirayama<sup>1</sup>, Y. Tanoue<sup>1</sup>, T. Hashimoto<sup>2</sup>, T. Higo<sup>2</sup>, H. Tsutsui<sup>2</sup>, A. Shiose<sup>1</sup>. <sup>1</sup>Cardiovascular Surgery, Kyushu University Hospital, Fukuoka, Japan, <sup>2</sup>Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan

**(1332) With and without You: LVAD Unplugged;** F. Loiacono, S. Vazquez, J. M. Dominguez, M. Farrero, M. Castel, F. Perez Villa. Heart Failure and Transplant Unit, Hospital Clinic, Barcelona, Spain

Wednesday, April 3, 2019

6:00 PM - 7:15 PM

**POSTER SESSION 1: JUNIOR FACULTY CASE REPORTS: PULMONARY HYPERTENSION**

**Room: Banda Sea 1**

**Poster Discussants:**

Marc De Perrot, MD, Toronto General Hospital, Toronto, Canada

Laurent Godinas, MD, PhD, University Hospitals Leuven, Leuven, Belgium

**(1333) Management of Right Ventricular Failure through Pulmonary Thromboendarterectomy: A Role for Percutaneous Ventricular Support?**; A. M. Schurman<sup>1</sup>, M. T. Cain<sup>1</sup>, D. L. Joyce<sup>2</sup>, L. D. Joyce<sup>2</sup>, L. A. Durham<sup>2</sup>, A. Mohammed<sup>3</sup>. <sup>1</sup>Medical College of Wisconsin, Milwaukee, WI, <sup>2</sup>Cardiothoracic Surgery, Medical College of Wisconsin, Milwaukee, WI, <sup>3</sup>Medicine, Division of Cardiology, Medical College of Wisconsin, Milwaukee, WI

**(1334) Salvage Therapy for Pulmonary Arterial Hypertension with Single Anomalous Pulmonary Vein Return via VV ECMO and Atrial Septostomy**; V. Y. Parikh, L. Simpson, D. Parekh, C. Castillo, R. Reddy, A. Nair. Baylor St. Luke's Medical Center/Texas Heart Institute, Houston, TX

**(1335) Injected Buprenorphine Tablets as Cause of Pulmonary Hypertension**; S. D. Khodjaev, C. Alpert, R. L. Benza, S. Mirza, K. Hoffman, A. Hadi. Advanced Heart Failure and Transplant Cardiology, Allegheny Health Network, Pittsburgh, PA

**(1336) Management of an Anomalous Right Coronary Artery with Underlying Pulmonary Arterial Hypertension**; S. Bhattacharya, N. Colaco, A. Schnell Heringer, N. Tarango, M. Aras, V. Selby, L. Klein, T. De Marco. Cardiology, University of California, San Francisco, San Francisco, CA

Thursday, April 4, 2019

5:45 PM - 7:00 PM

## **POSTER SESSION 2: INFECTIOUS DISEASES**

**Room: Gardenia 2**

### **Poster Discussants:**

Saima Aslam, MD, MS, UCSD Medical Center, San Diego, CA, USA

Ricardo La Hoz, MD, UT Southwestern Medical Center, Dallas, TX, USA

Orla Morrissey, MD, The Alfred Hospital, Melbourne, Australia

Joanna Schaeffer, MD, PhD, UCLA School of Medicine, Los Angeles, CA, USA

Cameron Wolfe, MBBS MPH, Duke University Medical Center, Durham, NC, USA

**(765) Hepatitis and Thoracic Transplantation - No More Virus Non-Grata;** C. R. Wolfe, S. Sen, M. R. Kappus, J. N. Schroder, M. A. Daneshmand, J. C. Haney, C. A. Milano, J. M. Reynolds, C. B. Patel. *Duke University Medical Center, Durham, NC*

**(766) Evaluation of Cytomegalovirus-Specific T Cell Response Can Improve Risk Stratification of CMV Infection in Heart Transplant Recipients;** E. Garcia-Romero, U. Lopez-Cardoza, C. Diez-Lopez, J. Roca-Elias, I. Tatjer, A. Cequier-Fillat, N. Sabe, N. Manito, O. Bestard, J. Gonzalez-Costello. *Hospital Universitario de Bellvitge, Barcelona, Spain*

**(767) Simultaneous Assessment of Plasma and Peripheral Mononuclear Cells for Multiple Viral Load Quantification in Peripheral Blood of Patients after Heart Transplantation;** N. Fukushima<sup>1</sup>, H. Sakaguchi<sup>2</sup>, K. Toda<sup>1</sup>, S. Kogaki<sup>3</sup>, J. Narita<sup>4</sup>, H. Ishida<sup>4</sup>, Y. Hashii<sup>4</sup>, T. Miyamura<sup>4</sup>, K. Imadome<sup>5</sup>. <sup>1</sup>Department of Transplant Medicine, National Cerebral and Cardiovascular Center, Suita, Japan, <sup>2</sup>Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, Suita, Japan, <sup>3</sup>Department of Pediatrics, Osaka General Medical Center, Osaka, Japan, <sup>4</sup>Department of Pediatrics, Osaka University, Suita, Japan, <sup>5</sup>Department of Advanced Medicine for Infections, National Center for Child Health and Development, Tokyo, Japan

**(768) Efficacy and Safety of Short-Term Universal Prophylaxis for Invasive Aspergillosis after Heart Transplantation;** A. Alam, H. Doshi, E. Hiltner, E. Rios, J. Kassotis, K. Mody, D. Iyer, J. Almendral. *Rutgers - Robert Wood Johnson University Hospital, New Brunswick, NJ*

**(769) Hepatitis E Virus after Heart Transplantation, Single Center Experience;** M. Hegarová<sup>1</sup>, S. Fraňková<sup>2</sup>, P. Trunečka<sup>2</sup>, I. Málek<sup>1</sup>, V. Melenovský<sup>1</sup>. <sup>1</sup>Clinic of Cardiology, IKEM, Prague, Czech Republic, <sup>2</sup>Clinic of Hepatogastroenterology, IKEM, Prague, Czech Republic

**(770) More Advanced Heart Failure Prior to Heart Transplant May Influence the Cytomegalovirus Specific T Cell Response in Cytomegalovirus Positive Recipients;** U. López Cardoza, E. García Romero, C. Carles Diez-López, J. Roca, N. Sabé, N. Manito, I. Tatjer, A. Cequier, O. Bestard, J. González Costello. *Bellvitge University Hospital, Hospitalet de Llobregat, Spain*

**(771) Impact of Mycophenolate Dosing on CMV Rates in Heart Transplant Recipients;** H. Brink, M. Hyden. *Nebraska Medicine, Omaha, NE*

**(772) Human Cytomegalovirus Immunoglobulin as an Early Adjunctive Therapy Increased CMV-Free Survival after Heart Transplantation;** M. J. Barten<sup>1</sup>, C. Neumaier<sup>2</sup>, A. Bernhardt<sup>2</sup>, M. Rybczynski<sup>2</sup>, H. Reichenspurner<sup>2</sup>. <sup>1</sup>Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany, <sup>2</sup>University Heart Center Hamburg, Hamburg, Germany

**(773) Does Thymoglobulin Induction Lead to Increased CMV Infection after Heart Transplantation in the Current Tacrolimus Era?;** M. Kittleson<sup>1</sup>, J. Patel<sup>1</sup>, R. Cole<sup>1</sup>, D. Geft<sup>1</sup>, S. Dimbil<sup>1</sup>, R. Levine<sup>1</sup>, S. Mersola<sup>1</sup>, L. Czer<sup>1</sup>, B. Azarbal<sup>1</sup>, R. Zabner<sup>2</sup>, P. Zakowski<sup>2</sup>, J. A. Kobashigawa<sup>1</sup>. <sup>1</sup>Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, <sup>2</sup>Cedars-Sinai Medical Center, Los Angeles, CA

**(774) Undue Infection Risk from Proliferation Signal Inhibitors When Initiated Later after Heart Transplantation;** M. Kittleson<sup>1</sup>, J. Patel<sup>1</sup>, E. Kransdorf<sup>1</sup>, D. Geft<sup>1</sup>, S. Dimbil<sup>1</sup>, R. Levine<sup>1</sup>, A. Velleca<sup>1</sup>, L. Czer<sup>1</sup>, A. Hage<sup>1</sup>, R. Zabner<sup>2</sup>, P. Zakowski<sup>2</sup>, J. Kobashigawa<sup>1</sup>. <sup>1</sup>Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA, <sup>2</sup>Cedars-Sinai Medical Center, Los Angeles, CA

**(775) Incidence of Pancreatitis in Recipients of Hepatitis C Donor Hearts;** M. Chowdhury, K. Schlendorf, S. Zalawadiya, M. Brinkley, M. Wigger, J. Menachem, H. Ooi, L. Punnoose, A. Shah, M. Danter, K. Balsara, J. Lindenfeld. *Vanderbilt University Medical Center, Nashville, TN*

**(776) Discontinuation of Anti-Fungal Prophylaxis in Lung Transplant Recipients: Why Does It Happen?;** K. Pennington, R. Razonable, S. Peters, R. Daly, J. Scott, M. Wylam, M. Brutinel, H. Sekiguchi, C. Kennedy. *Mayo Clinic, Rochester, MN*

**(777) Cytomegalovirus Infection and Disease in Lung Transplant Recipients;** B. L. Lynch<sup>1</sup>, P. Ging<sup>2</sup>, A. Ronayne<sup>3</sup>, C. De Gascun<sup>3</sup>, J. Kleinerova<sup>4</sup>, J. J. Egan<sup>4</sup>, M. M. Hannan<sup>1</sup>. <sup>1</sup>Clinical Microbiology, Mater Misericordiae University Hospital, Dublin 7, Ireland, <sup>2</sup>Department of Pharmacy, Mater Misericordiae University Hospital, Dublin 7, Ireland, <sup>3</sup>National Virus Reference Laboratory, Dublin 4, Ireland, <sup>4</sup>Department of Respiratory and Transplant, Mater Misericordiae University Hospital, Dublin 7, Ireland

**(778) Impact of Respiratory Syncytial Virus Infection on Bronchiolitis Obliterans Syndrome in Lung Transplant Recipients;** N. Permpalung<sup>1</sup>, T. Thaniyavarn<sup>2</sup>, J. H. Saullo<sup>3</sup>, S. Arif<sup>3</sup>, R. A. Miller<sup>3</sup>, J. M. Reynolds<sup>3</sup>, B. D. Alexander<sup>3</sup>. <sup>1</sup>Johns Hopkins University School of Medicine, Baltimore, MD, <sup>2</sup>Brigham and Women's Hospital, Boston, MA, <sup>3</sup>Duke University Medical Center, Durham, NC

**(779) Influences of Perioperative Airway Pathogens on the Clinical Course in Living and Cadaveric Lung Transplantation;** H. Oda, T. F. Chen-Yoshikawa, Y. Yokoyama, M. Ikeda, J. Tokuno, H. Kayawake, S. Ueda, H. Yamagishi, F. Gochi, R. Okabe, M. Saito, Y. Yutaka, Y. Yamada, D. Nakajima, M. Hamaji, A. Ohsumi, H. Date. *Thoracic Surgery, Kyoto University, Kyoto City, Japan*

**(780) Kaposi's Sarcoma in Lung Transplantation: A Decade's Single-Centre Case Series;** V. Rossetti<sup>1</sup>, L. Morlacchi<sup>1</sup>, L. Rosso<sup>2</sup>, A. Palleschi<sup>2</sup>, P. Mendogni<sup>2</sup>, E. Benazzi<sup>3</sup>, M. Corbellino<sup>4</sup>, P. Tarsia<sup>1</sup>. <sup>1</sup>Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Centre, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy, <sup>2</sup>Thoracic Surgery and Lung Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy, <sup>3</sup>Transplant Coordination (NITp); Dept. of Services and Preventive Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy, <sup>4</sup>Infectious Diseases Dept, Unit III, Ospedale Luigi Sacco di Milano, ASST FBF Sacco; Università degli Studi di Milano, Milano, Italy

**(781) Drug Resistant CMV Infection in Lung Transplantation Patients: Incidence, Characteristics and Clinical Outcomes;** E. Heliövaara, S. Husain, T. Martinu, L. Singer, M. Cypel, A. Humar, S. Keshavjee, J. Tikkanen. *University Health Network, Toronto, ON, Canada*

**(782) Antifungal Prophylaxis in Lung Transplant Recipients: A Network Meta-Analysis;** S. Herrera<sup>1</sup>, F. Foroutan<sup>2</sup>, S. Husain<sup>1</sup>. <sup>1</sup>Multi Organ Transplant Unit, Division of Infectious Diseases, University Health Network, Toronto, ON, Canada, <sup>2</sup>Ted Rogers Center of Excellence in Heart Function, Peter Munk Cardiac Centre, University Health Network, Toronto, ON, Canada

**(783) Analysis of Risk Factors for Invasive Mold Infections in Lung Transplant Recipients;** J. Sullivan<sup>1</sup>, N. Sharma<sup>2</sup>, K. Patel<sup>2</sup>, A. Logan<sup>2</sup>. <sup>1</sup>Jackson Memorial Hospital, Miami, FL, <sup>2</sup>Tampa General Hospital, Tampa, FL

**(784) Lung Transplantation for Patients with Cystic Fibrosis and *Achromobacter xylosoxidans* in the Lung Allocation Score Era;** E. Nolley<sup>1</sup>, K. Robinson<sup>1</sup>, J. Pilewski<sup>1</sup>, P. Sanchez<sup>2</sup>, J. D'Cunha<sup>2</sup>, M. Morrell<sup>1</sup>. <sup>1</sup>Pulmonary Allergy and Critical Care, University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>Division of Lung Transplantation and Lung Failure, University of Pittsburgh, Pittsburgh, PA

**(785) Risk of Skin Cancers with Long-Term Itraconazole in Lung Transplant Recipients;** K. Pennington, R. Razonable, S. Peters, R. Daly, J. Scott, M. Brutinel, H. Sekiguchi, M. Wylam, C. Kennedy. *Mayo Clinic, Rochester, MN*

**(786) Donor to Host Transmission of Infection in Lung Transplantation;** E. J. Wainstein<sup>1</sup>, A. Smud<sup>1</sup>, N. Mañez<sup>1</sup>, M. L. Orazi<sup>1</sup>, L. Barcan<sup>1</sup>, G. N. Svetliza<sup>1</sup>, C. Quinteros<sup>1</sup>, A. Dietrich<sup>2</sup>, A. Da Lozzo<sup>2</sup>, E. Beveraggi<sup>2</sup>, D. E. Smith<sup>2</sup>, H. M. Castro<sup>1</sup>. <sup>1</sup>Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, <sup>2</sup>Surgery, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

**(787) Susceptibility Testing of *Exophiala dermatitidis* to Inform Peri-Operative Prophylaxis at Time of Lung Transplantation;** A. Perry<sup>1</sup>, S. Mattu<sup>1</sup>, S. Peart<sup>1</sup>, A. Hague<sup>1</sup>, G. Meachery<sup>2</sup>, A. Fisher<sup>2</sup>, K. Gould<sup>1</sup>, J. Samuel<sup>1</sup>, A. Robb<sup>1</sup>. <sup>1</sup>Microbiology, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UK, <sup>2</sup>Institute of Transplantation, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UK

**(788) MSSA Bacteraemia Can Be Eliminated in LVAD Patients;** N. Robinson Smith<sup>1</sup>, A. Woods<sup>1</sup>, S. Tovey Brown<sup>1</sup>, G. A. MacGowan<sup>1</sup>, S. Schueler<sup>1</sup>, J. Samuel<sup>2</sup>. <sup>1</sup>MCS Service, Newcastle upon Tyne Hospital NHS Trust, Newcastle upon Tyne, United Kingdom, <sup>2</sup>Microbiology Department, Newcastle upon Tyne Hospital NHS Trust, Newcastle upon Tyne, United Kingdom

**(789) Cold Atmospheric Plasma as an Additional Tool for Successful Therapy of Left Ventricular Assist Device Related Infections;** L. Hilker<sup>1</sup>, T. von Woedtke<sup>2</sup>, K. Weltmann<sup>3</sup>, H. Wollert<sup>1</sup>, H. Reichenspurner<sup>4</sup>, M. Barten<sup>4</sup>. <sup>1</sup>Cardiovascular Surgery, Klinikum Karlsburg, Karlsburg, Germany, <sup>2</sup>Cardiovascular Surgery, Leibniz Institute for Plasma Science and Technology, Greifswald, Germany, <sup>3</sup>Leibniz Institute for Plasma Science and Technology, Greifswald, Germany, <sup>4</sup>Cardiovascular Surgery, University Heart Center, Hamburg, Germany

**(791) Pre-LVAD Blood-Borne Infection is a Harbinger of Poor Prognosis after LVAD Implantation;** B. Cagliostro<sup>1</sup>, A. M. Zuver<sup>1</sup>, L. Effner<sup>1</sup>, G. Parkis<sup>1</sup>, G. M. Mondellini<sup>1</sup>, E. A. Royzman<sup>1</sup>, C. A. Bravo<sup>2</sup>, R. Te-Frey<sup>3</sup>, E. F. Lin<sup>1</sup>, A. R. Garan<sup>1</sup>, H. Takayama<sup>3</sup>, K. Takeda<sup>3</sup>, Y. Naka<sup>3</sup>, P. C. Colombo<sup>1</sup>, M. Yuzefpolskaya<sup>1</sup>. <sup>1</sup>Department of Medicine, Columbia University Medical Center, New York, NY, <sup>2</sup>Department of Medicine, Montefiore Medical Center, Bronx, New York, NY, <sup>3</sup>Department of Surgery, Columbia University Medical Center, New York, NY

**(792) Etiology of Continuous-Flow LVAD (CF-LVAD) Infections;** N. Wang<sup>1</sup>, J. K. Ho<sup>2</sup>, F. I. Musfee<sup>3</sup>, H. K. Lamba<sup>2</sup>, F. H. Cheema<sup>2</sup>, D. A. Taylor<sup>4</sup>, L. C. Sampaio<sup>4</sup>, J. A. Morgan<sup>2</sup>, G. Loo<sup>2</sup>, O. H. Frazier<sup>2</sup>, G. V. Letsou<sup>2</sup>. <sup>1</sup>Heart Intensive Care Unit, First Affiliated Hospital of Dalian Medical University, Dalian, China, <sup>2</sup>Surgery, Baylor College of Medicine, Houston, TX, <sup>3</sup>Epidemiology, University of Texas School of Public Health, Houston, TX, <sup>4</sup>Research, Texas Heart Institute, Houston, TX

**(793) Total Replacement of Implantable Left Ventricular Assist Device for Pump Pocket/Device Infection;** Y. Itoda, M. Kimura, O. Kinoshita, H. Yamauchi, K. Nawata, M. Ono. Cardiac Surgery, The University of Tokyo Hospital, Tokyo, Japan

**(794) Blood Stream Infection in Patients with Permanent Mechanical Circulatory Support: Risk Factors for On-Pump Mortality;** N. K. Bart<sup>1</sup>, S. Malik<sup>1</sup>, S. Emmanuel<sup>2</sup>, D. Andresen<sup>3</sup>, K. Muthiah<sup>1</sup>, C. S. Hayward<sup>4</sup>. <sup>1</sup>Heart Transplant and Failure, St Vincents Hospital, Sydney, Australia, <sup>2</sup>Cardiothoracic Surgery, St Vincents Hospital, Sydney, Australia, <sup>3</sup>Infectious Disease, St Vincents Hospital, Sydney, Australia, <sup>4</sup>Heart Transplant and Failure, St Vincent's Hospital, Sydney, Australia

Thursday, April 4, 2019

5:45 PM - 7:00 PM

**POSTER SESSION 2: LUNG TRANSPLANTATION (ADULT)**

**Room: Hibiscus 1**

**Poster Discussants:**

Clemens Aigner, MD, Medical University of Vienna, Vienna, Austria

Bronwyn Levvey, RN, Grad Dip Clin Ep, Alfred Hospital, Melbourne, Australia

Wiebke Sommer, MD, Hannover Medical School, Hannover, Germany

Vincent Valentine, MD, University of Alabama, Birmingham, USA

Glen Westall, FRACP, PhD, Alfred Hospital, Melbourne, Australia

Chad Witt, MD, Washington University School of Medicine, St. Louis, MO, USA

**(795) Sequential Single Lung Transplant (SLT) with or without Ex-Vivo Lung Perfusion Maximizes on Donor to Transplant Conversion Rates;** B. Gadallah, A. Hudson, J. Egan, L. Nolke, K. Redmond. *Cardiothoracic Surgery, Mater Misericordiae University Hospital, Dublin, Ireland*

**(796) Lung Transplantation from Donation after Circulatory Death Donors Following Portable Ex-Vivo Lung Perfusion: Post-Hoc Analysis of OCS Lung EXPAND Trial;** L. J. Ceulemans<sup>1</sup>, A. Neyrinck<sup>2</sup>, G. Loor<sup>3</sup>, G. Warnecke<sup>4</sup>, M. Villavicencio<sup>5</sup>, J. C. Madsen<sup>5</sup>, J. Kukreja<sup>6</sup>, M. Hartwig<sup>7</sup>, A. Ardehali<sup>8</sup>, S. Huddleston<sup>3</sup>, M. Hertz<sup>3</sup>, D. Van Raemdonck<sup>1</sup>. <sup>1</sup>*Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium*, <sup>2</sup>*Anesthesiology, University Hospitals Leuven, Leuven, Belgium*, <sup>3</sup>*University of Minnesota Medical Center, Minneapolis, MN*, <sup>4</sup>*Hannover Medical School, Hannover, Germany*, <sup>5</sup>*Massachusetts General Hospital, Boston, MA*, <sup>6</sup>*University of California San Francisco Medical Center, San Francisco, CA*, <sup>7</sup>*Duke University, Durham, NC*, <sup>8</sup>*University of California Los Angeles Medical Center, Los Angeles, CA*

**(797) Long (>6h) versus Short (<6h) Clinical Normothermic Ex-Vivo Portable Lung Preservation: Post-Hoc Analysis of OCS Lung EXPAND Trial;** L. J. Ceulemans<sup>1</sup>, A. Neyrinck<sup>2</sup>, G. Loor<sup>3</sup>, G. Warnecke<sup>4</sup>, M. Villavicencio<sup>5</sup>, J. C. Madsen<sup>5</sup>, J. Kukreja<sup>6</sup>, M. Hartwig<sup>7</sup>, A. Ardehali<sup>8</sup>, S. Huddleston<sup>3</sup>, M. Hertz<sup>3</sup>, D. Van Raemdonck<sup>1</sup>. <sup>1</sup>*Thoracic Surgery, Univ Hospitals Leuven, Leuven, Belgium*, <sup>2</sup>*Anesthesiology, Univ Hospitals Leuven, Leuven, Belgium*, <sup>3</sup>*Univ of Minnesota Medical Center, Minneapolis, MN*, <sup>4</sup>*Hannover Medical School, Hannover, Germany*, <sup>5</sup>*Massachusetts General Hospital, Boston, MA*, <sup>6</sup>*Univ of California San Francisco Medical Center, San Francisco, CA*, <sup>7</sup>*Duke Univ, Durham, NC*, <sup>8</sup>*Univ of California Los Angeles Medical Center, Los Angeles, CA*

**(798) Better Oxygenation in Upper Lobes Than in Whole Lungs in Marginal Human Donor Lungs Utilized for Cellular Ex Vivo Lung Perfusion;** H. Niiikawa<sup>1</sup>, T. Okamoto<sup>1</sup>, K. S. Ayyat<sup>1</sup>, Y. Itoda<sup>1</sup>, C. F. Farver<sup>2</sup>, K. R. McCurry<sup>1</sup>. <sup>1</sup>*Thoracic & Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH*, <sup>2</sup>*Anatomic Pathology, Cleveland Clinic, Cleveland, OH*

**(799) Use of Phosphodiesterase Inhibition During Ex-Vivo Lung Perfusion of Donor Lungs Unsuitable for Transplantation;** M. I. Morrison, J. T. Barsby, T. L. Pither, C. P. Griffiths, L. Bates, C. A. Charlton, W. E. Scott III, J. H. Dark, A. J. Fisher. *Institute of Cellular Medicine, Newcastle University, Newcastle, United Kingdom*

**(800) Factors That Predict the Successful Utilization of Donor Lungs after Ex-Vivo Lung Perfusion;** P. H. Lemaître, E. Patel, K. Brar, R. J. Jeagal, J. C. Yeung, L. Donahoe, T. K. Waddell, S. Keshavjee, M. Cypel. *Division of Thoracic Surgery and Lung Transplantation, Toronto General Hospital, Toronto, ON, Canada*

**(801) Arrhythmias Following Lung Transplantation: A Single Centre Experience;** J. Dutton<sup>1</sup>, J. McLoughlin<sup>1</sup>, D. Garcia-Saez<sup>2</sup>, N. Lees<sup>1</sup>, A. Simon<sup>2</sup>, A. Hurtado-Doce<sup>1</sup>. <sup>1</sup>*Department of Anaesthesia and Critical Care, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom*, <sup>2</sup>*Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom*

**(802) Secondary Hemophagocytic Syndrome in Lung Transplant Recipients: Report of 4 Cases;** A. O. Morales Avalos, R. Laporta, M. Lazaro, M. Aguilar. *Neumology, Hospital Universitario Puerta de Hierro, Madrid, Spain*

**(803) Constrictive Pericarditis after Lung Transplant: Zebra or Horse?;** C. M. Wojnarski<sup>1</sup>, A. Y. Choi<sup>2</sup>, M. G. Hartwig<sup>1</sup>, J. A. Klapper<sup>1</sup>, J. C. Haney<sup>1</sup>, C. A. Milano<sup>1</sup>, M. A. Daneshmand<sup>1</sup>. <sup>1</sup>*Thoracic and Cardiovascular Surgery, Duke University, Durham, NC*, <sup>2</sup>*Duke University Medical School, Durham, NC*

**(804) Fractional Flow Reserve Guided Coronary Revascularization in Lung Transplant Recipients;** J. Shin<sup>1</sup>, M. Suryapalam<sup>2</sup>, K. Shenoy<sup>3</sup>, B. O'Neill<sup>4</sup>, R. Bashir<sup>4</sup>, V. Lakhter<sup>4</sup>, B. O'Murchu<sup>4</sup>, V. Aggarwal<sup>5</sup>. <sup>1</sup>*Internal Medicine, Temple University Hospital, Philadelphia, PA*, <sup>2</sup>*Biophysics and Computer Science, Temple University, Philadelphia, PA*, <sup>3</sup>*Thoracic Medicine and Surgery, Temple University Hospital, Philadelphia, PA*, <sup>4</sup>*Cardiology, Temple University Hospital, Philadelphia, PA*, <sup>5</sup>*Cardiology, Michigan University, Ann Arbor, MI*

- (805) Long-Term Outcomes are Worse in Patients Hospitalized Prior to Lung Transplantation;** X. Zhou<sup>1</sup>, A. Suarez-Pierre<sup>1</sup>, C. Lui<sup>1</sup>, P. D. Shah<sup>2</sup>, B. S. Kim<sup>2</sup>, J. S. Ha<sup>1</sup>, C. A. Merlo<sup>2</sup>, E. L. Bush<sup>1</sup>. <sup>1</sup>*Surgery, Johns Hopkins Hospital, Baltimore, MD*, <sup>2</sup>*Medicine, Johns Hopkins Hospital, Baltimore, MD*
- (806) Intra-Operative Transfusions are Associated with Worse Outcomes after Lung Transplantation;** O. Zou<sup>1</sup>, E. Granger<sup>2</sup>. <sup>1</sup>*University of New South Wales, Kensington, Australia*, <sup>2</sup>*Cardiothoracics, St. Vincent's Hospital, Sydney, Australia*
- (807) Not All Lungs are Dirty: Positive Sputum Culture in a Candidate with Pulmonary Fibrosis (PF) Should Not Always Deny the Option of Single Lung Transplant;** M. I. Mohamed Mydin<sup>1</sup>, A. Perry<sup>2</sup>, J. Trevis<sup>3</sup>, N. Chilvers<sup>1</sup>, J. Samuel<sup>2</sup>, K. Gould<sup>2</sup>, G. Parry<sup>4</sup>, O. Senbaklavaci<sup>1</sup>, S. C. Clark<sup>1</sup>, J. H. Dark<sup>1</sup>. <sup>1</sup>*Department of Cardiothoracic Surgery, Freeman Hospital, Newcastle upon Tyne, United Kingdom*, <sup>2</sup>*Department of Microbiology, Freeman Hospital, Newcastle upon Tyne, United Kingdom*, <sup>3</sup>*Newcastle University Medical School, Freeman Hospital, Newcastle upon Tyne, United Kingdom*, <sup>4</sup>*Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom*
- (808) Characteristics and Outcomes after Lung Transplantation among Patients with Advanced Lung Disease with Secondary Pulmonary Hypertension;** H. Ali, J. Mullins, M. Mohanka, S. Bollineni, V. Kaza, J. Joerns, F. Torres, M. Wait, M. Peltz, J. Murala, A. Banga. *UT Southwestern Medical Center, Dallas, TX*
- (809) Comparison of De Novo Donor-Specific Anti-HLA Antibodies (DSAs) between Living-Donor Lobar Lung Transplantation and Cadaveric Lung Transplantation;** T. Chen-Yoshikawa<sup>1</sup>, F. Gochi<sup>2</sup>, A. Ohsumi<sup>2</sup>, Y. Yamada<sup>2</sup>, Y. Yutaka<sup>2</sup>, D. Nakajima<sup>2</sup>, M. Hamaji<sup>2</sup>, H. Date<sup>2</sup>. <sup>1</sup>*Kyoto University, Kyoto, Japan*, <sup>2</sup>*Thoracic Surgery, Kyoto University, Kyoto, Japan*
- (810) Need for and Outcomes of Intraoperative Extracorporeal Circulatory Support in Lung Transplantation for Pulmonary Fibrosis;** J. Salman, F. Ius, T. Siemeni, W. Sommer, C. Kuehn, M. Avsar, D. Bobylev, J. Gottlieb, T. Welte, A. Haverich, G. Warnecke, I. Tudorache. *Hannover Medical School, Hannover, Germany*
- (811) Lung Transplantation for Familial Pulmonary Fibrosis;** S. M. Lari, D. J. Ross, R. Saggat, J. P. Lynch III, D. Sayah, A. Derhovanessian, M. Shino, A. Ardehali, J. A. Belperio, S. S. Weigt. *Lung Transplant, UCLA, Los Angeles, CA*
- (812) Point of Care Management of Perioperative Coagulopathy Reduces Blood Loss and Consumption of Blood Transfusion Products (Preliminary Results);** M. Durila<sup>1</sup>, J. Vajter<sup>1</sup>, R. Lischke<sup>2</sup>, J. Berousek<sup>1</sup>, T. Vymazal<sup>1</sup>. <sup>1</sup>*Anesthesiology and Intensive Care Medicine, Second Faculty of Medicine, Charles University, Prague, Prague, Czech Republic*, <sup>2</sup>*3rd Department of Surgery, 1st Faculty of Medicine, Charles University, Motol University Hospital, Prague, Prague, Czech Republic*
- (813) Progression of Mitral Valve Regurgitation after Lung Transplantation;** W. Y. Shi, B. Levvey, A. D. Zimmet, S. F. Marasco, G. Snell, D. C. McGiffin. *Alfred Hospital, Melbourne, Australia*
- (814) Alternative Therapeutic Approach for the Management of Symptomatic Hyperammonemia Syndrome after Lung Transplantation;** A. M. Emtiazjoo<sup>1</sup>, S. Chandrashekar<sup>1</sup>, C. Lin<sup>1</sup>, H. Alnuaimat<sup>1</sup>, A. Shahmohammadi<sup>1</sup>, A. Kamel<sup>2</sup>, T. Veasey<sup>2</sup>, T. Machuca<sup>3</sup>, M. Pipkin<sup>3</sup>, A. Pelaez<sup>1</sup>. <sup>1</sup>*Medicine, University of Florida, Gainesville, FL*, <sup>2</sup>*Pharmacy, University of Florida, Gainesville, FL*, <sup>3</sup>*Surgery, University of Florida, Gainesville, FL*
- (815) Association between Allograft Ischemic Time and Adverse Outcomes Following Lung Transplantation;** L. K. Tague<sup>1</sup>, W. Cherikh<sup>2</sup>, R. R. Lehman<sup>2</sup>, D. Chambers<sup>3</sup>, R. Yusen<sup>1</sup>, R. Hachem<sup>1</sup>. <sup>1</sup>*Internal Medicine, Pulmonary and Critical Care Medicine, Washington University in St. Louis, Saint Louis, MO*, <sup>2</sup>*United Network for Organ Sharing, Richmond, VA*, <sup>3</sup>*School of Medicine, University of Queensland, Brisbane, Queensland, Australia*
- (816) Alpha 1-Antitrypsin Deficiency: Diagnosis and Replacement in the Lung Transplantation Phase of Life- Survey among Lung Transplant Specialists;** A. M. Emtiazjoo<sup>1</sup>, S. Chandrashekar<sup>1</sup>, A. Pelaez<sup>1</sup>, H. Alnuaimat<sup>1</sup>, A. Shahmohammadi<sup>1</sup>, T. Machuca<sup>2</sup>, M. Pipkin<sup>2</sup>, E. Golts<sup>3</sup>, G. Yung<sup>4</sup>, T. Floreth<sup>4</sup>, C. Lin<sup>1</sup>, K. Afshar<sup>4</sup>. <sup>1</sup>*Medicine, University of Florida, Gainesville, FL*, <sup>2</sup>*Surgery, University of Florida, Gainesville, FL*, <sup>3</sup>*Surgery, UCSD, La Jolla, CA*, <sup>4</sup>*Medicine, UCSD, La Jolla, CA*
- (817) Factors Associated with Prolonged Survival (>15 Years) after Lung Transplantation: Analysis of the ISHLT Registry;** H. A. Ali<sup>1</sup>, M. Neely<sup>2</sup>, A. Long<sup>3</sup>, W. Cherikh<sup>4</sup>, D. Chambers<sup>5</sup>, J. Stehlik<sup>6</sup>, L. Snyder<sup>1</sup>. <sup>1</sup>*Internal Medicine, Duke University, Durham, NC*, <sup>2</sup>*Dept of Biostatistics & Bioinformatics, Duke University, Durham, NC*, <sup>3</sup>*DCRI, Duke University, Durham, NC*, <sup>4</sup>*Internal Medicine, ISHLT, ISHLT, VA*, <sup>5</sup>*Heart and Lung Transplantation, The Prince Charles Hospital, Brisbane, Australia*, <sup>6</sup>*Internal Medicine, Univ of Utah Sch of Med, Salt Lake City, UT*



**(818) Improvements in Health-Related Quality of Life with Lung Transplantation: A Prospective Multicenter Cohort Study;** L. D. Snyder<sup>1</sup>, M. Neely<sup>1</sup>, H. Kopetskie<sup>2</sup>, M. Sever<sup>2</sup>, J. Kirchner<sup>1</sup>, C. Frankel<sup>1</sup>, J. Todd<sup>1</sup>, P. Smith<sup>1</sup>, N. Williams<sup>3</sup>, M. Robien<sup>3</sup>, J. Belperio<sup>4</sup>, D. Ross<sup>4</sup>, D. Rozenberg<sup>5</sup>, M. Budev<sup>6</sup>, W. Tsuang<sup>6</sup>, P. Shah<sup>7</sup>, J. Reynolds<sup>1</sup>, S. Palmer<sup>1</sup>, L. Singer<sup>5</sup>, \* for CTOT-20 Investigators<sup>8</sup>.  
<sup>1</sup>Duke University Med Ctr, Durham, NC, <sup>2</sup>Rho Federal Systems Division, Chapel Hill, NC, <sup>3</sup>NIAID, Bethesda, MD, <sup>4</sup>UCLA, Los Angeles, CA, <sup>5</sup>University of Toronto, Toronto, ON, <sup>6</sup>Cleveland Clinic, Cleveland, OH, <sup>7</sup>Johns Hopkins, Baltimore, MD, <sup>8</sup>

**(819) Morbidity and Mortality in Hospitalized versus Outpatient Lung Transplant Recipients;** D. Rudym<sup>1</sup>, L. Benvenuto<sup>1</sup>, H. Kim<sup>2</sup>, L. Shah<sup>1</sup>, M. Aversa<sup>1</sup>, H. Robbins<sup>1</sup>, J. Hook<sup>1</sup>, F. D'Ovidio<sup>3</sup>, M. Bacchetta<sup>3</sup>, J. Sonett<sup>3</sup>, S. Arcasoy<sup>1</sup>. <sup>1</sup>Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Medical Center, New York, NY, <sup>2</sup>New York-Presbyterian Hospital, New York, NY, <sup>3</sup>Department of Surgery, Columbia University Medical Center, New York, NY

**(820) Return to Work in Lung Transplant Recipients: An Australian Perspective - Predictors, Health Status and Outcomes;** M. Munsif, K. Levin, G. Snell, M. Paraskeva. Lung Transplant Service, Alfred Health, Melbourne, Australia

**(821) Point of Care Management of Perioperative Bleeding or Coagulopathy and Volume Replacement Strategy with Albumin 5% Seems to Reduce Primary Graft Dysfunction after Lung Transplantation (Preliminary Results);** J. Vajter<sup>1</sup>, M. Durila<sup>1</sup>, J. Berousek<sup>1</sup>, T. Vymazal<sup>1</sup>, Z. Prikrylova<sup>1</sup>, R. Lischke<sup>2</sup>. <sup>1</sup>Anesthesiology and Intensive Care Medicine, Second Faculty of Medicine, Charles University, Prague, CZ, Prague, Czech Republic, <sup>2</sup>Department of Surgery, 1st Faculty of Medicine, Charles University, Motol University Hospital, Charles University, Prague, CZ, Prague, Czech Republic

**(822) Obesity Leads to Increased IL-18, Treg Impairment and Increased Risk of PGD;** T. Akimova<sup>1</sup>, T. Zhang<sup>1</sup>, U. H. Beier<sup>2</sup>, A. Samanta<sup>1</sup>, R. Han<sup>1</sup>, L. Wang<sup>1</sup>, J. Jiao<sup>1</sup>, J. M. Diamond<sup>3</sup>, D. S. Wilkes<sup>4</sup>, D. J. Lederer<sup>5</sup>, R. A. Simmons<sup>6</sup>, J. D. Christie<sup>7</sup>, W. W. Hancock<sup>1</sup>. <sup>1</sup>Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, <sup>2</sup>Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, <sup>3</sup>Pulmonary and Critical Care Medicine, University of Pennsylvania, Philadelphia, PA, <sup>4</sup>Medicine, University of Virginia, Charlottesville, VA, <sup>5</sup>Pulmonary, Allergy and Critical Care Medicine, Columbia University, New York, NY, <sup>6</sup>Neonatology, Children's Hospital of Philadelphia, Philadelphia, PA, <sup>7</sup>Pulmonary, Allergy and Critical Care Medicine, University of Pennsylvania, Philadelphia, PA

**(823) The Effect of the Elective Intra-Operative Use of Mechanical Circulatory Support on the Development of Primary Graft Dysfunction Following Bilateral Lung Transplantation;** F. Sertic, D. Diagne, L. Chavez, M. Molina, T. Richards, A. Habertheuer, M. Porteous, R. Gallop, M. Oyster, L. Kalman, E. Cantu, J. Christie, M. M. Crespo, C. Bermudez, J. Diamond. University of Pennsylvania, Philadelphia, PA

**(824) Extracorporeal Membrane Oxygenation for Primary Graft Dysfunction after Lung Transplantation;** T. Harano<sup>1</sup>, J. D'Cunha<sup>1</sup>, M. R. Morrell<sup>2</sup>, J. D. Luketich<sup>1</sup>, P. Sanchez<sup>1</sup>. <sup>1</sup>Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>2</sup>Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA

Thursday, April 4, 2019

5:45 PM - 7:00 PM

**POSTER SESSION 2: LUNG TRANSPLANTATION (ADULT)**

**Room: Hibiscus 2**

**Poster Discussants:**

Mark Greer, MB Bch, Hanover Medical School, Hannover, Germany  
Ramsey Hachem, MD, Washington University School of Medicine, St. Louis, MO, USA  
Are Holm, MD, PhD, Oslo University Hospital, Oslo, Norway  
Monique Malouf, FRACP, St. Vincent's Hospital, Sydney, Australia  
Ahmed Menaouar, PhD, Chum University De Montreal, Montreal, Canada  
David Weill, MD, Weill Consulting Group, New Orleans, LA, USA

**(825) Do Long Term Outcomes Justify Third Time Redo Lung Transplantation?; W. Ragalie, P. Downey, D. Ross, E. Depasquale, A. Ardehali. UCLA, Los Angeles, CA**

**(826) Predicting Long Term Survival in Lung Transplant: Analysis of United Network for Organ Sharing (UNOS) Database; J. Sethi<sup>1</sup>, G. A. Garrido Rosa<sup>2</sup>, K. Patel<sup>2</sup>, N. Sharma<sup>2</sup>. <sup>1</sup>Pulmonary and Critical Care Medicine, University of South Florida, Tampa, FL, <sup>2</sup>Advanced Lung Diseases & Lung Transplantation, University of South Florida, Tampa, FL**

**(827) A Real-Life Evaluation of Criteria for Listing for Lung Transplant: A Single-Center, Five-Year Experience; L. Morlacchi<sup>1</sup>, S. Henchi<sup>1</sup>, V. Rossetti<sup>1</sup>, A. Palleschi<sup>2</sup>, D. Tosi<sup>2</sup>, S. Aliberti<sup>1</sup>, G. Sotgiu<sup>3</sup>, P. Tarsia<sup>1</sup>, L. Rosso<sup>2</sup>. <sup>1</sup>Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Centre, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy, <sup>2</sup>Thoracic Surgery and Lung Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy, <sup>3</sup>Clinical Epidemiology and Medical Statistics Unit; Department of Medical, Surgical and Experimental, Università degli Studi di Sassari, Sassari, Italy**

**(828) Frailty is Highly Prevalent in Lung Transplant Candidates and Varies by Frailty Tool; A. O'Boye, K. Leitner, M. Kelly, J. Wright, J. Lee, R. Tomic, S. Bhorade. Northwestern Memorial Hospital, Chicago, IL**

**(829) Surgical and Endoscopic Lung Volume Reduction (LVR) Prior to Lung Transplantation (LuTX); A. Slama<sup>1</sup>, C. Raber<sup>1</sup>, C. Hedderich<sup>1</sup>, V. Besa<sup>2</sup>, D. Valdivia<sup>1</sup>, K. Darwiche<sup>2</sup>, A. Koch<sup>3</sup>, M. Kamler<sup>3</sup>, C. Taube<sup>2</sup>, C. Aigner<sup>1</sup>. <sup>1</sup>Department of Thoracic Surgery, University Medicine Essen - Ruhrlandklinik, Essen, Germany, <sup>2</sup>Department of Pneumology, University Medicine Essen - Ruhrlandklinik, Essen, Germany, <sup>3</sup>Department of Thoracic Transplantation, University Medicine Essen, Essen, Germany**

**(830) Lung Transplant Referral Consensus Guidelines for Individuals with Cystic Fibrosis: An Opportunity for Partnerships between CF and Lung Transplant Centers; K. J. Ramos<sup>1</sup>, P. J. Smith<sup>2</sup>, E. F. McKone<sup>3</sup>, J. M. Pilewski<sup>4</sup>, A. Lucy<sup>5</sup>, S. E. Hempstead<sup>6</sup>, E. Tallarico<sup>6</sup>, A. Faro<sup>6</sup>, D. B. Rosenbluth<sup>7</sup>, A. L. Gray<sup>8</sup>, J. M. Dunitz<sup>9</sup>, C. F. Lung Transplant Referral Guidelines Committee<sup>6</sup>. <sup>1</sup>Medicine, University of Washington, Seattle, WA, <sup>2</sup>Duke University, Durham, NC, <sup>3</sup>Medicine, University College, Dublin, Ireland, <sup>4</sup>Medicine, University of Pittsburgh, Pittsburgh, PA, <sup>5</sup>., MD, <sup>6</sup>Cystic Fibrosis Foundation, Bethesda, MD, <sup>7</sup>Medicine, Washington University School of Medicine in St Louis, St. Louis, MO, <sup>8</sup>Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado – Anschutz Medical Campus, Denver, CO, <sup>9</sup>Medicine, University of Minnesota, Minneapolis, MN**

**(831) Predictors of Mortality Post Lung Transplantation: Systematic Review and Meta-Analysis; F. Foroutan<sup>1</sup>, K. Clark<sup>1</sup>, A. Malik<sup>1</sup>, T. A. Buchan<sup>1</sup>, A. Akhtar<sup>2</sup>, A. Rigobon<sup>1</sup>, M. Stein<sup>1</sup>, J. Yepes Nuñez<sup>2</sup>, K. Quach<sup>3</sup>, D. C. Birriel<sup>4</sup>, A. Sidhu<sup>4</sup>, G. H. Guyatt<sup>5</sup>, M. O. Meade<sup>6</sup>. <sup>1</sup>Cardiology, Toronto General Hospital, Toronto, ON, Canada, <sup>2</sup>Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada, <sup>3</sup>Toronto General Hospital, Toronto, ON, Canada, <sup>4</sup>Lung Transplantation, Toronto General Hospital, Toronto, ON, Canada, <sup>5</sup>Department of Health Research Methods, Evidence, and Impact, McMaster, Hamilton, ON, Canada, <sup>6</sup>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada**

**(832) Single-Center Study Evaluating the Impact of Sarcopenia on Outcomes after Lung Transplantation; P. S. Garcha<sup>1</sup>, T. Nisar<sup>2</sup>, A. K. Jamil<sup>2</sup>, M. O. Edens<sup>2</sup>, V. L. Flores<sup>2</sup>, J. Felius<sup>2</sup>, G. Schwartz<sup>1</sup>, D. P. Mason<sup>1</sup>. <sup>1</sup>Baylor University Medical Center, Dallas, TX, <sup>2</sup>Baylor Scott & White Research Institute, Dallas, TX**

**(833) Is Combined Lung-Liver Transplantation Justified? 30-Year Review of UNOS Database; W. Ragalie, P. Downey, D. Ross, E. Depasquale, A. Ardehali. UCLA, Los Angeles, CA**

**(834) Outcomes and Long-Term Survival after Pulmonary Retransplantation-A Single Center Experience; A. Wallinder<sup>1</sup>, J. Magnusson<sup>2</sup>, C. Danielsson<sup>2</sup>, G. C. Riise<sup>2</sup>, G. Dellgren<sup>2</sup>. <sup>1</sup>Dep. of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden, <sup>2</sup>Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden**

**(835) Survival Analysis Evaluating Extracorporeal Membrane Oxygenation and Mechanical Ventilation as a Bridge to Lung Transplantation;** Y. Xia, J. Lee, H. Seethamraju, S. Scheinin, S. J. Forest. *Montefiore Medical Center, Bronx, NY*

**(836) Lung Transplant Listing of Idiopathic Pulmonary Fibrosis Patients at Pulmonary Fibrosis Care Centers;** J. Mooney<sup>1</sup>, J. Moore<sup>2</sup>, R. Raj<sup>1</sup>, G. Dhillon<sup>1</sup>. <sup>1</sup>Department of Medicine, Stanford University School of Medicine, Stanford, CA, <sup>2</sup>Department of Biostatistics, University of Michigan, Ann Arbor, MI

**(837) Outcomes of Lung Transplant Recipients 70 and Over;** S. Elnahas<sup>1</sup>, P. Kang<sup>2</sup>, S. Biswas Roy<sup>1</sup>, M. Olson<sup>3</sup>, M. A. Smith<sup>1</sup>, R. Walia<sup>1</sup>. <sup>1</sup>Norton Thoracic Institute, St. Joseph's Hospital & Medical Center, Phoenix, AZ, <sup>2</sup>University of Arizona - Phoenix Campus, Phoenix, AZ, <sup>3</sup>Grand Canyon University, Phoenix, AZ

**(838) Waitlist Mortality and Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplantation;** J. Hayanga<sup>1</sup>, S. D. Holmes<sup>1</sup>, H. K. Hayanga<sup>2</sup>, J. H. Fugett, II<sup>3</sup>, N. Shigemura<sup>4</sup>, V. Badhwar<sup>1</sup>, G. Abbas<sup>1</sup>. <sup>1</sup>Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, WV, <sup>2</sup>Anesthesiology, West Virginia University, Morgantown, WV, <sup>3</sup>Pathology, Anatomy and Laboratory Medicine, West Virginia University, Morgantown, WV, <sup>4</sup>Cardiovascular Surgery, Temple University Health System, Philadelphia, PA

**(839) IMPROVING Outcomes: Evaluating the Effect of an Ultra-Lung Protective Strategy for Patients with ARDS Treated with ECMO;** A. A. Grant<sup>1</sup>, A. Badiye<sup>2</sup>, C. Mehta<sup>3</sup>, Z. Wu<sup>4</sup>, M. Koerner<sup>5</sup>, R. Vianna<sup>6</sup>, M. Loebe<sup>2</sup>, A. Ghodsizad<sup>7</sup>. <sup>1</sup>Department of Surgery, Emory University School of Medicine/Miami Transplant Institute, Atlanta, GA, <sup>2</sup>University of Miami/Miami Transplant Institute, Miami, FL, <sup>3</sup>Biostatistics and Bioinformatics, Emory University Rollins School of Public Health, Atlanta, GA, <sup>4</sup>Emory University Rollins School of Public Health, Atlanta, GA, <sup>5</sup>Integrus Baptist Medical Center, Oklahoma City, OK, <sup>6</sup>Department of Surgery, University of Miami/Miami Transplant Institute, Miami, FL, <sup>7</sup>Heart and Lung Transplant and Mechanical Circulatory Support, University of Miami/Miami Transplant Institute, Miami, FL

**(840) Feasibility and Safety of Systemic Anticoagulation-Free Venovenous Extracorporeal Membrane Oxygenation in Adults Respiratory Failure Patients;** C. Kurihara, J. M. Walter, A. Karim, R. Wunderink, G. S. GR Scott Budinger, A. Bharat. *Northwestern University Feinberg School of Medicine, Chicago, IL*

**(841) Effect of PEEP-Induced Alveolar Recruitment on Lung Injury during Extracorporeal Membrane Oxygenation for ARDS;** B. M. Gomes<sup>1</sup>, R. V. Ribeiro<sup>1</sup>, K. Ramadan<sup>1</sup>, M. Galasso<sup>1</sup>, A. Ali<sup>1</sup>, Y. Watanabe<sup>1</sup>, E. Paradiso<sup>1</sup>, M. Meineri<sup>2</sup>, H. Chan<sup>2</sup>, Y. Zhang<sup>1</sup>, D. Hwang<sup>3</sup>, A. Slutsky<sup>4</sup>, E. Fan<sup>2</sup>, M. Liu<sup>1</sup>, S. Keshavjee<sup>1</sup>, M. Cypel<sup>1</sup>, L. del Sorbo<sup>1</sup>. <sup>1</sup>Lamer Thoracic Surgery Laboratories, UHN, Toronto, ON, Canada, <sup>2</sup>University Health Network, Toronto, ON, Canada, <sup>3</sup>Laboratory Medicine and Molecular Diagnostics Sunnybrook Health Sciences Centre, Toronto, ON, Canada, <sup>4</sup>St Michael's Hospital, Toronto, ON, Canada

**(842) Perioperative Extracorporeal Membrane Oxygenation-Based Protocol for Massive Acute Pulmonary Embolism;** F. Ius<sup>1</sup>, C. Fegbeutel<sup>1</sup>, C. Kühn<sup>1</sup>, I. Tudorache<sup>1</sup>, G. Warnecke<sup>1</sup>, K. Olsson<sup>2</sup>, M. M. Hoepfer<sup>2</sup>, A. Haverich<sup>1</sup>, S. Cebotari<sup>1</sup>. <sup>1</sup>Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany, <sup>2</sup>Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany

**(843) New Technique Which Was Combined Living Donor Lower Lobe with Cadaveric Marginal Lung as Called "Hybrid Lung Transplant";** T. Kurosaki, S. Otani, K. Miyoshi, M. Okazaki, S. Sugimoto, M. Yamane, T. Oto. *Organ Transplant Center, Okayama University Hospital, Okayama, Japan*

**(844) Including Cystic-Fibrosis-Specific Variables Improves Accuracy of the Lung Allocation Score;** C. J. Lehr<sup>1</sup>, M. Skeans<sup>2</sup>, E. Dasenbrook<sup>1</sup>, A. Faro<sup>3</sup>, A. Fink<sup>3</sup>, G. Fernandez<sup>3</sup>, M. Valapour<sup>1</sup>. <sup>1</sup>Pulmonary, Cleveland Clinic, Cleveland, OH, <sup>2</sup>Scientific Registry of Transplant Recipients, Minneapolis, MN, <sup>3</sup>Cystic Fibrosis Foundation, Bethesda, MD

**(846) Excellent Long-Term Outcome with Lungs Obtained from Uncontrolled Donation after Circulatory Death;** E. Miñambres, J. M. Cifrian, C. Alvarez, B. Suberviola, B. Fernandez, L. Sanchez, D. Iturbe, M. A. Ballesteros. *Hospital Univ Marques Valdecilla, Santander, Spain*

**(847) Characteristics & Outcomes of Second Time Lung Re-Transplant Patients: Retrospective Cohort Analysis of the United Network for Organ Sharing Database;** G. K. Dubey<sup>1</sup>, C. Dobrescu<sup>1</sup>, S. Bhalla<sup>1</sup>, H. H. Nguyen<sup>2</sup>, S. Kanangat<sup>3</sup>, I. C. Beulaygue<sup>4</sup>, D. S. Nath<sup>1</sup>. <sup>1</sup>Pediatric Cardiothoracic Surgery, Rush University Medical Center, Chicago, IL, <sup>2</sup>Pediatric Cardiology, Rush University Medical Center, Chicago, IL, <sup>3</sup>Pathology, Rush University Medical Center, Chicago, IL, <sup>4</sup>Education & Human Development, Boston University, Boston, MA

**(848) Should High Risk Donors Be Restricted to High Volume Lung Transplant Centers?;** J. Rice, J. Trivedi, V. VanBerkel, M. Fox. *Department of Cardiothoracic Surgery, The University of Louisville School of Medicine, Louisville, KY*

**(849) *The Use of Polytrauma Donor Organs Does Not Impair Long-Term Outcome after Lung Transplantation***; [S. Schwarz](#), N. Rahimi, M. Muckenhuber, A. Benazzo, B. Moser, J. R. Matilla, G. Lang, S. Taghavi, P. Jaksch, W. Klepetko, K. Hoetzenecker. *Thoracic Surgery, Medical University of Vienna, Vienna, Austria*

**(850) *Bigger is Better - Oversizing May Improve Survival in Single Lung Transplantation for Pulmonary Fibrosis***; [K. Freystaetter](#)<sup>1</sup>, J. Mehew<sup>2</sup>, S. Tait<sup>1</sup>, O. Senbaklavaci<sup>1</sup>, J. Dark<sup>1</sup>. <sup>1</sup>*Department of Cardiothoracic Surgery, Freeman Hospital, Newcastle Upon Tyne, United Kingdom*, <sup>2</sup>*Statistics and Clinical Studies, NHS Blood and Transplant, Bristol, United Kingdom*

**(851) *One-Year Outcome after Lung Transplantation from Controllo DCD with Long WIT. Initial Experience***; [A. Palleschi](#)<sup>1</sup>, D. Tosi<sup>1</sup>, L. Rosso<sup>1</sup>, P. Mendogni<sup>1</sup>, I. Righi<sup>1</sup>, A. Zanella<sup>2</sup>, P. Tarsia<sup>2</sup>, M. Nosotti<sup>1</sup>. <sup>1</sup>*Thoracic Surgery and Lung Transplant Unit, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy*, <sup>2</sup>*Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy*

**(852) *Outcome of Lung Transplantation Using Organ Donors with Evidence of Aspiration***; [S. Schwarz](#), M. Muckenhuber, N. Rahimi, A. Benazzo, B. Moser, J. R. Matilla, G. Lang, S. Taghavi, P. Jaksch, W. Klepetko, K. Hoetzenecker. *Thoracic Surgery, Medical University of Vienna, Vienna, Austria*

**(853) *Longer Duration of Donor Ventilation Does Not Impact Long-Term Lung Function after Lung Transplantation***; [A. Hirji](#), D. Li, A. Kapasi, J. Weinkauff, D. Lien, K. Halloran. *Lung Transplant Program, University of Alberta, Edmonton, AB, Canada*

Thursday, April 4, 2019

5:45 PM - 7:00 PM

**POSTER SESSION 2: MECHANICAL CIRCULATORY SUPPORT (ADULT)**

Room: Timor Sea 2

**Poster Discussants:**

Andrew Boyle, MD, Thomas Jefferson University, Philadelphia, PA, USA

Kavitha Muthiah, MBChB, PhD, St. Vincent's Hospital, Sydney, Australia

Stuart Russell, MD, Duke University, Durham, USA

Elena Sandoval, MD, Hosp Clinic De Barcelona, Barcelona, Spain

Tahir Yagdi, MD, Ege University Hospital, Izmir, Turkey

Rashad Zayat, MD, RWTH University Hospital, Aachen, Germany

**(854) Corwave LVAD Development Update;** T. Snyder, A. Bourquin, F. Cornat, J. Biasetti, C. Botterbusch. *Corwave SA, Clichy, France*

**(856) A 4-Chamber Model Heart with 3D Printed Silicone Aorta and Peripheral Arteries to Simulate the Human Cardiovascular System in a Mock Circulatory Loop;** Y. Wang<sup>1</sup>, P. A. Smith<sup>1</sup>, J. R. Wheeler<sup>1</sup>, M. M. John<sup>2</sup>, C. R. Broda<sup>3</sup>, O. H. Frazier<sup>1</sup>, D. A. Taylor<sup>4</sup>, L. C. Sampaio<sup>1</sup>. <sup>1</sup>*Cardiovascular Surgery Research, Texas Heart Institute, Houston, TX*, <sup>2</sup>*Texas Heart Institute, Houston, TX*, <sup>3</sup>*Department of Pediatrics, Section of Adult Congenital Heart Disease, Baylor College of Medicine/Texas Children's Hospital, Houston, TX*, <sup>4</sup>*Regenerative Medicine Research, Texas Heart Institute, Houston, TX*

**(857) First-in-Man Implantations of a Newly Developed Transaortic Axial Flow Ventricular Assist Device (Impella 5.5);** A. M. Bernhardt, S. Hakmi, C. Sinning, E. Lubos, H. Reichenspurner. *Department of Cardiovascular Surgery, Univ Heart Ctr Hamburg, Hamburg, Germany*

**(858) A Novel Rotary Blood Pump for HFpEF;** E. Gude<sup>1</sup>, A. Fiane<sup>2</sup>. <sup>1</sup>*Dept of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway*, <sup>2</sup>*Dept of Cardiothoracic Surgery, Oslo University Hospital Rikshospitalet, Oslo, Norway*

**(859) Mechanical Circulatory Support for Biventricular Heart Failure Using Continuous-Flow Total Artificial Heart;** J. H. Karimov, D. Horvath, N. Byram, A. Polakowski, J. Adams, Y. Kado, T. Miyamoto, S. Sale, B. Kuban, K. Fukamachi. *The Cleveland Clinic, Cleveland, OH*

**(860) Evaluation of New Left Ventricular Assist Device for Transapical Insertion Using Virtual Mock Loop Model;** Y. Kado<sup>1</sup>, W. A. Smith<sup>2</sup>, T. Miyamoto<sup>1</sup>, N. Byram<sup>1</sup>, J. Adams<sup>1</sup>, A. R. Polakowski<sup>1</sup>, R. Dessoiffy<sup>1</sup>, D. J. Horvath<sup>3</sup>, K. Fukamachi<sup>1</sup>, J. H. Karimov<sup>1</sup>. <sup>1</sup>*Cleveland Clinic Foundation, Cleveland, OH*, <sup>2</sup>*Perfusions Solutions Inc., South Euclid, OH*, <sup>3</sup>*RI Engineering, Euclid, OH*

**(861) Novel Extracorporeal Continuous-Flow Ventricular Assist System for Patients with Advanced Heart Failure;** O. Seguchi<sup>1</sup>, T. Fujita<sup>2</sup>, Y. Kumai<sup>1</sup>, K. Kuroda<sup>1</sup>, S. Nakajima<sup>1</sup>, T. Watanabe<sup>1</sup>, M. Yanase<sup>1</sup>, Y. Matsumoto<sup>2</sup>, S. Fukushima<sup>2</sup>, T. Tsukiya<sup>3</sup>, T. Mizuno<sup>3</sup>, N. Katagiri<sup>3</sup>, Y. Kakuta<sup>3</sup>, Y. Takewa<sup>3</sup>, T. Hamasaki<sup>4</sup>, H. Yamamoto<sup>5</sup>, E. Tatsumi<sup>3</sup>, J. Kobayashi<sup>3</sup>, N. Fukushima<sup>1</sup>. <sup>1</sup>*Dept of Transplant Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan*, <sup>2</sup>*Dept of Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan*, <sup>3</sup>*Dept of Artificial Organs, National Cerebral and Cardiovascular Center, Osaka, Japan*, <sup>4</sup>*Office of Biostatistics and Data Management, National Cerebral and Cardiovascular Center, Osaka, Japan*, <sup>5</sup>*Dept of Advanced Medical Technology Development, National Cerebral and Cardiovascular Center, Osaka, Japan*

**(862) Temporary MCS versus Durable MCS as a Bridge to Heart Transplantation;** F. Esmailian, S. Dimbil, R. Levine, M. Kittleson, R. Cole, L. Czer, D. Chang, D. Geft, J. Chung, D. Ramzy, J. Moriguchi, J. Kobashigawa. *Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA*

**(863) Preoperative Computational Fluid Dynamics Simulation of the Best Anastomosis Site and Angle of the Outflow Graft and Ascending Aorta in Continuous Flow Mechanical Assist Devices;** A. Giacomini<sup>1</sup>, A. Esposito<sup>2</sup>, T. Nisi<sup>1</sup>, E. Lapenna<sup>1</sup>, S. Bartesaghi<sup>3</sup>, D. Redaelli<sup>3</sup>, F. Pappalardo<sup>4</sup>, G. Colombo<sup>3</sup>, M. De Bonis<sup>1</sup>. <sup>1</sup>*Cardio-Thoracic and Vascular Surgery, San Raffaele Scientific Institute, Milan, Italy*, <sup>2</sup>*Experimental Imaging Center, San Raffaele Scientific Institute, Milan, Italy*, <sup>3</sup>*Department of Mechanical Engineering, Politecnico di Milano, Milan, Italy*, <sup>4</sup>*Cardio-Vascular Intensive Care Unit, San Raffaele Scientific Institute, Milan, Italy*

**(864) Getting Past the Spin: The CorWave LVAD, a Membrane Wave Pump Providing Physiologic Pulsatility without High Shear;** C. N. Botterbusch, P. Monticone, E. Illouz, B. Burg, L. Polverelli, T. Snyder. *Corwave SA, Clichy, France*

**(865) Effects of Residential Distance from LVAD Implanting Center on Survival;** T. Nelson, S. George, A. Phanco, A. El Banayosy, J. W. Long. *IACC/NZTI, Integris Baptist Medical Center, Oklahoma City, OK*

**(866) Is Diabetes Mellitus a Risk Factor for Adverse Outcomes in Patients with Left Ventricular Assist Device? A Systematic Review and Meta-Analysis;** P. Zhou<sup>1</sup>, P. Zhu<sup>1</sup>, Z. Nie<sup>2</sup>, S. Zheng<sup>1</sup>. <sup>1</sup>Department of Cardiovascular Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, <sup>2</sup>Department of Epidemiology, Guangdong Cardiovascular Institute, Guangdong Provincial Key Laboratory of South China Structural Heart Disease, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China

**(867) Acoustic Characterisation of the HeartWare Left Ventricular Assist Device;** X. Yeong<sup>1</sup>, N. Rainnie<sup>1</sup>, D. Robson<sup>2</sup>, S. Shehab<sup>3</sup>, A. Doyle<sup>3</sup>, M. Fetanat<sup>1</sup>, K. Muthiah<sup>4</sup>, P. Jansz<sup>5</sup>, M. Connellan<sup>5</sup>, P. Macdonald<sup>4</sup>, C. Hayward<sup>6</sup>, K. Dhital<sup>5</sup>. <sup>1</sup>The University of New South Wales, Sydney, Australia, <sup>2</sup>Heart Transplant Unit, St Vincent's Hospital, Sydney, Australia, <sup>3</sup>The Victor Chang Cardiac Research Institute, Sydney, Australia, <sup>4</sup>Department of Cardiology, St Vincent's Hospital, Sydney, Australia, <sup>5</sup>Department of Cardiothoracic Surgery, St Vincent's Hospital, Sydney, Australia, <sup>6</sup>Department of Cardiology, St Vincents Hospital, Sydney, Australia

**(868) Comparison of Bridge-to-Transplant Outcomes with HeartMate 3 and HeartMate II Left Ventricular Assist Devices: A UNOS Registry Analysis;** R. C. Givens, S. M. Kochav, P. C. Colombo, M. A. Farr, S. W. Restaino, V. K. Topkara. *Medicine*, Columbia University Medical Center, New York, NY

**(869) Gender Disparity in Left Ventricular Assist Device Utilization: Insights from Nationwide Inpatient Sample 2004-2016;** A. A. Joshi<sup>1</sup>, A. P. Sajja<sup>2</sup>, J. B. Lerman<sup>3</sup>, A. K. Dey<sup>4</sup>, M. Kanwar<sup>5</sup>, A. Raina<sup>5</sup>. <sup>1</sup>Internal Medicine, Allegheny General Hospital, Pittsburgh, PA, <sup>2</sup>Internal Medicine, Johns Hopkins University Medical Center, Baltimore, MD, <sup>3</sup>Internal Medicine, Duke University Medical Center, Durham, NC, <sup>4</sup>Cardiovascular Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, <sup>5</sup>Cardiovascular Disease, Allegheny General Hospital, Pittsburgh, PA

**(870) Temporal Trends and Outcomes of Patients on Left Ventricular Assist Devices and Inotropes at the Time Listing for Heart Transplant;** E. Akintoye, A. Briasoulis, E. Ruiz Duque, C. Inampudi, J. Bhama, P. Alvarez. *University of Iowa, Iowa City, IA*

**(871) Renal Function after Ventricular Assist Device Implantation;** R. Moayedifar<sup>1</sup>, S. Sandner<sup>1</sup>, J. Riebandt<sup>1</sup>, D. Wiedemann<sup>1</sup>, T. Haberl<sup>1</sup>, T. Schloeglhofer<sup>2</sup>, G. Laufer<sup>1</sup>, D. Zimpfer<sup>1</sup>. <sup>1</sup>Cardiac Surgery, Medical University Vienna, Vienna, Austria, <sup>2</sup>Medical Physics and Biomedical Engineering, Medical University Vienna, Vienna, Austria

**(872) Trends, Outcomes and Readmissions among Left Ventricular Assist Device Recipients with Acute Kidney Injury Requiring Hemodialysis: An Insight from the National Readmissions Database 2012-2014;** C. Inampudi<sup>1</sup>, O. Adegba<sup>2</sup>, E. Akintoye<sup>1</sup>, P. Alvarez<sup>1</sup>, A. Briasoulis<sup>1</sup>. <sup>1</sup>Internal Medicine - Cardiology, Univ of Iowa Hospital, Iowa City, IA, <sup>2</sup>Internal Medicine, Univ of Iowa Hospital, Iowa City, IA

**(873) Safety and Efficacy of Percutaneous Ventricular Assist Device Exclusion; a Review of Ten Cases;** M. Chowdhury, J. Lindenfeld, A. Shah, K. Schlendorf, J. Fredi, K. Balsara, K. Goel, M. Danter, M. Brinkley, M. Wigger, H. Ooi, L. Punnoose, S. Brown, J. Menachem, S. Zalawadiya. *Vanderbilt University Medical Center, Nashville, TN*

**(874) Using INTERMACS(IM) to Establish Objective Performance Criteria (OPC) for Clinical Trials in "Less Sick" Advanced CHF Patients: An Analysis of the STS IM Database;** V. Jeevanandam<sup>1</sup>, T. Song<sup>1</sup>, G. Sayer<sup>2</sup>, C. LaBuhn<sup>1</sup>, D. Koehl<sup>3</sup>, R. Cantor<sup>3</sup>, N. Uriel<sup>1</sup>. <sup>1</sup>Cardiac Surgery, University of Chicago, Chicago, IL, <sup>2</sup>Cardiology, University of Chicago, Chicago, IL, <sup>3</sup>University of Alabama, Birmingham, AL

**(876) Outcomes of Left Ventricular Assist Device as Bridge-to-Cardiac Transplant in Singapore;** M. Tan<sup>1</sup>, J. Seah<sup>1</sup>, K. L. Kerk<sup>2</sup>, T. E. Tan<sup>2</sup>, C. Sivathanan<sup>2</sup>, D. Sim<sup>1</sup>, C. P. Lim<sup>1</sup>. <sup>1</sup>Cardiology, National Heart Centre Singapore, Singapore, Singapore, <sup>2</sup>Cardiothoracic Surgery, National Heart Centre Singapore, Singapore, Singapore

**(877) Stability of Cardiac Function after Left Ventricular Assist Device Weaning in End-Stage Heart Failure;** I. Taleb, M. Yin, A. Koliopoulou, C. P. Kyriakopoulos, J. Nativi-Nicolau, O. Wever-Pinzon, S. H. McKellar, E. Dranow, J. Stehlik, E. M. Gilbert, J. C. Fang, C. H. Selzman, S. G. Drakos. *University of Utah, Salt Lake City, UT*

**(878) Is Frailty Reversible after LVAD?;** C. Falls, T. Lennie, M. Guglin. *University of Kentucky, Lexington, KY*

**(879) Is it Possible to Implant and Manage Patients with Durable LVADs Who Refuse Blood Products?;** E. Gonzales<sup>1</sup>, G. Sayer<sup>2</sup>, G. Kim<sup>3</sup>, N. Sarswat<sup>3</sup>, B. Smith<sup>3</sup>, S. Kalantari<sup>3</sup>, J. Raikhelkar<sup>3</sup>, C. Stonebraker<sup>4</sup>, T. Song<sup>4</sup>, T. Ota<sup>4</sup>, N. Uriel<sup>2</sup>, C. LaBuhn<sup>1</sup>, P. Combs<sup>1</sup>, D. Onsager<sup>4</sup>, V. Jeevanandam<sup>1</sup>. <sup>1</sup>Cardiac Surgery, University of Chicago, Chicago, IL, <sup>2</sup>Cardiology, University of Chicago, Chicago, IL, <sup>3</sup>Cardiology, University of Chicago Medicine, Chicago, IL, <sup>4</sup>Cardiac Surgery, University of Chicago Medicine, Chicago, IL

**(880) Concomitant Alfieri Stitch Mitral Valve Repair in Patients Undergoing Left Ventricular Assist Device Implantation;** F. Tan<sup>1</sup>, K. L. Kerk<sup>2</sup>, T. E. Tan<sup>2</sup>, C. Sivathanan<sup>2</sup>, D. Sim<sup>1</sup>, C. P. Lim<sup>1</sup>. <sup>1</sup>Cardiology, National Heart Centre Singapore, Singapore, Singapore, Singapore, <sup>2</sup>Cardiothoracic Surgery, National Heart Centre Singapore, Singapore, Singapore

**(881) Tricuspid Clipping during LVAD Support: First in Human Report;** S. Schulte-Eistrup<sup>1</sup>, N. Reiss<sup>2</sup>, J. Sindermann<sup>3</sup>, T. Schmidt<sup>2</sup>, H. Warnecke<sup>1</sup>, F. Ritter<sup>4</sup>, N. Franz<sup>4</sup>, M. Kowalski<sup>4</sup>. <sup>1</sup>Department for Cardiac Surgery, Schuechtermann Clinic Bad Rothenfelde, Bad Rothenfelde, Germany, <sup>2</sup>Department for Cardiovascular Research, Schuechtermann Clinic Bad Rothenfelde, Bad Rothenfelde, Germany, <sup>3</sup>Department for Cardiac Rehabilitation, Schuechtermann Clinic Bad Rothenfelde, Bad Rothenfelde, Germany, <sup>4</sup>Department for Cardiology, Schuechtermann Clinic Bad Rothenfelde, Bad Rothenfelde, Germany

**(882) Role of Immunocompetent Cells in Functional Recovery Post-Implantation of Ventricular Assist Device in Non-Ischemic Dilated Cardiomyopathy;** A. Koga<sup>1</sup>, S. Fukushima<sup>1</sup>, Y. Matsumoto<sup>1</sup>, K. Otani<sup>2</sup>, N. Fukushima<sup>3</sup>, H. Ishibashi-Ueda<sup>4</sup>, M. Harada-Shiba<sup>2</sup>, J. Kobayashi<sup>5</sup>, K. Suzuki<sup>6</sup>, T. Fukui<sup>7</sup>, T. Fujita<sup>1</sup>. <sup>1</sup>Department of Cardiac Surgery, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan, <sup>2</sup>Department of Regenerative Medicine and Tissue Engineering, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan, <sup>3</sup>Department of Transplantation, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan, <sup>4</sup>Department of Pathology, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan, <sup>5</sup>Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan, <sup>6</sup>William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary, University of London, London, United Kingdom, <sup>7</sup>Department of Cardiovascular Surgery, Kumamoto University, Kumamoto, Kumamoto, Japan

**(883) Minimally Invasive LVAD Implantation: Early and Mid-Term Results at a Single Center;** U. Kervan<sup>1</sup>, S. S. Kocabeyoglu<sup>1</sup>, D. E. Sert<sup>1</sup>, M. Karahan<sup>1</sup>, A. Temizhan<sup>2</sup>, B. Demirkan<sup>3</sup>, Y. Akin<sup>2</sup>, M. Pac<sup>1</sup>. <sup>1</sup>Cardiovascular Surgery, Turkey Yuksek Ihtisas Hospital, Ankara, Turkey, <sup>2</sup>Cardiology, Turkey Yuksek Ihtisas Hospital, Ankara, Turkey, <sup>3</sup>cardiology, Turkey Yuksek Ihtisas Hospital, Ankara, Turkey

**(884) Education and Decision-Making in Patients and Caregivers Considering Left Ventricular Assist Devices;** A. Oehler<sup>1</sup>, A. J. Kanelidis<sup>2</sup>, S. Kalantari<sup>1</sup>, B. Smith<sup>1</sup>, G. Sayer<sup>1</sup>, N. Narang<sup>1</sup>, H. L. Holzhauser<sup>1</sup>, A. Nguyen<sup>1</sup>, B. Chung<sup>1</sup>, M. Quinn<sup>1</sup>, C. Rhee<sup>3</sup>, M. Siegler<sup>1</sup>, N. Uriel<sup>1</sup>. <sup>1</sup>Cardiovascular Disease, University of Chicago, Chicago, IL, <sup>2</sup>Internal Medicine, University of Chicago, Chicago, IL, <sup>3</sup>Geriatric Medicine, University of Chicago, Chicago, IL

**(885) Functional Recovery Post Left Ventricular Assist Device Implantation in INTERMACS Profile 1 Population;** C. L. Neo, K. L. Kerk, J. H. Tay, J. L. Tan, J. L. Leam, T. E. Tan, C. Sivathasan. Department of Cardiothoracic Surgery, National Heart Centre Singapore, Singapore, Singapore

**(886) Improved Survival Trend Following the Introduction of Heartmate 3. A Single Centre Experience;** S. M. Shaw, P. Callan, S. Kore, R. Venkateswaran. Heart and Lung Transplant, Manchester University NHS Foundation Trust, Manchester, United Kingdom

**(887) INTERMACS Profile Does Not Predict Required Flow Rate of CF-LVAD at Discharge;** A. Critsinelis<sup>1</sup>, H. Lamba<sup>1</sup>, S. Oberton<sup>1</sup>, F. Cheema<sup>1</sup>, A. Civitello<sup>2</sup>, R. Delgado<sup>1</sup>, A. Nair<sup>1</sup>, A. Shafii<sup>1</sup>, G. Loor<sup>1</sup>, T. Rosengart<sup>1</sup>, O. Frazier<sup>1</sup>, J. Morgan<sup>1</sup>. <sup>1</sup>Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, TX, <sup>2</sup>Baylor College of Medicine, Houston, TX

**(888) Hypoalbuminemia in Patients Post LVAD Implantation;** C. Falls, M. K. Rayens, M. Guglin. University of Kentucky, Lexington, KY

**(889) Predictors of Change in Mitral Regurgitation Severity after Left Ventricular Assist Device Implantation;** W. Lin<sup>1</sup>, J. Bullen<sup>2</sup>, E. Soltész<sup>3</sup>, J. Estep<sup>1</sup>, W. Tang<sup>1</sup>, M. Sabe<sup>4</sup>, E. Joyce<sup>1</sup>, D. Kwon<sup>5</sup>. <sup>1</sup>Section of Heart Failure and Cardiac Transplantation, Cleveland Clinic, Cleveland, OH, <sup>2</sup>Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, <sup>3</sup>Department of Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, <sup>4</sup>Beth Israel Deaconess Medical Center, Boston, MA, <sup>5</sup>Section of Cardiovascular Imaging, Cleveland Clinic, Cleveland, OH

Thursday, April 4, 2019

5:45 PM - 7:00 PM

**POSTER SESSION 2: MECHANICAL CIRCULATORY SUPPORT (ADULT)**

Room: Timor Sea 1

**Poster Discussants:**

Cristiano Amarelli, MD, Monaldi, Azienda dei Colli, Naples, Italy  
Pavan Atluri, MD, University of Pennsylvania, Philadelphia, PA, USA  
Jay Bhama, MD, University of Iowa Health Care, Iowa City, IA, USA  
Sandra Chaparro, MD, University of Miami, Miami, FL, USA  
Hannah Copeland, MD, University of Mississippi Medical Center, Jackson, MS, USA  
Ioannis Dimarakis, PhD, FRCS, University Hospital of S. Manchester, Manchester, United Kingdom  
Eric Epailly, MD, Les Hopitaux University, Strasbourg, France  
Jerry Estep, MD, Cleveland Clinic, Cleveland, OH, USA  
Anna Meyer, MD, Leipzig Heart Center, Leipzig, Germany  
Sarah Schettle, PA-C, Mayo Clinic, Rochester, NY, USA

**(890) Delineating Pathways to Death by Multisystem Organ Failure in Patients with a Left Ventricular Assist Device (LVAD);** L. Seese<sup>1</sup>, F. Movahedi<sup>2</sup>, J. Antaki<sup>3</sup>, R. Padman<sup>4</sup>, S. Murali<sup>5</sup>, Y. Zhang<sup>6</sup>, A. Kilic<sup>1</sup>, C. Sciortino<sup>1</sup>, M. Keebler<sup>1</sup>, R. Kormos<sup>1</sup>. <sup>1</sup>Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>2</sup>Department of Electrical and Computer Engineering, University of Pittsburgh, Pittsburgh, PA, <sup>3</sup>Meinig School of Biomedical Engineering, Cornell University, New York, NY, <sup>4</sup>The H. John Heinz III College of Information Systems and Public Policy, Carnegie Mellon University, Pittsburgh, PA, <sup>5</sup>Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA, <sup>6</sup>Weill Cornell Medical, Cornell University, New York, NY

**(891) External Assessment of EUROMACS Right-Sided Heart Failure Risk Score;** H. Shah<sup>1</sup>, T. Murray<sup>2</sup>, A. El Rafei<sup>3</sup>, J. Schultz<sup>1</sup>, T. Thenappan<sup>1</sup>, T. Alexy<sup>1</sup>, R. John<sup>4</sup>, C. Martin<sup>1</sup>, M. Pritzker<sup>1</sup>, R. Cogswell<sup>1</sup>. <sup>1</sup>Cardiology, University of Minnesota, Minneapolis, MN, <sup>2</sup>Biostatistics, University of Minnesota, Minneapolis, MN, <sup>3</sup>Internal Medicine, University of Minnesota, Minneapolis, MN, <sup>4</sup>Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN

**(892) Reduced Adverse Events with Heartmate 3. The Manchester Experience;** P. D. Callan, S. M. Shaw, R. Venkateswaran, S. Kore. Heart and Lung Transplant Centre, Wythenshawe Hospital, Manchester, United Kingdom

**(893) Gore-Tex Mesh as Cause for Distal Outflow Graft Obstruction in Ventricular Assist Device Patients;** S. Bhattacharya, N. Colaco, M. Coleman, S. Sharma, M. Kassemos, M. Aras, V. Selby, T. De Marco, L. Klein, G. Wieselthaler. Cardiology, University of California, San Francisco, San Francisco, CA

**(894) Continuous-Flow Left Ventricular Assist Devices Have Very Low Rates of Mechanical Failure;** G. V. Letsou<sup>1</sup>, N. Wang<sup>2</sup>, G. Loor<sup>3</sup>, F. I. Musfee<sup>4</sup>, L. Sampaio<sup>5</sup>, D. A. Taylor<sup>5</sup>, F. Cheema<sup>1</sup>, J. A. Morgan<sup>1</sup>, H. K. Lamba<sup>3</sup>, J. K. Ho<sup>3</sup>, O. H. Frazier<sup>3</sup>. <sup>1</sup>Surgery, Baylor College of Med, Houston, TX, <sup>2</sup>Heart Intensive Care Unit, First Affiliated Hospital of Dalian, Dalian, China, <sup>3</sup>Surgery, Baylor College of Medicine, Houston, TX, <sup>4</sup>Epidemiology, University of Texas School of Public Health, Houston, TX, <sup>5</sup>Research, Texas Heart Institute, Houston, TX

**(896) Valvular Disease Management in Patients with Continuous-Flow Left Ventricular Assist Device;** S. Maeda, K. Toda, H. Hata, S. Miyagawa, Y. Yoshikawa, S. Kainuma, T. Kawamura, A. Kawamura, S. Yoshida, T. Ueno, T. Kuratani, Y. Sawa. Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Japan

**(897) Predicting Post LVAD Acute Severe Right Heart Failure Using Bayesian Analysis;** M. Kanwar<sup>1</sup>, C. Khoo<sup>2</sup>, L. Lohmueller<sup>3</sup>, S. Bailey<sup>1</sup>, S. Murali<sup>1</sup>, J. Antaki<sup>2</sup>. <sup>1</sup>Allegheny General Hospital, Pittsburgh, PA, <sup>2</sup>Cornell University, Ithaca, NY, <sup>3</sup>Carnegie Mellon University, Pittsburgh, PA

**(898) Trend in Pulmonary Artery Pulsatility Index Pre- to Post-LVAD Implantation;** S. Kumar<sup>1</sup>, A. Rahman<sup>1</sup>, J. S. Josephs<sup>1</sup>, O. Saeed<sup>2</sup>, S. Patel<sup>2</sup>, S. Murthy<sup>2</sup>, J. J. Shin<sup>2</sup>, S. Forest<sup>3</sup>, S. Vukelic<sup>2</sup>, D. J. Goldstein<sup>3</sup>, U. P. Jorde<sup>2</sup>, D. Sims<sup>2</sup>. <sup>1</sup>Internal Medicine, Montefiore Medical Center (Moses/Weiler Division), New York, NY, <sup>2</sup>Cardiology, Montefiore Medical Center (Moses/Weiler Division), New York, NY, <sup>3</sup>Cardiothoracic Surgery, Montefiore Medical Center (Moses/Weiler Division), New York, NY

**(899) Pulmonary Artery Pulsatility Index Early Post-LVAD Implantation Predicts Severe Right Ventricular Failure;** S. Kumar<sup>1</sup>, A. Rahman<sup>1</sup>, J. S. Josephs<sup>1</sup>, O. Saeed<sup>2</sup>, S. Patel<sup>2</sup>, S. Murthy<sup>2</sup>, J. J. Shin<sup>2</sup>, S. Forest<sup>3</sup>, S. Vukelic<sup>2</sup>, D. J. Goldstein<sup>3</sup>, U. P. Jorde<sup>2</sup>, D. Sims<sup>2</sup>. <sup>1</sup>Internal Medicine, Montefiore Medical Center (Moses/Weiler Division), New York, NY, <sup>2</sup>Cardiology, Montefiore Medical Center (Moses/Weiler Division), New York, NY, <sup>3</sup>Cardiothoracic Surgery, Montefiore Medical Center (Moses/Weiler Division), New York, NY



- (900) Long-Term Survival of Patients Requiring Early Temporary RVAD Support Following LVAD Implantation;** H. Vidula, S. McNitt, M. Wang, B. Polonsky, S. Sherazi, B. Ayers, K. Wood, B. Barrus, J. Alexis, L. Chen, V. Kutiyifa, I. Gosev, I. Goldenberg. *Univ of Rochester, Rochester, NY*
- (901) Right Ventricular Failure Risk Prediction Models in Patients Undergoing Left Ventricular Assist Device Implantation: A Systematic Review;** C. Frankfurter<sup>1</sup>, M. Molinero<sup>2</sup>, F. Foroutan<sup>3</sup>, J. Vishram<sup>2</sup>, A. Alba<sup>2</sup>. <sup>1</sup>Faculty of Medicine, University of Toronto, Toronto, ON, Canada, <sup>2</sup>Heart Failure and Transplant Program, University Health Network, Toronto, ON, Canada, <sup>3</sup>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
- (902) Early Renal Recovery after Left Ventricular Assist Device Implantation is Associated with Improved Clinical Outcomes in Patients with Kidney Disease at Baseline;** J. Grinstein<sup>1</sup>, A. Kadakkal<sup>1</sup>, M. Rodrigo<sup>1</sup>, M. Hofmeyer<sup>1</sup>, S. Mohammed<sup>1</sup>, N. Butt<sup>2</sup>, P. E. Craig<sup>1</sup>, R. Torguson<sup>1</sup>, E. Molina<sup>1</sup>, S. Najjar<sup>1</sup>, F. Sheikh<sup>1</sup>. <sup>1</sup>MedStar Heart and Vascular Institute, Washington, DC, <sup>2</sup>MedStar Washington Hospital Center, Washington, DC
- (903) Long-Term Outcomes in HeartMate 2 Short-to-Shield Patients on an Ungrounded Cable;** L. Coyle, N. Graney, C. Gallagher, R. Paliga, G. Yost, G. Macaluso, A. Tatoes. *Heart and Vascular Institute, Advocate Christ Medical Center, Oak Lawn, IL*
- (904) The Effect of Postoperative Vasoplegia to the Survival of LVAD Recipients;** M. Kawabori<sup>1</sup>, J. Soffer<sup>2</sup>, M. Mastorianni<sup>2</sup>, Y. Zhan<sup>1</sup>, K. G. Warner<sup>1</sup>, H. Rastegar<sup>1</sup>, M. S. Kiernan<sup>1</sup>, D. Denofrio<sup>1</sup>, F. Y. Chen<sup>1</sup>, G. S. Couper<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, Tufts Medical Center, Boston, MA, <sup>2</sup>Tufts University School of Medicine, Boston, MA
- (905) Length of Stay in the Intensive Care Unit during Index Admission for Left Ventricular Assist Device and Total Artificial Heart Insertion is a Risk Factor for Infection;** N. K. Bart<sup>1</sup>, S. Emmanuel<sup>1</sup>, P. C. Jansz<sup>2</sup>, K. Muthiah<sup>3</sup>, C. S. Hayward<sup>1</sup>. <sup>1</sup>Heart Transplant and Failure, St Vincents Hospital, Sydney, Australia, <sup>2</sup>Cardiothoracic Surgery, St Vincents Hospital, Sydney, Australia, <sup>3</sup>Heart Transplant and Failure, St Vincent's Hospital, Sydney, Australia
- (906) Characteristics of Left Ventricular Assist Device (LVAD) Supported Patients Who Experience Indication Changes during Time on Support;** D. McGrath<sup>1</sup>, B. Nisraiyya<sup>1</sup>, L. Berube<sup>1</sup>, J. Camuso<sup>2</sup>, K. Milley<sup>2</sup>, M. Villavicencio-Theoduloz<sup>2</sup>, D. D'Alessandro<sup>2</sup>, E. Coglianese<sup>1</sup>. <sup>1</sup>Cardiology, Massachusetts General Hospital, Boston, MA, <sup>2</sup>Cardiac Surgery, Massachusetts General Hospital, Boston, MA
- (907) Rehospitalization in Patients Implanted with the Total Artificial Heart and Discharged with a Portable Driver;** C. W. Lee<sup>1</sup>, E. J. Sawey<sup>2</sup>, K. Shah<sup>2</sup>, K. Desai<sup>3</sup>, D. Tang<sup>4</sup>, V. Kasirajan<sup>4</sup>, M. Quader<sup>4</sup>. <sup>1</sup>Internal Medicine, Virginia Commonwealth Univ Health System, Richmond, VA, <sup>2</sup>Cardiology, Virginia Commonwealth Univ Health System, Richmond, VA, <sup>3</sup>Virginia Commonwealth Univ School of Medicine, Richmond, VA, <sup>4</sup>Cardiothoracic Surgery, Virginia Commonwealth Univ Health System, Richmond, VA
- (908) Characterizing Sex-Specific Baseline Characteristics and Outcomes in Left Ventricular Assist Device (LVAD) Support;** B. Nisraiyya<sup>1</sup>, D. McGrath<sup>1</sup>, L. Berube<sup>1</sup>, J. Camuso<sup>2</sup>, K. Milley<sup>2</sup>, M. Villavicencio-Theoduloz<sup>2</sup>, D. D'Alessandro<sup>2</sup>, E. Coglianese<sup>1</sup>. <sup>1</sup>Cardiology, Massachusetts General Hospital, Boston, MA, <sup>2</sup>Cardiac Surgery, Massachusetts General Hospital, Boston, MA
- (909) MELD Score: A Predictor of Mortality for Patients Receiving RVAD after LVAD Implantation;** A. Bansal<sup>1</sup>, F. Akhtar<sup>1</sup>, D. Jacks<sup>1</sup>, S. Desai<sup>2</sup>. <sup>1</sup>Cardiothoracic Surgery, Ochsner Clinic Foundation, New Orleans, LA, <sup>2</sup>Heart Transplant Med, Ochsner Clinic Foundation, New Orleans, LA
- (910) ICD Therapy in LVAD: Rates and Predictors of Appropriate and Inappropriate Shock;** N. Dharmavaram<sup>1</sup>, R. Kipp<sup>2</sup>, T. Hess<sup>2</sup>, R. Dhingra<sup>3</sup>. <sup>1</sup>Department of Medicine, University of Wisconsin, Madison, WI, <sup>2</sup>Division of Cardiovascular Medicine, University of Wisconsin, Madison, WI, <sup>3</sup>Advanced Heart Failure and Transplantation, University of Wisconsin, Madison, WI
- (911) Once Bitten Twice Not So Shy: Outcomes of Left Ventricular Assist Device Pump Exchange;** N. A. Brozzi<sup>1</sup>, I. C. Saba<sup>1</sup>, T. Patricelli<sup>1</sup>, N. Thakkar Rivera<sup>2</sup>, A. Ghodsizad<sup>3</sup>, A. Badiye<sup>2</sup>, S. Chaparro<sup>2</sup>, M. Loebe<sup>1</sup>. <sup>1</sup>Surgery, University of Miami, Miami, FL, <sup>2</sup>Medicine, University of Miami, Miami, FL, <sup>3</sup>University of Miami & Jackson Memorial Hospital in the city of Miami, Miami, FL
- (912) How Do Mechanical Circulatory Support Patients Die? Autopsy Findings for Bridge to Transplant LVAD/TAH Patients Who Do Not Survive to Transplant;** N. K. Bart<sup>1</sup>, K. Muthiah<sup>1</sup>, P. C. Jansz<sup>2</sup>, C. S. Hayward<sup>1</sup>. <sup>1</sup>Heart Transplant and Failure, St Vincents Hospital, Sydney, Australia, <sup>2</sup>Cardiothoracic Surgery, St Vincents Hospital, Sydney, Australia
- (913) Psychosocial Evaluation of Candidates for Mechanical Circulatory Support and Risk for Adverse Post-Implantation Medical Outcomes;** M. A. Dew<sup>1</sup>, J. Hollenberger<sup>2</sup>, L. L. Obregon<sup>3</sup>, G. W. Hickey<sup>4</sup>, C. M. Sciortino<sup>4</sup>, K. L. Lockard<sup>4</sup>, N. M. Kunz<sup>4</sup>, M. A. Mathier<sup>4</sup>, R. N. Ramani<sup>4</sup>, A. Kilic<sup>4</sup>, D. M. McNamara<sup>4</sup>, M. A. Simon<sup>4</sup>, R. L. Kormos<sup>4</sup>. <sup>1</sup>University of Pittsburgh School of Medicine and Medical Center, Pittsburgh, PA, <sup>2</sup>Grove City College, Grove City, PA and University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>3</sup>Heart and Vascular Institute, University of Pittsburgh Medical Center, and Carnegie Mellon University, Pittsburgh, PA, <sup>4</sup>Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA

**(914) Magnitude of Bleeding and Blood Product Utilization Predict Early Right Ventricular Implantation in LVAD Recipients;** J. Conroy<sup>1</sup>, H. Lamba<sup>1</sup>, J. Ho<sup>1</sup>, J. Kraus<sup>2</sup>, S. Chatterjee<sup>1</sup>, S. Fedson<sup>1</sup>, S. Sattree<sup>1</sup>, F. Cheema<sup>1</sup>, A. Civitello<sup>1</sup>, R. Delgado<sup>1</sup>, A. Shafii<sup>1</sup>, G. Loor<sup>1</sup>, T. Rosengart<sup>1</sup>, O. Frazier<sup>1</sup>, J. Morgan<sup>1</sup>, A. Nair<sup>1</sup>. <sup>1</sup>Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, TX, <sup>2</sup>Baylor College of Medicine, Houston, TX

**(915) Surgical Management for Heart Failure: A Comparison of Left Ventricular Repair and Ventricular Assist Device;** H. Kanemitsu, K. Minatoya, K. Yamazaki, K. Sakamoto, M. Kawatou, J. Sakai, M. Kudo, M. Nakamura, R. Yamamoto, Y. Kitagata, Y. Ide, T. Ikeda. *Cardiovascular Surgery, Kyoto University, Kyoto, Japan*

**(916) Complete Sternal-Sparing LVAD Implantation Improves Mobility Compared to Full Sternotomy;** B. C. Ayers, K. Wood, S. Sheen, E. Morrison, H. Vidula, J. Alexis, S. Prasad, I. Gosev. *University of Rochester, Rochester, NY*

**(918) Relationship between Inflow Malposition and Clinical Outcomes in HVAD Recipients;** E. N. Sorensen<sup>1</sup>, E. D. Feller<sup>1</sup>, D. J. Kaczorowski<sup>1</sup>, L. M. Dees<sup>1</sup>, V. Ton<sup>1</sup>, R. J. Madathil<sup>1</sup>, Z. N. Kon<sup>2</sup>, B. P. Griffith<sup>1</sup>. <sup>1</sup>University of Maryland, Baltimore, MD, <sup>2</sup>NYU Langone Medical Center, New York, NY

**(919) Patient-Tailored Silicone Plug for HeartMate 3™ Left Ventricular Assist Device Explantation;** C. Heim, N. Ebel, D. W. Schubert, S. Werner, M. Kondruweit, R. Tandler, M. Weyand. *University of Erlangen, Erlangen, Germany*

**(920) “The Right Stuff”: Using a Caval Stent Valve to Mitigate the Effect of Right Heart Failure in LVAD Patients;** R. R. Gonzalez<sup>1</sup>, A. A. Grant<sup>2</sup>, E. DeMarchena<sup>3</sup>, A. Klima<sup>4</sup>, M. Armor<sup>4</sup>, A. Badiye<sup>5</sup>, M. Loebe<sup>6</sup>, M. Cohen<sup>7</sup>, A. Ghodsizad<sup>6</sup>. <sup>1</sup>Surgery, Miami Transplant Institute Univ of Miami, Miami, FL, <sup>2</sup>Miami Transplant Institute, Miami, FL, <sup>3</sup>Div of Cardiology, Dept of Medicine, Univ of Miami Leonard M Miller School of Medicine, Miami, FL, <sup>4</sup>Comprehensive Care Services, Inc., Livonia, MI, <sup>5</sup>Dept of Medicine, Div of Cardiology, Div of Heart and Lung Transplant and Mechanical, Miami Transplant Institute, Univ of Miami Leonard M Miller School of Medicine, Miami, FL, <sup>6</sup>Div of Heart and Lung Transplant and Mechanical Support, Miami Transplant Institute, Dewitt Daughtry Family Dept of Surgery, Div of Cardiothoracic Surgery, Univ of Miami Leonard M Miller School of Medicine, Miami, FL, <sup>7</sup>Dept of Medicine, Cardiovascular Div, Univ of Miami Leonard M Miller School of Medicine, Miami, FL

**(921) Results of Minimally Invasive HVAD Insertion in a Large Cohort of Unselected Patients;** D. J. Kaczorowski<sup>1</sup>, Z. N. Kon<sup>2</sup>, E. N. Sorensen<sup>1</sup>, S. M. Pham<sup>3</sup>, C. Pasrija<sup>1</sup>, L. M. Dees<sup>1</sup>, R. J. Madathil<sup>1</sup>, V. Ton<sup>1</sup>, E. D. Feller<sup>1</sup>, B. P. Griffith<sup>1</sup>. <sup>1</sup>University of Maryland, Baltimore, MD, <sup>2</sup>NYU Langone Medical Center, New York, NY, <sup>3</sup>Mayo Clinic Florida, Jacksonville, FL

**(922) Less Invasive HeartMate 3 Implantation is Safe and Reproducible with Excellent Outcomes;** I. Gosev, K. Wood, B. C. Ayers, H. Vidula, J. Alexis, N. Kumar, J. Delehanty, B. Barrus, P. Knight, L. Chen, S. Prasad. *University of Rochester, Rochester, NY*

**(923) Approaches to Repairing Outflow Graft Stenosis in Left Ventricular Assist Devices;** V. Kagan<sup>1</sup>, C. Mehta<sup>1</sup>, E. Michel<sup>1</sup>, A. Ward<sup>1</sup>, A. Jivan<sup>2</sup>, M. Ricciardi<sup>2</sup>, A. Anderson<sup>2</sup>, D. T. Pham<sup>1</sup>, J. Rich<sup>2</sup>. <sup>1</sup>Division of Cardiac Surgery, Northwestern Memorial Hospital, Chicago, IL, <sup>2</sup>Division of Cardiology, Northwestern Memorial Hospital, Chicago, IL

**(924) Left Thoracotomy Upper Hemisternotomy Left Ventricular Assist Device (LVAD) Implantation Offers Safe, Durable Option for Patients with Prior Sternotomy Undergoing LVAD Implantation;** N. M. Foley<sup>1</sup>, S. Zalawadiya<sup>2</sup>, M. Kuzemchak<sup>1</sup>, K. Balsara<sup>1</sup>, J. Menachem<sup>2</sup>, K. Schlendorf<sup>2</sup>, S. Maltais<sup>3</sup>, A. Shah<sup>1</sup>, M. Danter<sup>1</sup>. <sup>1</sup>Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN, <sup>2</sup>Cardiology, Vanderbilt University Medical Center, Nashville, TN, <sup>3</sup>Cardiac Surgery, Mayo Clinic, Rochester, MN

**(925) Complete Sternal-Sparing Technique Improves Outcomes and Decreases RV Failure Compared to Re-Operative Sternotomy;** B. C. Ayers, F. Sagebin, K. Wood, H. Vidula, J. Alexis, B. Barrus, S. Prasad, I. Gosev. *University of Rochester, Rochester, NY*

**(926) Concurrent Mitral Valve Repair during Placement of Continuous-Flow Left Ventricular Assist Device;** M. Cevasco, Y. Naka, A. Saha, A. R. Garan, L. Witer, J. Sanchez, P. Kurlansky, A. Melchey, J. Fried, M. Yusefpolskaya, P. Colombo, H. Takayama, K. Takeda. *Columbia University Medical Center, New York, NY*

**(927) Impact of Previous Sternotomy on Outcome after Left Ventricular Assist Device Implantation;** K. Zhigalov, A. Mashhour, M. Szczechowicz, S. Mkalaluh, J. Ennker, H. Eichstaedt, A. Weymann. *Department of Cardiac Surgery, Carl von Ossietzky University Oldenburg, Oldenburg, Germany*

**(928) Get Home, Stay Home: 90-Day Readmission Rate after Complete Sternal-Sparing HeartMate3 Implantation;** K. Wood, B. C. Ayers, H. Vidula, J. Alexis, J. Delehanty, B. Barrus, P. Knight, L. Chen, S. Prasad, I. Gosev. *University of Rochester, Rochester, NY*

**(929) Single Center Experience with 52 Less Invasive Left Ventricular Assist Device Implantations;** F. Sipahi, A. Mehdiani, A. Albert, H. Aubin, U. Boeken, P. Akhyari, R. Westenfeld, A. Lichtenberg, D. Saeed. *Cardiovascular Surgery, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany*

**(930) Experience with Long-Term Continuous Flow Ventricular Assist Devices Bridge to Recovery Concept;** R. Wieloch, A. Albert, A. Mehdiani, U. Boeken, H. Aubin, R. Westenfeld, P. Akhyari, A. Lichtenberg, D. Saeed. *Cardiovascular Surgery, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany*

**(931) Implantation of a HeartMate 3 Left Ventricular Assist Device in a Patient with Congenitally Corrected Transposition of the Great Arteries;** H. Kirov, G. Faerber, T. Doenst. *University Clinic Jena, Jena, Germany*

**(932) A New Less Invasive Technique of RVAD Insertion - Time to Lower the Threshold around LVAD Insertion;** S. Madassery<sup>1</sup>, D. O'Leary<sup>1</sup>, S. Schueler<sup>2</sup>, G. Macgowan<sup>3</sup>, N. Robinson<sup>4</sup>, A. Woods<sup>4</sup>, A. Samuel<sup>1</sup>. <sup>1</sup>Cardiothoracic Anesthesia, Freeman Hospital, Newcastle Upon Tyne, UK, <sup>2</sup>Cardiothoracic Surgery, Freeman Hospital, Newcastle Upon Tyne, UK, <sup>3</sup>Cardiology, Freeman Hospital, Newcastle Upon Tyne, UK, <sup>4</sup>Heart Transplantation, Freeman Hospital, Newcastle Upon Tyne, UK

**(933) Effect of Preoperative Cardiac Anatomy and Surgical Approach on HVAD Inflow Position;** E. N. Sorensen<sup>1</sup>, D. J. Kaczorowski<sup>1</sup>, E. D. Feller<sup>1</sup>, L. M. Dees<sup>1</sup>, V. Ton<sup>1</sup>, R. J. Madathil<sup>1</sup>, Z. N. Kon<sup>2</sup>, B. P. Griffith<sup>1</sup>. <sup>1</sup>University of Maryland, Baltimore, MD, <sup>2</sup>NYU Langone Medical Center, New York, NY

**(934) INTERMACS 3 and 4 Patients Have Excellent Outcomes after Complete Sternal-Sparing HeartMate 3 Implantation;** K. Wood, B. Ayers, H. Vidula, J. Alexis, B. Barrus, S. Prasad, I. Gosev. *University of Rochester, Rochester, NY*

**(935) Regional Nerve Block Decreases Opioid Use after Complete Sternal Sparing Left Ventricular Assist Device Implantation;** K. Wood, B. C. Ayers, S. Philippo, D. Lindenmuth, R. Stahl, J. Wyrobek, H. Vidula, J. Alexis, B. Barrus, S. Prasad, I. Gosev. *University of Rochester, Rochester, NY*

**(936) P2Y12 Receptor Antagonists: Do They Really Inhibit Shear-Mediated Platelet Activation within MCS?;** Y. Roka-Moija<sup>1</sup>, J. Sheriff<sup>2</sup>, D. Bluestein<sup>2</sup>, M. J. Slepian<sup>1</sup>. <sup>1</sup>Department of Medicine, Sarver Heart Center, University of Arizona, Tucson, AZ, <sup>2</sup>Department of Biomedical Engineering, Stony Brook University, Stony Brook, NY

**(937) Safety and Efficacy of Recombinant Factor VII in HeartMate 3 Recipients;** B. C. Ayers, K. Wood, J. Falvey, H. Vidula, J. Alexis, B. Barrus, S. Prasad, I. Gosev. *University of Rochester, Rochester, NY*

**(938) Impact of Concomitant Valve Surgery at the Time of HeartMate II Implantation; Japanese Multicenter Study;** H. Hata<sup>1</sup>, K. Toda<sup>1</sup>, Y. Saiki<sup>2</sup>, M. Ono<sup>3</sup>, A. Shiose<sup>4</sup>, D. Yoshioka<sup>1</sup>, Y. Sawa<sup>1</sup>. <sup>1</sup>Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan, <sup>2</sup>Cardiovascular Surgery, Tohoku University, Sendai, Japan, <sup>3</sup>Cardiovascular Surgery, University of Tokyo, Tokyo, Japan, <sup>4</sup>Cardiovascular Surgery, Kyusyu University, Fukuoka, Japan

**(939) Hemodynamic Improvement with Application of Mechanical Circulatory Support in Heart Failure with Preserved Ejection Fraction in a Mock Circulation Loop;** C. Broda<sup>1</sup>, P. A. Smith<sup>2</sup>, Y. Wang<sup>2</sup>, O. H. Frazier<sup>3</sup>, W. J. Dreyer<sup>4</sup>, I. Adachi<sup>5</sup>, D. A. Taylor<sup>6</sup>, L. C. Sampaio<sup>2</sup>. <sup>1</sup>Pediatrics; Section of Adult Congenital Heart Disease, Baylor College of Medicine, Houston, TX, <sup>2</sup>Cardiovascular Surgical Research Laboratory, Texas Heart Institute, Houston, TX, <sup>3</sup>Surgery, Section Cardiothoracic Transplantation & Circulatory Support, Baylor College of Medicine, Houston, TX, <sup>4</sup>Pediatrics; Section of Pediatric Cardiology, Baylor College of Medicine, Houston, TX, <sup>5</sup>Surgery; Section of Congenital Heart Surgery, Baylor College of Medicine, Houston, TX, <sup>6</sup>Regenerative Medicine Research, Texas Heart Institute, Houston, TX

**(940) Outcomes of Continuous-Flow Left Ventricular Assist Devices with No Antiplatelet Therapy: Systematic Review;** V. Kittipibul<sup>1</sup>, N. Angsubhakorn<sup>2</sup>, J. Kewchareon<sup>3</sup>, N. Prasitlumkum<sup>3</sup>, P. Rattanawong<sup>3</sup>. <sup>1</sup>Department of Internal Medicine, University of Miami Miller School of Medicine, MIAMI, FL, <sup>2</sup>Department of Internal Medicine, University of Minnesota, Minneapolis, MN, <sup>3</sup>Department of Internal Medicine, University of Hawaii, Honolulu, HI

**(941) Short-Term Efficacy and Safety of Tolvaptan in Patients with Left Ventricular Assist Devices;** T. Fujino, T. Imamura, D. Nitta, G. Kim, A. J. Kanelidis, M. Belkin, B. Chung, B. Smith, A. Nguyen, P. Combs, J. Raikhelkar, C. Juricek, V. Jeevanandam, I. Ebong, N. Narang, L. Holzhauser, G. Sayer, N. Uriel. *University of Chicago, Chicago, IL*

**(942) Opioid Use in LVAD Patients is Associated with Increased GI Bleed and Sepsis;** P. Combs, T. Imamura, C. Stonebraker, H. M. Bullard, P. Simone, C. LaBuhn, B. Chung, T. Ota, D. Onsager, T. Song, T. Lammy, G. Kim, B. Smith, S. Kalantari, A. Nguyen, J. Raikhelkar, N. Sarswat, G. Sayer, V. Jeevanandam, N. Uriel. *University of Chicago, Chicago, IL*

**(943) Efficacy and Safety of Ferric Carboxymaltose Therapy in Continuous Flow LVAD Patients;** E. Demir<sup>1</sup>, S. Nalbantgil<sup>1</sup>, P. Öztürk<sup>2</sup>, E. Simsek<sup>1</sup>, C. Engin<sup>2</sup>, T. Yagdi<sup>2</sup>, M. Özbaran<sup>2</sup>. <sup>1</sup>Cardiology, Ege University Medicine Faculty, İzmir, Turkey, <sup>2</sup>Cardiovascular Surgery, Ege University Medicine Faculty, İzmir, Turkey

Thursday, April 4, 2019

5:45 PM - 7:00 PM

**POSTER SESSION 2: JUNIOR FACULTY CASE REPORTS: HEART FAILURE/TRANSPLANTATION**

**Room: Banda Sea 1**

**Poster Discussants:**

Lavanya Bellumkonda, MD, Yale School of Medicine, New Haven, CT, USA

Alejandro Bertolotti, MD, University Hospital Favaloro Foundation, Buenos Aires, Argentina

Ryan Butts, MD, University of Texas Southwestern, Dallas, TX, USA

Robert Chen, MD, MPH, Indiana University Methodist Hospital, Indianapolis, IN, USA

Justin Godown, MD, Nashville, TN, USA

Douglas Greig, MD, University Health Network, Toronto, Canada

Jeremy Mazurek, MD, University of Pennsylvania, Philadelphia, PA, USA

Bruno Meiser, MD, University Munich/Grosshadern, Munich, Germany

**(1338) A Fatal Case of Bortezomib-Induced Lung Toxicity in a Young Heart Transplant Recipient;** E. L. Frandsen<sup>1</sup>, J. Otero<sup>2</sup>, J. C. Rutledge<sup>3</sup>, M. S. Kemna<sup>1</sup>, E. L. Albers<sup>1</sup>, B. J. Hong<sup>1</sup>, Y. M. Law<sup>1</sup>, J. M. Friedland-Little<sup>1</sup>. <sup>1</sup>Division of Cardiology, Seattle Children's Hospital, University of Washington, Seattle, WA, <sup>2</sup>Division of Pharmacy, Seattle Children's Hospital, University of Washington, Seattle, WA, <sup>3</sup>Division of Pathology, Seattle Children's Hospital, University of Washington, Seattle, WA

**(1339) A Case of Cellular Rejection in a Heart Transplant Recipient Detected by CardioMEMS;** I. Selevany, G. Lin, E. Adler, B. Greenberg, P. Kim. University of California, San Diego, San Diego, CA

**(1340) Initial Experience with Alemtuzumab as a Salvage Therapy for Refractory Cardiac Cellular Allograft Rejection;** M. E. Afari<sup>1</sup>, T. A. Lebeis<sup>1</sup>, K. J. Gaj<sup>1</sup>, K. Turvey<sup>1</sup>, J. K. Steiner<sup>1</sup>, R. V. Shah<sup>1</sup>, N. E. Ibrahim<sup>1</sup>, S. Shao<sup>1</sup>, T. Giff<sup>2</sup>, M. G. Naylor<sup>1</sup>, E. Coglianese<sup>1</sup>, J. E. Ho<sup>1</sup>, S. S. Thomas<sup>1</sup>, C. Newton-Cheh<sup>1</sup>, W. D. Carlson<sup>1</sup>, M. Villavicencio-Theoduloz<sup>3</sup>, D. D'Alessandro<sup>3</sup>, G. Lewis<sup>1</sup>. <sup>1</sup>Division of Advanced Heart Failure and Transplant Cardiology, Massachusetts General Hospital, Boston, MA, <sup>2</sup>Department of Pharmacy, Massachusetts General Hospital, Boston, MA, <sup>3</sup>Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA

**(1341) A Novel Therapy for an Unusual Problem: IL-1 Receptor Antagonist for Recurrent Post-Transplant Pericarditis;** J. Parizo<sup>1</sup>, Y. Moayed<sup>2</sup>, K. Nieman<sup>3</sup>, K. Town<sup>1</sup>, J. Teuteberg<sup>1</sup>, K. Khush<sup>1</sup>. <sup>1</sup>Cardiovascular Medicine, Stanford University, Stanford, CA, <sup>2</sup>Peter Munk Cardiac Center, University Health Network, Toronto, ON, Canada, <sup>3</sup>Departments of Cardiovascular Medicine and Radiology, Stanford University, Stanford, CA

**(1342) Successful Transplantation of a High-Risk DCD Heart Following Ex-Situ Coronary Angiography;** S. E. Scheuer, H. Chew, J. Nadel, C. Soto, P. Jansz, K. Kathir, K. Dhital, P. Macdonald. St Vincent's Hospital, Darlinghurst, Australia

**(1343) De Novo Eosinophilic Myocarditis in a Transplanted Heart;** J. R. Vilaro<sup>1</sup>, B. D. Stewart<sup>2</sup>, G. Rojas<sup>1</sup>, A. Shenoy<sup>1</sup>, R. Rogers<sup>1</sup>, J. Aranda<sup>1</sup>. <sup>1</sup>Cardiology, University of Florida, Gainesville, FL, <sup>2</sup>Pathology, University of Florida, Gainesville, FL

**(1344) Catastrophic Sickling Crisis in Patient Undergoing Cardiac Transplantation with Sick Cell Trait;** J. Ali, S. Bhagra, M. Goddard, M. Besser, P. Catarino, Y. Abu-Omar, M. Berman. Papworth Hospital, Cambridge, United Kingdom

**(1345) Eculizumab for the Treatment of Severe Antibody-Mediated Rejection in an Adult Heart Transplant Recipient;** J. P. Feliberti<sup>1</sup>, J. Huang<sup>2</sup>, J. E. Finan<sup>3</sup>, M. Lopez-Cepero<sup>4</sup>, D. A. Rinde-Hoffman<sup>1</sup>. <sup>1</sup>Cardiology, Tampa General Hospital, Tampa, FL, <sup>2</sup>Cardiology, University of South Florida, Tampa, FL, <sup>3</sup>Pathology, Tampa General Hospital, Tampa, FL, <sup>4</sup>Immunology, Lifelink, Tampa, FL

**(1346) Protein Losing Enteropathy (PLE) with Severe Gastrointestinal (GI) Bleeding: Safe to Transplant?;** B. S. Mantell, M. Richmond, W. Zuckerman, S. Law, T. Lee, L. Addonizio. Pediatric Cardiology, Columbia University Medical Center, New York, NY

**(1347) An Unusual Case of Infectious Mycotic Aneurysm in a Heart Transplant Patient;** W. G. Willeford<sup>1</sup>, E. Orozco-Hernandez<sup>1</sup>, J. Tallaj<sup>2</sup>, C. Hoopes<sup>1</sup>, J. Baddley<sup>1</sup>. <sup>1</sup>Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, <sup>2</sup>University of Alabama at Birmingham, Birmingham, AL

**(1348) Two Cases of Giant Cell Myocarditis with Complete Remission after Treatment with Rituximab;** J. Lundgren, O. Braun, B. Kornhall, Ö. Reitan, O. Gidlöf, J. Smith. Department of Cardiology, Clinical Sciences, Lund University and Skåne University Hospital, Lund, Sweden

- (1349) A Dual Targeting Approach to Desensitization with Belatacept & Bortezomib;** M. V. Habal<sup>1</sup>, D. Jennings<sup>1</sup>, K. Clerkin<sup>1</sup>, S. Geo<sup>2</sup>, E. Vasilescu<sup>2</sup>, F. Latif<sup>1</sup>, M. Farr<sup>1</sup>, S. Restaino<sup>1</sup>. <sup>1</sup>Cardiology, Columbia University, New York, NY, <sup>2</sup>Pathology & Cell Biology, Columbia University, New York, NY
- (1350) Successful Treatment of Donor-Derived Hepatitis C Virus Infection with Glecaprevir/Pibrentasvir Following Cardiac Re-Transplantation;** K. Martits-Chalangari<sup>1</sup>, S. Y. Wada<sup>2</sup>, J. F. Trotter<sup>2</sup>, P. P. Kale<sup>2</sup>, S. A. Hall<sup>2</sup>, R. L. Gottlieb<sup>2</sup>. <sup>1</sup>Baylor Scott & White Research Institute, Dallas, TX, <sup>2</sup>Baylor University Medical Center, Dallas, TX
- (1351) Safe and Successful Implantation of Micra in Post-Heart Transplantation as a Strategy to Reduce Infectious Complications in the Immunocompromised Population;** J. Maning<sup>1</sup>, N. T. Rivera<sup>2</sup>, S. Chaparro<sup>2</sup>, I. Mendoza<sup>3</sup>. <sup>1</sup>Internal Medicine, Jackson Memorial Hospital, Miami, FL, <sup>2</sup>Department of Medicine, Cardiovascular Division, University of Miami Miller School of Medicine, Miami, FL, <sup>3</sup>Department of Cardiac Electrophysiology, Jackson Memorial Hospital, Miami, FL
- (1352) Implantable Pulmonary Artery Pressure Sensor as a Guide to the Management of Bridge to Transplant Left Ventricular Assist Device Patient;** M. Afari<sup>1</sup>, T. Lebeis<sup>1</sup>, K. Milley<sup>2</sup>, J. M. Camuso<sup>2</sup>, D. Sullivan<sup>1</sup>, L. Arrighi<sup>1</sup>, M. Swan<sup>1</sup>, G. Lewis<sup>1</sup>, S. S. Thomas<sup>1</sup>. <sup>1</sup>Division of Advanced Heart Failure and Transplant Cardiology, Massachusetts General Hospital, Boston, MA, <sup>2</sup>Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA
- (1353) Recurrent Thrombotic Microangiopathy in a Heart Transplant Patient with Reintroduction of Calcineurin Inhibitors;** I. Ebong, A. J. Kanelidis, M. Belkin, N. Narang, H. Holzhauser, J. Schulte, D. Yu, B. Smith, N. Sarswat, J. Raikhelkar, B. Chung, A. Oehler, G. Kim, G. Sayer, N. Uriel. University of Chicago, Chicago, IL
- (1354) When the Wedding Ring Doesn't Fit: Identifying Reversible Causes of Cardiomyopathy;** N. A. Colaco, S. Bhattacharya, A. Schnell-Heringer, N. Tarango, M. Aras, V. N. Selby, L. Klein, T. De Marco. Cardiology, University of California, San Francisco, San Francisco, CA
- (1355) Isolated IgG4-RD Myocarditis Treated with Heart Transplantation;** E. F. Lin, J. R. Cook, J. E. Diamond, N. O. Palmeri. Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY
- (1356) Primary Cardiac ALK-Negative Anaplastic Large Cell Lymphoma Diagnosed in the Explanted Heart;** J. Newman<sup>1</sup>, Y. Brailovsky<sup>1</sup>, A. Haryani<sup>1</sup>, V. Ananthanarayanan<sup>2</sup>, A. Kini<sup>2</sup>, S. Nand<sup>3</sup>, E. Jaffe<sup>4</sup>, K. Mirza<sup>2</sup>, M. Liebo<sup>1</sup>. <sup>1</sup>Cardiology, Loyola University Medical Center, Chicago, IL, <sup>2</sup>Pathology, Loyola University Medical Center, Chicago, IL, <sup>3</sup>Hematology, Loyola University Medical Center, Chicago, IL, <sup>4</sup>Pathology, NIH National Cancer Institute, Center for Cancer Research, Bethesda, MD
- (1357) Orthotropic Heart Transplantation in Recipients with Persistent Left Superior Vena Cava: Anterior Rerouting Technique;** Y. Koda, N. Uriel, V. Jeevanandam, T. Ota. The University of Chicago, Chicago, IL
- (1358) Wireless PA Monitoring during Acute Cardiac Allograft Rejection;** D. Corbally, N. Wettersten, V. Pretorius, E. Adler, H. Tran. UCSD, San Diego, CA
- (1359) Amyloid Cardiomyopathy Heart-Liver Transplantation with Domino Liver Transplantation;** C. I. Tugulan, J. Mena, M. J. Bates, P. G. Parrino, A. Bansal. Cardiothoracic Surgery, Ochsner Medical Center, New Orleans, LA
- (1360) Antibody Mediated Rejection Causing LV Systolic Dysfunction with Improvement on Initiation of Sacubitril/Valsartan;** K. Morris<sup>1</sup>, K. Grant<sup>2</sup>, S. Chaudhry<sup>1</sup>, A. Patel<sup>1</sup>, T. Schleeter<sup>1</sup>, R. Garcia-Cortes<sup>1</sup>, A. Ravichandran<sup>1</sup>. <sup>1</sup>Cardiology, St. Vincent Hospital, Indianapolis, IN, <sup>2</sup>Internal Medicine, St. Vincent Hospital, Indianapolis, IN
- (1361) Successful Heart-Lung Transplant for a Patient on Continuous Flow Left Ventricular Assist Device Support Complicated with Amiodarone-Induced Pulmonary Fibrosis;** M. E. Currie, Y. Shudo, J. Mooney, J. Woo. Cardiothoracic Surgery, Stanford University, Stanford, CA
- (1362) A Case of Severe Necrotizing Pancreatitis in a Patient Who Received a Heart from a Hepatitis C Positive Donor;** M. Chowdhury, K. Schlendorf, S. Zalawadiya, J. Menachem, M. Brinkley, M. Wigger, H. Ooi, A. Shah, K. Balsara, M. Danter, J. Lindenfeld. Vanderbilt University Medical Center, Nashville, TN
- (1363) CardioMems to Guide Heart Transplant Timing in a Total Artificial Heart Patient;** V. Parikh<sup>1</sup>, L. Simpson<sup>1</sup>, J. Morgan<sup>1</sup>, M. Ono<sup>2</sup>, O. Frazier<sup>1</sup>, A. Civitello<sup>1</sup>, A. Nair<sup>1</sup>. <sup>1</sup>Baylor St. Luke's Medical Center/Texas Heart Institute, Houston, TX, <sup>2</sup>Methodist Hospital, San Antonio, TX

**(1364) A Case of Heart Transplantation Using a Distantly Procured Brain Dead Donor Heart That Was Preserved in a Novel Cold Storage System;** N. Naito<sup>1</sup>, M. Funamoto<sup>1</sup>, R. Pierson<sup>1</sup>, M. Villavicencio<sup>1</sup>, W. Riley<sup>2</sup>, G. Lewis<sup>3</sup>, D. D'Alessandro<sup>1</sup>. <sup>1</sup>Cardiac Surgery, Massachusetts General Hospital, Boston, MA, <sup>2</sup>Perfusion Services, Massachusetts General Hospital, Boston, MA, <sup>3</sup>Cardiology, Massachusetts General Hospital, Boston, MA

**(1365) Williams Beuren Syndrome with Diffuse Arteropathy, a Case of Successful Heart Transplantation;** N. Baez, R. Kirk, R. Butts, R. Davies. University of Texas Southwestern Medical Center, Dallas, TX

**(1366) Multiple Micro-Neo-Vessels Detected by Optical Coherence Tomography (OCT) Can Predict a Progression of Cardiac Allograft Vasculopathy in a 15-Year Post Transplant Recipient;** K. Shibata, T. S. Kato, T. Nishikura, N. Ikeda, C. Sato, K. Wakabayashi, K. Tanno. Division of Cardiology, Cardiovascular Center, Showa University Koto Toyosu Hospital, Tokyo, Japan

**(1367) Giant Cell Myocarditis as a Late Complication of DRESS Syndrome;** K. Murphy<sup>1</sup>, D. Steidley<sup>1</sup>, A. E. McCullough<sup>2</sup>, O. E. Pajaro<sup>3</sup>, J. L. Rosenthal<sup>1</sup>, B. W. Hardaway<sup>1</sup>, D. E. Jaroszewski<sup>3</sup>, R. L. Scott<sup>1</sup>, L. LeMond<sup>1</sup>. <sup>1</sup>Cardiovascular Diseases, Mayo Clinic Arizona, Phoenix, AZ, <sup>2</sup>Laboratory Medicine and Pathology, Mayo Clinic Arizona, Phoenix, AZ, <sup>3</sup>Cardiothoracic Surgery, Mayo Clinic Arizona, Phoenix, AZ

**(1368) Recurrence of Giant Cell Myocarditis after Successful LVAD Explantation;** R. Bhatt<sup>1</sup>, A. Borczuk<sup>2</sup>, M. Karas<sup>1</sup>, E. Horn<sup>1</sup>, I. Sobol<sup>1</sup>. <sup>1</sup>Division of Cardiology Perkin Center for Heart Failure, Weill Cornell Medical College, New York, NY, <sup>2</sup>Department of Pathology, Weill Cornell Medical College, New York, NY

**(1369) CardioMEMS Guides Successful CAR T-Cell Therapy;** A. J. Kanelidis<sup>1</sup>, J. Raikhelkar<sup>2</sup>, L. Holzhauser<sup>2</sup>, A. B. Nguyen<sup>2</sup>, B. B. Chung<sup>2</sup>, B. Smith<sup>2</sup>, G. Kim<sup>2</sup>, N. Narang<sup>2</sup>, G. Sayer<sup>2</sup>, T. S. Polonsky<sup>2</sup>, N. Uriel<sup>2</sup>. <sup>1</sup>Internal Medicine, University of Chicago, Chicago, IL, <sup>2</sup>Cardiology, University of Chicago, Chicago, IL

**(1370) Open Repair of a Juxtarenal Abdominal Aortic Aneurysm in a Left Ventricular Assist Device Patient;** S. R. LeJeune<sup>1</sup>, J. M. Titus<sup>2</sup>, K. Mudy<sup>2</sup>, R. Siddiqui<sup>3</sup>, P. M. Eckman<sup>2</sup>. <sup>1</sup>University of Minnesota, Minneapolis, MN, <sup>2</sup>Minneapolis Heart Institute, Minneapolis, MN, <sup>3</sup>Abbott Northwestern Hospital, Minneapolis, MN

**(1371) LVAD Deactivation after Cardiac Recovery and Pump Thrombosis;** R. C. Flowers<sup>1</sup>, V. Kittipibul<sup>1</sup>, S. Chaparro<sup>2</sup>. <sup>1</sup>Internal Medicine, University of Miami, Miami, FL, <sup>2</sup>Cardiovascular Medicine, University of Miami, Miami, FL

**(1372) A Case of Plasmacytoma in the Transplanted Heart;** C. Pereira Kessler Iglesias, J. Phan, K. Kearney, N. Song, A. Jabbour, A. Keogh, E. Kotlyar, C. Hayward, K. Muthiah, P. Macdonald. Heart Transplant, St Vincents Hospital, Sydney, Australia

**(1373) End-Stage Cardiomyopathy Due to Hydroxychloroquine Therapy;** A. M. Wolfson<sup>1</sup>, D. Chang<sup>1</sup>, S. Bannykh<sup>2</sup>, M. Kittleson<sup>1</sup>, E. Kransdorf<sup>1</sup>, J. Kobashigawa<sup>1</sup>. <sup>1</sup>Medicine - Division of Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA, <sup>2</sup>Pathology, Cedars-Sinai Medical Center, Los Angeles, CA

**(1374) Eculizumab as a Bridge to Re-Transplantation for Chronic Antibody Mediated Rejection in a Heart Transplant Patient;** K. Kearney, J. Phan, N. Song, N. Bart, A. Jabbour, E. Kotlyar, C. Hayward, P. Macdonald, K. Muthiah. St Vincents Hospital, Darlinghurst, Australia

**(1375) Cardiac Arrest and Wilson's Disease;** E. Bobbio<sup>1</sup>, M. Lingbrant<sup>2</sup>, E. Bollano<sup>2</sup>, S. Esmaily<sup>1</sup>, A. Oldfors<sup>3</sup>, B. Andersson<sup>2</sup>, N. Bergh<sup>2</sup>, C. L. Polte<sup>4</sup>, K. Karason<sup>2</sup>. <sup>1</sup>Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, <sup>2</sup>Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, <sup>3</sup>Pathology and Genetics, Sahlgrenska University Hospital, Gothenburg, Sweden, <sup>4</sup>Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden

**(1376) Early Recurrence of Cardiac Sarcoidosis after Heart Transplant;** J. Yossef, B. Goldman, L. Powley, H. Vidula. University of Rochester, Rochester, NY

**(1377) Fever of Unknown Origin in Orthotopic Heart Transplant;** M. Erlich. Yale New Haven Hospital, New Haven, MA

**(1378) A Case Series of Three Hepatitis C Donor Heart Transplant Recipients and 1-Year Cardiac Allograft Vasculopathy Follow-Up;** Q. M. Bui, N. Wettersten, E. Adler, S. Aslam, H. A. Tran. UCSD, San Diego, CA

**(1379) Resynchronization as an Early Therapeutic Target in Cardiac Amyloidosis: Time for a Clinical Trial?;** A. J. Kadado<sup>1</sup>, S. Atallah-Yunes<sup>1</sup>, A. Turk<sup>2</sup>, J. Hernandez-Montfort<sup>3</sup>. <sup>1</sup>University of Massachusetts Medical School - Baystate Medical Center, Springfield, MA, <sup>2</sup>Cardiology, University of Massachusetts Medical School - Baystate Medical Center, Springfield, MA, <sup>3</sup>Cardiology, University of Texas Medical Branch, Galveston, TX

**(1380) A Heart-Lung Transplantation Case for Refractory Diffuse Alveolar Hemorrhage after ST Segment Elevation Myocardial Infarction;** S. Lee<sup>1</sup>, J. Kim<sup>1</sup>, M. Ju<sup>2</sup>, G. Kim<sup>3</sup>. <sup>1</sup>Cardiology, Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of, <sup>2</sup>Thoracic Surgery, Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of, <sup>3</sup>Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of

**(1381) Improvement in Cognitive Assessment Score Following Left Ventricular Assist Device Implantation for End-Stage Heart Failure;** K. Rankin, F. Foroutan, M. Rodger, J. Kobulnik. Peter Munk Cardiac Centre, University Health Network, Toronto, ON, Canada

**(1383) Severe Hypertriglyceridemia without Pancreatitis Following Treatment with Everolimus after Heart Transplant;** P. Lo<sup>1</sup>, K. Kearney<sup>1</sup>, C. Muir<sup>2</sup>, N. Song<sup>1</sup>, J. Eisman<sup>2</sup>, P. Macdonald<sup>1</sup>. <sup>1</sup>Heart and Lung Transplantation, St Vincent's Hospital, Sydney, Australia, <sup>2</sup>Diabetes and Endocrinology, St Vincent's Hospital, Sydney, Australia

**(1385) Extreme Orthostatic Hypotension in a Veteran Heart Transplant Patient Treated for Tongue Squamous Cell Carcinoma;** E. Ram<sup>1</sup>, Y. Sharabi<sup>2</sup>, M. Wolf<sup>2</sup>, J. Lavee<sup>1</sup>, Y. Peled<sup>3</sup>. <sup>1</sup>Cardiac Surgery, Sheba Medical Center, Ramat Gan, Israel, <sup>2</sup>Sheba Medical Center, Ramat Gan, Israel, <sup>3</sup>Cardiology, Sheba Medical Center, Ramat Gan, Israel

**(1386) The Meddling Infiltrate That Never Went Away;** A. A. Arjuna<sup>1</sup>, M. Mody<sup>2</sup>, C. Migliore<sup>2</sup>, P. S. Patel<sup>2</sup>, T. Anandaragam<sup>2</sup>. <sup>1</sup>Pulmonary and Critical Care Medicine, University of Florida, Gainesville, NJ, <sup>2</sup>Pulmonary and Critical Care Medicine, Robertwood Johnson Newark Beth Israel Medical Center, Newark, NJ

**(1387) Dual Oral and Continuous Intravenous Chelation Therapy Recovers End-Stage Iron Overload Cardiomyopathy;** M. Aras, V. Selby, N. Colaco, S. Bhattacharya, L. Klein, T. De Marco. Cardiology, University of California, San Francisco, San Francisco, CA

Thursday, April 4, 2019

5:45 PM - 7:00 PM

**POSTER SESSION 2: JUNIOR FACULTY CASE REPORTS: HEART FAILURE/TRANSPLANTATION**

**Room: Banda Sea 2**

**Poster Discussants:**

Maria Crespo-Leiro, MD, Hospital Univ A Coruna, La Coruna, Spain

Maryjane Farr, MD, Columbia University Medical Center, New York, NY, USA

Farhan Zafar, MD, Children's Hospital Medical Center, Cincinnati, OH, USA

**(1388) Hemophagocytic Lymphohistiocytosis after Heart Transplantation;** C. Danielsson, E. Bobbio, S. Esmaily, G. Dellgren, K. Karason. *Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden*

**(1389) Left Ventricular Assist Device as a Bridge to Successful Heart-Liver Transplantation: A Case Report;** D. Rinewalt<sup>1</sup>, J. W. MacArthur<sup>1</sup>, W. Hiesinger<sup>1</sup>, M. E. Currie<sup>1</sup>, F. Haddad<sup>2</sup>, W. Concepcion<sup>3</sup>, Y. J. Woo<sup>1</sup>, D. Banerjee<sup>2</sup>. <sup>1</sup>*Cardiac Surgery, Stanford University, Palo Alto, CA*, <sup>2</sup>*Cardiovascular Medicine, Stanford University, Palo Alto, CA*, <sup>3</sup>*Surgery, Stanford University, Palo Alto, CA*

**(1390) Blood and IvIg Causing Takotsubo Cardiomyopathy: Chicken or Egg Dilemma!;** A. Arjuna, A. Emtiazjoo, A. Shahmohammadi, M. Pipkin, M. Massoomi. *Pulmonary and Critical Care Medicine, University of Florida, Gainesville, FL*

**(1391) When Blood is Not an Option: Transplanting a Jehovah's Witness Patient with Cardiogenic Shock and Thrombocytopenia;** L. Holzhauser, B. Chung, A. Nguyen, I. Ebong, N. Sarswat, J. Raikhelkar, B. Smith, G. Kim, G. Sayer, V. Jeevanandam, N. Uriel. *University of Chicago, Chicago, IL*

**(1392) A Case of Heart Transplantation from a Donor with Atrial Septal Defect Secundum;** H. Lee<sup>1</sup>, J. Shin<sup>1</sup>, S. Song<sup>2</sup>, S. Kim<sup>2</sup>, M. Kim<sup>2</sup>. <sup>1</sup>*Cardiology Department, Pusan National University Hospital, Busan, Korea, Republic of*, <sup>2</sup>*Thoracic Surgery Department, Pusan National University Hospital, Busan, Korea, Republic of*

**(1394) To Explant or Not to Explant - That is the Question;** A. Alam<sup>1</sup>, A. Mukherjee<sup>1</sup>, A. Ghaly<sup>1</sup>, M. Huang<sup>1</sup>, K. Mody<sup>1</sup>, D. Iyer<sup>1</sup>, J. Almendral<sup>2</sup>. <sup>1</sup>*Rutgers - Robert Wood Johnson University Hospital, New Brunswick, NJ*, <sup>2</sup>*Jersey Shore Medical Center, Neptune City, NJ*

**(1395) Left Ventricular Assist Device as Rescue Therapy for Giant Cell Myocarditis;** P. Mudigonda<sup>1</sup>, S. Jaganathan<sup>1</sup>, J. Vierecke<sup>2</sup>, D. Sharma<sup>3</sup>, D. S. Feldman<sup>2</sup>. <sup>1</sup>*Division of Cardiovascular Health and Disease, University of Cincinnati, Cincinnati, OH*, <sup>2</sup>*Advanced Heart Failure and Transplant, University of Cincinnati, Cincinnati, OH*, <sup>3</sup>*Division of Pathology, University of Cincinnati, Cincinnati, OH*

**(1396) Resolution of Early Oliguric Kidney Injury Post Heart Transplantation: Nesiritide Revisited;** H. Alwash, M. Soufi, W. Khalife, K. Chatila, G. Al-Dossari, P. Roughneen, G. Levy, J. Hernandez. *University of Texas Medical Branch, Galveston, TX*

**(1397) Heart Transplantation as Salvage Therapy for Intractable Prosthetic Valve Endocarditis;** K. Rankin, C. McGuinty, V. M. Molinero, A. Luk, H. J. Ross, R. J. Cusimano, M. Ouzounian, M. McDonald. *Peter Munk Cardiac Centre, University Health Network, Toronto, ON, Canada*

**(1398) Hypertrophic Cardiomyopathy Mimicking ATTR Cardiac Amyloidosis: False Positive Tc99-PYP Scanning;** E. J. Sawey, M. C. Smallfield, I. Tchoukina, R. Cooke, K. Rao, K. G. Rudisill, K. B. Shah. *Transplant Cardiology, VCU, Richmond, VA*

**(1400) An Unusual Case of Syncope after Heart Transplant;** F. Al-Saffar<sup>1</sup>, D. Jaroszewski<sup>2</sup>, P. DeValeria<sup>2</sup>, E. Steidley<sup>1</sup>, L. LeMond<sup>1</sup>. <sup>1</sup>*Cardiology, Mayo Clinic, Scottsdale, AZ*, <sup>2</sup>*Cardiothoracic Surgery, Mayo Clinic, Scottsdale, AZ*

**(1401) A Coronary Cameral Fistula Treated with Coil Embolization;** E. D. Hinds III<sup>1</sup>, M. J. Marin III<sup>2</sup>, J. George<sup>2</sup>, R. M. Delgado III<sup>2</sup>. <sup>1</sup>*University of Texas Medical Branch, Galveston, TX*, <sup>2</sup>*Texas Heart Institute, Houston, TX*

**(1402) Abrupt Onset of Chest Pain and Fever in a Young Man: A Case Report;** G. L. Leonor Lopez, A. Badiye, S. Chaparro, D. Rao, N. A. Brozzi. *Internal Medicine, Jackson Memorial Hospital/ University of Miami, Miami, FL*

**(1404) Fulminant Myocarditis: Should We Wait for Recovering? Biopsy Says No!;** S. Vazquez<sup>1</sup>, F. Loiacono<sup>1</sup>, J. M. Dominguez<sup>1</sup>, G. Frigola<sup>2</sup>, M. Farrero<sup>1</sup>, M. Castel<sup>1</sup>, F. Perez Villa<sup>1</sup>. <sup>1</sup>*Heart Failure and Transplant Unit, Hospital Clinic, Barcelona, Spain*, <sup>2</sup>*Department of Pathology, Hospital Clinic, Barcelona, Spain*



- (1405) Lamin Heart Disease: One Approach to Treating Conduction Disease and Progressive Arrhythmias;** D. Pedrotty<sup>1</sup>, L. Goldberg<sup>1</sup>, G. Supple<sup>2</sup>, A. Owens<sup>1</sup>. <sup>1</sup>Heart Failure Cardiology, University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Cardiology, Electrophysiology, University of Pennsylvania, Philadelphia, PA
- (1406) Heart-Liver Transplantation in a Patient with Familial Amyloidotic Polyneuropathy and High Titers of Anti-HLA Antibodies;** S. Bianca, M. Sandrigo, A. Barbara, L. Gabriela Cardoso, C. Iascara Wozniak, X. Leudo, B. Fernando, M. Thalita, B. Flavio, L. Gabriela Cardoso, M. Sergio, P. Lucas Tachoti, D. Marcio, P. Robinson, T. Margareth, P. Luciene, S. Marcia. *Hospital Israelita Albert Einstein, São Paulo, Brazil*
- (1407) A Case of Acute Heart Failure Due to Immune Checkpoint Blocker- Nivolumab;** M. Sharma, D. Silber, B. Kim. *Heart Failure and Pulmonary Hypertension, Hackensack University Medical Center, Hackensack, NJ*
- (1409) Atypical Pattern of Danon Disease with Advanced Heart Failure;** E. Anegawa<sup>1</sup>, K. Kuroda<sup>1</sup>, Y. Kimura<sup>1</sup>, K. Iwasaki<sup>1</sup>, Y. Kumai<sup>1</sup>, K. Toda<sup>1</sup>, Y. Matsumoto<sup>2</sup>, T. Watanabe<sup>1</sup>, O. Seguchi<sup>1</sup>, S. Nakajima<sup>1</sup>, S. Fukushima<sup>2</sup>, H. Ueda<sup>3</sup>, M. Yanase<sup>1</sup>, T. Fujita<sup>2</sup>, J. Kobayashi<sup>2</sup>, N. Fukushima<sup>1</sup>. <sup>1</sup>Heart Transplantation, National Cerebral and Cardiovascular Center, Suita, Japan, <sup>2</sup>Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Suita, Japan, <sup>3</sup>Pathology, National Cerebral and Cardiovascular Center, Suita, Japan
- (1410) Coronary Artery By-Pass Grafting in a Patient 4 Days Post Orthotopic Heart Transplantation: A Case Review;** L. Saiva<sup>1</sup>, J. O'Neill<sup>2</sup>, L. Nolke<sup>1</sup>. <sup>1</sup>Heart and Lung Transplant, Mater Misericordiae University Hospital, Dublin 7, Ireland, <sup>2</sup>Consultant Transplant Cardiologist, Mater Misericordiae University Hospital, Dublin 7, Ireland
- (1411) Maintaining Immunosuppression in the Setting of Posterior Reversible Encephalopathy Syndrome and Status Epilepticus in High-Risk Multi-Organ Transplantation;** N. T. Rivera, A. Badiye, N. Brozzi, M. Loebe, S. Chaparro. *Miami Transplant Institute, Jackson Health System in affiliation with University of Miami Health System, Miami, FL*
- (1412) Benefits and Challenges of Robotic Pelvic Surgery in a Cardiac Transplant Recipient;** W. A. Parker<sup>1</sup>, V. L. Parker<sup>2</sup>, H. J. Ramshaw<sup>1</sup>, E. K. D'Arcy<sup>1</sup>, A. Al-Mohammad<sup>1</sup>, O. Mateszko<sup>3</sup>, F. M. Kew<sup>2</sup>, P. C. Braidley<sup>1</sup>. <sup>1</sup>The Heart & Lung Transplant Unit, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom, <sup>2</sup>Department of Obstetrics & Gynaecology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom, <sup>3</sup>Department of Anaesthesia, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
- (1413) Mechanism of Sustained Action: Milrinone-Induced Priapism;** M. Ignaszewski<sup>1</sup>, N. Ejaz<sup>2</sup>, S. Bar<sup>3</sup>, M. Toma<sup>3</sup>, A. Ignaszewski<sup>3</sup>. <sup>1</sup>Cardiology, Cooper University Hospital, Camden, NJ, <sup>2</sup>Cardiology, Toronto General Hospital, Toronto, ON, Canada, <sup>3</sup>Cardiology, St. Paul's Hospital, Vancouver, BC, Canada
- (1414) Chronic Lymphocytic Myocarditis Confirmed by Electrogram-Guided Endomyocardial Biopsy;** J. Oh, H. Kim, J. Jang, S. Kang. *Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of*
- (1415) Differences in Dynamics of Alterations in Frailty and Sarcopenia Assessment Tools;** L. Roehrich<sup>1</sup>, J. Knierim<sup>1</sup>, M. Hajduczenia<sup>1</sup>, J. Mulzer<sup>1</sup>, M. Mueller<sup>1</sup>, P. Pergantis<sup>1</sup>, M. Hummel<sup>1</sup>, V. Falk<sup>1</sup>, E. Potapov<sup>1</sup>, S. Suendermann<sup>2</sup>, F. Schoenrath<sup>1</sup>. <sup>1</sup>Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany, <sup>2</sup>Department of Cardiothoracic Surgery, Charite - Universitätsmedizin Berlin, Berlin, Germany
- (1416) Stress Cardiomyopathy Induced by Dobutamine Stress Echocardiogram;** K. Sawalha<sup>1</sup>, H. Mahmaljy<sup>2</sup>, M. Al-Akchar<sup>3</sup>, A. Battisha<sup>1</sup>, A. Alsaied<sup>2</sup>. <sup>1</sup>Internal Medicine, University of Massachusetts Medical School-Baystate Medical Center, Springfield, MA, <sup>2</sup>Cardiology, Geisinger Medical Center, Danville, PA, <sup>3</sup>Internal Medicine, Southern Illinois University, Springfield, IL
- (1417) Hiding in Plain View: Antibody-Mediated Cardiac Allograft Rejection Presenting as Unilateral Pleural Effusion and Atrial Flutter;** B. Rasmussen, L. Stone, T. O'Neill. *Cardiology, Wake Forest Baptist Health, Winston Salem, NC*

Thursday, April 4, 2019

5:45 PM - 7:00 PM

**POSTER SESSION 2: JUNIOR FACULTY CASE REPORTS: LUNG FAILURE/TRANSPLANTATION**

**Room: Banda Sea 2**

**Poster Discussants:**

Michiel Erasmus, MD, PhD, University Medical Center Groningen, Groningen, The Netherlands

Jennifer Gray, PharmD, Vanderbilt University Medical Center, Nashville, TN, USA

Hanneke Kwakkel-van Erp, MD, PhD, Lung Transplantation Center, Antwerp, Belgium

Amit Parulekar, MD, Baylor College of Medicine, Houston, TX, USA

**(1418) Extracorporeal Liver Assist Device (MARS®) for Treatment of Hyperammonemia after Lung Transplantation;** M. Kwon<sup>1</sup>, A. Patel<sup>2</sup>, J. Canabal<sup>2</sup>, P. Moreno Franco<sup>2</sup>, T. J. Haddad<sup>2</sup>, F. Alvarez<sup>2</sup>, D. B. Erasmus<sup>2</sup>, J. M. Mallea<sup>2</sup>, T. Narula<sup>2</sup>. <sup>1</sup>*Pulmonary and Critical Care, Mayo Clinic, Jacksonville, FL*, <sup>2</sup>*Transplant Medicine, Mayo Clinic, Jacksonville, FL*

**(1419) A Successful Lung Transplant from a 3-Year-Old Donor after Controlled Cardiac Death Followed by Ex-Vivo Lung Perfusion: A Case Report;** M. Galasso<sup>1</sup>, R. D. Vanderlaan<sup>2</sup>, M. Solomon<sup>3</sup>, S. Keshavjee<sup>1</sup>, M. Cypel<sup>1</sup>, M. De Perrot<sup>1</sup>. <sup>1</sup>*Latner Thoracic Surgery Laboratories, University Health Network, Toronto, ON, Canada*, <sup>2</sup>*Division of Cardiac Surgery, University of Toronto, Toronto, ON, Canada*, <sup>3</sup>*Lung Transplant Program, The Hospital for Sick Children (SickKids), University Health Network, Toronto, ON, Canada*

**(1420) Lung Positioning during Ex-Vivo Lung Perfusion: Impact of Prone Ventilation;** A. Banga, J. Murala. *UT Southwestern Medical Center, Dallas, TX*

**(1421) Treatment of HLA Antibody Negative Acute Antibody-Mediated Lung Allograft Rejection with Eculizumab;** C. Kurihara, A. Bharat. *Northwestern University Feinberg School of Medicine, Chicago, IL*

**(1422) Donor Derived Lymphangiomyomatosis in a Lung Transplant Recipient;** B. Buddhdev, R. Walia, T. Panchabhai, A. Omar, S. Tokman. *Norton Thoracic Institute, St Joseph Hospital and Medical Center, Phoenix, AZ*

**(1423) Percutaneous RVAD and Oxygenator Support as an Alternative to VV ECMO in Pulmonary Graft Failure;** M. T. Cain<sup>1</sup>, D. L. Joyce<sup>1</sup>, L. D. Joyce<sup>1</sup>, L. A. Durham<sup>1</sup>, A. Mohammed<sup>2</sup>. <sup>1</sup>*Surgery - Division of Cardiothoracic Surgery, Medical College of Wisconsin, Milwaukee, WI*, <sup>2</sup>*Department of Medicine - Division of Cardiology, Medical College of Wisconsin, Milwaukee, WI*

**(1425) Sildenafil Improved Refractory Reflux and Gastroparesis Symptoms in a Lung Transplant Recipient;** A. Arjuna<sup>1</sup>, A. Pelaez<sup>1</sup>, A. Ouni<sup>2</sup>, T. Machuca<sup>3</sup>, M. Pipkin<sup>3</sup>, S. Chandrashekar<sup>1</sup>, A. Emtiazjoo<sup>1</sup>, H. Alnuaimat<sup>1</sup>, A. Shahmohammadi<sup>1</sup>, M. Amaris<sup>2</sup>. <sup>1</sup>*Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, Gainesville, FL*, <sup>2</sup>*Internal Medicine, Division of Gastroenterology, University of Florida, Gainesville, FL*, <sup>3</sup>*Internal Medicine, Division of Cardio-Thoracic Surgery, University of Florida, Gainesville, FL*

**(1426) Successful Use of Cangrelor as a Bridge to Lung Transplant;** P. Chung, E. Mancl, S. Quddus, D. Dilling. *Pulmonary and Critical Care, Loyola University Medical Center, Maywood, IL*

**(1427) End Stage Lung Disease with Severe Aortic Stenosis: Transcatheter Aortic Valve Replacement (TAVR) as a Bridge to Transplant;** A. Arjuna, A. Shahmohammadi, T. Machuca, M. Pipkin, G. Arnaoutakis. *Pulmonary and Critical Care Medicine, University of Florida, Gainesville, FL*

**(1428) Extracorporeal Membrane Oxygenation to Facilitate Chest Closure of Open Chest after Lung Transplantation with Oversized Allograft;** T. Harano<sup>1</sup>, J. D'Cunha<sup>1</sup>, S. Kilaru<sup>2</sup>, M. R. Morrell<sup>2</sup>, J. D. Luketich<sup>1</sup>, P. Sanchez<sup>1</sup>. <sup>1</sup>*Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA*, <sup>2</sup>*Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA*

**(1429) Lung Transplantation for Respiratory Failure Due to Anti-Synthetase Syndrome;** J. Rosenheck, E. Cantu, V. Ahya, C. Bermudez, J. Christie, M. Crespo, D. Hadjiliadis, J. Lee, N. Patel, M. K. Porteous, O. Shtraichman, N. Blumenthal, M. Burke, J. Golato, E. Hobson, M. Johnson, J. Adler, T. Claridge, T. Fallah, J. Diamond. *Advanced Lung Diseases and Lung Transplant, Hospital of the University of Pennsylvania, Philadelphia, PA*

**(1430) An Incidental Finding at Transplant Assessment;** J. Wallis, M. Mallouppas, I. Okpala, C. Sudarshan, J. S. Parmar. *Royal Papworth Hospital, Cambridge, United Kingdom*

**(1431) Use of ProtekDuo® as Venoarterial and Venovenous Extracorporeal Membrane Oxygenation during Bilateral Lung Transplantation;** C. Kurihara, A. Budd, A. Bharat, A. Kretzer. *Northwestern University Feinberg School of Medicine, Chicago, IL*

**(1432) Calcineurin Inhibitor-Induced Pain Syndrome, a Consequence of Transplant Immunosuppression;** A. M. Shah, D. Nnani, S. Murthy, J. Shin, O. Saeed, D. Sims, S. Vukelic, D. Goldstein, U. Jorde, S. Patel. *Division of Cardiology, Montefiore Medical Center, Bronx, NY*

**(1433) Lung Transplantation for Posttraumatic Acute Respiratory Distress Syndrome;** K. Hanlon, L. Allenspach, L. Stagner, J. Pinto, H. Nemeh. *Pulmonary and Critical Care Medicine, Henry Ford Hospital, Detroit, MI*

**(1434) Calcineurin Associated Sensorimotor Polyneuropathy after Lung Transplant Partly Recovered after Switching to Everolimus;** V. Verplancke<sup>1</sup>, S. K. Yogeswaran<sup>2</sup>, P. Lauwers<sup>2</sup>, P. Van Schil<sup>2</sup>, J. M. Hendriks<sup>2</sup>, J. P. Van Meerbeeck<sup>3</sup>, J. M. Kwakkel-van Erp<sup>1</sup>. <sup>1</sup>*Pulmonology, University Hospital Antwerp, Antwerp, Belgium*, <sup>2</sup>*Thoracic Surgery, University Hospital Antwerp, Antwerp, Belgium*, <sup>3</sup>*Pulmonology & Thoracic Oncology, Antwerp University and University Hospital, Antwerp, Belgium*

**(1435) Pleuroparenchymal Fibroelastosis;** C. Rutherford, J. Kleinerova, O. MacEaney, P. Ging, S. Winward, K. Redmond, M. Murray, J. J. Egan. *National Heart and Lung Transplant Centre, Mater Misericordiae University Hospital, Dublin, Ireland*

**(1436) Lung Allograft Assessed by Acellular Ex-Vivo Lung Perfusion with Dramatic Improvement in Severe Primary Graft Dysfunction Following Double-Lung Transplant;** I. Sakanoue, T. Okamoto, S. Unai, K. R. McCurry. *Thoracic & Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH*

**(1437) Atypical Presentation of Tacrolimus-Induced Posterior Reversible Encephalopathy Syndrome in Lung Transplantation;** S. El Hajj<sup>1</sup>, J. Dibu<sup>2</sup>, F. Hamed<sup>3</sup>. <sup>1</sup>*Pharmacy, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates*, <sup>2</sup>*Neurocritical Care, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates*, <sup>3</sup>*Transplant Pulmonology, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates*

**(1438) Respiratory Failure after Epidural Analgesia;** P. Shah, A. Arjuna, S. Chandrashekar. *Pulmonary, Critical Care and Sleep Medicine, University of Florida, Gainesville, FL*

**(1439) A Case of Constrictive Pericarditis after Bilateral Lung Transplantation;** N. Donthi<sup>1</sup>, J. L. Della-Santina<sup>2</sup>, H. Mani<sup>3</sup>, L. J. Bogar<sup>4</sup>, S. Aryal<sup>5</sup>. <sup>1</sup>*Internal Medicine, INOVA Fairfax Medical Center, Falls Church, VA*, <sup>2</sup>*INOVA Fairfax Medical Center, Falls Church, VA*, <sup>3</sup>*Inova Pathology Institute, INOVA Fairfax Medical Center, Falls Church, VA*, <sup>4</sup>*Inova Cardiac and Thoracic Surgery, INOVA Fairfax Medical Center, Falls Church, VA*, <sup>5</sup>*Inova Heart and Lung Transplant, INOVA Fairfax Medical Center, Falls Church, VA*

**(1440) Fulminant Hyperacute Rejection after Bilateral Lung Transplant: A Case Report;** P. Charoenpong, L. Chhatwani, J. J. Mooney. *Lung Transplant, Stanford Health Care, Palo Alto, CA*

**(1441) Tacrolimus Associated Thrombotic Microangiopathy Presenting with Renal Failure and Hemolysis Following Lung Transplant;** J. B. Smith<sup>1</sup>, J. Carney<sup>2</sup>, L. Morrison<sup>1</sup>. <sup>1</sup>*Department of Medicine, Duke University, Durham, NC*, <sup>2</sup>*Department of Pathology, Duke University, Durham, NC*

**(1442) First Bilateral Lobar Lung Transplantation in Poland;** B. Kubisa<sup>1</sup>, M. Nieborak-Raczowska<sup>2</sup>, M. Piotrowska<sup>3</sup>, T. Grodzki<sup>1</sup>, A. Kubisa<sup>2</sup>, J. Pieróg<sup>1</sup>, M. Wojtyś<sup>1</sup>, M. Bielewicz<sup>1</sup>, M. Czarnecka<sup>1</sup>, J. Wójcik<sup>1</sup>, N. Wójcik<sup>1</sup>, P. Sielicki<sup>4</sup>, M. Brykczyński<sup>4</sup>. <sup>1</sup>*Thoracic Surgery and Transplantation Department, Pomeranian Medical University of Szczecin, Szczecin, Poland*, <sup>2</sup>*Department of Internal Medicine and Hypertension, SPWSZ Sokołowskiego, Szczecin, Poland*, <sup>3</sup>*Thoracic Surgery and Transplantation Department, SPWSZ Sokołowskiego, Szczecin, Poland*, <sup>4</sup>*Cardiac Surgery Department, Pomeranian Medical University of Szczecin, Szczecin, Poland*

Friday, April 5, 2019

6:00 PM - 7:15 PM

**POSTER SESSION 3: HEART FAILURE/TRANSPLANTATION (ADULT)**

**Room: Hibiscus 2**

**Poster Discussants:**

Emanuele Bobbio, MD, Sahlgrenska University Hospital, Gothenburg, Sweden

Monica Colvin, MD, University of Michigan, Ann Arbor, MI, USA

Sofia Carolina Masri, MD, University of Washington, Seattle, WA, USA

Jorge Silva Enciso, MD, UCSD Medical Center, San Diego, CA, USA

Hao Tran, MD, UCSD Medical Center, San Diego, CA, USA

**(944) Deep Learning for Diagnosing Heart Failure from ECG Signals;** K. Kim, J. Kwon. *Sejong General Hospital, Kyunggi do, Korea, Republic of*

**(945) Cardiac Surgical Procedures with Concomitant vs. Staged Orthotopic Liver Transplant;** H. G. Reddy, J. Choi, E. J. Maynes, L. A. Carlson, J. Gordon, D. P. Horan, J. Khan, M. P. Weber, R. J. Morris, H. T. Massey, V. Tchanchaleishvili. *Division of Cardiac Surgery, Thomas Jefferson University, Philadelphia, PA*

**(946) Differences in Swan-Ganz Hemodynamics from Catheterization Lab Insertion to the Cardiac Care Unit: A Prospective Study;** M. Husaini, A. Bhatia, C. Lin, J. LeClair, N. Becker, A. Scott, E. De Togni, J. Acevedo-Cintron, J. Schilling. *Washington University in Saint Louis, St. Louis, MO*

**(947) Importance of a Partnered Heart Failure Network to Increase Access to Advanced Heart Failure Therapies;** S. Rodriguez, E. Melrose, S. George, M. Duke, D. A. Horstmanshof. *INTEGRIS Baptist Medical Center, Oklahoma City, OK*

**(948) Early- and Late-Onset Arrhythmias after Bioelectrical Impedance Analysis in End-Stage Heart Failure Patients under Inotropic Support;** L. Roehrich<sup>1</sup>, J. Knierim<sup>1</sup>, M. Hajduczenia<sup>1</sup>, J. Mulzer<sup>1</sup>, M. Mueller<sup>1</sup>, P. Pergantis<sup>1</sup>, M. Hummel<sup>1</sup>, V. Falk<sup>1</sup>, E. Potapov<sup>1</sup>, S. Suendermann<sup>2</sup>, F. Schoenrath<sup>1</sup>. <sup>1</sup>*Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany*, <sup>2</sup>*Department of Cardiothoracic Surgery, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany*

**(949) Correlation of Initial Echocardiographic Parameters and Emergency Room Admission Rates in Heart Failure Clinic Patients;** X. Cai<sup>1</sup>, S. Jia<sup>2</sup>, S. J. Smith<sup>3</sup>, S. De<sup>3</sup>, R. McKelvie<sup>3</sup>, R. A. Davey<sup>3</sup>. <sup>1</sup>*Medicine, London Health Sciences Centre, London, ON, Canada*, <sup>2</sup>*Schulich School of Medicine and Dentistry, Western University, London, ON, Canada*, <sup>3</sup>*Cardiology, London Health Sciences Centre, London, ON, Canada*

**(950) Use of Intra-Aortic Balloon Pump in Heart Failure Admissions Requiring Inotropic Support in the United States between 2004-2014;** A. Afzal<sup>1</sup>, T. Nisar<sup>2</sup>, A. K. Jamil<sup>2</sup>, A. Y. Kluger<sup>3</sup>, J. Felius<sup>2</sup>, S. A. Hall<sup>1</sup>, P. Kale<sup>1</sup>. <sup>1</sup>*Baylor University Medical Center, Dallas, TX*, <sup>2</sup>*Baylor Scott & White Research Institute, Dallas, TX*, <sup>3</sup>*Baylor Heart and Vascular Institute, Dallas, TX*

**(951) The Obesity Paradox and Predictors of Thirty Day Mortality in a Single Center Heart Failure Population;** C. P. Boyd<sup>1</sup>, K. Luskin<sup>2</sup>, D. Eastwood<sup>3</sup>, M. Conti<sup>4</sup>, A. Mohammed<sup>1</sup>. <sup>1</sup>*Cardiology, Medical College of Wisconsin, Milwaukee, WI*, <sup>2</sup>*Allergy and Immunology, Scripps Health, San Diego, CA*, <sup>3</sup>*Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI*, <sup>4</sup>*Cardiology, Froedtert Health, Milwaukee, WI*

**(952) How Dynamic are Hemodynamics?: Short-Term Changes in Hemodynamic Measures and Indices among Heart Failure Patients;** A. Bhatia<sup>1</sup>, M. Husaini<sup>1</sup>, C. Lin<sup>1</sup>, J. LeClair<sup>2</sup>, E. De Togni<sup>2</sup>, N. Becker<sup>2</sup>, A. Scott<sup>2</sup>, M. Terng<sup>2</sup>, J. Acevedo-Cintron<sup>2</sup>, J. Schilling<sup>1</sup>. <sup>1</sup>*Division of Cardiology, Washington University School of Medicine, St. Louis, MO*, <sup>2</sup>*Washington University School of Medicine, St. Louis, MO*

**(953) The Effect of Preload Change on QRS Amplitude in Advanced Heart Failure Patients;** P. Pergantis<sup>1</sup>, S. A. Dual<sup>2</sup>, M. Schmid Daners<sup>2</sup>, J. Keznickl-Pulst<sup>1</sup>, F. Schoenrath<sup>1</sup>, V. Falk<sup>1</sup>. <sup>1</sup>*German Heart Center Berlin, Berlin, Germany*, <sup>2</sup>*ETH Zurich, Zurich, Switzerland*

**(954) N-Terminal Pro-B Type Natriuretic Peptide Imply Left Ventricular Diastolic Function but is a Low Sensitivity Marker;** H. Choi, S. Lee, C. Park, W. Chung. *Cardiology, Gachon University Gil Medical Center, Incheon, Korea, Republic of*

**(955) Validating the Newly Reported ASA Score;** A. Alam<sup>1</sup>, A. Mukherjee<sup>1</sup>, J. Xu<sup>1</sup>, E. Pagan<sup>1</sup>, E. Hiltner<sup>1</sup>, E. Rios<sup>1</sup>, S. Pollack<sup>2</sup>, D. Iyer<sup>1</sup>, K. Mody<sup>1</sup>, J. Kassotis<sup>1</sup>, D. James<sup>3</sup>, R. Jermyn<sup>2</sup>, J. Almendral<sup>3</sup>. <sup>1</sup>*Rutgers - Robert Wood Johnson University Hospital, New Brunswick, NJ*, <sup>2</sup>*St. Francis University Hospital, Roslyn, NY*, <sup>3</sup>*Jersey Shore Medical Center, Neptune, NJ*

**(956) Positive Correlation between P Wave Analysis and Severity of Heart Failure with Preserved and Reduced Ejection Fraction;** H. Patel, B. Allen, S. Almhameed, C. Musser. *Carillon Clinic - Virginia Tech, Roanoke, VA*

**(957) Diagnostic Accuracy of D-dimer is Comparable to NT-proBNP in Decompensated Heart Failure;** N. Nair<sup>1</sup>, S. Yang<sup>2</sup>, C. Marzbani<sup>1</sup>, C. Cole<sup>1</sup>, P. Tantrachoti<sup>1</sup>, E. Gongora<sup>3</sup>. <sup>1</sup>Division of Cardiology, Dept of Internal Medicine, Texas Tech Health Sciences Center, Lubbock, TX, <sup>2</sup>Dept of Internal Medicine, Texas Tech HSC, Lubbock, TX, <sup>3</sup>Cardiothoracic Surgery, Memorial Cardiovascular Institute, Hollywood, FL

**(958) The Impact of Hand Carried Ultrasound on the Management of Acute Heart Failure with Chronic Kidney Disease;** W. Khalife, A. Albaeni, V. R. Mukku, M. Almahmoud. *Cardiology, University of Texas Medical Branch, Galveston, TX*

**(959) The Role of Hand Carried Ultrasound in Guiding Management of Challenging Heart Failure Patients;** W. Khalife, A. Albaeni, V. R. Mukku, M. Almahmoud. *Cardiology, University of Texas Medical Branch, Galveston, TX*

**(960) Hand Carried Ultrasound Utilization in Acute Heart Failure Patients, Does It Correlate with Physical Examination?;** W. Khalife, A. Albaeni, V. Mukku, M. Almahmoud. *Cardiology, University of Texas Medical Branch, Galveston, TX*

**(961) Physician Prediction versus Model Predicted Prognosis in Ambulatory Patients with Heart Failure;** T. A. Buchan<sup>1</sup>, H. J. Ross<sup>1</sup>, M. McDonald<sup>1</sup>, F. Billia<sup>1</sup>, D. Delgado<sup>1</sup>, J. G. Duero Posada<sup>1</sup>, A. Luk<sup>1</sup>, G. H. Guyatt<sup>2</sup>, A. C. Alba<sup>1</sup>. <sup>1</sup>Cardiology, Ted Rogers Centre for Heart Research, University Health Network, Toronto, ON, Canada, <sup>2</sup>Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada

**(962) Outpatient Weaning of Inotropes is Achievable in Patients with Advanced Heart Failure;** A. Afzal, A. Y. Lee, A. S. Bindra, P. Kale. *Baylor University Medical Center, Dallas, TX*

**(963) Multidisciplinary Care for End-Stage HF. How to Improve Care?;** S. Mirabet<sup>1</sup>, A. Pascual<sup>2</sup>, P. Fluvia<sup>3</sup>, M. Pirla<sup>1</sup>, N. Mesado<sup>1</sup>, I. Lumillo<sup>1</sup>, E. Villegas<sup>4</sup>, M. Llauger<sup>5</sup>, E. Roig<sup>1</sup>. <sup>1</sup>Cardiology, Hospital Sant Pau, Barcelona, Spain, <sup>2</sup>Palliative Care, Hospital Sant Pau, Barcelona, Spain, <sup>3</sup>Cardiology, Hospital Josep Trueta, Girona, Spain, <sup>4</sup>Intern Medicine, Creu Roja, Barcelona, Spain, <sup>5</sup>Primary Care, Sant Pau, Barcelona, Spain

**(964) Chloride Homeostasis in End Stage Heart Failure and LVAD Recipients;** K. Stawiariski<sup>1</sup>, O. Agboola<sup>2</sup>, D. Jacoby<sup>2</sup>, L. Bellumkonda<sup>2</sup>, T. Ahmad<sup>2</sup>, L. Sugeng<sup>2</sup>, M. Chen<sup>2</sup>, G. McCloskey<sup>2</sup>, A. Geirsson<sup>2</sup>, M. Anwar<sup>2</sup>, P. Bonde<sup>2</sup>. <sup>1</sup>Yale New Haven Health Bridgeport Hospital, New Haven, CT, <sup>2</sup>Yale School of Medicine, New Haven, CT

**(965) Home Inotropic Therapy as a Bridge and as Destination: Intended and Unintended Outcomes in a Single Center Contemporary Cohort;** C. S. Grubb, M. S. Bohnen, A. Kleet, V. K. Topkara, A. R. Garan, R. Bijou, M. S. Maurer, H. Garan, M. Farr. *Columbia University Medical Center, New York, NY*

**(966) Bariatric Surgery in Patients with Systolic and Diastolic Heart Failure: Insights from the Nationwide Inpatient Sample;** V. Blumer<sup>1</sup>, M. Ortiz<sup>2</sup>, G. A. Hernandez<sup>1</sup>, A. Vest<sup>3</sup>. <sup>1</sup>University of Miami, Miami, FL, <sup>2</sup>University of Iowa, Iowa City, IA, <sup>3</sup>Tufts Medical Center, Boston, MA

**(967) To Exchange or Not: Defibrillators, Ventricular Assist Devices and Hematomas;** R. Khedraki<sup>1</sup>, M. Rajeev<sup>2</sup>, J. Rogers<sup>1</sup>, J. T. Heywood<sup>2</sup>, A. Srivastava<sup>2</sup>. <sup>1</sup>Cardiology, Scripps Clinic, Prebys Cardiovascular Institute, La Jolla, CA, <sup>2</sup>Division of Cardiology, Section of Advanced Heart Failure, Scripps Clinic, Prebys Cardiovascular Institute, La Jolla, CA

**(968) Safety and Efficacy of Home Inotropes as Bridge to LVAD and Transplant;** J. Pillarella<sup>1</sup>, L. Albers<sup>1</sup>, P. Katrapati<sup>1</sup>, D. Abramov<sup>2</sup>, E. Birks<sup>1</sup>, R. Vijaykrishnan<sup>1</sup>. <sup>1</sup>University of Louisville, Louisville, KY, <sup>2</sup>Loma Linda, Loma Linda, CA

**(969) Positive Familial History Poses a Higher Risk for No Spontaneous Recovery in Patients with Peripartum Heart Failure: Left Ventricular Assist Device Implantation and Transplantation with Bromocriptine as Novel Therapeutic Options in These Patients;** K. Jawad<sup>1</sup>, J. Erdmann<sup>2</sup>, M. Borger<sup>1</sup>, S. Eifert<sup>1</sup>. <sup>1</sup>Leipzig, Heart Center, Leipzig, Germany, <sup>2</sup>University to Lübeck, Lübeck, Germany

**(971) Cell-Free DNA in Different Clinical Scenarios after Heart Transplantation: Shedding Light or Obscuring the Picture?;** J. Boehmer<sup>1</sup>, A. Ricksten<sup>2</sup>, J. Asp<sup>2</sup>, C. Wasslavik<sup>2</sup>, A. Stahlberg<sup>3</sup>, K. Karason<sup>4</sup>, H. Wahlander<sup>1</sup>, J. Sunnegardh<sup>1</sup>, G. Dellgren<sup>4</sup>. <sup>1</sup>Pediatric Heart Center, The Queen Silvia Children's Hospital, Sahlgrenska University Hospital, Gothenburg, Sweden, <sup>2</sup>Laboratory for Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Sweden, <sup>3</sup>Department of Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden, <sup>4</sup>Transplant Center, Sahlgrenska University Hospital, Gothenburg, Sweden

**(972) *Is Amiodarone Truly a Risk Factor for Primary Graft Dysfunction in Heart Transplantation?***; M. Kittleson, J. Patel, D. H. Chang, E. Kransdorf, S. Dimbil, R. Levine, K. Yabuno, B. Kearney, L. Czer, M. Hamilton, F. Esmailian, J. A. Kobashigawa. *Cedars-Sinai Smidt Heart Institute, Los Angeles, CA*

**(973) *Risk Factors for Cellular and Antibody-Mediated Rejections in the First-Year Post-Transplant: A Population-Based Study***; G. Coutance<sup>1</sup>, M. Racapé<sup>2</sup>, G. Bonnet<sup>3</sup>, J. Van Keer<sup>2</sup>, J. Duong Van Huyen<sup>2</sup>, P. Bruneval<sup>3</sup>, L. Lecuyer<sup>4</sup>, S. Varnous<sup>5</sup>, P. Rouvier<sup>5</sup>, J. Taupin<sup>6</sup>, X. Jouven<sup>3</sup>, A. Loupy<sup>2</sup>. <sup>1</sup>*Paris Transplant Group, Pitié-Salpêtrière Hospital, Paris, France*, <sup>2</sup>*Paris Transplant Group, Paris, France*, <sup>3</sup>*Paris Transplant Group, Hôpital Européen Georges Pompidou, Paris, France*, <sup>4</sup>*Hôpital Européen Georges Pompidou, Paris, France*, <sup>5</sup>*Pitié-Salpêtrière Hospital, Paris, France*, <sup>6</sup>*Saint Louis Hospital, Paris, France*

**(974) *Immunoabsorption for Acute Symptomatic Antibody-Mediated Rejection after Heart Transplantation***; A. Schaefer<sup>1</sup>, G. Böhmig<sup>2</sup>, A. Zuckermann<sup>1</sup>, G. Fischer<sup>3</sup>, G. Laufer<sup>1</sup>, A. Kaider<sup>4</sup>, A. Aliabadi-Zuckermann<sup>1</sup>. <sup>1</sup>*Department of Surgery, Division of Cardiac Surgery, Medical University of Vienna, Vienna, Austria*, <sup>2</sup>*Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria*, <sup>3</sup>*Department for Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria*, <sup>4</sup>*Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria*

**(975) *Combination of Cell-Free DNA with Gene-Expression Profiling in the Diagnosis of Acute Rejection***; E. Depasquale<sup>1</sup>, S. Hall<sup>2</sup>, M. Crespo-Leiro<sup>3</sup>, A. Kao<sup>4</sup>, J. Teuteberg<sup>5</sup>, D. Hiller<sup>6</sup>, J. Yee<sup>6</sup>. <sup>1</sup>*Department of Medicine-Cardiology, University of California, Los Angeles, Los Angeles, CA*, <sup>2</sup>*Baylor Scott&White Research Institute, Dallas, TX*, <sup>3</sup>*Hospital Universitario A Coruña, La Coruna, Spain*, <sup>4</sup>*Saint Luke's Mid America Heart Institute, Kansas, MO*, <sup>5</sup>*Stanford University, Stanford, CA*, <sup>6</sup>*CareDx, Inc., Brisbane, CA*

**(976) *Effects of Induction on the Risk of Post-Transplant De Novo DSA***; R. T. Cole<sup>1</sup>, J. Minto<sup>2</sup>, M. Flattery<sup>3</sup>, A. Parikh<sup>4</sup>, T. Dong<sup>1</sup>, R. Roy<sup>1</sup>, L. Bogar<sup>5</sup>, A. Morris<sup>1</sup>, J. Vega<sup>6</sup>, D. Gupta<sup>1</sup>, K. Bhatt<sup>1</sup>, A. Smith<sup>1</sup>, S. Laskar<sup>7</sup>, A. Lala<sup>4</sup>, K. Shah<sup>3</sup>, P. Shah<sup>8</sup>. <sup>1</sup>*Cardiology, Emory Univ Sch of Med, Atlanta, GA*, <sup>2</sup>*George Washington University School of Medicine, Washington DC, GA*, <sup>3</sup>*Virginia Commonwealth University, Richmond, VA*, <sup>4</sup>*Mount Sinai Hospital, New York, NY*, <sup>5</sup>*Department of Cardiac Surgery, Inova Heart and Vascular Institute, Falls Church, VA*, <sup>6</sup>*Cardiothoracic Surgery, Emory Univ Sch of Med, Atlanta, GA*, <sup>7</sup>*Cardiology, Emory University School of Medicine, Atlanta, GA*, <sup>8</sup>*Inova Heart and Vascular Institute, Falls Church, VA*

**(977) *Mixed Rejection: More Important Than Thought after Heart Transplantation***; E. Kransdorf, M. Kittleson, J. Patel, R. Cole, S. Dimbil, R. Levine, M. Olymbios, T. Kao, L. Czer, B. Azarbal, J. Chung, J. A. Kobashigawa. *Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA*

**(978) *Peri-Operative Serum Amiodarone Levels are Not Predictive of Graft Dysfunction in Orthotopic Heart Transplantation***; J. E. Sanchez, M. Farr, S. Restaino, D. Jennings, V. Topkara, A. R. Garan, P. Kurlansky, P. Colombo, H. Takayama, Y. Naka, K. Takeda. *Columbia University College of Physicians & Surgeons, New York, NY*

Friday, April 5, 2019

6:00 PM - 7:15 PM

**POSTER SESSION 3: HEART TRANSPLANTATION (ADULT)**

Room: Hibiscus 1

**Poster Discussants:**

Jaime-Juergen Eulert-Grehn, MD, Deutsches Herzzentrum Berlin, Berlin, Germany

Kristjan Karason, MD, Sahlgrenska Hospital, Goteborg, Sweden

Jamila Kremer, MD, University Hospital Heidelberg, Heidelberg, Germany

Farhana Latif, MD, Columbia University New York Presbyterian Hospital, New York, NY, USA

Marco Masetti, MD, PhD, University of Bologna, Bologna, Italy

Eulalia Roig, MD, Hospital Sant Pau, Barcelona, Spain

**(981) Directly to a DOAC? Safety of Alternatives to Warfarin for Anticoagulation in Heart Transplantation;** M. Tremblay-Gravel<sup>1</sup>, K. M. Alexander<sup>2</sup>, P. Czobor<sup>2</sup>, R. Lee<sup>2</sup>, F. Foroutan<sup>3</sup>, W. A. Yang<sup>2</sup>, A. Hayes<sup>4</sup>, W. Hiesinger<sup>5</sup>, H. J. Ross<sup>6</sup>, K. K. Khush<sup>2</sup>, J. J. Teuteberg<sup>2</sup>, Y. Moayed<sup>7</sup>. <sup>1</sup>Medicine, Division of Cardiology, Stanford University, Palo Alto, CA, <sup>2</sup>Medicine, Division of Cardiology, Stanford University, Stanford, CA, <sup>3</sup>Biostatistics, University of Toronto, Toronto, ON, Canada, <sup>4</sup>Cardiovascular Surgery, Stanford University, Stanford, CA, <sup>5</sup>Cardiovascular Surgery, Stanford University, Palo Alto, CA, <sup>6</sup>Medicine, Division of Cardiology, University Health Network, University of Toronto, Toronto, ON, Canada, <sup>7</sup>Medicine, Stanford University, Stanford, CA

**(983) Transpulmonary Gradient as a Predictor of Outcomes after Heart Transplantation;** J. Jahanyar<sup>1</sup>, J. M. Liao<sup>2</sup>, R. J. Butterfield III<sup>3</sup>, N. Zhang<sup>4</sup>, B. W. Hardaway<sup>5</sup>, E. D. Steidley<sup>5</sup>, R. L. Scott<sup>5</sup>. <sup>1</sup>Cardiothoracic Surgery, Mayo Clinic, Phoenix, AZ, <sup>2</sup>Medicine, University of Washington, Seattle, WA, <sup>3</sup>Biostatistics, Mayo Clinic, Phoenix, AZ, <sup>4</sup>Health Sciences Research, Mayo Clinic, Phoenix, AZ, <sup>5</sup>Cardiology, Mayo Clinic, Phoenix, AZ

**(984) Outcomes of Combined Heart-Liver Transplant: A Systematic Review;** S. A. Rizvi<sup>1</sup>, J. Challapalli<sup>2</sup>, E. J. Maynes<sup>1</sup>, M. P. Weber<sup>1</sup>, J. Choi<sup>1</sup>, S. Patel<sup>1</sup>, J. W. Entwistle<sup>1</sup>, R. J. Morris<sup>1</sup>, L. E. Samuels<sup>1</sup>, H. T. Massey<sup>1</sup>, V. Tchanchaleishvili<sup>1</sup>. <sup>1</sup>Division of Cardiac Surgery, Thomas Jefferson University, Philadelphia, PA, <sup>2</sup>College of Medicine, Drexel University, Philadelphia, PA

**(985) Risk Factors and Early Outcomes of Vasoplegia Syndrome (VS) after Heart Transplantation in CF-LVAD Patients;** T. Chinnadurai<sup>1</sup>, F. Jahufar<sup>1</sup>, O. Moussa<sup>1</sup>, A. Rahman<sup>1</sup>, S. Rangasamy<sup>1</sup>, E. Borukhov<sup>1</sup>, A. Miller<sup>1</sup>, O. Saeed<sup>1</sup>, D. Goldstein<sup>2</sup>, U. P. Jorde<sup>1</sup>, S. R. Patel<sup>1</sup>. <sup>1</sup>Cardiology, Montefiore Medical Center, Bronx, NY, <sup>2</sup>Cardiothoracic, Montefiore Medical Center, Bronx, NY

**(986) En-Block Heart-Liver Transplantation in Adults - Technique and Mid Term Outcomes;** N. A. Brozzi<sup>1</sup>, R. Vianna<sup>2</sup>, F. Souki<sup>1</sup>, I. C. Saba<sup>1</sup>, A. Ghodzisad<sup>1</sup>, A. Tekin<sup>2</sup>, G. Selvaggi<sup>2</sup>, T. Beduschi<sup>2</sup>, A. Badiye<sup>1</sup>, S. Chaparro<sup>1</sup>, O. Aljure<sup>3</sup>, A. Nicolau-Raducu<sup>3</sup>, M. Loebe<sup>1</sup>. <sup>1</sup>Thoracic Transplantation and Mechanical Circulatory Support, University of Miami, Miami, FL, <sup>2</sup>Liver Transplantation, University of Miami, Miami, FL, <sup>3</sup>Anesthesia, University of Miami, Miami, FL

**(987) Cervical Abnormalities and Gynecological Neoplasms in Heart Transplanted Recipients;** S. Mirabet<sup>1</sup>, V. Brossa<sup>1</sup>, C. Vanrell<sup>2</sup>, L. Lopez<sup>1</sup>, E. Roig<sup>1</sup>. <sup>1</sup>Cardiology, Hospital Sant Pau, Barcelona, Spain, <sup>2</sup>Gynecology, Hospital Sant Pau, Barcelona, Spain

**(988) Factors Influencing Access to Transplant, Waitlist Mortality, and Post-Transplant Survival in the Italian National Heart Transplant Database;** M. Frigerio<sup>1</sup>, M. Varrenti<sup>1</sup>, C. Santolamazza<sup>1</sup>, D. P. Bernasconi<sup>2</sup>, A. Nanni Costa<sup>3</sup>, A. Oliveti<sup>3</sup>, F. Puoti<sup>3</sup>, T. Bottio<sup>4</sup>, G. Gerosa<sup>4</sup>, C. F. Russo<sup>1</sup>, C. Giannattasio<sup>5</sup>, V. Tursi<sup>6</sup>, U. Livi<sup>6</sup>, C. Maiello<sup>7</sup>, C. Amarelli<sup>7</sup>, L. Potena<sup>8</sup>, S. Martin Suarez<sup>8</sup>, M. Boffini<sup>9</sup>, C. Pace Napoleone<sup>10</sup>, F. Clemenza<sup>11</sup>, F. Musumeci<sup>12</sup>, M. Maccherini<sup>13</sup>, G. Faggian<sup>14</sup>, C. Pellegrini<sup>15</sup>, A. Terzi<sup>16</sup>, C. Tramontin<sup>17</sup>, D. De Angelis<sup>18</sup>, A. D. Milano<sup>19</sup>, M. Valsecchi<sup>2</sup>. <sup>1</sup>DeGasperis CardioCenter, Niguarda Hospital, Milan, Italy, <sup>2</sup>Center of Biostatistics for Medical Epidemiology, School of Medicine and Surgery, Milano-Bicocca University, Milan, Italy, <sup>3</sup>CNT-National Transplant Center, Rome, Italy, <sup>4</sup>Dept of Cardiac, Thoracic and Vascular Sciences, Padua University Medical School, Padua, Italy, <sup>5</sup>Cardiovascular Medicine and Emergency Medicine School, School of Medicine and Surgery, Milano-Bicocca University, Milan, Italy, <sup>6</sup>University Hospital, Udine, Italy, <sup>7</sup>Dept of Cardiovascular Surgery and Transplants, AORN Ospedale dei Colli, Naples, Italy, <sup>8</sup>Heart Transplant Program, Bologna University Hospital, Bologna, Italy, <sup>9</sup>Dept of Surgical Sciences, Turin University, ASOU Città della Salute e della Scienza, Turin, Italy, <sup>10</sup>Pediatric Cardiosurgery, OIRM Sant'Anna, AOU Città della Salute e della Scienza, Turin, Italy, <sup>11</sup>IRCCS-ISMETT, Palermo, Italy, <sup>12</sup>Cardiac Surgery Unit and Heart Transplantation Center, S. Camillo-Forlanini Hospital, Rome, Italy, <sup>13</sup>AOU Siena, Siena, Italy, <sup>14</sup>Verona University Hospital, Verona, Italy, <sup>15</sup>Dept of Surgical, Clinical and Surgical, Diagnostic and Pediatric Sciences, Pavia Study University, Pavia, Italy, <sup>16</sup>ASST Papa Giovanni XXIII, Bergamo, Italy, <sup>17</sup>G Brotzu Hospital, Cagliari, Italy, <sup>18</sup>Thoracic Transplantation Unit, Bambino Gesù Childrens' Hospital, Rome, Italy, <sup>19</sup>Dept of Emergency and Organ Transplants, University of Bari Medical School, Bari, Italy

**(989) Trends in Exercise Capacity Following Heart Transplantation;** S. Lundgren, E. Lyden, M. Hyden, A. Burdorf, R. Zolty, B. Lowes, J. Um, D. Stoller. University of Nebraska Medical Center, Omaha, NE

**(990) A Conformational Anastomotic Device for Heart Transplantation;** J. Park, P. Bonde. *Yale School of Medicine, New Haven, CT*

**(991) Outcomes in Combined Heart-Liver Transplantation: A Single-Center Experience;** A. Akhmerov<sup>1</sup>, Q. Chen<sup>1</sup>, M. DeRobertis<sup>2</sup>, L. Czer<sup>2</sup>. <sup>1</sup>*Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA*, <sup>2</sup>*Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA*

**(992) Orthotopic Heart Transplant Volume Can Be Aggressively Increased While Maintaining Outcomes;** A. Iyengar, J. Han, M. Helmers, W. Patrick, J. Chung, N. Goel, P. Atluri. *University of Pennsylvania, Philadelphia, PA*

**(993) Impact of Blood Group A Subtyping on Heart Transplantation: A Single Center Experience;** H. Ilias Basha, S. Hussain, E. Raichlin, S. Gudipati, M. Liebo, E. McGee, P. De Christopher, A. Heroux. *Loyola University Medical Center, Maywood, IL*

**(994) Multimodal Prehabilitation in Patients Listed for Heart Transplantation: A Pilot Study;** M. J. Arguis<sup>1</sup>, M. A. Castel<sup>2</sup>, E. Gimeno<sup>3</sup>, R. Navarro<sup>1</sup>, M. Coca<sup>1</sup>, A. Lopez-Hernández<sup>1</sup>, M. Montane-Muntane<sup>1</sup>, B. Romano<sup>4</sup>, M. Farrero<sup>2</sup>, E. Sandoval<sup>5</sup>, F. Perez-Villa<sup>2</sup>, A. Garcia<sup>2</sup>, G. Martinez-Palli<sup>1</sup>. <sup>1</sup>*Anesthesiology, Hospital Clinic of Barcelona, Barcelona, Spain*, <sup>2</sup>*Cardiology, Hospital Clinic of Barcelona, Barcelona, Spain*, <sup>3</sup>*Pneumology, Hospital Clinic of Barcelona, Barcelona, Spain*, <sup>4</sup>*Nutrition and Dietetics, Hospital Clinic of Barcelona, Barcelona, Spain*, <sup>5</sup>*Cardiac Surgery, Hospital Clinic of Barcelona, Barcelona, Spain*

**(995) Impact of Center Volume on Post Heart Transplant Survival;** J. Rice<sup>1</sup>, M. Slaughter<sup>1</sup>, E. Birks<sup>2</sup>, J. Trivedi<sup>1</sup>. <sup>1</sup>*Department of Cardiovascular Surgery, The University of Louisville School of Medicine, Louisville, KY*, <sup>2</sup>*Department of Cardiology, The University of Louisville School of Medicine, Louisville, KY*

**(996) Is Left Main Stenting Long-Term after Heart Transplantation Worthwhile?;** S. Dimbil, J. Patel, B. Azarbal, M. Kittleson, D. H. Chang, D. Geft, R. Levine, L. Czer, J. Chung, F. Esmailian, J. A. Kobashigawa. *Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA*

**(997) Heart Transplantation in Muscular Dystrophy: Selection is Crucial for Success;** M. Kittleson, J. Patel, D. H. Chang, D. Geft, S. Dimbil, R. Levine, B. Kearney, L. Czer, M. Hamilton, A. Trento, J. A. Kobashigawa. *Cedars-Sinai Smidt Heart Institute, Los Angeles, CA*

**(998) Is There a Mortality “Weekend Effect” in Cardiac Transplantation?;** R. Chand<sup>1</sup>, C. J. Lum<sup>1</sup>, A. Chang<sup>1</sup>, A. Salimbanon<sup>1</sup>, M. Deng<sup>1</sup>, M. Cadeiras<sup>2</sup>, T. Khuu<sup>1</sup>, K. Pandya<sup>3</sup>, D. Vucicevic<sup>4</sup>, A. Ardehali<sup>1</sup>, E. DePasquale<sup>1</sup>. <sup>1</sup>*UCLA, Los Angeles, CA*, <sup>2</sup>*UC Davis, Sacramento, CA*, <sup>3</sup>*USC, Los Angeles, CA*, <sup>4</sup>*Newark Beth Israel, Newark, NJ*

**(999) Impact of Heart Rate and Left Ventricular Mass on Survival Following Heart Transplantation;** S. Lundgren, E. Lyden, M. Hyden, A. Burdorf, R. Zolty, B. Lowes, J. Um, D. Stoller. *University of Nebraska Medical Center, Omaha, NE*

**(1000) Gender Differences in Pre-Transplant Characteristics and Short-Term Clinical Outcomes Post Heart Transplantation;** A. Almufleh<sup>1</sup>, S. Fazelpour<sup>2</sup>, A. Merdad<sup>1</sup>, J. Marbach<sup>1</sup>, R. Davies<sup>1</sup>, L. Mielniczuk<sup>1</sup>, S. Chih<sup>1</sup>, E. Stadnick<sup>1</sup>. <sup>1</sup>*Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada*, <sup>2</sup>*The Ottawa Hospital, Ottawa, ON, Canada*

**(1001) Is There a Mortality “Weekend Effect” in Cardiac Transplantation - A Single Center Experience?;** A. Salimbanon<sup>1</sup>, D. Vucicevic<sup>2</sup>, C. Lum<sup>1</sup>, A. Chang<sup>1</sup>, T. Khuu<sup>1</sup>, M. Moore<sup>1</sup>, R. Chand<sup>1</sup>, M. Cadeiras<sup>3</sup>, M. Kwon<sup>1</sup>, M. Deng<sup>1</sup>, M. Kamath<sup>1</sup>, E. DePasquale<sup>1</sup>. <sup>1</sup>*UCLA, Los Angeles, CA*, <sup>2</sup>*Newark Beth Israel, Newark, NJ*, <sup>3</sup>*UC Davis, Sacramento, CA*

**(1002) Post-Transplant Trends in BNP Levels among Recipients of Heart versus Heart-Kidney Transplantation;** K. Schlendorf<sup>1</sup>, P. Hanna<sup>2</sup>, M. Wigger<sup>1</sup>, D. Brinkley<sup>1</sup>, J. Menachem<sup>1</sup>, A. Shah<sup>3</sup>, M. Danter<sup>3</sup>, K. Balsara<sup>3</sup>, L. Punnoose<sup>1</sup>, S. Brown Sacks<sup>1</sup>, H. Ooi<sup>1</sup>, J. Lindenfeld<sup>1</sup>, S. Zalawadiya<sup>1</sup>. <sup>1</sup>*Heart Failure and Transplantation, Vanderbilt University Medical Center, Nashville, TN*, <sup>2</sup>*Internal Medicine, Vanderbilt University Medical Center, Nashville, TN*, <sup>3</sup>*Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN*

**(1003) Interactive Maps for UNOS Data Visualization;** A. Rivard<sup>1</sup>, M. Gentili<sup>2</sup>, N. Koizumi<sup>3</sup>. <sup>1</sup>*Department of Radiology, Cleveland Clinic, Abu Dhabi, United Arab Emirates*, <sup>2</sup>*University of Louisville, Louisville, KY*, <sup>3</sup>*George Mason University, Arlington, VA*

**(1004) Heart and Heart-Lung Transplantation in Adult Congenital Heart Disease (ACHD): A 4-Year Single-Centre Experience;** A. Verzelli<sup>1</sup>, H. Hassan<sup>2</sup>, H. Smail<sup>3</sup>, D. Garcia-Saez<sup>3</sup>, T. Aw<sup>4</sup>, A. Simon<sup>3</sup>. <sup>1</sup>*Department of Anaesthesia and Critical Care, Harefield Hospital, Harefield, United Kingdom*, <sup>2</sup>*Cardiothoracic Surgery, Menoufia University Hospital, Menoufia, Egypt*, <sup>3</sup>*Cardiothoracic Transplantation and Mechanical Support, Harefield Hospital, Harefield, United Kingdom*, <sup>4</sup>*Department of Anaesthesia, Royal Brompton Hospital, London, United Kingdom*



- (1005) Comparison of Mortality Rate after In-Hospital Cardiac Arrest in Heart Transplant Recipients versus Non-Transplant Patients;** S. Sulaiman<sup>1</sup>, N. Yousef<sup>2</sup>, M. Asim<sup>3</sup>, N. Gagliannello<sup>3</sup>. <sup>1</sup>Medical College of Wisconsin, Milwaukee, WI, <sup>2</sup>Kalamoon University, Damascus, Syrian Arab Republic, <sup>3</sup>Department of Medicine, Division of Cardiology, Medical College of Wisconsin, Milwaukee, WI
- (1006) Psychosocial Contraindications to Heart Transplant Listing in an Urban Academic Medical Center;** B. Yang, A. J. Kanelidis, N. Narang, L. Holzhauser, A. Nguyen, B. Chung, J. Raikhelkar, B. Smith, N. Sarswat, I. Ebong, D. Rodgers, T. Imamura, C. Murks, T. Riley, J. Powers, M. Riley, V. Jeevanandam, G. Sayer, N. Uriel. *University of Chicago, Chicago, IL*
- (1007) The Impact of Insurance Type on Listing Status and Mortality on the Waiting List: Insights from the United Network for Organ Sharing (UNOS);** A. Briasoulis<sup>1</sup>, E. Akintoye<sup>1</sup>, E. Ruiz Duque<sup>1</sup>, C. Inampudi<sup>1</sup>, J. Bhama<sup>2</sup>, P. Alvarez<sup>1</sup>. <sup>1</sup>University of Iowa, Iowa City, IA, <sup>2</sup>Cardiovascular Surgery, University of Iowa, Iowa City, IA
- (1008) Comparison of Ambulatory, and Central Blood Pressure in Heart Transplant Recipients;** C. Lee, J. Oh, S. Park, S. Lee, S. Kang. *Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of*
- (1009) Denovo Malignancy in Chinese Patients Post-Heart Transplant in Current Era-A “Not So Bad Prognosis”?**; K. Fan, M. Wong, K. Cheng. *Cardiac Medical Unit, Grantham Hospital, Aberdeen, Hong Kong*
- (1010) Progression of Tricuspid Regurgitation after Heart Transplantation with Concomitant Tricuspid Valve Annuloplasty;** D. Nitta, T. Imamura, T. Fujino, A. Nguyen, B. Chung, B. Smith, J. Raikhelkar, L. Holzhauser, I. Ebong, N. Narang, L. Lourenco, T. Ota, J. Powers, T. Riley, C. Murks, G. Kim, V. Jeevanandam, G. Sayer, N. Uriel. *University of Chicago, Chicago, IL*
- (1011) A Higher Need for Permanent Pacing after Orthotopic Heart Transplantation Due to Increased Donor Age;** S. Roest<sup>1</sup>, F. Akca<sup>1</sup>, M. A. Kolff<sup>1</sup>, J. F. Veenis<sup>1</sup>, A. A. Constantinescu<sup>1</sup>, J. J. Brugs<sup>1</sup>, O. Birim<sup>2</sup>, O. C. Manintveld<sup>1</sup>, T. Szili-Torok<sup>1</sup>, K. Caliskan<sup>1</sup>. <sup>1</sup>Cardiology, Erasmus MC, University Medical Center, Thoraxcenter, Rotterdam, Netherlands, <sup>2</sup>Cardiothoracic Surgery, Erasmus MC, University Medical Center, Thoraxcenter, Rotterdam, Netherlands
- (1012) Vasoplegia in Patients Undergoing Heart Transplantation Bridged with an LVAD is Not Associated with Inferior Long-Term Outcomes;** J. Ali, S. Patel, P. Catarino, Y. Abu-Omar, S. Messer, A. Page, S. Pettit, S. Bhagra, J. Parameshwar, C. Lewis, A. Kydd, S. Large, C. Sudarshan, D. Jenkins, S. Tsui, M. Berman. *Papworth Hospital, Cambridge, United Kingdom*
- (1013) Incidence of Vasoplegia in Post-Heart Transplant Patients Treated with Phosphodiesterase-5 Inhibitors Secondary to Right Ventricular Dysfunction Post-Left Ventricular Assist Device;** C. Meloche, A. Kassier, K. Wachter, J. Parker, R. Grayburn. *Cardiology, Spectrum Health, Grand Rapids, MI*

Friday, April 5, 2019

6:00 PM - 7:15 PM

**POSTER SESSION 3: LUNG FAILURE/TRANSPLANTATION (ADULT)**

Room: Banda Sea 1

**Poster Discussants:**

Andrew Courtwright, MD, PhD, University of Pennsylvania, Philadelphia, PA, USA

Peter Hopkins, FRACP, Prince Charles Hospital, Brisbane, Australia

Lorriana Leard, MD, UCSF Medical Center, San Francisco, CA, USA

Deborah Levine, MD, UT Health Science Center, San Antonio, TX, USA

Sebastian Michel, MD, Ludwig Maximilian University/Munich University, Muenchen, Germany

Caroline Patterson, MD, Papworth Hospital, Cambridge, United Kingdom

Aida Venado, MD, UCSF Medical Center, San Francisco, CA, USA

Robin Vos, MD, PhD, University Hospitals Leuven, Leuven, Belgium

**(1014) Time to Therapeutic Tacrolimus Serum Concentrations and the Impact on Early Acute Cellular Rejection in Adult Lung Transplant Recipients;** K. Mecadon<sup>1</sup>, J. Scheffert<sup>2</sup>, L. Shah<sup>3</sup>, H. Robbins<sup>3</sup>, M. Aversa<sup>3</sup>, S. Arcasoy<sup>3</sup>, L. Benvenuto<sup>3</sup>. <sup>1</sup>Department of Pharmacy, Rhode Island Hospital, Providence, RI, <sup>2</sup>Department of Pharmacy, NewYork-Presbyterian Hospital, New York, NY, <sup>3</sup>Department of Medicine, Columbia University Irving Medical Center, New York, NY

**(1015) Acute Rejection (AR) and Lymphocytic Bronchiolitis (LB) in a Multicenter Lung Transplant Cohort;** J. L. Todd<sup>1</sup>, M. L. Neely<sup>1</sup>, H. Kopetskie<sup>2</sup>, M. Sever<sup>2</sup>, J. Kirchner<sup>1</sup>, C. W. Frankel<sup>1</sup>, L. D. Snyder<sup>1</sup>, E. N. Pavlisko<sup>1</sup>, T. Martinu<sup>3</sup>, W. Tsuang<sup>4</sup>, M. Shino<sup>5</sup>, N. Williams<sup>6</sup>, M. A. Robien<sup>6</sup>, L. G. Singer<sup>3</sup>, M. Budev<sup>4</sup>, P. D. Shah<sup>7</sup>, J. M. Reynolds<sup>1</sup>, S. M. Palmer<sup>1</sup>, J. A. Belperio<sup>5</sup>, S. S. Weigt<sup>5</sup>. <sup>1</sup>Duke Univ Med Ctr, Durham, NC, <sup>2</sup>Rho Federal Systems Division, Chapel Hill, NC, <sup>3</sup>University of Toronto, Toronto, ON, Canada, <sup>4</sup>Cleveland Clinic, Cleveland, OH, <sup>5</sup>University of California Los Angeles, Los Angeles, CA, <sup>6</sup>National Institute of Allergy and Infectious Disease, Bethesda, MD, <sup>7</sup>Johns Hopkins University, Baltimore, MD

**(1016) Impact of AMR Treatment on Graft Function in Lung Transplant Recipients;** L. Godinas, S. Verleden, B. Vanaudenaerde, D. Dierickx, D. Van Raemdonck, A. Neyrinck, G. Verleden, R. Vos. University Hospitals Leuven, Leuven, Belgium

**(1017) Peripheral Blood Eosinophil Count as a Marker of Pulmonary Allograft Rejection;** S. Aguado Ibáñez, J. Carrillo, M. Aguilar, R. Laporta, C. López, G. Díaz, C. Salas, M. Ussetti. Hospital Univ Puerta de Hierro, Majadahonda, Majadahonda, Spain

**(1018) Clinical Antibody Mediated Rejection of Lung is Not One Disease, but Includes Distinct Obstructive, Restrictive and Indolent Phenotypes;** D. Abelson<sup>1</sup>, S. Garnett<sup>2</sup>, A. Awford<sup>1</sup>, A. Kwok<sup>3</sup>, N. Watson<sup>4</sup>, J. Colgan<sup>1</sup>, A. Rigby<sup>1</sup>, M. Plit<sup>1</sup>, A. R. Glanville<sup>1</sup>. <sup>1</sup>Lung Transplant Unit, St. Vincent's Hospital, Sydney, Australia, <sup>2</sup>Integrative Biomedical Sciences, University of Capetown, Capetown, South Africa, <sup>3</sup>Department of Radiology, St. Vincent's Hospital, Sydney, Australia, <sup>4</sup>Solid Organ Transplantation, Australian Red Cross Blood Service, Sydney, Australia

**(1019) Anti-HLA Antibodies before and after Lung Transplantation: A Role on Medium-Long Term Outcomes?;** E. Benazzi<sup>1</sup>, L. Morlacchi<sup>2</sup>, A. Cannavò<sup>1</sup>, L. Rosso<sup>3</sup>, A. Palleschi<sup>3</sup>, V. Rossetti<sup>2</sup>, I. Righi<sup>3</sup>, S. Passamonti<sup>1</sup>, B. Dalpedri<sup>1</sup>, E. Longhi<sup>1</sup>, M. Cardillo<sup>1</sup>, P. Tarsia<sup>2</sup>. <sup>1</sup>Transplant Coordination (NITp); Dept. of Services and Preventive Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy, <sup>2</sup>Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Centre, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy, <sup>3</sup>Thoracic Surgery and Lung Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy

**(1020) Evaluating Novel Graft Failure Thresholds after Lung Transplantation;** J. Liu, D. Li, K. Jackson, J. Weinkauf, A. Kapasi, D. Lien, A. Hirji, K. Halloran. Department of Medicine, University of Alberta, Edmonton, AB, Canada

**(1021) Impact for Survival and Chronic Lung Allograft Dysfunction of ISHLT Consensus of Antibody Mediated Rejection after Lung Transplantation;** Y. Itoda<sup>1</sup>, M. Sato<sup>2</sup>, L. Thuita<sup>3</sup>, H. Nlikawa<sup>4</sup>, K. S. Ayyat<sup>4</sup>, T. Okamoto<sup>4</sup>, C. F. Farver<sup>5</sup>, A. Zhang<sup>6</sup>, M. Budev<sup>7</sup>, E. H. Balckstone<sup>3</sup>, K. R. McCurry<sup>4</sup>. <sup>1</sup>Cardiac Surgery, The University of Tokyo Hospital, Tokyo, Japan, <sup>2</sup>Thracic Surgery, The University of Tokyo Hospital, Tokyo, Japan, <sup>3</sup>Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, <sup>4</sup>Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, <sup>5</sup>Anatomic Pathology, Cleveland Clinic, Cleveland, OH, <sup>6</sup>Allogeneic Department, Cleveland Clinic, Cleveland, OH, <sup>7</sup>Respiratory Institute, Cleveland Clinic, Cleveland, OH

**(1022) COMBINATION Therapies Including TOCILIZUMAB Decrease the Progression of CLAD: Initial Clinical Experience;** D. J. Ross<sup>1</sup>, A. Der Hovanessian<sup>2</sup>, B. Kubak<sup>1</sup>, E. Reed<sup>3</sup>, C. Natori<sup>4</sup>, J. Schaeenman<sup>1</sup>, A. Ardehali<sup>5</sup>. <sup>1</sup>Medicine, David Geffen - UCLA School of Medicine, Los Angeles, CA, <sup>2</sup>Medicine, David Geffen - UCLA School of Medicine, Los Angeles, CA, <sup>3</sup>Immunogenetics, David

Geffen - UCLA School of Medicine, Los Angeles, CA, <sup>4</sup>Transplant Administration, David Geffen - UCLA School of Medicine, Los Angeles, CA, <sup>5</sup>Surgery, David Geffen - UCLA School of Medicine, Los Angeles, CA

**(1023) Impact of Donor-Recipient Sex Mismatch on the Incidence of Allograft Rejection in Clinical Lung Transplantation: A Review of the United Network of Organ Sharing Database;** F. H. Cheema<sup>1</sup>, A. Al-najar<sup>1</sup>, P. Loyalka<sup>2</sup>, K. Rajagopal<sup>3</sup>. <sup>1</sup>Surgery, Baylor College of Medicine, Houston, TX, <sup>2</sup>Cardiology, HCA Healthcare - Park Plaza Hospital, Houston, TX, <sup>3</sup>Surgery, University of Texas, Houston, TX

**(1024) Diagnosis of Restrictive Allograft Syndrome (RAS) in Single-Lung Transplantation Using PFTs and CT-Scan Volumetry and Score;** O. Brugiere<sup>1</sup>, Q. Philippot<sup>1</sup>, R. Bun<sup>2</sup>, C. Couffignal<sup>3</sup>, J. Frijat<sup>4</sup>, V. Bunel<sup>1</sup>, L. Morer<sup>1</sup>, G. Mourin<sup>1</sup>, G. Jebrak<sup>1</sup>, Y. Castier<sup>5</sup>, G. Dauriat<sup>1</sup>, P. Mordant<sup>5</sup>, H. Mal<sup>1</sup>, M. Debray<sup>6</sup>. <sup>1</sup>Transplantation Pulmonaire, Hopital Bichat, Paris, France, <sup>2</sup>Departement Biostatistique, Hopital Bichat, Paris, France, <sup>3</sup>Département Biostatistique, Hopital Bichat, Paris, France, <sup>4</sup>Explorations Fonctionnelles Respiratoires, Hopital Bichat, Paris, France, <sup>5</sup>Chirurgie Thoracique, Hopital Bichat, Paris, France, <sup>6</sup>Radiologie, Hopital Bichat, Paris, France

**(1025) Cytotoxic T Cells Early after Lung Transplantation Precede the Restrictive Allograft Syndrome;** T. Nakagiri, A. Knöfel, W. Sommer, J. Salman, T. Siemeni, M. Avsar, F. Ius, P. Zardo, I. Tudorache, A. Haverich, G. Warnecke. *Cardiothoracic, Transplantation, and Vascular Surgery, Hannover Medical School, Hannover, Germany*

**(1026) Decreased Serum Levels of Irisin are Associated with the Development of Chronic Lung Allograft Dysfunction after Bilateral Living-Donor Lobar Lung Transplantation;** T. Shiotani, S. Sugimoto, H. Yamamoto, T. Kurosaki, S. Otani, M. Okazaki, M. Yamane, S. Toyooka, T. Oto. *Department of General Thoracic Surgery, Organ Transplant Center, Okayama University, Okayama, Japan*

**(1027) Quantitative CT Imaging Analysis for Chronic Lung Allograft Dysfunction in Single Lung Transplant Recipients;** M. Horie<sup>1</sup>, T. Saito<sup>1</sup>, L. Levy<sup>1</sup>, P. Salazar<sup>2</sup>, C. Houbois<sup>1</sup>, S. Keshavjee<sup>1</sup>, N. Paul<sup>3</sup>, T. Martinu<sup>1</sup>. <sup>1</sup>Toronto Lung Transplant Program, Toronto, ON, Canada, <sup>2</sup>Vital Images, Minnetonka, MN, <sup>3</sup>Department of Medical Imaging, London Health Sciences, London, United Kingdom

**(1028) Phenotypical Diversity of Airway Pathology in Chronic Pulmonary GvHD after Hematopoietic Stem Cell Transplantation;** S. E. Verleden<sup>1</sup>, J. McDonough<sup>1</sup>, H. Schoemans<sup>1</sup>, C. Knoop<sup>2</sup>, J. Verschakelen<sup>1</sup>, A. Dubbeldam<sup>1</sup>, M. Boone<sup>3</sup>, L. Van Hoorebeke<sup>4</sup>, E. Verbeken<sup>1</sup>, B. Weynand<sup>1</sup>, D. Van Raemdonck<sup>1</sup>, G. Verleden<sup>1</sup>, R. Vos<sup>1</sup>, B. Vanaudenaerde<sup>1</sup>. <sup>1</sup>KU Leuven, Leuven, Belgium, <sup>2</sup>University of Brussels, Brussel, Belgium, <sup>3</sup>University of Ghent, Ghent, Belgium, <sup>4</sup>University of Ghent, Ghent, Belgium

**(1029) Risk Factors for the Development of Antibody-mediated Rejection (AMR) after Lung Transplantation;** S. Sunder, C. Witt, D. Byers, R. Hachem. *Pulmonary and Critical Care, Washington University, St Louis, MO*

**(1031) Differences in Onset of Chronic Lung Allograft Dysfunction between Living Donor and Cadaveric Lung Transplantation;** S. Sugimoto<sup>1</sup>, H. Yamamoto<sup>1</sup>, T. Kurosaki<sup>2</sup>, S. Otani<sup>2</sup>, M. Okazaki<sup>1</sup>, M. Yamane<sup>1</sup>, S. Toyooka<sup>1</sup>, T. Oto<sup>2</sup>. <sup>1</sup>General Thoracic Surgery, Okayama University Hospital, Okayama, Japan, <sup>2</sup>Organ Transplant Center, Okayama University Hospital, Okayama, Japan

**(1032) Outcomes Following Antithymocyte Globulin (ATGAM) for Chronic Lung Allograft Dysfunction Post Lung Transplantation;** S. Kotecha<sup>1</sup>, E. Paul<sup>2</sup>, J. Fuller<sup>1</sup>, B. J. Levvey<sup>1</sup>, G. I. Snell<sup>1</sup>, G. P. Westall<sup>1</sup>. <sup>1</sup>Lung Transplant Service, Alfred Hospital, Melbourne, Australia, <sup>2</sup>Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia

**(1033) Liposomal Cyclosporine A (L-CsA) via Inhalation to Treat Bronchiolitis Obliterans Syndrome: Novel Formulation and Drug-Specific Delivery System Improves Tolerability;** N. Henig, J. Teichmann, J. Paulukat, D. Kappeler, O. Denk, G. Boerner. *Breath Therapeutics, Menlo Park, CA*

**(1034) Immunosuppression and Outcomes in Elderly Lung Transplant Recipients;** J. K. McDermott, P. Nguyen, J. L. Parker, R. J. Hadley, A. Kumar, G. Sathiyamoorthy, M. Leacche, E. T. Murphy, R. E. Girgis. *Spectrum Health Hospitals, Grand Rapids, MI*

**(1035) Correlation of Tacrolimus Levels and Metabolizer Status Based on CYP3A5 Polymorphism in Indian Lung Transplant Recipients;** A. Jindal<sup>1</sup>, V. Rahulan<sup>2</sup>, S. Sagadevan<sup>2</sup>, P. Dutta<sup>2</sup>, S. Attawar<sup>2</sup>. <sup>1</sup>Pulmonary Critical Care and Sleep Medicine, Institute of Heart & Lung Transplant, Gleneagles Global Health City, Chennai, Tamil Nadu, India, <sup>2</sup>Pulmonary Critical Care and Sleep Medicine, Institute of Heart & Lung Transplant, Gleneagles Global Health City, Chennai, India

**(1036) Sirolimus Based Immunosuppression Regimen after Lung Transplantation Can Decrease CNI Related Nephrotoxicity;** A. Gandhi, M. Terrin, N. Costa, R. Young, M. Wijesinha, R. Vesselinov, C. Young, D. Kaczorowski, R. Madathil, B. Griffith, B. Thomas, A. Iacono, I. Timofte. *University of Maryland Medical Center, Baltimore, MD*

**(1037) Preservation of the Donor-Reactive T Cell Repertoire Following Extracorporeal Photopheresis;** P. Wang<sup>1</sup>, A. Pelonero<sup>2</sup>, T. Looney<sup>3</sup>, D. Topacio-Hall<sup>3</sup>, J. Chang<sup>3</sup>, J. Kukreja<sup>4</sup>, S. R. Hays<sup>1</sup>, J. A. Golden<sup>1</sup>, J. P. Singer<sup>1</sup>, G. M. Lowman<sup>3</sup>, J. R. Greenland<sup>2</sup>.

<sup>1</sup>Medicine, University of California, San Francisco, CA, <sup>2</sup>Medicine, VA Health Care System, San Francisco, CA, <sup>3</sup>Life Sciences Solutions Group, Thermo Fisher Scientific, Carlsbad, CA, <sup>4</sup>Surgery, University of California, San Francisco, CA

**(1038) A Phase II, Prospective, Open Label, Standard of Care (SOC) Controlled, Study to Evaluate the Safety and Efficacy of Glassia® in Lung Transplantation during the First 6 Months;** M. R. Kramer<sup>1</sup>, Y. Rosen-Krauss<sup>1</sup>, D. Rosengarten<sup>1</sup>, O. Shtreichman<sup>2</sup>, A. Avron<sup>3</sup>, S. Gai-Castro<sup>4</sup>, N. Jaffe<sup>4</sup>, N. Tov<sup>3</sup>. <sup>1</sup>Pulmonary Institute, Rabin Medical Center, Petah Tikva, Israel, <sup>2</sup>Pulmonary Institute, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel, <sup>3</sup>Clinical Development, Kamada, Rehovot, Israel, <sup>4</sup>Clinical Development, Kamada Ltd, Rehovot, Israel

**(1039) Steroid Dosing and Delirium after Lung Transplant Surgery;** G. N. Mody<sup>1</sup>, K. Townsend<sup>2</sup>, C. Kerwin<sup>3</sup>, D. Larios Chavez<sup>4</sup>, S. Boukedes<sup>5</sup>, A. Coppolino<sup>6</sup>, S. Singh<sup>6</sup>, G. Jin<sup>6</sup>, D. Wolfe<sup>7</sup>, H. Mallidi<sup>6</sup>, H. Goldberg<sup>5</sup>. <sup>1</sup>Surgery, University of North Carolina, Chapel Hill, NC, <sup>2</sup>Pharmacy, Brigham and Women's Hospital, Boston, MA, <sup>3</sup>Medicine, University of Colorado School of Medicine, Denver, CO, <sup>4</sup>Medicine, Harvard Medical School, Boston, MA, <sup>5</sup>Medicine, Brigham and Women's Hospital, Boston, MA, <sup>6</sup>Surgery, Brigham and Women's Hospital, Boston, MA, <sup>7</sup>Psychiatry, Brigham and Women's Hospital, Boston, MA

**(1040) Analysis of UNOS Database: Survival Outcome in Elderly Lung Transplant Recipients;** J. Levy, M. A. Kashem, G. Sunagawa, H. Zhao, S. Keshavamurthy, F. Kromah, J. Gomez-Abraham, K. Minakata, S. Brann, N. Shigemura, Y. Toyoda. Temple University Hospital, Philadelphia, PA

**(1041) Redo-Lung Transplantation in Elderly Patients: A Review of UNOS Database;** J. Levy, M. A. Kashem, G. Sunagawa, H. Zhao, S. Keshavamurthy, F. Kromah, J. Gomez-Abraham, K. Minakata, S. Brann, S. Norihisha, Y. Toyoda. Temple University Hospital, Philadelphia, PA

**(1042) Standard Use of Single Running Suture for Bronchial Anastomosis Results in Very Low Rates of Anastomotic Complications - Single-Center Experience with 3028 Anastomoses at Risk;** T. Schweiger, I. Nenewidwis, C. Ieromonaches, J. E. Stadler, A. Scheed, S. Schwarz, A. Benazzo, S. Taghavi, G. Lang, J. R. Matilla, B. Moser, P. Jaksch, K. Hoetzenecker, W. Klepetko. Medical University of Vienna, Vienna, Austria

**(1043) The Need for Haemofiltration after Lung Transplantation is a Marker of Poor Early Outcomes, but Has No Deleterious Long-Term Renal Effect - A UK Cohort Study;** L. Wang<sup>1</sup>, T. Wang<sup>2</sup>, S. N. Rushton<sup>3</sup>, G. Parry<sup>1</sup>, N. S. Sheerin<sup>4</sup>, J. H. Dark<sup>1</sup>. <sup>1</sup>Cardiothoracic Services, Freeman Hospital, Newcastle upon Tyne, UK, <sup>2</sup>University College London, London, UK, <sup>3</sup>National Health Service Blood and Transplant, Bristol, UK, <sup>4</sup>Renal Services, Freeman Hospital, Newcastle upon Tyne, UK

**(1044) Impact of Surgical Approach in Double Lung Transplantation: Median Sternotomy Decreases Operative and Cardiopulmonary Bypass Time Compared to Clamshell Thoracotomy;** Y. Shudo, D. Rinewalt, B. Lingala, F. Y. Kim, H. He, J. H. Boyd, A. M. Lee, W. Hiesinger, M. E. Currie, J. W. MacArthur, J. Woo. Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA

**(1045) Developing DSA Post-Lung Transplant - Identifying Risk Factors;** L. Wang<sup>1</sup>, A. Andreasson<sup>1</sup>, C. Straughan<sup>1</sup>, A. J. Sims<sup>2</sup>, K. J. Brennan<sup>1</sup>, A. J. Fisher<sup>1</sup>, S. C. Clark<sup>1</sup>, G. Parry<sup>1</sup>, K. L. Booth<sup>1</sup>, J. H. Dark<sup>1</sup>. <sup>1</sup>Cardiothoracic Services, Freeman Hospital, Newcastle upon Tyne, United Kingdom, <sup>2</sup>Regional Medical Physics Department, Freeman Hospital, Newcastle upon Tyne, United Kingdom

**(1046) Incisional Negative Pressure Wound Therapy Use to Reduced Surgical Site Complications in Lung Transplant Patients;** R. Anderson, M. Weder, S. Kilbourne. Lung Transplant, University of Virginia, Charlottesville, VA

**(1047) Risk Factors for Cancer after Lung Transplantation;** L. Fernandez<sup>1</sup>, M. Delgado<sup>1</sup>, A. Pinto<sup>2</sup>, D. Cruz<sup>3</sup>, E. Fieira<sup>1</sup>, M. Peradela<sup>1</sup>, J. Ovalle<sup>1</sup>, R. Fernández<sup>1</sup>, M. Trabazo<sup>1</sup>, M. De La Torre<sup>1</sup>. <sup>1</sup>Thoracic Surgery Department, A Coruña University Hospital, A Coruña, Spain, <sup>2</sup>Pneumology Department, Vila Nova de Gaia Espinho Hospital, Gaia, Portugal, <sup>3</sup>Pneumology Department, Ourense University Hospital, Ourense, Spain

**(1048) The Utility of Prophylactic Zoledronic Acid in Patients Undergoing Lung Transplantation - A Retrospective Analysis;** E. Ng<sup>1</sup>, D. Topliss<sup>2</sup>, M. Paraskeva<sup>3</sup>, E. Paul<sup>4</sup>, S. Sztal-Mazer<sup>5</sup>. <sup>1</sup>Department of Medicine, Alfred Health, Melbourne, Australia, <sup>2</sup>Department of Endocrinology and Diabetes, Department of Medicine, Alfred Health, Melbourne, Australia, <sup>3</sup>Department of Allergy, Immunology & Respiratory Medicine, Alfred Health, Melbourne, Australia, <sup>4</sup>School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia, <sup>5</sup>Department of Endocrinology and Diabetes, Alfred Health, Melbourne, Australia

**(1049) A New 3D CT Method to Analyze Bronchial Stenosis after Lung Transplantation;** Y. T. Nunes Dias<sup>1</sup>, R. C. Chate<sup>2</sup>, J. M. Nogueira Filho<sup>2</sup>, G. G. Cirillo<sup>3</sup>, P. M. Pêgo-Fernandes<sup>4</sup>, M. N. Samano<sup>4</sup>. <sup>1</sup>Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil, <sup>2</sup>Radiology Division, Heart Institute (InCor), São Paulo, Brazil, <sup>3</sup>Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Brazil, <sup>4</sup>Thoracic Surgery Division, Heart Institute (InCor), São Paulo, Brazil

**(1050) Pre-Transplant Opioid Use is Not Associated with Overall Graft Survival in Lung Transplant Recipients;** S. Vahidy, D. Li, A. Hirji, J. Weinkauff, A. Kapasi, D. C. Lien, K. Halloran. *Department of Medicine, University of Alberta, Edmonton, AB, Canada*

**(1051) Comparison of Bronchial Anastomotic Techniques in Lung Transplantation by 3D CT Analysis;** G. G. Cirillo<sup>1</sup>, R. C. Chate<sup>2</sup>, J. M. Nogueira Filho<sup>2</sup>, Y. N. Dias<sup>1</sup>, P. M. Pêgo-Fernandes<sup>3</sup>, M. N. Samano<sup>3</sup>. <sup>1</sup>*Faculdade de Medicina da USP, São Paulo, Brazil*, <sup>2</sup>*Radiology Div, Heart Institute (InCor), São Paulo, Brazil*, <sup>3</sup>*Thoracic Surgery Div, Heart Institute (InCor), São Paulo, Brazil*

**(1052) Outcomes of Donor-Recipient Gender Mismatched Lung Transplantation in the Eurotransplant Area;** J. M. Kwakkel-van Erp<sup>1</sup>, J. M. Smits<sup>2</sup>, V. Verplancke<sup>1</sup>, P. Evrard<sup>3</sup>, G. Lang<sup>4</sup>, R. Schramm<sup>5</sup>, R. Vos<sup>6</sup>, G. M. Verleden<sup>6</sup>, B. Rondelet<sup>7</sup>, D. Hoefler<sup>8</sup>, E. A. Verschuur<sup>9</sup>, W. van der Bij<sup>9</sup>, R. A. Hoek<sup>10</sup>, G. Laufer<sup>11</sup>, K. Hoetzenecker<sup>12</sup>, C. Knoop<sup>13</sup>, R. Buhl<sup>14</sup>, C. Witt<sup>15</sup>, J. Gotlieb<sup>16</sup>, E. A. van de Graaf<sup>17</sup>. <sup>1</sup>*Pulmonology, Univ Hosp Antwerpen, Antwerpen, Belgium*, <sup>2</sup>*Eurotransplant, Leiden, Netherlands*, <sup>3</sup>*Intensive Care, UCL, Namur Godinne, Belgium*, <sup>4</sup>*Thoracic Surgery, Medical Univ of Vienna, Vienna, Austria*, <sup>5</sup>*Cardiothoracic Surgery, Univ Muenich, Bad Oeynhausen, Germany*, <sup>6</sup>*Dept of Respiratory Diseases, Univ Hosps Leuven, Leuven, Belgium*, <sup>7</sup>*Dept of Thoracic Surgery, UCL, Namur Godinne, Belgium*, <sup>8</sup>*Cardiothoracic Surgery, Univ Hosp Innsbruck, Innsbruck, Austria*, <sup>9</sup>*Lung Transplantation, Univ Med Ctr Groningen, Groningen, Netherlands*, <sup>10</sup>*Pulmonary Medicine, Erasmus Univ Med Ctr, Rotterdam, Netherlands*, <sup>11</sup>*Cardiac Surgery, Univ Hosp, Vienna, Austria*, <sup>12</sup>*Thoracic Surgery, Univ Hosp, Vienna, Austria*, <sup>13</sup>*Respiratory Medicine, Hopital Erasme, Brussels, Belgium*, <sup>14</sup>*Respiratory Medicine, Univ Hosp Mainz, Mainz, Germany*, <sup>15</sup>*Pulmonology, Univ Hosp Charite, Berlin, Germany*, <sup>16</sup>*Respiratory Medicine, Hannover Med Sch, Hannover, Germany*, <sup>17</sup>*Pulmonology, Univ Med Ctr Utrecht, Utrecht, Netherlands*

**(1054) Sternum Sparing Bilateral Anterolateral Thoracotomy Approach Improves Early Respiratory Function after Bilateral Sequential Lung Transplantation;** G. K. Mathew<sup>1</sup>, G. J. Valooran<sup>1</sup>, M. C. Mathew<sup>1</sup>, G. Hariprasad<sup>1</sup>, J. Cho<sup>1</sup>, A. Mc George<sup>2</sup>, D. Haydock<sup>1</sup>, A. K. Sibal<sup>1</sup>. <sup>1</sup>*Greenlane Cardiothoracic Surgery Unit, Auckland City Hospital, Auckland, New Zealand*, <sup>2</sup>*Greenlane CTSU, Auckland City Hospital, Auckland, New Zealand*

**(1055) Institutional Algorithm for the Optimal Treatment Strategy for the Patients with Severe Coronary Artery Disease in Lung Transplantation;** S. H. Brann, N. Shigemura, B. O'Murchu, G. Sunagawa, F. Kromah, J. Gomez-Abraham, S. Keshavamurthy, K. Minakata, F. Cordova, Y. Toyoda. *Temple University Hospital, Philadelphia, PA*

**(1056) Institutional Algorithm for the Optimal Treatment Strategy for the Patients with Severe Coronary Artery Disease in Lung Transplantation;** S. H. Brann, N. Shigemura, B. O'Murchu, G. Sunagawa, F. Kromah, J. Gomez-Abraham, S. Keshavamurthy, K. Minakata, F. Cordova, Y. Toyoda. *Temple University Hospital, Philadelphia, PA*

**(1057) Assessing Levels of Frailty in a Cohort of Lung Transplant Candidates Using Pre-Transplant Frailty Assessments;** S. Jaladanki<sup>1</sup>, L. Shih<sup>1</sup>, D. D. Nanayakkara<sup>1</sup>, O. Kwon<sup>1</sup>, V. Dobaria<sup>1</sup>, N. Ventigan<sup>1</sup>, S. Weigt<sup>1</sup>, J. Singer<sup>2</sup>, A. Ardehali<sup>1</sup>, R. Biniwale<sup>1</sup>, D. Goldwater<sup>1</sup>, J. Schaenman<sup>1</sup>. <sup>1</sup>*Univ of California Los Angeles, Los Angeles, CA*, <sup>2</sup>*Univ of California San Francisco, San Francisco, CA*

**(1058) The Incidence of Acute Kidney Injury Following Lung Transplantation Performed on Cardiopulmonary Bypass; Risk Factors, Effect on Short and Long-Term Mortality;** C. Carlheim<sup>1</sup>, A. M. Holm<sup>2</sup>, J. F. Bugge<sup>1</sup>. <sup>1</sup>*Anesthesiology and Critical Care, Oslo University Hospital, Oslo, Norway*, <sup>2</sup>*Respiratory Medicine, Oslo University Hospital, Oslo, Norway*

**(1059) Anticoagulation Strategies in the Perioperative Period for Lung Transplant: 4-Factor Prothrombin Complex Concentrate for Warfarin Reversal;** Y. D. Barac<sup>1</sup>, J. Klapper<sup>1</sup>, J. Poisson<sup>2</sup>, L. Zaffiri<sup>3</sup>, A. Pollack<sup>4</sup>, T. Seay<sup>4</sup>, O. Jawitz<sup>1</sup>, J. Haney<sup>1</sup>, M. Daneshmand<sup>1</sup>, I. Welsby<sup>4</sup>, M. G. Hartwig<sup>1</sup>, B. Bottiger<sup>4</sup>. <sup>1</sup>*Department of Surgery, Cardiothoracic Division, Duke University, Durham, NC*, <sup>2</sup>*Department of Pathology, Duke University, Durham, NC*, <sup>3</sup>*Department of Pulmonary, Allergy and Critical Care, Duke University, Durham, NC*, <sup>4</sup>*Department of Anesthesiology, Duke University, Durham, NC*

**(1060) Various Anastomotic Techniques for Size Mismatch in Pulmonary Artery during Lung Implantation;** Y. Yokoyama, T. Chen Yoshikawa, Y. Yamada, Y. Yutaka, D. Nakajima, M. Hamaji, A. Ohsumi, H. Date. *Thoracic Surgery, Kyoto Univ, Kyoto, Japan*

**(1061) 'Side-Mismatched' Single Lung Transplantation Does Not Compromise the Transplant Outcomes;** G. Sunagawa<sup>1</sup>, M. Kashem<sup>1</sup>, E. Leotta<sup>1</sup>, F. Kromah<sup>1</sup>, S. Brann<sup>1</sup>, J. Gomez-Abraham<sup>1</sup>, S. Keshavamurthy<sup>1</sup>, K. Minakata<sup>1</sup>, F. Cordova<sup>2</sup>, Y. Toyoda<sup>1</sup>, N. Shigemura<sup>1</sup>. <sup>1</sup>*Cardiovascular Surgery, Temple University Hospital, Philadelphia, PA*, <sup>2</sup>*Thoracic Medicine and Surgery, Temple University Hospital, Philadelphia, PA*

**(1062) Comparison of Oto, MALT and ET-Score in Predicting Outcome after Lung Transplantation - A Large Single-Center Cohort Study;** S. Schwarz, N. Rahimi, M. Muckenhuber, A. Benazzo, B. Moser, J. R. Matilla, G. Lang, S. Taghavi, P. Jaksch, W. Klepetko, K. Hoetzenecker. *Thoracic Surgery, Medical University of Vienna, Vienna, Austria*

**(1063) Survival for Combined Heart-Lung Transplant (HLT) Recipients over the Past 30 Years;** C. J. Lum<sup>1</sup>, W. Ragalie<sup>1</sup>, R. Chand<sup>1</sup>, A. Salimbangon<sup>1</sup>, A. Chang<sup>1</sup>, T. Khuu<sup>1</sup>, M. Cadeiras<sup>2</sup>, M. Deng<sup>1</sup>, D. Vucicevic<sup>3</sup>, K. Pandya<sup>4</sup>, A. Ardehali<sup>1</sup>, E. DePasquale<sup>1</sup>. <sup>1</sup>*University of California, Los Angeles, Los Angeles, CA*, <sup>2</sup>*University of California, Davis, Davis, CA*, <sup>3</sup>*Newark Beth Israel, Newark, NJ*, <sup>4</sup>*University of Southern California, Los Angeles, CA*

Friday, April 5, 2019

6:00 PM - 7:15 PM

**POSTER SESSION 3: MECHANICAL CIRCULATORY SUPPORT (ADULT)**

Room: Timor Sea 2

**Poster Discussants:**

Peggy Blood, RN, MSN, University of Alabama, Birmingham, AL, USA

Paolo Colombo, MD, Columbia University, New York, NY, USA

Jaime Hernandez-Montfort, MD, MPH, University of Texas Medical Branch, Galveston, TX, USA

Colleen Juricek-LaBuhn, RN, MSN, University of Chicago, Chicago, IL, USA

Christiane Kugler, PhD, Albert-Ludwigs-University Freiburg, Dortmund, Germany

Brent Lampert, DO, Ohio State University, Columbus, OH, USA

Bhavadarini Ramu, MD, Medical University of South Carolina, Charleston, SC, USA

Thomas Schlöglhofer, MSc, Medical University of Vienna, Vienna, Austria

Nicola Robinson Smith, RN, Newcastle upon Tyne Hospital NHS Trust, Newcastle upon Tyne, United Kingdom

**(1064) Intracranial Hemorrhage in Patients with Continuous Flow LVAD;** E. Demir<sup>1</sup>, S. Nalbantgil<sup>1</sup>, P. Öztürk<sup>2</sup>, E. Simsek<sup>1</sup>, C. Engin<sup>2</sup>, T. Yagdi<sup>2</sup>, M. Özbaran<sup>2</sup>. <sup>1</sup>Cardiology, Ege University Medicine Faculty, İzmir, Turkey, <sup>2</sup>Cardiovascular Surgery, Ege University Medicine Faculty, İzmir, Turkey

**(1065) Comorbidities and Biomarkers Vary between United States and Japanese LVAD Patients;** T. Imamura<sup>1</sup>, A. Nguyen<sup>1</sup>, D. Nitta<sup>1</sup>, T. Fujino<sup>1</sup>, L. Holzhauser<sup>1</sup>, D. Rodgers<sup>1</sup>, S. Kalantari<sup>1</sup>, B. Smith<sup>1</sup>, J. Raikhelkar<sup>1</sup>, N. Narang<sup>1</sup>, B. Chung<sup>1</sup>, I. Ebong<sup>1</sup>, C. Juricek<sup>1</sup>, P. Combs<sup>1</sup>, D. Onsager<sup>1</sup>, T. Song<sup>1</sup>, T. Ota<sup>1</sup>, V. Jeevanandam<sup>1</sup>, G. Kim<sup>1</sup>, G. Sayer<sup>1</sup>, M. Ono<sup>2</sup>, N. Uriel<sup>1</sup>. <sup>1</sup>University of Chicago, Chicago, IL, <sup>2</sup>University of Tokyo, Tokyo, Japan

**(1066) Comparison of Unfractionated Heparin and Bivalirudin for Treatment of Suspected Device Thrombosis during Heart Mate II Support;** K. Shah<sup>1</sup>, D. B. Sims<sup>1</sup>, S. Forest<sup>2</sup>, T. Chinnadurai<sup>1</sup>, Y. Xia<sup>2</sup>, A. Luke<sup>1</sup>, D. Nnani<sup>3</sup>, C. Castillo<sup>1</sup>, M. Taveras<sup>1</sup>, S. Vukelic<sup>1</sup>, S. R. Patel<sup>1</sup>, J. Shin<sup>1</sup>, D. J. Goldstein<sup>2</sup>, U. P. Jorde<sup>1</sup>, O. Saeed<sup>1</sup>. <sup>1</sup>Medicine (Cardiology), Montefiore Medical Center, Bronx, NY, <sup>2</sup>Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY, <sup>3</sup>Pharmacy, Montefiore Medical Center, Bronx, NY

**(1067) Aspirin: Therapy or Trouble for LVAD Patients?;** R. Khedraki<sup>1</sup>, C. Vanichsarn<sup>1</sup>, A. Moitoza<sup>2</sup>, R. Mohan<sup>2</sup>, J. T. Heywood<sup>2</sup>, A. Srivastava<sup>2</sup>. <sup>1</sup>Cardiology, Scripps Clinic, Prebys Cardiovascular Institute, La Jolla, CA, <sup>2</sup>Division of Cardiology, Section of Advanced Heart Failure, Scripps Clinic, Prebys Cardiovascular Institute, La Jolla, CA

**(1068) Incidence and Outcomes of Prosthetic Valve Thrombosis during Extracorporeal Membrane Oxygenation Support for Postcardiotomy Shock;** M. Cevasco, A. Saha, A. R. Garan, L. Witer, J. Sanchez, P. Kurlansky, M. Yusefpolskaya, H. Takayama, Y. Naka, K. Takeda. Columbia University Medical Center, New York, NY

**(1069) Contemporary Use of Glycoprotein IIb/IIIa Inhibitors in Patients with Left Ventricular Assist Devices;** S. Duclos, K. Matsuda, S. Jimenez, M. Wheeler, K. Sallam, W. Hiesinger, D. Banerjee. Stanford, Palo Alto, CA

**(1070) Wall Shear Stress in the Middle Cerebral Artery of HM II Patients - A Prospective, Mechanistic Study Using Vector Flow Mapping;** K. Akiyama<sup>1</sup>, R. Ji<sup>2</sup>, F. Castagna<sup>2</sup>, A. Pinsino<sup>2</sup>, J. R. Cockcroft<sup>3</sup>, M. Yuzefpolskaya<sup>2</sup>, A. R. Garan<sup>2</sup>, V. K. Topkara<sup>2</sup>, K. Ross<sup>1</sup>, H. Takayama<sup>1</sup>, K. Takeda<sup>1</sup>, Y. Naka<sup>1</sup>, B. J. McDonnell<sup>3</sup>, P. C. Colombo<sup>2</sup>, J. Z. Willey<sup>4</sup>, E. J. Stöhr<sup>3</sup>. <sup>1</sup>Cardiothoracic Surgery, Columbia University Medical Center, New York, NY, <sup>2</sup>Medicine, Columbia University Medical Center, New York, NY, <sup>3</sup>Physiology & Health, Cardiff Metropolitan University, Cardiff, United Kingdom, <sup>4</sup>Neurology Stroke, Columbia University Medical Center, New York, NY

**(1071) Recurrent Pump Thrombosis is Common after Axial Continuous Flow LVAD Exchange;** C. Macdonald<sup>1</sup>, M. Urban<sup>1</sup>, M. Moulton<sup>2</sup>, N. McCain<sup>1</sup>, D. Stoller<sup>1</sup>, R. Zolty<sup>1</sup>, J. Um<sup>1</sup>, A. Siddique<sup>1</sup>. <sup>1</sup>University of Nebraska Medical Center, Omaha, NE, <sup>2</sup>University of Nebraska Medical Center, Omaha, NE

**(1072) Novel Oral Anticoagulants in Patients with Continuous Flow Left Ventricular Assist Devices;** V. Parikh<sup>1</sup>, U. Parikh<sup>2</sup>, A. M. Ramirez<sup>2</sup>, H. Lamba<sup>3</sup>, J. George<sup>2</sup>, S. Fedson<sup>2</sup>, F. Cheema<sup>2</sup>, A. Civitello<sup>2</sup>, A. Nair<sup>2</sup>, A. Shafii<sup>2</sup>, G. Loor<sup>2</sup>, T. Rosengart<sup>2</sup>, O. Frazier<sup>2</sup>, J. Morgan<sup>2</sup>, R. Delgado<sup>2</sup>. <sup>1</sup>Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, TX, <sup>2</sup>Baylor College of Medicine, Houston, TX, <sup>3</sup>Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Baylor College of Medicine, Houston, TX

**(1073) Perioperative Changes of Angiogenic Factors and Von Willebrand Factor: Comparison between HeartMate II and HeartMate 3 Patients;** E. Woelke<sup>1</sup>, O. Grottko<sup>2</sup>, A. Goetzenich<sup>2</sup>, U. Steinseifer<sup>1</sup>, T. Schmitz-Rode<sup>1</sup>, U. Ahmad<sup>3</sup>, R. Autschbach<sup>3</sup>, A. Moza<sup>3</sup>, R. Zayat<sup>3</sup>. <sup>1</sup>Department of Cardiovascular Engineering, Institute of Applied Medical Engineering, Helmholtz Institute, RWTH University Hospital, Aachen, Germany, <sup>2</sup>Department of Anaesthesiology, RWTH University Hospital, Aachen, Germany, <sup>3</sup>Department of Thoracic and Cardiovascular Surgery, RWTH University Hospital, Aachen, Germany

**(1074) Level of Power Increase on Admission Determines Successful Treatment with Enhanced Anticoagulation with HeartWare Ventricular Assist Device Thrombosis;** A. Woods<sup>1</sup>, S. Schueler<sup>1</sup>, S. Tovey<sup>2</sup>, N. Robinson Smith<sup>1</sup>, J. Jungshleger<sup>1</sup>, G. MacGowan<sup>1</sup>. <sup>1</sup>Cardiothoracic, Newcastle upon Tyne NHS Foundations Trust, Newcastle upon Tyne, United Kingdom, <sup>2</sup>Freeman Hospital, Newcastle upon Tyne, United Kingdom

**(1075) Argatroban Bridging in the Immediate Post-Operative Period in Recipients of Durable Left Ventricular Assist Devices;** G. Egnaczyk, H. Rohm, T. O'Brien, S. Gilardi, K. Weber, T. Raymond, T. Smith, E. Chung, M. Castillo-Sang. *The Christ Hospital, Cincinnati, OH*

**(1076) Aortic Root Thrombus after LVAD Implantation and Aortic Valve Replacement;** J. F. Veenis<sup>1</sup>, J. J. Brugts<sup>1</sup>, Y. C. Yalcin<sup>1</sup>, S. Roest<sup>1</sup>, J. A. Bekkers<sup>2</sup>, O. C. Manintveld<sup>1</sup>, A. A. Constantinescu<sup>1</sup>, A. J. Bogers<sup>1</sup>, K. Caliskan<sup>1</sup>. <sup>1</sup>Cardiology, Erasmus MC, Rotterdam, Netherlands, <sup>2</sup>Cardio-Thoracic Surgery, Erasmus MC, Rotterdam, Netherlands

**(1077) Association of Post Implant Thromboelastogram and Left Ventricular Assist Device Thrombosis;** C. L. Eshelbrenner, A. M. El Banyosy, D. Horstmanshof, S. George. *Integris Baptist Medical Center, Oklahoma City, OK*

**(1078) Surgical Device Exchange is Favorable to Treat Device Thrombosis Compared to Medical Therapy;** Y. Koda<sup>1</sup>, H. Kitahara<sup>1</sup>, G. Kim<sup>2</sup>, N. Sarswat<sup>2</sup>, S. Kalantari<sup>2</sup>, B. Smith<sup>2</sup>, J. Raikhelkar<sup>2</sup>, G. Sayer<sup>2</sup>, D. Onsager<sup>1</sup>, T. Song<sup>1</sup>, N. Uriel<sup>2</sup>, V. Jeevanandam<sup>1</sup>, T. Ota<sup>1</sup>. <sup>1</sup>Surgery, The University of Chicago, Chicago, IL, <sup>2</sup>Medicine, The University of Chicago, Chicago, IL

**(1079) Minimally Invasive Exchange of the HeartMate 2 (HM2) Left Ventricular Assist Device (LVAD) to HeartWare Ventricular Assist Device (HVAD) or HeartMate 3 (HM3);** I. Aljabban<sup>1</sup>, B. Hendriksen<sup>2</sup>, J. Conte<sup>3</sup>, B. Soleimani<sup>3</sup>. <sup>1</sup>Pennsylvania State University College of Medicine, Hershey, PA, <sup>2</sup>Department of Surgery, Pennsylvania State University College of Medicine, Hershey, PA, <sup>3</sup>Department of Cardiac Surgery, Pennsylvania State University College of Medicine, Hershey, PA

**(1080) The Implication of HeartWare HVAD Inflow Cannula Angle on Stroke and Thrombus Rate;** S. Emmanuel, D. Aktuerk, A. Chowdhury, C. Hurwitz, L. Beiglari, P. Jansz, C. Hayward. *St Vincent's Hospital (Sydney), Darlinghurst, Australia*

**(1081) Primary Exchange of Heart Mate II Comes with Less Mortality/Treatment Failure within Six Months Than Eptifibatide Treatment;** M. Dickinson, M. Leacche, N. Manandhar Shrestha, T. Boeve, S. V. Jovinge, S. Lee. *Fredrik Meijer Heart and Vascular Institute, Fredrik Meijer Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI*

**(1082) Surgical Outcomes of HeartMate2 to HeartMate3 Pump Exchange: A Single Center Experience;** A. Shaffer<sup>1</sup>, K. Goodwin<sup>2</sup>, R. Cogswell<sup>3</sup>, H. Shah<sup>3</sup>, J. M. Schultz<sup>3</sup>, C. M. Martin<sup>3</sup>, R. M. John<sup>1</sup>. <sup>1</sup>Department of Surgery, Division of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN, <sup>2</sup>Department of Surgery, University of Minnesota, Minneapolis, MN, <sup>3</sup>Department of Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN

**(1083) Cleavage and Re-Supply of von Willebrand Factor in Continuous Flow Blood Pump;** T. Mizuno<sup>1</sup>, Y. Eura<sup>2</sup>, K. Kokame<sup>2</sup>, T. Tsukiya<sup>1</sup>, Y. Takewa<sup>1</sup>, E. Tatsumi<sup>1</sup>. <sup>1</sup>Dept. of Artificial Organs, Nat'l Cerebral CV Ctr, Suita, Japan, <sup>2</sup>Dept. of Molecular Pathogenesis, Nat'l Cerebral CV Ctr, Suita, Japan

**(1084) Ischemic Cardiomyopathy is Associated with Increased Hemocompatibility Related Adverse Events Compared to Non-Ischemic Cardiomyopathy in LVAD Patients;** J. Raikhelkar, T. Fujino, T. Imamura, L. Holzhauser, I. Ebong, N. Narang, A. Nguyen, B. Chung, D. Rodgers, B. Smith, N. Sarswat, G. Kim, C. Juricek, T. Ota, V. Jeevanandam, G. Sayer, N. Uriel. *University of Chicago, Chicago, IL*

**(1085) Postcardiotomy Cardiogenic Shock: Initial Results of Oklahoma Hub-and-Spoke Model;** A. M. El Banayosy, M. D. Harper, M. M. Koerner, D. Vanhooser, J. Chaffin, M. Sasevich, J. W. Long, A. El Banayosy. *INTEGRIS Baptist Medical Center, Oklahoma City, OK*

**(1086) Reduction in Plasma Macrophage Migration Inhibitory Factor and Angiotensin-2 Levels during Venoarterial Extracorporeal Membrane Oxygenation Support;** J. Navarro<sup>1</sup>, E. Miller<sup>2</sup>, C. Heaney<sup>1</sup>, R. Vuthoori<sup>1</sup>, D. Majure<sup>1</sup>, K. Lin<sup>2</sup>, P. Wang<sup>2</sup>, K. Kennedy<sup>3</sup>, H. Fernandez<sup>4</sup>, B. Lima<sup>4</sup>, S. Maybaum<sup>1</sup>. <sup>1</sup>Cardiology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, <sup>2</sup>Feinstein Institute, Feinstein Institute for Medical Research, Manhasset, NY, <sup>3</sup>Mid America Heart Institute, Kansas City, MO, <sup>4</sup>Cardiovascular and Thoracic Surgery, North Shore University Hospital, Manhasset, NY

**(1088) Our Experience with the "Hub and Spoke" Model in Spain: Results from the First 4 Years;** M. Jimenez-Blanco Bravo<sup>1</sup>, F. Hernandez Perez<sup>2</sup>, J. Vazquez Lopez Ibor<sup>3</sup>, M. Gomez Bueno<sup>1</sup>, L. Alonso Pulpon<sup>3</sup>, J. Segovia Cubero<sup>3</sup>. <sup>1</sup>Cardiology, Hospital Puerta de Hierro Majadahonda, Madrid, Spain, <sup>2</sup>Hospital Puerta de Hierro Majadahonda, Madrid, Spain, <sup>3</sup>Hospital Puerta de Hierro Majadahonda, Madrid, Spain

**(1089) Acceptable Post-Heart Transplant Outcomes Support Temporary MCS as Status 2 for the New UNOS Donor Heart Allocation Policy;** F. Esmailian, S. Dimbil, R. Levine, M. Kittleson, R. Cole, L. Czer, D. Chang, D. Geft, J. Chung, D. Ramzy, J. Moriguchi, J. Kobashigawa. *Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA*

**(1090) Single Center Percutaneous Right Ventricular Assist Device Experience - 100% In-Hospital Survival Post-Left Ventricular Assist Device;** S. K. Sundararajan, M. Cain, B. Badu, L. Durham, L. Joyce, N. Gaglianella, M. Saltzberg, D. Ishizawar, D. Joyce, A. Mohammed. *Medicine, Medical College of Wisconsin, Milwaukee, WI*

**(1091) Single Center Experience with a Percutaneous Right Ventricular Assist Device in the Management of Right Ventricular Failure;** B. Badu<sup>1</sup>, M. Cain<sup>2</sup>, Z. Laste<sup>3</sup>, N. Gaglianella<sup>4</sup>, D. Ishizawar<sup>4</sup>, M. Saltzberg<sup>4</sup>, L. Durham<sup>5</sup>, L. Joyce<sup>5</sup>, A. Mohammed<sup>4</sup>, D. Joyce<sup>5</sup>. <sup>1</sup>Medical College of Wisconsin, Wauwatosa, WI, <sup>2</sup>Surgery, Medical College of Wisconsin, Milwaukee, WI, <sup>3</sup>Radiology, Medical College of Wisconsin, Milwaukee, WI, <sup>4</sup>Cardiology, Medical College of Wisconsin, Milwaukee, WI, <sup>5</sup>Cardiothoracic Surgery, Medical College of Wisconsin, Milwaukee, WI

**(1092) Upgrading of ECLS (ECMO versus STCF-VAD): Is It a Matter of Time?;** V. Tarzia, L. Bagozzi, R. Bianco, G. Bortolussi, E. Bellanti, G. Folino, T. Bottio, G. Gerosa. *Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Cardiac Surgery, Padova, Italy*

**(1093) Extracorporeal Cardiopulmonary Resuscitation (E-CPR) - 8 Years of Experience;** S. Liem, N. C. Cavarocchi, H. Hirose. *Surgery, Thomas Jefferson University, Philadelphia, PA*

**(1094) 10-Year Outcomes of Extracorporeal Cardiopulmonary Resuscitation for In-Hospital Cardiac Arrest at a Tertiary Center;** M. Salna, A. R. Garan, H. Takayama, M. Cevasco, L. J. Witer, J. Sanchez, P. Kurlansky, D. Brodie, P. C. Colombo, Y. Naka, K. Takeda. *Columbia University Medical Center, New York, NY*

**(1095) Predictors of Early Unplanned RVAD Use in Patients Undergoing LVAD Implantation;** H. Vidula, S. McNitt, M. Wang, B. Polonsky, S. Sherazi, B. Ayers, K. Wood, B. Barrus, J. Alexis, L. Chen, V. Kutyifa, I. Gosev, I. Goldenberg. *Univ of Rochester, Rochester, NY*

**(1096) Association of Time on Temporary Circulatory Support with Resolvment of Hemometabolic Shock;** M. Cikes<sup>1</sup>, J. Rocek<sup>2</sup>, N. Jakus<sup>1</sup>, D. Milicic<sup>1</sup>, I. Netuka<sup>2</sup>, J. Maly<sup>2</sup>. <sup>1</sup>Department of Cardiovascular Diseases, University Hospital Centre Zagreb, Zagreb, Croatia, <sup>2</sup>Department of Cardiovascular and Transplant Surgery, IKEM, Prague, Czech Republic

**(1097) Use of a Formal Stepwise Weaning Protocol to Assess Cardiac Recovery during Venoarterial ECMO;** R. Vuthoori<sup>1</sup>, B. Lima<sup>2</sup>, J. Navarro<sup>1</sup>, C. Heaney<sup>1</sup>, K. Bocchieri<sup>2</sup>, K. Kennedy<sup>3</sup>, D. Majure<sup>1</sup>, G. Stevens<sup>1</sup>, H. Fernandez<sup>2</sup>, S. Maybaum<sup>1</sup>. <sup>1</sup>Cardiology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, <sup>2</sup>Cardiovascular and Thoracic Surgery, North Shore University Hospital, Manhasset, NY, <sup>3</sup>Mid America Heart Institute, Kansas City, MO

**(1098) Impact of Veno-Arterial Membrane Oxygenation on Outcome of "Crash and Burn" Patients Transitioned to Durable Left Ventricular Assist Device;** M. Urban, H. Merritt-Genore, A. Siddique, M. Moulton, T. Ryan, J. Um. *University of Nebraska Medical Center, Omaha, NE*

**(1099) Model for End-Stage Liver Disease (MELD) Does Not Predict Mortality after Veno-Arterial Extracorporeal Membrane Oxygenation Support;** M. Karnib<sup>1</sup>, N. Tashtish<sup>1</sup>, S. Al-Kindi<sup>2</sup>, E. Zanath<sup>3</sup>, A. M. Johnson<sup>3</sup>, J. Sohn<sup>3</sup>, L. Chaaban<sup>3</sup>, T. Schwab<sup>2</sup>, M. A. Alaiti<sup>2</sup>, H. Bezerra<sup>2</sup>, M. Zacharias<sup>2</sup>, G. H. Oliveira<sup>2</sup>, B. Sareyyupoglu<sup>4</sup>, Y. Elgudin<sup>4</sup>, B. Medalion<sup>4</sup>, S. Park<sup>4</sup>, S. Deo<sup>4</sup>, F. Lytle<sup>3</sup>, C. Elamm<sup>2</sup>. <sup>1</sup>Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, <sup>2</sup>Cardiovascular Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, <sup>3</sup>Department of Anesthesia, University Hospitals Cleveland Medical Center, Cleveland, OH, <sup>4</sup>Cardiovascular Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH

**(1100) Incidence and Outcome of Neurological Complications in Veno-Arterial Extracorporeal Membrane Oxygenation Support for Cardiogenic Shock;** M. Nishikawa, J. Willey, A. R. Garan, M. Cevasco, L. Witer, J. Sanchez, P. Kurlansky, A. Kirtane, D. Brodie, M. Yuzefpolskaya, P. Colombo, H. Takayama, Y. Naka, K. Takeda. *Columbia University Irving Medical Center, New York, NY*

**(1101) Outcomes of Weaning Trial from Veno-Arterial Extracorporeal Membrane Oxygenation Using Inflow-Outflow Bridging;** M. Kawabori<sup>1</sup>, C. Cassidy<sup>2</sup>, Y. Zhan<sup>1</sup>, J. A. Reich<sup>1</sup>, K. G. Warner<sup>1</sup>, H. Rastegar<sup>1</sup>, A. Vest<sup>1</sup>, D. Denofrio<sup>1</sup>, F. Y. Chen<sup>1</sup>, G. S. Couper<sup>1</sup>. <sup>1</sup>Tufts Medical Center, Boston, MA, <sup>2</sup>Tufts University School of Medicine, Boston, MA



**(1102) Predictors of Outcomes in Patients Transitioned from ECMO to Durable LVADs;** D. Pabst, A. M. Manoskey, C. E. Brehm, B. Soleimani, Heart and Vascular Institute, PennState Health Milton S. Hershey Medical Center, Hershey, PA

**(1103) Extracorporeal Membrane Oxygenation is an Effective Bridge to Left Ventricular Assist Device Implantation;** B. C. Ayers, F. Sagebin, K. Wood, B. Barrus, S. Prasad, I. Gosev. University of Rochester, Rochester, NY

**(1104) Impella 5.0 as a Bridge to Clinical Decision Making;** D. Nelson, A. Mohammed, E. Klein. Medical College of Wisconsin, Wauwatosa, WI

**(1106) Single Center Experience in the Management of Cardiogenic Shock Using Temporary Mechanical Circulatory Support Devices - Impella CP, Impella 5.0, IABP, and ECMO;** C. Goulet<sup>1</sup>, D. Joyce<sup>2</sup>, A. Mohammed<sup>3</sup>, L. Joyce<sup>2</sup>. <sup>1</sup>Medical College of Wisconsin, Wauwatosa, WI, <sup>2</sup>Division of Cardiothoracic Surgery, Medical College of Wisconsin, Wauwatosa, WI, <sup>3</sup>Division of Cardiovascular Medicine, Medical College of Wisconsin, Wauwatosa, WI

**(1107) Self-Reported Physical Health with a Left Ventricular Assist Device: Findings from the Mechanical Circulatory Support Measures of Adjustment and Quality of Life (MCS A-QOL) Study;** K. L. Grady<sup>1</sup>, K. Jackson<sup>2</sup>, K. Wortman<sup>2</sup>, S. Buono<sup>2</sup>, D. Beiser<sup>3</sup>, C. Murks<sup>4</sup>, C. Lee<sup>5</sup>, Q. Denfeld<sup>6</sup>, J. Lindenfeld<sup>7</sup>, J. Rich<sup>8</sup>, C. Yancy<sup>8</sup>, D. Pham<sup>1</sup>, D. Cella<sup>2</sup>, P. Goetz<sup>1</sup>, D. Bannerjee<sup>9</sup>, M. Kiernan<sup>10</sup>, C. McIlvennan<sup>11</sup>, L. Allen<sup>11</sup>, L. Klein<sup>12</sup>, M. Walsh<sup>13</sup>, B. Ruo<sup>14</sup>, M. Kallen<sup>2</sup>, E. Hahn<sup>2</sup>. <sup>1</sup>Surgery / Cardiac Surgery, Northwestern University, Chicago, IL, <sup>2</sup>Medical Social Sciences, Northwestern University, Chicago, IL, <sup>3</sup>Medicine, University of Chicago, Chicago, IL, <sup>4</sup>Surgery, University of Chicago, Chicago, IL, <sup>5</sup>Nursing, Boston College, Chestnut Hill, MA, <sup>6</sup>Nursing, Oregon Health and Science University, Portland, OR, <sup>7</sup>Medicine, Vanderbilt University, Nashville, TN, <sup>8</sup>Medicine, Northwestern University, Chicago, IL, <sup>9</sup>Medicine, Stanford University, Stanford, CA, <sup>10</sup>Medicine, Tufts Medical Center, Boston, MA, <sup>11</sup>Medicine, University of Colorado - Denver, Aurora, CO, <sup>12</sup>Medicine, University of California, San Francisco, San Francisco, CA, <sup>13</sup>Medicine, St. Vincent Hospital, Indianapolis, IN, <sup>14</sup>Medicine, University of California, San Diego, San Diego, CA

**(1108) PROMISING New Tool Correlates Well with Kansas City Cardiomyopathy Questionnaire in Left Ventricular Assist Device Patients;** B. C. Ayers, K. Wood, E. Lee, J. Bruckel, F. Ling, V. Kutyifa, S. McNitt, H. Vidula, J. Alexis, S. Prasad, I. Gosev. University of Rochester, Rochester, NY

**(1109) Difficulty in Dying on LVAD: A Preliminary Analysis of Factors Associated with Time to LVAD Withdrawal;** S. Nakagawa<sup>1</sup>, M. Ando<sup>2</sup>, K. Takeda<sup>1</sup>, A. Rosen<sup>1</sup>, H. Takayama<sup>1</sup>, A. R. Garan<sup>1</sup>, V. K. Topkara<sup>1</sup>, M. Yuzefpolskaya<sup>1</sup>, P. C. Colombo<sup>1</sup>, Y. Naka<sup>1</sup>, C. D. Blinderman<sup>1</sup>. <sup>1</sup>Columbia University Medical Center, New York, NY, <sup>2</sup>Tokyo University, Tokyo, Japan

**(1110) Younger Patients Have Poorer Social Functioning Than Older Patients after LVAD Placement;** R. O. Hoffman III<sup>1</sup>, K. E. Sandau<sup>2</sup>, C. S. Lee<sup>3</sup>, S. P. Jaganathan<sup>1</sup>, P. Mudigonda<sup>1</sup>, P. Eckman<sup>4</sup>, R. Gaberich<sup>5</sup>, C. Weaver<sup>4</sup>, S. Joseph<sup>6</sup>, S. Hall<sup>6</sup>, S. Carey<sup>6</sup>, J. Cowger<sup>7</sup>, S. Chaudry<sup>8</sup>, S. E. Schroeder<sup>9</sup>, G. Conway<sup>1</sup>, E. Y. Barati<sup>10</sup>, M. Soni<sup>10</sup>, J. Marble<sup>11</sup>, K. M. Faulkner<sup>3</sup>, D. S. Feldman<sup>1</sup>. <sup>1</sup>Cardiology, University of Cincinnati College of Medicine, Cincinnati, OH, <sup>2</sup>Bethel University, Arden Hills, MN, <sup>3</sup>Boston College Connell School of Nursing, Chestnut Hill, MA, <sup>4</sup>Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN, <sup>5</sup>Minneapolis Heart Institute Foundation, Minneapolis, MN, <sup>6</sup>Baylor University Medical Center, Dallas, TX, <sup>7</sup>Henry Ford, Detroit, MI, <sup>8</sup>St. Vincent Center, Indianapolis, IN, <sup>9</sup>Bryan Heart Center, Lincoln, NE, <sup>10</sup>University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, <sup>11</sup>University of Pennsylvania, Philadelphia, PA

**(1111) Continuous Flow Left Ventricular Assist Devices Can Improve Sleep Quality of Advanced Heart Failure Patients;** K. Nakamoto<sup>1</sup>, T. Ohtani<sup>1</sup>, F. Sera<sup>1</sup>, Y. Tsukamoto<sup>1</sup>, K. Toda<sup>2</sup>, S. Hikoso<sup>1</sup>, Y. Sawa<sup>2</sup>, Y. Sakata<sup>1</sup>. <sup>1</sup>Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan, <sup>2</sup>Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Japan

**(1112) LVAD Strategy Reflects Emotional Functioning after Implant;** S. P. Jaganathan<sup>1</sup>, K. E. Sandau<sup>2</sup>, C. S. Lee<sup>3</sup>, R. P. Hoffman III<sup>4</sup>, P. Mudigonda<sup>1</sup>, P. Eckman<sup>5</sup>, K. M. Storey<sup>6</sup>, C. E. Weaver<sup>7</sup>, S. Joseph<sup>8</sup>, S. Hall<sup>8</sup>, S. Carey<sup>8</sup>, J. Cowger<sup>9</sup>, S. P. Chaudry<sup>10</sup>, S. E. Schroeder<sup>11</sup>, G. Conway<sup>4</sup>, E. Y. Birati<sup>12</sup>, M. Soni<sup>13</sup>, M. Judith<sup>14</sup>, K. M. Faulkner<sup>3</sup>, D. S. Feldman<sup>15</sup>. <sup>1</sup>Cardiovascular Health and Disease, University of Cincinnati Medical Center, Cincinnati, OH, <sup>2</sup>Bethel University; Allina Health, Minneapolis, MN, <sup>3</sup>Boston College Connell School of Nursing, Newton, MA, <sup>4</sup>University of Cincinnati Medical Center, Cincinnati, OH, <sup>5</sup>Section Head- Heart Failure, Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN, <sup>6</sup>Minneapolis Heart Institute Foundation, Minneapolis, MN, <sup>7</sup>Abbott Northwestern Hospital/Minneapolis Heart Institute, Minneapolis, MN, <sup>8</sup>Baylor University Medical Center, Dallas, TX, <sup>9</sup>Henry Ford, Detroit, MI, <sup>10</sup>Advanced Heart Failure and Transplant Cardiologist, St. Vincent Heart Center/St. Vincent Indianapolis, Indianapolis, IN, <sup>11</sup>Mechanical Circulatory Support (MCS) Nurse Practitioner and Program Coordinator, Bryan Heart Center, Lincoln, NE, <sup>12</sup>Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, <sup>13</sup>Department of Internal Medicine, Department of Medicine, University of Pennsylvania, Philadelphia, PA, <sup>14</sup>University of Pennsylvania, Philadelphia, PA, <sup>15</sup>Director of Cardiovascular Service Line Professor of Medicine, University of Cincinnati Medical Center, Cincinnati, OH

**(1113) Younger LVAD Recipients Fare Worse on Emotional and Spiritual Wellbeing Scores;** P. Mudigonda<sup>1</sup>, K. E. Sandau<sup>2</sup>, R. O. Hoffman III<sup>1</sup>, S. P. Jaganathan<sup>1</sup>, P. Eckman<sup>3</sup>, R. Garberich<sup>4</sup>, C. E. Weaver<sup>5</sup>, S. Joseph<sup>6</sup>, S. Hall<sup>6</sup>, S. Carey<sup>7</sup>, J. Cowger<sup>8</sup>, S. P. Chaudhry<sup>9</sup>, S. E. Schroeder<sup>10</sup>, G. Conway<sup>1</sup>, E. Y. Birati<sup>11</sup>, M. Soni<sup>12</sup>, J. Marble<sup>13</sup>, C. S. Lee<sup>14</sup>, K. M. Faulkner<sup>15</sup>, M. S. Kunz<sup>16</sup>, K. M. Storey<sup>16</sup>, D. S. Feldman<sup>1</sup>. <sup>1</sup>*Division of Cardiovascular Health and Disease, University of Cincinnati Medical Center, Cincinnati, OH,* <sup>2</sup>*Professor of Nursing, Bethel University; Allina Health, Minneapolis, MN,* <sup>3</sup>*Section Head - Heart Failure, Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN,* <sup>4</sup>*Senior Biostatistician, Minneapolis Heart Institute Foundation, Minneapolis, MN,* <sup>5</sup>*Lead VAD Coordinator, Abbott Northwestern Hospital/Minneapolis Heart Institute, Minneapolis, MN,* <sup>6</sup>*Advanced Heart Failure and Transplant Cardiology, Baylor University Medical Center, Dallas, TX,* <sup>7</sup>*Baylor University Medical Center, Dallas, TX,* <sup>8</sup>*Henry Ford, Detroit, MI,* <sup>9</sup>*Advanced Heart Failure and Transplant, St. Vincent Heart Center, Indianapolis, IN,* <sup>10</sup>*Mechanical Circulatory Support, Bryan Heart Center, Lincoln, NE,* <sup>11</sup>*Director, Advanced Heart Failure, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA,* <sup>12</sup>*Department of Medicine, University of Pennsylvania, Philadelphia, PA,* <sup>13</sup>*Department of Cardiovascular Health and Disease, University of Pennsylvania, Philadelphia, PA,* <sup>14</sup>*Professor and Associate Dean for Research, Boston College Connell School of Nursing, Chestnut Hill, MA,* <sup>15</sup>*Boston College Connell School of Nursing, Chestnut Hill, MA,* <sup>16</sup>*Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, MN*

**(1114) Digoxin is Associated with Higher Quality of Life in LVAD Recipients;** M. S. Kiernan<sup>1</sup>, G. Couper<sup>2</sup>, D. DeNofrio<sup>1</sup>, J. Cowger<sup>3</sup>, U. Jorde<sup>4</sup>. <sup>1</sup>*Cardiology, Tufts University, Boston, MA,* <sup>2</sup>*Cardiac Surgery, Tufts University, Boston, MA,* <sup>3</sup>*Cardiology, Henry Ford Hospital, Detroit, MI,* <sup>4</sup>*Cardiology, Albert Einstein School of Medicine, New York, NY*

**(1115) Gender and Spirituality Influence Patient Care Decisions after LVAD;** M. Soni<sup>1</sup>, E. Y. Birati<sup>2</sup>, J. Marble<sup>2</sup>, P. Eckman<sup>3</sup>, R. Garberich<sup>4</sup>, C. Weaver<sup>5</sup>, S. Joseph<sup>6</sup>, S. Hall<sup>6</sup>, S. Carey<sup>6</sup>, J. Cowger<sup>7</sup>, S. Chaudhry<sup>8</sup>, S. Schroeder<sup>9</sup>, R. Hoffman III<sup>10</sup>, D. Feldman<sup>10</sup>, G. Conway<sup>10</sup>, C. Lee<sup>11</sup>, K. M. Faulkner<sup>12</sup>, M. S. Kunz<sup>13</sup>, K. M. Storey<sup>14</sup>, K. E. Sandau<sup>15</sup>. <sup>1</sup>*Medicine, University of Pennsylvania, Philadelphia, PA,* <sup>2</sup>*Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA,* <sup>3</sup>*Cardiovascular Medicine, Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN,* <sup>4</sup>*Biostatistics, Minneapolis Heart Institute, Minneapolis, MN,* <sup>5</sup>*Cardiovascular Medicine, Abbott Northwestern Hospital/Minneapolis Heart Institute, Minneapolis, MN,* <sup>6</sup>*Cardiovascular Medicine, Baylor University Medical Center, Dallas, TX,* <sup>7</sup>*Cardiovascular Medicine, Henry Ford Health System, Detroit, MI,* <sup>8</sup>*Cardiovascular Medicine, St. Vincent Heart Center/St. Vincent Indianapolis, Indianapolis, IN,* <sup>9</sup>*Cardiovascular Medicine, Bryan Heart Center, Lincoln, NE,* <sup>10</sup>*Cardiovascular Medicine, University of Cincinnati Medical Center, Cincinnati, OH,* <sup>11</sup>*Research, Boston College Connell School of Nursing, Chestnut Hill, MA,* <sup>12</sup>*Cardiovascular Medicine, Boston College Connell School of Nursing, Chestnut Hill, MA,* <sup>13</sup>*Biostatistics, Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, MN,* <sup>14</sup>*Biostatistics, Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN,* <sup>15</sup>*Nursing, Bethel University, St. Paul, MN*

Friday, April 5, 2019

6:00 PM - 7:15 PM

**POSTER SESSION 3: MECHANICAL CIRCULATORY SUPPORT (ADULT)**

Room: Timor Sea 1

**Poster Discussants:**

Christopher Almond, MD, Stanford University, Stanford, CA, USA

Erin Coglianesse, MD, Massachusetts General Hospital, Boston, MA, USA

Peter Eckman, MD, Minneapolis Heart Institute, Minneapolis, MN, USA

Livia Goldraich, MD, Hospital de Clinicas Porto Alegre, Porto Alegre, Brazil

Maryl Johnson, MD, University of Wisconsin, Madison, WI, USA

Oliver Miera, MD, Deutsches Herzzentrum Berlin, Berlin, Germany

Emil Najjar, MD, Karolinska University Hospital, Stockholm, Sweden

George Sokos, DO, West Virginia University, Morgantown, WV, USA

Van-Khue Ton, MD PhD, University of Maryland School of Medicine, Baltimore, MD, USA

**(1116) Assessing Malnutrition Using Nutritional Risk Index Predicts Mortality after Left Ventricular Assist Device Implantation in Patients with End Stage D Heart Failure;** S. K. Sundararajan, Z. Garacci, M. Saltzberg, N. Gaglianello, R. Walker, J. S. Williams, D. Joyce, A. Mohammed. *Medicine, Medical College of Wisconsin, Milwaukee, WI*

**(1120) Lower Pulmonary Artery Pulsatility Index after Left Ventricular Assist Device Implantation is Associated with Worse Heart Failure Free Survival;** D. Nitta, T. Imamura, T. Fujino, D. Rodgers, A. Nguyen, L. Holzhauser, I. Ebong, N. Narang, B. Chung, T. Song, T. Ota, C. Juricek, V. Jeevanandam, J. Raikhelkar, G. Kim, G. Sayer, N. Uriel. *University of Chicago, Chicago, IL*

**(1121) Subjective Assessment Underestimates Frailty in Patients with Heart Failure Referred for Advanced Therapies;** C. Heaney<sup>1</sup>, H. Fernandez<sup>2</sup>, B. Lima<sup>2</sup>, J. Taylor<sup>2</sup>, R. Vuthoori<sup>1</sup>, J. Navarro<sup>1</sup>, K. Davidson<sup>2</sup>, Y. Jelcic<sup>2</sup>, D. Majure<sup>1</sup>, K. Kennedy<sup>3</sup>, G. Stevens<sup>1</sup>, S. Maybaum<sup>1</sup>. <sup>1</sup>Cardiology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, <sup>2</sup>Cardiovascular & Thoracic Surgery, North Shore University Hospital, Manhasset, NY, <sup>3</sup>Mid America Heart Institute, Kansas City, MO

**(1122) Readmission Rates and Outcomes at 90 Days in Patients with Perioperative Use of Temporary Circulatory Support at the Time of Heart Transplantation;** G. A. Hernandez<sup>1</sup>, A. Lemor<sup>2</sup>, V. Blumer<sup>1</sup>, S. Chaparro<sup>1</sup>, S. Zalawadiya<sup>3</sup>, J. Cowger<sup>2</sup>, J. Lindenfeld<sup>3</sup>. <sup>1</sup>University of Miami, Miami, FL, <sup>2</sup>Henry Ford Hospital, Detroit, MI, <sup>3</sup>Vanderbilt University, Nashville, TN

**(1123) Impaired Spirometry, but Not DLCO, is Associated with Risk of Death or Right Heart Failure Following LVAD Implantation;** G. Gulati<sup>1</sup>, N. Sutaria<sup>1</sup>, A. Vest<sup>1</sup>, D. DeNofrio<sup>1</sup>, M. Kawabori<sup>2</sup>, G. Couper<sup>2</sup>, M. Kiernan<sup>1</sup>. <sup>1</sup>Cardiology, Tufts Medical Center, Boston, MA, <sup>2</sup>Cardiac Surgery, Tufts Medical Center, Boston, MA

**(1124) Measurement of Pectoralis Muscle Quantity and Attenuation by Computed Tomography Using Routinely Available Software is Feasible and Predicts Mortality after LVAD Implantation;** R. Cogswell<sup>1</sup>, L. Teigen<sup>1</sup>, T. Allen<sup>2</sup>, J. Estep<sup>3</sup>, R. Araujo<sup>4</sup>, J. Schultz<sup>1</sup>, R. John<sup>5</sup>, C. Martin<sup>1</sup>, B. Trachtenberg<sup>4</sup>. <sup>1</sup>Department of Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN, <sup>2</sup>Department of Radiology, University of Minnesota, Minneapolis, MN, <sup>3</sup>Department of Medicine, Division of Cardiology, Cleveland Clinic, Cleveland, OH, <sup>4</sup>Department of Medicine, Division of Cardiology, Houston Methodist, Houston, TX, <sup>5</sup>Department of Surgery, Division of Cardiovascular Surgery, University of Minnesota, Minneapolis, MN

**(1125) Gender Bias in LVAD Referral Patterns - A Survey of Patients and Providers;** H. Lumish<sup>1</sup>, J. C. Hupf<sup>1</sup>, F. Latif<sup>1</sup>, J. H. Haythe<sup>1</sup>, M. A. Farr<sup>1</sup>, A. M. Zuver<sup>1</sup>, K. L. Antler<sup>2</sup>, A. R. Garan<sup>1</sup>, H. Takayama<sup>2</sup>, K. Takeda<sup>2</sup>, Y. Naka<sup>2</sup>, P. C. Colombo<sup>1</sup>, M. Yuzefpolskaya<sup>1</sup>. <sup>1</sup>Department of Medicine, Columbia University Medical Center, New York, NY, <sup>2</sup>Department of Surgery, Columbia University Medical Center, New York, NY

**(1126) Limitations of Preoperative Right Ventricular Failure Assessment in Patients Undergoing LVAD Insertion;** E. J. Coromilas, K. Takeda, M. Ando, M. Cevasco, P. Green, D. Karpaliotis, V. Topkara, M. Yuzefpolskaya, H. Takayama, Y. Naka, D. Burkhoff, P. C. Colombo, A. R. Garan. *Columbia University, New York, NY*

**(1127) Impact of Peripheral Artery Disease on Long-Term Outcomes Following Ventricular Assist Device Placement;** A. Ip, J. Roldan, N. Moss. *Icahn School of Medicine at Mount Sinai, New York, NY*

**(1128) Transthoracic Echocardiogram Can Accurately Assess Left Ventricular Thrombus in Patients Who Receive an LVAD: Comparison with Intraoperative Intraventricular Visualization;** I. D. Gregoric<sup>1</sup>, M. K. Jezovnik<sup>1</sup>, M. Ilic<sup>1</sup>, S. Shoukat<sup>1</sup>, R. Radovancevic<sup>1</sup>, T. Sharma<sup>1</sup>, S. S. Nathan<sup>1</sup>, I. A. Salas de Armas<sup>2</sup>, S. Plavljanic<sup>1</sup>, M. K. Patel<sup>1</sup>, M. H. Akay<sup>1</sup>, B. Kar<sup>1</sup>. <sup>1</sup>Department of Advanced Cardiopulmonary Therapies and Transplantation, The Univ. of Texas Health Science Center-Houston, Houston, TX, <sup>2</sup>Department of Advanced Cardiopulmonary Therapies and Transplantation, The University of Texas Health Science Center-Houston, Houston, TX

**(1129) Deep Y-Descent in Right Atrial Waveforms is Associated with RV Dysfunction and Worse Outcome in LVAD Patients;** T. Imamura, A. Nguyen, D. Nitta, S. Kalantari, B. Smith, J. Raikhelkar, N. Narang, B. Chung, I. Ebong, L. Holzhauser, T. Fujino, C. Juricek, P. Combs, D. Onsager, T. Song, T. Ota, V. Jeevanandam, G. Kim, G. Sayer, N. Uriel. *University of Chicago, Chicago, IL*

**(1130) SIPAT Scores Do Not Correlate with Outcomes in Patients with Ventricular Assist Devices;** K. L. Morris<sup>1</sup>, S. Wagner<sup>1</sup>, Y. Reddy<sup>2</sup>, C. Salerno<sup>1</sup>, A. Ravichandran<sup>1</sup>, R. Garcia-Cortes<sup>1</sup>, A. Patel<sup>1</sup>, S. Plotner<sup>1</sup>, J. Hart<sup>1</sup>, K. Neawedde<sup>1</sup>, M. N. Walsh<sup>1</sup>, S. P. Chaudhry<sup>1</sup>. <sup>1</sup>St. Vincent Heart Center of Indiana, Indianapolis, IN, <sup>2</sup>The Mayo Clinic, Rochester, MN

**(1131) Psychosocial Characteristics and Outcomes in Patients with Ventricular Assist Device;** C. Morreale<sup>1</sup>, R. Paliga<sup>2</sup>, S. Kothari<sup>1</sup>, K. Meehan<sup>2</sup>, L. Coyle<sup>2</sup>, M. Morack<sup>2</sup>, S. Pauwaa<sup>2</sup>, G. Macaluso<sup>2</sup>, A. Joshi<sup>2</sup>, C. Sciamanna<sup>2</sup>, A. Tautoles<sup>3</sup>, P. Pappas<sup>3</sup>, W. Cotts<sup>2</sup>, A. Andrade<sup>2</sup>. <sup>1</sup>Medicine, UIC/Advocate Christ Medical Center, Oak Lawn, IL, <sup>2</sup>Cardiology, Advocate Christ Medical Center, Oak Lawn, IL, <sup>3</sup>Cardiovascular and Thoracic Surgery, Advocate Christ Medical Center, Oak Lawn, IL

**(1132) Lower Pre-Implantation Psychosocial Risk Scores Do Not Correlate with Better Survival Following Left Ventricular Assist Device (LVAD) Placement;** N. Grigoryan, L. Brobst, H. Zhao, E. Hamad. *Temple University School of Medicine, Philadelphia, PA*

**(1133) Impact of Elevated Preoperative Blood Urea Nitrogen (BUN) Levels on Outcomes in CF-LVAD Patients;** A. Critsinelis<sup>1</sup>, H. Lamba<sup>2</sup>, W. Etheridge<sup>2</sup>, C. Walther<sup>2</sup>, S. Oberton<sup>2</sup>, F. Cheema<sup>1</sup>, A. Civitello<sup>2</sup>, R. Delgado<sup>2</sup>, A. Nair<sup>2</sup>, T. Rosengart<sup>2</sup>, O. Frazier<sup>2</sup>, J. Morgan<sup>2</sup>. <sup>1</sup>Baylor College of Medicine, Houston, TX, <sup>2</sup>Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, BCM, Houston, TX

**(1134) Outcomes of LVAD Implantation in Ischemic versus Nonischemic Cardiomyopathy;** B. Chou<sup>1</sup>, H. K. Lamba<sup>2</sup>, G. Long<sup>1</sup>, V. Parikh<sup>1</sup>, S. Chatterjee<sup>1</sup>, J. George<sup>1</sup>, F. Cheema<sup>1</sup>, A. Civitello<sup>1</sup>, R. Delgado<sup>1</sup>, A. Nair<sup>1</sup>, A. Shafii<sup>1</sup>, G. Loor<sup>1</sup>, T. Rosengart<sup>1</sup>, O. Frazier<sup>1</sup>, J. Morgan<sup>1</sup>. <sup>1</sup>Baylor College of Medicine, Houston, TX, <sup>2</sup>Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Baylor College of Medicine, Houston, TX

**(1135) Exploring Sex Differences in Gut Microbial Diversity, Endotoxemia, Inflammation and Oxidative Stress in Heart Failure, Left Ventricular Assist Device, and Heart Transplant Patients;** A. M. Zuver<sup>1</sup>, E. A. Royzman<sup>1</sup>, B. Bohn D.F.<sup>2</sup>, D. L. Brunjes<sup>1</sup>, M. Nasiri Ahmadabadi<sup>1</sup>, F. Latif<sup>1</sup>, M. A. Farr<sup>1</sup>, S. W. Restaino<sup>1</sup>, A. R. Garan<sup>1</sup>, H. Takayama<sup>3</sup>, K. Takeda<sup>3</sup>, P. C. Colombo<sup>1</sup>, Y. Naka<sup>3</sup>, R. T. Demmer<sup>4</sup>, M. Yuzefpolskaya<sup>1</sup>. <sup>1</sup>Department of Medicine, Columbia University Medical Center, New York, NY, <sup>2</sup>Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, <sup>3</sup>Department of Surgery, Columbia University Medical Center, New York, NY, <sup>4</sup>Epidemiology and Community Health, University of Minnesota, Minneapolis, MN

**(1136) Blood Flow Kinetic Energy of Right Ventricular Outflow Tract: A Marker for Right Ventricular Global Systolic Function;** K. Akiyama<sup>1</sup>, P. C. Colombo<sup>2</sup>, E. J. Stöhr<sup>3</sup>, R. Ji<sup>2</sup>, O. G. Jimenez<sup>4</sup>, I. Wu<sup>5</sup>, S. Shames<sup>2</sup>, K. Itatani<sup>6</sup>, S. Miyazaki<sup>7</sup>, T. Furusawa<sup>7</sup>, T. Nishino<sup>7</sup>, B. J. McDonnell<sup>8</sup>, A. R. Garan<sup>2</sup>, Y. Naka<sup>1</sup>, K. Takeda<sup>1</sup>, H. Takayama<sup>1</sup>, M. Yuzefpolskaya<sup>2</sup>. <sup>1</sup>Cardiothoracic Surgery, Columbia University Medical Center, New York, NY, <sup>2</sup>Cardiology, Columbia University Medical Center, New York, NY, <sup>3</sup>Cardiac Physiology and Health, Cardiff Metropolitan University, Cardiff, United Kingdom, <sup>4</sup>Surgery, Columbia University Medical Center, New York, NY, <sup>5</sup>Anesthesia, Columbia University Medical Center, New York, NY, <sup>6</sup>Cardiovascular Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan, <sup>7</sup>Cardio Flow Design, Tokyo, Japan, <sup>8</sup>Cardiff Metropolitan University, Cardiff, United Kingdom

**(1137) Inspiratory Breath-Hold - A Simple Clinical Intervention to Assess Risk Threshold for Suction Events in Stable LVAD Outpatients;** D. Robson, K. Muthiah, P. Jain, J. Engelman, M. Connellan, P. Jansz, C. Hayward. *Heart Lung Transplant Unit, St Vincent 's Hospital, Sydney, Australia*

**(1138) Aortic Insufficiency during LVAD Support: A Mock Loop Study;** V. Vu, C. Balagtas, A. Fujita-Willabus, M. Lok, K. May-Newman. *Bioengineering, San Diego State University, San Diego, CA*

**(1139) Hyponatremia after LVAD Implantation is Associated with Adverse Outcomes;** A. Duran, A. Guha, A. Bhimaraj, J. Estep, B. Trachtenberg, M. H. Park, F. Hussain, N. Salam, I. Hussain. *Houston Methodist Hospital, Houston, TX*

- (1140) The Effects of Echo-Optimization of Left Ventricular Assist Devices on Functional Capacity: A Randomized Controlled Trial (VAFRAC);** M. Lilliu<sup>1</sup>, F. Onorati<sup>1</sup>, L. Franceschini<sup>2</sup>, L. Gottin<sup>3</sup>, G. Faggian<sup>1</sup>. <sup>1</sup>Division of Cardiac Surgery, Department of Surgery, University of Verona, Verona, Italy, <sup>2</sup>Division of Cardiology, Department of Medicine, University of Verona, Verona, Italy, <sup>3</sup>Division of Cardiac Anesthesiology, University of Verona, Verona, Italy
- (1141) Similar Pumps, Different Flow Features;** M. Karahan<sup>1</sup>, S. Kocabeyoglu<sup>1</sup>, U. Kervan<sup>1</sup>, D. Sert<sup>1</sup>, O. Beyazal<sup>1</sup>, B. Demirkan<sup>2</sup>, M. Tola<sup>3</sup>, A. Yilmaz<sup>1</sup>, M. Pac<sup>1</sup>. <sup>1</sup>Cardiovascular Surgery, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey, <sup>2</sup>Cardiology, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey, <sup>3</sup>Radiology, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey
- (1142) Assessment of Wall Shear Stress on the Aortic Valve in Patients with Left Ventricular Assist Device Using Vector Flow Mapping;** K. Akiyama<sup>1</sup>, R. Ji<sup>2</sup>, E. J. Stöhr<sup>3</sup>, O. G. Jimenez<sup>4</sup>, I. Wu<sup>5</sup>, K. Itatani<sup>6</sup>, S. Miyazaki<sup>7</sup>, T. Furusawa<sup>7</sup>, T. Nishino<sup>7</sup>, B. J. McDonnell<sup>8</sup>, A. R. Garan<sup>2</sup>, M. Yuzefpolskaya<sup>2</sup>, P. C. Colombo<sup>2</sup>, Y. Naka<sup>1</sup>, K. Takeda<sup>1</sup>, H. Takayama<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, Columbia University Medical Center, New York, NY, <sup>2</sup>Cardiology, Columbia University Medical Center, New York, NY, <sup>3</sup>Cardiac Physiology and Health, Cardiff Metropolitan University, Cardiff, United Kingdom, <sup>4</sup>Surgery, Columbia University Medical Center, New York, NY, <sup>5</sup>Anesthesiology, Columbia University Medical Center, New York, NY, <sup>6</sup>Cardiovascular Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan, <sup>7</sup>Cardio Flow Design, Tokyo, Japan, <sup>8</sup>Cardiff Metropolitan University, Cardiff, United Kingdom
- (1143) Long- and Short-Term Changes in Serum Creatinine Prior to LVAD Surgery are Associated with Postoperative Outcomes;** A. Gaudig<sup>1</sup>, G. M. Mondellini<sup>1</sup>, K. Toma<sup>2</sup>, A. Pinsino<sup>3</sup>, R. Te-Frey<sup>4</sup>, G. Parkis<sup>4</sup>, M. Dominguez<sup>1</sup>, A. Masoumi<sup>1</sup>, A. R. Garan<sup>1</sup>, H. Takayama<sup>4</sup>, K. Takeda<sup>4</sup>, Y. Naka<sup>4</sup>, R. T. Demmer<sup>5</sup>, P. C. Colombo<sup>1</sup>, J. Radhakrishnan<sup>2</sup>, M. Yuzefpolskaya<sup>1</sup>. <sup>1</sup>Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY, <sup>2</sup>Medicine, Division of Nephrology, Columbia University Medical Center, New York, NY, <sup>3</sup>Medicine, Jacobi - AECOM, Bronx, NY, <sup>4</sup>Surgery, Columbia University Medical Center, New York, NY, <sup>5</sup>Epidemiology and Community Health, University of Minnesota, Minneapolis, MN
- (1144) Contrast Enhanced Ultrasound Evaluation of Skeletal Muscle Perfusion in Response to Left Ventricular Assist Device Therapy;** G. R. Reeves<sup>1</sup>, L. J. Jablonowski<sup>2</sup>, M. Stanczak<sup>2</sup>, P. Machado<sup>2</sup>, K. Fitzgerald<sup>3</sup>, F. Forsberg<sup>2</sup>. <sup>1</sup>Medicine, Thomas Jefferson University, Philadelphia, PA, <sup>2</sup>Radiology, Thomas Jefferson University, Philadelphia, PA, <sup>3</sup>Thomas Jefferson University, Philadelphia, PA
- (1145) Sensitization in LVAD Recipients with and without Transfusions;** T. Dong<sup>1</sup>, B. Demoss<sup>1</sup>, R. Roy<sup>1</sup>, A. Smith<sup>1</sup>, J. Vega<sup>1</sup>, S. Laskar<sup>2</sup>, K. Bhatt<sup>1</sup>, D. Gupta<sup>1</sup>, A. Morris<sup>1</sup>, R. T. Cole<sup>1</sup>. <sup>1</sup>Cardiology, Emory Univ Sch of Med, Atlanta, GA, <sup>2</sup>Emory University School of Medicine, Atlanta, GA
- (1146) Longitudinal Trends in Hemodynamics Following Left Ventricular Assist Device Implantation;** T. Fujino, T. Imamura, D. Nitta, A. J. Kanelidis, M. Belkin, B. Chung, B. Smith, A. Nguyen, P. Combs, J. Raikhelkar, C. Juricek, D. Onsager, T. Ota, T. Song, V. Jeevanandam, I. Ebong, N. Narang, L. Holzhauser, G. Kim, G. Sayer, N. Uriel. *University of Chicago, Chicago, IL*
- (1147) Intra-Aortic Balloon Pumps as Bridge to Heart Transplantation - A Single Center Experience;** F. Hussain<sup>1</sup>, M. Liebo<sup>2</sup>, H. Basha<sup>2</sup>, S. Morris<sup>1</sup>, A. Waqar<sup>1</sup>, A. Heroux<sup>2</sup>, E. McGee<sup>3</sup>, E. Raichlin<sup>2</sup>. <sup>1</sup>Internal Medicine, Loyola University Medical Center, Maywood, IL, <sup>2</sup>Cardiology, Loyola University Medical Center, Maywood, IL, <sup>3</sup>Thoracic & Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL
- (1148) Hemodynamic Support with Intra Aortic Balloon Pump Differs by Etiology of Cardiogenic Shock;** W. Malick, J. A. Fried, K. Takeda, A. Zuver, M. Cevasco, L. Witer, A. Masoumi, V. K. Topkara, M. Yuzefpolskaya, H. Takayama, Y. Naka, P. C. Colombo, D. Karpalotis, A. Kirtane, A. Garan. *Columbia University, New York, NY*
- (1149) Intra-Aortic Balloon Pump Use before Left Ventricular Assist Device Implantation;** A. Hadi<sup>1</sup>, C. Alpert<sup>1</sup>, S. Murali<sup>1</sup>, C. Khoo<sup>2</sup>, G. Williams<sup>1</sup>, R. Benza<sup>1</sup>, A. Raina<sup>1</sup>, M. Lander<sup>1</sup>, M. Kanwar<sup>1</sup>. <sup>1</sup>Allegheny General Hospital, Pittsburgh, PA, <sup>2</sup>Cornell University, Ithaca, NY
- (1150) Right Ventricular Dysfunction and Pulmonary Vascular Elastance Coupling in Candidates for Advanced Heart Failure Therapies;** S. P. Wright<sup>1</sup>, L. Groves<sup>2</sup>, H. Jang<sup>1</sup>, F. H. Valle<sup>1</sup>, S. Mak<sup>1</sup>. <sup>1</sup>Cardiology, Mount Sinai Hospital, Toronto, ON, Canada, <sup>2</sup>School of Biomedical Engineering, Western University, London, ON, Canada
- (1151) Echocardiographic Weaning in Temporary Mechanical Circulatory Support: The Role of LVOT VTI;** A. Z. Turk<sup>1</sup>, K. Gobeil<sup>2</sup>, A. J. Kadado<sup>2</sup>, F. Katsikeris<sup>2</sup>, V. A. Grewal<sup>1</sup>, K. Grady<sup>1</sup>, D. T. Engelman<sup>1</sup>, E. Y. Lau<sup>1</sup>, M. T. Slawsky<sup>1</sup>, J. A. Hernandez-Montfort<sup>3</sup>. <sup>1</sup>Cardiovascular Diseases, Baystate Medical Center-UMMS, Springfield, MA, <sup>2</sup>Internal Medicine, Baystate Medical Center-UMMS, Springfield, MA, <sup>3</sup>Cardiovascular Diseases, University of Texas Medical Branch, Galveston, TX

- (1152) Benefits of Ultra-Fast-Track Anaesthesia after HeartMate 3 Implantation: A Pilot Study;** R. Zayat<sup>1</sup>, U. Ahmad<sup>1</sup>, L. Tewarie<sup>1</sup>, G. Schaelte<sup>2</sup>, A. Moza<sup>1</sup>, R. Autschbach<sup>1</sup>. <sup>1</sup>Department of Thoracic and Cardiovascular Surgery, RWTH University Hospital, Aachen, Germany, <sup>2</sup>Department of Anesthesiology, RWTH University Hospital, Aachen, Germany
- (1153) What Should Be Done for Improving the Outcomes of Salvage from Cardiogenic Shock on ECMO Support?;** T. Mizuno, T. Fujiwara, H. Kuroki, K. Oishi, M. Takeshita, M. Yashima, K. Oi, H. Arai. *Dep. of Cardiovascular Surgery, Tokyo Medical and Dental University, Tokyo, Japan*
- (1154) Carboxyhemoglobinemia and Anemia are Associated with Unreliable Pulse Oximetry in the LVAD Population;** M. T. Hassanein<sup>1</sup>, S. S. Najjar<sup>2</sup>, N. Shah<sup>3</sup>. <sup>1</sup>Surgery, MedStar Georgetown/Washington Hospital Center, Washington, DC, <sup>2</sup>Advanced Heart Failure, Mechanical Circulatory Support, and Cardiac Transplantation, MedStar Washington Hospital Center, Washington, DC, <sup>3</sup>Surgical Cardiovascular Intensive Care Unit, MedStar Washington Hospital Center, Washington, DC
- (1155) High-Intensity Interval Training Induces Reverse Left Ventricular Remodeling in Patients with LVAD;** M. Alvarez Villela<sup>1</sup>, T. Chinnadurai<sup>1</sup>, A. Furlani<sup>1</sup>, K. Salkey<sup>1</sup>, J. Shin<sup>1</sup>, S. Drakos<sup>2</sup>, U. Jorde<sup>1</sup>, S. Patel<sup>1</sup>. <sup>1</sup>Cardiology, Montefiore Medical Center, New York, NY, <sup>2</sup>Cardiology, University of Utah, Salt Lake City, UT
- (1156) Worsening of Right Heart Function Following Left Ventricular Assist Device Implantation - Right Heart Catheter Waveform Analyses;** T. Imamura, A. Nguyen, D. Nitta, D. Rodgers, S. Kalantari, B. Smith, J. Raikhelkar, N. Narang, B. Chung, I. Ebong, L. Holzhauser, T. Fujino, C. Juricek, P. Combs, D. Onsager, T. Song, T. Ota, V. Jeevanandam, G. Kim, G. Sayer, N. Uriel. *University of Chicago, Chicago, IL*
- (1157) Outcomes Associated with Complete versus Partial LV Unloading in Patients with LVAD;** A. Duran, A. Guha, A. Bhimaraj, B. Trachtenberg, M. H. Park, J. Estep, F. Hussain, N. Salam, I. Hussain. *Houston Methodist Hospital, Houston, TX*
- (1158) Impact of Distance from Implant Center on Mechanical Circulatory Device Patient Outcomes;** C. J. Park, M. Murray, T. Kohmoto, E. Lushaj. *Cardiothoracic Surgery, University of Wisconsin, Madison, WI*
- (1159) Resolution of Right Atrial Congestion before LVAD Implantation is Associated with Improved Outcomes;** G. Gulati<sup>1</sup>, N. Sutaria<sup>1</sup>, A. Vest<sup>1</sup>, D. DeNofrio<sup>1</sup>, M. Kawabori<sup>2</sup>, G. Couper<sup>2</sup>, M. Kiernan<sup>1</sup>. <sup>1</sup>Cardiology, Tufts Medical Center, Boston, MA, <sup>2</sup>Cardiac Surgery, Tufts Medical Center, Boston, MA
- (1160) Cardiac CT Provides Complementary Parameters of Right Ventricle Function in LVAD Patients;** A. Scott, P. J. Kim, H. Tran, M. Brambatti, Y. Ignatyeva, S. Rosenberg, S. Kligerman, A. Hsiao, V. Pretorius, E. Adler, F. Contijoch. *University of California, San Diego, San Diego, CA*
- (1161) Invasive Hemodynamic after LVAD Implantation and Association with Outcomes;** A. Duran, A. Guha, A. Bhimaraj, J. Estep, B. Trachtenberg, M. H. Park, N. Salam, F. Hussain, I. Hussain. *Houston Methodist Hospital, Houston, TX*
- (1162) The Physiological Effects of Percutaneous Right Ventricular Assist Device;** D. Quinn<sup>1</sup>, S. Lim<sup>2</sup>. <sup>1</sup>Cardiac Surgery, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom, <sup>2</sup>Cardiology, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom
- (1163) Aortic Valve Opening Time, a Novel Parameter to Describe the Aortic Valve in Patients with Continuous Flow Devices;** X. Mai<sup>1</sup>, A. Reyentovich<sup>2</sup>, N. Moazami<sup>3</sup>, C. Soria<sup>4</sup>, D. Smith<sup>3</sup>, S. Katz<sup>2</sup>, S. Pan<sup>2</sup>, S. Rao<sup>2</sup>, T. Saraon<sup>2</sup>, C. Gidea<sup>2</sup>. <sup>1</sup>Cardiology, NYU Langone Medical Center, New York, NY, <sup>2</sup>Heart Transplant, NYU Langone Medical Center, New York, NY, <sup>3</sup>Cardiothoracic Surgery, NYU Langone Medical Center, New York, NY, <sup>4</sup>Internal Medicine, NYU Langone Medical Center, New York, NY
- (1164) Does Type of Mechanical Circulatory Support as Bridge to Heart Transplant Affect Outcomes?;** F. Hussain<sup>1</sup>, J. Newman<sup>2</sup>, H. Basha<sup>2</sup>, S. Morris<sup>1</sup>, A. Waqar<sup>1</sup>, A. Heroux<sup>2</sup>, E. McGee<sup>3</sup>, E. Raichlin<sup>2</sup>, M. Liebo<sup>2</sup>. <sup>1</sup>Internal Medicine, Loyola University Medical Center, Maywood, IL, <sup>2</sup>Cardiology, Loyola University Medical Center, Maywood, IL, <sup>3</sup>Thoracic & Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL
- (1165) Measurement of Frailty over Time in Ventricular Assist Device Patients: Use of the 5-Meter Walk Test;** S. E. Schroeder<sup>1</sup>, W. S. Alonso<sup>2</sup>, J. A. Steuter<sup>3</sup>, B. J. Pوزه<sup>4</sup>. <sup>1</sup>MCS Team, Cardiothoracic Surgery, Bryan Heart, Lincoln, NE, <sup>2</sup>College of Nursing, Post-Doctoral Research Associate, University of Nebraska Medical Center, Omaha, NE, <sup>3</sup>Division of Cardiology, Bryan Heart, Lincoln, NE, <sup>4</sup>Department of Nursing/Cardiology, University of Nebraska Medical Center, Omaha, NE

**(1166) REMEDIZER- An Innovative Program of Remote Home Care for Patients with Implanted Mechanical Heart Support. Single Centre Experience;** J. Szymański<sup>1</sup>, A. Juraszek<sup>1</sup>, M. Jasińska<sup>2</sup>, M. Sobieszcańska-Matek<sup>3</sup>, T. Zieliński<sup>3</sup>, M. Kuśmierczyk<sup>1</sup>.  
<sup>1</sup>Department of Cardiac Surgery and Transplantation, Warsaw Institute of Cardiology, Warsaw, Poland, <sup>2</sup>Department of Anesthesia, Warsaw Institute of Cardiology, Warsaw, Poland, <sup>3</sup>Department of Cardiac Failure and Transplantation, Warsaw Institute of Cardiology, Warsaw, Poland

**(1167) Preemptive Hemodynamic Transesophageal Echocardiography after Continuous Flow Ventricular Assist Device Implantation;** M. Krause<sup>1</sup>, J. Hastie<sup>2</sup>, O. Panzer<sup>2</sup>, P. C. Colombo<sup>3</sup>, M. Yuzeffpolskaya<sup>3</sup>, Y. Naka<sup>4</sup>, H. Takayama<sup>4</sup>, R. N. Sladen<sup>2</sup>.  
<sup>1</sup>Anesthesiology, University of Colorado, Denver, Denver, CO, <sup>2</sup>Anesthesiology, Columbia University Medical Center, New York, NY, <sup>3</sup>Medicine, Columbia University Medical Center, New York, NY, <sup>4</sup>Surgery, Columbia University Medical Center, New York, NY

**(1168) Lavare Cycle Does Not Induce Pulsatility in CF-LVAD Patients;** J. Engelman, K. Muthiah, P. Jain, D. Robson, P. Jansz, C. S. Hayward. Heart Failure and Transplant Unit, St Vincent's Hospital, Sydney, Australia

**(1169) Pathophysiological Insights into Persistent Hyponatremia after LVAD Implantation;** A. Duran, A. Guha, A. Bhimaraj, J. Estep, B. Trachtenberg, M. H. Park, F. Hussain, N. Salam, I. Hussain. Houston Methodist Hospital, Houston, TX

Friday, April 5, 2019

6:00 PM - 7:15 PM

## **POSTER SESSION 3: PEDIATRICS**

**Room: Banda Sea 2**

### **Poster Discussants:**

Carol Conrad, MD, Lucille Packard Children's Hospital, Palo Alto, CA, USA  
Samuel Goldfarb, MD, Children's Hospital of Philadelphia, Philadelphia, PA, USA  
Daphne Hsu, MD, Children's Hospital Montefiore, Bronx, NY, USA  
Beth Kaufman, MD, Stanford University, Stanford, CA, USA  
Kimberly Lin, MD, Children's Hospital of Philadelphia, Philadelphia, PA, USA  
Francesco Parisi, MD, Ospedale Ped Bambino Gesù, Rome, Italy  
David Peng, MD, University of Michigan, Ann Arbor, MI, USA  
Melinda Solomon, MD, FRCPC, Hospital for Sick Children, Toronto, Canada

**(1170) Clinical Features and Outcomes for Danon Disease: Data from Global Registry;** V. S. Escobedo<sup>1</sup>, N. Nguyen<sup>1</sup>, D. Teng<sup>2</sup>, Q. M. Bui<sup>2</sup>, G. S. Ma<sup>2</sup>, M. Brambatti<sup>2</sup>, E. Covarrubias<sup>2</sup>, M. Taylor<sup>3</sup>, E. A. Adler<sup>2</sup>. <sup>1</sup>Biology, University of California, San Diego, La Jolla, CA, <sup>2</sup>University of California, San Diego, La Jolla, CA, <sup>3</sup>University of Colorado, Aurora, CO

**(1171) Implantable Cardioverter Defibrillator Use in Males with Duchenne Muscular Dystrophy and Severe Left Ventricular Dysfunction;** M. A. McCulloch<sup>1</sup>, K. R. Knecht<sup>2</sup>, R. J. Butts<sup>3</sup>, C. R. Villa<sup>4</sup>, J. N. Johnson<sup>5</sup>, J. Conway<sup>6</sup>, M. J. Bock<sup>7</sup>, A. K. Lal<sup>8</sup>, K. R. Schumacher<sup>9</sup>, S. P. Law<sup>10</sup>, J. M. Friedland-Little<sup>11</sup>, S. R. Deshpande<sup>12</sup>, S. C. West<sup>13</sup>, I. D. Lytrivi<sup>14</sup>, K. E. Gambetta<sup>15</sup>, C. A. Wittlieb-Weber<sup>16</sup>. <sup>1</sup>Division of Pediatric Cardiology, University of Virginia Children's Hospital, Charlottesville, VA, <sup>2</sup>Division of Pediatric Cardiology, Arkansas Children's Hospital, Little Rock, AR, <sup>3</sup>Division of Pediatric Cardiology, Children's Medical Center of Dallas, Dallas, TX, <sup>4</sup>The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, <sup>5</sup>Division of Pediatric Cardiology, Mayo Clinic Children's Hospital, Rochester, MN, <sup>6</sup>Stollery Children's Hospital, Edmonton, AB, Canada, <sup>7</sup>Division of Pediatric Cardiology, Loma Linda University Children's Hospital, Loma Linda, CA, <sup>8</sup>Division of Pediatric Cardiology, Primary Children's Hospital, Salt Lake City, UT, <sup>9</sup>Division of Pediatric Cardiology, C.S. Mott Children's Hospital, Ann Arbor, MI, <sup>10</sup>Division of Pediatric Cardiology, Morgan Stanley Children's Hospital, New York, NY, <sup>11</sup>Division of Pediatric Cardiology, Seattle Children's Hospital, Seattle, WA, <sup>12</sup>Division of Pediatric Cardiology, Children's National Hospital, Washington, DC, <sup>13</sup>Division of Pediatric Cardiology, Children's Hospital of Pittsburgh, Pittsburgh, PA, <sup>14</sup>Division of Pediatric Cardiology, Kravis Children's Hospital, New York, NY, <sup>15</sup>Division of Pediatric Cardiology, Lurie Children's Hospital, Chicago, IL, <sup>16</sup>Division of Pediatric Cardiology, Golisano Children's Hospital, Rochester, NY

**(1172) Parent-Reported Symptoms and Effectiveness of Treatment in Children Hospitalized with Advanced Heart Disease;** E. S. DeWitt<sup>1</sup>, E. M. Balkin<sup>2</sup>, J. R. Reichman<sup>1</sup>, K. M. Moynihan<sup>1</sup>, J. McDermott<sup>1</sup>, M. Miller<sup>1</sup>, J. Wolfe<sup>3</sup>, L. A. Sleeper<sup>1</sup>, C. Samsel<sup>3</sup>, E. D. Blume<sup>1</sup>. <sup>1</sup>Cardiology, Boston Children's Hospital, Boston, MA, <sup>2</sup>Pediatrics, UCSF, San Francisco, CA, <sup>3</sup>Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, MA

**(1173) Anemia is Associated with Greater Morbidity and Resource Utilization in Pediatric Patients with Systolic Heart Failure - A Multi-Institutional Analysis;** K. Puri, R. Morales Demori, P. A. Checchia, M. M. Anders. *Pediatric Critical Care Medicine, Baylor College of Medicine, Houston, TX*

**(1174) Electrocardiographic Trends in Boys with Duchenne Muscular Dystrophy;** K. Gambetta<sup>1</sup>, C. W. Wittlieb-Weber<sup>2</sup>, C. R. Villa<sup>3</sup>, J. Conway<sup>4</sup>, J. N. Johnson<sup>5</sup>, M. J. Bock<sup>6</sup>, A. K. Lal<sup>7</sup>, K. R. Schumacher<sup>8</sup>, S. P. Law<sup>9</sup>, S. Deshpande<sup>10</sup>, S. C. West<sup>11</sup>, J. M. Friedland-Little<sup>12</sup>, J. M. Friedland-Little<sup>12</sup>, I. D. Lytrivi<sup>13</sup>, R. J. Butts<sup>14</sup>, K. J. Knecht<sup>15</sup>, M. A. Michael<sup>16</sup>. <sup>1</sup>Lurie Children's Hosp, Chicago, IL, <sup>2</sup>Pediatric Cardiology, University of Rochester Medical Center, Rochester, NY, <sup>3</sup>Pediatric Cardiology, Cincinnati Children's Hospital, Cincinnati, OH, <sup>4</sup>Pediatric Cardiology, University of Alberta Stollery Children's Hospital, Alberta, AB, Canada, <sup>5</sup>Pediatric Cardiology, Mayo Clinic, Rochester, MN, <sup>6</sup>Pediatric Cardiology, Loma Linda University, Loma Linda, IL, <sup>7</sup>Pediatric Cardiology, University of Utah, Salt Lake City, UT, <sup>8</sup>Pediatric Cardiology, Mott Children's Hospital, Ann Arbor, MI, <sup>9</sup>Pediatric Cardiology, New York-Presbyterian Morgan Stanley Children's Hospital, New York, NY, <sup>10</sup>Pediatric Cardiology, Emory University, Atlanta, GA, <sup>11</sup>Pediatric Cardiology, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, <sup>12</sup>Pediatric Cardiology, Seattle Children's Hospital, Seattle, WA, <sup>13</sup>Pediatric Cardiology, Mount Sinai Kravis Children's Hospital, New York, NY, <sup>14</sup>Pediatric Cardiology, Children's Medical Center Dallas, Dallas, TX, <sup>15</sup>Pediatric Cardiology, Arkansas Children's Hospital, Little Rock, AR, <sup>16</sup>Pediatric Cardiology, University of Virginia, Charlottesville, VA

**(1175) Pediatric Hypertrophic Cardiomyopathy: Survival and Prognostic Indicators in the Current Era;** J. Ashkanase, A. Jeewa, K. Arathoon, E. Cui, K. Dillon, S. Mital, E. Jean-St-Michel. *Division of Cardiology, The Labatt Family Heart Centre, The Hospital for Sick Children, Toronto, ON, Canada*



**(1176) Utilization of Heart Failure Medications in Duchenne Muscular Dystrophy Patients with Left Ventricular Systolic Dysfunction;** A. K. Lal<sup>1</sup>, C. A. Wittlieb-Weber<sup>2</sup>, C. R. Villa<sup>3</sup>, C. Cunningham<sup>4</sup>, M. J. Bock<sup>5</sup>, K. E. Gambetta<sup>6</sup>, J. N. Johnson<sup>7</sup>, K. R. Schumacher<sup>8</sup>, S. P. Law<sup>9</sup>, S. R. Deshpande<sup>10</sup>, S. C. West<sup>11</sup>, J. M. Friedland-Little<sup>12</sup>, I. D. Lytrivi<sup>13</sup>, M. A. McCulloch<sup>14</sup>, Z. Ou<sup>15</sup>, A. P. Presson<sup>15</sup>, R. J. Butts<sup>16</sup>. <sup>1</sup>University of Utah/Primary Children's Hospital, Salt Lake City, UT, <sup>2</sup>Golisano Children's Hospital, Rochester, NY, <sup>3</sup>Cincinnati Children's Hospital, Cincinnati, OH, <sup>4</sup>Stollery Children's Hospital, Edmonton, AB, Canada, <sup>5</sup>Loma Linda University Children's Hospital, Loma Linda, CA, <sup>6</sup>Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, <sup>7</sup>Mayo Clinic Children's Center, Rochester, MN, <sup>8</sup>C.S. Mott Children's Hospital, Ann Arbor, MI, <sup>9</sup>Morgan Stanley Children's Hospital, New York, NY, <sup>10</sup>Children's National Medical Center, Washington, DC, <sup>11</sup>Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, <sup>12</sup>Seattle Children's Hospital, Seattle, WA, <sup>13</sup>Kravis Children's Hospital at Mount Sinai, New York, NY, <sup>14</sup>University of Virginia Children's Hospital, Charlottesville, VA, <sup>15</sup>University of Utah, Salt Lake City, UT, <sup>16</sup>Children's Health at UT Southwestern Medical Center, Dallas, TX

**(1177) The Role of Prophylactic Heart Failure Therapy in Duchenne Muscular Dystrophy;** A. K. Lal<sup>1</sup>, C. A. Wittlieb-Weber<sup>2</sup>, C. R. Villa<sup>3</sup>, J. Conway<sup>4</sup>, M. J. Bock<sup>5</sup>, K. E. Gambetta<sup>6</sup>, K. R. Schumacher<sup>7</sup>, S. P. Law<sup>8</sup>, S. R. Deshpande<sup>9</sup>, S. C. West<sup>10</sup>, J. M. Friedland-Little<sup>11</sup>, I. D. Lytrivi<sup>12</sup>, M. A. McCulloch<sup>13</sup>, R. J. Butts<sup>14</sup>, K. R. Knecht<sup>15</sup>, Z. Ou<sup>16</sup>, A. P. Presson<sup>16</sup>, J. N. Johnson<sup>17</sup>. <sup>1</sup>Pediatrics, University of Utah/Primary Children's Hospital, Salt Lake City, UT, <sup>2</sup>Pediatrics, Golisano Children's Hospital, Rochester, NY, <sup>3</sup>Pediatrics, Cincinnati Children's Hospital, Cincinnati, OH, <sup>4</sup>Pediatrics, Stollery Children's Hospital, Edmonton, AB, Canada, <sup>5</sup>Pediatrics, Loma Linda University Children's Hospital, Loma Linda, CA, <sup>6</sup>Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, <sup>7</sup>Pediatrics, C.S. Mott Children's Hospital, Ann Arbor, MI, <sup>8</sup>Pediatrics, Morgan Stanley Children's Hospital, New York, NY, <sup>9</sup>Pediatrics, Children's National Medical Center, Washington, DC, <sup>10</sup>Pediatrics, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, <sup>11</sup>Pediatrics, Seattle Children's Hospital, Seattle, WA, <sup>12</sup>Pediatrics, Kravis Children's Hospital at Mount Sinai, New York, NY, <sup>13</sup>Pediatrics, UVA Children's Hospital, Charlottesville, VA, <sup>14</sup>Pediatrics, Children's Health at UT Southwestern Medical Center, Dallas, TX, <sup>15</sup>Pediatrics, Arkansas Children's Hospital, Little Rock, AR, <sup>16</sup>University of Utah, Salt Lake City, UT, <sup>17</sup>Mayo Clinic Children's Center, Rochester, MN

**(1178) Outcomes in Pediatric Hypertrophic Cardiomyopathy Patients with Reduced Systolic Ventricular Function;** J. Ashkanase, A. Jeewa, K. Arathoon, E. Cui, K. Dillon, S. Mital, E. Jean-St-Michel. Division of Cardiology, The Labatt Family Heart Centre, The Hospital for Sick Children, Toronto, ON, Canada

**(1179) Use of Pulmonary Arterial Catheters for Management of Acute Decompensated Heart Failure and Peri-Operative Monitoring in Children;** P. Estes<sup>1</sup>, E. D. Blume<sup>1</sup>, C. VanderPluym<sup>1</sup>, F. Fynn-Thompson<sup>2</sup>, K. P. Daly<sup>1</sup>. <sup>1</sup>Cardiology, Boston Children's Hospital, Boston, MA, <sup>2</sup>Cardiac Surgery, Boston Children's Hospital, Boston, MA

**(1180) Antihypertensive Treatment in the Immediate Post-Operative Period and One-Year after Pediatric Heart Transplantation;** J. S. Kerstein<sup>1</sup>, D. J. Donovan<sup>2</sup>, M. D. Zinn<sup>3</sup>, M. E. Richmond<sup>4</sup>, E. W. Cheung<sup>4</sup>, L. J. Addonizio<sup>4</sup>, W. A. Zuckerman<sup>4</sup>. <sup>1</sup>Department of Pediatrics, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, <sup>2</sup>Department of Pediatrics, Columbia University Medical Center, New York, NY, <sup>3</sup>Division of Pediatric Cardiology, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, <sup>4</sup>Division of Pediatric Cardiology, Columbia University Medical Center, New York, NY

**(1181) Dose-Dependent Response to Desensitization in Pediatric Heart Transplant Candidates Assessed by Single Antigen Bead Technology;** J. Edwards<sup>1</sup>, N. Seliktar<sup>2</sup>, S. Heron<sup>3</sup>, K. Lin<sup>1</sup>, D. Monos<sup>4</sup>, D. Sesok-Pizzini<sup>5</sup>, J. Rossano<sup>1</sup>, R. White<sup>1</sup>, M. O'Connor<sup>1</sup>. <sup>1</sup>Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, <sup>2</sup>Technion - Israel Institute of Technology, Haifa, Israel, <sup>3</sup>Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, <sup>4</sup>Division of Genomic Diagnostics, Children's Hospital of Philadelphia, Philadelphia, PA, <sup>5</sup>Blood Bank and Transfusion Medicine, Children's Hospital of Philadelphia, Philadelphia, PA

**(1182) Use of Bortezomib in the Treatment of Antibody Mediated Rejection (AMR) in Pediatric Heart Recipients;** J. Otero<sup>1</sup>, E. Albers<sup>1</sup>, J. Friedland-Little<sup>1</sup>, B. Hong<sup>1</sup>, M. Kemna<sup>1</sup>, I. Gimferrer<sup>2</sup>, Y. Law<sup>1</sup>. <sup>1</sup>Seattle Children's Hospital, Seattle, WA, <sup>2</sup>Bloodworks NW, Seattle, WA

**(1183) Total Parenteral Nutrition Portends Worse One-Year Survival in Pediatric Heart Transplantation;** M. F. Algahim, F. Zafar, K. W. Riggs, J. T. Broderick, A. Lorts, D. L. Morales. Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, OH

**(1184) Cardiovascular Health in Pediatric Heart Transplant Patients;** C. Bogle<sup>1</sup>, A. Marma Perak<sup>1</sup>, S. Wilkens<sup>1</sup>, A. Aljiffry<sup>1</sup>, K. Rychlik<sup>1</sup>, J. M. Costello<sup>1</sup>, D. Lloyd-Jones<sup>2</sup>, E. Pahl<sup>1</sup>. <sup>1</sup>Ann & Lurie Children's Hospital of Chicago, Chicago, IL, <sup>2</sup>Northwestern Memorial Hospital, Chicago, IL

**(1186) HLA Antibody Titer and CIQ Reactivity Reflect Response to Desensitization and Facilitate Donor Selection;** M. Mangiola<sup>1</sup>, M. D. Zinn<sup>2</sup>, S. West<sup>2</sup>, S. A. Miller<sup>2</sup>, K. Rose-Felker<sup>2</sup>, B. Feingold<sup>2</sup>, A. Zeevi<sup>1</sup>. <sup>1</sup>Transplant Pathology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, <sup>2</sup>Pediatrics, Univ of Pittsburgh Med Ctr, Pittsburgh, PA

- (1187) Readmission in the First Year Following Pediatric Heart Transplantation: Incidence, Indications, and Risk Factors;** A. N. Lambert<sup>1</sup>, J. G. Weiner<sup>1</sup>, M. Hall<sup>2</sup>, C. Thurm<sup>2</sup>, D. A. Dodd<sup>1</sup>, D. W. Bearl<sup>1</sup>, J. H. Soslow<sup>1</sup>, B. Feingold<sup>3</sup>, A. H. Smith<sup>1</sup>, J. Godown<sup>1</sup>. <sup>1</sup>Pediatrics, Vanderbilt University, Nashville, TN, <sup>2</sup>Children's Hospital Association, Lenexa, KS, <sup>3</sup>Pediatrics, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA
- (1188) Physical Activity, Exercise Capacity and Quality of Life in Adolescent Heart Transplant Patients;** N. Arora, A. De Souza, C. Galvin, T. Sueyoshi, S. Lui, A. Cote, D. Human, K. Armstrong. *Pediatric Cardiology, British Columbia Children's Hospital, Vancouver, BC, Canada*
- (1189) The Major Adverse Transplant Events (MATE) Score Applied to a Cohort of Pediatric Heart Transplant Recipients;** M. J. Bock<sup>1</sup>, P. Chau<sup>1</sup>, M. A. Kuhn<sup>1</sup>, T. Martens<sup>2</sup>, A. Razzouk<sup>2</sup>, R. E. Chinnock<sup>3</sup>. <sup>1</sup>Pediatric Cardiology, Loma Linda University Children's Hospital, Loma Linda, CA, <sup>2</sup>Cardiothoracic Surgery, Loma Linda University Children's Hospital, Loma Linda, CA, <sup>3</sup>Pediatrics, Loma Linda University Children's Hospital, Loma Linda, CA
- (1190) Standardized Donor Acceptance Criteria: Impact on Pediatric Waitlist and Heart Transplant Outcomes;** N. Baez, R. Kirk, R. Davies, D. Sutcliffe, M. Bano, R. Jaquiss, R. Butts. *University of Texas Southwestern Medical Center, Dallas, TX*
- (1191) The Use of Patient-Reported Outcomes to Screen for Underrecognized Psychiatric Co-Morbidities in Adolescent and Young Adult Cardiac Transplant Recipients;** T. N. Brown<sup>1</sup>, S. Chen<sup>2</sup>, J. Stehlik<sup>3</sup>, L. Bennett Murphy<sup>4</sup>, D. Cox<sup>5</sup>, A. Hoskoppal<sup>4</sup>, L. M. Schneider<sup>2</sup>, N. McDonald<sup>2</sup>, L. Barkoff<sup>2</sup>, L. J. May<sup>5</sup>. <sup>1</sup>Pediatrics, University of Utah, Salt Lake City, UT, <sup>2</sup>Stanford University, Palo Alto, CA, <sup>3</sup>Cardiology, University of Utah, Salt Lake City, UT, <sup>4</sup>University of Utah, Salt Lake City, UT, <sup>5</sup>Pediatric Cardiology, University of Utah, Salt Lake City, UT
- (1192) Low Utility of Nuclear Perfusion Exercise Stress Tests for Detecting Graft Vasculopathy in Children after Heart Transplantation;** D. S. Burstein, M. Shah, J. Del Grasso, R. White, J. W. Rossano, M. J. O'Connor, K. Y. Lin, M. G. McBride, S. Paridon. *Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA*
- (1193) MELD-XI Score Predicts Post-Heart Transplant Survival in Fontan Patients: A PHTS Analysis;** S. Amdani<sup>1</sup>, K. E. Simpson<sup>2</sup>, P. T. Thrush<sup>3</sup>, R. Shih<sup>4</sup>, J. D. Simmonds<sup>5</sup>, K. R. Knecht<sup>6</sup>, D. Mogul<sup>7</sup>, K. K. Hurley<sup>8</sup>, D. A. Koehl<sup>9</sup>, D. C. Naftel<sup>9</sup>, J. K. Kirklin<sup>9</sup>, K. P. Daly<sup>10</sup>. <sup>1</sup>Pediatric Cardiology, Cleveland Clinic Children's Hospital, Ohio, OH, <sup>2</sup>Pediatric Cardiology, St. Louis Children's Hospital, St. Louis, MO, <sup>3</sup>Pediatric Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, <sup>4</sup>Pediatric Cardiology, University of Florida, Gainesville, FL, <sup>5</sup>Paediatric Cardiology, Great Ormond Street Hospital for Children, London, United Kingdom, <sup>6</sup>Pediatric Cardiology, Arkansas Children's Hospital, Little Rock, AR, <sup>7</sup>Pediatric Gastroenterology, Hepatology and Nutrition, Johns Hopkins University, Baltimore, MD, <sup>8</sup>Transplant Services, St. Louis Children's Hospital, St. Louis, MO, <sup>9</sup>Surgery, University of Alabama at Birmingham, Birmingham, AL, <sup>10</sup>Pediatric Cardiology, Boston Children's Hospital & Harvard Medical School, Boston, MA
- (1194) Routine Surveillance Biopsies after Pediatric Heart Transplantation - Are They Still Necessary?;** T. P. Fleck, P. Nieratschker, B. Stiller. *Congenital Heart Disease and Pediatric Cardiology, University Heart Centre Freiburg, Germany, Freiburg im Breisgau, Germany*
- (1195) Alloantibody Reduction in Pediatric Heart Transplant Recipients;** K. Rose-Felker<sup>1</sup>, M. Zinn<sup>1</sup>, S. C. West<sup>1</sup>, S. A. Miller<sup>1</sup>, M. Mangiola<sup>2</sup>, A. Zeevi<sup>2</sup>, B. Feingold<sup>1</sup>. <sup>1</sup>Pediatrics, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, <sup>2</sup>Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA
- (1196) Tracheostomy and Pediatric Heart Transplantation: The Loma Linda University Experience;** J. Lee<sup>1</sup>, K. Soltad<sup>2</sup>, S. Abd-Allah<sup>1</sup>, J. Fitts<sup>3</sup>, M. Bock<sup>4</sup>. <sup>1</sup>Pediatric Critical Care, Loma Linda University Children's Hospital, Loma Linda, CA, <sup>2</sup>School of Medicine, Loma Linda University, Loma Linda, CA, <sup>3</sup>Cardiac Transplant, Loma Linda University, Loma Linda, CA, <sup>4</sup>Pediatric Cardiology/Heart Failure/Transplant, Loma Linda University Children's Hospital, Loma Linda, CA
- (1197) Over Sized Adult Hearts Can Be Used for Paediatric Transplant Recipients with Good Medium Term Outcomes;** K. Balakrishnan<sup>1</sup>, S. Rao<sup>2</sup>, S. Vijayashakaran<sup>1</sup>, G. Subramanian<sup>1</sup>, R. Subramanian<sup>1</sup>, M. Tungatru<sup>1</sup>. <sup>1</sup>Cardiac Surgery, Fortis Malar Hospital, Chennai, India, <sup>2</sup>Cardiac Anaesthesia, Fortis Malar Hospital, Chennai, India
- (1198) Combined Pediatric Heart-Liver Transplant Outcomes in the US: A 25 Year National Cohort Study;** S. Choudhry<sup>1</sup>, W. J. Dreyer<sup>1</sup>, Y. Wang<sup>1</sup>, A. G. Cabrera<sup>1</sup>, K. D. Hope<sup>1</sup>, J. F. Price<sup>1</sup>, J. A. Spinner<sup>2</sup>, H. P. Tunuguntla<sup>1</sup>, S. W. Denfield<sup>1</sup>. <sup>1</sup>Texas Children's Hospital, Baylor College of Medicine, Houston, TX, <sup>2</sup>Section of Pediatric Cardiology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, Houston, TX
- (1199) Epidural Analgesia Reduces Total Inhospital Morphine Requirements Post Heart Lung / Lung Transplant in Paediatric Population;** S. Karna, H. J. Sivakumar, P. Dhar, K. McLaughlin. *Department of Anaesthesia and Perioperative Medicine, The Alfred, Melbourne, Australia*

**(1200) Analysis of Status 1A Exceptions in Children Listed for Heart Transplantation;** D. W. Bearl<sup>1</sup>, D. Dodd<sup>1</sup>, B. A. Mettler<sup>2</sup>, R. R. Davies<sup>3</sup>, J. Winslow<sup>4</sup>, J. Godown<sup>1</sup>. <sup>1</sup>*Pediatric Cardiology, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN*, <sup>2</sup>*Pediatric Cardiothoracic Surgery, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN*, <sup>3</sup>*Cardiovascular and Thoracic Surgery, UT Southwestern Medical Center and Children's Health, Dallas, TX*, <sup>4</sup>*United Network for Organ Sharing, Richmond, VA*

**(1201) Persistence of Parvovirus B19 after Heart Transplantation in Dilated Cardiomyopathy Pediatric Patients: Predictor of Coronary Vasculopathy and Graft Loss;** B. B. Das<sup>1</sup>, B. Prusty<sup>2</sup>, J. Niu<sup>3</sup>, M. Huang<sup>4</sup>, H. Zhu<sup>4</sup>, E. Eliassen<sup>5</sup>, J. M. Kuypers<sup>4</sup>, K. R. Jerome<sup>4</sup>. <sup>1</sup>*Joe DiMaggio Children's Heart Institute, Hollywood, FL*, <sup>2</sup>*Institute for Virology and Immunobiology, Wuerzburg, Germany*, <sup>3</sup>*Memorial Healthcare System, Hollywood, FL*, <sup>4</sup>*University of Washington, Seattle, WA*, <sup>5</sup>*HHV-6 Foundation, Santa Barbara, CA*

**(1202) Pediatric Heart Transplantation in a National Pediatric Hospital J.P. Garrahan (Argentina);** I. G. Berra, H. Vogelfang, L. Quiroga, G. Sivori, G. Naiman, G. Abad. *Heart, Lung and Kidney Transplant Team, National Pediatric Hospital J.P. Garrahan, Buenos Aires, Argentina*

**(1205) Successful Percutaneous Lymphatic Intervention for Chylothorax after Pediatric Heart Transplantation;** D. Burstein, Y. Dori, C. L. Smith, E. Pinto, K. Y. Lin, J. W. Rossano, M. J. O'Connor. *Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA*

**(1206) ABO Incompatible Heart Transplantation in Young Children: Less Rejection and Infection;** S. Urschel<sup>1</sup>, M. McCoy<sup>1</sup>, R. S. Cantor<sup>2</sup>, D. A. Koehl<sup>2</sup>, W. A. Zuckerman<sup>3</sup>, A. Dipchand<sup>4</sup>, Z. Reinhardt<sup>5</sup>, K. R. Kanter<sup>6</sup>, J. A. Ballweg<sup>7</sup>, J. Sparks<sup>8</sup>, J. K. Kirklin<sup>2</sup>, W. F. Carlo<sup>9</sup>. <sup>1</sup>*Pediatrics, University of Alberta, Edmonton, AB, Canada*, <sup>2</sup>*Kirklins Institute for Research in Surgical Outcomes (KIRSO), Birmingham, AL*, <sup>3</sup>*Pediatrics, Columbia University Medical Center, New York, NY*, <sup>4</sup>*Pediatrics, Hospital for Sick Children, Toronto, ON, Canada*, <sup>5</sup>*Pediatrics, Freeman Hospital, Newcastle upon Tyne, United Kingdom*, <sup>6</sup>*Emory University School of Medicine, Atlanta, GA*, <sup>7</sup>*Pediatrics, Children's Hospital & Medical Center, Omaha, NE*, <sup>8</sup>*Pediatrics, University of Louisville, Louisville, KY*, <sup>9</sup>*Pediatrics, University of Alabama, Birmingham, AL*

**(1207) Post-Transplant Outcomes in Pediatric Patients Receiving Mechanical Circulatory Support: A Multicenter Study from the International Society for Heart and Lung Transplantation (ISHLT) Registry;** J. B. Edelson, Y. Huang, H. Griffis, C. E. Mascio, J. M. Chen, D. S. Burstein, K. Y. Lin, M. J. O'Connor, J. W. Rossano. *Children's Hospital of Philadelphia, Philadelphia, PA*

**(1208) Novel Trans-Septal Left Atrial VAD Cannulation Technique for Hypertrophic/Restrictive Cardiomyopathy;** K. Maeda<sup>1</sup>, T. Nasirov<sup>1</sup>, V. Yarlagadda<sup>2</sup>, S. A. Hollander<sup>2</sup>, M. Navarathnum<sup>3</sup>, D. N. Rosenthal<sup>2</sup>, S. Chen<sup>2</sup>, C. S. Almond<sup>2</sup>, B. D. Kaufman<sup>2</sup>, O. Reinhartz<sup>1</sup>, J. Murray<sup>2</sup>, J. C. Dykes<sup>2</sup>. <sup>1</sup>*Cardiothoracic Surgery, Stanford University, Stanford, CA*, <sup>2</sup>*Pediatrics, Stanford University, Stanford, CA*, <sup>3</sup>*Anesthesia, Stanford University, Stanford, CA*

**(1209) End Stage Liver Disease Models and Outcomes in Pediatric Patients Supported with Short-Term Continuous Flow Ventricular Assist Devices;** G. Malik<sup>1</sup>, T. Pidboyochynski<sup>2</sup>, H. Buchholz<sup>3</sup>, D. H. Freed<sup>4</sup>, M. Al-Aklabi<sup>4</sup>, S. J. Bozso<sup>3</sup>, S. Choudhry<sup>5</sup>, V. Anand<sup>6</sup>, P. Holinski<sup>6</sup>, J. Conway<sup>7</sup>. <sup>1</sup>*University of Alberta, Edmonton, AB, Canada*, <sup>2</sup>*Pediatrics, University of Alberta, Edmonton, AB, Canada*, <sup>3</sup>*Cardiac Surgery, Mazankowski Alberta Heart Institute, Edmonton, AB, Canada*, <sup>4</sup>*Pediatric Cardiac Surgery, Stollery Children's Hospital, Edmonton, AB, Canada*, <sup>5</sup>*Texas Children's Hospital, Houston, TX, Canada*, <sup>6</sup>*Pediatric Critical Care, University of Alberta, Edmonton, AB, Canada*, <sup>7</sup>*Pediatric Cardiology, University of Alberta, Edmonton, AB, Canada*

**(1210) Palliative Care Involvement in Pediatric VAD Patients - A Single Center Experience;** C. Knoll<sup>1</sup>, B. Kaufman<sup>1</sup>, S. Chen<sup>1</sup>, J. Murray<sup>1</sup>, B. Sourkes<sup>2</sup>, H. Cohen<sup>3</sup>, C. Almond<sup>1</sup>, D. Rosenthal<sup>1</sup>, S. A. Hollander<sup>1</sup>. <sup>1</sup>*Pediatric Cardiology, Lucile Packard Children's Hospital Stanford, Palo Alto, CA*, <sup>2</sup>*Psychology, Lucile Packard Children's Hospital Stanford, Palo Alto, CA*, <sup>3</sup>*Pediatrics - Hematology & Oncology, Lucile Packard Children's Hospital Stanford, Palo Alto, CA*

**(1211) Continuous Flow Ventricular Assist Device Implantation in Non Dilated Cardiomyopathy Pediatric Patients Using Complimentary 3D Techniques;** M. H. Desai<sup>1</sup>, S. M. Peer<sup>1</sup>, L. Oliveri<sup>2</sup>, P. Mass<sup>2</sup>, J. Opfermann<sup>2</sup>, S. Boyce<sup>3</sup>, R. A. Jonas<sup>1</sup>, P. Sinha<sup>1</sup>. <sup>1</sup>*Department of Cardiovascular Surgery, Children's National Medical Center, Washington, DC*, <sup>2</sup>*Department of Cardiology, Children's National Medical Center, Washington, DC*, <sup>3</sup>*Department of Cardiovascular Surgery, MedStar Washington Hospital Center, Washington, DC*

**(1212) Patients with Surgical Corrected TGA or Congenital Corrected TGA Supported with Durable VAD;** M. Schweiger<sup>1</sup>, T. de By<sup>2</sup>, E. Sandica<sup>3</sup>, O. Miera<sup>4</sup>, T. Fleck<sup>5</sup>, M. Hübler<sup>1</sup>, I. Netuka<sup>6</sup>. <sup>1</sup>*Children's Hospital Zurich, Zurich, Switzerland*, <sup>2</sup>*EUROMACS, EACTS, Windsor, United Kingdom*, <sup>3</sup>*Center for Congenital Heart Defects, Heart and Diabetes Centre North Rhine Westphalia, Zurich, Germany*, <sup>4</sup>*Dpt. of Congenital Heart Disease / Pediatric Cardiology, German Heart Centre, Berlin, Germany*, <sup>5</sup>*Bad Krozingen, Department of Congenital Heart Disease and Pediatric Cardiology, University Heart Center Freiburg, Freiburg, Germany*, <sup>6</sup>*Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Zurich, Czech Republic*

**(1213) Readmission to the Pediatric Cardiac Intensive Care Unit in Pediatric Patients with Durable Ventricular Assist Devices;** J. J. Chacko<sup>1</sup>, T. Pidborochynski<sup>2</sup>, H. Buchholz<sup>3</sup>, D. H. Freed<sup>4</sup>, M. Al-Aklabi<sup>4</sup>, V. Anand<sup>5</sup>, P. Holinski<sup>5</sup>, J. Conway<sup>2</sup>. <sup>1</sup>*Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada,* <sup>2</sup>*Department of Pediatric Cardiology, Stollery Children's Hospital, Edmonton, AB, Canada,* <sup>3</sup>*Division of Cardiac Surgery, Stollery Children's Hospital, Edmonton, AB, Canada,* <sup>4</sup>*Division of Pediatric Cardiac Surgery, Stollery Children's Hospital, Edmonton, AB, Canada,* <sup>5</sup>*Pediatric Critical Care, Stollery Children's Hospital, Edmonton, AB, Canada*

**(1214) Time in Therapeutic Range Using Bivalirudin for Pediatric Ventricular Assist Devices;** J. J. Daugherty, C. Heyrend, B. Kay, E. R. Griffiths, L. May. *Intermountain Healthcare, Salt Lake City, UT*

**(1215) Use of Bivalirudin in Pediatric Patients on Ventricular Assist Device Support;** K. Puri<sup>1</sup>, H. P. Tunuguntla<sup>2</sup>, T. J. Humlicek<sup>2</sup>, W. J. Dreyer<sup>2</sup>, S. W. Denfield<sup>2</sup>, A. G. Cabrera<sup>2</sup>, S. Hui<sup>3</sup>, L. Hensch<sup>3</sup>, J. F. Price<sup>2</sup>, S. Choudhry<sup>2</sup>, I. Adachi<sup>4</sup>, J. Teruya<sup>3</sup>. <sup>1</sup>*Pediatric Critical Care Medicine, Baylor College of Medicine, Houston, TX,* <sup>2</sup>*Pediatric Cardiology, Baylor College of Medicine, Houston, TX,* <sup>3</sup>*Pathology and Transfusion Medicine, Baylor College of Medicine, Houston, TX,* <sup>4</sup>*Congenital Heart Surgery, Baylor College of Medicine, Houston, TX*

**(1216) Explantation of Mechanical Circulatory Support Devices to Recovery is Possible and Should Be Considered in Selected Conditions in Children;** M. Ramaswamy<sup>1</sup>, A. Khushnood<sup>2</sup>, M. Kostolny<sup>1</sup>, Z. Reinhardt<sup>2</sup>, T. Chila<sup>2</sup>, F. De Rita<sup>2</sup>, M. Burch<sup>1</sup>, A. Hasan<sup>2</sup>, N. Muthialu<sup>1</sup>. <sup>1</sup>*Great Ormond Street Hospital for Children, London, United Kingdom,* <sup>2</sup>*Freeman Hospital, Newcastle upon Tyne, United Kingdom*

**(1217) Development of Continuous-Flow Total Artificial Heart for Use in Infants;** J. H. Karimov, A. Polakowski, D. Horvath, N. Byram, Y. Kado, T. Miyamoto, M. Ahmad, H. Najm, R. Stewart, E. Saarel, B. Kuban, K. Fukamachi. *The Cleveland Clinic, Cleveland, OH*

Friday, April 5, 2019

6:00 PM - 7:15 PM

## **POSTER SESSION 3: PULMONARY HYPERTENSION AND CTEPH**

Room: Gardenia 2

### **Poster Discussants:**

Marco Caccamo, DO, West Virginia University, Washington, PA, USA  
Agnieszka Ciarka, MD, PhD, Catholic University of Leuven, Leuven, Belgium  
Manreet Kanwar, MD, Allegheny General Hospital, Pittsburgh, PA, USA  
Anjali Vaidya, MD, Temple University, Philadelphia, PA, USA  
Helen Whitford, MBBS, FRACP, Alfred Hospital, Melbourne, Australia

**(494) Clinical Pharmacokinetic Performance of a Ralinepag Extended-Release Tablet;** J. Grundy, A. Blackburn, Y. Tang, C. King, J. Adams. Arena Pharmaceuticals, Inc, San Diego, CA

**(1218) Expression of MicroRNAs in Surgical Specimens of Patients with Chronic Thromboembolic Pulmonary Hypertension;** M. B. Kirschner<sup>1</sup>, M. Friess<sup>1</sup>, V. Orłowski<sup>1</sup>, B. Gray-Stocker<sup>1</sup>, W. Weder<sup>1</sup>, I. Inci<sup>1</sup>, R. Schüpbach<sup>2</sup>, D. Bettex<sup>3</sup>, S. Ulrich<sup>4</sup>, I. Opitz<sup>1</sup>. <sup>1</sup>Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland, <sup>2</sup>Department of Intensive Medicine, University Hospital Zurich, Zurich, Switzerland, <sup>3</sup>Department of Anaesthesiology, University Hospital Zurich, Zurich, Switzerland, <sup>4</sup>Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland

**(1219) Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Real-World Experience with Macitentan;** R. Channick<sup>1</sup>, V. McLaughlin<sup>2</sup>, K. Chin<sup>3</sup>, J. McConnell<sup>4</sup>, D. Poch<sup>5</sup>, M. Brand<sup>6</sup>, M. Selej<sup>7</sup>, A. Morganti<sup>6</sup>, N. Kim<sup>5</sup>. <sup>1</sup>University of California Los Angeles, Los Angeles, CA, <sup>2</sup>University of Michigan, Ann Arbor, MI, <sup>3</sup>UT Southwestern Medical Center, Dallas, TX, <sup>4</sup>Kentuckiana Pulmonary Associates, Louisville, KY, <sup>5</sup>University of California San Diego, La Jolla, CA, <sup>6</sup>Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, <sup>7</sup>Actelion Pharmaceuticals US, Inc, South San Francisco, CA

**(1220) National Estimates and Predictors for Pulmonary Hypertension Readmission Categorized by Pulmonary Hypertension Subtype;** P. T. Bhattacharya<sup>1</sup>, A. A. Hameed<sup>2</sup>, S. T. Bhattacharya<sup>3</sup>, J. A. Chirinos<sup>1</sup>, S. Chatterjee<sup>4</sup>, J. S. Giri<sup>1</sup>, S. M. Kawut<sup>1</sup>, J. A. Mazurek<sup>1</sup>. <sup>1</sup>Hospital of University of Pennsylvania, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, <sup>2</sup>Internal Medicine, Mercy Catholic Medical Center, Drexel University College of Medicine, Philadelphia, PA, <sup>3</sup>Johns Hopkins, Baltimore, MD, <sup>4</sup>Hoffman Heart Institute, St Francis Hospital of the University of Connecticut, Hartford, CT

**(1221) CMR Right Ventricular-Pulmonary Arterial Coupling and Right Ventricular Trabecular Complexity: Prognostic in Lung Transplant Assessment?;** K. Halim, G. Sarri, M. McCurry, A. Constantine, I. Pierce, Z. Chen, H. Samarasinghe, S. Rahman-Haley, A. Simon, M. Carby, A. Reed, J. Wong. Cardiology, Harefield Hospital, Royal Brompton and Harefield Foundation Trust, London, United Kingdom

**(1222) Rest ETCO<sub>2</sub> and V<sub>E</sub>/VCO<sub>2</sub> are Superior to Exercise Gas Exchange Parameters with Invasive Cardiopulmonary Exercise Testing to Predict Pulmonary Vascular Disease in Patients with Dyspnea of Unclear Etiology;** F. Raza<sup>1</sup>, A. Vaidya<sup>2</sup>, P. Forfia<sup>2</sup>. <sup>1</sup>Dept of Medicine, Univ of Wisconsin School of Medicine and Public Health, Madison, WI, <sup>2</sup>Temple Univ Hospital, Philadelphia, PA

**(1223) Determinants of Right Ventricular Dysfunction in Pulmonary Arterial Hypertension: Beyond Pulmonary Vascular Resistance;** A. Chaturvedi<sup>1</sup>, M. Naik<sup>1</sup>, A. A. Joshi<sup>1</sup>, J. PO<sup>2</sup>, T. Meeran<sup>3</sup>, A. Raina<sup>1</sup>. <sup>1</sup>Allegheny Health Network, Pittsburgh, PA, <sup>2</sup>Ascension Borgess Hospital, Kalamazoo, MI, <sup>3</sup>Advanced Heart Failure and Cardiac Transplant, Fortis Hospital, Mumbai, India

**(1224) Right Ventricular - Pulmonary Vascular Coupling at Rest and Exercise in Patients with Dyspnea and/or Suspected Pulmonary Hypertension;** S. P. Wright<sup>1</sup>, F. H. Valle<sup>1</sup>, L. Groves<sup>2</sup>, S. Esfandiari<sup>1</sup>, J. T. Granton<sup>3</sup>, S. Mak<sup>1</sup>. <sup>1</sup>Cardiology, Mount Sinai Hospital, Toronto, ON, Canada, <sup>2</sup>School of Biomedical Engineering, Western University, London, ON, Canada, <sup>3</sup>Respirology, University Health Network, Toronto, ON, Canada

**(1225) A New Strategy after Lung Transplantation for Pulmonary Hypertension: Tapering Epoprostenol Administration;** A. Ohsumi, A. Aoyama, H. Kinoshita, T. Yoneda, M. Okuda, K. Yamazaki, K. Minatoya, Y. Yamada, Y. Yutaka, D. Nakajima, M. Hamaji, T. F. Chen-Yoshikawa, H. Date. Kyoto University Hospital, Kyoto, Japan

**(1226) Clinical Course of Patients Transitioned from Another Prostacyclin Pathway Agent (PPA) to Selexipag in SPHERE;** K. M. Chin<sup>1</sup>, V. McLaughlin<sup>2</sup>, N. H. Kim<sup>3</sup>, M. M. Chakinala<sup>4</sup>, A. R. Hemnes<sup>5</sup>, H. W. Farber<sup>6</sup>, C. Zhao<sup>7</sup>, J. Colvin<sup>7</sup>, M. Shah<sup>7</sup>, K. B. Highland<sup>8</sup>. <sup>1</sup>Univ of Texas, Southwestern Medical Center, Dallas, TX, <sup>2</sup>Univ of Michigan Medical Center, Ann Arbor, MI, <sup>3</sup>Univ of California, San Diego, La Jolla, CA, <sup>4</sup>Washington Univ School of Medicine, St. Louis, MO, <sup>5</sup>Vanderbilt Univ Medical Center, Nashville, TN, <sup>6</sup>Boston Univ School of Medicine, Boston, MA, <sup>7</sup>Actelion, South San Francisco, CA, <sup>8</sup>Cleveland Clinic, Cleveland, OH

**(1227) Secular Trends and Outcome of Isolated versus Combined Type 2 Pulmonary Hypertension in Patients with End-Stage Heart Failure;** A. Nasri<sup>1</sup>, J. Dupuis<sup>1</sup>, L. Hausermann<sup>1</sup>, M. Tremblay-Gravel<sup>1</sup>, M. C. Parent<sup>1</sup>, M. Carrier<sup>1</sup>, N. Racine<sup>1</sup>, S. de Denus<sup>1</sup>, A. Ducharme<sup>1</sup>, A. Fortier<sup>2</sup>, M. White<sup>1</sup>. <sup>1</sup>Montreal Heart Institute, Montreal, QC, Canada, <sup>2</sup>Montreal Health Innovations Coordinating Centre, Montreal, QC, Canada

**(1229) Clinical Impact of Right Ventricular Diastolic Patterns in Idiopathic Pulmonary Arterial Hypertension by Speckle Tracking;** R. Badagliacca<sup>1</sup>, B. Pezzuto<sup>1</sup>, S. Papa<sup>1</sup>, R. Poscia<sup>1</sup>, G. Manzi<sup>1</sup>, A. Pascaretta<sup>1</sup>, R. Torre<sup>1</sup>, G. Casu<sup>2</sup>, S. Sciomer<sup>1</sup>, F. Fedele<sup>1</sup>, R. Naeije<sup>3</sup>, C. Vizza<sup>1</sup>. <sup>1</sup>Dept. of Cardiovascular and Respiratory Science, Univ of Rome Sapienza, Rome, Italy, <sup>2</sup>Dept. of Cardiology, Dept. of Cardiology, Nuoro, Italy, <sup>3</sup>Dept. of Cardiology, Erasme University Hospital, Brussels, Belgium

**(1230) Derivation of a Bayesian Network Model from an Existing Risk Score Calculator for Pulmonary Arterial Hypertension;** J. Kraissangka<sup>1</sup>, L. C. Lohmueller<sup>2</sup>, M. K. Kanwar<sup>3</sup>, C. Zhao<sup>4</sup>, M. J. Druzdel<sup>1</sup>, J. F. Antaki<sup>5</sup>, M. A. Simon<sup>6</sup>, R. L. Benza<sup>3</sup>. <sup>1</sup>School of Computing and Information, University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>Language Technologies Institute, Carnegie Mellon University, Pittsburgh, PA, <sup>3</sup>Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA, <sup>4</sup>Actelion Pharmaceuticals US, Inc., South San Francisco, CA, <sup>5</sup>Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY, <sup>6</sup>Department of Medicine, University of Pittsburgh, Pittsburgh, PA

**(1231) Pulmonary Hypertension in Rural Minnesota: Prevalence and Clinical Classification;** E. R. Fenstad<sup>1</sup>, N. Bonfig<sup>2</sup>, L. Mirfakhraie<sup>2</sup>, S. Ebnet<sup>2</sup>, P. Eckman<sup>2</sup>, B. Cabuay<sup>2</sup>, R. Garberich<sup>2</sup>, S. Reed<sup>1</sup>, T. Dirks<sup>1</sup>, P. Stokman<sup>1</sup>. <sup>1</sup>Minneapolis Heart Institute, Baxter, MN, <sup>2</sup>Minneapolis Heart Institute, Minneapolis, MN

**(1232) Clinical Implications of Idiopathic Pulmonary Arterial Hypertension Phenotypes Defined by Cluster Analysis;** R. Badagliacca<sup>1</sup>, F. Rischard<sup>2</sup>, S. Papa<sup>1</sup>, S. Kubba<sup>2</sup>, R. Vanderpool<sup>2</sup>, J. Yuan<sup>2</sup>, J. Garcia<sup>3</sup>, S. Airhart<sup>3</sup>, R. Poscia<sup>1</sup>, B. Pezzuto<sup>1</sup>, G. Manzi<sup>1</sup>, S. Sciomer<sup>1</sup>, R. Torre<sup>1</sup>, F. Fedele<sup>1</sup>, C. Vizza<sup>1</sup>. <sup>1</sup>Dept. of Cardiovascular and Respiratory Science, Univ of Rome Sapienza, Rome, Italy, <sup>2</sup>University of Arizona, Tucson, AZ, <sup>3</sup>Univ of Arizona, Tucson, AZ

**(1233) High Heart Rate and Pulmonary Vascular Resistance Predict Poor Prognosis after Referral for Lung Transplantation in Patients with Pulmonary Arterial Hypertension;** T. Hara<sup>1</sup>, M. Hatano<sup>2</sup>, A. Saito<sup>1</sup>, S. Minatsuki<sup>1</sup>, H. Maki<sup>1</sup>, E. Amiya<sup>1</sup>, Y. Hosoya<sup>1</sup>, K. Nagayama<sup>3</sup>, M. Sato<sup>3</sup>, M. Anraku<sup>3</sup>, J. Nakajima<sup>3</sup>, I. Komuro<sup>1</sup>. <sup>1</sup>Department of Cardiovascular Medicine, University of Tokyo, Tokyo, Japan, Tokyo, Japan, <sup>2</sup>Department of Therapeutic Strategy for Heart Failure, University of Tokyo, Tokyo, Japan, Tokyo, Japan, <sup>3</sup>Department of Thoracic Surgery, University of Tokyo, Tokyo, Japan, Tokyo, Japan

**(1234) Does Etiology of Pulmonary Hypertension Impact Survival? An ISHLT Registry Analysis;** K. Tsui<sup>1</sup>, J. Lasky<sup>2</sup>, C. Alex<sup>1</sup>, M. Dia<sup>1</sup>, E. Jweied<sup>1</sup>, P. Pappas<sup>1</sup>, C. Wigfield<sup>1</sup>. <sup>1</sup>Lung Transplant, Advocate Christ Medical Center, Chicago, IL, <sup>2</sup>Rosalind Franklin University of Medicine and Science, Chicago, IL

**(1235) Patient Characteristics and Treatment Patterns with Macitentan in Pulmonary Arterial Hypertension: Insights from the OPUS Registry;** R. Channick<sup>1</sup>, K. Chin<sup>2</sup>, N. Kim<sup>3</sup>, M. Brand<sup>4</sup>, A. Morganti<sup>4</sup>, M. Selej<sup>5</sup>, V. McLaughlin<sup>6</sup>. <sup>1</sup>University of California Los Angeles, Los Angeles, CA, <sup>2</sup>UT Southwestern Medical Center, Dallas, TX, <sup>3</sup>University of California San Diego, La Jolla, CA, <sup>4</sup>Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, <sup>5</sup>Actelion Pharmaceuticals US, Inc, South San Francisco, CA, <sup>6</sup>University of Michigan, Ann Arbor, MI

**(1236) Alteration of Right Ventricular to Pulmonary Artery Coupling in Systemic Sclerosis;** A. Krokos, C. Dewachter, A. Rimouche, J. Vachiéry. Department of Cardiology, Cliniques Universitaires de Bruxelles, Hôpital Académique Erasme, Bruxelles, Belgium, Brussels, Belgium

**(1237) Safety, Tolerability and Pharmacokinetics Study in Patients with Pulmonary Arterial Hypertension (PAH) Temporarily Switching from Oral to IV Selexipag;** H. Klose<sup>1</sup>, K. Chin<sup>2</sup>, R. Ewert<sup>3</sup>, H. Gall<sup>4</sup>, J. Parambil<sup>5</sup>, D. Poch<sup>6</sup>, H. Seyfarth<sup>7</sup>, L. Axelsen<sup>8</sup>, S. Hsu Schmitz<sup>9</sup>, C. Stein<sup>10</sup>, I. Preston<sup>11</sup>. <sup>1</sup>Department of Respiratory Medicine, University Medical Center Hamburg-Eppendorf, Center of Oncology, Hamburg, Germany, <sup>2</sup>University of Texas Southwestern, Medical Centre, Dallas, TX, <sup>3</sup>Clinic of Internal Medicine, Department of Respiratory Medicine, Ernst Moritz Arndt University of Greifswald, Greifswald, Germany, <sup>4</sup>Internal Medicine, University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany, <sup>5</sup>Department of Pulmonary, Allergy and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH, <sup>6</sup>Department of Pulmonary Critical Care, University of California, San Diego, CA, <sup>7</sup>Department of Respiratory Medicine, University of Leipzig, Leipzig, Germany, <sup>8</sup>Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, <sup>9</sup>Biostatistics, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, <sup>10</sup>Clinical Science, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, <sup>11</sup>Pulmonary, Critical Care and Sleep Division, Tufts Medical Center, Tufts University School of Medicine, Boston, MA

**(1238) Targeting CCL5 for Treatment of BMP-Mediated Pulmonary Hypertension;** X. Nie<sup>1</sup>, J. Chen<sup>1</sup>, J. Bian<sup>2</sup>. <sup>1</sup>Center of Clinical Research, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, China, <sup>2</sup>Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

**(1239) Feasibility of Exercise Hemodynamic Evaluation in the Clinical Cardiac Catheterization Laboratory;** F. Valle<sup>1</sup>, S. Esfandiari<sup>1</sup>, S. Wright<sup>1</sup>, J. Udell<sup>2</sup>, C. Overgaard<sup>2</sup>, S. Mak<sup>1</sup>. <sup>1</sup>Cardiology, Mount Sinai Hospital/University Health Network, Toronto, ON, Canada, <sup>2</sup>University Health Network, Toronto, ON, Canada

**(1240) The Effect of Left Ventricular Assist Devices (LVAD) on Pulmonary Hypertension: A Single Center Review;** P. L. Tremblay<sup>1</sup>, S. A. Stewart<sup>2</sup>, R. J. Baskett<sup>1</sup>. <sup>1</sup>Department of Surgery, Dalhousie University, Halifax, NS, Canada, <sup>2</sup>Department of Community Health & Epidemiology, Dalhousie University, Halifax, NS, Canada

**(1241) Platelet Derived Growth Factor (PDGF) and Bone Morphogenic Protein 4 (BMP4) Levels May Indicate Presence of Combined Pre and Post Capillary WHO Group II Pulmonary Hypertension;** H. Marcos-Abdala<sup>1</sup>, H. Karmouty-Quintana<sup>2</sup>, K. Youker<sup>1</sup>, A. Cruz-Solbes<sup>1</sup>, J. Amione-Guerra<sup>1</sup>, A. Ali<sup>1</sup>, R. Araujo-Gutierrez<sup>1</sup>, R. Thandavarayan<sup>1</sup>, G. Ashrith<sup>1</sup>. <sup>1</sup>Heart Failure, Houston Methodist Research Institute, Houston, TX, <sup>2</sup>Molecular Biology, UT Health and Medicine School, Houston, TX


**(1242) Echocardiographic Estimation of Pulmonary Artery Pulsatility Index in Pulmonary Hypertension;** S. Mirza, A. Khalif, S. Khodjaev, C. Alpert, A. Raina, M. Kanwar, S. Murali, R. Benza, A. Hadi. Allegheny Health Network, Pittsburgh, PA

**(1243) Role of Extracorporeal Membrane Oxygenation Support as a Bridge to Medical Therapy in Decompensated Pulmonary Hypertension;** M. Tsai<sup>1</sup>, C. Hsu<sup>2</sup>, P. Yang<sup>1</sup>, T. Lin<sup>3</sup>, D. Chen<sup>1</sup>, C. Luo<sup>1</sup>, Y. Hu<sup>1</sup>, J. Roan<sup>1</sup>. <sup>1</sup>Cardiovascular Surgery, National Cheng Kung University Hospital, Tainan, Tainan, Taiwan, <sup>2</sup>Cardiology, National Cheng Kung University Hospital, Tainan, Tainan, Taiwan, <sup>3</sup>Cardiovascular Surgery, Division of Cardiovascular Surgery, Department of Surgery, E-Da Hospital/I-Shou University, Kaohsiung, Kaohsiung, Taiwan

**(1244) Lower Socioeconomic Status Associated with Decreased Completion of Exercise Rehabilitation in Patients with Pulmonary Hypertension;** T. Cascino<sup>1</sup>, C. Ashur<sup>1</sup>, C. Richardson<sup>1</sup>, E. Jackson<sup>2</sup>, V. McLaughlin<sup>1</sup>. <sup>1</sup>University of Michigan, Ann Arbor, MI, <sup>2</sup>University of Alabama Birmingham, Birmingham, AL


**POSTER MAPS**

**Poster Session 1, Wednesday – Banda Sea 1**







Poster Session 1, Wednesday – Banda Sea 2




Poster Session 1, Wednesday – Gardenia 1




Poster Session 1, Wednesday – Gardenia 2




Poster Session 1, Wednesday – Hibiscus 1




Poster Session 1, Wednesday – Hibiscus 2




Poster Session 1, Wednesday – Timor Sea 1



Poster Session 1, Wednesday – Timor Sea 2




Poster Session 2, Thursday – Banda Sea 1







Poster Session 2, Thursday – Banda Sea 2




Poster Session 2, Thursday – Gardenia 2




Poster Session 2, Thursday – Hibiscus 1




Poster Session 2, Thursday – Hibiscus 2




Poster Session 2, Thursday – Timor Sea 1




Poster Session 2, Thursday – Timor Sea 2



Poster Session 3, Friday – Banda Sea 1




Poster Session 3, Friday – Banda Sea 2







Poster Session 3, Friday – Gardenia 2




Poster Session 3, Friday – Hibiscus 1




Poster Session 3, Friday – Hibiscus 2



Poster Session 3, Friday – Timor Sea 1



Poster Session 3, Friday – Timor Sea 2



## ISHLT ACADEMIES

### ISHLT ACADEMY: CORE COMPETENCIES IN NURSING, HEALTH SCIENCES AND ALLIED HEALTH Care of Patients Requiring Mechanical Circulatory Support and Transplantation

#### Scientific Program Chairs

**Chair:** Sarah Schettle, PA-C, Mayo Clinic College of Medicine, Rochester, MN, USA

**Co-Chairs:** Connie White-Williams PhD, RN, NE-BC, FAAN, Univ of Alabama at Birmingham Hospital, Birmingham, AL, USA  
Patricia M. Leisfield, RN, The Prince Charles Hospital, Queensland, Australia

#### Faculty

Nancy P. Blumenthal, DNP, CRNP, University of Pennsylvania Medical Center, Philadelphia, PA, USA

Caron Burch, RN, MSN, FNP, CCTC, UCSF Benioff Children's Hospital, Redwood City, CA, USA

Susan M. Chernenko, RN, MN, NP, Toronto General Hospital, Toronto, ON, Canada

Pamela S. Combs, PhD, RN, University of Chicago, Chicago, IL, USA

Margaret M. Fregoso, NP, Inova Transplant Center, Fairfax, VA, USA

Steven P. Ivulich, BPharm, Alfred Hospital, Melbourne, VC, Australia

Colleen J. Juricek-LaBuhn, University of Chicago, Chicago, IL, USA

Jane MacIver, RN, NP, PhD, Toronto General Hospital, Toronto, ON, Canada

Tara E. Miller, FNP, Duke University Medical Center, Durham, NC, USA

Linda Ohler, MSN, FAAN, FAST, New York University, New York, NY, USA

Michael G. Petty, PhD, RN, CNS, University of Minnesota Medical Center, Minneapolis, MN, USA

Nicola Robinson Smith, RN, Newcastle Upon Tyne Hospitals NHS, Newcastle Upon Tyne, UK

Desiree Robson, RN, BSc (Hons), St. Vincent's Hospital, Sydney, NSW, Australia

Thomas Schlöglhofer, BSc, Medical University of Vienna, Vienna, Austria

Sarah E. Schroeder, ACNP-BC, MSN RN, Bryan Heart, Lincoln, NE, USA

Angela W. Velleca, RN, BSN, CCTC, Cedars Sinai Heart Institute, Los Angeles, CA, USA

Jo Wray, PhD, Great Ormond Street Hospital, London, UK

#### Educational Goals

This Academy is intended to offer a concise synopsis of clinical knowledge to support mastery of the core competencies of the selection, pre-transplant, perioperative, and post-transplant management of the thoracic transplant organ recipient by Nursing, Health Sciences, and Allied Health professionals. In addition to basic knowledge, attention is also paid to patients with special needs who require transplantation and to the Nursing, Health Sciences, and Allied Health professionals caring for this unique population.

#### Target Audience

While all members are invited to enroll, this course is primarily designed to be of benefit for Nursing, Health Sciences, and Allied Health professionals who are in the early stages of their careers, or who are in training and/or are part of a new program, or desire an update on the current state of the field. The information presented covers core competencies and is intended to provide a strong foundation of the overarching principles of thoracic transplant and mechanical circulatory support, rather than as a detailed update for those who are already proficient experts in the field.

#### Learning Objectives

At the conclusion of this Course, participants will have improved competence and professional performance in their ability to:

1. Understand the role of the Transplant and MCS Coordinator and how to evaluate, manage, and care for patients for the short term and long term within this role.
2. Recognize and appreciate challenges with patients with special needs and identify strategies to implement quality care for all patients.
3. Identify patient needs at the end of life, how to meet these needs and how to practice self-care.

#### Accreditation & Credit Designation Statements

##### Physicians

Accreditation Statement - The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement - ISHLT designates this live activity for a maximum of 8.25 *AMA PRA Category 1 Credit(s)*<sup>TM</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

##### Nurses

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the International Society for Heart & Lung Transplantation. Amedco LLC is jointly accredited by the American Council for Continuing Medical Education

(ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 8.25 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

### **Transplant Coordinators**

As a designated Approved Provider by the American Board for Transplant Certification (ABTC), the International Society for Heart & Lung Transplantation grants up to 8.25 Category 1 Continuing Education Points for Transplant Coordinators (CEPTCs) for this offering. CEPTC Provider Number: #907-000.

### **Disclosure**

Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interests that may affect the program content or a speaker's presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.

## **Scientific Program**

<b>7:00 AM - 7:45 AM</b>	<b>REGISTRATION AND MORNING COFFEE</b>
<b>7:45 AM - 8:00 AM</b>	<b>WELCOME AND OVERVIEW</b>
<b>8:00 AM - 8:30 AM</b>	<b>SESSION 1 - ROLE OF THE TRANSPLANT AND MCS COORDINATOR: EVOLUTION AND CURRENT PRACTICE</b> <b>CHAIR:</b> Connie White-Williams, PhD, RN, NE-BC, FAAN
<b>8:00 AM</b>	<i>Evolution of the Heart and Lung Transplant and MCS Coordinator Role</i> Linda Ohler, MSN, FAAN, FAST, New York University, New York, NY, USA
<b>8:15 AM</b>	<i>Global Role Variations</i> Thomas Schlöglhofer, MSc, Medical University of Vienna, Vienna, Austria
<b>8:30 AM – 9:30 AM</b>	<b>SESSION 2 – EVALUATION AND MANAGEMENT OF THE ADVANCED THORACIC ORGAN FAILURE PATIENT</b> <b>CHAIR:</b> Patricia Leisfield, RN
<b>8:30 AM</b>	<i>When to Refer...and do They Meet Criteria?</i> Colleen J. Juricek-LaBuhn, University of Chicago, Chicago, IL, USA
<b>8:45 AM</b>	<i>Evaluation and Management</i> Nancy P. Blumenthal, DNP, CRNP, University of Pennsylvania Medical Center, Philadelphia, PA, USA
<b>9:00 AM</b>	<i>Psychosocial Issues pre-Transplant and pre-MCS</i> Sarah E. Schroeder, ACNP-BC, MSN RN, Bryan Heart, Lincoln, NE, USA
<b>9:15 AM</b>	<i>Hot Topics in Evaluation</i> Jane MacIver, RN, NP, PhD, Toronto General Hospital, Toronto, ON, Canada
<b>9:30 AM – 10:00 AM</b>	<b>COFFEE BREAK</b>
<b>10:00 AM – 11:00 AM</b>	<b>SESSION 3 – CARING FOR THE LISTED PATIENT</b> <b>CHAIR:</b> Connie White-Williams, PhD, RN, NE-BC, FAAN
<b>10:00 AM</b>	<i>Listing and Collaboration: Transplant/MCS Coordinators and Patients</i> Linda Ohler, MSN, FAAN, FAST, New York University, New York, NY, USA
<b>10:15 AM</b>	<i>Immunology 101</i> Tara E. Miller, FNP, Duke University Medical Center, Durham, NC, USA

- 10:30 AM** *Managing Patients with anti HLA Antibodies and Desensitization Therapies*  
Angela W. Velleca, RN, BSN, CCTC, Cedars Sinai Heart Institute, Los Angeles, CA, USA
- 10:45 AM** *Case Scenario: Cannabis Legality and Patient Evaluation*  
Nicola Robinson Smith, RN, Newcastle Upon Tyne Hospitals NHS, Newcastle Upon Tyne, UK
- 11:00 AM – 11:30 AM** **SESSION 4 – TRANSPLANT MANAGEMENT**  
**CHAIR:** Patricia Leisfield, RN
- 11:00 AM** *The Heart and Lung Donor*  
Margaret M. Fregoso, NP, Inova Transplant Center, Fairfax, VA, USA
- 11:15 AM** *Immunosuppression: Induction and Maintenance*  
Steven P. Ivulich, BPharm, Alfred Hospital, Melbourne, VC, Australia
- 11:30 AM – 12:00 PM** **SESSION 5 – MCS MANAGEMENT**  
**CHAIR:** Sarah Schettle, PA-C
- 11:30 AM** *Devices*  
Nicola Robinson Smith, RN, Newcastle Upon Tyne Hospitals NHS, Newcastle Upon Tyne, UK
- 11:45 AM** *Complications Overview*  
Thomas Schlöglhofer, MSc, Medical University of Vienna, Vienna, Austria
- 12:00 PM – 1:00 PM** **LUNCH/NETWORKING BREAK (a box lunch is included in the registration fee)**
- 1:00 PM – 1:45 PM** **SESSION 6 – IMMEDIATE POST TRANSPLANT CARE**  
**CHAIR:** Connie White-Williams, PhD, RN, NE-BC, FAAN
- 1:00 PM** *Primary Graft Dysfunction: Definitions and Treatment*  
Margaret M. Fregoso, NP, Inova Transplant Center, Fairfax, VA, USA
- 1:15 PM** *Management of Acute Cellular Rejection and Antibody Mediated Rejection*  
Tara E. Miller, FNP, Duke University Medical Center, Durham, NC, USA
- 1:30 PM** *Post-Transplant Heart and Lung Recipient and Caregiver Education*  
Susan M. Chernenko, RN, MN, NP, Toronto General Hospital, Toronto, ON, Canada
- 1:45 PM – 2:45 PM** **SESSION 7 – CARE OF THE PATIENT WITH SPECIAL NEEDS**  
**CHAIR:** Sarah Schettle, PA-C
- 1:45 PM** *Poor Social Support and Low Socioeconomic Status*  
Caron Burch, RN, MSN, FNP, CCTC, UCSF Benioff Children’s Hospital, Redwood City, CA, USA
- 2:00 PM** *Low Health Literacy and Adherence*  
Colleen J. Juricek-LaBuhn, University of Chicago, Chicago, IL, USA
- 2:15 PM** *Care of the Very Young, School Age and Adolescent*  
Jo Wray, PhD, Great Ormond Street Hospital, London, UK
- 2:30 PM** *Care of the Older Aged Patient*  
Patricia Leisfield, RN, The Prince Charles Hospital, Queensland, Australia
- 2:45 PM – 3:15 PM** **COFFEE BREAK**
- 3:15 PM – 4:15 PM** **SESSION 8 – LONG TERM FOLLOW UP**  
**CHAIR:** Patricia Leisfield, RN
- 3:15 PM** *Chronic Rejection: BOS*  
Michael G. Petty, PhD, RN, CNS, University of Minnesota Medical Center, Minneapolis, MN, USA



- 3:30 PM**                    ***Chronic Rejection: CAV***  
Angela W. Velleca, RN, BSN, CCTC, Cedars Sinai Heart Institute, Los Angeles, CA, USA
- 3:45 PM**                    ***Infection and Malignancy***  
Linda Ohler, MSN, FAAN, FAST, New York University, New York, NY, USA
- 4:00 PM**                    ***Return to Work, School and Quality of Life***  
Desiree Robson, RN, BSc (Hons), St. Vincent's Hospital, Sydney, NSW, Australia
- 4:15 PM – 4:45 PM**        **SESSION 9 – QUALITY**  
**CHAIR:** Connie White-Williams, PhD, RN, NE-BC, FAAN
- 4:15 PM**                    ***Quality Assurance and Interprofessional Collaborative Practice***  
Connie White-Williams, PhD, RN, NE-BC, FAAN, University of Alabama at Birmingham Hospital, Birmingham, AL, USA
- 4:30 PM**                    ***Readmissions***  
Sarah Schettle, PA-C, Mayo Clinic College of Medicine, Rochester, MN, USA
- 4:45 PM - 6:00 PM**        **SESSION 10 – CARING FOR OURSELVES AND OTHERS**  
**CHAIR:** Patricia Leisfield, RN
- 4:45 PM**                    ***Collaboration Strategies***  
Pamela Combs, PhD, RN, University of Chicago, Chicago, IL, USA
- 5:00 PM**                    ***Care for the Caregivers***  
Caron Burch, RN, MSN, FNP, CCTC, UCSF Benioff Children's Hospital, Redwood City, CA, USA
- 5:15 PM**                    ***Caring at the End of Life***  
Jane MacIver, RN, NP, PhD, Toronto General Hospital, Toronto, ON, Canada
- 5:30 PM**                    ***Career Development Strategies for MCS and Transplant Professionals***  
Connie White-Williams, PhD, RN, NE-BC, FAAN, University of Alabama at Birmingham Hospital, Birmingham, AL, USA
- 5:45 PM**                    ***Work-life Balance for the MCS and Transplant Professional – Making it all Work***  
Desiree Robson, RN, BSc (Hons), St. Vincent's Hospital, Sydney, NSW, Australia
- 6:00 PM**                    **SUMMARY / EVALUATION / Q&A**  
Sarah Schettle, PA-C, Mayo Clinic College of Medicine, Rochester, MN, USA  
Connie White-Williams, PhD, RN, NE-BC, FAAN, University of Alabama at Birmingham Hospital, Birmingham, AL, USA  
Patricia Leisfield, RN, The Prince Charles Hospital, Queensland, Australia
- 6:15 PM**                    **ADJOURN**

## ISHLT ACADEMY: CORE COMPETENCIES IN PEDIATRIC HEART FAILURE

### Scientific Program Chairs

Chair: Ryan Butts, MD, University of Texas Southwestern, Dallas, TX, USA

Co-Chair: Heather Henderson, MD, Medical University of South Carolina, Charleston, SC, USA

### Scientific Program Committee

Rachel Andrews, FRCPCH, Great Ormond Street Hospital for Children, London, UK

Jennifer Conway, MD, University of Alberta/Stollery Children's Hospital, Edmonton, AB, Canada

Claire Irving, FRACP, MD, Children's Hospital West Mead, Sydney, Australia

Joseph Rossano, MD, Children's Hospital of Philadelphia, Philadelphia, PA, USA

### Faculty

Rachel Andrews, FRCPCH, Great Ormond Street Hospital for Children, London, UK

Michael P. Carboni, MD, Duke Children's Hospital, Durham, NC, USA

Jennifer Conway, MD, Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada

Anne Dipchand, MD, Hospital for Sick Children, Toronto, ON, Canada

Claire Irving, FRACP, MD, Children's Hospital Westmead, Sydney, Australia

Robert Jaquiss, MD, Children's Medical Center, Dallas, TX, USA

Paul F. Kantor, MBBCh, FRCPC, Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada

Richard Kirk, FRCP, FRCPCH, University of Texas Southwestern Medical Center, Dallas, TX, USA

Jodie Lantz, MSN, RN, PCNSBC, Children's Health Dallas, Dallas, TX, USA

Jack F. Price, MD, Texas Children's Hospital, Houston, TX, USA

Joseph Rossano, MD, Children's Hospital of Philadelphia, Philadelphia, PA, USA

Leonardo Salazar, MD, Fundacion Cardiovascular de Colombia, Floridablanca, Colombia

Robert Shaddy, MD, The Children's Hospital, Los Angeles, CA, USA

Jeffrey Towbin, MD, Le Bonheur Children's Hospital, Memphis, TN, USA

### Course Summary

This course is designed for pediatric cardiologists, early career professionals and advance practice nurses with an interest in pediatric heart failure. Each section is designed with focused, didactic lectures followed by an interactive Q&A. The course will start by covering general topics of pediatric heart failure – epidemiology, pathophysiology and etiology of pediatric heart failure. The course will then move to the diagnostic approach and medical management of pediatric heart failure, including a section on acute decompensated heart failure. The course will then cover the topics of a multi-disciplinary approach to heart failure as well as activity restrictions, precautions and the management of co-morbidities. Next, the timing and outcomes of advanced heart failure therapies will be discussed. The course will conclude with a discussion on unique patient populations (including heart failure in congenital heart disease) as well as future directions of heart failure therapies and research topics to progress the field of pediatric heart failure.

### Educational Goals

The educational goals of this activity are to provide a concise review of clinical knowledge and essential professional skills to facilitate the development of core skills, diagnostic approach and management interventions to provide comprehensive care to pediatric heart failure patients.

### Target Audience

While all members are invited to enroll, this course is primarily designed to be of benefit for clinicians and allied health professionals who are in the early stages of their careers, or who are in training and/or are part of a new program, or desire an update on the current state of the field. The information presented covers core competencies and is intended to provide a strong foundation of the overarching principles of pediatric heart failure, rather than as a detailed update for those who are already proficient experts in the field.

### Learning Objectives

At the conclusion of this academy, participants will have improved competence and professional performance in their ability to:

1. Discuss the different etiologies, natural history, pathophysiology and prognosis of pediatric heart failure.
2. Understand diagnostic approaches and therapies for acute and chronic heart failure.
3. Recognize challenges, co-morbidities, and complications in the multidisciplinary care of pediatric heart failure.

## Accreditation & Credit Designation Statements

### Physicians

Accreditation Statement - The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement - ISHLT designates this live activity for a maximum of 7.50 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### Nurses

In support of improving patient care, this activity has been planned and implemented by Amedco and the International Society for Heart & Lung Transplantation. Amedco is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 7.50 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

### Disclosure

Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker's presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.

## Scientific Program

<b>7:00 AM – 7:55 AM</b>	<b>REGISTRATION AND MORNING COFFEE</b>
<b>7:55 AM – 8:00 AM</b>	<b>WELCOME AND OVERVIEW</b> Ryan Butts, MD, University of Texas Southwestern, Dallas, TX, USA
<b>8:00 AM - 9:10 AM</b>	<b>SESSION 1 – DEFINING THE PROBLEM: PEDIATRIC HEART FAILURE</b> <b>CHAIR:</b> Rachel Andrews, FRCPC
<b>8:00 AM</b>	<i>What is Heart Failure &amp; Who Gets It? Definitions, Etiologies and Natural History</i> Joseph Rossano, MD, Children's Hospital of Philadelphia, Philadelphia, PA, USA
<b>8:15 AM</b>	<i>Symptoms, Signs &amp; Staging of Pediatric Heart Failure</i> Ryan Butts, MD, University of Texas Southwestern, Dallas, TX, USA
<b>8:30 AM</b>	<i>Cellular and Genetic Basis of Pediatric Heart Failure</i> Jeffrey Towbin, MD, Le Bonheur Children's Hospital, Memphis, TN, USA
<b>8:45 AM</b>	<b>Q&amp;A with Panel</b>
<b>9:00 AM – 10:00 AM</b>	<b>SESSION 2 – DIAGNOSIS AND TESTING IN PEDIATRIC HEART FAILURE</b> <b>CHAIR:</b> Jennifer Conway, MD
<b>9:00 AM</b>	<i>What Can Laboratory Values Tell Me about My Patient in Heart Failure?</i> Claire Irving, FRACP, MD, Children's Hospital Westmead, Sydney, Australia
<b>9:15 AM</b>	<i>What Imaging Should I Do in My Patient with Heart Failure?</i> Paul F. Kantor, MBBCh, FRCPC, Stollery Children's Hospital, Univ of Alberta, Edmonton, AB, Canada
<b>9:30 AM</b>	<i>What Testing is Useful in the Follow-up of Patients with Heart Failure?</i> Heather T. Henderson, MD, Medical University of South Carolina, Charleston, SC, USA
<b>9:45 AM</b>	<b>Q&amp;A with Panel</b>
<b>10:00 AM – 10:30 AM</b>	<b>COFFEE BREAK</b>

- 10:30 AM – 11:30 AM**    **SESSION 3 – ACUTE HEART FAILURE IN PEDIATRICS**  
**CHAIR:** Ryan Butts, MD
- 10:30 AM**                    *Diagnosing and Managing Acute Decompensated Heart Failure*  
Joseph Rossano, MD, Children’s Hospital of Philadelphia, Philadelphia, PA, USA
- 10:45 AM**                    *Using Mechanical Circulatory Support in Acute Decompensated Heart Failure*  
Robert Jaquiss, MD, Children’s Medical Center, Dallas, TX, USA
- 11:00 AM**                    *Myocarditis: More than just Whether or Not to Give IVIG---Case Presentation*  
Leonardo Salazar, MD, Fundacion Cardiovascular de Colombia, Floridablanca, Colombia
- 11:15 AM**                    **Q&A with Panel**
- 11:30 AM – 12:30 PM**    **LUNCH / NETWORKING BREAK (a box lunch is included in the registration fee)**
- 12:30 PM – 1:45 PM**    **SESSION 4 – CHRONIC HEART FAILURE IN PEDIATRICS**  
**CHAIR:** Claire Irving, FRACP, MD
- 12:30 PM**                    *The Multidisciplinary Approach to Heart Failure Management*  
Jodie Lantz, MSN, RN, PCNSBC, Children's Health Dallas, Dallas, TX, USA
- 12:45 PM**                    *Medications for Chronic Heart Failure*  
Rachel Andrews, FRCPC, Great Ormond Street Hospital for Children, London, UK
- 1:00 PM**                    *Recognizing and Managing Comorbidities*  
Jack F. Price, MD, Texas Children’s Hospital, Houston, TX, USA
- 1:15 PM**                    *Promotion of Healthy Lifestyle*  
Anne Dipchand, MD, Hospital for Sick Children, Toronto, ON, Canada
- 1:30 PM**                    **Q&A with Panel**
- 1:45 PM - 2:45 PM**    **SESSION 5 – ADVANCED HEART FAILURE THERAPIES**  
**CHAIR:** Heather T. Henderson, MD
- 1:45 PM**                    *Arrhythmia’s, Pacers, ICD’s and CRT*  
Michael P. Carboni, MD, Duke Children's Hospital, Durham, NC, USA
- 2:00 PM**                    *Advanced Circulatory Support*  
Jennifer Conway, MD, Stollery Children’s Hospital, University of Alberta, Edmonton, AB, Canada
- 2:15 PM**                    *When is it Time to Talk Transplant?*  
Richard Kirk, FRCP, FRCPC, University of Texas Southwestern Medical Center, Dallas, TX, USA
- 2:30 PM**                    **Q&A with Panel**
- 2:45 PM - 3:15 PM**    **COFFEE BREAK**
- 3:15 PM - 4:15 PM**    **SESSION 6 – UNIQUE PATIENT POPULATIONS**  
**CHAIR:** Heather T. Henderson, MD
- 3:15 PM**                    *Managing Chemotherapy-Induced Cardiomyopathy*  
Rachel Andrews, FRCPC, Great Ormond Street Hospital for Children, London, UK
- 3:30 PM**                    *Managing Neuromuscular Cardiomyopathy*  
Claire Irving, FRACP, MD, Children’s Hospital Westmead, Sydney, Australia
- 3:45 PM**                    *Heart Failure in the Single Ventricle Patient*  
Jennifer Conway, MD, Stollery Children’s Hospital, University of Alberta, Edmonton, AB, Canada

**4:00 PM**

**Q&A with Panel**

**4:15 PM - 5:15 PM**

**SESSION 7 – DEBATE: FUTURE DIRECTIONS AND RESEARCH IN PEDIATRIC HEART FAILURE: REGISTRY VS RANDOMIZED CONTROL TRIALS**  
**CHAIR:** Joseph Rossano, MD

**4:15 PM**

*Randomized Trials in Pediatric Heart Failure and Why We Need Them*  
Robert Shaddy, MD, The Children's Hospital, Los Angeles, CA, USA

**4:25 PM**

*Research from Registries in Heart Failure and Why We Need Them*  
Anne Dipchand, MD, Hospital for Sick Children, Toronto, ON, Canada

**4:35 PM**

*Rebuttal*  
Robert Shaddy, MD, Children's Hospital, Philadelphia, PA, USA

**4:40 PM**

*Rebuttal*  
Anne Dipchand, MD, Hospital for Sick Children, Toronto, ON, Canada

**4:45 PM**

**Q&A with Panel**

**5:00 PM**

**SUMMARY / EVALUATION**  
Heather T. Henderson, MD Medical University of South Carolina, Charleston, SC, USA

**5:15 PM**

**ADJOURN**

**ISHLT ACADEMY: MASTER CLASS IN HEART FAILURE AND TRANSPLANTATION****Scientific Program Chairs**

Chair: Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria  
 Co-Chair: Lynn Punnoose, MD, Vanderbilt University, Nashville, TN, USA

**Case Moderators**

Patricia Chang, MD, MHS, University of North Carolina, Chapel Hill, NC, USA  
 Hannah Copeland, MD, University of Mississippi Medical Center, Jackson, MS, USA  
 Heather Ross, MD, MHSc, FRCP (C), FACC, University of Toronto, Toronto, ON, Canada  
 Luciano Potena, MD, PhD, University of Bologna, Bologna, Italy

**Case Discussants**

Luke Burchill, MBBS, PhD, FRACP, Oregon Health and Science University, Portland, Oregon, USA  
 Maria Crespo-Leiro, MD, Hospital Universitario a Coruna, La Coruna, Spain  
 Marta Farrero Torres, MD, PhD, Hospital Clinic de Barcelona, Barcelona, Spain  
 Steven Tsui, MD, FRCS, Papworth Hospital NHS Trust, Cambridge, UK

**Course Summary**

The HFTX Master Class is designed for clinicians with higher levels of expertise in advanced heart failure and transplantation (completed the core curriculum course on HFTX and/or primary practice in advanced heart failure management ( $\geq 5$  years)). The course format is intended to generate highly interactive discussion among experienced users of these technologies, in order to tackle the most complex nuances of managing these complex patients. Rather than didactic lectures, this course will employ the concept of “convergent discussion” composed of small groups. Faculty moderators and case discussants will engage the audience by focusing on areas with gaps in knowledge and absence of consensus in the field. The case-based format will allow moderators and discussants to use real-world complex situations in order to lead the group through active audience participation towards specific answers designed to address the practice gaps and learning objectives.

**Practice Gaps**

1. Transplant clinicians lack the immunology expertise required to effectively integrate the results of HLA antibody testing into patient management.
2. The diagnostic and therapeutic approaches to cardiac allograft rejection are evolving, and transplant clinicians face difficulties in incorporating newer diagnostic modalities such as MRI, molecular diagnostics, and newer immunosuppressive agents into current algorithms.
3. Specific approaches to optimize the matching of donor hearts to the most appropriate recipients are not well delineated for clinicians.
4. With the availability of multiple combinations of immunosuppressive agents, some transplant clinicians lack the expertise required to select the most effective agents for different subgroups of patients and to individualize immunosuppression to prevent or minimize long-term complications.

**Target Audience**

This course has been developed for cardiologists, cardiothoracic surgeons, nurses, advanced practice providers, and allied health professionals with at least 5 years of experience in the field of heart transplantation/advanced heart failure or who have attended a prior ISHLT core competency course in advanced heart failure and cardiac transplant medicine. While all members are invited to enroll, Master Classes are primarily designed to be of benefit for health care and allied professionals who are beyond the training stages of their careers. This may be professionals who are seeking additional proficiencies, who wish to understand current areas of controversy, or who desire an update on the current advanced topics of the field. The information presented is intended to provide insights beyond core competencies established in the specialty.

**Objectives**

After completion of this Class, participants will have improved competence and professional performance in their ability to:

1. Identify the risk of HLA sensitization on cardiac rejection and outcomes, management strategies for sensitized patients pre-transplant and approach to heart transplant recipients with antibody-mediated rejection.
2. Understand perioperative strategies for (a) assessing extended-criteria (marginal) heart donors and optimizing outcomes after transplantation and (b) identifying type and severity of primary graft dysfunction (PGD), including donor, procedural and recipient risk factors for PGD; signs of PGD during reperfusion and challenges with weaning off cardio - pulmonary bypass.
3. Evaluate the candidacy of adults with congenital heart disease for heart transplant, incorporating prognostic testing, and relative contraindications to transplant in this high-risk population. Develop insights into mechanisms of late graft

dysfunction, including (a) role of CAV and rejection, (b) diagnostic strategies including IVUS, OCT and MRI, and (c) treatment strategies including modification in immunosuppression and decision for re-transplant.

## **Accreditation & Credit Designation Statements**

### **Physicians**

Accreditation Statement - The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement - ISHLT designates this live activity for a maximum of 4.25 *AMA PRA Category 1 Credit(s)*<sup>TM</sup>. Offered in the morning and repeated in the afternoon. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **Nurses**

In support of improving patient care, this activity has been planned and implemented by Amedco and the International Society for Heart & Lung Transplantation. Amedco is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 4.25 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

### **Disclosure**

Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker's presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. Please refer to the Participant Notification document for a list of all disclosures. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.

## **Scientific Program – Morning Course**

<b>8:00 AM – 8:10 AM</b>	<b>WELCOME AND OVERVIEW</b> Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria Lynn Punnoose, MD, Vanderbilt University, Nashville, TN, USA
<b>8:10 AM – 10:15 AM</b>	<b>SMALL GROUP INTERACTIVE DISCUSSION A: SENSITIZATION AND ANTIBODY MEDIATED REJECTION (AMR)</b> <b>Moderator:</b> Patricia Chang, MD, MHS  <b>CASE SCENARIO A1: Sensitized LVAD Patient with Chronic Infection</b> Patricia Chang, MD, MHS, University of North Carolina, Chapel Hill, NC, USA  <b>CASE SCENARIO A2: Asymptomatic AMR Management</b> Maria G. Crespo-Leiro, MD, Hospital University A Coruna, La Coruna, Spain  <b>SMALL GROUP INTERACTIVE DISCUSSION B: DONOR SELECTION AND PRIMARY GRAFT DYSFUNCTION</b> <b>Moderator:</b> Hannah Copeland, MD  <b>CASE SCENARIO B1: Approach to the Extended Criteria (Marginal) Donor</b> Hannah Copeland, MD, University of Mississippi Medical Center, Jackson, MS, USA  <b>CASE SCENARIO B2: Identification and Diagnosis of Primary Graft Dysfunction</b> Steven Tsui, MD, FRCS, Papworth Hospital NHS Trust, Cambridge, UK
<b>10:15 AM – 10:45 AM</b>	<b>COFFEE BREAK</b>
<b>10:45 AM – 12:50 PM</b>	<b>SMALL GROUP INTERACTIVE DISCUSSION C: RECIPIENT SELECTION (CONGENITAL HEART DISEASE)</b> <b>Moderator:</b> Heather Ross, MD, MHSc, FRCP (C), FACC

**CASE SCENARIO C1: Timing of Transplantation in Adult Congenital Heart Disease**  
Heather Ross, MD, MHSc, FRCP (C), FACC, University of Toronto, Toronto, ON, Canada

**CASE SCENARIO C2: Transplant as a Strategy for the Failing Fontan Patient**  
Luke Burchill, MBBS, FRACP, Oregon Health and Science University, Portland, Oregon, USA

**SMALL GROUP INTERACTIVE DISCUSSION D: LONG TERM CHALLENGES IN TRANSPLANT (LATE GRAFT DYSFUNCTION, CANCER)**  
**Moderator: Luciano Potena, MD, PhD**

**CASE SCENARIO D1: Late Graft Dysfunction**  
Marta Farrero Torres, MD, PhD, Hospital Clinic de Barcelona, Barcelona, Spain  
Luciano Potena, MD, PhD, University of Bologna, Bologna, Italy

**CASE SCENARIO D2: Malignancy in the Heart Transplant Patient**  
Luciano Potena, MD, PhD, University of Bologna, Bologna, Italy  
Marta Farrero Torres, MD, PhD, Hospital Clinic de Barcelona, Barcelona, Spain

**12:50 PM – 1:00 PM** **CLOSING REMARKS/EVALUATION**  
Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria  
Lynn Punnoose, MD, Vanderbilt University, Nashville, TN, USA

**1:00 PM** **ADJOURN**

### **Scientific Program – Afternoon Course**

**2:00 PM – 2:10 PM** **WELCOME AND OVERVIEW**  
Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria  
Lynn Punnoose, MD, Vanderbilt University, Nashville, TN, USA

**2:10 PM – 4:10 PM** **SMALL GROUP INTERACTIVE DISCUSSION A: SENSITIZATION AND ANTIBODY MEDIATED REJECTION (AMR)**  
**Moderator: Patricia Chang, MD, MHS**

**CASE SCENARIO A1: Sensitized LVAD Patient with Chronic Infection**  
Patricia Chang, MD, MHS, University of North Carolina, Chapel Hill, NC, USA

**CASE SCENARIO A2: Asymptomatic AMR Management**  
Maria G. Crespo-Leiro, MD, Hospital University A Coruna, La Coruna, Spain

**SMALL GROUP INTERACTIVE DISCUSSION B: DONOR SELECTION AND PRIMARY GRAFT DYSFUNCTION**  
**Moderator: Hannah Copeland, MD**

**CASE SCENARIO B1: Approach to the Extended Criteria (Marginal) Donor**  
Hannah Copeland, MD, University of Mississippi Medical Center, Jackson, MS, USA

**CASE SCENARIO B2: Identification and Diagnosis of Primary Graft Dysfunction**  
Steven Tsui, MD, FRCS, Papworth Hospital NHS Trust, Cambridge, UK

**4:15 PM – 4:45 PM** **COFFEE BREAK**

**4:45 PM – 6:50 PM** **SMALL GROUP INTERACTIVE DISCUSSION C: RECIPIENT SELECTION (CONGENITAL HEART DISEASE)**  
**Moderator: Heather Ross, MD, MHSc, FRCP (C), FACC**

**CASE SCENARIO C1: Timing of Transplantation in Adult Congenital Heart Disease**  
Heather Ross, MD, MHSc, FRCP (C), FACC, University of Toronto, Toronto, ON, Canada

**CASE SCENARIO C2: Transplant as a Strategy for the Failing Fontan Patient**



Luke Burchill, MBBS, FRACP, Oregon Health and Science University, Portland, Oregon, USA

**SMALL GROUP INTERACTIVE DISCUSSION D: LONG TERM CHALLENGES IN TRANSPLANT (LATE GRAFT DYSFUNCTION, CANCER)**

**Moderator: Luciano Potena, MD, PhD**

**CASE SCENARIO D1: Late Graft Dysfunction**

Marta Farrero, MD, PhD, Hospital Clinic de Barcelona, Barcelona, Spain

Luciano Potena Torres, MD, PhD, University of Bologna, Bologna, Italy

**CASE SCENARIO D2: Malignancy in the Heart Transplant Patient**

Luciano Potena, MD, PhD, University of Bologna, Bologna, Italy

Marta Farrero Torres, MD, PhD, Hospital Clinic de Barcelona, Barcelona, Spain

**6:50 PM – 7:00 PM**

**CLOSING REMARKS/EVALUATION**

Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria

Lynn Punnoose, MD, Vanderbilt University, Nashville, TN, USA

**7:00 PM**

**ADJOURN**

## ISHLT ACADEMY: MASTER CLASS IN MECHANICAL CIRCULATORY SUPPORT

### Scientific Program Chairs

Chair: Susan Joseph, MD, Baylor University and Vascular Hospital, Dallas, TX, USA

Co-Chair: Daniel Zimpfer, MD, MBA, Medical University of Vienna, Vienna, Austria

### Case Moderators

Jens Garbade, MD, PhD, MHBA, University of Leipzig, Leipzig, Germany

Finn Gustafsson, MD, PhD, Rigshospitalet, Copenhagen, Denmark

Scott Silvestry, MD, Florida Hospital Transplant Network, Orlando, FL, USA

Melana Yuzefpolskaya, MD, New York-Presbyterian/Columbia University Medical Center, New York, NY, USA

### Case Discussants

Peter Eckman, MD, Minneapolis Heart Institute, Minneapolis, MN, USA

Kelsey Flint, MD, University of Colorado, Aurora, CO, USA

P. Christian Schulze, MD, PhD, University Hospital Jena, Jena, Germany

Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, ON, Canada

### Course Summary

The MCS Master Class is designed for clinicians with higher levels of expertise in MCS (completed the core curriculum course on MCS and/or primary practice in MCS ( $\geq 5$  years)). The course format is intended to generate highly interactive discussion among experienced users of these technologies, in order to tackle the most complex nuances of managing these complex patients. Rather than didactic lectures, this course will employ the concept of “convergent discussion” composed of small groups. Faculty moderators and case discussants will engage the audience by focusing on areas with gaps in knowledge and absence of consensus in the field. The case-based format will allow moderators and discussants to use real-world complex situations in order to lead the group through active audience participation, towards specific answers designed to address the practice gaps and learning objectives.

### Practice Gaps

1. The outcomes of cardiogenic shock have remained poor, large randomized trials are scarce and the management of these patients remains challenging. Comprehensive clinical expertise of advanced usage of evolving MCS options including patient and device selection and transition to next step therapies continue to constitute major limitations in the care of these critically ill patients. Knowledge in this area is rapidly evolving and frequent updates are necessary.
2. The diagnosis and management of complex and combined adverse events such as cerebrovascular hemorrhagic accidents, device thrombosis and gastrointestinal bleeding is challenging and practitioners often face difficulties in developing effective strategies to appropriately identify and treat these adverse events. Recent improvements in device technology have eliminated thrombosis and new anticoagulation strategies continue to evolve.
3. The diagnostic and therapeutic approaches for early and late right ventricular failure in MCS patients have been evolving with the introduction of new diagnostic criteria and new technologies/therapeutic options. Such practice gaps in specialist knowledge and clinical skills constitute major limitations in the care of MCS patients.
4. The implantation of results from large clinical studies such as MOMENTUM 3 and ENDURENCE supplement into clinical practice is still lagging. The Master Academy will review the information from those studies and discuss their use in daily practice.

### Target Audience

This course has been developed for cardiac and mechanical circulatory support surgeons, advanced heart failure cardiologists, VAD Coordinators, and allied health professionals with at least 5 years of experience in the field of mechanical circulatory support or who have attended a prior ISHLT core competency course in mechanical circulatory support. While all members are invited to enroll, Master Classes are primarily designed to be of benefit for health care professionals who are beyond the training stages of their careers. This may be professionals who are seeking additional proficiencies, who wish to understand current areas of controversy, or who desire an update on the current advanced topics of the field. The information presented is intended to provide insights beyond core competencies established in the specialty.

### Educational Need

Mechanical circulatory support is a rapidly growing and rapidly evolving therapy for advanced heart failure. There are now several options approved for use to support patients both acutely in the short term, as well as for durable support. Optimizing outcomes and survival in these complex patients requires mastery of the identification of cardiogenic shock phenotypes, knowledge of device choice and timing, as well as pre-operative optimization of these patients. Multidisciplinary teams are an essential part of modern day

mechanical circulatory support management. This Class is designed to meet the target audience's need for an advanced learning opportunity that explores and seeks to address the unique clinical challenges faced by specialists and developing experts in the field of MCS for treatment of heart failure patients.

## Objectives

After completion of this Class, participants will have improved competence and professional performance in their ability to:

1. Identify patients with cardiogenic shock, including complex presentation, appropriate devices for short-term mechanical circulatory support, and factors impacting transition to longer term support platforms.
2. Understand the management of durable MCS patients with complex hemo-compatibility related adverse events, including recurrent GI bleed, bleeding in the setting of thrombosis, or the patient with a history of confounding events (i.e. bleeding and thrombosis).
3. Review predictors of early and late right ventricular failure post LVAD implantation, understand the utility of presently available risk scores, and identify management strategies.
4. Understand the implications of the Momentum 3 and Endurance clinical trials for clinical practice.

## Accreditation & Credit Designation Statements

### Physicians

Accreditation Statement - The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement - ISHLT designates this live activity for a maximum of 4.25 *AMA PRA Category 1 Credit(s)*<sup>TM</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### Nurses

In support of improving patient care, this activity has been planned and implemented by Amedco and the International Society for Heart & Lung Transplantation. Amedco is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 4.25 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

## Disclosure

Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker's presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. Please refer to the Participant Notification document for a list of all disclosures. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.

## Scientific Program – Morning Course

**8:00 AM – 8:10 AM**

### **WELCOME AND OVERVIEW**

Susan Joseph, MD, Baylor University and Vascular Hospital, Dallas, TX, USA  
Daniel Zimpfer, MD, MBA, Medical University of Vienna, Vienna, Austria

**8:10 AM – 10:15 AM**

### **SMALL GROUP INTERACTIVE DISCUSSION A: IABP, ECMO AND BEYOND - SHORT TERM MCS FOR PROFOUND CARDIOGENIC SHOCK / INTERMACS 0-1 PROFILES**

**Moderator:** Jens Garbade, MD, PhD, MHBA

#### **CASE SCENARIO A1: Short-Term MCS for Cardiogenic Shock: Timing and Device Selection**

Jens Garbade, MD, PhD, MHBA, University of Leipzig, Leipzig, Germany

#### **CASE SCENARIO A2: MCS Weaning and Transition to Permanent MCS**

P. Christian Schulze, MD, PhD, University Hospital Jena, Jena, Germany

### **SMALL GROUP INTERACTIVE DISCUSSION B: TO PULSE OR NOT TO PULSE: IMPLICATIONS ON COAGULATION AND PHYSIOLOGY**

Moderator: Scott Silvestry, MD, Florida Hospital Transplant Institute, Orlando, FL, USA

#### **CASE SCENARIO B1: Bleeding and Clotting and Both, Oh My!**

Scott Silvestry, MD, Florida Hospital Transplant Institute, Orlando, FL, USA

**CASE SCENARIO B2: Systemic Infection, Stroke and Secondary Bleeding – The Unhappy Triad of VAD Therapy**

Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, ON, Canada

**10:15 AM – 10:45 AM COFFEE BREAK**

**10:45 AM – 12:50 PM SMALL GROUP INTERACTIVE DISCUSSION C: PATIENT SELECTION AND PRE-OPERATIVE OPTIMIZATION**

**Moderator:** Melana Yuzefpolskaya, MD

**CASE SCENARIO C1: The RV Looks “Bad” - Strategies for Management**

Melana Yuzefpolskaya, MD, New York-Presbyterian/Columbia University Medical Center, New York, NY, USA

**CASE SCENARIO C2: The Patient Looks Frail- Should We Move Forward?**

Kelsey Flint, MD, University of Colorado, Aurora, CO, USA

**SMALL GROUP INTERACTIVE DISCUSSION D: LONG TERM MANAGEMENT OF THE LVAD RECIPIENT**

**Moderator:** Finn Gustafsson, MD, PhD

**CASE SCENARIO D1: What to Do with ICD: Pacing Strategies and Minimizing Shocks**

Finn Gustafsson, MD, PhD, Rigshospitalet, Copenhagen, Denmark

**CASE SCENARIO D2: Low Flow Alarms and Blood Pressure Management: Nuances Among Different Devices**

Peter Eckman, MD, Minneapolis Heart Institute, Minneapolis, MN, USA

**12:50 PM – 1:00 PM CLOSING REMARKS/EVALUATION**

Susan Joseph, MD, Baylor University and Vascular Hospital, Dallas, TX, USA

Daniel Zimpfer, MD, MBA, Medical University of Vienna, Vienna, Austria

**1:00 PM ADJOURN**

**Scientific Program – Afternoon Course**

**2:00 PM – 2:10 PM WELCOME AND OVERVIEW**

Susan Joseph, MD, Baylor University and Vascular Hospital, Dallas, TX, USA

Daniel Zimpfer, MD, MBA, Medical University of Vienna, Vienna, Austria

**2:10 PM – 4:15 PM SMALL GROUP INTERACTIVE DISCUSSION A: IABP, ECMO AND BEYOND - SHORT TERM MCS FOR PROFOUND CARDIOGENIC SHOCK / INTERMACS 0-1 PROFILES**

**Moderator:** Jens Garbade, MD, PhD, MHBA

**CASE SCENARIO A1: Short-Term MCS for Cardiogenic Shock: Timing and Device Selection**

Jens Garbade, MD, PhD, MHBA, University of Leipzig, Leipzig, Germany

**CASE SCENARIO A2: MCS Weaning and Transition to Permanent MCS**

P. Christian Schulze, MD, PhD, University Hospital Jena, Jena, Germany

**SMALL GROUP INTERACTIVE DISCUSSION B: TO PULSE OR NOT TO PULSE: IMPLICATIONS ON COAGULATION AND PHYSIOLOGY**

**Moderator:** Scott Silvestry, MD, Florida Hospital Transplant Institute, Orlando, FL, USA

**CASE SCENARIO B1: Bleeding and Clotting and Both, Oh My!**

Scott Silvestry, MD, Florida Hospital Transplant Institute, Orlando, FL, USA

**CASE SCENARIO B2: Systemic Infection, Stroke and Secondary Bleeding – The Unhappy Triad of**

**VAD Therapy**

Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, ON, Canada

**4:15 PM – 4:45 PM**

**COFFEE BREAK**

**4:45 AM – 6:50 PM**

**SMALL GROUP INTERACTIVE DISCUSSION C: PATIENT SELECTION AND PRE-OPERATIVE OPTIMIZATION**

**Moderator:** Melana Yuzefpolskaya, MD

**CASE SCENARIO C1: The RV Looks “Bad” - Strategies for Management**

Melana Yuzefpolskaya, MD, New York-Presbyterian/Columbia University Medical Center, New York, NY, USA

**CASE SCENARIO C2: The Patient Looks Frail- Should We Move Forward?**

Kelsey Flint, MD, University of Colorado, Aurora, CO, USA

**SMALL GROUP INTERACTIVE DISCUSSION D: LONG TERM MANAGEMENT OF THE LVAD RECIPIENT**

**Moderator:** Finn Gustafsson, MD, PhD

**CASE SCENARIO D1: What to Do with ICD: Pacing Strategies and Minimizing Shocks**

Finn Gustafsson, MD, PhD, Rigshospitalet, Copenhagen, Denmark

**CASE SCENARIO D2: Low Flow Alarms and Blood Pressure Management: Nuances Among Different Devices**

Peter Eckman, MD, Minneapolis Heart Institute, Minneapolis, MN, USA

**6:50 PM – 7:00 PM**

**CLOSING REMARKS/EVALUATION**

Susan Joseph, MD, Baylor University and Vascular Hospital, Dallas, TX, USA

Daniel Zimpfer, MD, MBA, Medical University of Vienna, Vienna, Austria

**7:00 PM**

**ADJOURN**

## **ISHLT AFFILIATE EVENTS**

(as of March 20, 2019)

### **Tuesday, April 2, 2019**

12:00 PM – 6:00 PM

Toronto Annual Lung Transplant Biospecimen Workshop  
(Hard Rock Café)

2:00 PM - 6:00 PM

Infectious Diseases/HCV Consensus Document  
Consensus Statement on the Use of Hepatitis C Virus-Infected Organ Donors for Cardiothoracic Transplantation  
(Grand Caribbean 8-10)

6:00 PM - 9:00 PM

Advanced Cardiac Therapies Improving Outcomes Network (ACTION) Learning Network Meeting  
(Oceana 3)

### **Wednesday, April 3, 2019**

7:00 AM – 7:45 AM

SUSTAIN-IT Trial Investigator Meeting  
(St. Croix 1)

12:15 PM – 1:45 PM

Cystic Fibrosis Foundation Lung Transplant Initiative Surgeon Lunch  
(Caicos 5)

12:15 PM – 1:30 PM

PEDS Council Pediatric Lung Failure Workforce Meeting  
(St. Croix 1)

12:30 PM – 1:30 PM

Donor Heart Selection Consensus Paper Meeting  
(Grand Caribbean 10)

12:30 PM – 2:00 PM

MCS Guidelines Update Task Force Meeting  
(Turks 1)

12:45 PM - 1:45 PM

Pediatrics Council – Donor Consensus Document Meeting  
(Caicos 3)

6:00 PM - 8:00 PM

UPMC Cocktail Reception  
(Grand Caribbean 12)

6:15 PM - 10:00 PM

ICCAC Annual Meeting  
(Oceana 3-5)

### **Thursday, April 4, 2019**

7:00 AM – 8:00 AM

ISHLT Consensus Statement on Lung Transplantation in Patients with Connective Tissue Disease (CTD): Epidemiology, Risk Factors, Candidate Selection Criteria, Surgical and ICU management and Post-transplant care” SSc Subgroup Meeting  
(Admiralty Boardroom)

9:45 AM – 10:15 AM

BAL Standardization Workforce Meet and Greet

(Caicos 3)

12:00 PM– 12:45 PM

ID Council Symposia Submission Working Group Meeting

(Oceana 1)

12:00 PM - 1:30 PM

Junior Faculty and Trainee Council Planning Session for ISHLT2020 Symposium Development

(St. Croix 1)

12:00 PM - 1:45 PM

Pulmonary Transplant Council Quality of Life Workforce Meeting

(Admiralty Boardroom)

12:00 PM – 1:45 PM

NIH-Funded DTRT Investigators Meeting

(Barbados Boardroom)

12:10 PM – 1:10 PM

ISHLT Consensus Statement on Lung Transplantation in Patients with Connective Tissue Disease (CTD): Epidemiology, Risk Factors, Candidate Selection Criteria, Surgical and ICU management and Post-transplant care” Chairs and Co-Chairs Meeting

(Grand Caribbean 12)

12:30 PM – 1:30 PM

STS INTERMACS Taskforce Committee Meeting

(St. Croix 2)

12:45 PM – 1:30 PM

ID Council Workforce: Optimizing Outcomes in Older Thoracic Transplant and MCSD Recipients Group Meeting

(Oceana 1)

3:30 PM – 4:00 PM

Education Workforce Leaders Group Meeting

(Barbados Boardroom)

7:15 - 8:15 pm

International Engagement Committee Latin America Regional Meeting

(Oceana 3-5)

## **Friday, April 5**

7:00 AM-8:00 AM

EUROMACS Committee Meeting

(Barbados Boardroom)

7:30 AM – 8:00 AM

Peri-operative PH Consensus Workgroup Meeting

(Admiralty Boardroom)

12:30 PM – 2:00 PM

SimVAD Study Investigators Meeting

(Grand Caribbean 10)

7:15 - 8:15 pm

International Engagement Committee Asia Pacific Regional Meeting

(Oceana 3-5)

## **ISHLT CORPORATE EVENTS and INDUSTRY THEATERS**

(as of March 19, 2019)

### **Wednesday, April 3, 2019**

12:30 PM – 1:30 PM

TAI Diagnostics Lunch Symposium

Cell-free DNA Done Right! An Overview of the myTAIHEART™ Test and Examples of its Clinical Application in Monitoring of Heart Transplant Rejection.

(Private event, pre-registration required)

(Oceana 3-5)

12:15 PM – 2:00 PM

SynCardia Symposium

Patient Selection for MCS – The Right Patient, The Right Time and The Right Device

(Grand Caribbean 11)

12:30 PM – 1:30 PM

Medtronic Lunch Symposium

Don't Be Misled...A Scientific Analysis of VAD Data

(Oceana 1)

12:30 PM – 1:30 PM

Bayer Industry Theater

Evolutions in CTEPH: Then & Now

(Oceana 2)

8:00 PM – 10:00 PM

CareDX, Inc. Reception

(Cayman Court)

### **Thursday, April 4, 2019**

7:00 AM – 8:00 AM

NuPulse iVas Study Meeting

(Barbados Boardroom)

9:45 AM – 10:15 AM

TandemLife | LivaNova Industry Theater

MCS: Who, What, When, Where, and Why

(Oceana 2)

12:00 PM – 1:00 PM

One Lambda, Inc., A Thermo Fisher Scientific Brand Industry Theater

The Journey from DSA to Molecular Microscope® in Heart & Lung Transplant Recipients

(Oceana 2)

12:00 PM – 1:45 PM

TransMedics Organ Care System (OCS™)

State-of-the-Art Thoracic Organ Perfusion Symposium – Redefining What's Possible in Heart and Lung Transplantation

(Oceana 3-5)

12:00 PM – 1:45 PM

CareDX, Inc. Lunch Symposium

HeartCare: Comprehensive Surveillance for Personalized Transplant Care

(Pacifica 10-12)

12:00 PM – 2:00 PM

Paragonix SherpaPak™

CTS 2019 International Heart Summit

(Grand Caribbean 10)



12:15 PM – 1:15 PM  
Medtronic Athena Physician Update Meeting  
(Grand Caribbean 11)

6:00 PM – 7:00 PM  
SynCardia Symposium  
Red Flags, Inflow, Outflow, and Obstructions with the Artificial Heart Patient  
(Gardenia 1)

6:00 PM – 9:30 PM  
Bayer CTEPH Mini-Advisory Board Dinner  
(Hard Rock Café)

6:30 PM – 8:30 PM  
United Therapeutics Jenesis Innovative Research Awards Dinner  
(Grand Caribbean 12)

6:30 PM – 8:30 PM  
Medtronic Dinner  
The Power of Strategic Outreach: Successful VAD Programs in Today's Changing Landscape  
(South China Sea)

### **Friday, April 5**


6:30 AM – 8:00 AM  
Medtronic O.H. Frazier Fellowship Recipient Breakfast  
(Grand Caribbean 10)

12:15 PM – 1:15 PM  
XVIVO Perfusion AB Industry Theater  
Ex-Vivo Lung Perfusion – Current Practices and Future Opportunities  
(Oceana 2)

### **Saturday, April 6**

2:00 PM – 4:00 PM  
Biotest AG Corporate Event  
The Role of IgM and DSA Development in Transplantation  
(South China Sea)

# EXHIBIT HALL FLOOR PLAN



**2019 EXHIBITORS AND BOOTH NUMBERS  
BY EXHIBITOR NAME**

<b>BOOTH #</b>	<b>EXHIBITOR NAME</b>
211	Abbott Laboratories
323	Abiomed
105	Acelis Connected Health
107	Actelion Pharmaceuticals US Inc
434	ActiCare Health
429	AdventHealth Transplant Institute
329	Atara Biotherapeutics
127	Bayer
307	Berlin Heart
113	CareDx, Inc.
204	CARMAT
428	CD Leycom
408	CHF Solutions
335	Elsevier
410	Essential Pharmaceuticals
404	Evaheart
232	Getinge
206	Hibernicor LLC
305	Hugo Sachs, Harvard Apparatus
407	ISHLT Mechanically Assisted Circulatory Support Registry (IMACS)
134	International Institute for the Advancement of Medicine – IIAM
423	ISHLT Registries
425	Jackson Health System   Miami Transplant Institute
208	Jarvik Heart, Inc.
433	Kroger Specialty Pharmacy
427	Leviticus Cardio
413	Mallinckrodt Pharmaceuticals
119	Medtronic
417	Memorial Healthcare System
419	Miller Pharmacal Group, Inc.
106	Nebraska Medicine/UNMC
108	One Lambda, Inc. A Thermo Fisher Scientific Brand
409	Paragonix Technologies, Inc.
405	Pediatric Heart Transplant Society (PHTS)
132	Scanlan International, Inc.
235	SynCardia Systems, LLC
133	TAI Diagnostics
415	TandemLife   LivaNova
334	Texas Children’s Hospital
315	TransMedics, Inc.
431	UF Health Transplant Center
205	United Therapeutics
430	University of Chicago Medicine
331	UPMC   University of Pittsburgh Medical Center
227	XVIVO Perfusion AB

**2019 EXHIBITORS AND BOOTH NUMBERS  
BY BOOTH NUMBER**

<b>BOOTH #</b>	<b>EXHIBITOR NAME</b>
105	Acelis Connected Health
106	Nebraska Medicine/UNMC
107	Actelion Pharmaceuticals US Inc
108	One Lambda, Inc. A Thermo Fisher Scientific Brand
113	CareDx, Inc.
119	Medtronic
127	Bayer
132	Scanlan International, Inc.
133	TAI Diagnostics
134	International Institute for the Advancement of Medicine – IIAM
204	CARMAT
205	United Therapeutics
206	Hibernicor LLC
208	Jarvik Heart, Inc.
211	Abbott Laboratories
227	XVIVO Perfusion AB
232	Getinge
235	SynCardia Systems, LLC
305	Hugo Sachs, Harvard Apparatus
307	Berlin Heart
315	TransMedics, Inc.
323	Abiomed
329	Atara Biotherapeutics
331	UPMC   University of Pittsburgh Medical Center
334	Texas Children’s Hospital
335	Elsevier
404	Evaheart
405	Pediatric Heart Transplant Society (PHTS)
407	ISHLT Mechanically Assisted Circulatory Support Registry (IMACS)
408	CHF Solutions
409	Paragonix Technologies, Inc.
410	Essential Pharmaceuticals
413	Mallinckrodt Pharmaceuticals
415	TandemLife   LivaNova
417	Memorial Healthcare System
419	Miller Pharmacal Group, Inc.
423	ISHLT Registries
425	Jackson Health System   Miami Transplant Institute
427	Leviticus Cardio
428	CD Leycom
429	AdventHealth Transplant Institute
430	University of Chicago Medicine
431	UF Health Transplant Center
433	Kroger Specialty Pharmacy
434	ActiCare Health

## 2019 EXHIBITORS PRODUCT DESCRIPTIONS

### **Abbott Laboratories BOOTH No. 211**

100 Abbott Park Road  
Abbott Park, Illinois 60064-3500 USA  
<https://www.abbott.com/>

At Abbott, we're committed to helping you live your best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world — in nutrition, diagnostics, medical devices and branded generic pharmaceuticals — that create more possibilities for more people at all stages of life. Today, 94,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve. Connect with us at [www.abbott.com](http://www.abbott.com), on Facebook at [www.facebook.com/Abbott](https://www.facebook.com/Abbott) and on Twitter @AbbottNews and @AbbottGlobal.

### **Abiomed BOOTH No. 323**

22 Cherry Hill Drive  
Danvers, MA 01923 USA  
<http://www.abiomed.com/>

Abiomed is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. CEO, Chairman, and President Michael R. Minogue has focused the company's efforts on developing ground-breaking technologies designed to improve the patient outcomes focused on native heart recovery. Founded in 1981 for the purpose of developing the world's first artificial heart, Abiomed has remained dedicated to finding ways to bring the most advanced and beneficial technology to patients and physicians.

### **Acelis Connected Health BOOTH No. 105**

6465 National Drive  
Livermore, CA 94550 USA  
<http://www.acelis.com>

At Acelis Connected Health we help individuals manage their health. Our ecosystem of products and services supports the management of people's health away from hospitals and labs with remote monitoring and connected data solutions. With a focus on engaging the individual in their own care, our services center around real-time biometric data management, certified training, and clinical support — creating a comprehensive and effortless digital health experience focused on the individual. Currently, our offerings enable individuals to monitor their warfarin therapy or ventricular assist device implant from their home or wherever they want to be.

### **Actelion Pharmaceuticals US Inc BOOTH No. 107**

5000 Shoreline Court  
South Francisco, CA 94080 USA  
<http://www.actelionus.com>

"In June 2017, Actelion Ltd. became part of the Janssen Pharmaceutical Companies of Johnson & Johnson. The company is a leading biopharmaceutical company focused on the discovery, development, and commercialization of innovative drugs for diseases with significant unmet medical needs."

### **ActiCare Health BOOTH No. 434**

6111 Southfront Road, Suite M  
Livermore, CA 94551 USA  
[www.acticarehealth.com](http://www.acticarehealth.com)

ActiCare Health (Booth #434) offers the first and only VAD, heart transplant and lung transplant tele-health and advanced monitoring platform with 24x7 support, empowering both patients and clinicians to achieve remarkable outcomes with reduced stress. In response to the immense administrative and operational challenges faced by VAD and transplant departments, we've designed a program to provide enhanced visibility into patients' health status, modernize patient safety and communication, optimize discharge plan adherence, and minimize adverse clinical and financial events. Our program is designed to positively affect health outcomes and quality of life, enhance care coordination and staff efficiency, and reduce costs.

**AdventHealth Transplant Institute BOOTH No. 429**

2415 N. Orange Ave, Suite 700

Orlando, FL 32804 USA

<http://www.AdventHealthTransplantInstitute.com>

As the only transplant center in the AdventHealth system and ranked as one of the top transplant facilities in the nation, the AdventHealth Transplant Institute is your multi-organ specialists for all your treatment needs. Along with the best in class physicians and facilities, we provide you with your own transplant team so you're never alone on your journey. Starting back with kidney transplants in 1973, we have created a multi-organ program that is in the top one percent nationally for patient satisfaction, with median transplant wait times and 1-year survival outcomes better than national averages.

**Atara Biotherapeutics BOOTH No. 329**

611 Gateway Blvd

South San Francisco, California 94080 USA

<https://www.atarabio.com/>

Atara Biotherapeutics, Inc. (@Atarabio) is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara's most advanced T-cell immunotherapy, tab-cel® (tabelecleucel), is in Phase 3 development for patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLTD), as well as other EBV-associated hematological malignancies and solid tumors, including nasopharyngeal carcinoma. Atara is also developing T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis.

**Bayer BOOTH No. 127**

100 Bayer Boulevard

Whippany, NJ 07981 USA

<http://www.bayer.com>

Bayer is a global Life Sciences leader in cardiopulmonology, hematology, neurology, oncology and women's health. Building on a 150-year legacy in healthcare, Bayer is committed to improving patient lives by developing innovative therapies and delivering first-in-class educational and support programs to meet their needs. For more information, visit [www.bayer.us](http://www.bayer.us).

**Berlin Heart BOOTH No. 307**

200 Valleywood Rd, Ste B100

The Woodlands, TX 77380 USA

<http://www.berlinheart.com/>

Berlin Heart, the only company worldwide, that develops, manufactures and distributes VADs for patients of every age and body size. EXCOR® Pediatric provides medium to long-term circulatory support specifically for infants and children awaiting heart transplants. EXCOR Pediatric is approved for use in the USA under HDE regulations by FDA.

**CareDx, Inc. BOOTH No. 113**

3260 Bayshore Blvd

Brisbane, CA 94005 USA

[www.CareDx.com](http://www.CareDx.com)

CareDx is a recognized leader in transplant care. We are dedicated to improving the lives of organ transplant patients through innovative and non-invasive diagnostics.

HeartCare is a non-invasive blood test for heart transplant patients. HeartCare provides information about transplant recipient immune activity and donor graft injury, including both AlloMap® (gene expression profiling) and AlloSure-Heart® (donor-derived cell-free DNA analysis).

**CARMAT BOOTH No. 204**

36, avenue de l'Europe - CS 40533  
Velizy-Villacoublay, 78140 FRANCE  
[www.carmatsa.com](http://www.carmatsa.com)

CARMAT (contraction of founders' names Professor Carpentier and Matra – now part of Airbus Group) develops a bioprosthetic implantable artificial heart with its power supply and monitoring systems. Key differentiating features of this device are: use of bovine pericardium for most parts in contact with blood, which potentially reduces thromboembolic risks, and automatically adjustable pulsatile flow in response to patients' physiological needs thanks to embedded sensors and electronics. CARMAT heart is an investigational device only and is not commercially available. The First-in-Man feasibility study was completed early in 2016. A CE MARK pivotal study is currently ongoing in Europe.

**Elsevier BOOTH No. 335**

230 Park Avenue, Suite 800  
New York, NY 10169 USA  
[www.elsevier.com](http://www.elsevier.com)

Elsevier is a world-leading provider of information solutions that help you make better decisions, deliver better care, and sometimes make groundbreaking discoveries in science, health, and technology. We provide web-based, digital solutions - among them ScienceDirect, Scopus, Evolve, Knovel, Reaxys, and ClinicalKey - and publish over 2,500 journals and more than 33,000 book titles.

**Getinge BOOTH No. 232**

45 Barbour Pond Dr  
Wayne, NJ 07470 USA  
<http://www.getinge.com>

Getinge is a leading global provider of innovative solutions for operating rooms, intensive-care units, hospital wards, sterilization departments and for life science companies and institutions. From now on, names you already know like Maquet, Lancer, Atrium, Pulsion, Datascope, Steritec, Getinge, Stericool and Trans will be working even closer together under one brand, Getinge. Our job is to simplify your workflow and raise the bar in terms of how efficient, safe and productive you and your colleagues can be. Getinge offers innovative healthcare solutions that improve every-day life for people, today and tomorrow.

**Hibernicor LLC BOOTH No. 206**

253 Ridge Dr  
Jackson, MS 39216 USA  
<http://www.hibernicor.com>

Hibernicor is a innovative technology company developing the Asporto device which addresses a problem that many donated hearts – about 20 percent – are not used because the current ice cooler method only allows 3-4 hours of transport time. The solution to this problem is Asporto; an microcomputer controlled cardioplegic pump and hypothermic carbon-fiber cooler designed to improve the quality of the donor heart; thus allowing a greater transport distance. Asporto is not FDA or CE approved and is available only for laboratory research. For more information: [www.hibernicor.com](http://www.hibernicor.com)

**Hugo Sachs, Harvard Apparatus BOOTH No. 305**

84 October Hill Rd  
Holliston, MA 01746 USA  
<http://www.harvardapparatus.com>

Hugo Sachs Elektronik provides Advanced Tools for Physiology. It is the industry leader for providing advanced isolated organ and tissue perfusion systems as well as the PLUGSYS modular amplifier system for cardiovascular and respiratory applications. Harvard Apparatus is a major US manufacturer of specialized physiological research laboratory equipment with current headquarters in Holliston, Massachusetts, serving your research needs since 1901. Hugo Sachs and Harvard Apparatus are both part of the Harvard Bioscience family of companies. Harvard Bioscience (Nasdaq: HBIO) is a global developer, manufacturer and marketer of a broad range of specialized products, primarily scientific instruments.

### **ISHLT Mechanically Assisted Circulatory Support Registry (IMACS) BOOTH No. 407**

ZRB 739 703 19th Street South

University of Alabama at Birmingham

Birmingham, AL 35294 USA

<https://www.ishlt.org/registries/international-registry-for-mechanically-assisted-c>

IMACS is an international registry intended to enroll and follow patients who receive durable mechanically assisted circulatory support devices (MCSD) in all countries and hospitals that wish to participate. Durable devices are defined as those devices that are capable of allowing patient discharge with the device in place. The primary goal of the IMACS Registry is to create, implement and analyze a registry that contains high standards for complete enrollment of patients and complete and accurate submission of MCSD data that allows participating centers to engage in important outcomes research about mechanical support devices.

### **International Institute for the Advancement of Medicine - IIAM BOOTH No. 134**

125 May Street

Edison, NJ 08837 USA

<http://www.iiam.org>

IIAM is a world-leading provider of non-transplantable, healthy and diseased, human organs and tissues for medical research, education and development. These tissues are recovered with minimal ischemia from organ transplant donors who have authorized use of the non-transplantable organs for research. Stored in preservation solution, the organs are shipped directly from the recovery suite and delivered to the researcher's lab in 12-24 hours. With access to over 15,000 organs for research each year, IIAM enables qualified researchers, healthcare and biotech professionals to study human tissues in order to alleviate human disease and advance medicine. Please visit our website at [www.iiam.org](http://www.iiam.org).

### **ISHLT Registries BOOTH No. 423**

700 N 4th Street

Richmond, VA 23219 USA

[www.ishlt.org](http://www.ishlt.org)

The International Thoracic Organ Transplant (TTX) Registry was created to provide on-going, current data regarding patient, donor, and transplant characteristics as well as post-transplant outcomes. Our Registry is the only one of its kind. All institutions and countries performing heart, heart-lung, and/or lung transplantation are invited to submit data to the TTX Registry.

### **Jackson Health System |Miami Transplant Institute BOOTH No. 425**

1801 N.W. 9th Avenue, Miami, FL 33136

Miami, FL 33136 USA

[www.MiamiTransplant.org](http://www.MiamiTransplant.org)

The Miami Transplant Institute (MTI), an affiliation between Jackson Health System and UHealth – University of Miami Health System, has been giving a second chance at life to patients on a local, national, and international level for more than 45 years. The MTI transplant team performs more than 650 transplant surgeries annually at Jackson Memorial Hospital, one of the largest public teaching hospitals in the United States, and is one of the largest and most comprehensive programs in the nation. It is also the only center in South Florida that performs all organ transplants for both adult and pediatric patients.



**Jarvik Heart, Inc. BOOTH No. 208**

333 West 52nd St  
New York, NY 10019 USA  
[www.jarvikheart.com](http://www.jarvikheart.com)

Jarvik Heart, Inc. is a privately held, New York City based company that develops, manufactures and sells unique cardiac assist devices for the treatment of severe heart failure. The Jarvik 2000 is a battery- powered axial-flow left ventricular assist device (LVAD). It is the smallest implantable blood pump available\* for the long-term treatment of Heart Failure. The New Jarvik 15mm VAD has been designed for pediatric and small patients and will enter clinical trials in the USA and EU in 2019.

\*Jarvik 2000 available, in US, only in FDA clinical trial.

**Kroger Specialty Pharmacy BOOTH No. 433**

7373 Lincoln Way  
Garden Grove, CA 92841 USA  
<http://krogerspecialtypharmacy.com>

Kroger Specialty Pharmacy is a nationwide Clinical Pharmacy dedicated to servicing patients with chronic illnesses requiring complex care. We offer unique programs designed to empower patients, including education and resources, counseling and side effect management, and financial assistance options.

**Leviticus Cardio BOOTH No. 427**

Odem 14 St, PO 6711  
Petach, Tikva 4934829 Israel

Leviticus Cardio - FiVAD Fully Implanted Ventricular Assist Device

Leviticus Cardio's wireless power transfer technology, Coplanar Energy Transfer (CET), combined with an existing Ventricular Assist system, provides a new, comprehensive hybrid solution for CHF patients. FiVAD is wirelessly charged using an external belt along with an internal battery that lasts 6-8 hours. The system completely removes the risk of infection often caused by the transcutaneous drive line which protrudes from the abdomen in standard Ventricular Assist devices. FiVAD also allows patients to walk without external equipment up to 8 hours a day, thereby significantly improving the patient's quality of life.

**Mallinckrodt Pharmaceuticals BOOTH No. 413**

3 Lotus Park, The Causeway,  
Staines Upon Thames, Surrey TW18 3AG United Kingdom  
[www.mallinckrodt.com](http://www.mallinckrodt.com)

Mallinckrodt Pharmaceuticals is a multibillion dollar specialty pharmaceutical company focused on our mission: Managing Complexity. Improving Lives. We provide medicines to address unmet patient needs, stemming from 150 years of using our unique strengths, experience and expertise to help improve people's lives. Mallinckrodt's growing portfolio of specialty pharmaceuticals help treat a wide variety of health conditions. We invest in our areas of focus that include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. For more information, please visit our website [www.mallinckrodt.com](http://www.mallinckrodt.com).

**Medtronic BOOTH No. 119**

Operational Headquarters  
710 Medtronic Parkway  
Minneapolis, MN 55432 USA  
<http://www.medtronic.com>

Patients are at the center of everything we do —and we believe medical technology can play an even greater role in improving people's lives. Medtronic Mechanical Circulatory Support is committed to continuous learning and innovation, to further advance the treatment of end-stage heart failure. We strive to improve patient outcomes and the clinical experience of your practice. Stop by the Medtronic booth to learn more and to see the latest HeartWare™ HVAD™ System enhancements. Join us in our commitment to take healthcare Further, Together. Be inspired at [medtronic.com](http://medtronic.com).

**Memorial Healthcare System BOOTH No. 417**

3501 Johnson Street  
Hollywood, FL 33021 USA  
<http://www.memorialphysician.com>

Memorial Healthcare System, one of the largest public healthcare systems in the U.S., has several physician career opportunities available for an adult cardiac surgeon, adult HF/HT cardiologist, and pediatric HF/HT cardiologist. The Memorial Cardiac and Vascular Institute's program has earned and maintained a three-star rating. Joe DiMaggio Children's Hospital, part of Memorial, has just celebrated their 50th pediatric heart transplant. Memorial Healthcare System is located in South Florida, a region with a high quality of life and no state income tax that attracts new residents from all over the country. Stop by booth #417 to learn more about these opportunities.

**Miller Pharmacal Group, Inc. BOOTH No. 419**

350 Randy Rd, Ste 2  
Carol Stream, IL 60188 USA

Miller Pharmacal's magnesium supplement "MG Plus Protein" is used at many transplant centers for the treatment and prevention of the hypomagnesemia caused by CI's, without the GI disturbances common with magnesium oxide. "MG Plus Protein" is: Well-tolerated, effective, inexpensive and easy for patients to swallow.

**Nebraska Medicine/UNMC BOOTH No. 106**

S 42nd & Emile St.  
Omaha, NE 68198-8132 USA  
<http://nebraskamed.com>

The Heart and Vascular Network at Nebraska Medicine includes physicians who subspecialize in areas such as structural heart disease, diagnostic cardiovascular imaging, congenital heart disease, advanced heart failure, heart transplantation and lung transplantation. Our Heart Failure and Transplant/MCS Program was one of the top 10 enrollment centers in the MOMENTUM 3 clinical trial. In 2018 they performed 41 transplants and implanted 51 VAD's and our skilled team of cardiac surgeons performed 74 ECMO cases. Our Lung Transplant Program accommodates dual listings with a median wait list time of 33 days. In 2018 this multidisciplinary team performed 11 lung transplants.

**One Lambda, Inc. A Thermo Fisher Scientific Brand BOOTH No. 108**

22801 Roscoe Blvd  
Los Angeles, CA 91304 USA  
<http://www.onelambda.com/en/home.html>

One Lambda, Inc., is a global leader in transplant diagnostics with a commitment to improve the lives of patients worldwide by driving innovation and delivering quality products. Our comprehensive product portfolio includes a broad range of industry-leading antibody detection and monitoring solutions, HLA Typing products, laboratory instrumentation and software, and industry-leading customer support.

**Paragonix Technologies, Inc. BOOTH No. 409**

639 Granite Street, Suite 408  
Braintree, MA 02184, MA 02184 USA  
<http://www.paragonixtechnologies.com>

The Paragonix SherpaPak™ Cardiac Transport System (CTS) safeguards hearts during the journey from donor to patient. Our device incorporates clinically proven and medically trusted cold preservation techniques in a novel suspension system to provide unprecedented physical and thermal protection. Paragonix SherpaPak™ CTS is the only commercially available FDA cleared and CE marked medical device for heart transportation.

### **Pediatric Heart Transplant Society (PHTS) BOOTH No. 405**

PO Box 55904

Birmingham, AL 35255 USA

<https://www.uab.edu/medicine/phts/>

The Pediatric Heart Transplant Society is a multidisciplinary, professional organization dedicated to advancing the science and treatment of children during listing and following heart transplantation. The ultimate goal is to improve the lives of pediatric heart transplant recipients. The purposes of the Society are to maintain an international, prospective, event driven, quality improvement registry for pediatric heart transplantation; promote collaboration among professionals in the field of pediatric heart transplantation; encourage and stimulate basic and clinical research; promote new therapeutics; provide educational resources for patients and families and develop best practices and procedures for caring for children after transplant.

### **Scanlan International, Inc. BOOTH No. 132**

One Scanlan Plaza

Saint Paul, MN 55107 USA

<https://www.scanlaninternational.com/>

The Scanlan Family has been designing and manufacturing the highest quality surgical products since 1921. Quality is important because a surgical instrument is an extension of a surgeon's hand. When purchasing instruments, consider precision, balance, feel and durability then demand Scanlan. Featured instruments include the SCANLAN® LEGACY titanium needle holders and forceps, Scanlan® SUPER CUT™ and PREMIER Scissors. Full line of VATS/MIS Thoracoscopic instruments including the Chitwood Aortic Clamp, Knot Pusher and SUPER CUT™ Suture Cutter. Also offering custom instrument designs and modifications for your individual needs. See our full-line of instrumentation at our Exhibit #132.

### **SynCardia Systems, LLC BOOTH No. 235**

1992 E. Silverlake Rd

Tucson, AZ 85713 USA

The SynCardia temporary Total Artificial Heart (TAH-t), the world's most used artificial heart, is now available in two sizes to serve more patients. The 70cc TAH-t is FDA, Health Canada and CE approved as a bridge to transplant for patients with end-stage biventricular failure. The new, smaller 50cc TAH-t, CE approved in Europe and undergoing an Investigational Device Exemption clinical study in the U.S., is designed for patients of smaller stature, including women and adolescents. Stable patients can be discharged to wait for a matching donor heart at home using the Freedom® portable driver. Visit our booth to learn more.

### **TAI Diagnostics BOOTH No. 133**

10101 Innovation Dr, Suite 600

Milwaukee, WI 53226 USA

<https://www.taidiagnostics.com/>

TAI Diagnostics, Inc. is a leading biotechnology company focused on providing accurate, fast, cost-effective, non-invasive diagnostic tests to monitor the health of transplanted organs in patients who have received solid organ transplants. The myTAI-HEART™ test measures the donor fraction of cell-free DNA as a direct measure of selective damage to a recipient's donated heart. The level of donor fraction is used to stratify the recipient as at low versus increased risk of moderate to severe acute cellular rejection. This ultra-sensitive test also detects other forms of selective donor organ injury, such as acute antibody mediated rejection and graft vasculopathy.

### **TandemLife|LivaNova BOOTH No. 415**

620 Alpha Drive

Pittsburgh, PA 15238 USA

<http://www.livanova.com/>

TandemLife is now LivaNova! Emergent cardiac & respiratory rescue for more patients in more places. The TandemLife family of temporary CPB support devices, provides a "Time to Decide™" strategy with rapid device deployment to stabilize and support the patient, giving you time to diagnose and treat the underlying issue. Stop by the LivaNova booth to see how our devices are delivering life support simplified.

### **Texas Children's Hospital BOOTH No. 334**

6621 Fannin Street  
Houston, TX 77030 USA  
[www.texaschildrens.org](http://www.texaschildrens.org)

Texas Children's Hospital, a not-for-profit health care organization, is committed to creating a healthier future for children and women throughout the global community by leading in patient care, education and research. Consistently ranked as the best children's hospital in Texas, and among the top in the nation, Texas Children's has garnered widespread recognition for its expertise and breakthroughs in pediatric and women's health. The hospital includes the Jan and Dan Duncan Neurological Research Institute; the Feigin Center for pediatric research; Texas Children's Pavilion for Women, a comprehensive obstetrics/gynecology facility; Texas Children's Hospital West Campus; and Texas Children's Hospital The Woodlands.

### **TransMedics, Inc. BOOTH No. 315**

200 Minuteman Rd, Suite 302  
Andover, MA 01982 USA  
<http://www.transmedics.com>

TransMedics Organ Care System (OCS™) The Organ Care System is a portable organ perfusion, optimization and monitoring system that replicates near-physiologic conditions for donor organs outside of the human body. The OCS technology platform is designed to maintain organs in a living, functioning state. Because the OCS significantly reduces injurious ischemic time on donor organs as compared to cold storage, and enables the optimization and assessment of these organs, it has demonstrated improved clinical outcomes relative to cold storage and offers the potential to significantly improve donor organ utilization.

### **UF Health Transplant Center BOOTH No. 431**

1329 SW 16th St, Ste. 3120/83  
Gainesville, FL 32608 USA  
<http://UFHealth.org>

UF Health Lung Transplant Program is in the top 10 facilities in the United States for volume, performing 70 combined adult and pediatric transplants in 2018. Superior outcomes exceed national averages for patient survival and wait list. ECMO is used before and during surgery along with unique treatments such as XVIVO to help create an expanded pool of donor lungs. The UF Health Congenital Heart Center is the largest, nationally ranked pediatric heart, heart-lung and the only pediatric lung transplant program in Florida, as well as one of the largest in the southeastern United States. UF Health Pediatrics offers a complete range of pediatric cardiac and pulmonary subspecialties and diagnostic procedures.

### **United Therapeutics BOOTH No. 205**

55 TW Alexander Dr  
Research Triangle Park, NC 27709 USA  
<http://www.unither.com>

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life threatening conditions.

### **XVIVO Perfusion AB BOOTH No. 227**

Box 53015  
Gothenburg, 40014 Sweden  
[www.xvivoperfusion.com](http://www.xvivoperfusion.com)

XVIVO Perfusion develops, manufactures and markets solutions and systems for transplantation; - Perfadex® Plus for hypothermic flushing and preservation of donor lungs during transport - STEEN Solution™ for normothermic ex vivo lung perfusion and evaluation - XPS™ and LS™ platforms for warm perfusion and evaluation of lungs ex vivo XPS™ is approved in Europe, USA, Canada and Australia and LS™ is approved in Europe, Canada and Australia XVIVO Perfusion aims to increase the number of organs available for transplantation and to improve success rates through developing new transplantation concepts and techniques. We believe that nobody should die waiting for a new organ.

## **FUTURE ANNUAL MEETINGS**

### **2020**

#### **40th Annual Meeting and Scientific Sessions**

Palais de Congrès de Montréal

Montréal, Canada

April 22-25, 2020

### **2021**

#### **41st Annual Meeting and Scientific Sessions**

International Convention Center Sydney

Sydney, Australia

April 21-24, 2021

### **2022**

#### **42<sup>nd</sup> Annual Meeting and Scientific Sessions**

John B. Hynes Veterans Memorial Convention Center

Boston, MA, USA

April 27-30, 2022



International Society for Heart and Lung Transplantation  
14673 Midway Road, Suite 200  
Addison, TX 75001 USA  
972-490-9495  
[www.isHLT.org](http://www.isHLT.org)